Disease	Gene	Model_KB	Model_KB_CONTEXT	Sentence	Label
seizures	ARX	0.8187	0.894	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
epileptic encephalopathy-2	CDKL5	0.8091	0.8588	PURPOSE: Mutations in the CDKL5 gene have been associated with an X-linked dominant early infantile epileptic encephalopathy-2.	1
SMEI/DS	ARX	0.801	0.8779	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
acute encephalopathy	SCN1A	0.7965	0.7281	SIGNIFICANCE: These findings provide further evidence that SCN1A mutations are a predisposing factor for the onset of various types of acute encephalopathy.	-1
seizure	CDKL5	0.7957	0.5894	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
seizures	CDKL5	0.7919	0.3631	In conclusion, our report suggests that searching for large rearrangements in CDKL5 should be considered in girls with early onset seizures and Rett-like features.	-1
epileptic encephalopathies	GABRA1	0.7911	0.9055	Those reports suggest that GABRA1 mutations are associated with infantile epilepsy including early onset epileptic encephalopathies.	1
seizures	CDKL5	0.7833	0.8411	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
cognitive deficit	EPM2A	0.7831	0.5936	Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.	-1
SMEI/DS	CDKL5	0.7632	0.8187	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
focal epilepsy	SCN1A	0.759	0.5519	Our findings suggest that SCN1A mutations may cause susceptibility to an idiopathic focal epilepsy phenotype, the final phenotype depending on other (genetic or nongenetic) factors.	-1
RTT-like	CDKL5	0.7585	0.1087	Our report suggests that the clinical features associated with CDKL5 deletions could be implicated in Japanese patients, and that genetic testing of CDKL5, including both sequencing and deletion analyses, should be considered in girls with early-onset epileptic encephalopathy and RTT-like features.	-1
hypotonia	MECP2	0.7574	0.4873	The MECP2 duplication syndrome is characterized by severe mental retardation, infantile hypotonia, progressive spasticity and recurrent infections.	-1
spasticity	MECP2	0.7573	0.5344	The MECP2 duplication syndrome is characterized by severe mental retardation, infantile hypotonia, progressive spasticity and recurrent infections.	-1
hypotonia	CDKL5	0.7454	0.6751	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
epileptic encephalopathies	GABRA1	0.7428	0.7773	SIGNIFICANCE: Our study suggests that de novo GABRA1 mutations can cause early onset epileptic encephalopathies, including Ohtahara syndrome and West syndrome.	1
epileptic encephalopathy	cyclin-dependent kinase-like 5 and aristaless-related homeobox	0.7415	0.3045	Two genes causally involved in refractory epilepsy with mental retardation, cyclin-dependent kinase-like 5 and aristaless-related homeobox, could account for at least some forms of early onset epileptic encephalopathy that still lack etiological explanation.	1
infantile spasms	CDKL5	0.7406	0.5756	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
RTT-like	CDKL5	0.7394	0.1469	Our report suggests that the clinical features associated with CDKL5 deletions could be implicated in Japanese patients, and that genetic testing of CDKL5, including both sequencing and deletion analyses, should be considered in girls with early-onset epileptic encephalopathy and RTT-like features.	-1
Epilepsies	SCN1A	0.7384	0.5707	CONCLUSION: Epilepsies associated with SCN1A mutations range in severity from febrile seizures to severe epileptic encephalopathies including Dravet syndrome and severe infantile multifocal epilepsy.	1
epilepsy	GABRA1	0.731	0.3662	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epileptic	SCN1A	0.7289	0.4071	SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients.	1
epilepsy	GABRB3	0.7272	0.2951	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
Rett-like	CDKL5	0.7268	0.1501	In conclusion, our report suggests that searching for large rearrangements in CDKL5 should be considered in girls with early onset seizures and Rett-like features.	-1
epilepsy	SCN1A	0.7236	0.5435	UNASSIGNED: OBJECT Mutations in the sodium channel alpha 1 subunit gene (SCN1A) have been associated with a wide range of epilepsy phenotypes including Dravet syndrome.	1
epilepsy	MBD5	0.7229	0.3024	Partial or complete deletion of MBD5 was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features.	-1
inherited	KCNQ2	0.7229	0.4258	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	-1
epilepsy	CDKL5	0.72	0.3915	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	1
idiopathic epilepsy syndromes	GABRA1	0.7196	0.4155	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
infantile onset epilepsies	SCN1A	0.7188	0.5294	Rather than ascribing multiple different names to marginally different phenotypes, the term Dravet syndrome is now preferred to describe the group of severe infantile onset epilepsies (OMIM #607208, #182389, #604403) associated with mutations in SCN1A (OMIM *182389).	1
Rett syndrome	Netrin G1	0.7166	0.7206	Netrin G1 mutations are an uncommon cause of atypical Rett syndrome with or without epilepsy.	-1
West syndrome	GABRA1	0.7147	0.613	SIGNIFICANCE: Our study suggests that de novo GABRA1 mutations can cause early onset epileptic encephalopathies, including Ohtahara syndrome and West syndrome.	-1
polymorphic seizures	CDKL5	0.7145	0.7063	Genetic testing looking for CDKL5 mutation is indicated in each female child with impaired psychomotor development, refractory epilepsy with early onset polymorphic seizures and clinical _ EEG phenotype of atypical Rett/Angelman syndrome.	-1
seizures	SCN1A	0.7144	0.1567	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
genetic	GABRA1	0.713	0.3378	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
hypotonia	KANSL1-related	0.7129	0.167	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
SMEI	SCN1A	0.7128	0.5168	In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome.	-1
seizures	CDKL5	0.7124	0.7994	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
Rett/Angelman syndrome	CDKL5	0.7117	0.5867	Genetic testing looking for CDKL5 mutation is indicated in each female child with impaired psychomotor development, refractory epilepsy with early onset polymorphic seizures and clinical _ EEG phenotype of atypical Rett/Angelman syndrome.	-1
genetic	GABRB3	0.7091	0.2698	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
intractable epilepsy	CDKL5	0.7087	0.7257	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	1
epileptic encephalopathies	SCN1A	0.7083	0.8713	Knowledge of an expanded spectrum of epileptic encephalopathies associated with SCN1A mutations allows earlier diagnostic confirmation for children with these devastating disorders.	1
epileptic encephalopathy	CDKL5	0.7069	0.177	Our report suggests that the clinical features associated with CDKL5 deletions could be implicated in Japanese patients, and that genetic testing of CDKL5, including both sequencing and deletion analyses, should be considered in girls with early-onset epileptic encephalopathy and RTT-like features.	1
epilepsy	CDKL5	0.7047	0.6993	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	1
seizures	Nav1.1	0.7042	0.3117	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
seizures	MECP2	0.7036	0.6703	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
epileptic conditions	SCN2A	0.7031	0.4458	Given the wide clinical spectrum associated with SCN2A mutations, genetic testing for SCN2A should be considered for children with different epileptic conditions.	1
epilepsy	SCN2A	0.7024	0.6954	While a causal role for these mutations cannot be directly established, these findings contribute to growing evidence that mutation of SCN2A is associated with a range of epilepsy phenotypes including severe infantile-onset epilepsy.	1
Meckel syndrome	CC2D2A	0.7016	0.5363	CC2D2A mutations are a relatively common cause of JS and also cause Meckel syndrome.	-1
epileptic seizures	CDKL5	0.7011	0.8288	CDKL5 mutations are a significant cause of infantile spasms and early epileptic seizures in female patients, and of a later intractable seizure disorder, irrespective of whether they have suspected Rett syndrome.	1
Rett syndrome-like	CDKL5	0.6992	0.5667	Mutations in the human CDKL5 gene have been shown to cause infantile spasms, as well as Rett syndrome-like phenotype.	-1
infantile spasms	CDKL5	0.6981	0.6784	Here, we report that de novo missense mutations in CDKL5 are associated with a severe phenotype of early-onset infantile spasms and clinical features that overlap those of other neurodevelopmental disorders, such as Rett syndrome and Angelman syndrome.	-1
encephalitis	CXCL10-CXCR3	0.698	0.3543	We studied the implication of CXCL10-CXCR3, a chemotactic axis involved in the pathogenesis of several cases of immune encephalitis.	-1
RTT	CDKL5	0.6974	0.5439	Although mutations in the CDKL5 gene have been described in association with the early-onset variant of RTT, in our study the majority did not meet these criteria.	-1
idiopathic epilepsy syndromes	GABRB3	0.697	0.2478	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
dysmorphisms	KANSL1-related	0.697	0.1676	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
seizures	MECP2	0.6962	0.5002	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
neurodevelopmental disorder	CDKL5	0.6961	0.4287	The mutations are located within the protein kinase domain and affect highly conserved amino acids; this strongly suggests that impaired CDKL5 catalytic activity plays an important role in the pathogenesis of this neurodevelopmental disorder.	-1
epilepsy	Netrin G1	0.6961	0.6405	Netrin G1 mutations are an uncommon cause of atypical Rett syndrome with or without epilepsy.	-1
epilepsy	MBD5	0.6959	0.3331	Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder.	-1
seizures	CDKL5	0.6946	0.2472	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
Rett syndrome	CDKL5	0.6943	0.5045	CDKL5 mutations are a significant cause of infantile spasms and early epileptic seizures in female patients, and of a later intractable seizure disorder, irrespective of whether they have suspected Rett syndrome.	-1
epilepsy	FOXG1	0.6943	0.4444	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
epilepsy	GABRG2	0.6934	0.3342	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epilepsy	GABRA1	0.6925	0.4044	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epileptic conditions	SCN2A	0.6917	0.3419	Given the wide clinical spectrum associated with SCN2A mutations, genetic testing for SCN2A should be considered for children with different epileptic conditions.	1
seizure	CDKL5	0.6916	0.3036	Novel pathogenic CDKL5 mutations were identified in three girls, two of whom had initially been diagnosed with the early onset seizure variant of RTT and the other with early onset seizures and some features of RTT.	-1
Dravet syndrome	SCN1A	0.6914	0.1989	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
epilepsy	MECP2	0.6912	0.102	BACKGROUND: Duplications of the X-linked MECP2 gene are associated with moderate to severe intellectual disability, epilepsy, and neuropsychiatric illness in males, while triplications are associated with a more severe phenotype.	1
sleep abnormalities	SCN1A	0.6907	0.7177	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
infancy	CLCN2	0.6905	0.5414	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
seizures	TCF4	0.6893	0.132	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
epilepsy	GABRB3	0.6885	0.3297	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
SMEI/DS	CDKL5	0.6884	0.7726	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
migrating	CLCN2	0.6881	0.5763	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
seizures	TTR	0.6876	0.3104	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
epileptic encephalopathy	CDKL5	0.6868	0.1409	Our report suggests that the clinical features associated with CDKL5 deletions could be implicated in Japanese patients, and that genetic testing of CDKL5, including both sequencing and deletion analyses, should be considered in girls with early-onset epileptic encephalopathy and RTT-like features.	1
infantile spasms	interleukin-6	0.6865	0.6043	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
West syndrome	interleukin-6	0.6857	0.4653	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
seizure	CDKL5	0.6843	0.4467	CDKL5 mutations are a significant cause of infantile spasms and early epileptic seizures in female patients, and of a later intractable seizure disorder, irrespective of whether they have suspected Rett syndrome.	-1
inherited	KCNQ3	0.6839	0.4444	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	-1
refractory epilepsy	CDKL5	0.6838	0.6235	Genetic testing looking for CDKL5 mutation is indicated in each female child with impaired psychomotor development, refractory epilepsy with early onset polymorphic seizures and clinical _ EEG phenotype of atypical Rett/Angelman syndrome.	1
infantile hypotonia	MECP2	0.6829	0.2486	Duplication of MECP2 causes a recently described X-linked mental retardation syndrome, of which the typical features are infantile hypotonia, poor speech development, recurrent infections, epilepsy, and progressive spasticity.	-1
FCs	SCN1A	0.6829	0.3315	These data suggest that the SCN1A gene might not be one of the susceptibility factors for FCs.	-1
Myoclonic Epilepsy of Infancy	SCN1A	0.6825	0.07951	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
Severe myoclonic epilepsy of infancy	SCN1A	0.6807	0.2806	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
epilepsy	NRXN1	0.68	0.7142	Compound heterozygous deletion of NRXN1 causing severe developmental delay with early onset epilepsy in two sisters.	-1
RTT	CDKL5	0.6799	0.2812	Novel pathogenic CDKL5 mutations were identified in three girls, two of whom had initially been diagnosed with the early onset seizure variant of RTT and the other with early onset seizures and some features of RTT.	-1
WS	interleukin-6	0.6788	0.5917	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
infantile-onset epilepsy	SCN1A	0.6775	0.1735	DS is a severe infantile-onset epilepsy caused by a heterozygote loss-of-function mutation in SCN1A, which encodes the voltage-gated-sodium channel NaV 1.1.	1
BFNC	KCNQ2	0.6767	0.8253	In this report, we describe a family with BFNC due to a KCNQ2 mutation, the first such family to be described in the Korean population.	-1
DS	SCN1A	0.6764	0.09447	Dravet syndrome (DS) is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment.	-1
congenital malformations	KANSL1-related	0.6761	0.1497	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
Ohtahara syndrome	GABRA1	0.675	0.6483	SIGNIFICANCE: Our study suggests that de novo GABRA1 mutations can cause early onset epileptic encephalopathies, including Ohtahara syndrome and West syndrome.	-1
idiopathic epilepsy	KCNQ2	0.6749	0.5667	Role of KCNQ2 and KCNQ3 genes in juvenile idiopathic epilepsy in Arabian foals.	-1
epilepsy	GABRG2	0.6744	0.3961	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
seizures	CDKL5	0.6743	0.3544	Thus, a CDKL5 investigation should be performed in developmentally delayed patients with early-onset seizures, including drug-resistant subjects with severe EEG changes, as well as in patients with milder, drug-responsive forms of epilepsy.	-1
epileptic encephalopathy	CDKL5	0.6739	0.4588	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	1
epileptic	SCN1B	0.6738	0.2601	SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients.	1
seizures	CDKL5	0.6734	0.05362	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	-1
autism	Mecp2	0.6729	0.3691	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	-1
genetic epilepsy syndrome	SCN1A	0.6725	0.1684	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
familial Ohtahara syndrome	SCN2A	0.6714	0.6923	This is the first report of familial Ohtahara syndrome due to a germline mosaic SCN2A mutation.	-1
intellectual disability	MBD5	0.671	0.2785	Partial or complete deletion of MBD5 was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features.	-1
seizures	SCN1A	0.6708	0.1401	Heterozygous loss-of-function mutations in SCN1A result in Dravet syndrome, a severe infant-onset epileptic encephalopathy characterized by intractable seizures, developmental delays and increased mortality.	-1
childhood disorder	SCN1A	0.6703	0.1695	Dravet syndrome is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment, thus well illustrating the concept of epileptic encephalopathy.	-1
childhood disorder	SCN1A	0.6703	0.1695	Dravet syndrome (DS) is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment.	-1
Dravet syndrome	SCN1A	0.6693	0.5251	UNASSIGNED: OBJECT Mutations in the sodium channel alpha 1 subunit gene (SCN1A) have been associated with a wide range of epilepsy phenotypes including Dravet syndrome.	-1
seizures	cyclin-dependent kinase-like 5	0.6687	0.05673	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	-1
Dravet syndrome	SCN1A	0.6684	0.7242	CONCLUSIONS: Dravet syndrome due to an SCN1A mutation is twice as common in the United States as previously thought.	-1
encephalopathy	CDKL5	0.6682	0.1748	The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.	-1
amyloidosis	TTR	0.6676	0.4288	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
genetic epilepsy	SCN1A	0.6669	0.2598	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
seizures	CDKL5	0.6664	0.4822	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
Rasmussen encephalitis	SCN 1 A	0.6664	0.3969	Rasmussen encephalitis associated with SCN 1 A mutation.	-1
seizures	CDKL5	0.6663	0.5116	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
epileptic encephalopathy	MECP2	0.6654	0.575	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	1
seizures	CLCN2	0.6654	0.5449	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
autism	CDKL5	0.6651	0.4369	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
Rett syndrome	CDKL5	0.6648	0.421	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	-1
epileptic encephalopathies	KCNQ2	0.6641	0.8102	Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation.	1
mental retardation syndrome	PIGW	0.6636	0.3582	Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome.	-1
Rett syndrome	MECP2	0.663	0.5635	Mutations in the MECP2 gene in a cohort of girls with Rett syndrome.	-1
developmental	KANSL1-related	0.6629	0.2575	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
seizures	CDKL5	0.6614	0.1259	Novel pathogenic CDKL5 mutations were identified in three girls, two of whom had initially been diagnosed with the early onset seizure variant of RTT and the other with early onset seizures and some features of RTT.	-1
seizures	SCN1A	0.6612	0.4213	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
HHE syndrome	SCN1A	0.6611	0.6853	Our study suggests that SCN1A genetic mutation is only a rare predisposing cause of HHE syndrome.	1
epileptic seizures	PEHO	0.6602	0.4779	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
Rett syndrome	cyclin-dependent kinase-like 5	0.66	0.4356	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	-1
seizures	ARX-related	0.66	0.4475	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
West syndrome	PIGA	0.66	0.8116	METHODS: Whole-exome sequencing was performed as a comprehensive genetic analysis for a cohort of 172 patients with EOEEs including early myoclonic encephalopathy, Ohtahara syndrome, and West syndrome, and PIGA mutations were carefully investigated.	-1
CAE	GABRA1	0.6599	0.4211	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
BFNC	KCNQ2	0.659	0.6611	KCNQ2 mutations may be associated with BFNC in a number of different races, as has been reported in other ethnic groups.	-1
RTT-like	CDKL5	0.6583	0.5816	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
genetic epilepsy	SCN1A	0.658	0.2872	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
syndromes	GABRA1	0.6576	0.406	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
seizures	CDKL5	0.6574	0.6305	CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.	-1
seizures	CDKL5	0.6574	0.6366	A screen for CDKL5 mutations is useful in patients, mainly females, with a history of early onset intractable seizures and becomes mandatory when idiopathic infantile spasms and/or atypical Rett syndrome features are also present.	-1
LGS	SCN1A	0.6566	0.6548	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
autism	MECP2	0.6565	0.5532	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
intractable epilepsy	cyclin-dependent kinase-like 5	0.6564	0.6041	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	1
Dravet syndrome	SCN1A	0.6558	0.1511	Dravet syndrome is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment, thus well illustrating the concept of epileptic encephalopathy.	-1
impaired psychomotor development	CDKL5	0.6558	0.6695	Genetic testing looking for CDKL5 mutation is indicated in each female child with impaired psychomotor development, refractory epilepsy with early onset polymorphic seizures and clinical _ EEG phenotype of atypical Rett/Angelman syndrome.	-1
SMEI	SCN1A	0.6557	0.2728	The clinical history of 37 patients with clinical diagnosis of SMEI, associated with a point mutation of SCN1A gene in 84% of cases, were reviewed with particular attention to the symptoms of onset.	-1
genetic epilepsy	SCN1A	0.6555	0.2828	Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel.	-1
generalized epilepsy	GABRA1	0.6555	0.4145	Our results confirm that mutation of GABRA1 predisposes towards a common idiopathic generalized epilepsy syndrome in humans.	-1
epilepsy	CDKL5	0.6548	0.2842	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	1
epilepsy	SYN2	0.6543	0.4811	The aim of this study was to investigate the association between the SYN2 rs3773364 A>G polymorphism and susceptibility against epilepsy in a case-control study and a meta-analysis.	-1
sclerosis	SCN1A	0.6538	0.7636	After observing mesial temporal sclerosis in a child with SCN1A gene mutation, we retrospectively reviewed magnetic resonance imaging (MRI) findings in all patients with SCN1A gene mutation identified between 2005 and 2010.	-1
epilepsy	SYN2	0.6538	0.185	METHODS: The SYN2 rs3773364 A>G polymorphism was successfully genotyped in 1182 samples (618 epilepsy patients) of Chinese, Indian, and Malay ethnicities.	-1
EE	CDKL5	0.6538	0.7643	SIGNIFICANCE: CDKL5 gene mutations accounted for 5.4% of boys with early onset EE.	1
epilepsy	MRI	0.6538	0.2219	Role of MRI in patient selection for surgical treatment of intractable epilepsy in infancy.	-1
ISs	MAGI2	0.6536	0.2522	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
neurodevelopmental disease	KPNA7	0.6527	0.5568	Our data show that compound heterozygous mutations in KPNA7 are associated with a human neurodevelopmental disease, and provide the first example of a human disease associated with mutation of a nuclear transport receptor.	-1
epilepsy	SYN2	0.6526	0.3045	CONCLUSIONS: Our study indicated that SYN2 rs3773364 A>G polymorphism is not a risk factor for susceptibility to epilepsy.	-1
OS	SCN2A	0.6524	0.6502	CONCLUSIONS: Our study confirmed that SCN2A mutations are an important genetic cause of OS.	-1
JS	CC2D2A	0.6523	0.7405	CC2D2A mutations are a relatively common cause of JS and also cause Meckel syndrome.	-1
Pitt-Hopkins syndrome	TCF4	0.6521	0.5217	Disruption of the TCF4 gene in a girl with mental retardation but without the classical Pitt-Hopkins syndrome.	-1
IES	GABRB3	0.6521	0.2796	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Ohtahara syndrome	PIGA	0.6518	0.6628	METHODS: Whole-exome sequencing was performed as a comprehensive genetic analysis for a cohort of 172 patients with EOEEs including early myoclonic encephalopathy, Ohtahara syndrome, and West syndrome, and PIGA mutations were carefully investigated.	-1
seizures	CHD2	0.6516	0.284	Our study provides evidence that de novo loss-of-function mutations in CHD2 are a cause of epileptic encephalopathy with generalized seizures.	-1
DS	SCN1A	0.6514	0.1161	UNASSIGNED: Dravet syndrome (DS) is a severe childhood epilepsy typically caused by de novo dominant mutations in SCN1A.	-1
genetic	GABRG2	0.6511	0.3279	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Aicardi syndrome	CDKL5	0.651	0.2379	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
LGS	CHD2	0.6509	0.4173	Our findings suggest that CHD2 mutations are important in the etiological spectrum of LGS.	-1
epilepsy syndromes	SCN1A	0.6505	0.6846	SCN1A mutations are associated with a variety of epilepsy syndromes; the more severe syndromes are associated with truncation or complete loss of function of the protein.	1
epileptic encephalopathies	CDKL5	0.65	0.3799	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	1
RTT	CDKL5	0.65	0.1209	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	-1
epilepsy	KCNQ2	0.6499	0.4497	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	1
deafness	TBC1D24	0.6499	0.309	Of the 18 individuals with DOORS syndrome from 17 families without TBC1D24 mutations, eight did not have seizures and three did not have deafness.	-1
epilepsy	GABRA1	0.6495	0.3412	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
seizures	SCN1A	0.6483	0.5418	SCN1A gene analysis is not commonly performed in subjects with generalised seizures without FS.	-1
SMEI	SCN 1 A	0.6477	0.335	Mutations in the SCN 1 A gene, encoding the neuronal voltage-gated sodium channel alpha1 subunit, cause SMEI, GEFS+, and related epileptic syndromes.	-1
epileptic	SCN1A	0.6475	0.237	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	1
myoclonus epilepsy	EPM2A	0.6471	0.6222	Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.	-1
intellectual disability	CDKL5	0.6467	0.2069	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
epilepsy	CDKL5	0.6465	0.7401	CDKL5 mutations as a cause of severe epilepsy in infancy: clinical and electroencephalographic long-term course in 4 patients.	1
systemic iron-overload	PIGA	0.6463	0.5615	A novel germline PIGA mutation in Ferro-Cerebro-Cutaneous syndrome: a neurodegenerative X-linked epileptic encephalopathy with systemic iron-overload.	-1
CAE	GABRB3	0.646	0.2265	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
focal epilepsy	GRIN2B	0.6459	0.5256	GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy.	-1
epileptic encephalopathy	CDKL5-related	0.6452	0.5859	As yet, few studies report on long-term observations in patients with CDKL5-related epileptic encephalopathy.	1
epilepsy	SCN1A	0.6451	0.4479	Prevalence of SCN1A mutations in children with suspected Dravet syndrome and intractable childhood epilepsy.	1
HH	GLI3	0.6449	0.2031	Together, these data provide evidence that the development of chromosomal abnormalities within GLI3 is associated with the pathogenesis of HH lesions in sporadic, nonsyndromic patients with HH and intractable epilepsy.	-1
seizures	MECP2-containing	0.6449	0.3426	A case report of Chinese brothers with inherited MECP2-containing duplication: autism and intellectual disability, but not seizures or respiratory infections.	-1
Dravet syndrome	SCN1A	0.6449	0.4971	Dravet syndrome is a rare epileptic encephalopathy linked to mutations in SCN1A (neuronal sodium channel a1 subunit) and characterized by an onset in infancy with polymorphous seizure types and developmental decline.	-1
Dravet syndrome	SCN1A-gene	0.6447	0.264	Dravet syndrome, often caused by mutations of SCN1A-gene, presents with prolonged clonic, generalized or unilateral seizures often occurring with fever during the first year of life, followed by usually severe epilepsy.	-1
epileptic encephalopathy	CDKL5	0.6446	0.6382	A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5.	1
Dravet syndrome	CHD2	0.6444	0.3429	De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome.	-1
infantile spasms	CDKL5	0.6442	0.4468	Mutations in the human CDKL5 gene have been shown to cause infantile spasms, as well as Rett syndrome-like phenotype.	-1
CAE	GABRA1	0.6439	0.4243	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsies	SCN2A	0.6438	0.3361	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	1
X-linked epileptic encephalopathy	PIGA	0.6437	0.8018	A novel germline PIGA mutation in Ferro-Cerebro-Cutaneous syndrome: a neurodegenerative X-linked epileptic encephalopathy with systemic iron-overload.	-1
Dravet syndrome	SCN1A	0.6435	0.086	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
RTT	CDKL5	0.6434	0.5059	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
DS	SCN1A	0.6434	0.5119	An overwhelmingly high number of SCN1A mutations have been associated with DS.	-1
idiopathic generalised epilepsy	SCN1A	0.6434	0.2863	SCN1A mutation may be a clinically-useful genetic marker in order to distinguish GEFS+ patients from those with classic idiopathic generalised epilepsy, even if they present an atypical clinical picture.	-1
obesity	PHF6	0.6432	0.144	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
epileptic encephalopathies	SCN1A	0.6425	0.3797	To explore the phenotypic variability associated with SCN1A mutations, 188 patients with a range of epileptic encephalopathies were examined for SCN1A sequence variations by denaturing high performance liquid chromatography and sequencing.	1
intellectual disability	MECP2	0.6425	0.3041	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
infantile epilepsy	GABRA1	0.6425	0.6604	Those reports suggest that GABRA1 mutations are associated with infantile epilepsy including early onset epileptic encephalopathies.	1
neurologic deterioration	SCN1A	0.6423	0.4653	This report adds to the spectrum and mechanism of acute neurologic deterioration and functional deficit associated with SCN1A mutations, which remains to be fully understood.	-1
Aicardi syndrome	MECP2	0.6422	0.3325	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
epileptic encephalopathy	CDKL5	0.642	0.3445	METHODS: A total of 125 patients with epileptic encephalopathy were examined for genomic copy number aberrations, and 119 patients with no such aberrations were further examined for CDKL5 mutations.	1
epileptic	CYP2C9	0.6418	0.2816	Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.	-1
juvenile myoclonic epilepsy	GABRA1	0.6416	0.3955	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizures	CDKL5	0.6416	0.5686	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
autosomal recessive AOS	DOCK6	0.6413	0.351	Whole-genome sequencing documented two rare truncating variants in DOCK6, a gene associated with a type of autosomal recessive AOS that recurrently features periventricular calcification and impaired neurodevelopment.	-1
infantile spasm	CDKL5	0.6411	0.647	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
calcification	DOCK6	0.6408	0.1472	Whole-genome sequencing documented two rare truncating variants in DOCK6, a gene associated with a type of autosomal recessive AOS that recurrently features periventricular calcification and impaired neurodevelopment.	-1
infantile spasms	CDKL5	0.6408	0.3808	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	-1
epileptic encephalopathy	SCN1A	0.6407	0.3113	Heterozygous loss-of-function mutations in SCN1A result in Dravet syndrome, a severe infant-onset epileptic encephalopathy characterized by intractable seizures, developmental delays and increased mortality.	1
febrile seizures	GABRA1	0.6405	0.4129	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
infancy	CDKL5-related	0.64	0.2715	CDKL5-related epileptic encephalopathies are a group of refractory seizure disorders starting in early infancy.	-1
hypotonia	KANSL1-Related	0.6398	0.2735	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
diabetes	TRMT10A	0.6396	0.2061	TRMT10A sequencing should be considered in children or adults with young-onset diabetes who have a history of intellectual disability, microcephaly and epilepsy.	-1
hypotonia	CDKL5	0.6391	0.2145	Interestingly these missense mutations that result in a mislocalisation of the CDKL5 protein are associated with severe developmental delay which was apparent within the first months of life characterised by early and generalised hypotonia, and autistic features, and as well as early infantile spasms.	-1
epileptic encephalopathy	SCN1A	0.6388	0.7511	Dravet syndrome is a rare epileptic encephalopathy linked to mutations in SCN1A (neuronal sodium channel a1 subunit) and characterized by an onset in infancy with polymorphous seizure types and developmental decline.	1
neurological health	APP	0.6382	0.2885	In addition, APP and its proteolytic fragments are emerging as biomarkers for neurological health, and pharmacological interventions that modulate their levels, such as secretase inhibitors, passive immunotherapy against Ab and mGluR5 antagonists, are reviewed.	-1
epileptic encephalopathy	CDKL5-related	0.6381	0.6183	METHOD: We used video-EEG to monitor six infants (five females, one male) with CDKL5-related epileptic encephalopathy (five mutations; one deletion), at ages 45 days to 12 months and followed them up to the ages of 14 months to 5 years (mean age 23 mo).	1
MCDs	SCN1A	0.6379	0.3889	METHODS: Through our database of epileptic encephalopathies, we identified 120 patients with SCN1A mutations, of which 4 had magnetic resonance imaging (MRI) evidence of MCDs.	-1
idiopathic epilepsy syndromes	GABRG2	0.6379	0.3031	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
RTT	CDKL5	0.6378	0.2825	These results also suggest that mutations in CDKL5 can lead to a clinical phenotype that overlaps RTT.	-1
epilepsy	SCN2A	0.6375	0.1653	Infantile epilepsy associated with mosaic 2q24 duplication including SCN2A and SCN3A.	1
PHS	TCF4	0.6375	0.7207	Our study indicates that TCF4 gene mutations are not always associated with classical PHS but can give rise to a much milder clinical phenotype.	-1
borderline SMEI syndrome	SCN1A	0.637	0.6762	We describe a case of a new missense de novo mutation of SCN1A in a child with the clinical features of borderline SMEI syndrome.	-1
epilepsy	CDKL5	0.6369	0.1944	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	1
DS	SCN1A	0.6366	0.112	DS is a severe infantile-onset epilepsy caused by a heterozygote loss-of-function mutation in SCN1A, which encodes the voltage-gated-sodium channel NaV 1.1.	-1
myoclonic epilepsy	CDKL5	0.6362	0.6493	CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.	-1
seizures	CDKL5	0.636	0.4892	We screened the entire coding region of CDKL5 for mutations in 183 females with encephalopathy with early seizures by denaturing high liquid performance chromatography and direct sequencing, and we identified in 20 unrelated girls, 18 different mutations including 7 novel mutations.	-1
encephalopathy	PDHX	0.636	0.4141	Mutations in the PDHX gene (five cases) were correlated with non-progressive encephalopathy and long-term survival in four cases.	-1
infantile spasms	cyclin-dependent kinase-like 5	0.636	0.3949	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	-1
epilepsy	GABRD	0.6354	0.4443	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
microcephaly	TRMT10A	0.6352	0.5267	tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy.	-1
RTT	CDKL5	0.6352	0.1746	Novel pathogenic CDKL5 mutations were identified in three girls, two of whom had initially been diagnosed with the early onset seizure variant of RTT and the other with early onset seizures and some features of RTT.	-1
DS	SCN1A	0.6344	0.8695	OBJECTIVE: To summarize the early clinical features of Dravet syndrome (DS) patients with SCN1A gene mutations before the age of one.	-1
infancy	SCN1A	0.6341	0.3541	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
SMEI	SCN1A	0.6341	0.118	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
SMEI/DS	ARX-related	0.6339	0.4085	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.6337	0.7969	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
IES	GABRA1	0.6336	0.3251	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
febrile seizures	SCN1A	0.6335	0.2157	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
neurological diseases	SCN1A	0.6334	0.7314	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
myoclonic ataxia	SCA-14	0.6332	0.1361	We suggest that SCA-14 should be considered in the differential diagnosis of progressive myoclonic ataxia.	-1
diverse epilepsy syndromes	GRIN2A	0.6332	0.1357	We sought to delineate the pathogenic role of GRIN2A in 519 probands with epileptic encephalopathies with diverse epilepsy syndromes.	1
migrating focal seizures of infancy	SCN2A	0.6328	0.8133	Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy.	-1
SMEI/DS	CDKL5	0.6327	0.4655	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
Dravet syndrome	SCN1A	0.6327	0.7346	It is well established that SCN1A gene mutations are associated with Dravet syndrome.	-1
generalized epilepsy with febrile seizures	SCN1A	0.6326	0.4404	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
hyperventilation	TCF4	0.6326	0.05473	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
syndromes	GABRB3	0.6326	0.2405	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
microcephaly	TRMT10A	0.6322	0.07566	TRMT10A sequencing should be considered in children or adults with young-onset diabetes who have a history of intellectual disability, microcephaly and epilepsy.	-1
epilepsy	GABRA1	0.6321	0.3215	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epilepsy	GABRD	0.6321	0.4026	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epilepsy	GABRB3	0.6319	0.2028	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
hydrocephalus	CC2D2A-related	0.6316	0.2209	Patients with CC2D2A-related JS should be monitored for hydrocephalus and seizures.	-1
seizures	CDKL5	0.6315	0.4188	Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.	-1
Adams-Oliver syndrome	DOCK6	0.6312	0.6191	Diffuse angiopathy in Adams-Oliver syndrome associated with truncating DOCK6 mutations.	-1
autosomal recessive fatal disorder	EPM2A	0.631	0.4307	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
Dravet syndrome	SCN1A	0.631	0.07378	Rather than ascribing multiple different names to marginally different phenotypes, the term Dravet syndrome is now preferred to describe the group of severe infantile onset epilepsies (OMIM #607208, #182389, #604403) associated with mutations in SCN1A (OMIM *182389).	-1
infantile spasms	CDKL5	0.6308	0.5124	A screen for CDKL5 mutations is useful in patients, mainly females, with a history of early onset intractable seizures and becomes mandatory when idiopathic infantile spasms and/or atypical Rett syndrome features are also present.	-1
neonatal diabetes	ABCC8	0.6303	0.2523	We therefore hypothesized that activating mutations in the ABCC8 gene, which encodes SUR1, might cause neonatal diabetes.	-1
neurodevelopmental defects	MeCP2	0.6298	0.3989	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
sensorineural hearing loss	TBC1D24	0.6298	0.6	In fact, early-onset epileptic encephalopathy with sensorineural hearing loss is an additional phenotype observed in patients with recessive TBC1D24 mutations.	-1
Dravet syndrome	SCN1A	0.6298	0.3947	BACKGROUND: Dravet syndrome is a severe infantile epileptic encephalopathy caused in approximately 80% of cases by mutations in the voltage gated sodium channel subunit gene SCN1A.	-1
CAE	GABRB3	0.6297	0.2288	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
neurodevelopmental disorders	CDKL5	0.6293	0.2687	Here, we report that de novo missense mutations in CDKL5 are associated with a severe phenotype of early-onset infantile spasms and clinical features that overlap those of other neurodevelopmental disorders, such as Rett syndrome and Angelman syndrome.	-1
migrating	SCN1A	0.6291	0.4252	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
West syndrome	IL-6	0.629	0.4607	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
generalized epilepsy	SCN1A	0.6288	0.5298	Although a few candidate disease alleles were identified, the patient survey suggests that SCN1A is not a major contributor to idiopathic generalized epilepsy.	-1
West syndrome	MECP2	0.6283	0.3195	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
severe myoclonic epilepsy of infancy	Na(V)1.1	0.6279	0.2079	PURPOSE: Mutations in SCN1A, encoding the human Na(V)1.1 neuronal voltage-gated sodium channel, cause the syndrome of severe myoclonic epilepsy of infancy (SMEI).	-1
Rett syndrome	EP300	0.6276	0.2141	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Dravet syndrome	SCN1A	0.6273	0.3257	Mutations of SCN1A generate phenotypes ranging from the extremely severe form of Dravet syndrome (DS) to a mild form of generalized epilepsy with febrile seizures plus (GEFS+).	-1
acute encephalopathy	SCN1A	0.6267	0.6298	To determine whether SCN1A mutations are a predisposing factor of acute encephalopathy, we sought to identify SCN1A mutations in a large case series of acute encephalopathy including various syndromes.	-1
DS	SCN1A	0.6267	0.3188	A large number of SCN1A mutations identified from the DS patients lead to the loss of function or truncation of Nav1.1 that result in a haploinsufficiency effects, indicating that the exact expression level of SCN1A should be essential to maintain normal brain function.	-1
Dravet syndrome	SCN1A	0.6262	0.3319	We describe a Roma/Gypsy family, where a missense mutation in SCN1A, p.D194N, is transmitted from a mosaic GEFS+ father to a child with Dravet syndrome.	-1
Sj  gren's syndrome	MECP2	0.6262	0.5863	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
epileptic	NF1	0.6259	0.3522	Anecdotal cases of unilateral PMG in the setting of NF1 have been described in association with other-than-opercular epileptic syndromes.	-1
Rett syndrome	MeCP2	0.6258	0.1549	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
familial epilepsies	SCN1A	0.6254	0.4253	It is suspected that mosaic mutations of SCN1A may cause other types of familial epilepsies with febrile seizures (FS), which are more common clinically.	1
infancy	SCN1A	0.6253	0.4019	Although initially thought to be within the same spectrum as severe myoclonic epilepsy of infancy, the exclusion of SCN1A mutations in non-generalized epilepsy with febrile seizures plus (GEFS+) MAE cases has confirmed the genetic distinction of MAE.	-1
JME	GABRA1	0.6252	0.2473	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
systemic lupus erythematosus	MECP2	0.625	0.3203	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
seizure	CDKL5	0.6244	0.4095	Moreover, this report reinforces the observation that the CDKL5 phenotype overlaps with Rett syndrome and that CDKL5 gene analysis is recommended in females with a seizure disorder commencing in the first weeks of life.	-1
Coffin-Siris syndrome	PHF6	0.6243	0.376	This review will summarize and characterize the female phenotype caused by de novo aberrations in PHF6 and will discuss the overlapping and distinguishing features with Coffin-Siris syndrome.	-1
with febrile seizures plus	GABRA1	0.6241	0.2402	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
febrile seizures	GABRA1	0.6241	0.4161	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
DS	SCN1A	0.6239	0.05991	BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome (DS) is a distinctive epilepsy syndrome often associated with de novo mutations in the SCN1A gene.	-1
cardio-facio-cutaneous (CFC) syndrome	BRAF	0.6238	0.4447	A girl with cardio-facio-cutaneous (CFC) syndrome due to a BRAF gene mutation (c.1454T > C, p.L485S) experienced repetitive epileptic spasms at the corrected age of 4 months.	-1
BFNE	KCNQ2	0.6237	0.6073	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
hyperventilation	TCF4	0.6228	0.09127	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
congenital malformations	KANSL1-Related	0.6227	0.2689	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
epilepsies	KCNQ2	0.6226	0.4184	The phenotypic spectrum associated with KCNQ2 mutations is probably broader than initially thought, as patients with severe epilepsies and developmental delay, or with Rolando epilepsy have been described.	1
West syndrome	3-phosphoglycerate dehydrogenase	0.6224	0.1519	3-phosphoglycerate dehydrogenase deficiency is a treatable congenital error that probably leads to West syndrome.	-1
epilepsy	SCN1A	0.6223	0.121	In this case, the combination of de novo single nucleotide polymorphisms (SNPs) and CNVs in the SCN1A and KCNA1 genes, respectively, is suspected to be the principal risk factor for both epilepsy and premature death.	1
Pitt-Hopkins syndrome	TCF4	0.6221	0.07663	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
Angelman syndrome	CDKL5	0.6221	0.298	Here, we report that de novo missense mutations in CDKL5 are associated with a severe phenotype of early-onset infantile spasms and clinical features that overlap those of other neurodevelopmental disorders, such as Rett syndrome and Angelman syndrome.	-1
febrile seizures	SCN1A	0.6221	0.3074	Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy.	-1
dysmorphisms	KANSL1-Related	0.622	0.2743	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
genetic syndrome	ATP6V0A2	0.622	0.4736	One patient with severe cortical malformations and mild skin abnormalities was diagnosed with a known genetic syndrome, due to an ATP6V0A2 defect.	-1
epilepsy	STK9	0.6219	0.6287	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	1
developmental delay	MECP2	0.6216	0.1946	Xq28 duplication syndrome including MECP2 is a neurodevelopmental disorder characterized by axial hypotonia at infancy, severe intellectual disability, developmental delay, mild characteristic facial appearance, epilepsy, regression, and recurrent infections in males.	-1
epileptic encephalopathies	CHD2	0.6215	0.4668	In this study, we aimed to explore the role of CHD2 in LGS, as CHD2 mutations have been described recently in various epileptic encephalopathies.	1
Rett syndrome-like	CDKL5	0.6214	0.1806	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
Ohtahara syndrome	KCNQ2	0.6213	0.4353	SIGNIFICANCE: De novo KCNQ2 mutations are involved in EOEE, most of which cases were diagnosed as Ohtahara syndrome.	-1
epileptic encephalopathies	SCN1A	0.6212	0.6335	To explore the phenotypic variability associated with SCN1A mutations, 188 patients with a range of epileptic encephalopathies were examined for SCN1A sequence variations by denaturing high performance liquid chromatography and sequencing.	1
DS	GABRA1	0.6211	0.217	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Lennox-Gastaut syndrome	MT-ND1	0.621	0.06926	Whole-exome sequencing identifies a variant of the mitochondrial MT-ND1 gene associated with epileptic encephalopathy: west syndrome evolving to Lennox-Gastaut syndrome.	-1
infantile spasms	IL-6	0.621	0.3979	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
an epilepsy syndrome	SCN1A	0.6208	0.132	Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions.	1
febrile seizures	GABRB3	0.6206	0.1914	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsy	NRXN1	0.6202	0.2303	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
Angelman syndrome	ATP10C	0.6197	0.2035	A novel maternally expressed gene, ATP10C, encodes a putative aminophospholipid translocase associated with Angelman syndrome.	-1
Lennox-Gastaut syndrome	SCN1A	0.6196	0.6639	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
Rett-like	CDKL5	0.6194	0.24	Early onset seizures and Rett-like features associated with mutations in CDKL5.	-1
ISs	GRIN2A	0.6193	0.3275	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
cerebral involvement	FGFR3	0.619	0.521	An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation.	-1
DS	SCN1A	0.619	0.2196	Mutations of SCN1A generate phenotypes ranging from the extremely severe form of Dravet syndrome (DS) to a mild form of generalized epilepsy with febrile seizures plus (GEFS+).	-1
Dravet syndrome	SCN1A	0.6186	0.2845	Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel.	-1
Epilepsies	SCN1A	0.6185	0.6784	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	1
seizures	SCN1A	0.6183	0.3937	Dravet syndrome is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment, thus well illustrating the concept of epileptic encephalopathy.	-1
seizures	SCN1A	0.6183	0.3937	Dravet syndrome (DS) is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment.	-1
juvenile myoclonic epilepsy	GABRB3	0.6182	0.2118	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
febrile seizures	SCN1A	0.6181	0.362	It is suspected that mosaic mutations of SCN1A may cause other types of familial epilepsies with febrile seizures (FS), which are more common clinically.	-1
epilepsy	CDKL5	0.6175	0.2991	We screened the entire coding region of CDKL5 in 151 affected girls with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome by denaturing high liquid performance chromatography and direct sequencing, and we identified three novel missense mutations located in catalytic domain (p.Ala40Val, p.Arg65Gln, p.Leu220Pro).	1
hypotonia	CDKL5	0.6175	0.5162	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
febrile seizures	SCN1A	0.6173	0.2981	Severe myoclonic epilepsy of infancy (SMEI, also known as Dravet syndrome) and genetic epilepsy with febrile seizures plus (mild febrile seizures) can both arise due to mutations of SCN1A, the gene encoding alpha 1 pore-forming subunit of the Nav1.1 voltage-gated sodium channel.	-1
Dravet syndrome	SCN1A	0.6173	0.08897	Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions.	-1
autosomal dominant diseases	KCNQ3	0.6171	0.08717	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
GPI-anchor deficiencies	PIGA	0.617	0.3329	CONCLUSIONS: Our study confirmed that PIGA mutations are one genetic cause of EOEE, suggesting that GPI-anchor deficiencies may be an underlying cause of EOEE.	-1
neuronal migration disorders	protocadherin 19	0.6167	0.3285	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
syncope	hERG	0.6165	0.3856	Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy.	-1
Dravet syndrome	SCN1A	0.6159	0.1239	Dravet syndrome (DS) is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment.	-1
infancy	KCNQ2	0.6158	0.3839	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
infancy	SCN1A	0.6158	0.4862	Recurrent de novo mutations of SCN1A in severe myoclonic epilepsy of infancy.	-1
epilepsy	MECP2	0.6156	0.2921	Xq28 duplication syndrome including MECP2 is a neurodevelopmental disorder characterized by axial hypotonia at infancy, severe intellectual disability, developmental delay, mild characteristic facial appearance, epilepsy, regression, and recurrent infections in males.	1
West syndrome	KCNQ2	0.6156	0.7066	Myoclonic epilepsy evolved into West syndrome: a patient with a novel de novo KCNQ2 mutation.	-1
Rett syndrome	CDKL5	0.6156	0.5819	A screen for CDKL5 mutations is useful in patients, mainly females, with a history of early onset intractable seizures and becomes mandatory when idiopathic infantile spasms and/or atypical Rett syndrome features are also present.	-1
syndrome	KCNQ3	0.6155	0.4032	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	-1
West syndrome	CDKL5	0.6155	0.3684	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
infantile epileptic encephalopathy	SCN1A	0.6151	0.5405	BACKGROUND: Dravet syndrome is a severe infantile epileptic encephalopathy caused in approximately 80% of cases by mutations in the voltage gated sodium channel subunit gene SCN1A.	1
SMEI/DS	ARX	0.6149	0.1807	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
infancy	SCN2A	0.6147	0.3485	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
congenital occipital plagiocephaly	neurofibromatosis type 1	0.6145	0.312	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
epilepsy	GABRB3	0.6142	0.1888	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
febrile seizures	SCN1A	0.6141	0.3948	Novel mutation of SCN1A in familial generalized epilepsy with febrile seizures plus.	-1
delay/intellectual disability	KANSL1-related	0.614	0.2476	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
IES	GABRG2	0.614	0.3175	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsy	hERG	0.6139	0.3117	Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy.	-1
epilepsy	COX8A	0.6136	0.7255	In a patient with Leigh-like syndrome presenting with leukodystrophy and severe epilepsy, we identified a homozygous splice site mutation in COX8A, which codes for the ubiquitously expressed isoform of subunit VIII, the smallest nuclear-encoded subunit of complex IV.	-1
DS	GABRA1	0.6134	0.2216	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsies	SCN1A	0.613	0.5727	The clinical spectrum of epilepsies harboring SCN1A mutations may be consisted of various phenotypes with GEFS+ on the mildest end and SMEI on the severest end of the spectrum.	1
Rett syndrome	CDKL5	0.6126	0.3145	Here, we report that de novo missense mutations in CDKL5 are associated with a severe phenotype of early-onset infantile spasms and clinical features that overlap those of other neurodevelopmental disorders, such as Rett syndrome and Angelman syndrome.	-1
epileptic	KCNQ2	0.6124	0.3174	KCNQ2 mutation screening, alongside genetic counseling, should be included in diagnostic evaluations of neonatal epileptic patients, potentially sparing the need for unnecessary investigations and treatment.	1
syndromic neurodevelopmental disorder	KCNH1	0.6124	0.6132	Our report confirms that KCNH1 mutations are associated with syndromic neurodevelopmental disorder, and also support the functional importance of the S4 domain.Journal of Human Genetics advance online publication, 28 January 2016; doi:10.1038/jhg.2016.1.	-1
febrile seizures	SCN1A	0.6122	0.3412	A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy.	-1
sleep abnormalities	SCN1A	0.6119	0.6592	In addition to seizures, patients with SCN1A mutations often experience sleep abnormalities, suggesting that SCN1A may also play a role in the neuronal pathways involved in the regulation of sleep.	-1
anti-epileptic	SCN1A	0.6119	0.3389	Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs.	1
Dandy-Walker malformation	ZIC1	0.6117	0.3333	We report on a female patient with Dandy-Walker malformation possibly caused by heterozygous loss of ZIC1 and ZIC4.	-1
spinocerebellar ataxia	CMT2	0.6116	0.4429	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
classic Dravet syndrome	SCN1A	0.6114	0.2551	A role for SCN1A genetic mutations in the development of hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome was recently suggested based on the observation that HHE syndrome and classic Dravet syndrome share many clinical features.	-1
movement disorders	CDKL5	0.6112	0.3388	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
epileptic disorders	SRPX2-related	0.611	0.2946	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
genetic	GABRD	0.6109	0.3729	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
infancy	KCNQ3	0.6108	0.2463	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
epileptic encephalopathies	CHD2	0.6108	0.6117	In this study, we aimed to explore the role of CHD2 in LGS, as CHD2 mutations have been described recently in various epileptic encephalopathies.	1
migrating	KCNQ2	0.6107	0.4567	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
Dravet syndrome	GABRA1	0.6106	0.6376	RESULTS: We detected disease-causing mutations in 2 novel genes for Dravet syndrome, with mutations in GABRA1 in 4 cases and STXBP1 in 3.	-1
Rett syndrome	CDKL5	0.6105	0.779	Furthermore, in contrast to Rett syndrome, patients with CDKL5 mutations, have seizures or infantile spasms starting in the first weeks of life.	-1
DS	SCN1A	0.6104	0.6681	All identified variants were found in DS patients with 85.7% sensitivity, thus supporting the role of profound SCN1A gene variants in etiology of DS phenotype.	-1
seizures	TCF4	0.6102	0.08156	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
partial epilepsy	SCN1A	0.6101	0.6533	Mosaic SCN1A mutations in familial partial epilepsy with antecedent febrile seizures.	1
epilepsy	SUR1	0.61	0.2081	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
epileptic encephalopathy	PEHO-like	0.61	0.4483	Atypical cases are often known as PEHO-like, and there is an overlap with 'early infantile epileptic encephalopathy'.	-1
dyskinetic	CDKL5	0.6099	0.3743	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
Myoclonic epilepsy	KCNQ2	0.6099	0.6686	Myoclonic epilepsy evolved into West syndrome: a patient with a novel de novo KCNQ2 mutation.	-1
seizures	KCNQ2	0.6097	0.4027	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
migrating	SCN2A	0.6096	0.4191	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
SSPE	SCN1A	0.6096	0.5296	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	-1
Lennox-Gastaut syndrome	SCN1A	0.6094	0.4632	SCN1A mutation screening in adult patients with Lennox-Gastaut syndrome features.	-1
developmental	KANSL1-Related	0.6092	0.3716	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
RTT	MECP2	0.6091	0.8204	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	-1
epilepsy	GABRA1	0.6088	0.2854	In conclusion, mutations in GABRA1, GABRB2 and GABRG2 do not seem to be a major genetic cause of epilepsy with typical and atypical absences in Japanese subjects.	1
intellectual disability	NRXN1	0.6087	0.2418	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
hyperphosphatasia	PIGW	0.6087	0.3672	Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome.	-1
JME	GABRA1	0.6085	0.2497	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
brachytelephalangy	PHF6	0.6085	0.2456	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
Dravet syndrome	SCN1A	0.6085	0.6584	Dravet syndrome: patients with co-morbid SCN1A gene mutations and mitochondrial electron transport chain defects.	-1
seizures	SCN2A	0.6083	0.2321	Of interest, de novo SCN2A mutations have also been reported in five patients without seizures but with ID (n  =  3) and/or autism (n  =  3).	-1
epileptic encephalopathies	SCN1A-related	0.6083	0.6272	The spectrum of SCN1A-related infantile epileptic encephalopathies.	1
WS	IL-6	0.6083	0.4997	The objective of this study was to investigate the possible role of interleukin-6 (IL-6) in the pathogenesis of infantile spasms in West syndrome (WS).	-1
epilepsy	GABRB3	0.6082	0.1675	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	1
migrating	KCNQ3	0.6081	0.2735	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
SMEI	SCN1A	0.6079	0.675	METHODS: The electroclinical data and the mutation of SCN1A gene in 13 children with SMEI were analyzed.	-1
Leigh-like syndrome	COX8A	0.6075	0.6377	In a patient with Leigh-like syndrome presenting with leukodystrophy and severe epilepsy, we identified a homozygous splice site mutation in COX8A, which codes for the ubiquitously expressed isoform of subunit VIII, the smallest nuclear-encoded subunit of complex IV.	-1
trisomy 21	PWP2H	0.6073	0.2868	PWP2H cDNA was isolated from a 14 week human trisomy 21 fetal brain cDNA library by using a modification of a direct cDNA selection method.	-1
RS	MECP2	0.6071	0.2792	MECP2 mutation screening results were available on 190 patients with a clinical diagnosis of RS (140 cases with classic RS, 50 with atypical RS).	-1
seizures	SCN1A	0.607	0.3573	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
infections	MECP2	0.6068	0.2261	Duplication of MECP2 causes a recently described X-linked mental retardation syndrome, of which the typical features are infantile hypotonia, poor speech development, recurrent infections, epilepsy, and progressive spasticity.	-1
Dravet syndrome	SCN1A	0.6068	0.37	Mutations in SCN1A explain about 75% of cases with Dravet syndrome; 90% of these mutations arise de novo.	-1
IS	CDKL5	0.6067	0.6071	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
epilepsies	SCN1A	0.6067	0.2335	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	1
severe myoclonic epilepsy of infancy	SCN1A	0.6065	0.1988	PURPOSE: Mutations in SCN1A, encoding the human Na(V)1.1 neuronal voltage-gated sodium channel, cause the syndrome of severe myoclonic epilepsy of infancy (SMEI).	-1
permanent and transient neonatal diabetes	ABCC8	0.6064	0.2523	Activating mutations in the ABCC8 gene that encodes the sulfonylurea receptor 1 (SUR1) regulatory subunit of the pancreatic islet ATP-sensitive K(+) channel (K(ATP) channel) cause both permanent and transient neonatal diabetes.	-1
West syndrome	MECP2	0.6064	0.4821	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
lissencephaly	LIS1	0.6064	0.2753	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
epilepsy	KCNQ3	0.6063	0.4686	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	1
epilepsy	MECP2	0.6061	0.2226	Duplication of MECP2 causes a recently described X-linked mental retardation syndrome, of which the typical features are infantile hypotonia, poor speech development, recurrent infections, epilepsy, and progressive spasticity.	1
SMEI/SMEB	SCN1A	0.606	0.4603	SCN1A analysis by dHPLC/sequencing revealed 40 mutations in 37 SMEI/SMEB (67%) and 3 GEFS+ (11.5%) probands.	-1
autosomal dominant diseases	KCNQ2	0.6059	0.1365	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
generalized epilepsy	SCN1A	0.6059	0.3255	Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation.	-1
Dravet syndrome	SCN2A	0.6059	0.374	This finding suggests that both nonsense mutations and missense SCN2A mutations cause Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.6058	0.5736	Identifying SCN1A mutations has become useful as a means to support an early diagnosis of Dravet syndrome, to benefit counseling, and to avoid use of antiepileptic drugs (AEDs) that may have adverse effects.	-1
epilepsy	GABRG2	0.6057	0.1658	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	1
Rett syndrome	CASK	0.6056	0.2164	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
ILS	LIS1	0.6053	0.2962	We analyzed 29 non-deletion ILS patients carrying a mutation of LIS1 and we report 15 novel mutations.	-1
RTT	MECP2	0.6052	0.4731	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
hypotonia	MECP2	0.6048	0.3319	Xq28 duplication syndrome including MECP2 is a neurodevelopmental disorder characterized by axial hypotonia at infancy, severe intellectual disability, developmental delay, mild characteristic facial appearance, epilepsy, regression, and recurrent infections in males.	-1
neurological problems	Biotinidase	0.6048	0.4069	Biotinidase deficiency is a treatable cause of severe neurological problems.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.6047	0.6327	Different SCN1A mutations are known to cause a variety of phenotypes, such as generalized epilepsy with febrile seizures plus (GEFS+), Dravet syndrome and familial hemiplegic migraine (FHM).	-1
infancy	GABRB3	0.6047	0.2217	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
delay/intellectual disability	KANSL1-Related	0.6045	0.324	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
syndrome	KCNQ2	0.6043	0.5223	In humans, mutations in the KCNQ2 or KCNQ3 potassium-channel genes are associated with an inherited epilepsy syndrome.	-1
ASD	MECP2	0.6042	0.3513	Since that time, MECP2 alterations have been recognized in idiopathic ASD patients by us and others.	-1
epilepsy	MECP2	0.604	0.1808	SIGNIFICANCE: Although these cases and a review of the literature indicate that epilepsy associated with MECP2 duplication syndrome cannot be considered a useful marker for early diagnosis, epilepsy is present in >90% of adolescent patients and shows a peculiar electroclinical pattern.	1
epileptic encephalopathy	SCN1A	0.6039	0.1179	While not a common cause of MPSI, SCN1A screening should now be considered in patients with this devastating epileptic encephalopathy.	1
seizures	KCNQ2	0.6039	0.3122	Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization.	-1
refractory epilepsy	CDKL5	0.6039	0.3331	Patients bearing missense mutations in the ATP binding site such as the p.Ala40Val mutation typically walked unaided, had normocephaly, better hand use ability, and less frequent refractory epilepsy when compared to girls with other CDKL5 mutations.	1
febrile seizures	GABRB3	0.6038	0.1934	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizures	TBC1D24	0.6038	0.5246	Of the 18 individuals with DOORS syndrome from 17 families without TBC1D24 mutations, eight did not have seizures and three did not have deafness.	-1
PTHS	TCF4	0.6037	0.349	No significant difference in clinical severity has been reported to date between PTHS patients carrying 18q21 deletions including the TCF4 gene, and those harboring TCF4 point mutations, suggesting a lack of genotype/phenotype correlation.	-1
epileptic encephalopathy	SCN1A	0.6037	0.2233	The well established role of de novo mutations of sodium channel SCN1A in Dravet Syndrome supports this view, but the etiology of many cases of epileptic encephalopathy remains unknown.	1
epilepsy	GABRA1	0.6036	0.3395	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
focal epilepsy	GRIN2A	0.6036	0.3078	GRIN2A, a green semaphore on the lumping route to idiopathic focal epilepsy in childhood.	-1
Dravet syndrome	SCN1A	0.6035	0.1054	Dravet syndrome is a well-defined epileptic syndrome that needs larger recognition, particularly because commercial testing for SCN1A gene mutations is now available in the United States.	-1
epilepsy	SLK	0.6035	0.2325	We accept the hypothesis that SLK, POCSL and atypical EPB are clinical forms of the same syndrome of epilepsy.	-1
human immunodeficiency virus (HIV)-associated muscular disorders	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.603	0.2592	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
epilepsy	GLI3	0.603	0.1293	Together, these data provide evidence that the development of chromosomal abnormalities within GLI3 is associated with the pathogenesis of HH lesions in sporadic, nonsyndromic patients with HH and intractable epilepsy.	-1
FS	SCN1A	0.6029	0.4993	SCN1A gene analysis is not commonly performed in subjects with generalised seizures without FS.	-1
epilepsy syndrome	SCN1A	0.6028	0.195	Over 40 missense mutations in the human SCN1A sodium channel gene are linked to an epilepsy syndrome termed genetic epilepsy with febrile seizures plus (GEFS+).	1
seizure-induced	SCN1A	0.6027	0.187	Recent descriptions of Rasmussen syndrome and of the hemiconvulsion-hemiplegia syndrome in isolated patients with SCN1A mutations are of uncertain meaning but might indicate that co-occurring immunomediated or seizure-induced structural changes can, in turn, become a substrate for the severe epileptic encephalopathy.	-1
lateral temporal epilepsy	KCNAB1	0.6027	0.4635	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
JME	GABRB3	0.6026	0.1146	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
schizophrenia	NRXN1	0.6025	0.2741	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
seizures	CDKL5	0.6023	0.4227	Using array comparative genomic hybridization, we identified variable-sized microdeletions involving exons 1-4 of the CDKL5 gene in three females with early-onset seizures.	-1
T-cell acute lymphoblastic leukemia	PHF6	0.6023	0.3211	Mutations in the PHF6 gene have also been associated with T-cell acute lymphoblastic leukemia and acute myeloid leukemia.	-1
infantile spasms	CDKL5	0.6022	0.6694	CDKL5 mutations are a significant cause of infantile spasms and early epileptic seizures in female patients, and of a later intractable seizure disorder, irrespective of whether they have suspected Rett syndrome.	-1
SLE	anti-NMDA-NR2A/B	0.6022	0.1168	Some of the anti-NMDA-NR2A/B antibodies associate with neuropsychiatric/cognitive/behavior/mood impairments in SLE patients, while others do not.	-1
dystonia	CDKL5	0.6021	0.7004	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
generalized	GABRA1	0.6021	0.285	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Epilepsy	SCN1A	0.6021	0.5165	Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epilepsy Syndromes.	1
encephalopathy	CDKL5	0.6019	0.3814	Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.	-1
CAE	GABRG2	0.6018	0.2269	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
LGS	SCN1A	0.6018	0.6315	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
HH lesions	GLI3	0.6015	0.2583	Together, these data provide evidence that the development of chromosomal abnormalities within GLI3 is associated with the pathogenesis of HH lesions in sporadic, nonsyndromic patients with HH and intractable epilepsy.	-1
with febrile seizures plus	GABRB3	0.6015	0.1108	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
familial amyloid syndrome	TTR	0.6014	0.4816	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
paraneoplastic	CRMP5	0.6014	0.1455	After a three-year period of progressive neurological deterioration, a high titre of anti-CV2/CRMP5 antibodies was detected, on the basis of which the clinical syndrome was diagnosed as paraneoplastic.	-1
multiple congenital anomalies	PIGA	0.6013	0.5332	A single family with a germline PIGA mutation has been reported; affected males had a phenotype characterized by multiple congenital anomalies and severe neurologic impairment resulting in infantile lethality.	-1
infantile spasms	PEHO	0.601	0.188	The PEHO syndrome should be borne in mind in the diagnostic work-up of patients with infantile spasms, so that potentially harmful treatment can be avoided, and the parents can be counseled about the inheritability of the disorder.	-1
severe myoclonic epilepsy of infancy	SCN1A	0.6006	0.3357	PURPOSE: Mutations of the a-1 subunit sodium channel gene (SCN1A) cause severe myoclonic epilepsy of infancy (SMEI).	-1
generalized epilepsy with febrile seizures plus	GABRA1	0.6006	0.419	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizure	SCN1A	0.6006	0.7466	Instead, seizure susceptibility due to SCN1A mutation may have contributed to acute encephalopathy in our patient.	-1
hypotonia	AGC1	0.6003	0.1557	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
encephalopathy	PEHO	0.6	0.6587	PEHO syndrome is a rare progressive infantile encephalopathy with onset within the first few months of life.	-1
LQTS-susceptibility	SCN5A/gastrointestinal	0.6	0.3742	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
sclerosis	SCN1A	0.5996	0.4612	We conclude that mesial temporal sclerosis is a common finding in children with SCN1A mutations.	-1
seizures	MECP2	0.5995	0.503	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
rheumatoid arthritis	MECP2	0.5994	0.259	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
multiple epilepsy syndromes	SCN1A	0.5993	0.5498	SCN1A gene mutations are linked to multiple epilepsy syndromes with patients frequently presenting with prolonged febrile seizures.	1
generalized epilepsy	SCN1A	0.5993	0.5209	Novel mutation of SCN1A in familial generalized epilepsy with febrile seizures plus.	-1
myoclonic seizures	CHD2	0.5992	0.3368	All three individuals with a CHD2 mutation had intellectual disability and fever-sensitive generalized seizures, as well as prominent myoclonic seizures starting in the second year of life or later.	-1
epilepsy	GABRB3	0.599	0.2714	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
myoclonic seizures	CDKL5	0.5988	0.3922	CONCLUSIONS: Patients with the CDKL5 mutation have an early onset, epileptic encephalopathy in infancy that evolves into myoclonic seizures in childhood with a unique EEG pattern.	-1
acute encephalopathy	SCN1A	0.5987	0.5023	To determine whether SCN1A mutations are a predisposing factor of acute encephalopathy, we sought to identify SCN1A mutations in a large case series of acute encephalopathy including various syndromes.	-1
epilepsy	SRPX2-related	0.5986	0.1635	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
hyperventilation	TCF4	0.5985	0.4285	Pitt-Hopkins syndrome is characterized by mental retardation, hyperventilation, and dysmorphic features due to TCF4 mutations.	-1
epilepsy disorders	KCC2-related	0.5985	0.5135	KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described.	1
DS	GABRB3	0.5983	0.09848	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Rett	MECP2	0.5982	0.5005	Our results also suggest the need of screening for CDKL5 mutations in patients with Rett phenotype tested negative for MECP2 mutations.	-1
epilepsy	GABRB2	0.5982	0.3503	In conclusion, mutations in GABRA1, GABRB2 and GABRG2 do not seem to be a major genetic cause of epilepsy with typical and atypical absences in Japanese subjects.	1
acute lymphoblastic leukemia	L-asparaginase	0.5982	0.4035	L-asparaginase is a critical component in the treatment of acute lymphoblastic leukemia in children.	-1
infantile spasms	CDKL5	0.5979	0.3888	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
focal epilepsies	GRIN2A	0.5979	0.4658	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.	-1
seizure	TCF4	0.5978	0.6634	Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations.	-1
myoclonic epilepsy of infancy	SCN1A	0.5976	0.6264	De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy.	-1
leukemias and lymphomas	Jun	0.5975	0.329	Between Jan 1982 to Jun 1994, 154 children with malignant non-central nervous system tumors, excluding leukemias and lymphomas, were admitted and treated at the UKMC.	-1
neurodevelopmental disorder	MECP2	0.5975	0.5323	Rett syndrome (RTT) is a rare neurodevelopmental disorder, linked to MECP2 gene mutations in the majority of cases, which results in severe disability and is associated with several comorbidities.	-1
Dravet syndrome	SCN1A-related	0.5974	0.2728	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
epilepsy	IER3IP1	0.5973	0.2777	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	1
idiopathic epilepsy syndromes	GABRD	0.5971	0.3465	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizures	CDKL5	0.597	0.483	We screened the CDKL5 gene in a cohort of 177 patients with early-onset seizures, including 30 men and 10 girls with Aicardi syndrome.	-1
infantile spasms	cyclin-dependent kinase-like 5	0.597	0.3474	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
Dravet syndrome	SCN1A	0.5967	0.2288	Mutation of SCN1A, the gene encoding the voltage gated sodium channel (VGSC) alpha subunit type 1 (Nav1.1), causes Dravet syndrome spectrum disorders.	-1
Dravet syndrome	SCN1A-negative	0.5966	0.2722	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
dysmorphic features	TCF4	0.5965	0.7833	Pitt-Hopkins syndrome is characterized by mental retardation, hyperventilation, and dysmorphic features due to TCF4 mutations.	-1
dystonia	MECP2	0.5964	0.3932	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
neurological disorder	MeCP2	0.5964	0.1005	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
encephalopathy	Netrin G1	0.5964	0.4354	Our study suggests that Netrin G1 is not involved in atypical Rett syndrome or in unexplained encephalopathy with epilepsy, but in specific forms to be delineated better in the future.	-1
epileptic encephalopathies	SCN2A	0.5962	0.7404	OBJECTIVE: We aimed to investigate the possible association between SCN2A mutations and early-onset epileptic encephalopathies (EOEEs).	1
RTT	MECP2	0.5961	0.4278	Patients without detectable MECP2 defects were screened for mutations of cyclin-dependent kinase-like 5 (CDKL5) gene, responsible for the early-onset variant of RTT.	-1
febrile seizures	NaV1.1	0.5961	0.2211	Familial febrile seizures is caused by mild loss-of-function mutations in NaV1.1 channels; mutations in these channels are implicated in febrile seizures associated with vaccination; and impaired alternative splicing of the mRNA encoding these channels may also predispose some children to febrile seizures.	-1
PME	Laforin	0.596	0.3611	Laforin, malin, and cystatin B are non-ion channel gene mutations that cause PME.	-1
mental retardation	CDKL5	0.5959	0.4376	Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.	-1
Dravet syndrome	SCN1A	0.5959	0.1931	METHODS: A hundred children with severe epilepsy were divided into Dravet syndrome and non-Dravet syndrome groups and screened for SCN1A mutations by direct sequencing.	-1
Pitt-Hopkins syndrome	TCF4	0.5959	0.3232	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
DS	SCN1A	0.5959	0.4791	Our objective was to prospectively analyze the neuropsychological features in a large cohort of DS patients and its relationships with epilepsy and SCN1A mutation.	-1
SVT	JAK2(V617F	0.5958	0.4298	Anticoagulation is the treatment of choice for all SVT and proper treatment of the MPD is recommended in patients with SVT associated with the JAK2(V617F) mutation.	-1
familial epilepsy	protocadherin 19	0.5957	0.3241	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	1
encephalopathy	CDKL5	0.5953	0.2712	We screened the entire coding region of CDKL5 in 151 affected girls with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome by denaturing high liquid performance chromatography and direct sequencing, and we identified three novel missense mutations located in catalytic domain (p.Ala40Val, p.Arg65Gln, p.Leu220Pro).	-1
epilepsy	ARX-related	0.5953	0.2097	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
cataracts	CRYAA	0.5951	0.2887	Mutations in CRYAA, a gene that shares the same locus as AIRE, may cause recessive inheritance of cataracts.	-1
West syndrome	CDKL5	0.5949	0.2708	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	-1
seizures	SCN1A	0.5949	0.2025	"Three criteria that were best evident in SCN1A mutation positive patients are as follows: ""Normal development before the onset of seizures, onset of seizure before age of one year, and psychomotor retardation after onset of seizures."	-1
epilepsy	GABRA1	0.5947	0.271	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	1
inheritability of the disorder	PEHO	0.5946	0.1691	The PEHO syndrome should be borne in mind in the diagnostic work-up of patients with infantile spasms, so that potentially harmful treatment can be avoided, and the parents can be counseled about the inheritability of the disorder.	-1
infantile spasms	CDKL5	0.5943	0.2453	Interestingly these missense mutations that result in a mislocalisation of the CDKL5 protein are associated with severe developmental delay which was apparent within the first months of life characterised by early and generalised hypotonia, and autistic features, and as well as early infantile spasms.	-1
incomplete deficit	SMA	0.5943	0.2868	In 12 patients the SMA was resected completely: nine of these patients demonstrated a complete and three an incomplete deficit.	-1
febrile seizures	SCN1A	0.5943	0.2465	Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel.	-1
febrile seizures	SCN1A	0.5943	0.5524	Mosaic SCN1A mutations in familial partial epilepsy with antecedent febrile seizures.	-1
refractory epilepsy	PUFA-enriched	0.5942	0.2694	PUFA-enriched diet therapy is likely to increase the efficacy of diet therapy and reduce complications of a high-fat diet in children with refractory epilepsy.	-1
epilepsy	MVP	0.5941	0.3023	We conclude that rs4788187, rs3815824, rs3815823 variants of the MVP gene are associated neither with predisposition for epilepsy nor with AED-resistance in the population that we have studied.	-1
epidermal nevus	FGFR3	0.5941	0.1814	The disorder is caused by a mosaic R248C mutation of the FGFR3 gene, which is characterized by a keratinocytic epidermal nevus, acanthosis nigricans, and neurological abnormalities like seizures, intellectual impairment, cortical atrophy, and underdevelopment of corpus callosum.	-1
seizure disorder	CDKL5	0.594	0.3887	Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.	1
Greig syndrome	GCK	0.594	0.212	In order to delineate the genetic aberrations relevant both to MODY2 and Greig syndrome in this patient, we performed cytogenetic analysis, real-time PCR of the GCK gene, and comparative genomic hybridization (CGH) array.	-1
infantile lethality	PIGA	0.5938	0.143	A single family with a germline PIGA mutation has been reported; affected males had a phenotype characterized by multiple congenital anomalies and severe neurologic impairment resulting in infantile lethality.	-1
Dravet syndrome	SCN2A	0.5936	0.5865	This study examines whether SCN2A mutations are associated with Dravet syndrome.	-1
syndromes	GABRG2	0.5936	0.2752	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
mental retardation	TCF4	0.5936	0.395	Disruption of the TCF4 gene in a girl with mental retardation but without the classical Pitt-Hopkins syndrome.	-1
seizures	SCN1A	0.5936	0.4578	The early clinical features of DS patients with SCN1A mutations were reviewed with attention to the seizures induced by fever and other precipitating factors before the first year of life.	-1
seizures	PEHO	0.5936	0.1173	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
epilepsy syndromes	SCN1A	0.5935	0.3814	Mutations in the gene encoding the a1 subunit of the voltage gated sodium channel (SCN1A) are associated with several epilepsy syndromes, ranging from relatively mild phenotypes found in families with genetic epilepsy with febrile seizures plus (GEFS+) to the severe infant-onset epilepsy Dravet syndrome.	1
seizures	SCN1A	0.5929	0.277	"Three criteria that were best evident in SCN1A mutation positive patients are as follows: ""Normal development before the onset of seizures, onset of seizure before age of one year, and psychomotor retardation after onset of seizures."	-1
infantile epileptic encephalopathies	PCDH19	0.5927	0.4117	METHODS: Fifteen unrelated children with MPSI were screened for mutations in genes associated with infantile epileptic encephalopathies: SCN1A, CDKL5, STXBP1, PCDH19, and POLG.	1
infantile epileptic encephalopathies	CDKL5	0.5927	0.6096	METHODS: Fifteen unrelated children with MPSI were screened for mutations in genes associated with infantile epileptic encephalopathies: SCN1A, CDKL5, STXBP1, PCDH19, and POLG.	1
epilepsy	SCN1A	0.5925	0.5428	CONCLUSIONS: Our patient supports the hypothesis that SCN1A mutation might have a role as a common substrate to both epilepsy and cardiac arrhythmia.	1
myotonia	SCN4A	0.5924	0.6182	However, there was no increase in persistent sodium current as observed for SCN4A mutations causing myotonia or periodic paralysis.	-1
epilepsy	SCN1A	0.5924	0.3686	UNASSIGNED: Dravet syndrome (DS) is a severe childhood epilepsy typically caused by de novo dominant mutations in SCN1A.	1
language delay	NRXN1	0.5921	0.2053	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
Dravet syndrome	SCN1A	0.592	0.1925	AIM: To show that atypical multifocal Dravet syndrome is a recognizable, electroclinical syndrome associated with sodium channel gene (SCN1A) mutations that readily escapes diagnosis owing to later cognitive decline and tonic seizures.	-1
infantile spasms	CDKL5	0.5919	0.1544	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
Dravet syndrome	SCN1A	0.5919	0.2424	UNASSIGNED: Dravet syndrome (DS) is a severe childhood epilepsy typically caused by de novo dominant mutations in SCN1A.	-1
febrile seizures	SCN1A	0.5918	0.387	Does a SCN1A gene mutation confer earlier age of onset of febrile seizures in GEFS+?	-1
RTT	MECP2	0.5917	0.256	BACKGROUND: Rett syndrome (RTT) is a neurodevelopmental disorder primarily seen in females, most with a mutation in MECP2.	-1
DS	SCN1A	0.5914	0.1039	Mutations of the gene encoding the a1 subunit of neuronal sodium channel, SCN1A, are reported to cause Dravet syndrome (DS).	-1
epileptic disorders	STXBP1-related	0.591	0.1992	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
epilepsy	TRMT10A	0.5909	0.06133	TRMT10A sequencing should be considered in children or adults with young-onset diabetes who have a history of intellectual disability, microcephaly and epilepsy.	-1
encephalopathy	CDKL5	0.5909	0.1064	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
epilepsy	SCN1A	0.5909	0.3783	SCN1A testing for epilepsy: application in clinical practice.	1
infantile epileptic encephalopathies	SCN1A	0.5908	0.5477	METHODS: Fifteen unrelated children with MPSI were screened for mutations in genes associated with infantile epileptic encephalopathies: SCN1A, CDKL5, STXBP1, PCDH19, and POLG.	1
alcoholism	GRIN2B	0.5908	0.3459	One aim of the present study was to test whether the association between the GRIN2B polymorphism rs1806201 and early-onset alcoholism can be replicated in a larger sample.	-1
epilepsy	GABRG2	0.5907	0.1853	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epileptic syndrome	SCN1A	0.5907	0.4612	Our observations are consistent with the genotype-phenotype correlation studies suggesting that mutations in the pore-forming loop of SCN1A can lead to a clinically more severe epileptic syndrome.	1
DS	GABRB3	0.5905	0.1009	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
generalized epilepsy	SCN1A	0.5902	0.4834	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
infancy	SCN1A	0.5902	0.2663	Genetic diagnosis of severe myoclonic epilepsy of infancy (Dravet syndrome) with SCN1A mutations in the Hong Kong Chinese patients.	-1
plus--	SCN1A	0.5902	0.245	A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy.	-1
myoclonic seizures	CDKL5	0.5899	0.2728	Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms.	-1
lissencephaly	ARX	0.5899	0.8075	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
autism spectrum disorders	NRXN1	0.5897	0.3737	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
atypical Panayiotopoulos syndrome	SCN1A	0.5896	0.4071	SCN1A mutation associated with atypical Panayiotopoulos syndrome.	-1
Rett syndrome	CDKL5	0.5896	0.2634	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
neurodegeneration	TBC1D24	0.5893	0.4031	TBC1D24 truncating mutation resulting in severe neurodegeneration.	-1
SMEI	GABRB3	0.5892	0.1342	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Susac's syndrome	Tumour necrosis factor	0.5889	0.2621	Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome.	-1
Fukuyama congenital muscular dystrophy	fukutin	0.5889	0.2031	Fukuyama congenital muscular dystrophy is due to mutations of the fukutin gene and is accompanied by polymicrogyria.	-1
West syndrome	fibrinogen	0.5887	0.1369	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
epileptic	SCN1A	0.5887	0.6094	No causative variants were identified in any of non-DS epileptic patients in our cohort, suggesting a minor, but not irrelevant role for SCN1A in patients with other types of childhood epilepsy.	1
Dravet syndrome	GABRA1	0.5882	0.3091	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
RTT	CDKL5	0.5879	0.3344	Patients without detectable MECP2 defects were screened for mutations of cyclin-dependent kinase-like 5 (CDKL5) gene, responsible for the early-onset variant of RTT.	-1
seizure-related disorders	a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1	0.5878	0.2711	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	1
infantile epileptic encephalopathies	STXBP1	0.5878	0.4125	METHODS: Fifteen unrelated children with MPSI were screened for mutations in genes associated with infantile epileptic encephalopathies: SCN1A, CDKL5, STXBP1, PCDH19, and POLG.	1
West syndrome	CDKL5	0.5877	0.1614	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
Rett syndrome	CREBBP	0.5876	0.2628	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
mental retardation	TCF4	0.5875	0.5369	Pitt-Hopkins syndrome is characterized by mental retardation, hyperventilation, and dysmorphic features due to TCF4 mutations.	-1
Rett syndrome	MECP2	0.5874	0.5454	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
cSE	SCN1A	0.5871	0.4049	METHODS: In a cohort of 10 adult patients with DS caused by SCN1A mutations, we investigated seizure frequency, history of cSE, and gait.	-1
seizures	SCN2A	0.587	0.3517	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
FS	GABRA1	0.5868	0.2261	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsies	SCN1A	0.5868	0.4	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	1
infantile spasms	cyclin-dependent kinase-like 5	0.5868	0.1624	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
DS	SCN1A	0.5867	0.634	METHODS: In a cohort of 10 adult patients with DS caused by SCN1A mutations, we investigated seizure frequency, history of cSE, and gait.	-1
epileptic seizures	SCN1A	0.5865	0.2375	These results suggest that SCN1A mutations may confer susceptibility to psychiatric disorders in addition to variable epileptic seizures.	1
seizures	CDKL5	0.5865	0.2677	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
absence seizures	GABRA1	0.5864	0.3472	Mutation screen of GABRA1, GABRB2 and GABRG2 genes in Japanese patients with absence seizures.	-1
epilepsy	GABRD	0.5861	0.2039	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	1
tonic seizures	CDKL5	0.5859	0.2188	Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms.	-1
epilepsy	Mecp2	0.5859	0.3537	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	1
LTE	KCNAB1	0.5858	0.5559	These results support KCNAB1 as a susceptibility gene for LTE, in agreement with previous studies showing that this gene may alter susceptibility to focal epilepsy.	-1
Diffuse angiopathy	DOCK6	0.5858	0.2119	Diffuse angiopathy in Adams-Oliver syndrome associated with truncating DOCK6 mutations.	-1
Rett syndrome-like	MECP2	0.5858	0.5284	Mutations in the MECP2 gene are not a major cause of Rett syndrome-like or related neurodevelopmental phenotype in male patients.	-1
JME	GABRB3	0.5856	0.116	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
infancy	GABRA1	0.5854	0.2	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Christianson syndrome	TCF4	0.5852	0.3658	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Dravet syndrome	SCN1A	0.5852	0.07996	BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome (DS) is a distinctive epilepsy syndrome often associated with de novo mutations in the SCN1A gene.	-1
focal epilepsy	KCNAB1	0.5849	0.37	These results support KCNAB1 as a susceptibility gene for LTE, in agreement with previous studies showing that this gene may alter susceptibility to focal epilepsy.	-1
congenital heart disease	SKI	0.5849	0.2812	576 kb deletion in 1p36.33-p36.32 containing SKI is associated with limb malformation, congenital heart disease and epilepsy.	-1
acanthosis nigricans, and neurological abnormalities	FGFR3	0.5848	0.1241	The disorder is caused by a mosaic R248C mutation of the FGFR3 gene, which is characterized by a keratinocytic epidermal nevus, acanthosis nigricans, and neurological abnormalities like seizures, intellectual impairment, cortical atrophy, and underdevelopment of corpus callosum.	-1
CAE	GABRG2	0.5848	0.2292	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
febrile seizures	GABRG2	0.5847	0.202	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsy	GABRG2	0.5847	0.4363	In conclusion, mutations in GABRA1, GABRB2 and GABRG2 do not seem to be a major genetic cause of epilepsy with typical and atypical absences in Japanese subjects.	1
RTT	CDKL5	0.5847	0.3463	However, it remains to be determined whether CDKL5 mutations are more prevalent in specific clinical subgroups of RTT or in other clinical presentations.	-1
SVT	JAK2(V617F	0.5846	0.2002	Anticoagulation is the treatment of choice for all SVT and proper treatment of the MPD is recommended in patients with SVT associated with the JAK2(V617F) mutation.	-1
epilepsy	GABRB2	0.5845	0.1537	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	1
epilepsy	GABRA6	0.5845	0.1537	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
myoclonus	MECP2	0.5844	0.7166	Early-onset encephalopathy and cortical myoclonus in a boy with MECP2 gene mutation.	-1
CAE	GABRD	0.5842	0.2847	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
West syndrome	ARX	0.5842	0.511	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
SMEI/DS	SCN1A	0.5842	0.4074	CONCLUSIONS: Based on the early age of presentation and the severity of the epilepsy reported for the majority of the seizure-positive cases it was concluded that SMEI/DS could be the epileptic encephalopathy associated with deletions within the 2q22.1-q33.3 region, due to haploinsuffiency of SCN1A and/or complete or partial deletion of other voltage-gated sodium channel genes caused by the aberration.	-1
infantile-onset epilepsy	SCN2A	0.5841	0.6136	While a causal role for these mutations cannot be directly established, these findings contribute to growing evidence that mutation of SCN2A is associated with a range of epilepsy phenotypes including severe infantile-onset epilepsy.	1
neurologic impairment	PIGA	0.584	0.46	A single family with a germline PIGA mutation has been reported; affected males had a phenotype characterized by multiple congenital anomalies and severe neurologic impairment resulting in infantile lethality.	-1
seizures	CDKL5	0.584	0.3085	These results suggest that pathogenic CDKL5 mutations are unlikely to be identified in the absence of severe early-onset seizures and highlight the importance of screening for large intragenic and whole gene deletions.	-1
infantile epileptic encephalopathies	POLG	0.5836	0.3358	METHODS: Fifteen unrelated children with MPSI were screened for mutations in genes associated with infantile epileptic encephalopathies: SCN1A, CDKL5, STXBP1, PCDH19, and POLG.	1
malformations	neurofibromatosis type 1	0.5836	0.2375	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
seizure	SCN1A	0.5834	0.2153	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
epileptic disorders	ARX-related	0.5834	0.3288	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
rheumathoid arthritis	neurofibromatosis type 1	0.5832	0.3319	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
seizures	KCNQ3	0.5831	0.2489	The mutational analysis of potassium (KCNQ2, KCNQ3), sodium (SCN1A, SCN2A), and chloride (CLCN2) ion channels was performed in three children with typical features of the recently described syndrome of migrating partial seizures in infancy.	-1
intellectual disability	KCNT1	0.583	0.2473	Emerging role of the KCNT1 Slack channel in intellectual disability.	-1
affected to syndromal	SCN1A	0.583	0.2986	Moreover, our results demonstrate that SCN1A haploinsufficiency can cause a significant intrafamilial clinical variability including moderately affected to syndromal patients.	-1
neonatal diabetes	SUR1	0.5828	0.4578	Our results demonstrate that SUR1 mutations constitute a new genetic aetiology for neonatal diabetes and that they act by reducing the K(ATP) channel's ATP sensitivity.	-1
Dravet syndrome	SCN1A	0.5828	0.3061	Dravet syndrome: seizure control and gait in adults with different SCN1A mutations.	-1
seizures	CDKL5	0.5827	0.08831	Early onset seizures and Rett-like features associated with mutations in CDKL5.	-1
Rett-like	CDKL5	0.5826	0.2657	Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.	-1
Hermansky-Pudlak syndrome	AP3D1	0.5826	0.307	Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.	-1
demyelination	TNFalpha	0.5825	0.252	TNFalpha seems to be an important factor in the cascade of events leading to demyelination and even axonal damage.	-1
dominantly inherited syndrome	NF2	0.5825	0.07005	Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein.	-1
paraneoplastic	anti-CV2	0.5825	0.1345	After a three-year period of progressive neurological deterioration, a high titre of anti-CV2/CRMP5 antibodies was detected, on the basis of which the clinical syndrome was diagnosed as paraneoplastic.	-1
Dravet syndrome	SCN1A	0.5823	0.4499	Genetic diagnosis of severe myoclonic epilepsy of infancy (Dravet syndrome) with SCN1A mutations in the Hong Kong Chinese patients.	-1
juvenile myoclonic epilepsy	GABRG2	0.5823	0.2232	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Myopathic Form	TK2-Related	0.5823	0.3526	"TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form
DISEASE CHARACTERISTICS: TK2-related mitochondrial DNA (mtDNA) depletion syndrome is a phenotypic continuum that ranges from severe to mild."	-1
X-linked condition	PHF6	0.5822	0.3281	B  rjeson-Forssman-Lehmann syndrome is an X-linked condition caused by PHF6 mutations.	-1
optic atrophy	PEHO-like	0.5821	0.1978	A PEHO-like syndrome has been described, in which the affected individuals have neither optic atrophy nor the typical neuroradiological findings.	-1
RTT	MECP2	0.5821	0.1777	Rett syndrome (RTT) is a rare neurodevelopmental disorder, linked to MECP2 gene mutations in the majority of cases, which results in severe disability and is associated with several comorbidities.	-1
Garcia-Hafner-Happle syndrome	Fibroblast growth factor receptor 3	0.5819	0.6049	Garcia-Hafner-Happle syndrome, also known as Fibroblast growth factor receptor 3 epidermal nevus syndrome, is a new neurocutaneous phenotype, which has been identified in 2008 by Garc  'a-Vargas et al.	-1
movement disorders	FOXG1	0.5819	0.2818	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
epileptic encephalopathy	SCN1A	0.5818	0.2754	Dravet syndrome is a severe infantile onset epileptic encephalopathy associated with mutations in the sodium channel alpha 1 subunit gene SCN1A.	1
neurodevelopmental retardation	CDKL5/STK9	0.5815	0.3501	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.	-1
seizures	cyclin-dependent kinase-like 5	0.5813	0.2795	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
hypotonia	KCNH1	0.5813	0.6663	De novo KCNH1 mutations in four patients with syndromic developmental delay, hypotonia and seizures.	-1
hemiconvulsion-hemiplegia-epilepsy	SCN1A	0.5813	0.4485	A role for SCN1A genetic mutations in the development of hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome was recently suggested based on the observation that HHE syndrome and classic Dravet syndrome share many clinical features.	-1
epilepsy	NF 1	0.5811	0.3485	These results suggest that children with NF 1 have a spectrum of MRI abnormalities, irrespective of existence of epilepsy.	-1
RTT	MECP2	0.581	0.4336	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
acute encephalopathy	SCN1A	0.581	0.412	Mutations of the SCN1A gene in acute encephalopathy.	-1
Rett syndrome	MeCP2	0.581	0.1107	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
cognitive decline and tonic seizures	SCN1A	0.5809	0.288	AIM: To show that atypical multifocal Dravet syndrome is a recognizable, electroclinical syndrome associated with sodium channel gene (SCN1A) mutations that readily escapes diagnosis owing to later cognitive decline and tonic seizures.	-1
mental retardation	STXBP1-related	0.5808	0.3769	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
epilepsy	KCC2	0.5808	0.4359	KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described.	1
dyskinetic	FOXG1	0.5806	0.3141	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
Lennox-Gastaut syndrome	GABRA1	0.5806	0.4078	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
IGE	KCNQ2	0.5804	0.1532	None of the three SNPs in the voltage-gated potassium channel gene, KCNQ2, was associated with IGE.	-1
myoclonic epilepsy	ARX	0.5802	0.6569	CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.	-1
cerebellar malformation	KPNA7	0.5802	0.4388	Autosomal recessive mutations in nuclear transport factor KPNA7 are associated with infantile spasms and cerebellar malformation.	-1
clinodactyly	PHF6	0.5801	0.1932	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
non-DS	SCN1A	0.58	0.5577	No causative variants were identified in any of non-DS epileptic patients in our cohort, suggesting a minor, but not irrelevant role for SCN1A in patients with other types of childhood epilepsy.	-1
complex I deficiency	ND3	0.58	0.5587	It is concluded that a Chinese boy with isolated complex I deficiency due to 10191T>C mutation in ND3 gene was firstly diagnosed by peripheral leukocytes mitochondrial respiratory chain enzyme assay and gene analysis.	-1
RS	MECP2	0.5799	0.1412	MECP2 mutation screening results were available on 190 patients with a clinical diagnosis of RS (140 cases with classic RS, 50 with atypical RS).	-1
verbal and figural memory	LTLE-LAT	0.5799	0.2283	In LTLE-LAT, however, mood was significantly related to verbal and figural memory performance.	-1
X-linked myopathy with postural muscle atrophy	FHL1	0.5798	0.291	FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718).	-1
periodic limb movements	Met1Val	0.5798	0.3883	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
hypotonia	MECP2	0.5796	0.2836	Consistently, the boys displayed clinical features in common with other patients carrying MECP2 duplications, including intellectual disability, autism, lack of speech, slight hypotonia and unsteadiness of movement.	-1
SMEI	SCN1A	0.5794	0.3045	Recently, mutations in SCN1A and GABRG2 have been described in SMEI patients.	-1
edema, visual deficit	PEHO	0.5793	0.113	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
generalized	GABRB3	0.579	0.1358	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
developmental delay	CDKL5	0.579	0.02274	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	-1
bitemporal narrowing	PHF6	0.5789	0.3558	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
CADASIL	VIII	0.5788	0.137	The other patient with cranial neuropathies of VII, VIII and XII nerves associated with intellectual impairment was diagnosed with CADASIL only with the help of control MRI examination.	-1
complex I deficiency	ND3	0.5788	0.3608	[Mitochondrial respiratory chain complex I deficiency due to 10191T>C mutation in ND3 gene].	-1
MERRF	tripeptidyl peptidase 1	0.5787	0.09253	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
epilepsy syndromes	SCN2A	0.5787	0.2335	SCN2A is another important subtype associated with epilepsy syndromes, across a range of severe and less severe epilepsies.	1
cortical dysplasia	TRPC3	0.5785	0.1759	TRPC3 mediates hyperexcitability and epileptiform activity in immature cortex and experimental cortical dysplasia.	-1
epilepsy	STXBP1-related	0.5784	0.1043	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
DOORS syndrome	TBC1D24	0.5783	0.3428	INTERPRETATION: Our findings suggest that mutations in TBC1D24 seem to be an important cause of DOORS syndrome and can cause diverse phenotypes.	-1
Angelman syndrome	EP300	0.5783	0.1704	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
LQTS	LQT1 and 6 LQT2	0.5782	0.3234	METHODS: Seventeen individuals with confirmed LQTS related to potassium channel mutations (11 LQT1 and 6 LQT2) were prospectively studied with 21-channel electroencephalography (EEG) LQTS -related symptoms, comorbidity, medication, and QTc (12-lead ECG) were recorded.	-1
epileptic syndromes	SCN1A	0.5782	0.4493	THE AIM: To diagnose and describe epileptic syndromes caused by SCN1A mutations.	1
febrile seizures	SCN1A	0.5782	0.1199	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	-1
epilepsy	Netrin G1	0.5781	0.2857	Our study suggests that Netrin G1 is not involved in atypical Rett syndrome or in unexplained encephalopathy with epilepsy, but in specific forms to be delineated better in the future.	-1
epileptic seizure	CDKL5	0.5781	0.4673	Group 1 comprised 73 patients (57 female, 16 male) referred to Cardiff for CDKL5 analysis, of whom 49 (42 female, 7 male) had epileptic seizure onset in the first six months of life.	1
epileptic disorders	CDKL5/STK9	0.578	0.3883	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
developmental delay	NRXN1	0.578	0.3038	Compound heterozygous deletion of NRXN1 causing severe developmental delay with early onset epilepsy in two sisters.	-1
febrile seizures	NaV1.1	0.5779	0.427	Familial febrile seizures is caused by mild loss-of-function mutations in NaV1.1 channels; mutations in these channels are implicated in febrile seizures associated with vaccination; and impaired alternative splicing of the mRNA encoding these channels may also predispose some children to febrile seizures.	-1
epilepsy	SCN2A-associated	0.5778	0.4539	We report a novel SCN2A-associated epilepsy phenotype in monozygotic twins with tonic seizures soon after birth and a suppression-burst electroencephalography (EEG) pattern.	1
epilepsy	MECP2	0.5777	0.531	SIGNIFICANCE: Although these cases and a review of the literature indicate that epilepsy associated with MECP2 duplication syndrome cannot be considered a useful marker for early diagnosis, epilepsy is present in >90% of adolescent patients and shows a peculiar electroclinical pattern.	1
Rett syndrome	FOXG1	0.5777	0.1498	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
RTT	CDKL5	0.5776	0.2111	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
Dravet syndrome	SCN1A	0.5776	0.504	Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome.	-1
neurodevelopmental disorder	MECP2	0.5773	0.5444	BACKGROUND: Rett syndrome (RTT) is a neurodevelopmental disorder primarily seen in females, most with a mutation in MECP2.	-1
PLMs	Met1Val	0.5771	0.3312	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
epileptic encephalopathies	SCN1A	0.5769	0.4892	De novo SCN1A mutations in Dravet syndrome and related epileptic encephalopathies are largely of paternal origin.	1
CSS	SMARCB1	0.5768	0.5187	As SMARCB1 encodes a subunit of the BAF complex functioning as a chromatin remodeling factor, mutations in 15 other subunit genes may cause CSS and thus were analyzed in 23 CSS patients.	-1
Rett syndrome	Netrin G1	0.5768	0.4607	Our study suggests that Netrin G1 is not involved in atypical Rett syndrome or in unexplained encephalopathy with epilepsy, but in specific forms to be delineated better in the future.	-1
infancy	GABRA1	0.5766	0.09505	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
HH	GLI3	0.5766	0.3683	We have investigated the possibility that HH pathogenesis in sporadic cases is due to a somatic (tumor-only) mutation in GLI3.	-1
infancy	CDKL5	0.5765	0.4731	CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.	-1
Dravet syndrome	SCN1A	0.5764	0.5685	Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome.	-1
RS	MECP2	0.5764	0.1397	MECP2 mutation screening results were available on 190 patients with a clinical diagnosis of RS (140 cases with classic RS, 50 with atypical RS).	-1
neonatal diabetes	SUR1	0.5763	0.3016	We therefore hypothesized that activating mutations in the ABCC8 gene, which encodes SUR1, might cause neonatal diabetes.	-1
myoclonic epilepsy	SCN1A	0.5763	0.7089	A novel SCN1A mutation in a cytoplasmic loop in intractable juvenile myoclonic epilepsy without febrile seizures.	-1
generalized epilepsy with febrile seizures plus	GABRB3	0.5763	0.2284	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
complex epileptic syndrome	NF1	0.5762	0.3087	We report on a 10-year-old (molecularly proven) NF1 girl manifesting a complex epileptic syndrome resembling the Foix-Chavany-Marie spectrum (also known as opercular syndrome) associated with bilateral (opercular and paracentral lobular) polymicrogyria (PMG).	-1
Encephalitis	Anti-NMDA-NR2A/B	0.5762	0.3542	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
Rett syndrome	MECP2	0.5762	0.7765	Spectrum of MECP2 gene mutations in a cohort of Indian patients with Rett syndrome: report of two novel mutations.	-1
epilepsy	CDKL5	0.576	0.4791	CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.	1
epilepsy	Cyclin-Dependent Kinase-like 5	0.5758	0.2551	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	1
seizure	CDKL5	0.5757	0.4834	Most individuals with CDKL5 mutations had severe developmental delay from birth, seizure onset before the age of 3 months and similar non-dysmorphic features.	-1
infantile spasms	LIS1	0.5757	0.2825	With few exceptions, children with LIS1 mutations have isolated lissencephaly, with severe developmental delay and infantile spasms.	-1
status epilepticus	NF2	0.5756	0.3276	Here, we describe an adult case of NF2 in which the onset of symptoms was characterised by status epilepticus.	-1
Susac's syndrome	TNF	0.5756	0.2682	Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome.	-1
Aicardi syndrome	CDKL5	0.5753	0.3054	We screened the CDKL5 gene in a cohort of 177 patients with early-onset seizures, including 30 men and 10 girls with Aicardi syndrome.	-1
West syndrome	fibrinogen	0.5753	0.1843	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
DS	SCN1A	0.5752	0.5478	Finally, this study shows that in DS, crouch gait can be observed in up to 50% of adults with SCN1A mutation.	-1
long QT syndrome	KCNQ1	0.5752	0.4876	Brain and heart K+ channelopathies are a separate group due to KCNQ1 mutation (severe type 2 long QT syndrome).	-1
temporal lobe anomalies	FGFR3	0.5752	0.3977	Hypochondroplasia with FGFR3 mutation associated with bilateral medial temporal lobe anomalies and focal epilepsy was previously reported in several patients.	-1
Epilepsy	CDKL5	0.5751	0.3128	OBJECTIVE: Epilepsy with mutation of the CDKL5 gene causes early seizures and is a variant of Rett syndrome (MIM (312750), which is reported typically as infantile spasms.	1
systemic lupus erythematosus	MeCP2	0.5751	0.1181	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
HD	IT15	0.575	0.1988	Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline, behavioural abnormalities and progressive disease course proves negative to the genetic testing for HD causative mutations, that is, IT15 gene trinucleotide-repeat expansion.	-1
myoclonic epilepsy	SCN1A	0.5749	0.4533	Recurrent de novo mutations of SCN1A in severe myoclonic epilepsy of infancy.	-1
Rett syndrome	SLC9A6	0.5748	0.1536	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
stroke	alien	0.5747	0.4144	We report the case of a woman with a transient alien hand syndrome caused by a stroke limited to the middle and posterior portions of the body of the corpus callosum.	-1
migraine	SCN1A	0.5745	0.2989	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
ID	SCN2A	0.5745	0.2166	Of interest, de novo SCN2A mutations have also been reported in five patients without seizures but with ID (n  =  3) and/or autism (n  =  3).	-1
RTT	BDNF	0.5743	0.2234	We investigated, according to the MECP2 genotype, the role of the BDNF functional polymorphism (Val66Met) on the severity of RTT.	-1
epilepsy	SCN3A	0.5742	0.1297	Infantile epilepsy associated with mosaic 2q24 duplication including SCN2A and SCN3A.	1
ID	interleukin-6	0.5741	0.2751	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
Dravet syndrome	STXBP1	0.5741	0.4029	RESULTS: We detected disease-causing mutations in 2 novel genes for Dravet syndrome, with mutations in GABRA1 in 4 cases and STXBP1 in 3.	-1
seizures	TCF4	0.574	0.1451	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
developmental delay	cyclin-dependent kinase-like 5	0.5738	0.02411	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	-1
seizures	Vit	0.5737	0.2122	The applied therapy (calcium, magnesium, Vit D3 preparations) allowed for seizures disapearance.	-1
epilepsy	SCN1A	0.5737	0.3372	No causative variants were identified in any of non-DS epileptic patients in our cohort, suggesting a minor, but not irrelevant role for SCN1A in patients with other types of childhood epilepsy.	1
dystonia	ARX	0.5737	0.5986	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
diabetes mellitus	TRMT10A	0.5736	0.4864	CASE REPORT: We report two siblings from the fourth family reported to have diabetes mellitus as a result of a TRMT10A mutation.	-1
tuberous sclerosis	neurofibromatosis type 1	0.5735	0.4508	We included in the study 23 children diagnosed with different types of neurocutaneous syndrome (10 patients with tuberous sclerosis, 5 with Sturge-Weber syndrome and 8 with neurofibromatosis type 1 and epilepsy'.	-1
Dravet syndrome	SCN1A	0.5732	0.05221	A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.	-1
rheumatoid arthritis	MeCP2	0.5731	0.09946	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
Kallmann syndrome	PROK2/PROKR2	0.573	0.4372	OBJECTIVES: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.	-1
neurocognitive impairment	SCN1A	0.5729	0.541	Establishment of isogenic iPSCs from an individual with SCN1A mutation mosaicism as a model for investigating neurocognitive impairment in Dravet syndrome.	-1
kyphoscoliosis	HSD17B10	0.5729	0.1208	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Rasmussen encephalitis	CXCR3-CXCL10	0.5728	0.386	CONCLUSIONS: Our results suggest that the CXCR3-CXCL10 axis has a role in recruiting pathogenic T lymphocytes into the brains of patients with Rasmussen encephalitis.	-1
Dravet syndrome	SCN1A	0.5727	0.5048	SCN1A mutational analysis in Korean patients with Dravet syndrome.	-1
SMEI	GABRA1	0.5727	0.1538	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
HH	HFE	0.5726	0.3935	The HFE gene H63D mutation underlies Hereditary Haemochromatosis (HH), which needs treatment to prevent organ damages by iron overload.	-1
cognitive decline and frequent tonic seizures	SCN1A	0.5723	0.434	INTERPRETATION: Atypical, multifocal Dravet syndrome with SCN1A mutations may not be recognized because of later cognitive decline and frequent tonic seizures.	-1
neurodevelopmental disorders	methyl-CpG-binding protein 2	0.5723	0.3052	These articles explain how mutation of the gene (MECP2) for methyl-CpG-binding protein 2 causes the particular disorders of Rett syndrome, and also induces other neurodevelopmental disorders, clarifying the situation for future studies.	-1
IES	GABRD	0.5723	0.362	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsy	GABRG2	0.5723	0.1722	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
SUDEP	SCN1A	0.5722	0.5189	A case of SUDEP in a patient with Dravet syndrome with SCN1A mutation.	-1
dysmorphic features	GRIN2A	0.5722	0.276	Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.	-1
DS	SCN1A	0.5721	0.4554	Analysis of SCN1A revealed a heterozygous de novo frameshift mutation (c.4205_4208delGAAA) in the patient with DS, and a recurrent missense mutation (c.3521C>G) in that suffering from MAE.	-1
malignant non-central nervous system tumors	Jun	0.5721	0.3103	Between Jan 1982 to Jun 1994, 154 children with malignant non-central nervous system tumors, excluding leukemias and lymphomas, were admitted and treated at the UKMC.	-1
myoclonic epilepsy	GABRG2	0.5719	0.3693	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
seizure	LQT2-epilepsy	0.5717	0.1203	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
seizure-free	SCN2A	0.5716	0.282	All 15 of the patients with novel SCN2A missense mutations had intractable seizures; 3 of them were seizure-free at the last medical examination.	-1
infantile spasms	CDKL5	0.5715	0.3095	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
absence seizures	GABRA1	0.5715	0.3128	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
spasm	ARHGDIA	0.5714	0.5109	ARHGDIA expression was assayed in the brain samples of five infantile spasm patients.	-1
dyspraxia	STXBP1-related	0.5714	0.2641	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
Rett syndrome	CDKL5	0.5714	0.2201	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
FS	SCN1A	0.5713	0.5775	We found that patients with FS and FS+ with SCN1A mutations had earlier median onset of febrile seizures compared to the population median.	-1
X-linked mental retardation	MECP2	0.5713	0.5137	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
seizure	MECP2	0.5712	0.4704	Cases without a detectable MECP2 mutation had a higher risk of seizure onset up to 4 years of age (P < .001) but a lower risk after 4 years (P = .08).	-1
RTT	CDKL5	0.5712	0.2907	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
microcephalic	NRXN1	0.5712	0.3285	It thus appears that the phenotype of the mildly affected mother can be explained by the NRXN1 deletion, whereas the more severe and complex microcephalic phenotype of the two affected brothers is due to the simultaneous deletion in NRXN1 and the homozygous missense mutation affecting RBBP8.	-1
seizure-related disorders	SCN1A	0.5711	0.2074	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	1
generalized epilepsy with	SCN1A	0.5711	0.4651	A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy.	-1
Dravet syndrome	GABRA1	0.571	0.3119	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
infantile spasms	CDKL5	0.5709	0.4083	Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.	-1
DOORS syndrome	TBC1D24	0.5708	0.3722	BACKGROUND: Recent studies have shown that recessive mutations in the TBC1D24 gene cause a variety of epilepsy syndromes, DOORS syndrome and nonsyndromic deafness.	-1
focal epilepsy	GRIN2B	0.5706	0.3724	INTERPRETATION: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe developmental delay as well as of ID with childhood onset focal epilepsy.	-1
seizure	SCN1A	0.5706	0.5347	Here we report that knock-in of a GEFS+ SCN1A mutation (K1270T) into the Drosophila sodium channel gene, para, causes a semidominant temperature-induced seizure phenotype.	-1
seizures	CDKL5	0.5705	0.5663	The common features of all female patients with CDKL5 gene mutations included refractory seizures starting before 4 months of age, severe psychomotor retardation, Rett-like features such as hand stereotypies, deceleration of head growth after birth and poor prognosis.	-1
leukodystrophy	COX8A	0.5702	0.4844	In a patient with Leigh-like syndrome presenting with leukodystrophy and severe epilepsy, we identified a homozygous splice site mutation in COX8A, which codes for the ubiquitously expressed isoform of subunit VIII, the smallest nuclear-encoded subunit of complex IV.	-1
epilepsy	LIS1	0.5702	0.09727	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	1
seizures	MRI	0.5701	0.2253	METHODS: Twelve patients who met the following criteria were included: (1) normal preoperative MRI; (2) intracranial EEG findings consistent with mesial temporal onset of seizures; (3) selective amygdalohippocampectomy (AHE) was performed, and the patient was followed for more than 2years postoperatively; and (4) hippocampal histopathology was nonspecific.	-1
encephalopathies	CDKL5	0.57	0.4558	Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.	-1
seizures	SCN1A	0.57	0.3498	Prolonged seizures were associated with acute encephalopathy in three SCN1A mutation-positive patients.	-1
EAE	RANTES	0.5699	0.1357	RANTES may be a biomarker for susceptibility to CARs in EAE patients.	-1
epileptic encephalopathy	CDKL5-related	0.5696	0.3727	We performed video-electroencephalography (video-EEG) monitoring early in the course of CDKL5-related epileptic encephalopathy in order to examine the early electroclinical characteristics of the condition.	1
FS	GABRA1	0.5696	0.2284	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsy	CDKL5/STK9	0.5696	0.2732	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
West syndrome	CDKL5	0.5695	0.3295	CDKL5 disruption by t(X;18) in a girl with West syndrome.	-1
Dravet syndrome	SCN1A	0.5694	0.3943	In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome.	-1
FCD	SCN1A-related	0.5692	0.2383	MCDs, particularly FCD, can influence the electroclinical phenotype in patients with SCN1A-related epilepsy.	-1
neonatal diabetes	ABCC8	0.5691	0.3862	The functional consequence of this ABCC8 mutation mirrors that of KCNJ11 mutations causing neonatal diabetes and provides new insights into the interaction of Kir6.2 and SUR1.	-1
epilepsy	SCN1A	0.5689	0.1617	METHODS: A hundred children with severe epilepsy were divided into Dravet syndrome and non-Dravet syndrome groups and screened for SCN1A mutations by direct sequencing.	1
infantile spasm	ARX	0.5687	0.5888	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
polymicrogyria	fukutin	0.5687	0.2366	Fukuyama congenital muscular dystrophy is due to mutations of the fukutin gene and is accompanied by polymicrogyria.	-1
Dravet syndrome	SCN1A	0.5687	0.4516	In this study, we report a 12-year-old girl with Dravet syndrome carrying an SCN1A mutation, c.2785Cdel (L929del fsX934).	-1
encephalopathy	MECP2	0.5685	0.4029	Early-onset encephalopathy and cortical myoclonus in a boy with MECP2 gene mutation.	-1
infancy	GABRG2	0.5684	0.2335	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsy	SCN1A	0.5683	0.08289	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	1
MPD	JAK2(V617F	0.5683	0.3304	Anticoagulation is the treatment of choice for all SVT and proper treatment of the MPD is recommended in patients with SVT associated with the JAK2(V617F) mutation.	-1
epileptic encephalopathy	CDKL5	0.5682	0.5508	CONCLUSIONS: Patients with the CDKL5 mutation have an early onset, epileptic encephalopathy in infancy that evolves into myoclonic seizures in childhood with a unique EEG pattern.	1
epilepsy	MECP2	0.5682	0.2774	MECP2 mutations most frequently associated with epilepsy were T158M (74%) and R106W (78%), and less frequently R255X and R306C (both 49%).	1
LKS	MEG	0.5682	0.181	The clinical course of this patient suggests that MEG findings are useful not only in making precise diagnosis of LKS but also in assessing and predicting the effects of treatment.	-1
familial hemiplegic migraine	SCN1A	0.5682	0.4325	Mutations in the central nervous system-specific voltage-gated sodium channel alpha1 subunit gene (SCN1A) lead not only to seizure syndromes but also to familial hemiplegic migraine.	-1
epilepsy	CHD2	0.5681	0.6475	Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency.	1
autosomal recessive primary microcephaly	WDR62	0.568	0.2314	Both approaches prioritized the same homozygous novel frameshift mutation (p.Arg608Serfs*26) in WDR62, a gene known to cause autosomal recessive primary microcephaly.	-1
lissencephaly	DCX	0.5679	0.1988	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
gating impairments	SCN1A	0.5679	0.2652	In summary, SCN1A mutations associated with ICEGTC result in a wide spectrum of biophysical defects, including mild-to-moderate gating impairments, shifted voltage dependence and reduced use dependence.	-1
myoclonic epilepsy	CARS2	0.5679	0.4523	A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy.	-1
seizures	KCNQ3	0.5677	0.3805	Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization.	-1
Dravet syndrome	Nav1.1	0.5676	0.1907	Here, we examined the possible effects on cognition of Nav1.1 down-regulation, a sodium channel principally involved in Dravet syndrome but also implicated in other cognitive disorders, including autism and Alzheimer's disease.	-1
Panayiotopoulos syndrome	SCN1A	0.5676	0.2799	A novel inherited mutation in the voltage sensor region of SCN1A is associated with Panayiotopoulos syndrome in siblings and generalized epilepsy with febrile seizures plus.	-1
periventricular nodular heterotopia	Phf10	0.5676	0.2558	Silencing of the contiguous Phf10 or Dll1 genes only produced slightly delayed migration but not periventricular nodular heterotopia.	-1
infancy	CDKL5	0.5675	0.5469	CDKL5 mutations as a cause of severe epilepsy in infancy: clinical and electroencephalographic long-term course in 4 patients.	-1
febrile seizures	GABRG2	0.5675	0.2041	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
febrile seizures	SCN1A	0.5674	0.6188	A novel SCN1A mutation in a cytoplasmic loop in intractable juvenile myoclonic epilepsy without febrile seizures.	-1
Dravet syndrome	GABRB3	0.5674	0.1309	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsy	SCN2A	0.5674	0.3646	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	1
RTT	cyclin-dependent kinase-like 5	0.5673	0.4158	Patients without detectable MECP2 defects were screened for mutations of cyclin-dependent kinase-like 5 (CDKL5) gene, responsible for the early-onset variant of RTT.	-1
epilepsy	MECP2	0.5672	0.2195	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	1
MBD	SETDB1	0.5672	0.2427	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
epilepsy	MBD5	0.5672	0.04153	Notably a deletion in a psychotic VCFS patient at 2q23.1 hit the gene MBD5 which when deleted gives rise to intellectual disability, epilepsy, and autistic features.	-1
permanent neonatal diabetes	IER3IP1	0.5669	0.1345	The triad of microcephaly, generalized seizures, and permanent neonatal diabetes should prompt screening for mutations in IER3IP1.	-1
Rett syndrome	MECP2	0.5669	0.1907	These articles explain how mutation of the gene (MECP2) for methyl-CpG-binding protein 2 causes the particular disorders of Rett syndrome, and also induces other neurodevelopmental disorders, clarifying the situation for future studies.	-1
SJS/TEN	CYP2C9	0.5669	0.1912	The CYP2C9*3 variant was significantly associated with phenytoin-related SJS/TEN, but not DRESS.	-1
seizure	CDKL5	0.5667	0.5574	A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.	-1
impaired social interactions	MECP2	0.5667	0.2215	Mutations of MECP2 cause Rett syndrome (RTT), a neurodevelopmental disorder leading to loss of motor and cognitive functions, impaired social interactions, and seizure at young ages.	-1
DEND syndrome	SUR1	0.5666	0.3623	Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome.	-1
myoclonic encephalopathy	PIGA	0.5664	0.5968	METHODS: Whole-exome sequencing was performed as a comprehensive genetic analysis for a cohort of 172 patients with EOEEs including early myoclonic encephalopathy, Ohtahara syndrome, and West syndrome, and PIGA mutations were carefully investigated.	-1
epileptic syndromes	SCN 1 A	0.5664	0.254	Mutations in the SCN 1 A gene, encoding the neuronal voltage-gated sodium channel alpha1 subunit, cause SMEI, GEFS+, and related epileptic syndromes.	1
neonatal epilepsies	KCNQ2	0.5663	0.1968	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
JME	GABRG2	0.5663	0.1216	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Rett syndrome	cyclin-dependent kinase-like 5	0.5662	0.2305	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.	-1
EPMR	CLN8	0.5661	0.289	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
intellectual disability syndrome	KANSL1-Related	0.566	0.3054	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
genetic epilepsies	MECP2	0.5659	0.3996	Eating-induced epileptic spasms in a boy with MECP2 duplication syndrome: insights into pathogenesis of genetic epilepsies.	-1
HHE syndrome	SCN1A	0.5658	0.5483	A role for SCN1A genetic mutations in the development of hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome was recently suggested based on the observation that HHE syndrome and classic Dravet syndrome share many clinical features.	1
microcephaly	IER3IP1	0.5658	0.1479	The triad of microcephaly, generalized seizures, and permanent neonatal diabetes should prompt screening for mutations in IER3IP1.	-1
Cognitive Deficits	Nav1.1	0.5657	0.3067	Cognitive Deficits Associated with Nav1.1 Alterations: Involvement of Neuronal Firing Dynamics and Oscillations.	-1
Ohtahara syndrome	SCN2A	0.5657	0.512	In conclusion, we have identified a de novo SCN2A mutation as the etiology for Ohtahara syndrome in monozygotic twins associated with a unique dentate-olivary dysplasia in the deceased twin.	-1
SMEI/DS	SCN1A	0.5656	0.1926	However, 25-30% patients with SMEI/DS are negative for SCN1A mutation screening, suggesting that other molecular mechanisms may account for these disorders.	-1
epilepsies	SCN2A	0.5652	0.2429	SCN2A is another important subtype associated with epilepsy syndromes, across a range of severe and less severe epilepsies.	1
with febrile seizures plus	GABRG2	0.5651	0.1176	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
absence seizures	GABRG2	0.5651	0.2221	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
epileptic encephalopathy	SCN8A	0.565	0.5131	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
Dravet syndrome	SCN1A	0.5649	0.4448	Nowadays, more than 60 heterozygous pattern SCN1A mutations, which many are de novo mutations, have been detected in Dravet syndrome.	-1
genetic epilepsy	SCN1A	0.5649	0.2972	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
osteoporosis	SATB2	0.5648	0.179	Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects.	-1
dentate-olivary dysplasia	SCN2A	0.5648	0.3766	In conclusion, we have identified a de novo SCN2A mutation as the etiology for Ohtahara syndrome in monozygotic twins associated with a unique dentate-olivary dysplasia in the deceased twin.	-1
seizure	SCN1A	0.5647	0.3611	Mutations in the central nervous system-specific voltage-gated sodium channel alpha1 subunit gene (SCN1A) lead not only to seizure syndromes but also to familial hemiplegic migraine.	-1
febrile seizures	SCN1A	0.5647	0.09143	Over 40 missense mutations in the human SCN1A sodium channel gene are linked to an epilepsy syndrome termed genetic epilepsy with febrile seizures plus (GEFS+).	-1
psychiatric disorders	SCN1A	0.5647	0.2108	These results suggest that SCN1A mutations may confer susceptibility to psychiatric disorders in addition to variable epileptic seizures.	-1
SMEI	SCN1A	0.5646	0.4192	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
rarer epilepsies	SCN1A	0.5645	0.1452	Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs.	1
myoclonic epilepsy	SCN1A	0.5645	0.1516	A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.	-1
seizures	SCN1A-related	0.5645	0.2381	Of all reported seizures following vaccinations in the first year of life, 2.5% (95%CI:1.3 to 3.6%) were due to SCN1A-related Dravet syndrome, as were 5.9% of reported seizures (95%CI:3.1 to 8.7%) after 2(nd) or 3(rd) DTP-IPV-Hib vaccination.	-1
developmental delay	SUR1	0.5644	0.1928	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
Rett syndrome	methyl-CpG-binding protein 2	0.5644	0.3483	These articles explain how mutation of the gene (MECP2) for methyl-CpG-binding protein 2 causes the particular disorders of Rett syndrome, and also induces other neurodevelopmental disorders, clarifying the situation for future studies.	-1
RTT	CDKL5	0.5644	0.1756	Therefore, the CDKL5 disorder should be considered separate to RTT, rather than another variant.	-1
Dravet syndrome	SCN1A	0.5644	0.09657	Dravet syndrome is a severe infantile onset epileptic encephalopathy associated with mutations in the sodium channel alpha 1 subunit gene SCN1A.	-1
Batten disease	tripeptidyl peptidase 1	0.5643	0.2055	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
epilepsy	AAAS	0.5643	0.4459	A case report of 4A (Allgrove) syndrome with epilepsy and a new AAAS gene mutation.	-1
west syndrome	MT-ND1	0.5642	0.1933	Whole-exome sequencing identifies a variant of the mitochondrial MT-ND1 gene associated with epileptic encephalopathy: west syndrome evolving to Lennox-Gastaut syndrome.	-1
dentadorubropallidoluysian atrophy	tripeptidyl peptidase 1	0.5641	0.1496	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
intellectual disability	MBD5	0.5639	0.5047	Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder.	-1
DS	SCN1A	0.5639	0.2038	This study examines whether microdeletions and duplications of the gene encoding a1 subunit of the sodium channel (SCN1A) are underlying causes in Dravet syndrome (DS) with SCN1A missense mutation.	-1
platybasia	neurofibromatosis type 1	0.5638	0.2263	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
epileptic encephalopathy	CDKL5	0.5637	0.09658	Mutations of the cyclin-dependent kinase-like 5 gene (CDKL5), reported almost exclusively in female subjects, have been recently found to be the cause of a phenotype overlapping Rett syndrome with early-onset epileptic encephalopathy.	1
FS	GABRB3	0.5635	0.1033	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
SMEI	GABRA1	0.5634	0.1127	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
intractable epilepsy	GRIN2A	0.5633	0.2843	Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation.	1
memory deficit	Nav1.1	0.5632	0.1667	We show that reduction of Nav1.1 expression in the medial septum and diagonal band of Broca leads to a dysregulation of hippocampal oscillations in association with a spatial memory deficit.	-1
epilepsy	LIS1	0.5631	0.7722	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
sclerosis	SCN1A	0.5629	0.6276	After observing mesial temporal sclerosis in a child with SCN1A gene mutation, we retrospectively reviewed magnetic resonance imaging (MRI) findings in all patients with SCN1A gene mutation identified between 2005 and 2010.	-1
SMEI	SCN1A	0.5629	0.1093	PURPOSE: Mutations in SCN1A, encoding the human Na(V)1.1 neuronal voltage-gated sodium channel, cause the syndrome of severe myoclonic epilepsy of infancy (SMEI).	-1
complex I deficiency	ND3	0.5628	0.4044	This study reviews a case of mitochondrial respiratory chain complex I deficiency due to the 10191T>C mutation in mitochondrial ND3 gene.	-1
epilepsy	SCN1A	0.5627	0.3691	Two novel mutations in SCN1A gene in Iranian patients with epilepsy.	1
SMEI	GABRG2	0.5627	0.2772	In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome.	-1
neuropathy	prion protein	0.5626	0.08756	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
epilepsy	GABRG2	0.5626	0.2848	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
LTE	KCNAB1	0.5624	0.3732	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
common epilepsy syndrome	SCN1A	0.5623	0.3869	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	1
HH	GLI3	0.5621	0.3444	Resequencing of GLI3 did not identify causative germline mutations but did identify LOH within the GLI3 gene in the HH tissue samples of three patients.	-1
Rett syndrome	MECP2	0.5621	0.4395	BACKGROUND: Rett syndrome (RTT) is a neurodevelopmental disorder primarily seen in females, most with a mutation in MECP2.	-1
SMEI	SCN1A	0.562	0.2118	PURPOSE: Mutations of the a-1 subunit sodium channel gene (SCN1A) cause severe myoclonic epilepsy of infancy (SMEI).	-1
DS	GABRG2	0.5619	0.1046	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epilepsy	SCN1A	0.5619	0.3812	Among the epilepsy genes, the SCN1A gene perhaps known to have the largest number of disease-associated alleles.	1
RTT-like	MECP2	0.5618	0.2978	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
epilepsy	KCNQ2-5	0.5617	0.1262	Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2-7.5) ion channels defines RTG/EZG as the first neuronal potassium (K(+)) channel opener for the treatment of epilepsy.	1
neurodevelopmental disorders	NRXN1	0.5615	0.2511	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
RTT	cyclin-dependent kinase-like 5	0.5614	0.2126	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
DS	Na(V)1.1	0.5613	0.2984	About 50% of SCN1A DS mutations truncate Na(V)1.1, possibly causing complete loss of its function.	-1
Rett syndrome	MECP2	0.5613	0.2703	Multiplex ligation-dependent Probe Amplification (MLPA) has become available for the detection of a large deletion on the MECP2 gene allowing genetic confirmation of previously unconfirmed cases of clinical Rett syndrome.	-1
behavioral abnormalities	SCN1A	0.5612	0.1625	Our findings suggest that SCN1A mutation leads to changes in the dopamine system that may contribute to the behavioral abnormalities in DS.Journal of Human Genetics advance online publication, 4 February 2016; doi:10.1038/jhg.2016.5.	-1
malformations	ATP6V0A2	0.5612	0.1555	One patient with severe cortical malformations and mild skin abnormalities was diagnosed with a known genetic syndrome, due to an ATP6V0A2 defect.	-1
RTT	MECP2-mutated	0.5611	0.4806	RESULTS: Prevalence of DRE was 16% (i.e. 16 DRE out of 100 MECP2-mutated RTT epileptic patients).	-1
Ohtahara syndrome	SCN8A	0.5611	0.2162	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
epileptic encephalopathies	cyclin-dependent kinase-like 5	0.561	0.3903	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	1
Dravet syndrome	SCN1A	0.5609	0.145	Mutations of the gene encoding the a1 subunit of neuronal sodium channel, SCN1A, are reported to cause Dravet syndrome (DS).	-1
CS	PTEN	0.5608	0.4175	Genetic testing of PTEN gene confirmed a diagnosis of Cowden syndrome (CS).	-1
myoclonic epilepsy	SCN1A	0.5608	0.2832	Although initially thought to be within the same spectrum as severe myoclonic epilepsy of infancy, the exclusion of SCN1A mutations in non-generalized epilepsy with febrile seizures plus (GEFS+) MAE cases has confirmed the genetic distinction of MAE.	-1
Rett syndrome-like	CDKL5	0.5608	0.4206	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome-like phenotype.	-1
haploinsufficiency syndrome	KANSL1	0.5607	0.3627	The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan   McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion).	-1
seizure	KCNQ1/deafness	0.5605	0.1274	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
convulsive	SCN1A	0.5604	0.135	Because of early and correct diagnosis by genotyping of SCN1A mutations, the avoidance of sodium channel blockers, and aggressive treatment of prolonged convulsive status, there is hope that Dravet's syndrome may not be as severe as observed in all past reports.	-1
Dravet syndrome	SCN1A	0.5604	0.2812	Dravet syndrome, for example, is mainly due to de novo mutations in SCN1A, the gene encoding the voltage-gated neuronal sodium channel alpha 1 subunit, which explains why most patients are isolated cases.	-1
epilepsy	CDKL5	0.5603	0.1335	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	1
autism	SETDB1	0.5599	0.2365	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
Dravet syndrome	SCN1A	0.5599	0.1263	The advent of social networking via the Internet and the commercial availability of tests for SCN1A mutations permitted the rapid development and growth of parent-led associations that provide advocacy and support, as well as promote education and research regarding Dravet syndrome (DS) in the last 10 years.	-1
encephalopathy	CDKL5-related	0.5597	0.4037	With more than 80 reported patients, the phenotype of CDKL5-related encephalopathy is well-defined.	-1
SJS/TEN	HLA-B	0.5596	0.05108	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
isolated SMEI	SCN1A	0.5595	0.4265	These findings demonstrate that de novo mutations in SCN1A are a major cause of isolated SMEI.	-1
developmentally delayed	CDKL5	0.5595	0.3122	Thus, a CDKL5 investigation should be performed in developmentally delayed patients with early-onset seizures, including drug-resistant subjects with severe EEG changes, as well as in patients with milder, drug-responsive forms of epilepsy.	-1
ASD	SETDB1	0.5594	0.1812	We identified 17 ASD specific, nonsynonymous variants, four of which were concordant in multiplex families: MBD5 Tyr1269Cys, MBD6 Arg883Trp, MECP2 Thr240Ser, and SETDB1 Pro1067del.	-1
non-Dravet syndrome	SCN1A	0.5593	0.3206	SCN1A missense and truncated mutations were detected significantly more often in the Dravet syndrome group than in the non-Dravet syndrome group.	-1
focal epilepsy	FGFR3	0.5593	0.2168	Hypochondroplasia with FGFR3 mutation associated with bilateral medial temporal lobe anomalies and focal epilepsy was previously reported in several patients.	-1
Rett syndrome	CDKL5	0.5592	0.1673	OBJECTIVE: Epilepsy with mutation of the CDKL5 gene causes early seizures and is a variant of Rett syndrome (MIM (312750), which is reported typically as infantile spasms.	-1
infancy	GABRB3	0.5591	0.04718	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
myoclonic epilepsy	GABRA1	0.559	0.5024	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
AEDs	IL-22	0.5588	0.2135	IL-22 may be a research target for specific therapeutic effects of mood stabilizers and AEDs.	-1
epileptic encephalopathy	cyclin-dependent kinase-like 5	0.5585	0.1019	Mutations of the cyclin-dependent kinase-like 5 gene (CDKL5), reported almost exclusively in female subjects, have been recently found to be the cause of a phenotype overlapping Rett syndrome with early-onset epileptic encephalopathy.	1
epileptic seizures	SCN4A	0.5585	0.1872	The combination of activation and fast inactivation defects can explain the occurrence of epileptic seizures, but the effects were much more subtle than the inactivation defects described previously for mutations in SCN4A causing disease in skeletal muscle.	1
myoclonic epilepsy	GABRA1	0.5584	0.1599	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
mental retardation	CDKL5	0.5584	0.54	CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.	-1
dental anomalies	PHF6	0.5584	0.2079	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
WRS	MEDS	0.5583	0.3593	While liver and renal symptoms are more severe in WRS, neurodevelopmental characteristics are more pronounced in MEDS patients, in which microcephaly and uncontrolled epilepsy are uniformly present.	-1
epilepsy	SCN1A	0.5581	0.4706	In addition, encephalopathy is not a pure consequence of epilepsy but SCN1A mutation seems to play an additional, direct role.	1
autism	MBD5	0.5579	0.2213	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
epilepsy	CBPS	0.5577	0.138	Congenital bilateral perisylvian syndrome(CBPS) is a recently described disease identify characterized by pseudobulbar palsy, epilepsy, mental retardation, and migration disorders in the bilateral perisylvian area.	1
LQTS	SCN5A	0.5577	0.1162	The patient and the patient's asymptomatic family members underwent genetic screening of the three genes most frequently associated with LQTS: KCNQ1, KCNH2, and SCN5A.	-1
ISs	GRIN2A	0.5576	0.1735	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
syndrome	PEHO-like	0.5574	0.2676	We describe two sisters with a PEHO-like syndrome.	-1
Lissencephaly	ARX	0.5574	0.3031	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
myoclonic epilepsy	CARS2	0.5574	0.2672	CONCLUSION: CARS2 is a novel disease gene associated with a severe progressive myoclonic epilepsy most resembling MERRF syndrome.	-1
ID	GRIN2B	0.5574	0.2012	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
acute myeloid leukemia	PHF6	0.5572	0.2123	Mutations in the PHF6 gene have also been associated with T-cell acute lymphoblastic leukemia and acute myeloid leukemia.	-1
childhood absence epilepsy	GABRA1	0.5571	0.3135	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epileptic encephalopathies	CDKL5	0.5571	0.07678	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	1
febrile seizures	SCN1A	0.557	0.3576	We found that patients with FS and FS+ with SCN1A mutations had earlier median onset of febrile seizures compared to the population median.	-1
diabetes	GLUT4	0.557	0.3125	Moreover, GLUT4, a member of the solute carrier family 2, may play a role in the patient's type 2 diabetes.	-1
kyphoscoliosis	HMGCS2	0.557	0.114	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
ventriculomegaly (p<0.0001) and seizures	CC2D2A-related	0.557	0.3635	Subjects with CC2D2A-related JS were more likely to have ventriculomegaly (p<0.0001) and seizures (p=0.024) than subjects without CC2D2A mutations.	-1
injuries	alien	0.5569	0.1312	The neuroanatomic substrate of the alien hand syndrome has remained controversial due to the noncircumscribed nature of cerebral injuries present in most cases.	-1
seizures	SCN1A	0.5568	0.2311	In a retrospective evaluation of 70 patients with Dravet syndrome and SCN1A mutations, seizures following vaccinations were reported in 27%.	-1
DOORS syndrome	TBC1D24	0.5565	0.1071	Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for TBC1D24 mutations.	-1
seizures	SCN1A-gene	0.5564	0.2181	Dravet syndrome, often caused by mutations of SCN1A-gene, presents with prolonged clonic, generalized or unilateral seizures often occurring with fever during the first year of life, followed by usually severe epilepsy.	-1
epilepsy	SCN1A	0.5563	0.1639	METHODS: The 34 unrelated Iranian families with epilepsy were selected and screened for SCN1A mutations by MLPA, ARMS, and PCR-RFLP confirmed by direct sequencing.	1
seizure	CDKL5	0.5561	0.2534	Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms.	-1
West syndrome	LAMA2	0.556	0.5302	METHODS/RESULTS: We present a patient with primary partial laminin a2 deficiency due to a homozygous novel LAMA2 missense mutation who developed West syndrome in his first year of life.	-1
atherosclerosis	CYP2C9	0.556	0.1481	PURPOSE: We investigated the influence of the CYP2C9 polymorphism on the lipid profile, insulin resistance, and subclinical atherosclerosis in young epileptic patients.	-1
diabetes, skeletal defects	MEDS	0.5559	0.2731	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
malformation	LIS1	0.5559	0.5729	LIS1 mutations cause a more severe malformation posteriorly.	-1
SVT	JAK2(V617F	0.5557	0.5603	CONCLUSIONS: In these patients with SVT, the detection of JAK2(V617F) mutation is diagnostic for masked MPD as could be documented by bone marrow histopathology.	-1
ISs	KCNQ2	0.5557	0.2814	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
epilepsy	KCNA1	0.5557	0.1399	In this case, the combination of de novo single nucleotide polymorphisms (SNPs) and CNVs in the SCN1A and KCNA1 genes, respectively, is suspected to be the principal risk factor for both epilepsy and premature death.	-1
ISs	CDKL5	0.5557	0.1791	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
seizures	CDKL5	0.5556	0.4249	Combining our three new cases with the previously published cases, 13/14 patients with CDKL5 mutations presented with seizures before the age of 3 months.	-1
seizures	SCN1A	0.5556	0.3221	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
autism	CDKL5	0.5554	0.07283	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
LQTS	KCNH2	0.5552	0.333	The patient and the patient's asymptomatic family members underwent genetic screening of the three genes most frequently associated with LQTS: KCNQ1, KCNH2, and SCN5A.	-1
Dravet syndrome	SCN1A	0.5551	0.6982	Prevalence of SCN1A mutations in children with suspected Dravet syndrome and intractable childhood epilepsy.	-1
IS	NF1	0.5551	0.3742	WS and NF1: Onset of IS took place between 4 and 9 months of age.	-1
SMEI	SCN1A	0.555	0.186	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
myokymia	EA1	0.5549	0.3257	EA1 is a dominant human neurological disorder characterized by variable phenotypes of brief episodes of ataxia, myokymia, neuromyotonia, and associated epilepsy.	-1
encephalopathy	beta 2 microglobulin	0.5549	0.269	[Usefulness of the beta 2 microglobulin for the diagnosis of acute encephalopathy].	-1
epileptic encephalopathy	KCNQ2	0.5548	0.3101	PURPOSE: KCNQ2 mutations have been found in patients with benign familial neonatal seizures, myokymia, or early onset epileptic encephalopathy (EOEE).	1
DS	SCN1A	0.5548	0.2652	CONCLUSION: This study extended the spectrum of SCN1A mutations in Taiwanese DS patients and confirms the high sensitivity of SCN1A for the DS phenotype.	-1
ILS	PAFAH1B1	0.5548	0.2591	Using a spectrum of ILS patients, we confirm the importance of specific WD40 repeats and a putative microtubule-binding domain for PAFAH1B1 function.	-1
epileptic encephalopathy	SCN1A	0.5547	0.5407	CONCLUSIONS: Based on the early age of presentation and the severity of the epilepsy reported for the majority of the seizure-positive cases it was concluded that SMEI/DS could be the epileptic encephalopathy associated with deletions within the 2q22.1-q33.3 region, due to haploinsuffiency of SCN1A and/or complete or partial deletion of other voltage-gated sodium channel genes caused by the aberration.	1
infantile spasms	CDKL5/STK9	0.5546	0.1449	New gene defects associated with the CDKL5/STK9 and ARX genes are associated with infantile spasms, but these illustrate that, when studying neurodevelopmental outcomes, it is necessary to deal also with heterogeneity at the level of genotype-phenotype correlation.	-1
ICCA	KST1	0.5544	0.2704	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
microcephaly	MBD5	0.5544	0.419	Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.	-1
hypertension	ARPKD	0.5544	0.06282	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
epilepsy	MECP2	0.5543	0.2508	Late onset epileptic spasms is frequent in MECP2 gene duplication: electroclinical features and long-term follow-up of 8 epilepsy patients.	1
gyral pattern	IER3IP1	0.5543	0.3593	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
DOORS syndrome	TBC1D24	0.5542	0.6661	Of the 18 individuals with DOORS syndrome from 17 families without TBC1D24 mutations, eight did not have seizures and three did not have deafness.	-1
B  rjeson-Forssman-Lehmann syndrome	PHF6	0.5542	0.4128	Mutations in PHF6 are associated with B  rjeson-Forssman-Lehmann syndrome.	-1
seizure	L-asparaginase	0.5541	0.4075	We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.	-1
epileptic encephalopathy	KCC2	0.5541	0.09313	Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.	1
DS	GABRG2	0.5539	0.1071	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
psychomotor retardation	KCNQ2	0.5539	0.2636	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
Noonan syndrome	neurofibromatosis type 1	0.5538	0.2167	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
Dravet syndrome	SCN1A	0.5537	0.2469	In addition to Dravet syndrome, several other types of acute and subacute encephalopathic syndromes having clinical and electroencephalographic resemblance to SSPE are associated with SCN1A gene mutations.	-1
epileptic encephalopathy	cyclin-dependent kinase-like 5	0.5536	0.5137	Herein, we report the first two Turkish cases of cyclin-dependent kinase-like 5 gene-related epileptic encephalopathy with novel mutations in exon 8, which is located in the catalytic domain of the gene.	1
seizures	SCN2A	0.5535	0.3525	All 15 of the patients with novel SCN2A missense mutations had intractable seizures; 3 of them were seizure-free at the last medical examination.	-1
PME	malin	0.5535	0.1495	Laforin, malin, and cystatin B are non-ion channel gene mutations that cause PME.	-1
ILS	LIS1	0.5534	0.6381	Our results suggest that the lissencephaly severity in ILS caused by LIS1 mutations may be predicted by the type and location of the mutation.	-1
FS	SCN1A	0.5533	0.2023	It is suspected that mosaic mutations of SCN1A may cause other types of familial epilepsies with febrile seizures (FS), which are more common clinically.	-1
hyperglycemia	SUR1	0.5532	0.4367	Although ketoacidosis is frequent at presentation, SUR1 mutations associate mainly with transient hyperglycemia, with possible recurrence later in life.	-1
syndrome	PEHO-like	0.5531	0.238	A PEHO-like syndrome has been described, in which the affected individuals have neither optic atrophy nor the typical neuroradiological findings.	-1
CSS	SMARCB1	0.5531	0.6187	As SMARCB1 encodes a subunit of the BAF complex functioning as a chromatin remodeling factor, mutations in 15 other subunit genes may cause CSS and thus were analyzed in 23 CSS patients.	-1
myoclonic epilepsy	GABRB3	0.5529	0.4004	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
seizure disorder	CDKL5	0.5529	0.3627	In conclusion, this report reinforces the observation that the CDKL5 phenotype overlaps with RTT and that CDKL5 analysis is recommended in patients with a seizure disorder commencing during the first months of life.	1
temporal lobe epilepsy	MVP	0.5528	0.3346	Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis.	-1
autosomal dominant diseases	KCNQ1	0.5528	0.1942	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
SMEI	GABRG2	0.5526	0.1422	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Angelman syndrome	CASK	0.5525	0.1244	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
IHH	PROK2/PROKR2	0.5525	0.3702	OBJECTIVES: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.	-1
childhood absence epilepsy	GABRB3	0.5524	0.2486	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
recessive ataxia syndrome	CMT2	0.5523	0.3406	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation	PHF6	0.5523	0.2347	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
convulsion	SCN1A	0.5522	0.5039	The patient with SCN1A mutation had the earliest onset of febrile convulsion and hemiparesis.	-1
epilepsy	GABRD	0.5521	0.1852	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epileptic encephalopathy	TBC1D24	0.552	0.4115	In fact, early-onset epileptic encephalopathy with sensorineural hearing loss is an additional phenotype observed in patients with recessive TBC1D24 mutations.	1
epileptic syndrome	SCN1A	0.552	0.1607	Dravet syndrome is a well-defined epileptic syndrome that needs larger recognition, particularly because commercial testing for SCN1A gene mutations is now available in the United States.	1
PRES	L-asparaginase	0.5519	0.5305	The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment.	-1
myoclonic epilepsy	CoQ2	0.5519	0.2109	CONCLUSIONS: In contrast to previously reported patients with CoQ2 the proband presented with early myoclonic epilepsy, hypertrophic cardiomyopathy and only in a later stage developed a nephrotic syndrome.	-1
epilepsy	SCN1A	0.5519	0.5086	Our objective was to prospectively analyze the neuropsychological features in a large cohort of DS patients and its relationships with epilepsy and SCN1A mutation.	1
myopathy	FKBP14	0.5518	0.2826	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
convulsions	SCN1A	0.5518	0.1964	To assess the contribution that SCN1A makes to other types of epilepsy, 226 patients with either juvenile myoclonic epilepsy, absence epilepsy, or febrile convulsions were screened by conformation-sensitive gel electrophoresis and manual sequencing of variants; the sample included 165 probands from multiplex families and 61 sporadic cases.	-1
Rubinstein-Taybi syndrome	TCF4	0.5517	0.2459	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
benign familial neonatal epilepsy	KCNQ2	0.5516	0.5402	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
myopathy	HMGCS2	0.5516	0.1084	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
congenital hyperinsulinism	somatostatin	0.5515	0.1984	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
Generalized epilepsy	SCN1A	0.5515	0.3238	Generalized epilepsy with febrile seizures plus: novel SCN1A mutation.	-1
benign familial neonatal-infantile seizures	SCN2A	0.5515	0.4256	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
PME	cystatin B	0.5513	0.4288	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
SMEI	SCN1A	0.5513	0.147	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
metabolic abnormalities	CYP2C9	0.5512	0.4268	Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.	-1
Macrocephalic mental retardation	MECP2	0.5511	0.1764	Macrocephalic mental retardation associated with a novel C-terminal MECP2 frameshift deletion.	-1
ASD	MBD6	0.5511	0.2677	We identified 17 ASD specific, nonsynonymous variants, four of which were concordant in multiplex families: MBD5 Tyr1269Cys, MBD6 Arg883Trp, MECP2 Thr240Ser, and SETDB1 Pro1067del.	-1
ASD	MECP2	0.5511	0.2677	We identified 17 ASD specific, nonsynonymous variants, four of which were concordant in multiplex families: MBD5 Tyr1269Cys, MBD6 Arg883Trp, MECP2 Thr240Ser, and SETDB1 Pro1067del.	-1
encephalopathy	KCNQ2	0.5511	0.5021	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
SMEI	Na(V)1.1	0.551	0.08054	PURPOSE: Mutations in SCN1A, encoding the human Na(V)1.1 neuronal voltage-gated sodium channel, cause the syndrome of severe myoclonic epilepsy of infancy (SMEI).	-1
sCJD	PrP	0.5509	0.06582	Western blot analysis of the protease-resistant PrP (PrP(Sc) ) in the right temporal pole revealed the type 2 pattern, which is characterized by a single unglycosylated band, in contrast to the doublet described for the typical MV2 subtype of sCJD.	-1
Dravet syndrome	SCN1A	0.5507	0.2993	We identified two non-synonymous pSNMs in SCN1A, a causal gene for Dravet syndrome, from these two unrelated adults and found that the mutant alleles were transmitted to their children, highlighting the clinical importance of detecting pSNMs in genetic counseling.	-1
epilepsy	SCN1A	0.5507	0.4176	Variability in severity favors the concept that SCN1A loss of function causes a spectrum of epilepsy phenotypes in which seizures, often prolonged and precipitated by fever, are the prominent feature and schematic subdivisions would be inappropriate, at least in the early stages.	1
ISs	STXBP1	0.5506	0.2821	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
dysplastic	TRPC3	0.5505	0.2182	TRPC3 staining was highly enriched in immature, but very weak in mature, control cortex, whereas it was strong in dysplastic cortex at all ages.	-1
immune dysregulation	FOXP3	0.5505	0.6013	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
SMEI	SCN1A	0.5505	0.05283	BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome (DS) is a distinctive epilepsy syndrome often associated with de novo mutations in the SCN1A gene.	-1
MBD	MBD6	0.5501	0.2738	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
ISs	STXBP1	0.5501	0.1527	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
atrophy	cerebrospinal fluid (CSF) IGF-1 and insulin-like growth-binding protein (IGFBP)-3	0.5501	0.1909	METHODS: We used a sensitive enzyme immunoassay kit for measuring cerebrospinal fluid (CSF) IGF-1 and insulin-like growth-binding protein (IGFBP)-3 in four groups of patients: PEHO syndrome patients (eight), PEHO-like patients (seven), age-matched controls (31), and patients with other types of cerebellar atrophy (11).	-1
neuromyotonia	EA1	0.55	0.3199	EA1 is a dominant human neurological disorder characterized by variable phenotypes of brief episodes of ataxia, myokymia, neuromyotonia, and associated epilepsy.	-1
seizures	SCN1A	0.55	0.3295	None of the remaining patients with seizures precipitated by fever carried SCN1A mutations.	-1
AMRF	beta-GC	0.55	0.1994	In contrast to the reduced binding properties of the nonsense mutations, the only missense mutation (H363N) found in AMRF leads to increased binding of beta-GC to LIMP-2, indicating that this highly conserved histidine modifies the affinity of LIMP-2 to its ligand.	-1
Dravet syndrome	GABRB3	0.55	0.1324	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
cardiovascular risk factor	CB1	0.5499	0.179	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
epileptic seizure	MECP2	0.5499	0.536	PURPOSE: To investigate the association between genotype (methyl-CpG-binding protein 2 (MECP2 gene mutation)) and epileptic seizure phenotype in Rett syndrome.	1
neurological disorders	Mammalian target of rapamycin	0.5498	0.1617	Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.	-1
pseudobulbar palsy	CBPS	0.5498	0.214	Congenital bilateral perisylvian syndrome(CBPS) is a recently described disease identify characterized by pseudobulbar palsy, epilepsy, mental retardation, and migration disorders in the bilateral perisylvian area.	-1
epileptic encephalopathies	GRIN2A	0.5497	0.4231	The identification of GRIN2A as a major gene for these epileptic encephalopathies provides crucial insights into the underlying pathophysiology.	1
tonic-clonic seizures	NARP	0.5497	0.1113	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
encephalopathy	SCN1A	0.5495	0.1827	In addition, encephalopathy is not a pure consequence of epilepsy but SCN1A mutation seems to play an additional, direct role.	-1
Atypical RS	CDKL5	0.5495	0.1899	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	-1
ISs	KCNQ2	0.5494	0.1516	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
PTHS	TCF4	0.5494	0.6286	During a search for TCF4 mutations in 78 patients with a suspected PTHS, haploinsufficiency of TCF4 was identified in 18.	-1
Sj  gren's syndrome	MeCP2	0.5494	0.178	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
infancy	SCN1A	0.5494	0.3216	Mutations in the voltage-gated sodium channel gene SCN1A are a major cause of severe myoclonic epilepsy of infancy (Dravet syndrome) and generalized epilepsy with febrile seizures plus.	-1
Dravet syndrome	SCN1A, 2A, 1B, 2B	0.5493	0.3349	This study involved search for mutations in candidate genes for Dravet syndrome, namely SCN1A, 2A, 1B, 2B, GABRA1, B2, and G2.	-1
AMRF	LIMP-2	0.5492	0.1996	In contrast to the reduced binding properties of the nonsense mutations, the only missense mutation (H363N) found in AMRF leads to increased binding of beta-GC to LIMP-2, indicating that this highly conserved histidine modifies the affinity of LIMP-2 to its ligand.	-1
epileptic encephalopathy	CDKL5	0.5492	0.5138	Mutations of the CDKL5 gene cause early epileptic encephalopathy.	1
SMEI	GABRB3	0.5492	0.06684	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Dravet's syndrome	SCN1A	0.5492	0.1364	Because of early and correct diagnosis by genotyping of SCN1A mutations, the avoidance of sodium channel blockers, and aggressive treatment of prolonged convulsive status, there is hope that Dravet's syndrome may not be as severe as observed in all past reports.	-1
genetic epilepsy	SCN1A	0.5491	0.1622	Over 40 missense mutations in the human SCN1A sodium channel gene are linked to an epilepsy syndrome termed genetic epilepsy with febrile seizures plus (GEFS+).	-1
tonic-clonic seizures	SCN1A	0.549	0.4733	We describe a 15-year-old girl with SCN1A mutation (Dravet syndrome), refractory generalized tonic-clonic seizures, and prior posterior instrumentation and fusion for scoliosis, who presented with progressive lower extremity weakness.	-1
Dravet syndrome	SCN1A	0.549	0.4781	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	-1
RTT	MECP2	0.5489	0.4714	We have studied MECP2 mutations in 142 Japanese sporadic patients diagnosed clinically as having RTT.	-1
deep vein thrombosis	JAK2(V617F	0.5489	0.1801	The presence of JAK2(V617F) mutation should be considered per se a prothrombotic state for cerebral, coronary and peripheral microvascular disturbances and for SVT but not for deep vein thrombosis.	-1
JME	GABRG2	0.5489	0.123	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
syndrome type 2	hERG	0.5488	0.5117	Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy.	-1
myoclonic epilepsy	SCN1A	0.5488	0.0728	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
Dravet syndrome	SCN1A	0.5487	0.6358	We screened for mutations of SCN1A, SCN2A and GABRG2 (the gene encoding gamma2 subunit of the GABA(A) receptor) in 59 patients with Dravet syndrome and found 29 SCN1A mutations and three missense SCN2A mutations.	-1
encephalopathy	RMND1	0.5485	0.3674	An RMND1 Mutation causes encephalopathy associated with multiple oxidative phosphorylation complex deficiencies and a mitochondrial translation defect.	-1
sleep abnormalities	SCN1A	0.5485	0.8966	To fill this gap, we tested the hypothesis that SCN1A contributes to the regulation of sleep architecture, and by extension, that SCN1A dysfunction contributes to the sleep abnormalities observed in patients with SCN1A mutations.	-1
PTHS	TCF4	0.5485	0.2136	Altogether 78 PTHS patients with abnormalities of the TCF4 gene have been published since 2007 when the etiology of PTHS was revealed.	-1
generalized epilepsy	SCN1A	0.5485	0.2307	A novel inherited mutation in the voltage sensor region of SCN1A is associated with Panayiotopoulos syndrome in siblings and generalized epilepsy with febrile seizures plus.	-1
Dravet syndrome	SCN1A-confirmed	0.5484	0.4721	Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN.	-1
neonatal seizures	KCNQ2	0.5484	0.3503	In one of those three children, a de novo missense mutation was detected in the voltage gated potassium channel gene KCNQ2, indicating a genetic relationship between drug refractory neonatal seizures of unknown etiology with tonic clonic or myoclonic sequences and the well-known syndrome of benign familial neonatal convulsions (BFNC).	-1
incomplete deficit	SMA	0.5484	0.135	In 16 patients the SMA resection was incomplete: 13 of these patients displayed an incomplete deficit, whereas three had no deficit.	-1
Coffin-Siris syndrome	PHF6	0.5482	0.2867	Females with de novo aberrations in PHF6: clinical overlap of Borjeson-Forssman-Lehmann with Coffin-Siris syndrome.	-1
epilepsies	SCN2A	0.5482	0.3067	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	1
genetic epilepsies	SCN1A	0.5482	0.1562	Some of the rare genetic epilepsies enable treatment stratification through testing for the causal mutation, for example SCN1A mutations in patients with Dravet's syndrome.	-1
epilepsy	ARX	0.5481	0.1293	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	1
seizures	SCN1A-related	0.548	0.3099	Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort study.	-1
kyphoscoliosis	FKBP14	0.5479	0.3538	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
encephalopathy	KCNQ2	0.5478	0.2088	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
convulsion	SCN1A	0.5478	0.4313	METHODS: We retrospectively studied patients with Dravet syndrome who had mutations in SCN1A, whose first seizure was a convulsion, and for whom validated source data were available.	-1
JS	CC2D2A-related	0.5478	0.3307	Patients with CC2D2A-related JS should be monitored for hydrocephalus and seizures.	-1
encephalopathy	CDKL5-associated	0.5477	0.5298	So far, there are still little data on the key clinical diagnosis criteria and on the natural history of CDKL5-associated encephalopathy.	-1
non-Dravet syndrome	SCN1A	0.5476	0.3994	METHODS: A hundred children with severe epilepsy were divided into Dravet syndrome and non-Dravet syndrome groups and screened for SCN1A mutations by direct sequencing.	-1
seizure	cyclin-dependent kinase-like 5	0.5476	0.1255	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
congenital hyperinsulinism	SUR1	0.5475	0.2787	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
alcoholism	GRIN2B	0.5475	0.3109	Moreover, we hypothesized that another genetic variation within GRIN2B (rs1806191) may have an effect in the etiology of alcoholism or withdrawal-related traits.	-1
cardiac arrhythmia	KCNQ3	0.5474	0.1132	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
periventricular nodular heterotopia	Dll1	0.5474	0.388	Silencing of the contiguous Phf10 or Dll1 genes only produced slightly delayed migration but not periventricular nodular heterotopia.	-1
permanent and transient neonatal diabetes	sulfonylurea receptor 1	0.5471	0.2926	Activating mutations in the ABCC8 gene that encodes the sulfonylurea receptor 1 (SUR1) regulatory subunit of the pancreatic islet ATP-sensitive K(+) channel (K(ATP) channel) cause both permanent and transient neonatal diabetes.	-1
epilepsy	CDKL5	0.5471	0.1652	These findings confirm CDKL5 as another locus associated with epilepsy and X-linked mental retardation.	1
idiopathic epilepsy syndromes	KCNQ2	0.5471	0.3837	KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes.	-1
epileptic encephalopathies	SCN1A	0.547	0.6332	METHODS: Through our database of epileptic encephalopathies, we identified 120 patients with SCN1A mutations, of which 4 had magnetic resonance imaging (MRI) evidence of MCDs.	1
epilepsy	SCN1A	0.5469	0.3282	We studied the correlation between DQ/IQ/SQPS and age, epilepsy characteristics, and whether patients presented SCN1A mutation.	1
childhood epilepsies	SCN1A	0.5468	0.1406	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	1
autism	cyclin-dependent kinase-like 5	0.5468	0.06655	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
epileptic encephalopathy	SCN1A	0.5466	0.2287	We studied concordant and discordant monozygous twins with de novo mutations in the sodium channel a1 subunit gene (SCN1A) causing Dravet's syndrome, a severe epileptic encephalopathy.	1
seizures	CDKL5	0.5466	0.2555	Recent studies have shown that aberrations of CDKL5 in female patients cause early-onset intractable seizures, severe developmental delay or regression, and Rett syndrome-like features.	-1
endocrine diseases	multiple endocrine neoplasia 2A	0.5465	0.3313	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
hearing loss	TBC1D24	0.5463	0.6778	Early-onset epileptic encephalopathy with hearing loss in two siblings with TBC1D24 recessive mutations.	-1
myoclonic epilepsy	TBC1D24	0.5462	0.7153	BACKGROUND: Recessive TBC1D24 gene mutations have been described in two families: an Italian family afflicted with familial infantile myoclonic epilepsy, and an Arab family with focal epilepsy and intellectual disability syndrome.	-1
epilepsy	TRMT10A	0.5462	0.2919	tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy.	-1
PTHS	TCF4	0.5462	0.2982	The current report describes a new TCF4 deletion associated with a PTHS phenotype.	-1
encephalopathy	CMT2	0.5462	0.307	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
seizure	SCN1A	0.5462	0.5163	METHODS: In a cohort of 10 adult patients with DS caused by SCN1A mutations, we investigated seizure frequency, history of cSE, and gait.	-1
absence seizures	GABRB2	0.5461	0.2081	Mutation screen of GABRA1, GABRB2 and GABRG2 genes in Japanese patients with absence seizures.	-1
familial Dravet syndrome	SCN1A	0.5461	0.3689	Parental SCN1A mutation mosaicism in familial Dravet syndrome.	-1
FS	GABRB3	0.5461	0.1045	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
LQTS	LQT1 and 6 LQT2	0.546	0.5194	METHODS: Seventeen individuals with confirmed LQTS related to potassium channel mutations (11 LQT1 and 6 LQT2) were prospectively studied with 21-channel electroencephalography (EEG) LQTS -related symptoms, comorbidity, medication, and QTc (12-lead ECG) were recorded.	-1
WS	NF1	0.546	0.2439	Fifteen patients with neurofibromatosis type one (NF1) and West syndrome (WS) were studied.	-1
infantile spasms	CDKL5	0.546	0.4644	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome (RTT)-like phenotype.	-1
infantile spasms	CDKL5	0.546	0.4644	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome-like phenotype.	-1
intellectual disability	TRMT10A	0.5459	0.5167	tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy.	-1
Lennox-Gastaut syndrome	GABRB3	0.5458	0.3922	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
temporal lobe epilepsy	Major vault protein	0.5458	0.3497	Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis.	-1
seizure	SCN1A	0.5457	0.162	The three criteria that best predicted a mutation in SCN1A included exacerbation with hyperthermia, normal development before seizure onset, and the appearance of ataxia, pyramidal signs, or interictal myoclonus.	-1
related-epilepsies	SCN1A	0.5457	0.524	Dravet syndrome and SCN1A gene mutation related-epilepsies: cognitive impairment and its determinants.	1
epilepsy	SCN1A	0.5457	0.2636	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	1
MERRF	CLN3	0.5456	0.04386	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
Dravet syndrome	SCN1A	0.5456	0.4752	Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients.	-1
epilepsy-aphasia	GRIN2A	0.5456	0.3668	GRIN2A mutations cause epilepsy-aphasia spectrum disorders.	-1
RS	MECP2	0.5455	0.1387	Classic Rett Syndrome (RS) is a neurodevelopmental disorder due to mutations in the MECP2 gene in Xq28.	-1
permanent and transient neonatal diabetes	SUR1	0.5455	0.3156	Activating mutations in the ABCC8 gene that encodes the sulfonylurea receptor 1 (SUR1) regulatory subunit of the pancreatic islet ATP-sensitive K(+) channel (K(ATP) channel) cause both permanent and transient neonatal diabetes.	-1
encephalopathy	CDKL5	0.5455	0.4182	We screened the entire coding region of CDKL5 for mutations in 183 females with encephalopathy with early seizures by denaturing high liquid performance chromatography and direct sequencing, and we identified in 20 unrelated girls, 18 different mutations including 7 novel mutations.	-1
epileptic seizures	Nav1.1	0.5454	0.3868	Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents.	1
epileptic encephalopathy	CDKL5	0.5453	0.4673	CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life.	1
epileptic encephalopathy	CDKL5	0.5453	0.4673	CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life.	1
hypsarrhythmia	PEHO	0.5453	0.1967	[A case of PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome: changes in clinical and neuroradiological findings].	-1
neonatal diabetes	KCNJ11	0.5451	0.4801	The functional consequence of this ABCC8 mutation mirrors that of KCNJ11 mutations causing neonatal diabetes and provides new insights into the interaction of Kir6.2 and SUR1.	-1
epilepsy	neurofibromatosis type 1	0.5451	0.1877	PARTICIPANTS: Patients with neurofibromatosis type 1, epilepsy, or Tourette syndrome diagnosed using traditional clinical criteria; controls without disease; and controls with neurologic disease.	-1
Angelman syndrome	FOXG1	0.545	0.1412	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
fragile X syndrome	prion protein	0.545	0.09545	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
myoclonus epilepsies	SCN1A-related	0.5449	0.1651	In this review we describe the genetic advances in progressive myoclonus epilepsies, which are strictly monogenic disorders, genetic generalized epilepsies, mostly exhibiting complex genetic inheritance, and SCN1A-related phenotypes, namely genetic generalized epilepsy with febrile seizure plus and Dravet syndrome.	-1
seizure	LQT2-causing	0.5449	0.09296	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
epilepsy syndromes	TBC1D24	0.5448	0.4136	BACKGROUND: Recent studies have shown that recessive mutations in the TBC1D24 gene cause a variety of epilepsy syndromes, DOORS syndrome and nonsyndromic deafness.	1
X-linked mental retardation	CDKL5	0.5448	0.2306	In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54).	-1
neonatal diabetes	ABCC8	0.5447	0.2796	A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.	-1
) syndrome	PEHO	0.5445	0.32	Dutch patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.	-1
SMEI	SCN1A	0.5444	0.3682	This wide spectrum of functional defects observed among SCN1A mutations suggests that SMEI may result from more than a single molecular or cellular mechanism, or require other factors for pathogenesis.	-1
Dravet syndrome	SCN1A	0.5444	0.4741	We report the first case of musicogenic reflex seizures in a 7-year-old male with a mutation in the SCN1A gene causing Dravet syndrome.	-1
Paraneoplastic Encephalitis	Anti-NMDA-NR2A/B	0.5443	0.2537	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
Dravet syndrome	SCN1A	0.5443	0.08608	Deletions of SCN1A 5' genomic region with promoter activity in Dravet syndrome.	-1
infancy-borderland/ borderline	SCN1A	0.5441	0.1427	A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.	-1
Dravet syndrome	SCN1A-negative	0.5441	0.3837	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
diabetes	TRMT10A	0.5441	0.5268	tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy.	-1
hypotonia	CDKL5	0.544	0.1552	Early epilepsy with normal interictal EEG and severe hypotonia are the key clinical features in identifying patients likely to have CDKL5 mutations.	-1
BFNE	KCNQ2	0.5438	0.166	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
genetic epilepsy	SCN1A	0.5438	0.4131	Mutations of the SCN1A subunit of the sodium channel is a cause of genetic epilepsy with febrile seizures plus (GEFS(+) ) in multiplex families and accounts for 70-80% of Dravet syndrome (DS).	-1
Dravet syndrome	SCN1A	0.5437	0.08168	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	-1
epileptic	CYP2C9	0.5437	0.1327	PURPOSE: We investigated the influence of the CYP2C9 polymorphism on the lipid profile, insulin resistance, and subclinical atherosclerosis in young epileptic patients.	-1
deficiency	fibrinogen	0.5436	0.3525	These data and our previous reports suggest that heterozygous patients with dysfibrinogenemia or fibrinogen deficiency do not demonstrate markedly prolonged PT and APTT values, differing from patients with afibrinogenemia.	-1
non-ASD	MBD5	0.5436	0.2451	We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense variant, p.79Gly>Glu (c.236G>A) (p = 0.012).	-1
juvenile myoclonic epilepsy	GABRD	0.5435	0.223	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
congenital deafness	KCNQ3	0.5435	0.2709	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
spasms	MECP2	0.5434	0.4486	CONCLUSION: Although late onset epileptic spasms are common in patients with MECP2 duplication, no specific electroclinical phenotype emerges, probably due to genetic heterogeneity of the syndrome.	-1
epileptic encephalopathy	CHD2	0.5434	0.4648	De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome.	1
Borjeson-Forssman-Lehmann syndrome	PHF6	0.5433	0.09766	Our report confirms that PHF6 loss in females results in a recognizable phenotype overlapping with Coffin-Siris syndrome and distinct from Borjeson-Forssman-Lehmann syndrome.	-1
behavioral abnormalities	Scn1a	0.5433	0.5265	Our results suggest that the behavioral abnormalities associated with Scn1a dysfunction encompass a wider range of phenotypes than previously reported and factors such as stress exposure may alter disease severity in patients with SCN1A mutations.	-1
epileptic encephalopathies	PIGA	0.5432	0.5762	PIGA mutations cause early-onset epileptic encephalopathies and distinctive features.	1
seizures	CDKL5	0.5432	0.1341	Our findings demonstrate the first instance of genomic deletion as the molecular basis of CDKL5 deficiency in females and highlight the importance of exon targeted array-CGH analysis for this gene in females with drug-resistant early-onset seizures.	-1
DS	SCN1A	0.543	0.4515	Although the mutational spectra are distinct, these disorders share major features and 10% of DS patients have an inherited SCN1A mutation.	-1
dysmorphic features	CDKL5	0.543	0.2007	Available photographs of CDKL5 patients were examined for dysmorphic features.	-1
craniofacial dysmorphism	SATB2	0.5429	0.4904	Of 59 unrelated patients with craniofacial dysmorphism, with or without mental retardation, one 36-year-old man had a nonsynonymous mutation in SATB2.	-1
myopathy	HSD17B10	0.5429	0.1045	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
seizures	CDKL5	0.5428	0.6089	Our observation and review of the literature suggest that a broader polymorphic electroclinical pattern with both generalized and focal seizures may occur in patients with CDKL5 mutations.	-1
autism	MECP2	0.5428	0.1862	One such gene is the transcription factor MECP2, whose loss of function in females results in Rett syndrome, while its duplication in males results in developmental delay and autism.	-1
Lafora disease	SCN1A	0.5428	0.2698	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
neuromyotonia	KCNQ2	0.5428	0.3337	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
seizures	Scn1a	0.5427	0.2954	Focal Scn1a knockdown induces cognitive impairment without seizures.	-1
CSS	PHF6	0.5427	0.1716	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
kyphoscoliosis	DHCR7	0.5427	0.1227	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	SCN1A	0.5426	0.2986	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	1
retinoblastoma	KPNA2	0.5425	0.2185	On the basis of the crystal structure of the paralog KPNA2 bound to a bipartite nuclear localization signal from the retinoblastoma protein, the amino-acid substitutions in the affected subjects were predicted to occur within the seventh armadillo repeat that forms one of the two nuclear localization signal-binding sites in KPNA family members.	-1
refractory seizure disorders	CDKL5-related	0.5425	0.2774	CDKL5-related epileptic encephalopathies are a group of refractory seizure disorders starting in early infancy.	1
CAE	GABRD	0.5423	0.2661	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
febrile seizures	GABRD	0.5423	0.2358	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
Rett Syndrome	CDKL5	0.5422	0.2979	Patients with CDKL5 mutations sometimes also show features similar to those seen in Rett Syndrome (RTT).	-1
kyphoscoliosis	AUH	0.5422	0.1194	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
generalized	GABRG2	0.5422	0.1439	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
long QT syndrome	KCNQ3	0.5422	0.1248	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
Hereditary Haemochromatosis	HFE	0.5422	0.4858	The HFE gene H63D mutation underlies Hereditary Haemochromatosis (HH), which needs treatment to prevent organ damages by iron overload.	-1
Angelman syndrome	SLC9A6	0.5421	0.1448	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
global developmental arrest	STK9	0.5421	0.4012	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
epilepsy	CDKL5	0.542	0.1698	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	1
neurological impairment	SMA	0.542	0.1256	RESULTS: After resection in the region of the SMA, 23 patients (59%) developed postoperative neurological impairment; 17 (74%) were identified as SMA syndrome.	-1
DS	SCN1A	0.542	0.5365	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	-1
antiepileptic drugs	MECP2	0.542	0.135	Because most cases of RTT are caused by mutations in the MECP2 gene it is reasonable to assume that convulsions are based on common pathogenetic mechanisms and thus should have a similar response to antiepileptic drugs.	-1
myopathic	TK2-related	0.5419	0.1933	GENETIC COUNSELING: TK2-related mtDNA depletion syndrome, myopathic form is inherited in an autosomal recessive manner.	-1
Dravet syndrome	GABRA1	0.5419	0.3442	GABRA1 and STXBP1: novel genetic causes of Dravet syndrome.	-1
microcephaly	IER3IP1	0.5418	0.4289	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
Dandy-Walker malformation	ZIC4	0.5417	0.2594	We report on a female patient with Dandy-Walker malformation possibly caused by heterozygous loss of ZIC1 and ZIC4.	-1
Dravet syndrome	SCN1A-mutations	0.5417	0.5194	OBJECTIVES: To determine the prevalence of Dravet syndrome, an epileptic encephalopathy caused by SCN1A-mutations, often with seizure onset after vaccination, among infants reported with seizures following vaccination.	-1
MERRF	CLN2	0.5417	0.0621	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
absence epilepsy	SCN1A	0.5417	0.1267	To assess the contribution that SCN1A makes to other types of epilepsy, 226 patients with either juvenile myoclonic epilepsy, absence epilepsy, or febrile convulsions were screened by conformation-sensitive gel electrophoresis and manual sequencing of variants; the sample included 165 probands from multiplex families and 61 sporadic cases.	-1
DS	SCN1A	0.5415	0.4132	RESULTS: DNA sequencing revealed a mutation in the SCN1A gene in five (55.6%) of the DS patients, within which three missense mutations, c.719T>C (p.Leu240Pro), c.2807A>T (p.Asp936Val), c.4349A>C (p.Gln1450Pro), and two frameshift mutations, c.2277insAACA (p.His759fsX772) and c.3972insT (p.Leu1324fsX1331) were observed.	-1
global cerebral hypomyelination	AGC1	0.5415	0.166	AGC1 deficiency associated with global cerebral hypomyelination.	-1
RTT	MECP2	0.5414	0.4585	In this pilot study we have analyzed MECP2 mutations in ten Indian sporadic patients diagnosed clinically as having RTT.	-1
myeloproliferative disease	JAK2	0.5413	0.1837	JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.	-1
epilepsy syndrome	SCN1A	0.5413	0.2527	BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome (DS) is a distinctive epilepsy syndrome often associated with de novo mutations in the SCN1A gene.	1
SBH	Met1Val	0.5412	0.1737	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
seizure	interleukin-6	0.5412	0.2042	Elevation of cerebrospinal fluid interleukin-6 may be related to the severe neurologic sequelae of our patient despite the relatively short seizure duration.	-1
epilepsy	SCN1A	0.5412	0.5095	METHODS Medical records of SCN1A mutation-positive children with treatment-resistant epilepsy who had undergone resective epilepsy surgery were reviewed retrospectively.	1
spasticity	ARX	0.5411	0.3574	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
GISTs	neurofibromatosis type 1	0.5411	0.357	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
encephalopathy	SCN1A	0.5411	0.204	FINDINGS: SCN1A mutations were identified in 11 of 14 patients with alleged vaccine encephalopathy; a diagnosis of a specific epilepsy syndrome was made in all 14 cases.	-1
Dravet syndrome	SCN1A	0.541	0.3389	A putative disease-associated haplotype within the SCN1A gene in Dravet syndrome.	-1
idiopathic epilepsy	KCNQ3	0.5409	0.3612	Role of KCNQ2 and KCNQ3 genes in juvenile idiopathic epilepsy in Arabian foals.	-1
epilepsy	SCN1A	0.5409	0.1501	SCN1A mutations account for a large proportion of Dravet syndrome patients, and are reported in other cases of epilepsy, such as some families with genetic epilepsy with febrile seizures plus (GEFS+).	1
epileptic encephalopathies	CDKL5-related	0.5409	0.3577	CDKL5-related epileptic encephalopathies are a group of refractory seizure disorders starting in early infancy.	1
autism	MECP2	0.5409	0.2234	Consistently, the boys displayed clinical features in common with other patients carrying MECP2 duplications, including intellectual disability, autism, lack of speech, slight hypotonia and unsteadiness of movement.	-1
epileptic encephalopathies	CDKL5	0.5409	0.3991	Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome.	1
IS	SCN1A	0.5408	0.1951	METHOD: The authors screened SCN1A in 24 patients with SMEI and 23 with IS.	-1
DS	SCN1A	0.5408	0.4234	In this report we aim to make the molecular analysis of the SCN1A and SCN1B genes in two Tunisian patients affected with DS.	-1
Dravet syndrome	SCN1A	0.5408	0.6988	OBJECTIVE: To summarize the early clinical features of Dravet syndrome (DS) patients with SCN1A gene mutations before the age of one.	-1
deafness	LQT1	0.5408	0.132	Mutations in this channel can cause one form of inherited long QT syndrome (LQT1), as well as being associated with a form of deafness.	-1
permanent deficits	SMA	0.5407	0.2212	In conclusion, although the SMA is known to control important functions such as initiation of motor activity or speech, our findings show that unilateral SMA removal can be accomplished without resulting in significant permanent deficits.	-1
SMEI/DS	SCN1A	0.5406	0.1964	METHODS: Twenty-eight patients with early onset SMEI/DS before 6 months negative for SCN1A mutational screening were selected and screened for mutations in the ARX gene in males (n=14) or the CDKL5 gene in females (n=14).	-1
neurodevelopmental disorder	MECP2	0.5406	0.3451	Classic Rett Syndrome (RS) is a neurodevelopmental disorder due to mutations in the MECP2 gene in Xq28.	-1
PTHS	TCF4	0.5405	0.06402	The cause of PTHS is de novo haploinsufficiency of the TCF4 gene (MIM *602272) at 18q21.2.	-1
seizures	IER3IP1	0.5405	0.1303	The triad of microcephaly, generalized seizures, and permanent neonatal diabetes should prompt screening for mutations in IER3IP1.	-1
LTE	LGI1	0.5404	0.2156	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
Dravet syndrome	SCN1A	0.5404	0.5307	SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome.	-1
mental retardation	MECP2	0.5403	0.2912	The MECP2 duplication syndrome is characterized by severe mental retardation, infantile hypotonia, progressive spasticity and recurrent infections.	-1
Rett syndrome	CDKL5	0.5403	0.4889	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome (RTT)-like phenotype.	-1
BFNS	KCNQ2	0.5403	0.225	No mutations were found in the genes (KCNQ2, KCNQ3) associated with BFNS, and CGH was negative.	-1
seizures	CDKL5	0.5402	0.4751	Furthermore, in contrast to Rett syndrome, patients with CDKL5 mutations, have seizures or infantile spasms starting in the first weeks of life.	-1
DS	Nav1.1	0.5401	0.158	These findings suggest a fundamental role for Nav1.1 in facilitating fast-firing properties in neurons, highlight the importance of precise temporal control of theta frequency for working memory, and imply that Nav1.1 deficits may disrupt information processing in DS via a dysregulation of brain rhythms.	-1
epilepsy	MECP2	0.5401	0.1709	METHODS: We performed mutation screening of CDKL5 in 60 female patients who had been identified as negative for the methyl CpG-binding protein 2 gene (MECP2) mutations, but who had current or past epilepsy, regardless of the age of onset, type, and severity.	1
seizure	CDKL5	0.5401	0.1307	Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism.	-1
epileptic	CHD2	0.54	0.3368	A third CHD2 mutation was identified in an epileptic proband of a second (stage 2) cohort.	1
Dravet's syndrome	SCN1A	0.5399	0.4679	We studied concordant and discordant monozygous twins with de novo mutations in the sodium channel a1 subunit gene (SCN1A) causing Dravet's syndrome, a severe epileptic encephalopathy.	-1
epilepsy	POLR3G	0.5399	0.1088	It included five genes: CETN3, AC093510.2, POLR3G, LYSMD3 and the proximal part of GPR98/MASS1, a known epilepsy gene.	-1
epilepsies	SCN1A-related	0.5399	0.2684	Genotype-phenotype associations in SCN1A-related epilepsies.	1
NCLs	CLN8	0.5399	0.07042	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
CMD	laminin alpha-2	0.5398	0.1354	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
DS	SCN1A	0.5398	0.09171	(2) SCN1A testing should be considered in people with possible DS where the typical initial presentation is of a developmentally normal infant presenting with recurrent, febrile or afebrile prolonged, hemiclonic seizures or generalized status epilepticus.	-1
SPs	A beta	0.5397	0.1346	A beta deposition in the form of senile plaques (SPs) has recently been described in patients with temporal lobe epilepsy (TLE).	-1
seizures	MECP2	0.5396	0.2369	Evaluations include clinical status (classic vs atypical RTT), MECP2 mutations, clinical severity, and presence, frequency, and treatment of seizures.	-1
epidermal nevus syndrome	FGFR3	0.5396	0.1302	An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation.	-1
epilepsy	CLN8	0.5396	0.2171	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	1
channelopathies	KCNQ2	0.5396	0.05701	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
RTT	MECP2	0.5395	0.5428	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
seizures	CDKL5	0.5395	0.147	Noteworthy, the CDKL5 mutation rate is high (28%) in women with early-onset seizures and IS.	-1
generalized epilepsy with febrile seizures plus	GABRG2	0.5394	0.2405	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsy syndrome-specific	SCN1A	0.5393	0.3875	In particular, the SCN1A gene coding for the pore-forming a-subunit of the voltage-gated sodium channel Na(V)1.1 appears to be a common target for epilepsy syndrome-specific mutations.	1
MBD	MBD5	0.5393	0.1728	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
RTT	MECP2	0.5392	0.36	The preliminary result necessitates a large-scale study of RTT patients to determine more precisely the influence of MECP2 mutations in Indian patients and their correlation with clinical phenotypes.	-1
SOC	HLA-A	0.5392	0.2059	HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC and AR-SJS/TEN with SOC.	-1
OS	SCN2A	0.5392	0.3316	RESULTS: We found 14 novel SCN2A missense mutations in 15 patients: 9 of 67 OS cases (13.4%), 1 of 150 West syndrome cases (0.67%), and 5 of 111 with unclassified EOEEs (4.5%).	-1
Lennox-Gastaut syndrome	GABRB2	0.5392	0.2694	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
Intellectual Disability	KANSL1-Related	0.5392	0.4172	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
Ferro-Cerebro-Cutaneous syndrome	PIGA	0.5392	0.5284	A novel germline PIGA mutation in Ferro-Cerebro-Cutaneous syndrome: a neurodegenerative X-linked epileptic encephalopathy with systemic iron-overload.	-1
LQTS-susceptibility	LQT2-epilepsy	0.5391	0.1348	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
West syndrome	LIS1	0.539	0.2351	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
JME	MECP2	0.539	0.2749	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
hypogonadism	PHF6	0.5388	0.154	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
RTT	MECP2	0.5388	0.4436	Evaluations include clinical status (classic vs atypical RTT), MECP2 mutations, clinical severity, and presence, frequency, and treatment of seizures.	-1
seizure	SCN1A	0.5387	0.1375	"Three criteria that were best evident in SCN1A mutation positive patients are as follows: ""Normal development before the onset of seizures, onset of seizure before age of one year, and psychomotor retardation after onset of seizures."	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.5387	0.3459	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
epileptic encephalopathy	CHD2	0.5386	0.4236	Our study provides evidence that de novo loss-of-function mutations in CHD2 are a cause of epileptic encephalopathy with generalized seizures.	1
epilepsy	SKI	0.5385	0.1917	576 kb deletion in 1p36.33-p36.32 containing SKI is associated with limb malformation, congenital heart disease and epilepsy.	-1
Rett syndrome-like	CDKL5	0.5385	0.07127	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
Dravet syndrome	SCN1A	0.5384	0.1048	In a previous retrospective study, 11 of 14 patients with so-called vaccine encephalopathy had Dravet syndrome that was associated with de-novo mutations of the sodium channel gene SCN1A.	-1
hypsarrhythmia	PEHO	0.5384	0.227	We reported serial clinical, radiological, and neurophysiological findings of a patient with PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome.	-1
juvenile myoclonic epilepsy	SCN1A	0.5383	0.2227	To assess the contribution that SCN1A makes to other types of epilepsy, 226 patients with either juvenile myoclonic epilepsy, absence epilepsy, or febrile convulsions were screened by conformation-sensitive gel electrophoresis and manual sequencing of variants; the sample included 165 probands from multiplex families and 61 sporadic cases.	-1
mental retardation	SATB2	0.5383	0.4914	Of 59 unrelated patients with craniofacial dysmorphism, with or without mental retardation, one 36-year-old man had a nonsynonymous mutation in SATB2.	-1
senile plaques	A beta	0.5382	0.2433	A beta deposition in the form of senile plaques (SPs) has recently been described in patients with temporal lobe epilepsy (TLE).	-1
tonic-clonic seizures	MECP2	0.5382	0.6063	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
LQTS-susceptibility	KCNQ1/deafness	0.5381	0.4535	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
corpus callosum	TUBA3	0.5381	0.09186	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
epileptic encephalopathy	CDKL5	0.538	0.5322	These findings indicate that alterations in CDKL5 are associated with early epileptic encephalopathy in both female and male patients.	1
generalized epilepsy	SCN1A	0.538	0.5652	A novel SCN1A missense mutation causes generalized epilepsy with febrile seizures plus in a Chinese family.	-1
RTT	MECP2	0.538	0.1694	We investigated, according to the MECP2 genotype, the role of the BDNF functional polymorphism (Val66Met) on the severity of RTT.	-1
epilepsy	CDKL5	0.538	0.4489	CDKL5 mutations cause severe epilepsy in infancy with subsequent epileptic encephalopathy.	1
epileptic encephalopathy	CDKL5-related	0.538	0.6201	INTERPRETATION: Infants with CDKL5-related early epileptic encephalopathy can present in the first year of life with an unusual electroclinical pattern of 'prolonged' generalized tonic-clonic seizures.	1
congenital muscular dystrophy	LAMA2-related	0.538	0.4156	LAMA2-related congenital muscular dystrophy complicated by West syndrome.	-1
West syndrome	LAMA2-related	0.538	0.4112	LAMA2-related congenital muscular dystrophy complicated by West syndrome.	-1
seizure	TBC1D24	0.5379	0.5121	The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms.	-1
epilepsy	SCN1A-related	0.5378	0.2585	MCDs, particularly FCD, can influence the electroclinical phenotype in patients with SCN1A-related epilepsy.	1
febrile seizure	SCN1A	0.5378	0.3854	CONCLUSIONS: Results from this relatively small series provide evidence that vaccinations do not significantly affect clinical and cognitive evolution of Dravet syndrome and generalized epilepsy with febrile seizure plus  patients even if they carry SCN1A mutations.	-1
epilepsies	Nav1.1	0.5378	0.3739	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	1
syndrome/toxic epidermal necrolysis	HLA-A	0.5377	0.215	AIM: To construct a simple, low-cost typing method for the surrogate marker of HLA-A*31:01, a risk factor for carbamazepine (CBZ) related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).	-1
BFIS	KCNQ2	0.5377	0.1335	Linkage analysis in this family confirmed a previous report of genetic heterogeneity in BFIS - since linkage was excluded at the above-mentioned known BFIS loci - and suggested a possible linkage to the KCNQ2 gene, which is believed to be a voltage gated potassium channel gene responsible for benign familial neonatal seizures (BFNS).	-1
seizures	SCN1A	0.5376	0.2384	Variability in severity favors the concept that SCN1A loss of function causes a spectrum of epilepsy phenotypes in which seizures, often prolonged and precipitated by fever, are the prominent feature and schematic subdivisions would be inappropriate, at least in the early stages.	-1
intellectual disability	GRIN2B	0.5375	0.4984	GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy.	-1
psychomotor retardation	CDKL5	0.5375	0.3925	The common features of all female patients with CDKL5 gene mutations included refractory seizures starting before 4 months of age, severe psychomotor retardation, Rett-like features such as hand stereotypies, deceleration of head growth after birth and poor prognosis.	-1
Rett syndrome	CDKL5	0.5374	0.3996	The CDKL5 gene has been implicated in the molecular etiology of early-onset intractable seizures with infantile spasms (IS), severe hypotonia and atypical Rett syndrome (RTT) features.	-1
RTT-like	MECP2	0.5374	0.4255	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
myopathy	DHCR7	0.5372	0.1167	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Ohtahara syndrome	SCN2A	0.5372	0.4836	The broad clinical spectrum of SCN2A mutations now includes Ohtahara syndrome.	-1
developmental delay	CDKL5	0.537	0.2176	Interestingly these missense mutations that result in a mislocalisation of the CDKL5 protein are associated with severe developmental delay which was apparent within the first months of life characterised by early and generalised hypotonia, and autistic features, and as well as early infantile spasms.	-1
LD	laforin	0.5368	0.4432	Our results also provide clues for distinct roles for the CBD-4 and DSP domains of laforin in the etiology of two subsyndromes of LD.	-1
epilepsy	CDKL5	0.5368	0.09746	Thus, a CDKL5 investigation should be performed in developmentally delayed patients with early-onset seizures, including drug-resistant subjects with severe EEG changes, as well as in patients with milder, drug-responsive forms of epilepsy.	1
Dravet syndrome	SCN1A	0.5368	0.3717	SCN1A missense and truncated mutations were detected significantly more often in the Dravet syndrome group than in the non-Dravet syndrome group.	-1
myopathy	AUH	0.5368	0.1135	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
autosomal dominant diseases	KCNQ4	0.5367	0.08322	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
Unverricht-Lundborg disease	tripeptidyl peptidase 1	0.5367	0.2737	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
myoclonic epilepsy	COQ2	0.5367	0.4081	Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2).	-1
nonsyndromic deafness	TBC1D24	0.5367	0.1998	BACKGROUND: Recent studies have shown that recessive mutations in the TBC1D24 gene cause a variety of epilepsy syndromes, DOORS syndrome and nonsyndromic deafness.	-1
neurologic deficits	SCN1A	0.5367	0.535	(4) The test is not recommended for children with phenotypes that are not clearly associated with SCN1A mutations such as those characterized by abnormal development or neurologic deficits apparent at birth or structural abnormalities of the brain.	-1
Dravet syndrome	GABRA1	0.5366	0.2759	This study involved search for mutations in candidate genes for Dravet syndrome, namely SCN1A, 2A, 1B, 2B, GABRA1, B2, and G2.	-1
Encephalopathy	Spin	0.5365	0.1656	Epileptic Ictal Hyperperfusion on Arterial Spin Labeling Perfusion and Diffusion-Weighted Magnetic Resonance Images in Posterior Reversible Encephalopathy Syndrome.	-1
febrile seizures	SCN1A	0.5364	0.09334	A novel inherited mutation in the voltage sensor region of SCN1A is associated with Panayiotopoulos syndrome in siblings and generalized epilepsy with febrile seizures plus.	-1
epilepsy	DCX	0.5364	0.04843	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	1
strokes	COX1	0.5363	0.2347	A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis.	-1
Norrie disease	prion protein	0.5361	0.215	These include fatal familial insomnia, with involvement of the prion protein gene on chromosome 20, Norrie disease, the Prader-Willi syndrome and the Moebius syndrome.	-1
Angelman syndrome	CDKL5	0.536	0.1554	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
epileptic encephalopathy	CDKL5	0.536	0.3486	CDKL5 mutations cause severe epilepsy in infancy with subsequent epileptic encephalopathy.	1
febrile seizures	a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1	0.536	0.1184	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	-1
RTT	CDKL5	0.536	0.4012	Patients with CDKL5 mutations sometimes also show features similar to those seen in Rett Syndrome (RTT).	-1
tumor	anti-CV2	0.5359	0.2257	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
convulsions	MECP2	0.5359	0.2647	Because most cases of RTT are caused by mutations in the MECP2 gene it is reasonable to assume that convulsions are based on common pathogenetic mechanisms and thus should have a similar response to antiepileptic drugs.	-1
neurodegeneration	TBC1D24/sky-induced	0.5358	0.3255	Reduced synaptic vesicle protein degradation at lysosomes curbs TBC1D24/sky-induced neurodegeneration.	-1
cardiac arrhythmia	KCNQ2	0.5358	0.1745	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
oculomotor apraxia	SPG7	0.5355	0.06723	"This produced an early-onset clinical syndrome that combines the severe phenotypes of SPG7 and SCA28, in additional to other ""mitochondrial"" features such as oculomotor apraxia, extrapyramidal dysfunction, and myoclonic epilepsy."	-1
PNDM	KCNJ11	0.5354	0.1203	Heterozygous mutations in ABCC8, KCNJ11, and INS genes account for around half of cases of PNDM; mutations in 10 further genes account for a further 10%, and the remaining 40% of cases are currently without a molecular genetic diagnosis.	-1
Rett syndrome	MECP2	0.5354	0.4856	The clinical picture was consistent with Rett syndrome, confirmed by MECP2 mutation R133C.	-1
Dravet syndrome	SCN1A	0.5354	0.3328	We have demonstrated a high-sensitivity testing strategy for detecting mutations of SCN1A in children with suspected Dravet syndrome.	-1
macrocytosis	KLF13	0.5354	0.2549	According to knock-out experiments the deletion of KLF13 could be an explanation for macrocytosis.	-1
MCDs	SCN1A-related	0.5352	0.3919	MCDs, particularly FCD, can influence the electroclinical phenotype in patients with SCN1A-related epilepsy.	-1
RS	MECP2	0.5351	0.2558	Different mutations in MECP2 are found in up to 95% of typical cases of RS.	-1
Rett syndrome	MECP2	0.5351	0.2074	Diagnosis of Rett syndrome was confirmed by molecular detection of the Ser134Cys mutation in the MECP2 gene, which has previously been described only in classic Rett syndrome.	-1
Emery-Dreifuss muscular dystrophy	FHL1	0.5351	0.4641	FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718).	-1
Genetic Epilepsies	SCN1A	0.5349	0.5507	Diseases caused by mutations in SCN1A are currently named Genetic Epilepsies with Febrile Seizures Plus, and this term stands for expanded spectrum of syndrome previously called as GEFS+ (Generalized Epilepsy with Febrile Seizures Plus).	-1
diverse as myotonia	CLC	0.5349	0.2486	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
MAS	inv	0.5349	0.08393	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
dysmorphic features	PEHO	0.5349	0.1149	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
respiratory infections	MECP2-containing	0.5349	0.1613	A case report of Chinese brothers with inherited MECP2-containing duplication: autism and intellectual disability, but not seizures or respiratory infections.	-1
generalized epilepsy	SCN1A	0.5348	0.5393	CONCLUSIONS: Results from this relatively small series provide evidence that vaccinations do not significantly affect clinical and cognitive evolution of Dravet syndrome and generalized epilepsy with febrile seizure plus  patients even if they carry SCN1A mutations.	-1
myoclonic epilepsy	GABRB3	0.5348	0.06978	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsies	CDKL5	0.5347	0.1806	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	1
hydrocephalus	CSF	0.5347	0.1802	RESULTS: In this cohort, 30% of the patients required CSF shunts, of which 8% developed late hydrocephalus up to 3 years posthemispherectomy.	-1
epilepsy	SCN1A	0.5346	0.36	We describe three children with genetically different sodium channel alpha 1 subunit (SCN1A) mutation associated epilepsy who experienced a sudden and sustained neurologic regression following status epilepticus in two and acute sepsis in one.	1
cataracts	AIRE	0.5345	0.1372	Mutations in CRYAA, a gene that shares the same locus as AIRE, may cause recessive inheritance of cataracts.	-1
epilepsy	EAG-like	0.5345	0.03612	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	1
WBS	FZD9	0.5345	0.3204	Other two carry a shorter deletion of ~1.2 Mb at centromeric side that excludes the distal WBS genes BAZ1B and FZD9.	-1
epilepsy	CHD2-related	0.5344	0.4373	The patient had prominent myoclonic seizures and photosensitivity, thus, sharing phenotypic features with previously reported patients with CHD2-related epilepsy.	1
absence seizures	CLCN2	0.5344	0.4565	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
Permanent neonatal diabetes	ABCC8	0.5342	0.2438	Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11.	-1
tonic-clonic seizures	LBSL	0.5341	0.07687	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
encephalopathy	CDKL5	0.534	0.06943	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	-1
Angelman syndrome	CREBBP	0.534	0.155	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Ohtahara syndrome	KCNQ2	0.534	0.183	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
Dravet syndrome	GABRD	0.5339	0.1529	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
ID	KANSL1	0.5339	0.1255	The degree of intellectual disability (ID) appears to be milder than expected in a considerable number of subjects with either chromosome deletion or KANSL1 mutation.	-1
febrile seizures	SCN1A	0.5339	0.1789	Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A.	-1
RS	MECP2	0.5339	0.4867	Molecular studies of the MECP2 gene have shown that the clinical phenotype of RS is far broader than the one initially described and has numerous variants, which may be either more or less severe, and there are even mutations in males and in other non-Rett phenotypes, as well as in cases of mental retardation in which the aetiology is unknown.	-1
DS	SCN1A	0.5339	0.1724	OBJECTIVES AND PATIENTS 19 selected families with at least one DS patient were studied to describe the mechanisms accounting for inherited SCN1A mutations in DS.	-1
Dravet syndrome	SCN1A	0.5339	0.3161	In three patients with either Dravet syndrome or myoclonic epilepsy, we detected SCN1A mutations (p.R222X, p.P231P, p.R393H), even though other laboratories had previously excluded aberrations of this gene by Sanger sequencing or high-resolution melting analysis.	-1
seizure disorder	CDKL5	0.5338	0.2356	A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.	1
COX-deficient	COX subunits I and II	0.5338	0.2671	Severe and selective reduction of mtDNA-encoded COX subunits I and II was consistently observed in all these patients and was restricted to COX-deficient fibres.	-1
DS	SCN1A	0.5337	0.4436	We report the first case of reflex seizures triggered by diaper change in a girl at 9 months old and 2 years old with a mutation in the SCN1A gene causing DS.	-1
MPD	JAK2(V617F	0.5337	0.4241	CONCLUSIONS: In these patients with SVT, the detection of JAK2(V617F) mutation is diagnostic for masked MPD as could be documented by bone marrow histopathology.	-1
RS	DLX5	0.5337	0.2425	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
neonatal sepsis	CRP	0.5336	0.05261	CONCLUSION: In place where blood culture is limited neonates having clinical features of neonatal sepsis with positive qualitative CRP assay and increased WBC should urgently be initiated on appropriate sepsis management in order to reduce morbidity and mortality associated with neonatal sepsis.	-1
autoimmune diseases	MeCP2	0.5336	0.1255	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
generalized epilepsy	GABRG2	0.5334	0.4769	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
absence seizures	myoclonin/EFHC1	0.5334	0.1319	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
Dravet syndrome	SCN1A	0.5333	0.3753	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	-1
epilepsy	GABRD	0.5333	0.1721	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
epileptic encephalopathies	cyclin-dependent kinase-like 5	0.5332	0.2866	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	1
febrile seizures	SCN1A	0.5331	0.2447	Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 * 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59].	-1
spasticity	MECP2	0.5331	0.1456	Non-progressive neuropsychiatric symptoms in female relatives of a male child with learning disability, ataxia and progressive spasticity may constitute a clue to inherited, MECP2 pathogenesis.	-1
neurological disorder	EA1	0.533	0.3681	EA1 is a dominant human neurological disorder characterized by variable phenotypes of brief episodes of ataxia, myokymia, neuromyotonia, and associated epilepsy.	-1
epilepsy-associated	SCN1A	0.533	0.4788	Impaired inactivation gate stabilization predicts increased persistent current for an epilepsy-associated SCN1A mutation.	1
spasticity	CDKL5	0.533	0.4143	In addition, they might reflect that other phenotypic features associated with CDKL5 mutations (Rett-like features, infantile spasm) or ARX mutations (dystonia, spasticity) are more distinctive.	-1
infantile spasms	GABRA1	0.5328	0.5279	In addition, de novo GABRA1 mutations were recently reported in a patient with infantile spasms and four patients with Dravet syndrome.	-1
axonal damage	TNFalpha	0.5328	0.1594	TNFalpha seems to be an important factor in the cascade of events leading to demyelination and even axonal damage.	-1
epileptic	SCN1A	0.5327	0.09378	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	1
severe cutaneous adverse reactions	cytochrome P450 2C9	0.5327	0.2252	Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.	-1
skin lesions	PTEN	0.5327	0.5755	Phosphatase and tensin homolog (PTEN) gene mutations are associated with a spectrum of clinical disorders characterized by skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers.	-1
spinal schwannoma	Neurofibromatosis 1	0.5327	0.4005	Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1.	-1
SMEI	SCN1A	0.5326	0.4617	To investigate the contribution of SCN1A mutations to the etiology of SMEI, we examined nine additional SMEI patients.	-1
autosomal recessive condition	PEHO-like	0.5326	0.08259	This is the second report of siblings with a PEHO-like syndrome, and supports the existence of a distinct, autosomal recessive condition in which neuroimaging abnormalities may be misinterpreted.	-1
related disorders	Cyclin-dependent kinase-like 5	0.5325	0.3019	Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders.	-1
Dravet syndrome	SCN1A	0.5324	0.3703	SCN1A mutations account for a large proportion of Dravet syndrome patients, and are reported in other cases of epilepsy, such as some families with genetic epilepsy with febrile seizures plus (GEFS+).	-1
posterior reversible encephalopathy syndrome	L-asparaginase-induced	0.5324	0.3714	L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.	-1
status epilepticus	neurofibromatosis type 2	0.5324	0.4684	Novel neurofibromatosis type 2 mutation presenting with status epilepticus.	-1
ketoacidosis	SUR1	0.5324	0.1903	Although ketoacidosis is frequent at presentation, SUR1 mutations associate mainly with transient hyperglycemia, with possible recurrence later in life.	-1
LGS	CHD2	0.5323	0.3583	In this study, we aimed to explore the role of CHD2 in LGS, as CHD2 mutations have been described recently in various epileptic encephalopathies.	-1
fever	SCN1A	0.5323	0.3168	The early clinical features of DS patients with SCN1A mutations were reviewed with attention to the seizures induced by fever and other precipitating factors before the first year of life.	-1
infancy	SCN1A	0.5322	0.09465	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
FIRES	SCN1A	0.5322	0.3949	We found no SCN1A mutations or copy number variants in 10 patients with FIRES.	1
cognitive impairment	CDKL5	0.5322	0.2736	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
seizure-positive	SCN1A	0.5322	0.3246	CONCLUSIONS: Based on the early age of presentation and the severity of the epilepsy reported for the majority of the seizure-positive cases it was concluded that SMEI/DS could be the epileptic encephalopathy associated with deletions within the 2q22.1-q33.3 region, due to haploinsuffiency of SCN1A and/or complete or partial deletion of other voltage-gated sodium channel genes caused by the aberration.	-1
septicaemia	CRP	0.5322	0.1749	The sensitivities of CRP assay in the diagnosis of septicaemia using culture as gold standard on day 1, 2, 3 and any positive were 40.4%, 53.2%, 54.8% and 62.9% respectively.	-1
neurodevelopmental disorders	MECP2	0.5321	0.6071	Understanding of the influence of the MECP2 mutation on other neurodevelopmental disorders has increased.	-1
myoclonic seizures	CHD2-related	0.5321	0.2293	The patient had prominent myoclonic seizures and photosensitivity, thus, sharing phenotypic features with previously reported patients with CHD2-related epilepsy.	-1
epileptic encephalopathy	SCN1A	0.5319	0.2741	Dravet syndrome is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment, thus well illustrating the concept of epileptic encephalopathy.	1
CMT	CMT2	0.5319	0.1887	Significant genetic heterogeneity is found in CMT, with 15 genes or loci for CMT2.	-1
ventriculomegaly	CC2D2A-related	0.5319	0.2718	Genotype-phenotype correlation in CC2D2A-related Joubert syndrome reveals an association with ventriculomegaly and seizures.	-1
autistic spectrum disorders	MECP2	0.5318	0.2051	Furthermore, the panorama of phenotypes with MECP2 mutations now extends far beyond RS to include normal girls and women, mild learning disability, autistic spectrum disorders, and X-linked mental retardation.	-1
RTT	MECP2	0.5318	0.1702	However, a large scale study of adult RTT patients is required to determine more precisely the influence of MECP2 mutation types on the natural history and clinical phenotypes of RTT.	-1
epilepsy	Met1Val	0.5317	0.2536	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
epilepsy	PAFAH1B1	0.5317	0.05207	BACKGROUND: Genetic aberrations in PAFAH1B1 result in isolated lissencephaly sequence (ILS), a neuronal migration disorder associated with severe mental retardation and intractable epilepsy.	1
malformation	PTEN	0.5317	0.3924	An atypical patient with Cowden syndrome and PTEN gene mutation presenting with cortical malformation and focal epilepsy.	-1
epileptic	SCN1A	0.5315	0.07601	MATERIALS AND METHODS: In this cross-sectional study, genotype distribution and allele frequency of six non-synonymous exonic single nucleotide polymorphisms (SNPs) of the SCN1A and B genes were selected and determined using PCR-RFLP in 70 epileptic patients treated with CBZ for at least 6 months.	1
corpus callosum	ARX	0.5315	0.1426	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
PTHS	TCF4	0.5313	0.6455	During a search for TCF4 mutations in 78 patients with a suspected PTHS, haploinsufficiency of TCF4 was identified in 18.	-1
RTT	CDKL5	0.5312	0.327	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome (RTT)-like phenotype.	-1
LQTS	KCNQ1	0.5312	0.2433	The patient and the patient's asymptomatic family members underwent genetic screening of the three genes most frequently associated with LQTS: KCNQ1, KCNH2, and SCN5A.	-1
X-linked lissencephaly	ARX	0.5311	0.2094	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
seizures	LBSL	0.531	0.1281	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
CBZ-SJS/TEN	HLA-DRB1	0.5309	0.06498	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
EA	HNF1B	0.5308	0.3997	This is the second report of HNF1B mutation associated with EA.	-1
dysmorphism	neurofibromatosis type 1	0.5307	0.278	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
long QT syndrome	KCNQ2	0.5305	0.1911	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
syndromic developmental delay	KCNH1	0.5304	0.6613	De novo KCNH1 mutations in four patients with syndromic developmental delay, hypotonia and seizures.	-1
optic nerve/cerebellar atrophy	PEHO	0.5304	0.2904	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
epileptic encephalopathies	STXBP1	0.5304	0.4665	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
Dravet syndrome	GABRG2	0.5304	0.1387	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
autism	MECP2	0.53	0.3628	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
X-linked mental retardation disorder	PHF6	0.5299	0.1684	The plant homeodomain finger 6 (PHF6) was originally identified as the gene mutated in the X-linked mental retardation disorder B  rjeson-Forssman-Lehmann syndrome.	-1
infancy	ARX	0.5299	0.4386	CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.	-1
autosomal recessive condition	PEHO	0.5299	0.3239	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
DS	SCN1A	0.5299	0.6775	OBJECTIVES AND PATIENTS 19 selected families with at least one DS patient were studied to describe the mechanisms accounting for inherited SCN1A mutations in DS.	-1
Lennox-Gastaut syndrome	CHD2	0.5298	0.4517	CHD2 mutations in Lennox-Gastaut syndrome.	-1
dystonia	MECP2	0.5297	0.1976	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
cerebral amyloid angiopathy	Aura	0.5296	0.1837	Aura attacks from acute convexity subarachnoid haemorrhage not due to cerebral amyloid angiopathy.	-1
epilepsies	ARX	0.5296	0.1774	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	1
sclerosis	CA4	0.5296	0.1574	Maximal neuron loss (mean loss 38%) occurred in the CA4 region in six patients with PTLE (end folium sclerosis).	-1
obese	cannabinoid-1 receptor	0.5295	0.1162	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
Dravet syndrome	SLC6A1	0.5295	0.3106	Among these transmissions were two likely disease-causing mutations: an SCN1A mutation transmitted to an SUDC proband and her sibling with Dravet syndrome, as well as an SLC6A1 mutation in a proband with epileptic encephalopathy.	-1
PNH	KCNQ2	0.5295	0.2706	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
Severe myoclonic epilepsy of infancy	SCN1A	0.5293	0.06784	BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome (DS) is a distinctive epilepsy syndrome often associated with de novo mutations in the SCN1A gene.	-1
epilepsy	PCDH19	0.5293	0.321	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
epilepsy	ARX	0.5292	0.2899	Investigation of genes associated with infantile forms of epilepsy such as SCN1A, SCN1B, and ARX were negative, but we identified a novel single-nucleotide duplication mutation, c.931dupT (p.S311FfsX3), in exon 11 of the STXBP1 gene.	1
myoclonic epilepsy	SCN1A	0.5291	0.05425	A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.	-1
Dravet syndrome	SCN1A	0.5291	0.239	The majority of Dravet syndrome patients have de novo mutations in SCN1A, resulting in haploinsufficiency.	-1
PNDM	ABCC8	0.5289	0.1574	Heterozygous mutations in ABCC8, KCNJ11, and INS genes account for around half of cases of PNDM; mutations in 10 further genes account for a further 10%, and the remaining 40% of cases are currently without a molecular genetic diagnosis.	-1
lateral temporal epilepsy	KCNAB1	0.5288	0.2687	Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsy.	-1
infection	ARPKD	0.5288	0.07799	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
Temple-Baraitser syndrome	KCNH1	0.5287	0.1982	Recently, de novo missense KCNH1 mutations have been identified in six patients with Zimmermann-Laband syndrome and in four patients with Temple-Baraitser syndrome.	-1
myoclonic epilepsy of infancy	SCN1A	0.5287	0.2665	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
Pitt-Hopkins syndrome	TCF4	0.5286	0.1773	Pitt-Hopkins syndrome: report of a case with a TCF4 gene mutation.	-1
Stevens-Johnson	HLA-A	0.5286	0.194	AIM: To construct a simple, low-cost typing method for the surrogate marker of HLA-A*31:01, a risk factor for carbamazepine (CBZ) related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).	-1
epilepsy	SCN1A	0.5285	0.2347	To assess the contribution that SCN1A makes to other types of epilepsy, 226 patients with either juvenile myoclonic epilepsy, absence epilepsy, or febrile convulsions were screened by conformation-sensitive gel electrophoresis and manual sequencing of variants; the sample included 165 probands from multiplex families and 61 sporadic cases.	1
Rett syndrome	MECP2	0.5285	0.2864	Diagnostic criteria have been modified only slightly over time, even after discovering that MECP2 gene alterations are present in >90% of patients with typical Rett syndrome but only in 50-70% of atypical cases.	-1
intellectual impairment	VIII	0.5284	0.2097	The other patient with cranial neuropathies of VII, VIII and XII nerves associated with intellectual impairment was diagnosed with CADASIL only with the help of control MRI examination.	-1
partial agenesis of the corpus callosum	KPNA7	0.5283	0.3135	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
cognitive impairment	PHF6	0.5283	0.2087	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
infantile epileptic encephalopathy	KLHL17	0.5283	0.1738	Finally, we provide evidence that ISS in deletion 1p36 may be associated with deletion of KLHL17 and expand the epilepsy phenotype in that syndrome to include early infantile epileptic encephalopathy.	-1
myopathies	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.5282	0.3355	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
X-linked lissencephaly	TUBA3	0.5282	0.09339	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
Rett syndrome	methyl CpG binding protein 2	0.5281	0.1143	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
malignancy	ARPKD	0.5281	0.07657	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
paralysis	SCN4A	0.528	0.5268	However, there was no increase in persistent sodium current as observed for SCN4A mutations causing myotonia or periodic paralysis.	-1
DS	SCN1A	0.528	0.1094	Dravet syndrome (DS) is an epileptic encephalopathy related mainly to mutations in the SCN1A gene, encoding for neuronal sodium channels.	-1
epileptic encephalopathy	MT-ND1	0.5279	0.2642	Whole-exome sequencing identifies a variant of the mitochondrial MT-ND1 gene associated with epileptic encephalopathy: west syndrome evolving to Lennox-Gastaut syndrome.	-1
autism spectrum disorders	MECP2	0.5278	0.164	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
epilepsy	NaV1.1	0.5277	0.443	Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: Properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum.	1
CP	NF1	0.5276	0.08825	MATERIAL AND METHODS: We studied 15 patients with WS and DS with a follow-up of 1.5 to 9 years, 5 patients with WS and NF1 followed-up form 2 to 6 years and 10 patients with WS associated with CP and PL followed-up during 2.5 to 12 years.	-1
dentadorubropallidoluysian atrophy	CLN3	0.5276	0.05123	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
epileptic encephalopathy	CDKL5	0.5275	0.3086	CDKL5 alterations lead to early epileptic encephalopathy in both genders.	1
limb malformation	SKI	0.5275	0.1856	576 kb deletion in 1p36.33-p36.32 containing SKI is associated with limb malformation, congenital heart disease and epilepsy.	-1
SMEI	SCN1A	0.5274	0.2264	To test whether ICEGTC arises from molecular mechanisms similar to those involved in SMEI, we characterized eight ICEGTC missense mutations by whole-cell patch clamp recording of recombinant human SCN1A heterologously expressed in cultured mammalian cells.	-1
AMRF	LIMP-2	0.5274	0.1615	In contrast to the reduced binding properties of the nonsense mutations, the only missense mutation (H363N) found in AMRF leads to increased binding of beta-GC to LIMP-2, indicating that this highly conserved histidine modifies the affinity of LIMP-2 to its ligand.	-1
Rett syndrome	methyl-CpG binding protein 2	0.5273	0.4892	Mutational analysis of methyl-CpG binding protein 2 (MECP2) gene in Indian cases of Rett syndrome.	-1
Febrile Seizures	SCN1A	0.5273	0.4394	Diseases caused by mutations in SCN1A are currently named Genetic Epilepsies with Febrile Seizures Plus, and this term stands for expanded spectrum of syndrome previously called as GEFS+ (Generalized Epilepsy with Febrile Seizures Plus).	-1
X-SCID	IL2RG	0.5273	0.2242	We report a male infant who suffered from WS and X-linked T-B+NK- severe combined immunodeficiency (X-SCID) with a missense mutation of the IL2RG gene (c.202G>A, p.Glu68Lys).	-1
Dravet syndrome	SCN1A	0.5273	0.2941	Establishment of isogenic iPSCs from an individual with SCN1A mutation mosaicism as a model for investigating neurocognitive impairment in Dravet syndrome.	-1
Lafora's disease	EPM2A	0.5272	0.4225	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
Batten disease	CLN2	0.5271	0.1438	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
rare disorder	GRIN2A	0.5271	0.2032	Further prospective studies in additional patients with mutations in GRIN2A will be required to optimize seizure management for this rare disorder.	-1
intractable epilepsy	SCN2A	0.5271	0.2926	Here, we report three patients with infantile-onset severe intractable epilepsy found to have de novo mutations in SCN2A.	1
hypogonadism	PROK2/PROKR2	0.5271	0.2319	OBJECTIVES: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.	-1
Dravet syndrome	PCDH19	0.5271	0.5973	Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome.	-1
Rett syndrome	CDKL5	0.5269	0.4248	Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.	-1
dentadorubropallidoluysian atrophy	CLN2	0.5269	0.1025	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
seizure	KCNQ3	0.5269	0.1547	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
RTT-like	MECP2	0.5269	0.1393	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
cataracts	AIRE	0.5269	0.1502	Additional involvement of CRYAA, that possibly causes cataracts in two of the patients, might support this hypothesis, due to the proximity of this gene to AIRE.	-1
epilepsies	KCNQ2	0.5268	0.1695	OBJECTIVE: To explore the involvement of M-type potassium channels KCNQ2, Q3, and Q5 in the pathogenesis of common idiopathic epilepsies.	1
neonatal epilepsies	Kv 7.2	0.5268	0.1895	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
epilepsy	LQT1	0.5266	0.2896	Here, we find that epilepsy occurs in mouse lines bearing dominant human LQT1 mutations for the most common form of cardiac long QT syndrome, which causes syncopy and sudden death.	-1
polyendocrinopathy	FOXP3	0.5265	0.4308	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
FS	GABRG2	0.5264	0.1096	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
neuronal ceroid lipofuscinoses	CLN8	0.5264	0.09139	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
benign familial neonatal convulsions	KCNQ2	0.5264	0.4201	Two voltage-gated potassium channel genes, KCNQ2 on chromosome 20q13.3 and KCNQ3 on chromosome 8q24, have been identified as the genes responsible for benign familial neonatal convulsions.	-1
fever	SCN1A	0.5263	0.2289	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
amyloidosis	TTR	0.5262	0.316	We report three non-inbred patients with Val 107 transthyretin (TTR) amyloidosis.	-1
Rett syndrome	CDKL5	0.5262	0.2552	Five patients with Rett syndrome, who did not show methyl CpG-binding protein 2 gene (MECP2) mutations, were also examined for CDKL5 mutations.	-1
psychomotor retardation	SCN1A	0.5261	0.4033	CONCLUSION: In this study, normal development before seizure onset, seizures beginning before age of one year and psychomotor retardation after age of two years are the most significant criteria in SCN1A mutation positive patients.	-1
fever	SCN1A-gene	0.5261	0.1239	Dravet syndrome, often caused by mutations of SCN1A-gene, presents with prolonged clonic, generalized or unilateral seizures often occurring with fever during the first year of life, followed by usually severe epilepsy.	-1
behavioral abnormalities	SCN1A	0.5261	0.4539	Our results suggest that the behavioral abnormalities associated with Scn1a dysfunction encompass a wider range of phenotypes than previously reported and factors such as stress exposure may alter disease severity in patients with SCN1A mutations.	-1
MERRF-syndrome	LBSL	0.526	0.1971	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
epileptic encephalopathy	SCN1A	0.526	0.3054	Dravet syndrome (DS) is an epileptic encephalopathy related mainly to mutations in the SCN1A gene, encoding for neuronal sodium channels.	1
syndromes	GABRD	0.5259	0.3376	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
hyperglycemia	MODY2	0.5258	0.2546	Maturity-onset diabetes of the young type 2 (MODY2) is a form of monogenic diabetes, characterized by mild fasting hyperglycemia.	-1
(HHE) syndrome	SCN1A	0.5258	0.4907	A role for SCN1A genetic mutations in the development of hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome was recently suggested based on the observation that HHE syndrome and classic Dravet syndrome share many clinical features.	1
ICEGTC	SCN1A	0.5256	0.2674	In summary, SCN1A mutations associated with ICEGTC result in a wide spectrum of biophysical defects, including mild-to-moderate gating impairments, shifted voltage dependence and reduced use dependence.	-1
WS	NF1	0.5256	0.1198	WS with NF1 seems remarkably benign and resembles idiopathic WS more than symptomatic WS.	-1
epilepsies	SCN1A	0.5255	0.3307	We investigated the roles of mutations in voltage-gated sodium channel alpha 1 subunit gene (SCN1A) in epilepsies and psychiatric disorders.	1
Dravet syndrome	ARX-related	0.5255	0.3462	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
sclerosis	SCN1A	0.5255	0.2051	Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 * 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59].	-1
neuropsychiatric symptoms	MECP2	0.5254	0.2228	Non-progressive neuropsychiatric symptoms in female relatives of a male child with learning disability, ataxia and progressive spasticity may constitute a clue to inherited, MECP2 pathogenesis.	-1
Dravet syndrome	SCN1A	0.5254	0.1472	BACKGROUND: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the a-subunit of the voltage-gated sodium channel Na(v)1.1.	-1
seizure	alpha1B-adrenergic receptor	0.5254	0.2764	"Overstimulation of the alpha1B-adrenergic receptor causes a ""seizure plus"" syndrome."	-1
MERRF	COX	0.5253	0.4516	In two patients with MERRF, neither SSV nor COX positive RRFs were seen and A8344G mutations were found from both muscle and blood samples.	-1
Dravet syndrome	SCN1A	0.5253	0.03322	Dravet syndrome is associated with mutations of the gene encoding the alpha-1 subunit of the sodium channel, SCN1A, in >70% of patients.	-1
Rett syndrome	CDKL5	0.5253	0.3167	Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.	-1
Ohtahara syndrome	STXBP1	0.5252	0.3747	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
PTHS	TCF4	0.5252	0.2941	Altogether 78 PTHS patients with abnormalities of the TCF4 gene have been published since 2007 when the etiology of PTHS was revealed.	-1
LGS	SCN1A	0.5252	0.3564	This finding emphasizes the significance of SCN1A mutations also in epileptic disorders with features of LGS, particularly in the myoclonic variant of the disorder.	-1
seizures	CDKL5	0.5252	0.4307	Mutations in the X-linked gene cyclin-dependent kinase-like 5 (CDKL5) have been detected in patients presenting with seizures in the first few months of life and Rett syndrome features.	-1
neuronal loss	CA4	0.5251	0.2328	A routine neuropathological examination showed no pronounced changes, such as neuronal loss, morphologically abnormal neurons, inflammation, vascular changes, Lafora bodies and tumor cells, except that mild gliosis was seen only in CA4 of the hippocampus.	-1
Dravet syndrome	SCN1A	0.525	0.29	Mutations in the sodium channel alpha 1 subunit (SCN1A) gene are most notably associated with Dravet syndrome.	-1
scapuloperoneal myopathy	FHL1	0.525	0.2226	FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718).	-1
LQTS-susceptibility	LQT2-causing	0.525	0.09554	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
epilepsy	SCN1A-related	0.5249	0.5302	Model systems for studying cellular mechanisms of SCN1A-related epilepsy.	1
dominantly inherited syndrome	Neurofibromatosis type 2	0.5248	0.3603	Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein.	-1
Pitt-Hopkins syndrome	TCF4	0.5248	0.3931	263.4  kb deletion within the TCF4 gene consistent with Pitt-Hopkins syndrome, inherited from a mosaic parent with normal phenotype.	-1
neurodevelopmental disorders	MECP2	0.5248	0.161	These articles explain how mutation of the gene (MECP2) for methyl-CpG-binding protein 2 causes the particular disorders of Rett syndrome, and also induces other neurodevelopmental disorders, clarifying the situation for future studies.	-1
Korean Dravet syndrome	SCN1A	0.5247	0.3309	CONCLUSIONS: SCN1A mutational analysis of Korean Dravet syndrome patients resulted in the identification of 15 novel mutations, which could expand the spectrum of SCN1A mutations and confirms the current understanding of genotype-phenotype correlations.	-1
febrile seizures	GABRD	0.5247	0.2382	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
macrocephaly	KANSL1	0.5246	0.1817	Striking clinical criteria for enrolling patients into KANSL1 analysis include speech delay, distinctive facial dysmorphism, macrocephaly and friendly behaviour.	-1
CoQ10 deficiency	BRAF	0.5246	0.6679	We report the case of a 4-year-old girl who presented a CFC syndrome, confirmed by the presence of a pathogenic R257Q BRAF gene mutation, together with a muscular CoQ10 deficiency.	-1
epilepsy	NF1	0.5246	0.0931	Individuals with seizures and NF1 typically require more aggressive therapy than those without NF1 and should be considered for epilepsy surgery when appropriate.	-1
encephalopathy	PEHO	0.5246	0.3484	We reported serial clinical, radiological, and neurophysiological findings of a patient with PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome.	-1
Permanent neonatal diabetes	KCNJ11	0.5246	0.1697	Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11.	-1
ISs	CDKL5	0.5244	0.2145	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
Cushing's syndrome	corticosteroid-binding-globulin	0.5244	0.1359	Therefore, patients investigated for Cushing's syndrome may show a falsely positive dexamethasone suppression test, and patients with adrenal insufficiency on steroid replacement may require increased doses of steroids; furthermore, increased corticosteroid-binding-globulin levels are also associated with chronic anticonvulsant administration.	-1
epilepsy	CDKL5	0.5244	0.3908	Both patients with CDKL5 mutation presented therapy-resistant epilepsy and a phenotype fitting with the diagnosis of early-onset variant of RTT.	1
Severe Myoclonic Epilepsy of Infancy	SCN1A	0.5243	0.4096	SCN1A Genetic Test for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy and its Clinical Subtypes) for use in the Diagnosis, Prognosis, Treatment and Management of Dravet Syndrome.	-1
epileptic encephalopathies	SCN8A	0.5242	0.5198	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
Rett syndrome	MECP2	0.5242	0.1157	One such gene is the transcription factor MECP2, whose loss of function in females results in Rett syndrome, while its duplication in males results in developmental delay and autism.	-1
genetic epilepsy	SCN1A	0.5241	0.3644	BACKGROUND Mutations in SCN1A can cause genetic epilepsy with febrile seizures plus (GEFS+, inherited missense mutations) or Dravet syndrome (DS, de novo mutations of all types).	-1
cardiovascular risk factor	cannabinoid-1 receptor	0.524	0.1877	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
dominant epilepsy syndrome	SCN1A	0.524	0.3931	Lossin and colleagues from Al George's lab report in this issue of Neuron that three missense mutations of SCN1A found in a dominant epilepsy syndrome disrupt inactivation, thereby producing small persistent inward Na(+) currents that may result in hyperexcitability and seizures.	1
TBS	KCNH1	0.5239	0.1407	Consistent with this result, we find that two mothers of children with TBS, who have epilepsy but are otherwise healthy, are low-level (10% and 27%) mosaic carriers of pathogenic KCNH1 mutations.	-1
periodic limb movements	DCX	0.5238	0.2431	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
neurologic diseases	prion protein	0.5238	0.3694	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
hypsarrhythmia	STK9	0.5238	0.2714	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
seizures	CHD2	0.5238	0.324	All three individuals with a CHD2 mutation had intellectual disability and fever-sensitive generalized seizures, as well as prominent myoclonic seizures starting in the second year of life or later.	-1
epilepsy	KCNQ2	0.5237	0.3263	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
Dravet syndrome	SCN1A	0.5237	0.5437	OBJECTIVE: To determine the genes underlying Dravet syndrome in patients who do not have an SCN1A mutation on routine testing.	-1
Rett syndrome	MECP2	0.5237	0.263	PURPOSE: To investigate the association between genotype (methyl-CpG-binding protein 2 (MECP2 gene mutation)) and epileptic seizure phenotype in Rett syndrome.	-1
myoclonic epilepsy	SCN1A	0.5236	0.595	In three patients with either Dravet syndrome or myoclonic epilepsy, we detected SCN1A mutations (p.R222X, p.P231P, p.R393H), even though other laboratories had previously excluded aberrations of this gene by Sanger sequencing or high-resolution melting analysis.	-1
JME	GABRD	0.5235	0.1444	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
neurodevelopmental disorder	CDKL5	0.5232	0.4334	Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.	-1
dysplastic	TRPC3	0.5232	0.3853	Intracellular application of anti-TRPC3 antibody to block TRPC3 channels and bath application of the selective TRPC3 inhibitor Pyr3 greatly diminished depolarization in immature control and both immature and mature dysplastic cortex with strong TRPC3 expression.	-1
rolandic epilepsy	KCNQ3	0.5232	0.1574	RESULTS: An in-frame deletion of codon 116 in KCNQ2 (p.Lys116del) and a missense mutation in KCNQ3 (p.Glu299Lys) were detected in two index cases exhibiting rolandic epilepsy and benign neonatal convulsions.	-1
Cerebellar hypoplasia	PEHO	0.5232	0.5385	Cerebellar hypoplasia, characteristic of true PEHO syndrome, was absent.	-1
DS	SCN1A	0.5232	0.3133	Mosaic SCN1A mutations have been identified in rare familial DS.	-1
DS.Journal	SCN1A	0.5232	0.13	Our findings suggest that SCN1A mutation leads to changes in the dopamine system that may contribute to the behavioral abnormalities in DS.Journal of Human Genetics advance online publication, 4 February 2016; doi:10.1038/jhg.2016.5.	-1
Arrhythmia	KCNQ1	0.5232	0.2037	Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death.	-1
Ohtahara syndrome	SCN2A	0.5231	0.38	Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome.	-1
premenstrual syndrome	AKR1C1	0.5231	0.1209	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
Dravet syndrome	SCN1A	0.5231	0.2276	Mutations involving the voltage-gated sodium channel alpha(I) gene SCN1A are major genetic causes of childhood epileptic disorders, as typified by Dravet syndrome.	-1
Rett syndrome	Netrin G1	0.523	0.1113	One report described a patient with atypical Rett syndrome who presented with early epilepsy and a de novo translocation which disrupted the Netrin G1 gene.	-1
neurological disorder	methyl CpG binding protein 2	0.523	0.08881	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
seizures	TCF4	0.5229	0.435	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
CM-SJS/TEN	HLA-A	0.5228	0.2187	HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC and AR-SJS/TEN with SOC.	-1
Rett syndrome	methyl CpG binding protein 2	0.5228	0.1718	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
RS	MECP2	0.5228	0.08239	INTRODUCTION: Rett syndrome (RS) was first reported in 1966 and in 1999 it was discovered that it was associated to mutations in the MECP2 gene.	-1
RTT	MECP2	0.5228	0.2741	A relationship between MECP2 loss-of-function mutations and oxidative stress has been previously documented in RTT patients and murine models.	-1
DS	SCN1A	0.5226	0.2001	METHODS: Ten patients with the diagnosis of DS associated with mutations in the SCN1A gene were investigated using simultaneous recording of electroencephalography and functional magnetic resonance imaging ((EEG-fMRI).	-1
acute lymphoblastic leukemia	L-asparaginase	0.5226	0.1905	We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.	-1
sclerosis	MVP	0.5223	0.2111	Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis.	-1
with febrile seizures plus	GABRD	0.5223	0.1398	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
SOC	HLA-A	0.5223	0.09435	HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC and AR-SJS/TEN with SOC.	-1
WS	NF1	0.5223	0.1313	WS with NF1 seems remarkably benign and resembles idiopathic WS more than symptomatic WS.	-1
epileptic encephalopathies	MECP2	0.5222	0.6631	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	1
encephalopathy	CMT2	0.5221	0.404	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
Rett syndrome	MECP2	0.5221	0.2623	Low bone mass is reported in growth-retarded patients harboring mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene causing Rett syndrome (RTT).	-1
acute lymphoblastic leukemia	L-asparaginase-induced	0.522	0.4155	L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.	-1
epileptic seizure	methyl-CpG-binding protein 2	0.522	0.6381	PURPOSE: To investigate the association between genotype (methyl-CpG-binding protein 2 (MECP2 gene mutation)) and epileptic seizure phenotype in Rett syndrome.	1
SMEI	SCN1A	0.5219	0.154	We describe the five gene loci localized in children with febrile seizures (FEB 1 5), the three genes identified in patients with generalized epilepsy with febrile seizures plus (GEFS+ 1 3) and the de novo mutations of gene SCN1A that have been identified to date in children with SMEI.	-1
SJS/TEN	HLA-C	0.5219	0.07253	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
ILS	PAFAH1B1	0.5219	0.4846	CONCLUSIONS: This study expanded the spectrum of PAFAH1B1 variants and identified a unique genomic architecture including microhomology sequences in PAFAH1B1 underlying an intragenic tandem duplication leading to ILS.	-1
HIV-infected	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.5219	0.3178	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
mental retardation	Mecp2	0.5218	0.2798	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	-1
seizure	LQT1	0.5218	0.1325	LQT1 and LQT3 combined cohorts did not differ significantly from expected, background rates of a seizure phenotype.	-1
developmental delay	ABCC8	0.5216	0.272	Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation.	-1
epilepsy	methyl CpG-binding protein 2	0.5216	0.1677	METHODS: We performed mutation screening of CDKL5 in 60 female patients who had been identified as negative for the methyl CpG-binding protein 2 gene (MECP2) mutations, but who had current or past epilepsy, regardless of the age of onset, type, and severity.	1
SMEI	SCN1A	0.5216	0.44	CONCLUSIONS: The rate of SCN1A mutations in this cohort of SMEI patients suggests that other factors may be important in SMEI.	-1
type of epilepsy	SCN1A	0.5215	0.2383	SCN1A is the uniquely identified gene directly linked to specific type of epilepsy, and its testing has been included in the screening processes.	1
Rett syndrome	MECP2	0.5215	0.4633	Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome.	-1
FHM	NaV1.1	0.5214	0.4503	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	-1
convulsions	KCNQ2	0.5214	0.06793	Two highly homologous voltage-gated potassium channels, KCNQ2 and KCNQ3, were found to be mutated in benign familial neonatal convulsions.	-1
deafness	TBC1D24	0.5214	0.1102	Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for TBC1D24 mutations.	-1
RTT	MeCP2	0.5213	0.3987	While evidence on an intimate involvement of MeCP2 in the immune response is cumulating, we have recently shown a cytokine dysregulation in RTT.	-1
CSS	BAF	0.5212	0.5244	As SMARCB1 encodes a subunit of the BAF complex functioning as a chromatin remodeling factor, mutations in 15 other subunit genes may cause CSS and thus were analyzed in 23 CSS patients.	-1
LQTS	SCN5A	0.5212	0.3072	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
neuroaxonal dystrophy	PKAN	0.5212	0.2263	Infantile neuroaxonal dystrophy is briefly described as there have been suggestions that it is a variety of PKAN, but the evidence is in favour of the two diseases being separate entities.	-1
Dravet syndrome	SCN1A	0.5212	0.285	PURPOSE: Dravet syndrome is an autosomal dominant epileptic encephalopathy of childhood, which is caused mainly by SCN1A and PCHD19 mutations.	-1
intellectual disability syndrome	KANSL1-related	0.5212	0.2202	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
Rett syndrome	CDKL5	0.5211	0.4634	A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.	-1
epilepsy	Nav1.1	0.521	0.356	Febrile temperatures unmask biophysical defects in Nav1.1 epilepsy mutations supportive of seizure initiation.	1
febrile seizures	SCN1A	0.5209	0.334	A novel SCN1A missense mutation causes generalized epilepsy with febrile seizures plus in a Chinese family.	-1
autosomal dominant nocturnal frontal lobe epilepsy	MECP2	0.5209	0.2006	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
epilepsy	KCNH2	0.5208	0.5345	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
familial hemiplegic migraine	SCN1A	0.5208	0.2497	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
encephalopathy	PEHO	0.5207	0.352	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
DS	SCN1A	0.5207	0.3008	This is the first report of mosaic SCN1A mutations in families with probands that do not exhibit DS, but manifest only a milder phenotype.	-1
DS	SCN1A	0.5207	0.05669	Dravet syndrome (DS) is a genetically determined epileptic encephalopathy mainly caused by de novo mutations in the SCN1A gene.	-1
LGS	CHD2	0.5206	0.4644	In this study, we aimed to explore the role of CHD2 in LGS, as CHD2 mutations have been described recently in various epileptic encephalopathies.	-1
RS	MeCP2	0.5206	0.2451	Neither the type of hearing loss nor the presence of preserved speech seemed to be correlated with the type of mutation in methyl-CpG-binding protein 2 (MeCP2) gene that is associated with RS.	-1
classic AGS syndrome	CSF	0.5205	0.1825	The absence of pleocytosis and normal CSF interferon alpha was a characteristic finding compared to the classic AGS syndrome.	-1
generalized epilepsy with	SCN1A	0.5205	0.3712	Mutations of SCN1A generate phenotypes ranging from the extremely severe form of Dravet syndrome (DS) to a mild form of generalized epilepsy with febrile seizures plus (GEFS+).	-1
epileptic encephalopathies	KCNQ2	0.5204	0.5014	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
sclerosis	SCN1A	0.5204	0.2777	Mesial temporal sclerosis in a cohort of children with SCN1A gene mutation.	-1
TSC	RIPK2	0.5204	0.3191	Furthermore, developmental differences were discernible in patients with TSC, compared with gene expression levels for patients 0 to 5 years to those 6 to 11 years of age, the latter with marked expression of IL-6 IL-1A, IL-1B, RIPK2, but also IL-10.	-1
Rett syndrome	MECP2	0.5202	0.3654	Mutational analysis of methyl-CpG binding protein 2 (MECP2) gene in Indian cases of Rett syndrome.	-1
fever	SCN1A	0.5202	0.352	None of the remaining patients with seizures precipitated by fever carried SCN1A mutations.	-1
febrile seizures	SCN1A	0.5202	0.4305	[Clinical analysis and screening for SCN1A gene mutation in two pedigrees of generalized epilepsies with febrile seizures plus].	-1
intellectual disability	KANSL1-related	0.5201	0.1132	The majority of individuals with the KANSL1-related intellectual disability syndrome function in the mild to moderate range of intellectual disability.	-1
BFNIS	SCN2A	0.5201	0.2593	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
myoclonic epilepsy	SCN1A	0.5201	0.3838	Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB).	-1
encephalopathy	SCN1A	0.5201	0.6205	Prolonged seizures were associated with acute encephalopathy in three SCN1A mutation-positive patients.	-1
neuronal hyperexcitability	SCN1A	0.5199	0.6422	We propose that, in addition to neuronal hyperexcitability, SCN1A haploinsufficiency alters cardiac electrical function and produces arrhythmias, providing a potential mechanism for SUDEP.	-1
epilepsy	KCC2-related	0.5199	0.2143	KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described.	1
epilepsy	Netrin G1	0.5199	0.2927	This study tested a sample of 91 female patients with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome without epilepsy for mutations in the Netrin G1 gene, to evaluate its involvement in this condition.	-1
febrile seizures	SCN1A	0.5197	0.2164	Mutations of the SCN1A subunit of the sodium channel is a cause of genetic epilepsy with febrile seizures plus (GEFS(+) ) in multiplex families and accounts for 70-80% of Dravet syndrome (DS).	-1
Dravet syndrome	SCN1A	0.5197	0.3619	CONCLUSION: A high percentage of SCN1A mutations was identified in our Chinese cohort of Dravet syndrome patients but none in the rest of patients.	-1
epileptic encephalopathy	SCN1A	0.5196	0.2332	Among these transmissions were two likely disease-causing mutations: an SCN1A mutation transmitted to an SUDC proband and her sibling with Dravet syndrome, as well as an SLC6A1 mutation in a proband with epileptic encephalopathy.	1
idiopathic	GABRA1	0.5196	0.306	Our results confirm that mutation of GABRA1 predisposes towards a common idiopathic generalized epilepsy syndrome in humans.	-1
severe mental retardation	CDKL5	0.5196	0.385	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	-1
Semi-dominant X-chromosome linked learning disability	MECP2	0.5196	0.08936	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
neurotoxicity	DPD	0.5195	0.47	5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.	-1
SJS/TEN	HLA-A	0.5193	0.08212	RESULTS: HLA-A*31:01 was confirmed to be significantly associated with definite/probable cases of CBZ-related SJS/TEN (p = 0.0040).	-1
intellectual disability	MECP2	0.5193	0.2825	Xq28 duplication syndrome including MECP2 is a neurodevelopmental disorder characterized by axial hypotonia at infancy, severe intellectual disability, developmental delay, mild characteristic facial appearance, epilepsy, regression, and recurrent infections in males.	-1
infancy	SCN1A	0.5192	0.165	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
plus	SCN1A	0.5191	0.1953	SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome.	-1
KS	PROK2/PROKR2	0.519	0.355	OBJECTIVES: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.	-1
seizures	NARP	0.5189	0.1756	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Rett syndrome	Netrin G1	0.5189	0.2584	This study tested a sample of 91 female patients with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome without epilepsy for mutations in the Netrin G1 gene, to evaluate its involvement in this condition.	-1
epileptic encephalopathy	TBC1D24	0.5188	0.4445	Early-onset epileptic encephalopathy with hearing loss in two siblings with TBC1D24 recessive mutations.	1
Hemophilia A	factor VIII	0.5188	0.1471	Hemophilia A is a genetic disorder leading to factor VIII (FVIII) deficiency, an important factor in the coagulation system.	-1
Dravet syndrome	SCN1A	0.5188	0.1604	We present two children who exhibited the characteristics of Dravet syndrome during infancy and young childhood, with SCN1A mutation, but nevertheless achieved seizure freedom for at least four years during adolescence.	-1
rolandic epilepsy	KCNQ2	0.5188	0.3517	RESULTS: An in-frame deletion of codon 116 in KCNQ2 (p.Lys116del) and a missense mutation in KCNQ3 (p.Glu299Lys) were detected in two index cases exhibiting rolandic epilepsy and benign neonatal convulsions.	-1
RTT	cyclin-dependent kinase-like 5	0.5187	0.0839	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	-1
TSC	IL-1B	0.5187	0.317	Furthermore, developmental differences were discernible in patients with TSC, compared with gene expression levels for patients 0 to 5 years to those 6 to 11 years of age, the latter with marked expression of IL-6 IL-1A, IL-1B, RIPK2, but also IL-10.	-1
KS	PROK2	0.5187	0.2618	Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation.	-1
epileptic	CYP2C9	0.5186	0.2448	METHODS: We performed a cross-sectional study to evaluate the association between CYP2C9 polymorphism and lipid profile, glucose homeostasis, and subclinical atherosclerosis in young epileptic patients via the ankle brachial index.	-1
autosomal-dominant epilepsy syndrome	SCN1A	0.5186	0.07845	Recent studies provided evidence that mutations in SCN1A represent the most frequent cause of generalized epilepsy with febrile seizures plus an autosomal-dominant epilepsy syndrome.	1
West/Ohtahara syndromes	STXBP1-related	0.5186	0.394	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
RTT	MECP2	0.5186	0.2878	METHODS: Retrospective survey of a large population of patients (n=154) evaluated between 1978 to 2007 (May) at the Child Psychiatry and Neurology Unit of Siena (Italy) with both clinical and genetic (i.e. MECP2 mutated) diagnoses of RTT.	-1
Dravet syndrome	SCN1A	0.5185	0.4348	OBJECTIVE: The aim of this study was to characterize the SCN1A mutation spectrum in Korean patients with Dravet syndrome.	-1
epilepsy syndrome	SCN1A	0.5185	0.2878	FINDINGS: SCN1A mutations were identified in 11 of 14 patients with alleged vaccine encephalopathy; a diagnosis of a specific epilepsy syndrome was made in all 14 cases.	1
Myoclonic Epilepsy of Infancy	NaV1.1	0.5185	0.0086	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
febrile seizure plus	SCN1A	0.5184	0.275	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
X-linked mental retardation syndrome	MECP2	0.5184	0.3623	Duplication of MECP2 causes a recently described X-linked mental retardation syndrome, of which the typical features are infantile hypotonia, poor speech development, recurrent infections, epilepsy, and progressive spasticity.	-1
febrile seizures	SCN1A	0.5183	0.352	We describe the five gene loci localized in children with febrile seizures (FEB 1 5), the three genes identified in patients with generalized epilepsy with febrile seizures plus (GEFS+ 1 3) and the de novo mutations of gene SCN1A that have been identified to date in children with SMEI.	-1
XMPMA	FHL1	0.5183	0.2301	FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718).	-1
Rett syndrome	MECP2	0.5182	0.2189	Rett syndrome (RTT) is a rare neurodevelopmental disorder, linked to MECP2 gene mutations in the majority of cases, which results in severe disability and is associated with several comorbidities.	-1
seizures	LIS1	0.5182	0.2067	A 6-month-old infant with LIS1 17p13.3 deletion-positive Miller-Dieker syndrome (MDS) presented with increased seizures in the setting of a Pseudomonal and Enterococcal urinary tract infection and a buttock abscess associated with a lumbosacral dermal sinus tract.	-1
seizure	SCN5A/gastrointestinal	0.5182	0.08337	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
mesial frontal lobe area	alien	0.5181	0.1985	The alien hand syndrome is rare, occurring with lesions in the mesial frontal lobe area and corpus callosum.	-1
Hypochondroplasia	FGFR3	0.5181	0.3367	Hypochondroplasia with FGFR3 mutation associated with bilateral medial temporal lobe anomalies and focal epilepsy was previously reported in several patients.	-1
Dravet syndrome	GAPDH's	0.5181	0.1551	A novel variant in the 3' UTR of human SCN1A gene from a patient with Dravet syndrome decreases mRNA stability mediated by GAPDH's binding.	-1
epilepsy	SCN1A	0.518	0.1599	CONCLUSIONS: Based on the early age of presentation and the severity of the epilepsy reported for the majority of the seizure-positive cases it was concluded that SMEI/DS could be the epileptic encephalopathy associated with deletions within the 2q22.1-q33.3 region, due to haploinsuffiency of SCN1A and/or complete or partial deletion of other voltage-gated sodium channel genes caused by the aberration.	1
facial dysmorphism	KANSL1	0.518	0.2208	Striking clinical criteria for enrolling patients into KANSL1 analysis include speech delay, distinctive facial dysmorphism, macrocephaly and friendly behaviour.	-1
epilepsy	SCN1B	0.5179	0.6093	Investigation of genes associated with infantile forms of epilepsy such as SCN1A, SCN1B, and ARX were negative, but we identified a novel single-nucleotide duplication mutation, c.931dupT (p.S311FfsX3), in exon 11 of the STXBP1 gene.	1
seizure	interleukin-4, -6, and-8	0.5179	0.4031	An elevation of interleukin-6, -8, and -10, and tumor necrosis factor in the serum and that of interleukin-4, -6, and-8 in the cerebrospinal fluid were observed at the onset of a late seizure.	-1
Dravet syndrome	STXBP1	0.5178	0.3693	GABRA1 and STXBP1: novel genetic causes of Dravet syndrome.	-1
epilepsy	MRI	0.5178	0.2271	MRI for patients with localization-related intractable epilepsy should have high-resolution, multiplanar and multisequence.	-1
infantile spasms	CDKL5-related	0.5178	0.09421	The affected 4-year-old girl presented with infantile spasms, beginning at the age of 9 months, but subsequent progression of the disease was consistent with the classical CDKL5-related phenotype.	-1
autism	MBD6	0.5177	0.2395	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
aVWS	VWF	0.5176	0.1504	Changes of VWF parameters were also found but no patient developed laboratory defined aVWS.	-1
mucosal involvement	HLA-A	0.5175	0.1461	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.	-1
seizure	KCNH2-encoded	0.5174	0.07281	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
Pitt-Hopkins syndrome	TCF4	0.5174	0.4348	Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations.	-1
Knobloch syndrome	collagen XVIII	0.5173	0.2426	Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome.	-1
BFLS	PHF6	0.5172	0.4267	Among these, a novel, widely expressed zinc-finger (plant homeodomain (PHD)-like finger) gene (PHF6) had eight different missense and truncation mutations in seven familial and two sporadic cases of BFLS.	-1
ADPEAF	LGI2	0.5172	0.2066	ADPEAF is genetically heterogeneous, but mutations in LGI2, LGI3, or LGI4 did not account for families without LGI1 mutations.	-1
infancy	GABRD	0.5172	0.2154	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
) syndrome	MECP2	0.5172	0.2214	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
WHS	WFS1	0.5171	0.143	To explain the complex phenotype of a patient with WHS and features reminiscent of Wolfram syndrome (WFS (MIM 222300)), we performed extensive clinical evaluation and classical and molecular cytogenetic (GTG banding, FISH and array-CGH) and WFS1 gene mutation analyses.	-1
absence seizures	CACNA1A	0.5171	0.1474	However, the subjects harboring SCN1A mutations and CACNA1A variants had absence seizures more frequently than the patients with only SCN1A mutations (8/20 vs. 0/20, p=0.002).	-1
intellectual disability syndrome	KANSL1-related	0.5171	0.2402	GENETIC COUNSELING: The KANSL1-related intellectual disability syndrome, caused by a microdeletion or a mutation of KANSL1, is inherited in an autosomal dominant manner, but to date almost all cases result from a de novo deletion or KANSL1 mutation.	-1
pulmonary stenosis	Neurofibromatosis 1	0.5171	0.4078	Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1.	-1
intracranial neoplasm	NF1	0.5169	0.1112	SIGNIFICANCE: Compared to the general population, seizures are more common in individuals with NF1, where they are often focal and related to an intracranial neoplasm.	-1
HH	GLI3	0.5169	0.3064	Resequencing of GLI3 did not identify causative germline mutations but did identify LOH within the GLI3 gene in the HH tissue samples of three patients.	-1
encephalopathy	PEHO	0.5169	0.3114	[A case of PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome: changes in clinical and neuroradiological findings].	-1
CAH	multiple endocrine neoplasia 2A	0.5168	0.2156	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
neurodevelopmental disorder	NRXN1	0.5167	0.1242	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
lissencephaly	LIS1	0.5167	0.4053	With few exceptions, children with LIS1 mutations have isolated lissencephaly, with severe developmental delay and infantile spasms.	-1
seizures	NaV1.1	0.5167	0.2327	Like other voltage-gated sodium channels, NaV1.1 function contributes to the rising phase of the neuronal action potential; thus, the observation that loss-of-function mutations in this channel gene are associated with seizures has created a paradox for the field.	-1
myopathy	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.5165	0.08625	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Pitt-Hopkins syndrome	TCF4	0.5165	0.226	Pitt-Hopkins syndrome is characterized by mental retardation, hyperventilation, and dysmorphic features due to TCF4 mutations.	-1
channelopathy	SCN1a	0.5165	0.276	Evidence has emerged of the consequences of SCN1a dysfunction in different neuronal networks across the brain pointing toward a channelopathy model causing the neurologic features of Dravet syndrome that is beyond purely seizure related damage.	-1
neuronal excitability	KCC2	0.5164	0.05934	Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.	-1
Dravet syndrome	GABRD	0.5163	0.1546	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizure	SCN1A	0.5163	0.128	SCN1A testing can be done through bi-directional DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) for: 1) individuals with electroclinical phenotype of Dravet Syndrome or clinical sub-types - several seizure types in one individual with onset in infancy, refractory to medication and with generalised spike and wave on EEG, or 2) infants less than 1 year old with 2 or more prolonged hemiclonic febrile seizures in early infancy.	-1
deficiency	fibrinogen	0.5163	0.3109	Three patients with dysfibrinogenemia or fibrinogen deficiency showed normal or slightly prolonged PT values and normal APTT values.	-1
benign neonatal epilepsy	KCNQ3	0.5163	0.5777	Novel KCNQ2 and KCNQ3 mutations in a large cohort of families with benign neonatal epilepsy: first evidence for an altered channel regulation by syntaxin-1A.	-1
kyphoscoliosis	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.5162	0.1067	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Coffin-Siris syndrome	PHF6	0.5162	0.1829	Our report confirms that PHF6 loss in females results in a recognizable phenotype overlapping with Coffin-Siris syndrome and distinct from Borjeson-Forssman-Lehmann syndrome.	-1
systemic sclerosis	MECP2	0.5162	0.2991	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
seizures	SCN1A	0.5162	0.4292	De novo SCN1A mutations in migrating partial seizures of infancy.	-1
benign familial neonatal epilepsy	KCNQ2	0.5162	0.1379	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
seizures	KCNQ2	0.5161	0.2028	Infantile seizures and other epileptic phenotypes in a Chinese family with a missense mutation of KCNQ2.	-1
craniosynostosis	FGFR3-related	0.516	0.2329	Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.	-1
infancy	GABRG2	0.5159	0.04239	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
speech impairment	MBD5	0.5159	0.2581	Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.	-1
cleft palate	SATB2	0.5158	0.2	Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects.	-1
hypsarrhythmia	PEHO	0.5158	0.2395	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
edema	PEHO	0.5158	0.2146	[A case of PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome: changes in clinical and neuroradiological findings].	-1
febrile seizures plus syndrome	protocadherin 19	0.5158	0.229	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
congenital hyperinsulinism	ABCC8	0.5158	0.4005	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
cognitive impairment	SCN1A	0.5157	0.2599	Dravet syndrome is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment, thus well illustrating the concept of epileptic encephalopathy.	-1
cognitive impairment	SCN1A	0.5157	0.2599	Dravet syndrome (DS) is a childhood disorder associated with loss-of-function mutations in SCN1A and is characterized by frequent seizures and severe cognitive impairment.	-1
Creutzfeld-Jakob disease	CSF and EEG	0.5157	0.1616	In a 64-year old woman with progressive visual impairment for 4 weeks, probable Creutzfeld-Jakob disease without myoclonus was diagnosed after rapidly progressive mental deterioration had also developed, and CSF and EEG showed characteristic findings.	-1
MERRF	CLN5	0.5156	0.04264	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
infantile spasms	LIS1	0.5154	0.06708	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
dominantly inherited neonatal seizures	KCNQ3	0.5154	0.07747	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
RTT	CDKL5	0.5154	0.02246	In order to clarify the CDKL5 genotype-phenotype correlations in Chinese patients, CDKL5 mutational screening in cases with early-onset epileptic encephalopathies and RTT without MECP2 mutation were performed.	-1
West syndrome	GRIN1	0.5152	0.4242	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
Epilepsy	Anti-NMDA-NR2A/B	0.5152	0.289	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	1
atherosclerosis	CYP2C9	0.5152	0.1961	Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.	-1
seizures	CC2D2A-related	0.5152	0.2031	Genotype-phenotype correlation in CC2D2A-related Joubert syndrome reveals an association with ventriculomegaly and seizures.	-1
neonatal diabetes	IER3IP1	0.5152	0.4158	Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder.	-1
PTLE	CA4	0.5151	0.181	Maximal neuron loss (mean loss 38%) occurred in the CA4 region in six patients with PTLE (end folium sclerosis).	-1
autosomal dominant seizure disorders	KCNQ2	0.5151	0.2107	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
epileptic	MECP2	0.5151	0.3772	Drug-resistant epilepsy and epileptic phenotype-EEG association in MECP2 mutated Rett syndrome.	1
intellectual disability	TRMT10A	0.515	0.08408	TRMT10A sequencing should be considered in children or adults with young-onset diabetes who have a history of intellectual disability, microcephaly and epilepsy.	-1
Dravet syndrome	SCN1A	0.515	0.4148	CONCLUSIONS: We show that GABRA1 and STXBP1 make a significant contribution to Dravet syndrome after SCN1A abnormalities have been excluded.	-1
autonomic dysfunction	TCF4	0.5149	0.05186	Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction.	-1
NES	CLN8	0.5148	0.2744	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
neonatal diabetes	sulphonylurea receptor SUR1	0.5148	0.3096	A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.	-1
familial Dravet syndrome	SCN1A	0.5148	0.3862	This report of parental SCN1A nonsense mutation mosaicism in familial Dravet syndrome suggests that mosaicism might be more common than previously suspected and emphasizes the importance of taking mosaicism into account in genetic counselling of Dravet syndrome and SCN1A mutations.	-1
neurological symptoms	CDKL5/STK9	0.5147	0.2672	Recently, we showed that truncation of the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene caused mental retardation and severe neurological symptoms in two female patients.	-1
generalized epilepsy	SCN1A	0.5147	0.3601	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
JS	CC2D2A-related	0.5147	0.2524	No mutation-specific genotype-phenotype correlations could be identified, but the findings confirm the observation that mutations that cause CC2D2A-related JS are predicted to be less deleterious than mutations that cause CC2D2A-related Meckel syndrome.	-1
mental retardation	MECP2	0.5146	0.1834	Molecular studies of the MECP2 gene have shown that the clinical phenotype of RS is far broader than the one initially described and has numerous variants, which may be either more or less severe, and there are even mutations in males and in other non-Rett phenotypes, as well as in cases of mental retardation in which the aetiology is unknown.	-1
dominantly inherited syndrome	NF2	0.5146	0.2404	Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein.	-1
motor impairment	SMA	0.5146	0.2617	BACKGROUND: In adults, resection of the medial frontal lobe has been shown to result in supplementary motor area (SMA) syndrome, a disorder characterized by transient motor impairment.	-1
epileptic	CYP3A4	0.5145	0.1021	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2 and CYP2C19 in vivo in epileptic patients.	-1
neurodevelopmental disorder	MECP2	0.5145	0.2735	Xq28 duplication syndrome including MECP2 is a neurodevelopmental disorder characterized by axial hypotonia at infancy, severe intellectual disability, developmental delay, mild characteristic facial appearance, epilepsy, regression, and recurrent infections in males.	-1
tonic-clonic	TBC1D24	0.5145	0.3386	The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms.	-1
diabetic	MODY2	0.5143	0.06569	Fasting hyperglycemia in the diabetic range, impaired glucose tolerance, and lack of diabetes autoantibodies were compatible with MODY2.	-1
corpus callosum	LIS1	0.5143	0.1047	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
HHE	SCN1A	0.5142	0.3327	We subsequently screened 10 additional HHE patients for SCN1A.	1
temporal lobe epilepsy	parvalbumin	0.5142	0.2541	We studied hippocampus and temporal cortex from human CJD and control autopsy brains and surgical cryptogenic temporal lobe epilepsy specimens for distribution and density of parvalbumin (PV) and calbindin-D28K (Cal) -positive neurons that are subpopulations of GABAergic neurons.	-1
Dravet syndrome	SCN1A	0.5142	0.2761	The sequencing analyses of the SCN1A gene revealed the presence of a putative disease-associated haplotype in two patients affected with Dravet syndrome.	-1
Rett syndrome	MECP2	0.5142	0.2113	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
Febrile infection-related	SCN1A	0.5142	0.08334	Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations.	-1
long-QT-syndromes	KCNH2	0.5141	0.0646	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
non-syndromic facial port-wine stain	GNAQ	0.5141	0.3983	Our understanding of the disease process has vastly improved since it was first described in 1879, with recent identification of an activating somatic mutation in the GNAQ gene found in association with both Sturge-Weber syndrome and non-syndromic facial port-wine stain.	-1
epileptic encephalopathy	CDKL5	0.5141	0.3803	Optimizing the molecular diagnosis of CDKL5 gene-related epileptic encephalopathy in boys.	1
PS	SCN1A	0.514	0.3612	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
epilepsia	Alien	0.514	0.3128	Alien hand syndrome after epilepsia partialis continua: FDG PET and MRI studies.	-1
CSS	BAF	0.5139	0.3751	As SMARCB1 encodes a subunit of the BAF complex functioning as a chromatin remodeling factor, mutations in 15 other subunit genes may cause CSS and thus were analyzed in 23 CSS patients.	-1
epilepsy	SCN1A	0.5139	0.5215	In patients with MCDs and a history of polymorphic seizures precipitated by fever, SCN1A gene testing should be performed before discussing any epilepsy surgery option, due to the possible implications for outcome.	1
infantile spasms	CDKL5	0.5139	0.3916	CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.	-1
CBZ-SJS/TEN	HLA-A	0.5139	0.1491	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
rare disease	Gs-alpha	0.5138	0.1413	This is a rare disease due to post-zygotic and somatic mutations of the Gs-alpha gene, that results in cellular mosaicism.	-1
dystroglycanopathies	laminin alpha-2	0.5137	0.106	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizures	TBC1D24	0.5136	0.1501	Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for TBC1D24 mutations.	-1
cognitive impairment	FOXG1	0.5135	0.2329	Over the last several years, intragenic or genomic alterations of the CDKL5 and FOXG1 genes have been associated with severe cognitive impairment, early onset epilepsy and, often, dyskinetic movement disorders, which have variably been defined as Rett variants.	-1
Dravet syndrome	SCN8A	0.5135	0.3176	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
brain MRI abnormalities	CREBBP	0.5135	0.3521	There were no remarkable significant differences in the clinical features between those with and without a CREBBP mutation, although brain MRI abnormalities were more frequently observed in those with a CREBBP mutation.	-1
Stevens-Johnson syndrome	HLA-A	0.5135	0.1761	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.	-1
epilepsy	KCNT1	0.5134	0.2816	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
sclerosis	prion protein	0.5134	0.244	Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant.	-1
Unverricht-Lundborg disease	EPM1	0.5134	0.253	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
FHM	SCN1A	0.5133	0.1536	Different SCN1A mutations are known to cause a variety of phenotypes, such as generalized epilepsy with febrile seizures plus (GEFS+), Dravet syndrome and familial hemiplegic migraine (FHM).	-1
myokymia	KCNQ2	0.5133	0.4041	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
epileptic encephalopathy	SRPX2-related	0.5133	0.4992	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
Seizure	Neurofibromatosis 1	0.5133	0.3578	Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1.	-1
DS	Nav1.1	0.5133	0.2144	These findings suggest a fundamental role for Nav1.1 in facilitating fast-firing properties in neurons, highlight the importance of precise temporal control of theta frequency for working memory, and imply that Nav1.1 deficits may disrupt information processing in DS via a dysregulation of brain rhythms.	-1
MDC1A	laminin alpha-2	0.5132	0.2056	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
FHM	NaV1.1	0.5131	0.474	However, functional studies of NaV1.1 FHM mutations have generated controversial results.	-1
seizures	COX1	0.5129	0.1745	A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis.	-1
PHS	TCF4	0.5128	0.2817	We subsequently identified two de novo heterozygous missense mutations of a conserved amino acid in the basic region of the TCF4 gene in three additional subjects with PHS.	-1
Dravet syndrome	GABRG2	0.5127	0.1403	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epileptic encephalopathy	SLC6A1	0.5126	0.5665	Among these transmissions were two likely disease-causing mutations: an SCN1A mutation transmitted to an SUDC proband and her sibling with Dravet syndrome, as well as an SLC6A1 mutation in a proband with epileptic encephalopathy.	1
ataxia	EA1	0.5126	0.3847	EA1 is a dominant human neurological disorder characterized by variable phenotypes of brief episodes of ataxia, myokymia, neuromyotonia, and associated epilepsy.	-1
myoclonic epilepsy	SCN1A	0.5126	0.2305	Mutations in the alpha-subunit of the first neuronal sodium channel gene SCN1A have been described in isolated patients with severe myoclonic epilepsy in infancy or Dravet syndrome and in families with generalized epilepsy with febrile seizures plus.	-1
seizure	SCN1A	0.5125	0.2798	Dravet syndrome is a rare epileptic encephalopathy linked to mutations in SCN1A (neuronal sodium channel a1 subunit) and characterized by an onset in infancy with polymorphous seizure types and developmental decline.	-1
developmental delay	CDKL5	0.5123	0.1928	Recent studies have shown that aberrations of CDKL5 in female patients cause early-onset intractable seizures, severe developmental delay or regression, and Rett syndrome-like features.	-1
Viral encephalitis	CSF	0.5123	0.1034	Viral encephalitis causes an altered level of consciousness, which may be associated with fever, seizures, focal deficits, CSF pleocytosis, and abnormal neuroimaging.	-1
ID	GRIN2B	0.5123	0.4325	INTERPRETATION: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe developmental delay as well as of ID with childhood onset focal epilepsy.	-1
cancer	major vault protein	0.5122	0.2027	The human major vault protein (MVP) has been implicated in the development of drug resistance in cancer cells.	-1
seizures	NF1	0.5122	0.1323	Individuals with seizures were more likely to have inherited NF1 from their mother (p = 0.001).	-1
Dravet syndrome	SCN1A	0.512	0.5038	Approximately 80% of patients with Dravet syndrome have been associated with heterozygous mutations in SCN1A gene encoding voltage-gated sodium channel (VGSC) a(I) subunit, whereas a homozygous mutation (p.Arg125Cys) of SCN1B gene encoding VGSC b(I) subunit was recently described in a patient with Dravet syndrome.	-1
migraine	NaV1.1	0.512	0.3458	Nonfunctional NaV1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects.	-1
SMEI	GABRG2	0.5119	0.07115	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
seizures	SCN1A	0.5119	0.2166	Moreover, our data show that SCN1A gene does not contribute significantly to susceptibility to autonomic seizures during fever in patients with PS.	-1
obese	CB1	0.5119	0.1105	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
LD	EPM2A	0.5117	0.3033	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
Rett syndrome	CDKL5	0.5115	0.4961	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
childhood absence epilepsy	GABRG2	0.5115	0.284	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
myoclonic epilepsy of infancy	protocadherin 19	0.5115	0.2037	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
autoimmune diseases	MECP2	0.5115	0.4186	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
epilepsy	SCN1A	0.5115	0.2207	We presented five new cases with a chromosome 2q24.3 deletion involving SCN1A and investigated their epilepsy phenotype in relation to the extent of the deletion.	1
subarachnoid haemorrhage	Aura	0.5115	0.3412	Aura attacks from acute convexity subarachnoid haemorrhage not due to cerebral amyloid angiopathy.	-1
long QT syndrome	KCNQ1	0.5114	0.3028	That long QT syndrome mutations in KCNQ1 cause epilepsy reveals the dual arrhythmogenic potential of an ion channelopathy coexpressed in heart and brain and motivates a search for genetic diagnostic strategies to improve risk prediction and prevention of early mortality in persons with seizure disorders of unknown origin.	-1
Dravet syndrome	SCN1A-related	0.5113	0.3043	Seizures in children with SCN1A-related Dravet syndrome occurred more often with a body temperature below 38.5  C (57.9% vs. 32.6%, p=0.020) and reoccurred more often after following vaccinations (26.7% vs. 4.0%, p=0.003), than in children without a diagnosis of SCN1A-related Dravet Syndrome.	-1
epileptic encephalopathies	GRIN2A	0.5113	0.2672	We sought to delineate the pathogenic role of GRIN2A in 519 probands with epileptic encephalopathies with diverse epilepsy syndromes.	1
epileptic seizure disorder	CDKL5	0.5113	0.3576	CONCLUSIONS: The spectrum of the epileptic seizure disorder, and associated EEG changes, in those with CDKL5 mutations is broader than previously reported.	1
epilepsy	GABRD	0.5112	0.2641	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	1
absence seizures	GABRB3	0.5112	0.2496	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
amyloidosis	TTR	0.5111	0.1523	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
encephalopathy	PEHO	0.5111	0.503	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
ID	NR2B	0.511	0.1951	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
Dravet syndrome	SCN1A	0.5109	0.4062	Our aim was the molecular analysis of SCN1A gene in affected Iranian patients with GEFS+ and Dravet syndrome diagnosed clinically to explain genotype-phenotype correlation and exact classification.	-1
symptomatic generalized epilepsy	SCN1A	0.5109	0.2502	We identified the first partial SCN1A duplications in two siblings with typical DS and in a patient with early-onset symptomatic generalized epilepsy.	-1
seizure	QPRT	0.5108	0.03461	Sequencing analyses showed no mutations in DOC2A, QPRT, and SEZ6L2, genes within the duplicated 16p11.2 region that have been implicated in neuronal function and/or seizure related phenotypes.	-1
BFNC	EBN1	0.5107	0.179	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
SLE	anti-NMDA-NR2A/B	0.5106	0.3119	The exact percentage of SLE patients having anti-NMDA-NR2A/B antibodies varies in different studies from 14 to 35%, and in one study such antibodies were found in 81% of patients with diffuse 'Neuropshychiatric SLE', and in 44% of patients with focal 'Neuropshychiatric SLE'.	-1
DS	SCN1A	0.5106	0.4427	About 50% of SCN1A DS mutations truncate Na(V)1.1, possibly causing complete loss of its function.	-1
ICEGTC	SCN1A	0.5106	0.1697	To test whether ICEGTC arises from molecular mechanisms similar to those involved in SMEI, we characterized eight ICEGTC missense mutations by whole-cell patch clamp recording of recombinant human SCN1A heterologously expressed in cultured mammalian cells.	-1
PME	SCN1A	0.5106	0.1553	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
DS	GABRD	0.5106	0.09526	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
severe myoclonic epilepsy of infancy	SCN1A	0.5105	0.2333	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
cognitive impairment	Nav1.1	0.5105	0.3279	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
DS	SCN1A	0.5105	0.2766	However, the genetic causes of DS without mutations in SCN1A remain largely unknown.	-1
myoclonic epilepsy of infancy	SCN1A	0.5104	0.3602	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
epileptic encephalopathies	SCN1A	0.5104	0.3371	The SCN1A gene variants and epileptic encephalopathies.	1
SMEI	SCN1A	0.5104	0.3323	Mutations in SCN1A are found in both SMEI and ICEGTC at high rates of 70-81%.	-1
seizures	CDKL5	0.5102	0.3647	In light of the data presented we discuss the possible phenotypic modulatory effects of the supernumerary wild type X allele and pattern of X chromosome inactivation and stress the importance of considering the causal involvement of CDKL5 in developmentally delayed males with early-onset seizures.	-1
hereditary diseases	cystathionine beta-synthase	0.5102	0.07989	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
catamenial epilepsy	AKR1C1	0.5102	0.1278	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
endometriosis	AKR1C1	0.5102	0.1125	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
channelopathies	SCN2A	0.51	0.09544	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
channelopathies	SCN1B	0.51	0.09544	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
TSC	IL-10	0.51	0.2833	Furthermore, developmental differences were discernible in patients with TSC, compared with gene expression levels for patients 0 to 5 years to those 6 to 11 years of age, the latter with marked expression of IL-6 IL-1A, IL-1B, RIPK2, but also IL-10.	-1
volvulus	CSF	0.51	0.1226	Polymerase chain reaction (PCR) of O. volvulus was performed in skin and CSF.	-1
long-QT-syndromes	SCN5A	0.51	0.1556	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
SMEI	SCN1A-mutation-negative	0.51	0.4545	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
T/T	T-bet	0.5099	0.1988	Regarding SNPs in promoter regions (rs4794067 and rs17250932) of T-bet, however, IQ below 50 was found in 19% of wild type (T/T) and 0% of heterologous (T/C) genotype of rs4794067, and in 19% of wild type (T/T) and 0% of heterologous (T/C) genotype of rs17250932.	-1
CMD	SEPN1-related	0.5098	0.2865	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
prolonged febrile seizures	SCN1A	0.5098	0.4691	SCN1A gene mutations are linked to multiple epilepsy syndromes with patients frequently presenting with prolonged febrile seizures.	-1
epileptic encephalopathy	ARX-related	0.5098	0.5751	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
infantile spasms	GABRA1	0.5097	0.3323	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
myoclonic epilepsy	SCN1A	0.5097	0.3841	Mutations in the voltage-gated sodium channel gene SCN1A are a major cause of severe myoclonic epilepsy of infancy (Dravet syndrome) and generalized epilepsy with febrile seizures plus.	-1
myoclonic epilepsy	SCN1A	0.5097	0.1643	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
Dravet syndrome	TSPYL4	0.5096	0.1311	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
epilepsy	MECP2	0.5096	0.3569	Neither aBMD(spine) , vBMAD(spine) , nor aBMD(total hip) were significantly associated with epilepsy, antiepileptic treatment, MECP2 mutation group, XCI, or vitamin D status.	1
Panayiotopoulos syndrome	SCN1A	0.5094	0.1925	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
DS	SCN1A	0.5094	0.3368	Approximately 80% of Chinese DS patients have SCN1A mutations.	-1
epilepsy	ERG	0.5094	0.03831	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
infantile spasms	GRIN2B	0.5094	0.1573	Subsequent screening of 47 patients with unexplained infantile spasms did not reveal additional de novo mutations, but detected a carrier of a novel inherited GRIN2B splice site variant in close proximity (c.2011-5_2011-4delTC).	-1
genetic epilepsy	protocadherin 19	0.5092	0.2542	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
sclerosis	Major vault protein	0.5092	0.2396	Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis.	-1
genetic disease	CLC	0.5092	0.1872	Every human CLC channel gene has been linked to a genetic disease, and studying these mutations has provided much information about the physiological roles and the molecular basis of CLC channel function.	-1
infancy	SCN1A	0.5092	0.03813	A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.	-1
Dravet syndrome	SCN1A-mutations	0.5091	0.228	Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome.	-1
epileptic encephalopathies	STXBP1	0.509	0.1403	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	1
long-QT-syndromes	KCNQ1	0.509	0.03969	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
Ohtahara syndrome	KCNQ2	0.5089	0.1606	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
Dravet syndrome	SCN1A	0.5089	0.4363	We evaluated clinical differences, if any, between young patients with and without a SCN1A mutations and a definite clinical diagnosis of Dravet syndrome.	-1
edema	PEHO	0.5088	0.2468	We reported serial clinical, radiological, and neurophysiological findings of a patient with PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome.	-1
FS	GABRG2	0.5088	0.1109	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Rett syndrome-like	CDKL5	0.5088	0.4277	The CDKL5 gene has been implicated in infantile spasms and more recently in a Rett syndrome-like phenotype.	-1
macrocephaly	PTEN	0.5087	0.4946	Phosphatase and tensin homolog (PTEN) gene mutations are associated with a spectrum of clinical disorders characterized by skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers.	-1
intellectual disability	MECP2	0.5087	0.1119	BACKGROUND: Duplications of the X-linked MECP2 gene are associated with moderate to severe intellectual disability, epilepsy, and neuropsychiatric illness in males, while triplications are associated with a more severe phenotype.	-1
Dravet syndrome	SCN1A-related	0.5086	0.4056	To determine differences in characteristics of reported seizures after vaccination in children with and without SCN1A-related Dravet syndrome.	-1
seizure	KCNQ2	0.5085	0.2494	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
hemiparesis	SCN1A	0.5083	0.3286	The patient with SCN1A mutation had the earliest onset of febrile convulsion and hemiparesis.	-1
epileptic encephalopathies	KCNQ2	0.5083	0.1392	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	1
Myeloneuropathy and Limb Contractures	Phosphoserine Phosphatase	0.5083	0.3051	Novel Report of Phosphoserine Phosphatase Deficiency in an Adult with Myeloneuropathy and Limb Contractures.	-1
epilepsy	CDKL5	0.5083	0.2031	Early epilepsy with normal interictal EEG and severe hypotonia are the key clinical features in identifying patients likely to have CDKL5 mutations.	1
severe myoclonic epilepsy of infancy	SCN1A	0.5083	0.377	The frequencies of SCN1A mutations in suspected severe myoclonic epilepsy of infancy (SMEI), its borderline phenotype (SMEB) and intractable epilepsy were 56.2%, 41.9% and 28.9% respectively.	-1
MBD	MECP2	0.5081	0.1625	The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1.	-1
Rubinstein-Taybi syndrome	SLC9A6	0.5081	0.5283	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
cortical atrophy	FGFR3	0.5081	0.1536	The disorder is caused by a mosaic R248C mutation of the FGFR3 gene, which is characterized by a keratinocytic epidermal nevus, acanthosis nigricans, and neurological abnormalities like seizures, intellectual impairment, cortical atrophy, and underdevelopment of corpus callosum.	-1
epidermal nevus syndrome	Fibroblast growth factor receptor 3	0.508	0.4416	Garcia-Hafner-Happle syndrome, also known as Fibroblast growth factor receptor 3 epidermal nevus syndrome, is a new neurocutaneous phenotype, which has been identified in 2008 by Garc  'a-Vargas et al.	-1
genetic disorder	factor VIII	0.5079	0.3409	Hemophilia A is a genetic disorder leading to factor VIII (FVIII) deficiency, an important factor in the coagulation system.	-1
intellectual disability syndrome function	KANSL1-related	0.5078	0.288	The majority of individuals with the KANSL1-related intellectual disability syndrome function in the mild to moderate range of intellectual disability.	-1
neonatal epilepsies	KCNQ3	0.5077	0.1775	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
encephalopathy	PEHO	0.5075	0.2256	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
epilepsy	MECP2	0.5075	0.4409	Associations with MECP2 mutations or epilepsy were not demonstrated, contrary to previous findings.	1
epileptic	insulin	0.5075	0.3497	PURPOSE: We investigated the influence of the CYP2C9 polymorphism on the lipid profile, insulin resistance, and subclinical atherosclerosis in young epileptic patients.	-1
epilepsy	CETN3	0.5074	0.123	It included five genes: CETN3, AC093510.2, POLR3G, LYSMD3 and the proximal part of GPR98/MASS1, a known epilepsy gene.	-1
generalized epilepsies	SCN1A	0.5073	0.6322	[Clinical analysis and screening for SCN1A gene mutation in two pedigrees of generalized epilepsies with febrile seizures plus].	-1
hypercalciuric nephrolithiasis	cystathionine beta-synthase	0.5073	0.2471	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
atherosclerosis	CYP2C9	0.5073	0.3143	METHODS: We performed a cross-sectional study to evaluate the association between CYP2C9 polymorphism and lipid profile, glucose homeostasis, and subclinical atherosclerosis in young epileptic patients via the ankle brachial index.	-1
ataxia	MECP2	0.5072	0.1192	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
seizures	ANKH	0.5072	0.2716	A mutation within the ANKH gene on chromosome 5p has been found previously in this family; other patients with familial CCAL (but without seizures) have mutations in the same gene.	-1
long QT syndrome	KCNQ2-5	0.5072	0.14	Neuronal KCNQ (Kv7) channels (KCNQ2-5 or Kv7.2-7.5, disclosed to date) were discovered by virtue of their homology with a known cardiac channel involved in long QT syndrome (KvLQT or KCNQ1, Kv7.1) and first disclosed in 1998.	-1
haploinsufficiency syndrome	MBD5	0.5072	0.1374	The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan   McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion).	-1
rigidity	ATP13A2	0.5071	0.03666	The youngest 5 of 17 children of nonconsanguineous parents, carrying compound-heterozygous ATP13A2 mutations, had normal development until ages    10 to 12 years, when school performance deteriorated and slowness, rigidity, and frequent falls developed.	-1
inherited syndrome	KCNQ2	0.5071	0.2404	In 1998, mutations in the voltage gated potassium channel gene KCNQ2 were found to be the main cause underlying the autosomal dominant inherited syndrome of benign familial neonatal convulsions (BFNC).	-1
PEHO syndrome	cerebrospinal fluid (CSF) IGF-1 and insulin-like growth-binding protein (IGFBP)-3	0.5071	0.213	METHODS: We used a sensitive enzyme immunoassay kit for measuring cerebrospinal fluid (CSF) IGF-1 and insulin-like growth-binding protein (IGFBP)-3 in four groups of patients: PEHO syndrome patients (eight), PEHO-like patients (seven), age-matched controls (31), and patients with other types of cerebellar atrophy (11).	-1
myotonic dystrophy	prion protein	0.5069	0.07076	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
epileptic encephalopathy	cyclin-dependent kinase-like 5	0.5069	0.1212	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	1
Dravet syndrome	STXBP1-related	0.5068	0.2512	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
benign familial neonatal seizures	KCNQ2	0.5068	0.3042	Linkage analysis in this family confirmed a previous report of genetic heterogeneity in BFIS - since linkage was excluded at the above-mentioned known BFIS loci - and suggested a possible linkage to the KCNQ2 gene, which is believed to be a voltage gated potassium channel gene responsible for benign familial neonatal seizures (BFNS).	-1
epilepsy	LYSMD3	0.5068	0.1176	It included five genes: CETN3, AC093510.2, POLR3G, LYSMD3 and the proximal part of GPR98/MASS1, a known epilepsy gene.	-1
slowness	ATP13A2	0.5068	0.0568	The youngest 5 of 17 children of nonconsanguineous parents, carrying compound-heterozygous ATP13A2 mutations, had normal development until ages    10 to 12 years, when school performance deteriorated and slowness, rigidity, and frequent falls developed.	-1
atrophy	brain 4	0.5067	0.3428	Follow-up magnetic resonance images of the brain 4 years later showed atrophy of bilateral cerebral hemispheres.	-1
hearing loss	EDSKMH	0.5067	0.3301	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsies	SCN1A	0.5067	0.1128	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	1
neuropsychiatric/cognitive/behavior	anti-NMDA-NR2A/B	0.5066	0.1224	Some of the anti-NMDA-NR2A/B antibodies associate with neuropsychiatric/cognitive/behavior/mood impairments in SLE patients, while others do not.	-1
epileptic spasms	BRAF	0.5065	0.3416	A girl with cardio-facio-cutaneous (CFC) syndrome due to a BRAF gene mutation (c.1454T > C, p.L485S) experienced repetitive epileptic spasms at the corrected age of 4 months.	-1
PME	cystatin B	0.5064	0.2357	Laforin, malin, and cystatin B are non-ion channel gene mutations that cause PME.	-1
MERRF	laforin	0.5063	0.05415	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
febrile seizures	SCN1A	0.5063	0.4442	Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation.	-1
SJS/TEN	HLA-B	0.5062	0.06587	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
SJS/TEN	HLA-B	0.5062	0.06587	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
SJS/TEN	HLA-B	0.5062	0.06587	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
Myoclonic epilepsy	NCL	0.5062	0.1227	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
seizure	SCN1A	0.5061	0.444	We present two children who exhibited the characteristics of Dravet syndrome during infancy and young childhood, with SCN1A mutation, but nevertheless achieved seizure freedom for at least four years during adolescence.	-1
febrile seizures	SCN1A	0.5061	0.1515	Mutations of SCN1A generate phenotypes ranging from the extremely severe form of Dravet syndrome (DS) to a mild form of generalized epilepsy with febrile seizures plus (GEFS+).	-1
epilepsy	COX8A	0.5061	0.06181	Loss of the smallest subunit of cytochrome c oxidase, COX8A, causes Leigh-like syndrome and epilepsy.	-1
abnormalities of the brain	SCN1A	0.506	0.4511	(4) The test is not recommended for children with phenotypes that are not clearly associated with SCN1A mutations such as those characterized by abnormal development or neurologic deficits apparent at birth or structural abnormalities of the brain.	-1
Kleefstra syndrome	SLC9A6	0.506	0.1153	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Rolando epilepsy	KCNQ2	0.506	0.2296	The phenotypic spectrum associated with KCNQ2 mutations is probably broader than initially thought, as patients with severe epilepsies and developmental delay, or with Rolando epilepsy have been described.	1
extrapyramidal dysfunction	SPG7	0.5059	0.03225	"This produced an early-onset clinical syndrome that combines the severe phenotypes of SPG7 and SCA28, in additional to other ""mitochondrial"" features such as oculomotor apraxia, extrapyramidal dysfunction, and myoclonic epilepsy."	-1
JME	GABRD	0.5058	0.1461	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
X-linked infantile spasm syndrome	CDKL5	0.5057	0.1145	CDKL5 truncation due to a t(X;2)(p22.1;p25.3) in a girl with X-linked infantile spasm syndrome.	-1
epilepsy	SCN1A	0.5057	0.05666	Four generations of epilepsy caused by an inherited microdeletion of the SCN1A gene.	1
cancer	MVP	0.5055	0.2524	The human major vault protein (MVP) has been implicated in the development of drug resistance in cancer cells.	-1
Dravet syndrome	SCN1A	0.5054	0.2635	More than 70% of patients with Dravet syndrome have mutations of SCN1A; these include both truncation and missense mutations.	-1
intellectual disability	TCF4	0.5053	0.2203	It is mainly characterized by severe intellectual disability, overbreathing, a typical facial gestalt, tendency to epilepsy and is caused by TCF4 haploinsufficiency.	-1
Dravet syndrome	SCN1A	0.5053	0.2893	INTERPRETATION: Vaccination might trigger earlier onset of Dravet syndrome in children who, because of an SCN1A mutation, are destined to develop the disease.	-1
MNGIE	ECGF1	0.5053	0.2401	Here, we report the first Thai patient with MNGIE confirmed genetically by the identification of a homozygous novel ECGF1 gene mutation, c.100insC, which causes a frameshift and premature truncation of TP protein.	-1
absence seizures	GABRG2	0.5053	0.3914	Mutation screen of GABRA1, GABRB2 and GABRG2 genes in Japanese patients with absence seizures.	-1
autosomal dominant nocturnal frontal lobe epilepsy	cystatin B	0.5052	0.3323	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
DS	SCN1A	0.5052	0.124	Causative variants in SCN1A gene which codes the main, pore-forming subunit of the channel expressed in central nervous system are associated predominantly with Dravet syndrome (DS), as well as with generalized epilepsy with febrile seizures plus (GEFS+) making it one of the most significant epilepsy gene.	-1
seizures	CDKL5	0.5052	0.1521	Generalized intractable seizures, as infantile spasms, and generalized tonic-clonic seizures and myoclonic seizures characterize the clinical picture of CDKL5 mutations.	-1
seizure	SCN3A	0.5052	0.1745	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
SJS/TEN	HLA-A	0.5051	0.1799	AIM: To construct a simple, low-cost typing method for the surrogate marker of HLA-A*31:01, a risk factor for carbamazepine (CBZ) related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).	-1
epilepsy	SCN1A	0.5051	0.4833	Investigation of genes associated with infantile forms of epilepsy such as SCN1A, SCN1B, and ARX were negative, but we identified a novel single-nucleotide duplication mutation, c.931dupT (p.S311FfsX3), in exon 11 of the STXBP1 gene.	1
epileptic encephalopathy	cyclin-dependent kinase-like 5	0.5051	0.4473	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	1
West syndrome	PIGA	0.505	0.2389	RESULTS: We identified 4 PIGA mutations in probands showing early myoclonic encephalopathy, West syndrome, or unclassified EOEE.	-1
dysfibrinogenemia	fibrinogen	0.505	0.5616	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
Lafora disease	laforin	0.5049	0.2124	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
neurodevelopmental disorders	NRXN1	0.5049	0.2357	NRXN1 deletions identified by array comparative genome hybridisation in a clinical case series - further understanding of the relevance of NRXN1 to neurodevelopmental disorders.	-1
(MEMSA) syndrome	LBSL	0.5049	0.1103	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
BFIS	KCNQ2	0.5048	0.2031	Linkage analysis in this family confirmed a previous report of genetic heterogeneity in BFIS - since linkage was excluded at the above-mentioned known BFIS loci - and suggested a possible linkage to the KCNQ2 gene, which is believed to be a voltage gated potassium channel gene responsible for benign familial neonatal seizures (BFNS).	-1
tonic-clonic seizures	CDKL5-related	0.5048	0.1247	INTERPRETATION: Infants with CDKL5-related early epileptic encephalopathy can present in the first year of life with an unusual electroclinical pattern of 'prolonged' generalized tonic-clonic seizures.	-1
seizures	CC2D2A-related	0.5047	0.1187	Patients with CC2D2A-related JS should be monitored for hydrocephalus and seizures.	-1
Zellweger syndrome	PEX 26	0.5047	0.3045	AIM: To report a novel mutation in the PEX 26 gene in infant with typical Zellweger syndrome.	-1
epileptic	CDKL5	0.5046	0.2764	The results were evaluated against those of a comparison group of nine infants (aged below 1y) with epileptic encephalography who had tested negative for CDKL5 mutations and deletions.	1
epileptic encephalopathies	PIGA	0.5045	0.363	OBJECTIVE: To investigate the clinical spectrum caused by mutations in PIGA at Xp22.2, which is involved in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor, among patients with early-onset epileptic encephalopathies (EOEEs).	1
epileptic encephalopathy	SCN8A	0.5045	0.5531	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
cognitive decline	CMT2	0.5044	0.1866	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
epilepsy	EAG	0.5044	0.07919	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	1
EA	HNF1B	0.5043	0.2529	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
Dravet syndrome	SCN1A-related	0.5042	0.3056	15 (1.2% of 1,269; 95%CI:0.6 to 1.8%) children were diagnosed with SCN1A-related Dravet syndrome.	-1
neurogastrointestinal encephalomyopathy	ECGF1	0.5041	0.7382	A novel ECGF1 mutation in a Thai patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).	-1
arachnodactyly	alpha 1 antitrypsin	0.5041	0.06081	One of them also had a marfanoid habitus, thoracic kyphosis, and arachnodactyly, and was heterozygous for alpha 1 antitrypsin deficiency.	-1
LKS	GRIN2A	0.5041	0.4179	Here, we present the case of a 3-year-old boy with LKS found to have a GRIN2A heterozygous missense mutation, whose clinical symptoms and EEG responded to a course of combination oral steroids and monthly infusions of intravenous immunoglobulin.	-1
seizure	SCN1A	0.5041	0.1863	Dravet syndrome: seizure control and gait in adults with different SCN1A mutations.	-1
PTHS	TCF4	0.504	0.1159	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
recessive mental retardation syndrome	NRXN1	0.5039	0.3639	Our report confirms that biallelic NRXN1 mutations result in a severe recessive mental retardation syndrome and broadens the range of phenotypes associated with this gene.	-1
idiopathic neonatal epilepsy	KCNQ4	0.5039	0.3963	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
TSC	IL-6	0.5038	0.3179	Furthermore, developmental differences were discernible in patients with TSC, compared with gene expression levels for patients 0 to 5 years to those 6 to 11 years of age, the latter with marked expression of IL-6 IL-1A, IL-1B, RIPK2, but also IL-10.	-1
SJS/TEN	HLA-A	0.5038	0.07263	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
epileptic	KCNQ2	0.5038	0.188	Infantile seizures and other epileptic phenotypes in a Chinese family with a missense mutation of KCNQ2.	1
seizure	MECP2	0.5038	0.1997	Mutations of MECP2 cause Rett syndrome (RTT), a neurodevelopmental disorder leading to loss of motor and cognitive functions, impaired social interactions, and seizure at young ages.	-1
HIV polymyositis	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.5037	0.2117	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
DS	SCN1A	0.5036	0.2176	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
Meckel syndrome	CC2D2A-related	0.5036	0.3099	No mutation-specific genotype-phenotype correlations could be identified, but the findings confirm the observation that mutations that cause CC2D2A-related JS are predicted to be less deleterious than mutations that cause CC2D2A-related Meckel syndrome.	-1
FCD	MRI	0.5035	0.4092	The MRI features of some lesions such as FCD may differ in infants compared to children and adults; the white matter adjacent to FCD may demonstrate lower T2 and higher T1 signal in some infants due to premature myelination, while in others, the white matter demonstrates higher T2 or lower T1 signal due to demyelination, dysmyelination or gliosis, similar to children and adults.	-1
seizures	SCN1A	0.5035	0.4631	In addition to seizures, patients with SCN1A mutations often experience sleep abnormalities, suggesting that SCN1A may also play a role in the neuronal pathways involved in the regulation of sleep.	-1
long QT syndrome	KCNQ1	0.5034	0.2598	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
syndrome	GABRA1	0.5033	0.4191	Our results confirm that mutation of GABRA1 predisposes towards a common idiopathic generalized epilepsy syndrome in humans.	-1
learning disability	MECP2	0.5033	0.1817	Furthermore, the panorama of phenotypes with MECP2 mutations now extends far beyond RS to include normal girls and women, mild learning disability, autistic spectrum disorders, and X-linked mental retardation.	-1
myoclonic epilepsy	SCN1A	0.5033	0.2297	Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy.	-1
RS	MECP2	0.5032	0.4898	Furthermore, the panorama of phenotypes with MECP2 mutations now extends far beyond RS to include normal girls and women, mild learning disability, autistic spectrum disorders, and X-linked mental retardation.	-1
DS	SCN1A	0.5032	0.2273	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	-1
epileptic encephalopathy	SCN1A	0.5031	0.104	Recent descriptions of Rasmussen syndrome and of the hemiconvulsion-hemiplegia syndrome in isolated patients with SCN1A mutations are of uncertain meaning but might indicate that co-occurring immunomediated or seizure-induced structural changes can, in turn, become a substrate for the severe epileptic encephalopathy.	1
benign familial infantile convulsions	KCNQ2	0.5031	0.3376	[A novel mutation in KCNQ2 gene causes benign familial infantile convulsions (BFIC) in a Chinese family].	-1
severe developmental delay	GRIN2B	0.503	0.3631	INTERPRETATION: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe developmental delay as well as of ID with childhood onset focal epilepsy.	-1
CCAL	ANKH	0.503	0.3056	A mutation within the ANKH gene on chromosome 5p has been found previously in this family; other patients with familial CCAL (but without seizures) have mutations in the same gene.	-1
Intellectual Disability	KANSL1-related	0.503	0.1355	"KANSL1-Related Intellectual Disability Syndrome
DISEASE CHARACTERISTICS: The KANSL1-related intellectual disability syndrome is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features."	-1
infancy or Dravet syndrome	SCN1A	0.5029	0.05352	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
myoclonic variant of the disorder	SCN1A	0.5029	0.1758	This finding emphasizes the significance of SCN1A mutations also in epileptic disorders with features of LGS, particularly in the myoclonic variant of the disorder.	-1
thrombotic	L-asparaginase	0.5028	0.1341	Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.	-1
Dravet syndrome	SCN1A-related	0.5028	0.2965	Of all reported seizures following vaccinations in the first year of life, 2.5% (95%CI:1.3 to 3.6%) were due to SCN1A-related Dravet syndrome, as were 5.9% of reported seizures (95%CI:3.1 to 8.7%) after 2(nd) or 3(rd) DTP-IPV-Hib vaccination.	-1
JS	CC2D2A-related	0.5028	0.3489	Subjects with CC2D2A-related JS were more likely to have ventriculomegaly (p<0.0001) and seizures (p=0.024) than subjects without CC2D2A mutations.	-1
Epileptic encephalopathy	CDKL5	0.5027	0.1592	Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.	1
seizures	SCN1A	0.5027	0.5102	In patients with MCDs and a history of polymorphic seizures precipitated by fever, SCN1A gene testing should be performed before discussing any epilepsy surgery option, due to the possible implications for outcome.	-1
encephalopathy	SCN1A	0.5027	0.03635	In a previous retrospective study, 11 of 14 patients with so-called vaccine encephalopathy had Dravet syndrome that was associated with de-novo mutations of the sodium channel gene SCN1A.	-1
pharmacoresistant epilepsy syndrome	SLC12A5	0.5026	0.5649	Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS).	1
channelopathies	SCN9A	0.5026	0.07985	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
Schizophrenia	Anti-NMDA-NR2A/B	0.5026	0.1816	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
Glycosylphosphatidylinositol (GPI) anchor deficiency	PIGW	0.5026	0.4042	Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome.	-1
Dravet syndrome	SRPX2-related	0.5025	0.3274	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
FHM	NaV1.1	0.5025	0.3603	Our results are consistent with gain of function as the functional effect of NaV1.1 FHM mutations and hyperexcitability of GABAergic neurons as the pathomechanism of FHM type 3.	-1
DS	GABRD	0.5025	0.0976	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
inherited syndrome	MECP2	0.5024	0.2269	A family study indicates that this inherited syndrome is most likely due to an unreported MECP2 variant, p.V122A, located in the methyl binding domain of the MECP2 protein.	-1
Rett-like	CDKL5	0.5024	0.1857	CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.	-1
genetic disease	CLC	0.5023	0.1262	Physiological functions of CLC Cl- channels gleaned from human genetic disease and mouse models.	-1
deep-set eyes	PHF6	0.5022	0.431	We present three males with PHF6 mutations whose features included deep-set eyes, large ears, coarse face, tapering fingers, and truncal obesity.	-1
HH	GLI3	0.5022	0.2727	Chromosomal abnormalities including the GLI3 locus were seen in 8 of 55 (15%) of the resected HH tissue samples.	-1
epilepsy	MECP2	0.5021	0.3443	RESULTS: We observed a partial MECP2 duplication in an adult male with epilepsy and mild neurocognitive impairment who was able to function independently; this phenotype has not previously been reported among males harboring gains in MECP2 copy number.	1
RTT	CDKL5	0.502	0.3881	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
hyperferritinemia	HFE	0.502	0.4229	Family history showed that his mother was also affected by hyperferritinemia without HFE gene mutations.	-1
epileptic encephalopathy	CDKL5	0.502	0.1215	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	1
Dravet syndrome	SCN1A	0.5019	0.4272	Early clinical features and diagnosis of Dravet syndrome in 138 Chinese patients with SCN1A mutations.	-1
Dravet syndrome	SCN1A	0.5019	0.2481	Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome.	-1
X-linked lissencephaly	LIS1	0.5019	0.1224	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
autism	DLX5	0.5018	0.5556	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
epileptic encephalopathy	KCNQ2	0.5018	0.2023	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
cognitive impairment	SCN1A	0.5018	0.2371	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
Dravet syndrome	SCN1A	0.5017	0.2628	Mutations of the SCN1A gene are the most prevalent genetic cause of Dravet syndrome.	-1
seizure	DOC2A	0.5017	0.05249	Sequencing analyses showed no mutations in DOC2A, QPRT, and SEZ6L2, genes within the duplicated 16p11.2 region that have been implicated in neuronal function and/or seizure related phenotypes.	-1
SME	SCN1A	0.5017	0.2486	One third of children harbor mutation of the SCN1A gene, but the genetics of SME is probably more complex than expected with simple monogenic disorders.	-1
GISTs	NF1	0.5016	0.4713	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
Rett syndrome	neurofibromatosis-1	0.5016	0.2796	Several paediatric neurological disorders such as neurofibromatosis-1, Fragile X syndrome, Rett syndrome, and other syndromic and non-specific forms of mental retardation involve lesions in these signalling pathways.	-1
Dravet syndrome	SCN1A	0.5016	0.126	Among these transmissions were two likely disease-causing mutations: an SCN1A mutation transmitted to an SUDC proband and her sibling with Dravet syndrome, as well as an SLC6A1 mutation in a proband with epileptic encephalopathy.	-1
psychomotor retardation	TCF4	0.5015	0.1296	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
arrhythmias	SCN1A	0.5015	0.2051	We propose that, in addition to neuronal hyperexcitability, SCN1A haploinsufficiency alters cardiac electrical function and produces arrhythmias, providing a potential mechanism for SUDEP.	-1
drug-resistant seizures	KCNQ2	0.5015	0.2496	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
Zellweger syndrome	PEX 26	0.5014	0.3817	[A novel mutation in PEX 26 gene in Zellweger syndrome: a case report].	-1
related disorders	CDKL5	0.5014	0.318	Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders.	-1
optic atrophy	PEHO-like	0.5013	0.04802	We present the case of a child with PEHO-like syndrome and underline the need for a careful follow-up of these patients to identify signs and symptoms that can have a later onset, such as optic atrophy.	-1
SJS/TEN	HLA-DRB1	0.5013	0.08659	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
Gorlin syndrome	NF2	0.5013	0.2003	Nine patients had NF2 and two had Gorlin syndrome.	-1
epilepsy	SCN1A	0.5013	0.1726	Severe epilepsy syndromes of early childhood: the link between genetics and pathophysiology with a focus on SCN1A mutations.	1
epileptic seizures	CT/MRI	0.5011	0.1818	Common factors in 4 children who were continuously seizure free include (1) normal or almost normal findings of brain CT/MRI, (2) normal development prior to the onset of epileptic seizures, and (3) a short time interval between the onset of seizures and the acute viral infection.	-1
epilepsy-associated	SCN1A	0.5011	0.2501	Here we present a meta-analysis on the SCN1A gene variants and provide comprehensive information on epilepsy-associated gene variants, their frequency, the predicted effect on the protein, the ethnicity of the affected along with the inheritance pattern and the associated epileptic phenotype.	1
SMEI	GABRD	0.5011	0.13	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
sleep abnormalities	SCN1A	0.5011	0.3822	In addition to seizures, patients with SCN1A mutations often experience sleep abnormalities, suggesting that SCN1A may also play a role in the neuronal pathways involved in the regulation of sleep.	-1
epilepsy	EAG-related	0.501	0.04127	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	1
Joubert syndrome	CC2D2A-related	0.5009	0.2042	Genotype-phenotype correlation in CC2D2A-related Joubert syndrome reveals an association with ventriculomegaly and seizures.	-1
skin abnormalities	ATP6V0A2	0.5008	0.1594	One patient with severe cortical malformations and mild skin abnormalities was diagnosed with a known genetic syndrome, due to an ATP6V0A2 defect.	-1
dentadorubropallidoluysian atrophy	CLN5	0.5008	0.07135	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
myoclonus	EPM2A	0.5008	0.3925	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
Angelman syndrome	inv	0.5008	0.3297	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
syndromic developmental delay	KCNH1	0.5007	0.3337	Here we report three de novo missense KCNH1 mutations in four patients with syndromic developmental delay and epilepsy.	-1
epilepsy	NaV1.1	0.5005	0.165	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	1
Landau-Kleffner syndrome	MEG	0.5005	0.4261	[Serial MEG change in a boy with Landau-Kleffner syndrome].	-1
cardiac long QT syndrome type 2	EAG-like	0.5005	0.04983	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
acid decarboxylase deficiency	3-phosphoglycerate dehydrogenase	0.5005	0.1346	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
juvenile myoclonic epilepsy	GABRA1	0.5005	0.4887	Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy.	-1
epileptic encephalopathies	KCNQ2	0.5004	0.5133	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	1
DS	SCN1A	0.5004	0.3052	In addition, a patient with DS had a partial SCN1A amplification of 5-6 copies.	-1
speech delay	KANSL1	0.5003	0.2572	Striking clinical criteria for enrolling patients into KANSL1 analysis include speech delay, distinctive facial dysmorphism, macrocephaly and friendly behaviour.	-1
ASD	MBD5	0.5003	0.2397	We identified 17 ASD specific, nonsynonymous variants, four of which were concordant in multiplex families: MBD5 Tyr1269Cys, MBD6 Arg883Trp, MECP2 Thr240Ser, and SETDB1 Pro1067del.	-1
Zimmermann-Laband syndrome	KCNH1	0.5003	0.2367	Recently, de novo missense KCNH1 mutations have been identified in six patients with Zimmermann-Laband syndrome and in four patients with Temple-Baraitser syndrome.	-1
Dravet syndrome	SCN1A	0.5002	0.4531	INTERPRETATION: Atypical, multifocal Dravet syndrome with SCN1A mutations may not be recognized because of later cognitive decline and frequent tonic seizures.	-1
cognitive defects	SATB2	0.5001	0.1501	Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects.	-1
seizures	KCNH1	0.5001	0.4317	De novo KCNH1 mutations in four patients with syndromic developmental delay, hypotonia and seizures.	-1
epilepsies	SRPX2-related	0.5001	0.5514	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
synaptic disorders	NMT--	0.5001	0.1513	In conclusion, the term NMT--LE--VGKC should be changed to NMT--LE with LGII and CASPR2 antibodies and classified as auto immune synaptic disorders.	-1
generalized epilepsy with febrile seizures plus	GABRD	0.5001	0.2403	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
ADNFLE	CRH	0.5	0.1497	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
infantile spasms	GABRB2	0.4999	0.2091	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
epilepsy and neonatal diabetes (DEND) syndrome	ABCC8	0.4999	0.3671	Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation.	-1
Wolfram syndrome	WFS1	0.4999	0.2715	Despite similarities with Wolfram syndrome, we excluded the WFS1 gene as responsible for this disease.	-1
West syndrome	STK9	0.4998	0.302	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	-1
simple monogenic disorders	SCN1A	0.4998	0.2435	One third of children harbor mutation of the SCN1A gene, but the genetics of SME is probably more complex than expected with simple monogenic disorders.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.4998	0.3847	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
hypoplastic nails, and teeth anomalies	PHF6	0.4997	0.3015	METHODS AND RESULTS: We performed PHF6 mutational analysis and screening for intragenic deletions and duplications by quantitative real-time PCR and multiplex ligation dependent probe amplification (MLPA) in female patients with variable ID and a distinct appearance of sparse hair, remarkable facial features, hypoplastic nails, and teeth anomalies.	-1
cognitive decline	IT15	0.4995	0.1458	Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline, behavioural abnormalities and progressive disease course proves negative to the genetic testing for HD causative mutations, that is, IT15 gene trinucleotide-repeat expansion.	-1
Dravet syndrome	SCN1A	0.4995	0.09394	Causative variants in SCN1A gene which codes the main, pore-forming subunit of the channel expressed in central nervous system are associated predominantly with Dravet syndrome (DS), as well as with generalized epilepsy with febrile seizures plus (GEFS+) making it one of the most significant epilepsy gene.	-1
oedema	PEHO	0.4994	0.1947	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
lissencephaly	LIS1	0.4993	0.4111	Given the lack of mutation in known lissencephaly genes such as LIS1, 14-3-3epsilon, and DCX, this syndrome may constitute a new phenotype with autosomal recessive inheritance.	-1
generalized	GABRD	0.4991	0.17	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
epileptic disorders	SCN1A	0.4991	0.3336	Mutations involving the voltage-gated sodium channel alpha(I) gene SCN1A are major genetic causes of childhood epileptic disorders, as typified by Dravet syndrome.	1
RS	MeCP2	0.499	0.3067	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
PME	cystatin B	0.4989	0.214	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
PLMs	DCX	0.4989	0.2105	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
Cowden syndrome	PTEN	0.4987	0.465	Genetic testing of PTEN gene confirmed a diagnosis of Cowden syndrome (CS).	-1
DS	SCN1A	0.4986	0.109	The advent of social networking via the Internet and the commercial availability of tests for SCN1A mutations permitted the rapid development and growth of parent-led associations that provide advocacy and support, as well as promote education and research regarding Dravet syndrome (DS) in the last 10 years.	-1
Ehlers-Danlos syndrome	HSD17B10	0.4985	0.114	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
syndrome	PEHO-like	0.4984	0.2824	This is the second report of siblings with a PEHO-like syndrome, and supports the existence of a distinct, autosomal recessive condition in which neuroimaging abnormalities may be misinterpreted.	-1
seizure	GRIN2A	0.4983	0.134	Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.	-1
Rett syndrome	CDKL5	0.4983	0.2621	Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome.	-1
epileptic encephalopathy	SCN1A	0.4982	0.1959	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	1
epilepsy	PHF6	0.4982	0.1022	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	1
LQTS	KCNH2	0.4981	0.4742	The appropriate MLPA kit contained probes for selected exons in LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2.	-1
HIV-wasting syndrome	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.4981	0.1125	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
migrating focal seizures of infancy	SCN2A	0.4981	0.4026	DISCUSSION: This report expands our knowledge of the genetic basis of migrating focal seizures of infancy to include mutations in SCN2A gene.	-1
WS	NF1	0.4981	0.09026	MATERIAL AND METHODS: We studied 15 patients with WS and DS with a follow-up of 1.5 to 9 years, 5 patients with WS and NF1 followed-up form 2 to 6 years and 10 patients with WS associated with CP and PL followed-up during 2.5 to 12 years.	-1
infantile epilepsy	IER3IP1	0.498	0.1944	Identification of IER3IP1 mutations sheds light on the mechanisms of brain development and on the pathogenesis of infantile epilepsy and early-onset permanent diabetes.	1
DS	SCN1A	0.498	0.7041	The early clinical features of DS patients with SCN1A mutations were reviewed with attention to the seizures induced by fever and other precipitating factors before the first year of life.	-1
Epilepsy	SCN1A	0.4979	0.1521	Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A.	1
afibrinogenemia	fibrinogen	0.4979	0.1107	These data and our previous reports suggest that heterozygous patients with dysfibrinogenemia or fibrinogen deficiency do not demonstrate markedly prolonged PT and APTT values, differing from patients with afibrinogenemia.	-1
autism	MECP2-containing	0.4979	0.3623	A case report of Chinese brothers with inherited MECP2-containing duplication: autism and intellectual disability, but not seizures or respiratory infections.	-1
hypsarrhythmia	PEHO	0.4978	0.2669	Epilepsy and the electroencephalogram in progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (the PEHO syndrome).	-1
Batten disease	CLN3	0.4978	0.4795	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
MAE	inv	0.4977	0.06858	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
epilepsy syndromes	SCN2A	0.4976	0.4216	Mutations in SCN2A gene cause a variety of epilepsy syndromes.	1
X-linked mental retardation disorder	plant homeodomain finger 6	0.4976	0.1914	The plant homeodomain finger 6 (PHF6) was originally identified as the gene mutated in the X-linked mental retardation disorder B  rjeson-Forssman-Lehmann syndrome.	-1
SMEI	SCN1A	0.4976	0.2778	We selected 11 SMEI patients with or without additional features who had no SCN1A mutation detectable with sequencing analysis.	-1
SMEI	SCN1A	0.4975	0.3762	SCN1A mutations may need to be further explored in patients with HH syndrome without features of SMEI.	-1
DS	SCN2A	0.4975	0.105	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
MERRF-syndrome	NARP	0.4974	0.1927	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
myoclonic epilepsy	GABRG2	0.4974	0.07427	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Semi-dominant X-chromosome linked learning disability	MECP2	0.4974	0.1978	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
seizures	SCN1A	0.4974	0.5747	RESULTS: Vaccination-related seizures occurred in 25% of patients with SCN1A mutation and 18% of patients without the mutation (no significant difference).	-1
infantile spasms	STK9	0.4974	0.2208	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
Prader-Willi syndrome and the Moebius syndrome	prion protein	0.4973	0.1947	These include fatal familial insomnia, with involvement of the prion protein gene on chromosome 20, Norrie disease, the Prader-Willi syndrome and the Moebius syndrome.	-1
seizure	SCN1A-related	0.4973	0.4052	SCN1A-related seizure disorders can be inherited in an autosomal dominant manner but most are due to de novo mutations.	-1
febrile seizures	SCN1A	0.4972	0.2134	BACKGROUND Mutations in SCN1A can cause genetic epilepsy with febrile seizures plus (GEFS+, inherited missense mutations) or Dravet syndrome (DS, de novo mutations of all types).	-1
ASD	GRIN2A	0.4972	0.02742	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
ASD	MDGA2	0.4972	0.02742	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
ASD	DIAPH3	0.4972	0.02742	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RTT	CDKL5	0.4971	0.3264	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
spasticity	MECP2	0.4971	0.06774	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
epilepsy of infancy with migrating focal seizures	SLC12A5	0.497	0.3851	Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures.	-1
) syndrome	SMA	0.497	0.4969	BACKGROUND: In adults, resection of the medial frontal lobe has been shown to result in supplementary motor area (SMA) syndrome, a disorder characterized by transient motor impairment.	-1
Dravet syndrome	GABRA1	0.4969	0.3615	In addition, de novo GABRA1 mutations were recently reported in a patient with infantile spasms and four patients with Dravet syndrome.	-1
seizures	SCN2A-associated	0.4969	0.3562	We report a novel SCN2A-associated epilepsy phenotype in monozygotic twins with tonic seizures soon after birth and a suppression-burst electroencephalography (EEG) pattern.	-1
seizure	inv	0.4968	0.2878	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
FHM	NaV1.1	0.4966	0.5629	Our results are consistent with gain of function as the functional effect of NaV1.1 FHM mutations and hyperexcitability of GABAergic neurons as the pathomechanism of FHM type 3.	-1
SMEI/SMEB	SCN1A	0.4966	0.2917	This study confirms the high sensitivity of SCN1A for SMEI/SMEB phenotypes.	-1
Dravet syndrome	CDKL5/STK9	0.4966	0.655	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
seizure	SEZ6L2	0.4965	0.05238	Sequencing analyses showed no mutations in DOC2A, QPRT, and SEZ6L2, genes within the duplicated 16p11.2 region that have been implicated in neuronal function and/or seizure related phenotypes.	-1
isolated lissencephaly sequence	PAFAH1B1	0.4964	0.2626	Characterization of intragenic tandem duplication in the PAFAH1B1 gene leading to isolated lissencephaly sequence.	-1
Wilson syndrome	TCF4	0.4964	0.1681	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
seizure	CDKL5	0.4963	0.1353	Moreover, this report reinforces the observation that the CDKL5 phenotype overlaps with Rett syndrome and that CDKL5 gene analysis is recommended in females with a seizure disorder commencing in the first weeks of life.	-1
Epileptic Encephalopathy	KCNQ2	0.4963	0.3222	KCNQ2 Potassium Channel Epileptic Encephalopathy Syndrome: Divorce of an Electro-Mechanical Couple?	1
PHA	CD 4/8	0.4963	0.2362	We measured white blood cell counts, lymphocyte counts, T/B cell counts, CD4(+) and CD8(+) T cell counts, CD 4/8 ratio, lymphocyte blastoid transformation by PHA or Con-A, and the levels of IgA, IgM, and IgG before, immediately after, and 1, 3, 6, and 12 months after ACTH therapy.	-1
genetic epilepsies	NaV1.1	0.4962	0.2439	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
SMEI	SCN1A	0.4962	0.1287	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
infancy	SCN1A	0.4961	0.2251	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
epilepsy	Neurofibromatosis type 1	0.4961	0.2512	RESULTS: Neurofibromatosis type 1 and childhood epilepsy treated with carbamazepine or valproic acid are associated with distinct patterns of blood gene expression.	-1
AMRF	beta-GC	0.4961	0.3546	With the present study, we demonstrate that disruption of the coiled-coil structure or AMRF disease-causing mutations abolish beta-GC binding, indicating the importance of an intact coiled-coil structure for the interaction of LIMP-2 and beta-GC.	-1
psychotic VCFS	MBD5	0.496	0.1126	Notably a deletion in a psychotic VCFS patient at 2q23.1 hit the gene MBD5 which when deleted gives rise to intellectual disability, epilepsy, and autistic features.	-1
MDS	LIS1	0.496	0.3221	A 6-month-old infant with LIS1 17p13.3 deletion-positive Miller-Dieker syndrome (MDS) presented with increased seizures in the setting of a Pseudomonal and Enterococcal urinary tract infection and a buttock abscess associated with a lumbosacral dermal sinus tract.	-1
premenstrual syndrome	AKR1C1	0.4959	0.1148	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
benign familial neonatal convulsions	KCNQ2-5	0.4959	0.1041	KCNQ2-5 channels are predominantly expressed in neurons and are important determinants of cellular excitability, as indicated by the occurrence of human genetic mutations in KCNQ channels that underlie inheritable disorders including, in the case of KCNQ2/3, the syndrome of benign familial neonatal convulsions.	-1
dravet syndrome	SCN1A-related	0.4959	0.3124	Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort study.	-1
microcephaly	SCN3A	0.4959	0.1267	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
brain structure abnormalities	SCN1A	0.4958	0.2338	The present findings describe DS-related brain structure abnormalities probably linked to the expression of the SCN1A mutation.	-1
nephrotic syndrome	COQ2	0.4958	0.4161	Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2).	-1
infancy	CDKL5	0.4958	0.4423	CDKL5 mutations cause severe epilepsy in infancy with subsequent epileptic encephalopathy.	-1
RTT	MECP2	0.4957	0.1987	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
seizures	TTR	0.4957	0.1873	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
intellectual disability	PHF6	0.4957	0.2107	Recently, de novo aberrations in PHF6 were identified in females with intellectual disability and with a distinct phenotype including a characteristic facial gestalt with bitemporal narrowing, prominent supraorbital ridges, synophrys, a short nose and dental anomalies, tapering fingers with brachytelephalangy, clinodactyly and hypoplastic nails, short toes with hypoplastic nails, and linear skin hyperpigmentation.	-1
autosomal recessive disorder	PEHO	0.4957	0.366	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
congenital disorders of glycosylation	ATPase-related	0.4957	0.2149	Here, we present unique congenital disorders of glycosylation type 2-associated anomalies, including both ATPase-related and unrelated cutis laxa and sensorineural hearing loss, a recently recognized symptom of congenital disorders of glycosylation.	-1
simple febrile seizures	SCN1A-Related	0.4956	0.1088	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
MCDs	SCN1A	0.4956	0.2943	In patients with MCDs and a history of polymorphic seizures precipitated by fever, SCN1A gene testing should be performed before discussing any epilepsy surgery option, due to the possible implications for outcome.	-1
Mohr-Tranebjaerg syndrome	CMT2	0.4956	0.3844	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
Rett syndrome	methyl-CpG-binding protein 2	0.4955	0.3527	PURPOSE: To investigate the association between genotype (methyl-CpG-binding protein 2 (MECP2 gene mutation)) and epileptic seizure phenotype in Rett syndrome.	-1
neonatal asphyxia	neurofibromatosis type 1	0.4955	0.1966	On the other hand, response to these drugs was correlated with some clinical findings in symptomatic cases; all infants with neurocutaneous syndrome (tuberous sclerosis, neurofibromatosis type 1) had controlled infantile spasms, while none of patients with severe neonatal asphyxia or with prior other seizures responded.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	FKBP14	0.4955	0.3694	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
hypsarrhythmia	STK9	0.4955	0.2522	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
epilepsy	TBC1D24	0.4954	0.251	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
optic atrophy	PEHO	0.4954	0.1156	[A case of PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome: changes in clinical and neuroradiological findings].	-1
JME	cystatin B	0.4953	0.3983	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
seizures	SCN1A	0.4953	0.2938	Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?	-1
epilepsy	SCN1A	0.4953	0.2915	Clinical and histopathological outcomes in patients with SCN1A mutations undergoing surgery for epilepsy.	1
Dravet syndrome	SCN1A	0.4953	0.2666	INTRODUCTION: Mutations in the voltage-gated sodium channel SCN1A gene are the main genetic cause of Dravet syndrome (previously called severe myoclonic epilepsy of infancy or SMEI).	-1
West syndromes	GABRA1	0.4953	0.4537	De novo GABRA1 mutations in Ohtahara and West syndromes.	-1
infancy	SCN1A	0.4952	0.05376	PURPOSE: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients.	-1
DS	SCN1A	0.4952	0.2463	We identified the first partial SCN1A duplications in two siblings with typical DS and in a patient with early-onset symptomatic generalized epilepsy.	-1
benign familial neonatal convulsions	KCNQ2	0.4952	0.3298	A novel mutation in KCNQ2 gene causes benign familial neonatal convulsions in a Chinese family.	-1
Dravet syndrome	SCN1A	0.4952	0.1888	We screened for mutations of SCN1A, SCN2A and GABRG2 (the gene encoding gamma2 subunit of the GABA(A) receptor) in 59 patients with Dravet syndrome and found 29 SCN1A mutations and three missense SCN2A mutations.	-1
seizures	SCN1A	0.4952	0.2022	CONCLUSION: In this study, normal development before seizure onset, seizures beginning before age of one year and psychomotor retardation after age of two years are the most significant criteria in SCN1A mutation positive patients.	-1
infantile spasms	TBC1D24	0.4951	0.269	The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms.	-1
RTT	CDKL5	0.4951	0.2198	Both patients with CDKL5 mutation presented therapy-resistant epilepsy and a phenotype fitting with the diagnosis of early-onset variant of RTT.	-1
myoclonic epilepsy	SMA	0.4951	0.2739	In particular, the association of SMA and progressive myoclonic epilepsy (PME) has been rarely described.	-1
epilepsy	CLN8	0.495	0.4894	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	1
seizure	LQT3	0.4949	0.1811	LQT1 and LQT3 combined cohorts did not differ significantly from expected, background rates of a seizure phenotype.	-1
RS	methyl-CpG-binding protein 2	0.4949	0.1413	Neither the type of hearing loss nor the presence of preserved speech seemed to be correlated with the type of mutation in methyl-CpG-binding protein 2 (MeCP2) gene that is associated with RS.	-1
CCA	ARPKD	0.4949	0.1129	Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years).	-1
kyphoscoliosis	ACADSB	0.4949	0.119	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
inherited epilepsy syndrome	SCN1A	0.4949	0.1401	These results provide a deeper level of understanding of mutant SCN1A dysfunction in an inherited epilepsy syndrome, which will enable more precise computational studies of abnormal neuronal activity in epilepsy and may help guide new targeted therapeutic strategies.	-1
LTE	KCNAB1	0.4949	0.2681	Single SNP analysis revealed one SNP (rs992353) located near the 3'end of KCNAB1 slightly associated with LTE after multiple testing correction (odds ratio=2.25; 95% confidence interval 1.26-4.04; P=0.0058).	-1
RS	NMDA-R2B	0.4946	0.3097	In patients with RS, several kinds of autoantibodies against neuronal molecules, for example, GluR3, GluRepsilon2 (NMDA-R2B), etc., are reported.	-1
bleeding	Vit-K	0.4945	0.4504	Pediatrician's alertness is needed to anticipate and deal with the bleeding manifestation due to deficiency of Vit-K dependent clotting factors and various anticonvulsant drug (AED) withdrawal symptoms.	-1
DS	SCN1A	0.4945	0.02536	In >=  75% of cases, DS is associated with mutations of the gene encoding the a1 subunit of the sodium channel, SCN1A.	-1
hypsarrhythmia	PEHO	0.4945	0.2416	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
deficiency	fibrinogen	0.4944	0.3654	[Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency].	-1
endometrial cancer	AKR1C1	0.4944	0.2106	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
metabolic syndrome	cannabinoid-1 receptor	0.4944	0.1338	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
seizure	PrP(c	0.4944	0.156	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	-1
seizure disorder	CDKL5	0.4944	0.1463	In conclusion, this report reinforces the observation that the CDKL5 phenotype overlaps with RTT and that CDKL5 analysis is recommended in patients with a seizure disorder commencing during the first months of life.	1
epilepsy	SCN1A	0.4943	0.2336	METHODS Medical records of SCN1A mutation-positive children with treatment-resistant epilepsy who had undergone resective epilepsy surgery were reviewed retrospectively.	1
seizure	CDKL5	0.4942	0.08527	Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms.	-1
Dravet syndrome	SCN1A	0.4942	0.2396	We identified 241 cases with SCN1A mutation-positive Dravet syndrome, 207 of which were UK-based.	-1
febrile seizures	GABRG2	0.494	0.4317	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
epilepsy	SCN1A	0.4938	0.1852	SCN1A mutated patients (n = 58) seemed to exhibit worse psychomotor course than non-mutated ones (n = 9) (severe SQPS in 26% vs 0%), although their epilepsy tended to be less severe (tonic seizures in 12% vs 44% [p = 0.04], first status epilepticus before 6 m in 26% vs 67% [p = .02], mean number of SE 2.5 vs 4.5 [p = .09]).	1
tumor	CRMP5	0.4937	0.1567	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
infantile epileptic encephalopathy	cyclin-dependent kinase-like 5	0.4937	0.2052	Turkish cases of early infantile epileptic encephalopathy: two novel mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene.	1
MNGIE	ECGF1	0.4937	0.5319	A novel ECGF1 mutation in a Thai patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).	-1
neonatal seizures	KCNQ2 p.Ile592Met	0.4936	0.2742	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
ataxia	MECP2	0.4935	0.1456	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
CSS	SMARCB1	0.4934	0.2884	We applied WES on five CSS patients and found two de novo mutations in SMARCB1.	-1
Dravet syndrome	Na(V)1.1	0.4934	0.3023	Pure haploinsufficiency for Dravet syndrome Na(V)1.1 (SCN1A) sodium channel truncating mutations.	-1
tter-T  nz syndrome	ROGDI	0.4933	0.1797	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
encephalopathies	GRIN2A	0.4933	0.3472	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.	-1
childhood absence epilepsy	GABRD	0.4933	0.3497	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
autism	DLX5	0.4932	0.2056	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
seizures	CDKL5	0.4932	0.1024	RESULTS: We have identified mosaic exonic deletions of CDKL5 in one male and two females with developmental delay and medically intractable seizures.	-1
hypotonia	CDKL5	0.4932	0.3693	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
RS	MeCP2	0.4932	0.2439	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
microcephaly	MECP2	0.4931	0.1789	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
SMEI	SCN1A-mutation-negative	0.4931	0.272	Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI patients.	-1
seizure	SCN1A	0.493	0.1567	This feature was observed in five of seven patients from groups A and B. SIGNIFICANCE: This study shows that seizure control improves and cSE become less frequent in DS as patients age, independent of their SCN1A mutation type.	-1
DS	SCN1A	0.4929	0.3491	DS cases without SCN1A mutation inherited have predicted SCN9A susceptibility variants, which may contribute to complex inheritance for these unexplained cases of DS.	-1
seizures	SCN1A	0.4928	0.1427	Intrafamilial variability in phenotype severity indicates that SCN1A loss of function causes a phenotypic spectrum in which seizures precipitated by fever are prominent and schematic syndrome subdivisions would be inappropriate.	-1
GCPS	MODY2	0.4928	0.4138	We describe the clinical features and the underlying genetic defect of MODY2 in a patient with atypical Greig cephalopolysyndactyly syndrome (GCPS).	-1
lactic acidosis	CMT2	0.4928	0.576	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
severe myoclonic epilepsy of infancy	SCN1A	0.4928	0.2656	We postulated that cases of so-called vaccine encephalopathy could have mutations in the neuronal sodium channel alpha1 subunit gene (SCN1A) because of a clinical resemblance to severe myoclonic epilepsy of infancy (SMEI) for which such mutations have been identified.	-1
channelopathies	SCN1A	0.4927	0.05743	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
myokymia	KCNQ2	0.4927	0.1332	PURPOSE: KCNQ2 mutations have been found in patients with benign familial neonatal seizures, myokymia, or early onset epileptic encephalopathy (EOEE).	-1
epilepsy	SCN1A	0.4927	0.387	Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: Properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum.	1
MRI abnormalities	NF 1	0.4927	0.3074	These results suggest that children with NF 1 have a spectrum of MRI abnormalities, irrespective of existence of epilepsy.	-1
hyperthermia	SCN1A	0.4926	0.1896	The three criteria that best predicted a mutation in SCN1A included exacerbation with hyperthermia, normal development before seizure onset, and the appearance of ataxia, pyramidal signs, or interictal myoclonus.	-1
Lafora body disease	NCL	0.4925	0.1897	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
Dandy-Walker malformation	ZIC1	0.4924	0.1949	Dandy-Walker malformation associated with heterozygous ZIC1 and ZIC4 deletion: Report of a new patient.	-1
RRFs	COX	0.4923	0.2844	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
myoclonic encephalopathy	PIGA	0.4923	0.3579	RESULTS: We identified 4 PIGA mutations in probands showing early myoclonic encephalopathy, West syndrome, or unclassified EOEE.	-1
LGS	SCN1A	0.4923	0.3902	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
WBS	BAZ1B	0.4922	0.3687	Other two carry a shorter deletion of ~1.2 Mb at centromeric side that excludes the distal WBS genes BAZ1B and FZD9.	-1
seizure disorders	SCN1A-related	0.4922	0.4063	GENETIC COUNSELING: SCN1A-related seizure disorders are inherited in an autosomal dominant manner.	1
seizure	SCN1A	0.4922	0.3377	CONCLUSION: In this study, normal development before seizure onset, seizures beginning before age of one year and psychomotor retardation after age of two years are the most significant criteria in SCN1A mutation positive patients.	-1
PL	NF1	0.4921	0.256	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
Mania	Anti-NMDA-NR2A/B	0.4921	0.1775	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
Stroke	Anti-NMDA-NR2A/B	0.4921	0.1775	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
DS	Scn1a	0.492	0.08524	The majority of children with DS carry mutations of the gene Scn1a, which codes for the alpha subunit of the type 1 voltage-gated sodium channel and is important for the function of interneurons.	-1
Dravet syndrome	SCN1A	0.492	0.2849	CONCLUSIONS: Dravet syndrome can be result of several different types of mutation in SCN1A gene.	-1
Rasmussen encephalitis	CD8	0.492	0.2571	A definite involvement of adaptive and innate immune mechanisms driven by cytotoxic CD8(+) T lymphocytes and neuroglial responses has been demonstrated in Rasmussen encephalitis, although the triggering factor of these responses remains unknown.	-1
myoclonic epilepsies	SCN1A	0.4919	0.3137	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
congenital deafness	KCNQ4	0.4919	0.2786	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
MELAS	COII/tRNA	0.4919	0.1965	High prevalence of the COII/tRNA(Lys) intergenic 9-bp deletion in mitochondrial DNA of Taiwanese patients with MELAS or MERRF syndrome.	-1
Ohtahara syndrome	KCNQ2	0.4919	0.1416	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
epileptic encephalopathies	MAGI2	0.4918	0.4684	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
Generalized epilepsy with	SCN1A	0.4917	0.1708	Generalized epilepsy with febrile seizures plus (GEFS+) spectrum: clinical manifestations and SCN1A mutations in Indonesian patients.	-1
leuko-encephalopathy	CMT2	0.4916	0.386	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
permanent deficits	SMA	0.4915	0.2767	In conclusion, although the SMA is known to control important functions such as initiation of motor activity or speech, our findings show that unilateral SMA removal can be accomplished without resulting in significant permanent deficits.	-1
benign tumors	mammalian target of rapamycin	0.4913	0.1237	The mammalian target of rapamycin (mTOR) signaling pathway is activated in several disorders associated with benign tumors and malformations of the cerebral cortex.	-1
RS	MECP2	0.4913	0.2319	We aimed to improve the understanding of genotype-phenotype correlations in Rett syndrome (RS) by adopting a novel approach to categorising phenotypic dimensions - separating typicality of presentation, outcome severity and age of onset - and by classifying MECP2 mutations strictly by predicted functional attributes.	-1
Dravet syndrome	SCN2A	0.4913	0.1642	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
SMEI	SCN1A-mutation-negative	0.4913	0.0943	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
nervous toxicity	L-asparaginase-provoked	0.4912	0.401	L-asparaginase-provoked seizures as singular expression of central nervous toxicity.	-1
polymicrogyria	neurofibromatosis type 1	0.4912	0.3454	Complex epileptic (Foix-Chavany-Marie like) syndrome in a child with neurofibromatosis type 1 (NF1) and bilateral (opercular and paracentral) polymicrogyria.	-1
epileptic encephalopathy	Cyclin-dependent kinase-like 5	0.4911	0.4334	AIM: Cyclin-dependent kinase-like 5 (CDKL5) gene abnormalities cause an early-onset epileptic encephalopathy.	1
CSS	SMARCB1	0.4911	0.2748	SMARCB1 was completely sequenced in 23 CSS patients and the mutations were found in two more patients.	-1
dystroglycanopathies	POMT1	0.4911	0.3341	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
IBD	HMGCS2	0.491	0.234	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Unverricht-Lundborg disease	EBN1	0.491	0.05676	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
limbic Encephalitis	Anti-NMDA-NR2A/B	0.491	0.2646	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
enteropathy X-linked syndrome	FOXP3	0.4909	0.4473	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
DS	SCN1A	0.4909	0.7458	RESULTS: The clinical data of 138 DS patients with SCN1A gene mutations were reviewed.	-1
epilepsy	GPR98/MASS1	0.4908	0.1121	It included five genes: CETN3, AC093510.2, POLR3G, LYSMD3 and the proximal part of GPR98/MASS1, a known epilepsy gene.	-1
epilepsy	SCN1A	0.4908	0.09468	A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus--and prevalence of variants in patients with epilepsy.	1
West syndrome	SCN1A	0.4907	0.5663	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
lissencephaly	14-3-3epsilon, and DCX	0.4907	0.3357	Given the lack of mutation in known lissencephaly genes such as LIS1, 14-3-3epsilon, and DCX, this syndrome may constitute a new phenotype with autosomal recessive inheritance.	-1
infantile spasms	ARX	0.4906	0.1207	New gene defects associated with the CDKL5/STK9 and ARX genes are associated with infantile spasms, but these illustrate that, when studying neurodevelopmental outcomes, it is necessary to deal also with heterogeneity at the level of genotype-phenotype correlation.	-1
seizure	CA4	0.4906	0.2177	Furthermore, greater SG widths correlated with lower hilar and CA4 neuron densities, but not with age at first seizure or duration of epilepsy.	-1
axonal neuropathy	TK2-mutation	0.4903	0.115	Clinical application of whole exome sequencing reveals a novel compound heterozygous TK2-mutation in two brothers with rapidly progressive combined muscle-brain atrophy, axonal neuropathy, and status epilepticus.	-1
myoclonic epilepsy	SCN1A	0.4902	0.2343	Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies.	-1
hemiclonic febrile seizures	SCN1A	0.4902	0.03786	SCN1A testing can be done through bi-directional DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) for: 1) individuals with electroclinical phenotype of Dravet Syndrome or clinical sub-types - several seizure types in one individual with onset in infancy, refractory to medication and with generalised spike and wave on EEG, or 2) infants less than 1 year old with 2 or more prolonged hemiclonic febrile seizures in early infancy.	-1
EA	HNF1B	0.4901	0.2321	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
osteogenesis imperfecta	neurofibromatosis type 1	0.4901	0.2239	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
epileptic	a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1	0.49	0.09253	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	1
seizure	tumor necrosis factor-alpha	0.4899	0.2772	Authors observed the data of clinical and laboratory investigations concerning the cytokines and TF-neurotropic effects and also the original results dedicated to investigation of tumor necrosis factor-alpha and interleukin-1-beta influence on experimental seizure syndrome.	-1
Dravet syndrome	mammalian target of rapamycin	0.4898	0.3768	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
Wilson-syndrome	MK1	0.4898	0.247	[Oral rehabilitation of a patient with Wilson-syndrome using MK1 bolt attachment.	-1
West syndrome	LIS1	0.4898	0.05115	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
Rett syndrome	MECP2	0.4897	0.08588	INTRODUCTION: Rett syndrome (RS) was first reported in 1966 and in 1999 it was discovered that it was associated to mutations in the MECP2 gene.	-1
autosomal dominant	FGFR1	0.4897	0.2677	It can be confirmed by identification of either an FGFR1 heterozygous pathogenic variant (in those with autosomal dominant inheritance) or FGFR1 biallelic pathogenic variants (in those with autosomal recessive inheritance).	-1
developmental delay	CDKL5	0.4897	0.3597	Most individuals with CDKL5 mutations had severe developmental delay from birth, seizure onset before the age of 3 months and similar non-dysmorphic features.	-1
Dravet syndrome	GABRG2	0.4897	0.3303	In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome.	-1
epilepsy	SCN1A	0.4894	0.2362	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	1
ADPEAF	LGI2	0.4894	0.1875	No mutations in LGI2, LGI3, or LGI4 were found in the other two ADPEAF families.	-1
congenital muscular dystrophy	LAMA2	0.4894	0.3876	BACKGROUND: Mutations in the LAMA2 gene cause autosomal recessive laminin a2 related congenital muscular dystrophy.	-1
epilepsy	PRNP	0.4894	0.08795	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	1
17-beta-hydroxysteroid dehydrogenase X deficiency	HMGCS2	0.4894	0.1041	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
DS	SCN1A	0.4894	0.2077	DS cases without SCN1A mutation inherited have predicted SCN9A susceptibility variants, which may contribute to complex inheritance for these unexplained cases of DS.	-1
TSC	LAT1	0.4893	0.3756	MATERIALS AND METHODS: LAT1 expression was investigated by LAT1 mRNA using reverse transcription-polymerase chain reaction and immunohistochemical staining with anti-human LAT1 antibody in nine patients with TSC and three control brains.	-1
intellectual disability	KCNQ3	0.4893	0.06152	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
Meckel syndrome	CC2D2A-related	0.4892	0.3219	No mutation-specific genotype-phenotype correlations could be identified, but the findings confirm the observation that mutations that cause CC2D2A-related JS are predicted to be less deleterious than mutations that cause CC2D2A-related Meckel syndrome.	-1
classic Dravet syndrome	SCN1A	0.4891	0.1471	Genetic mutations in SCN1A account for more than two-thirds of patients with classic Dravet syndrome.	-1
infantile epilepsy	GABRA1	0.4891	0.2954	In this study, we searched for GABRA1 mutations in patients with infantile epilepsy to investigate the phenotypic spectrum of GABRA1 mutations.	1
SMEI	subunit-SCN1A-have	0.4891	0.6149	Recently mutations in the gene encoding a voltage-gated alpha-1 sodium channel subunit-SCN1A-have been identified as a common cause of SMEI.	-1
MDS	MECP2	0.4891	0.3323	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
DS	SCN1A	0.4891	0.2047	CONCLUSION: This study extended the spectrum of SCN1A mutations in Taiwanese DS patients and confirms the high sensitivity of SCN1A for the DS phenotype.	-1
systemic sclerosis	MeCP2	0.4891	0.1188	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
epilepsy	GRIN2A	0.489	0.06033	We did not detect pathogenic variants in GRIN2A in other epileptic encephalopathies (n = 475) nor in probands with benign childhood epilepsy with centrotemporal spikes (n = 81).	1
ID	MECP2	0.489	0.3205	Patients with MECP2 duplications show severe ID, intractable seizures and recurrent infections.	-1
dentadorubropallidoluysian atrophy	laforin	0.489	0.1037	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
dysfibrinogenemia	L-asparaginase	0.489	0.1325	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
DS	SCN1A	0.489	0.4707	CONCLUSION: This study extended the spectrum of SCN1A mutations in Taiwanese DS patients and confirms the high sensitivity of SCN1A for the DS phenotype.	-1
epilepsy	Netrin G1	0.489	0.4957	This study tested a sample of 91 female patients with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome without epilepsy for mutations in the Netrin G1 gene, to evaluate its involvement in this condition.	-1
generalized epilepsies	SCN1A	0.4889	0.361	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
DS	SCN9A	0.4889	0.09137	DS cases without SCN1A mutation inherited have predicted SCN9A susceptibility variants, which may contribute to complex inheritance for these unexplained cases of DS.	-1
epileptic encephalopathy	CDKL5	0.4889	0.4645	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	1
intellectual impairment	FGFR3	0.4888	0.1434	The disorder is caused by a mosaic R248C mutation of the FGFR3 gene, which is characterized by a keratinocytic epidermal nevus, acanthosis nigricans, and neurological abnormalities like seizures, intellectual impairment, cortical atrophy, and underdevelopment of corpus callosum.	-1
seizures	KCNT1	0.4888	0.2464	We report the case of a child with migrating partial seizures of infancy secondary to an activating mutation in KCNT1 treated with quinidine.	-1
Dravet syndrome	SCN1A	0.4888	0.09949	The relationship between severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) and the related syndrome SMEI-borderland (SMEB) with mutations in the sodium channel alpha 1 subunit gene SCN1A is well established.	-1
Dravet syndrome	SCN2A	0.4888	0.2152	Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome.	-1
non-dysmorphic features	CDKL5	0.4888	0.2525	Most individuals with CDKL5 mutations had severe developmental delay from birth, seizure onset before the age of 3 months and similar non-dysmorphic features.	-1
RTT	methyl-CpG binding protein-2	0.4888	0.4673	Since the discovery of mutations in the methyl-CpG binding protein-2 (MECP2) gene in Rett Syndrome (RTT) a large number of females have been diagnosed worldwide.	-1
epilepsy	STXBP1	0.4887	0.0842	Investigation of genes associated with infantile forms of epilepsy such as SCN1A, SCN1B, and ARX were negative, but we identified a novel single-nucleotide duplication mutation, c.931dupT (p.S311FfsX3), in exon 11 of the STXBP1 gene.	1
cortical malfunctions	Mecp2	0.4886	0.3419	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	-1
infantile spasms	KPNA7	0.4886	0.2146	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
Lafora disease	tripeptidyl peptidase 1	0.4886	0.2258	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
seizures	CDKL5	0.4886	0.2875	Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females.	-1
heart disease	CMD1O	0.4885	0.2552	KATP channelopathies implicated in patients with mechanical and/or electrical heart disease include dilated cardiomyopathy (with ventricular arrhythmia; CMD1O) and adrenergic atrial fibrillation.	-1
encephalopathy	SCN1A	0.4885	0.3145	Instead, seizure susceptibility due to SCN1A mutation may have contributed to acute encephalopathy in our patient.	-1
myoclonic epilepsy	CLCN2	0.4885	0.2457	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
epilepsy	SCN1A-mutations	0.4884	0.3681	Our observations are consistent with the hypothesis that SCN1A-mutations can be responsible not only for epilepsy, but also for early and progressive severe mental impairment.	1
hamartoma	neurofibromatosis type 1	0.4884	0.2565	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
West syndrome	3-phosphoglycerate dehydrogenase	0.4883	0.4728	3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.	-1
Asperger disorder	MeCP2	0.4883	0.1709	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
temporal lobe epilepsy	PIP-syndrome	0.4882	0.2339	Carbamazepine and PIP-syndrome in temporal lobe epilepsy.	-1
early epilepsy	Netrin G1	0.4882	0.1356	One report described a patient with atypical Rett syndrome who presented with early epilepsy and a de novo translocation which disrupted the Netrin G1 gene.	-1
Pitt-Hopkins syndrome	TCF4	0.4882	0.244	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
seizures	SCN3A	0.4882	0.1205	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
epileptic	MECP2-mutated	0.4881	0.3859	RESULTS: Prevalence of DRE was 16% (i.e. 16 DRE out of 100 MECP2-mutated RTT epileptic patients).	1
HD	IT15	0.4881	0.2943	The disorder was diagnosed as Huntington's disease (HD), but analysis of the IT15 gene for HD revealed normal alleles.	-1
phenylketonuria	biotinidase	0.4881	0.2453	Rarely, infantile spasms in association with biotinidase deficiency, phenylketonuria, and pyridoxine-dependent seizures are successfully treated with biotin, a low phenylalanine diet, and pyridoxine, respectively.	-1
epileptic encephalopathy	STXBP1-related	0.4881	0.2788	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
Miller-Dieker syndrome	DCX	0.4881	0.08854	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
Rett Syndrome	MECP2	0.488	0.2506	Classic Rett Syndrome (RS) is a neurodevelopmental disorder due to mutations in the MECP2 gene in Xq28.	-1
neonatal epilepsies	KCNQ2	0.488	0.1744	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
SJS/TEN	HLA-A	0.488	0.1757	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
ASD	ATP13A4	0.4879	0.05152	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
haploinsufficiency syndrome	KANSL1	0.4878	0.327	CONCLUSIONS: In KANSL1 haploinsufficiency syndrome, chromosome deletions are greatly prevalent compared with KANSL1 mutations.	-1
intellectual disability syndrome	KANSL1-related	0.4878	0.2912	No individuals with KANSL1-related intellectual disability syndrome have been known to reproduce.	-1
encephalopathy	SCN1A	0.4878	0.2498	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
DS	SCN1A	0.4878	0.1482	DISCUSSION: Duplication and amplification involving SCN1A are now added to molecular mechanisms of DS patients.	-1
lissencephaly	DCX	0.4878	0.1708	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
LBD	NCL	0.4877	0.1698	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
Miller-Dieker syndrome	TUBA3	0.4877	0.1236	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
benign familial neonatal convulsions	KCNQ3	0.4877	0.3452	Two voltage-gated potassium channel genes, KCNQ2 on chromosome 20q13.3 and KCNQ3 on chromosome 8q24, have been identified as the genes responsible for benign familial neonatal convulsions.	-1
seizures	SCN1A	0.4877	0.1032	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	-1
Genetic epilepsies	SCN1A	0.4876	0.5613	Genetic epilepsies with febrile seizures plus: clinical spectrum of Polish patients with SCN1A mutation - preliminary report.	-1
myoclonic epilepsy	SCN1A	0.4875	0.1482	Genetic diagnosis of severe myoclonic epilepsy of infancy (Dravet syndrome) with SCN1A mutations in the Hong Kong Chinese patients.	-1
benign familial neonatal-infantile seizures	SCN1A	0.4875	0.102	The band 2q24 constitutes the smallest commonly deleted segment in these patients, and contains the voltage-gated sodium channel genes SCN1A and SCN2A, associated with Dravet syndrome and benign familial neonatal-infantile seizures, respectively.	-1
febrile seizures	SCN1A	0.4874	0.2654	De-novo mutations and genetic variation in the SCN1A gene in Malaysian patients with generalized epilepsy with febrile seizures plus (GEFS+).	-1
tuberous sclerosis	neurofibromatosis type 1	0.4874	0.5136	On the other hand, response to these drugs was correlated with some clinical findings in symptomatic cases; all infants with neurocutaneous syndrome (tuberous sclerosis, neurofibromatosis type 1) had controlled infantile spasms, while none of patients with severe neonatal asphyxia or with prior other seizures responded.	-1
Febrile Seizures	SCN1A	0.4874	0.4935	"One patient has a family history consistent with the family epilepsy syndrome diagnosis of GEFS+, whilst the second has a de novo SCN1A mutation in the setting of ""severe"" Febrile Seizures."	-1
DS	SCN1A	0.4874	0.2254	METHODS: Multiplex ligation-dependent probe amplification (MLPA) was applied to detect SCN1A CNVs among 289 cases (126 DS, 97 GEFS+, and 66 with other phenotypes).	-1
diabetes	MODY2	0.4873	0.2252	Maturity-onset diabetes of the young type 2 (MODY2) is a form of monogenic diabetes, characterized by mild fasting hyperglycemia.	-1
Dravet syndrome	SCN1A	0.4873	0.2635	A relatively favorable cognitive outcome in patients with Dravet syndrome patients may be explained by somatic mosaicism for the SCN1A mutation in brain tissue.	-1
infantile spasms	STK9	0.4872	0.2119	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
epilepsy	MECP2	0.4871	0.2352	The aim of the study is to describe the electroclinical features of epilepsy in MECP2 duplication patients in order to refine the epilepsy phenotype and its evolution.	1
Dravet syndrome	SCN1A-mutations	0.4871	0.2095	We conclude that bromide holds promise in patients with SCN1A-mutations suffering from Dravet syndrome.	-1
febrile seizure	GABRG2	0.4871	0.279	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
Dandy-Walker malformation	ZIC4	0.487	0.06627	Dandy-Walker malformation associated with heterozygous ZIC1 and ZIC4 deletion: Report of a new patient.	-1
seizures	Nav1.1	0.4869	0.08659	Both diseases can result from mutations in the Nav1.1 sodium channel, and initially, seizures are typically triggered by fever.	-1
neurodegenerative disorders	CB1	0.4869	0.1566	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety, and stroke.	-1
myoclonus epilepsy	U2 snRNP auxiliary factor small 35-kDa subunit (U2AF1	0.4869	0.2041	The gene for human U2 snRNP auxiliary factor small 35-kDa subunit (U2AF1) maps to the progressive myoclonus epilepsy (EPM1) critical region on chromosome 21q22.3.	-1
RTT	CDKL5	0.4868	0.1254	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	-1
febrile seizures	SCN1A	0.4868	0.2973	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
epileptic encephalopathies	CDKL5	0.4868	0.2142	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	1
Ehlers-Danlos syndrome	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4867	0.1034	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
developmental delay	MECP2	0.4866	0.1743	One such gene is the transcription factor MECP2, whose loss of function in females results in Rett syndrome, while its duplication in males results in developmental delay and autism.	-1
KS	PROKR2	0.4865	0.2592	Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation.	-1
epileptic encephalopathy	CDKL5	0.4865	0.1251	PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay.	1
channelopathies	KCNQ3	0.4865	0.04093	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
Dravet-syndrome-affected	SCN1A	0.4865	0.377	We studied a cohort of nine Dravet-syndrome-affected individuals without an SCN1A mutation (these included some atypical cases with onset at up to 2 years of age) by using whole-exome sequencing in proband-parent trios.	-1
West syndrome	LIS1	0.4865	0.1749	In this study, it was suggested that the identified gain or loss of genomic copy numbers within 17p13.3 result in epileptogenesis and that triplication of LIS1 can cause symptomatic West syndrome.	-1
lissencephaly	TUBA3	0.4864	0.2022	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
neuroimaging abnormalities	PEHO-like	0.4864	0.02799	This is the second report of siblings with a PEHO-like syndrome, and supports the existence of a distinct, autosomal recessive condition in which neuroimaging abnormalities may be misinterpreted.	-1
amyloidosis	TTR	0.4864	0.401	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
Dravet syndrome	KCNQ2	0.4863	0.5446	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
LQTS	SCN5A	0.4863	0.2903	The appropriate MLPA kit contained probes for selected exons in LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2.	-1
encephalopathy	PEHO	0.4862	0.2276	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
seizure	CDKL5	0.4862	0.3493	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
neurodevelopmental defects	methyl CpG binding protein 2	0.4862	0.1685	The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA.	-1
epilepsies	SCN2A	0.4862	0.144	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	1
cholesteryl ester transfer protein deficiency	SLC12A3	0.4862	0.2152	He was diagnosed with Gitelman's syndrome and cholesteryl ester transfer protein deficiency by identifying homozygous mutations of causative genes, SLC12A3 and CETP, respectively.	-1
Rett syndrome	CDKL5	0.4861	0.1999	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
craniosynostosis syndromes	FGFR3	0.486	0.189	The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.	-1
global developmental delay	GRIN2A	0.4858	0.1326	Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation.	-1
infantile convulsions and choreoathetosis	KST1	0.4858	0.3071	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
PTHS	TCF4	0.4857	0.4107	This scoring system is also proposed for a clinically based diagnosis of PTHS in absence of a proven TCF4 mutation.	-1
generalized epilepsy with	SCN1A	0.4857	0.2573	We describe the five gene loci localized in children with febrile seizures (FEB 1 5), the three genes identified in patients with generalized epilepsy with febrile seizures plus (GEFS+ 1 3) and the de novo mutations of gene SCN1A that have been identified to date in children with SMEI.	-1
TBS	KV10.1	0.4857	0.1734	Here we report damaging de novo mutations in KCNH1 (encoding a protein called ether    go-go, EAG1 or KV10.1), a voltage-gated potassium channel that is predominantly expressed in the central nervous system (CNS), in six individuals with TBS.	-1
Ehlers-Danlos syndrome	DHCR7	0.4857	0.1356	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
hearing loss	FKBP14	0.4856	0.2402	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
SMEI	SCN1A	0.4855	0.2352	METHOD: The authors screened SCN1A in 24 patients with SMEI and 23 with IS.	-1
Dravet syndrome	SCN1A	0.4855	0.1129	De novo mutations of SCN1A, which encode the Na(v)1.1 neuronal voltage-gated sodium channel, are considered the major cause of Dravet syndrome.	-1
epileptic aphasia	GRIN2A	0.4855	0.5613	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.	1
neurocognitive decline	SCN1A	0.4854	0.4798	We describe here the progressive neurocognitive decline in two children (one male), carrying de novo SCN1A truncating mutations and presenting with different epileptic phenotypes.	-1
developmental delay	MECP2	0.4854	0.3098	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
Pitt-Hopkins syndrome	TCF4	0.4854	0.2419	Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction.	-1
seizure	alien	0.4853	0.4248	"We report an unusual presentation of seizures in a 65-year-old woman with a presumed low-grade glioma involving the mesial frontal lobe region, with the ""alien hand"" seen only during a seizure."	-1
epilepsy	SCN9A	0.4853	0.1374	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	1
microcephaly	methyl-CpG-binding protein 2	0.4853	0.1907	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
neuronal migration disorders	SCN1A-related	0.4852	0.08567	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
RTT	CDKL5	0.4852	0.2016	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
deficiency disorder	3-phosphoglycerate dehydrogenase	0.4852	0.2195	So far, three serine deficiency disorders have been reported; 3-phosphoglycerate dehydrogenase deficiency, 3-phosphoserine phosphatase deficiency and a still unexplained serine deficiency disorder.	-1
myoclonus	SCN1A	0.4852	0.164	The three criteria that best predicted a mutation in SCN1A included exacerbation with hyperthermia, normal development before seizure onset, and the appearance of ataxia, pyramidal signs, or interictal myoclonus.	-1
Comprehensive psychological evaluations	MECP2	0.4852	0.1585	Comprehensive psychological evaluations were used to assess 17 boys with MECP2 duplication syndrome.	-1
Ehlers-Danlos syndrome	AUH	0.4852	0.1319	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
cardiac long QT syndrome type 2	ERG	0.4851	0.05182	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
seizures	MeCP2	0.485	0.105	Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures.	-1
MAS	inv	0.4848	0.1947	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
idiopathic epilepsy	BFIC	0.4848	0.352	G812T of KCNQ2 gene is a novel mutation found in BFIC and functional expression of KCNQ2 G812T is required for understanding the mechanism of BFIC and other idiopathic epilepsy.	-1
hydrocephalus	CSF	0.4848	0.5248	METHODS: Patients who underwent cerebral hemispherectomy in whom a standardized perioperative protocol was used, including the use of ventriculostomies (n = 79), were classified into those who developed and those who did not develop hydrocephalus requiring CSF shunts.	-1
RRFs	cytochrome oxidase	0.4848	0.2599	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
Dravet syndrome	SCN1A	0.4847	0.2143	Pure haploinsufficiency for Dravet syndrome Na(V)1.1 (SCN1A) sodium channel truncating mutations.	-1
epilepsy	KPNA7	0.4847	0.2611	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
genetic abnormalities	SCN2B	0.4847	0.07944	We screened for genetic abnormalities within exons and their flanking introns of the genes encoding major subunits of the Na+ channels (SCN1A, SCN2A, SCN1B, and SCN2B) by using a direct sequencing method.	-1
WS	NF1	0.4846	0.3169	MATERIAL AND METHODS: We studied 15 patients with WS and DS with a follow-up of 1.5 to 9 years, 5 patients with WS and NF1 followed-up form 2 to 6 years and 10 patients with WS associated with CP and PL followed-up during 2.5 to 12 years.	-1
RTT	MECP2	0.4846	0.4701	METHOD: Information on 685 females with RTT recruited to the international Rett syndrome database (InterRett) with a pathogenic MECP2 mutation was obtained from family and clinician questionnaires.	-1
psychomotor retardation	TCF4	0.4846	0.125	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
infantile spasms	DCX	0.4846	0.04742	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
febrile seizures	SCN1A	0.4846	0.6703	Genetic epilepsies with febrile seizures plus: clinical spectrum of Polish patients with SCN1A mutation - preliminary report.	-1
encephalopathy	Cyclin-Dependent Kinase-like 5	0.4844	0.06746	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	-1
intellectual disability	MECP2	0.4844	0.1538	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
BFNIS	SCN2A	0.4843	0.1053	Mutations of the gene encoding the alpha2 subunit of the neuronal sodium channel, SCN2A, have been found in benign familial neonatal-infantile seizures (BFNIS).	-1
West syndrome	PIGW	0.4843	0.3829	Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome.	-1
DS	SCN1A	0.4842	0.1821	(4) It is important to note that a negative test does not rule out the clinical diagnosis of DS or other conditions because genes other than SCN1A may be involved.	-1
infantile spasms	KPNA7	0.4841	0.3812	Autosomal recessive mutations in nuclear transport factor KPNA7 are associated with infantile spasms and cerebellar malformation.	-1
epilepsy	CSF	0.4841	0.3641	OBJECT: The authors sought to determine if clinical epilepsy variables, maximum daily temperature (Tmax), and blood and CSF findings were associated with the risk of developing hydrocephalus after first-time resection-disconnection hemispherectomy.	-1
myoclonic epilepsies	PME	0.4839	0.207	The still-unknown relationship between the pathologic level of ASA activity and myoclonic epilepsies suggests introduction of ASA assays in patients with PME.	-1
B  rjeson-Forssman-Lehmann syndrome	PHF6	0.4838	0.1424	The clinical picture of the B  rjeson-Forssman-Lehmann syndrome in males and heterozygous females with PHF6 mutations.	-1
West/Ohtahara syndromes	SRPX2-related	0.4838	0.2547	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
myopathy	EDSKMH	0.4838	0.1388	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
WFS	WFS1	0.4837	0.244	To explain the complex phenotype of a patient with WHS and features reminiscent of Wolfram syndrome (WFS (MIM 222300)), we performed extensive clinical evaluation and classical and molecular cytogenetic (GTG banding, FISH and array-CGH) and WFS1 gene mutation analyses.	-1
endometriosis	AKR1C1	0.4837	0.08708	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
plus	SCN1A	0.4837	0.1406	Mutations of SCN1A generate phenotypes ranging from the extremely severe form of Dravet syndrome (DS) to a mild form of generalized epilepsy with febrile seizures plus (GEFS+).	-1
gliosis	CA4	0.4837	0.3421	A routine neuropathological examination showed no pronounced changes, such as neuronal loss, morphologically abnormal neurons, inflammation, vascular changes, Lafora bodies and tumor cells, except that mild gliosis was seen only in CA4 of the hippocampus.	-1
Seizure	SCN1A-related	0.4837	0.2018	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
Dravet syndrome	Nav1.1	0.4836	0.3498	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	-1
CBZ-SJS/TEN	HLA-B	0.4836	0.08432	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
ASD	MBD5	0.4836	0.2473	These results suggest that genetic alterations of MBD5 cause features of 2q23.1 microdeletion syndrome and that this epigenetic regulator significantly contributes to ASD risk, warranting further consideration in research and clinical diagnostic screening and highlighting the importance of chromatin remodeling in the etiology of these complex disorders.	-1
EA	HNF1B	0.4836	0.5428	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
seizures	GAMT	0.4835	0.1402	The majority of patients with GAMT deficiency have seizures and approximately half are drug-resistant.	-1
neurofibromas	neurofibromatosis type 1	0.4835	0.1242	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
Rett syndrome	CDKL5	0.4835	0.1453	We screened the entire coding region of CDKL5 in 151 affected girls with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome by denaturing high liquid performance chromatography and direct sequencing, and we identified three novel missense mutations located in catalytic domain (p.Ala40Val, p.Arg65Gln, p.Leu220Pro).	-1
epilepsy	IER3IP1	0.4834	0.2752	Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder.	1
myopathy	ACADSB	0.4834	0.0964	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
DRE	MECP2	0.4833	0.08146	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
inherited epilepsy syndrome	Kv7.2	0.4833	0.07752	Mutations in voltage-gated potassium channel Kv7.2 are responsible for benign familial neonatal seizures type 1, a rare monogenic autosomal dominant inherited epilepsy syndrome.	-1
partial loss of function	NaV1.1	0.4833	0.2831	In previous studies, some rescuable epileptogenic folding defective mutants located in domain IV of NaV1.1 have been identified, showing partial loss of function also with maximal rescue.	-1
FS	GABRD	0.4832	0.1305	Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with genetic epilepsy syndromes including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS)/severe myoclonic epilepsy in infancy (SMEI).	-1
DS	Nav1.1	0.4832	0.1252	We previously characterized two Nav1.1 mutants-R859H (GEFS+) and R865G (DS)-at room temperature and reported a mixture of biophysical gating defects that could not easily predict the phenotype presentation as either GEFS+ or DS.	-1
neurodevelopmental disorders	MECP2	0.4832	0.1638	In studies on related neurodevelopmental disorders, a relationship is suggested between the MECP2 gene and autism-related gene, with overlapping pathways, but this is not common to other neurodevelopmental disorders.	-1
familial epilepsy	SCN1A-related	0.4832	0.1364	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	1
leukoencephalopathy	L-asparaginase	0.483	0.1246	[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase].	-1
ID	TCF4	0.483	0.1161	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
Emery-Dreifuss muscular dystrophy	FHL1	0.483	0.06009	Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy.	-1
FCD	MRI	0.4829	0.286	The MRI features of some lesions such as FCD may differ in infants compared to children and adults; the white matter adjacent to FCD may demonstrate lower T2 and higher T1 signal in some infants due to premature myelination, while in others, the white matter demonstrates higher T2 or lower T1 signal due to demyelination, dysmyelination or gliosis, similar to children and adults.	-1
Leigh syndrome	CMT2	0.4829	0.2337	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
epilepsies	STXBP1-related	0.4828	0.2771	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
encephalopathies	FOXG1-gene-related	0.4827	0.2491	Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.	-1
Rett syndrome	methyl CpG binding protein 2	0.4827	0.127	Mutations in methyl CpG binding protein 2 (MECP2) are identified in most patients with classic Rett syndrome.	-1
PME	SMA	0.4826	0.3261	CASE REPORT: We present the clinical and electrophysiological data of a boy with childhood-onset SMA associated with PME and reviewed cases of the literature.	-1
idiopathic epilepsy	KCNQ2	0.4825	0.2802	G812T of KCNQ2 gene is a novel mutation found in BFIC and functional expression of KCNQ2 G812T is required for understanding the mechanism of BFIC and other idiopathic epilepsy.	-1
malformations of cortical development	SCN1A	0.4825	0.3482	Co-occurring malformations of cortical development and SCN1A gene mutations.	-1
myoclonic epilepsy of infancy	SCN1A	0.4825	0.6257	Four novel SCN1A mutations in Turkish patients with severe myoclonic epilepsy of infancy (SMEI).	-1
intellectual disability	CHD2	0.4825	0.317	All three individuals with a CHD2 mutation had intellectual disability and fever-sensitive generalized seizures, as well as prominent myoclonic seizures starting in the second year of life or later.	-1
autosomal recessive fatal disorder	laforin	0.4825	0.3351	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
epilepsies	SCN1A-related	0.4824	0.3667	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	1
epilepsy	KCNQ2	0.4824	0.1666	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	1
encephalopathies	CDKL5	0.4824	0.0873	The CDKL5 disorder presents with a distinct clinical profile and a subtle facial, limb and hand phenotype that may assist in differentiation from other early-onset encephalopathies.	-1
SMEI	SCN1A	0.4823	0.1254	These findings demonstrate that a substantial percentage of SCN1A-mutation-negative SMEI patients with or without additional features carry a chromosomal microdeletion comprising the SCN1A gene and that haploinsufficiency of the SCN1A gene is a cause of SMEI.	-1
Ehlers-Danlos syndrome	HMGCS2	0.4823	0.1076	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
West syndrome	NR2B	0.4823	0.134	The patient with ID and focal epilepsy had a missense mutation in the extracellular glutamate-binding domain (p.Arg540His), whereas both West syndrome patients carried missense mutations within the NR2B ion channel-forming re-entrant loop (p.Asn615Ile, p.Val618Gly).	-1
dysarthria	CBPS	0.4822	0.2282	We have identified four CBPS patients based on neuroimaging and dysarthria patterns among the candidates for epilepsy surgery.	-1
cardiac arrhythmia	KCNQ1	0.4822	0.2815	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
benign neonatal epilepsy	KCNQ2	0.4822	0.5007	Novel KCNQ2 and KCNQ3 mutations in a large cohort of families with benign neonatal epilepsy: first evidence for an altered channel regulation by syntaxin-1A.	-1
optic atrophy	PEHO	0.4821	0.1329	We reported serial clinical, radiological, and neurophysiological findings of a patient with PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) syndrome.	-1
epilepsy	neurofibromatosis type 1	0.4821	0.2582	We included in the study 23 children diagnosed with different types of neurocutaneous syndrome (10 patients with tuberous sclerosis, 5 with Sturge-Weber syndrome and 8 with neurofibromatosis type 1 and epilepsy'.	-1
infancy	SCN1A	0.482	0.1658	Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy.	-1
Rett syndrome	FOXG1	0.4819	0.2762	Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.	-1
RTT	cyclin-dependent kinase-like 5	0.4819	0.3171	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
epileptic encephalopathy	Cyclin-dependent kinase-like 5	0.4818	0.3063	Cyclin-dependent kinase-like 5 gene-related epileptic encephalopathy is gradually becoming better known in child neurology practice.	1
Bartter syndrome	CLC	0.4818	0.08848	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
dominantly inherited neonatal seizures	SCN2A	0.4817	0.04996	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
septicaemia	CRP	0.4816	0.2681	Higher sensitivity of 75% was observed when CRP was used to diagnose gram negative septicaemia compared to 50% that was observed in the diagnosis of gram positive septicaemia.	-1
seizures	CDKL5	0.4816	0.2248	In our study, the overall frequency of mutations in CDKL5 in women with early-onset seizures is around 8.6%, a result comparable with previous reports.	-1
neurodevelopmental disorder	MECP2	0.4816	0.2081	Mutations of MECP2 cause Rett syndrome (RTT), a neurodevelopmental disorder leading to loss of motor and cognitive functions, impaired social interactions, and seizure at young ages.	-1
Rett	CDKL5	0.4816	0.3799	A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.	-1
periventricular leukomalacia	NF1	0.4815	0.2537	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
febrile seizures	SCN1A	0.4815	0.1922	Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs.	-1
Sturge-Weber syndrome	GNAQ	0.4814	0.5511	Our understanding of the disease process has vastly improved since it was first described in 1879, with recent identification of an activating somatic mutation in the GNAQ gene found in association with both Sturge-Weber syndrome and non-syndromic facial port-wine stain.	-1
Asperger disorder	methyl-CpG-binding protein 2	0.4813	0.1888	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
epilepsy	SCN1A	0.4813	0.1704	The most important sodium channel subunit of relevance to epilepsy is SCN1A, in which over 650 genetic variants have been discovered.	1
Dravet syndrome	SCN1A-negative	0.4813	0.2709	METHODS: We performed whole-exome sequencing in 13 SCN1A-negative patients with Dravet syndrome and targeted resequencing in 67 additional patients to identify new genes for this disorder.	-1
Virus Encephalitis	Anti-NMDA-NR2A/B	0.4813	0.2441	Anti-NMDA-NR2A/B antibodies are also present in subpopulations of patients with Epilepsy of several types, Encephalitis of several types (e.g., chronic progressive limbic Encephalitis, Paraneoplastic Encephalitis or Herpes Simplex Virus Encephalitis), Schizophrenia, Mania, Stroke, or Sjorgen syndrome.	-1
encephalopathy	CDKL5	0.4812	0.06715	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
hypsarrhythmia	PEHO	0.4811	0.2269	Dutch patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.	-1
long QT syndrome	Kv7.2-7	0.4811	0.1171	Neuronal KCNQ (Kv7) channels (KCNQ2-5 or Kv7.2-7.5, disclosed to date) were discovered by virtue of their homology with a known cardiac channel involved in long QT syndrome (KvLQT or KCNQ1, Kv7.1) and first disclosed in 1998.	-1
cytotoxicity	GluA3	0.481	0.1836	These antibodies have been shown to cause excitotoxicity through GluA3, complement-dependent cytotoxicity, etc.	-1
NES	NCL	0.481	0.2117	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
Dravet syndrome	a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1	0.481	0.06687	Genetic alterations in the SCN1A gene coding for the a-subunit of the neuronal voltage-gated sodium ion channel, type 1 (NaV 1.1), is associated with a spectrum of seizure-related disorders in human, ranging from a relatively milder form of febrile seizures to a more severe epileptic condition known as the Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.4809	0.2539	INTRODUCTION: Alterations in SCN1A gene cause most cases of Dravet syndrome.	-1
Kennedy's syndrome	prion protein	0.4809	0.1197	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
seizures	CDKL5	0.4808	0.1722	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
infantile spasms	STK9	0.4807	0.2424	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
febrile seizures	GABRA1	0.4807	0.1884	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
sclerosing panencephalitis	SCN1A	0.4807	0.2312	Are SCN1A gene mutations responsible for genetic susceptibility to subacute sclerosing panencephalitis?	-1
rare disorder	IER3IP1	0.4806	0.1188	Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder.	-1
intellectual disability	tRNA methyltransferase 10 homologue A	0.4805	0.2751	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
deficiency, fatty acid hydroxylase deficiency	phospholipase A2	0.4805	0.3405	(1) Leukodystrophy and/or iron deposits in basal ganglia is a common feature of phospholipase A2 deficiency, fatty acid hydroxylase deficiency, and pantothenate kinase-associated neurodegeneration.	-1
encephalopathies	CDKL5	0.4805	0.2077	Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.	-1
Batten disease	laforin	0.4803	0.1209	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
Wolff-Parkinson-White syndrome	cystathionine beta-synthase	0.4802	0.1246	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
SMEI	malin	0.4801	0.3017	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
cardiac long QT syndrome type 2	EAG	0.4801	0.1055	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
hypotonia	NRXN1	0.4801	0.146	BACKGROUND: Microdeletions in the NRXN1 gene have been associated with a range of neurodevelopmental disorders, including autism spectrum disorders, schizophrenia, intellectual disability, speech and language delay, epilepsy and hypotonia.	-1
epileptic encephalopathies	CDKL5	0.48	0.1534	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	1
seizures	TCF4	0.48	0.1025	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
Dravet syndrome	SCN1A	0.4799	0.202	Our data present a case of Dravet syndrome caused by a novel heterozygous SCN1A deletion (c.1458_1465delCTCTAAGT) in two affected siblings.	-1
SBH	DCX	0.4799	0.08283	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	-1
epilepsy	SYN2	0.4799	0.1236	OBJECTIVE: The SYN2 rs3773364 A>G polymorphism has been proposed to be involved in susceptibility to epilepsy, but research results have been inconclusive.	-1
epileptic	SCN1A	0.4799	0.1546	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	1
Lafora's disease	laforin	0.4799	0.3424	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
CJD	parvalbumin	0.4798	0.1437	We studied hippocampus and temporal cortex from human CJD and control autopsy brains and surgical cryptogenic temporal lobe epilepsy specimens for distribution and density of parvalbumin (PV) and calbindin-D28K (Cal) -positive neurons that are subpopulations of GABAergic neurons.	-1
hydrocephalus	CSF	0.4798	0.08287	In univariate analysis, other factors associated with developing hydrocephalus were elevated maximum daily temperatures, elevated white blood cell counts, decreased CSF protein, and increased CSF red blood cell counts.	-1
IBD	HSD17B10	0.4798	0.2075	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
edema	PEHO	0.4798	0.212	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
intellectual disability	SCN2A	0.4797	0.04448	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
Dravet syndrome	SCN1A	0.4797	0.2021	Dravet syndrome (DS) is an epileptic encephalopathy related mainly to mutations in the SCN1A gene, encoding for neuronal sodium channels.	-1
idiopathic generalized epilepsy	cystathionine beta-synthase	0.4796	0.1996	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
febrile seizure	SCN1A	0.4796	0.576	METHODS: Seventy-two patients diagnosed with Dravet syndrome or generalized epilepsy with febrile seizure plus, carrying SCN1A mutations or not, were included.	-1
RTT	MECP2	0.4796	0.1632	The relationship between DRE and RTT genotype category (i.e. gene deletion, gene duplication, early truncating mutation, late truncating mutation, and missense mutation) or a specific MECP2 genotype was tested using the chi-square test.	-1
intestinal polyposis	STK11	0.4796	0.2075	BACKGROUND: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene.	-1
generalized epilepsy	SCN1A	0.4796	0.08846	DS is caused by a mutation in the neuronal sodium channel gene, SCN1A , that is also mutated in generalized epilepsy with FS+ (GEFS+).	-1
developmental delay	LIS1	0.4795	0.3985	With few exceptions, children with LIS1 mutations have isolated lissencephaly, with severe developmental delay and infantile spasms.	-1
SMEI	SCN1A	0.4795	0.1552	Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB).	-1
myoclonic epilepsy of infancy	SCN1A	0.4794	0.4469	[Clinical features and SCN1A gene mutation analysis of severe myoclonic epilepsy of infancy].	-1
seizures	GABRD	0.4794	0.2186	Other genes deleted in a subset of the patients likely play a contributory role in the phenotypes, including GABRD and seizures, PRKCZ and neurologic features, and SKI and dysmorphic and neurologic features.	-1
TBS	EAG1	0.4794	0.07565	Here we report damaging de novo mutations in KCNH1 (encoding a protein called ether    go-go, EAG1 or KV10.1), a voltage-gated potassium channel that is predominantly expressed in the central nervous system (CNS), in six individuals with TBS.	-1
epileptic encephalopathies	GRIN2A	0.4793	0.2919	We did not detect pathogenic variants in GRIN2A in other epileptic encephalopathies (n = 475) nor in probands with benign childhood epilepsy with centrotemporal spikes (n = 81).	1
lissencephaly	LIS1	0.4793	0.231	Our results suggest that the lissencephaly severity in ILS caused by LIS1 mutations may be predicted by the type and location of the mutation.	-1
AMRF	GBA	0.4793	0.2284	We demonstrate that GBA is almost absent in lysosomes of AMRF fibroblasts.	-1
spasticity	MECP2	0.4792	0.1155	Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?	-1
Borjeson-Forssman-Lehmann syndrome	PHF6	0.4791	0.2716	Mutations in PHF6 have been reported in individuals with Borjeson-Forssman-Lehmann syndrome, a condition present almost exclusively in males.	-1
progressive myoclonic epilepsy	malin	0.4791	0.2882	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
West syndrome	GRIN2B	0.4791	0.468	GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy.	-1
autism	SCN2A	0.4791	0.1608	Of interest, de novo SCN2A mutations have also been reported in five patients without seizures but with ID (n  =  3) and/or autism (n  =  3).	-1
low copper	ceruloplasmin	0.4791	0.3207	Their diagnosis was based on the characteristic morphological features, microscopic evidence of pili torti and low copper and ceruloplasmin levels.	-1
neonatal epilepsies	KCNQ3	0.4791	0.1535	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
epilepsy	GABRA3	0.4791	0.08247	Further multivariate logistic regression and multifactor dimensionality reduction analyses of interactions between these genes showed that under adjustment of clinical factors, the epilepsy treatment outcomes were significantly associated with the genotype combinations of GABRA1 rs6883877, GABRA2 rs511310 and GABRA3 rs4828696 (p < 0.0001; adjusted r(2) = 0.149).	-1
absence seizures	SCN1A	0.4789	0.2285	However, the subjects harboring SCN1A mutations and CACNA1A variants had absence seizures more frequently than the patients with only SCN1A mutations (8/20 vs. 0/20, p=0.002).	-1
myoclonic epilepsy	SCN1A	0.4788	0.1586	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
seizure disorders	SCN1A-Related	0.4788	0.1865	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	1
Dravet syndrome	PCDH19	0.4788	0.1707	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
LQTS	KCNE1	0.4787	0.2927	The appropriate MLPA kit contained probes for selected exons in LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2.	-1
seizures	FGFR3	0.4787	0.07845	The disorder is caused by a mosaic R248C mutation of the FGFR3 gene, which is characterized by a keratinocytic epidermal nevus, acanthosis nigricans, and neurological abnormalities like seizures, intellectual impairment, cortical atrophy, and underdevelopment of corpus callosum.	-1
Dravet syndrome	TSPYL4	0.4787	0.1316	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
seizure	tumor necrosis factor	0.4786	0.1517	An elevation of interleukin-6, -8, and -10, and tumor necrosis factor in the serum and that of interleukin-4, -6, and-8 in the cerebrospinal fluid were observed at the onset of a late seizure.	-1
plus	SCN1A	0.4786	0.2539	Generalized epilepsy with febrile seizures plus (GEFS+) spectrum: clinical manifestations and SCN1A mutations in Indonesian patients.	-1
neurocutanoeus disorder	neurofibromatosis 1	0.4786	0.203	An association between moyamoya disease and neurofibromatosis 1, a neurocutanoeus disorder, is well established in the literature.	-1
epileptic encephalopathy	KCNQ2	0.4786	0.4189	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
Bethlem myopathy	CMD1C	0.4786	0.3215	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
encephalitis	SCN1A-R1575C	0.4785	0.593	The SCN1A-R1575C mutation was detected in a patient with a history of acute encephalitis with refractory, repetitive partial seizures (AERRPS) and also in the patient's apparently healthy father.	-1
drug-resistant seizures	KCNQ2	0.4785	0.2278	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
diabetes	GCK	0.4784	0.3706	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
acute encephalopathy	SCN1A	0.4783	0.2905	To determine whether SCN1A mutations are a predisposing factor of acute encephalopathy, we sought to identify SCN1A mutations in a large case series of acute encephalopathy including various syndromes.	-1
LQTS-susceptibility	KCNH2-encoded	0.4783	0.05776	Like noncardiac organ phenotypes observed in other LQTS-susceptibility genes such as KCNQ1/deafness and SCN5A/gastrointestinal symptoms, this novel LQT2-epilepsy association raises the possibility that LQT2-causing perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity.	-1
neurofibromas	NF1	0.4782	0.2462	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
febrile seizure	SCN1A	0.4781	0.2428	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
ADPEAF	LGI1	0.478	0.2638	ADPEAF is genetically heterogeneous, but mutations in LGI2, LGI3, or LGI4 did not account for families without LGI1 mutations.	-1
autoimmune polyglandular disease	EPM1	0.4779	0.3472	In conclusion, the map location and the homology to a gene family involved in a large variety of biological processes including signal transduction and development make PWP2H an intriguing candidate for EPM1 as well as for APECED (autoimmune polyglandular disease) and HPE1 (holoprosencephaly-1) that also map in this region of chromosome 21.	-1
encephalopathies	blood-cerebrospinal fluid (CSF	0.4777	0.1972	As the role of the blood-cerebrospinal fluid (CSF) and brain-blood barriers in mitochondrial encephalopathies is better understood, manipulation of their functions offers promises for therapeutic interventions.	-1
epilepsy	malin	0.4777	0.2725	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	1
hearing loss	KCNQ2/3	0.4776	0.06962	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Dravet syndrome	SCN1A	0.4775	0.2927	Novel SCN1A variants in Dravet syndrome and evaluating a wide approach of patient selection.	-1
encephalopathy	SCN1A	0.4773	0.3667	It was reported recently that a proportion of patients previously diagnosed with alleged vaccine encephalopathy might possess SCN1A mutations and clinical histories that enabled a diagnosis of Dravet syndrome, but these results have not been replicated.	-1
seizure	estrogen receptor-dependent	0.4773	0.04625	We hypothesize that soy phytoestrogens interfere with metabotropic glutamate receptor signaling through an estrogen receptor-dependent mechanism, which results in elevated production of key synaptic proteins and decreased seizure threshold.	-1
Unverricht-Lundborg disease	CLN5	0.4773	0.1549	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
dysplastic	TRPC3	0.4773	0.06125	Intracellular application of anti-TRPC3 antibody to block TRPC3 channels and bath application of the selective TRPC3 inhibitor Pyr3 greatly diminished depolarization in immature control and both immature and mature dysplastic cortex with strong TRPC3 expression.	-1
mental retardation	CLN8	0.4773	0.1303	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
cognitive impairments	anti-NMDA-NR2A/B	0.4772	0.06745	The anti-NMDA-NR2A/B antibodies can undoubtedly be very pathogenic, since they can kill neurons by activating NMDA receptors and inducing 'Excitotoxicity', damage the brain, cause dramatic decrease of membranal NMDA receptors expressed in hippocampal neurons, and also induce behavioral cognitive impairments in animal models.	-1
Lafora disease	malin	0.4771	0.1481	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
autism spectrum disorders	CDKL5	0.4771	0.1345	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
epilepsy-aphasia	GRIN2A	0.477	0.257	Epilepsy: GRIN2A mutations identified as key genetic drivers of epilepsy-aphasia spectrum disorders.	-1
autism	MeCP2	0.477	0.3092	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
global developmental arrest	STK9	0.477	0.1652	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
infantile epilepsy	GABRA1-targeted	0.4769	0.1067	METHODS: In total, 526 and 145 patients with infantile epilepsy were analyzed by whole-exome sequencing and GABRA1-targeted resequencing, respectively.	1
) syndrome	PEHO	0.4769	0.3265	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
epilepsy	KCNQ2	0.4769	0.1817	In KCNQ2, a silent single nucleotide polymorphism (rs1801545) was found overrepresented in both epilepsy samples (IGE, p = 0.004).	1
RTT	MECP2	0.4769	0.2228	Low bone mass is reported in growth-retarded patients harboring mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene causing Rett syndrome (RTT).	-1
epilepsy with febrile seizures plus	SCN1A	0.4769	0.5285	Although initially thought to be within the same spectrum as severe myoclonic epilepsy of infancy, the exclusion of SCN1A mutations in non-generalized epilepsy with febrile seizures plus (GEFS+) MAE cases has confirmed the genetic distinction of MAE.	-1
metabolic syndrome	CB1	0.4767	0.1274	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
CHARGE syndrome	RGMA	0.4767	0.3154	The deletion encompasses only 2 genes: CHD2, which is part of a gene family already involved in CHARGE syndrome, and RGMA which exerts a negative control on axon growth.	-1
myoclonic epilepsy	GABRA1	0.4766	0.1471	OBJECTIVE: GABRA1 mutations have been identified in patients with familial juvenile myoclonic epilepsy, sporadic childhood absence epilepsy, and idiopathic familial generalized epilepsy.	-1
rolandic epilepsy	SRPX2-related	0.4766	0.3572	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
Dravet syndrome	SCN1A	0.4766	0.2176	Different SCN1A mutations are known to cause a variety of phenotypes, such as generalized epilepsy with febrile seizures plus (GEFS+), Dravet syndrome and familial hemiplegic migraine (FHM).	-1
ASD	MECP2	0.4765	0.06923	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
DS	SCN1A	0.4765	0.2982	Since 2003, we have performed molecular analyses in a large series of patients with DS, 27% of whom were negative for mutations or rearrangements in SCN1A.	-1
idiopathic neonatal epilepsy	KCNQ2	0.4764	0.1984	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
Epilepsy in Rett syndrome	FOXG1-gene-related	0.4764	0.1305	Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.	-1
neonatal epilepsies	Kv 7.3	0.4764	0.1518	Mutations in the KCNQ2 and KCNQ3 genes encoding for Kv 7.2 (KCNQ2; Q2) and Kv 7.3 (KCNQ3; Q3) voltage-dependent K(+) channel subunits, respectively, cause neonatal epilepsies with wide phenotypic heterogeneity.	1
NES	NCL	0.4763	0.1373	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
autosomal recessive congenital hyperinsulinism	ABCC8	0.4762	0.1101	There was homozygous mutation in the ABCC8 gene encoding SUR1, which confirmed the diagnosis of autosomal recessive congenital hyperinsulinism.	-1
Rett syndrome	MECP2	0.4762	0.236	Mutations of MECP2 cause Rett syndrome (RTT), a neurodevelopmental disorder leading to loss of motor and cognitive functions, impaired social interactions, and seizure at young ages.	-1
ADNFLE	CHRNA2	0.4762	0.08456	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
epileptic syndromes	SCN1A	0.4761	0.1397	Our goal was to determine whether SCN1A screening is relevant in patients with a broad range of epileptic syndromes.	1
RTT	MECP2	0.4761	0.207	Early epileptic variant had severe seizure types in the first year of life, followed by a typical RTT picture; all were MECP2 negative.	-1
Rett syndrome	cyclin-dependent kinase-like 5	0.4761	0.3871	Mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene in Xp22.13 have been associated with infantile spasms, early-onset intractable epilepsy, and a Rett syndrome (RTT)-like phenotype.	-1
reduction in seizures	SCN1A	0.476	0.3175	An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in seizures when treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine.	-1
ASD	MBD5	0.476	0.5142	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
long-QT-syndromes	SCN5A	0.476	0.3319	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
LQTS	KCNQ1	0.476	0.3847	The appropriate MLPA kit contained probes for selected exons in LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2.	-1
seizures	Nav1.1	0.4759	0.142	Using an siRNA approach to knockdown Nav1.1 selectively in the basal forebrain region, we were able to target a learning and memory network while avoiding the generation of spontaneous seizures.	-1
adrenal pheochromocytoma	neurofibromatosis type 1	0.4759	0.2146	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
epilepsies	SCN1A	0.4758	0.1197	Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities.	1
seizure	GRIN2A	0.4758	0.1503	Further prospective studies in additional patients with mutations in GRIN2A will be required to optimize seizure management for this rare disorder.	-1
ICEGTC	SCN1A	0.4758	0.1814	To test whether ICEGTC arises from molecular mechanisms similar to those involved in SMEI, we characterized eight ICEGTC missense mutations by whole-cell patch clamp recording of recombinant human SCN1A heterologously expressed in cultured mammalian cells.	-1
syndrome	PHF6	0.4757	0.1241	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
infantile spasms	CDKL5	0.4757	0.3675	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
epileptic	SCN1A	0.4757	0.1756	Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes.	1
Dent's disease	CLC	0.4756	0.06422	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
hearing loss	methyl-CpG-binding protein 2	0.4756	0.1562	Neither the type of hearing loss nor the presence of preserved speech seemed to be correlated with the type of mutation in methyl-CpG-binding protein 2 (MeCP2) gene that is associated with RS.	-1
febrile seizures	SCN1A	0.4756	0.471	Generalized epilepsy with febrile seizures plus: novel SCN1A mutation.	-1
cataracts	CRYAA	0.4756	0.1863	Additional involvement of CRYAA, that possibly causes cataracts in two of the patients, might support this hypothesis, due to the proximity of this gene to AIRE.	-1
vascular dysfunction	A beta	0.4756	0.1702	These data add to evidence that inflammation against A beta can cause vascular dysfunction, a potential mechanism for the toxic response recently observed in clinical trials of A beta immunization.	-1
Myopathic Form	TK2-related	0.4755	0.2453	"TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form
DISEASE CHARACTERISTICS: TK2-related mitochondrial DNA (mtDNA) depletion syndrome is a phenotypic continuum that ranges from severe to mild."	-1
epilepsy	GluR3	0.4755	0.2438	"Autoantibodies (Ab's) to the ""B"" peptide (amino acids 372-395) of glutamate/AMPA receptor subtype 3 (GluR3) are found in serum and cerebrospinal fluid of some patients with different types of epilepsy."	-1
epilepsy	KCNQ1	0.4755	0.2789	Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death.	-1
Rett syndrome	methyl CpG-binding protein 2	0.4754	0.3602	Five patients with Rett syndrome, who did not show methyl CpG-binding protein 2 gene (MECP2) mutations, were also examined for CDKL5 mutations.	-1
Greig cephalopolysyndactyly syndrome	MODY2	0.4754	0.546	We describe the clinical features and the underlying genetic defect of MODY2 in a patient with atypical Greig cephalopolysyndactyly syndrome (GCPS).	-1
mental retardation	MECP2	0.4754	0.1292	METHODS: Genomic copy number was investigated for patients with unexplained mental retardation, and phenotypic features of the patients having interstitial duplications including MECP2 were analyzed.	-1
epilepsy	SCN3A	0.4753	0.1831	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	1
RTT-like	CDKL5	0.4753	0.2017	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
developmental disorders	Mecp2	0.4752	0.2806	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	-1
encephalopathies	FOXG1-gene-related	0.4752	0.2948	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
epilepsy	DCX	0.4752	0.1467	"We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel ""de novo"" missense substitution, Met1Val (M1V), was identified in the DCX gene."	1
SMEI	SCN1A	0.4752	0.3028	To investigate the contribution of SCN1A mutations to the etiology of SMEI, we examined nine additional SMEI patients.	-1
RSTS	CREBBP	0.4752	0.6604	CONCLUSIONS: We investigated the spectrum of CREBBP mutations in Korean patients with RSTS for the first time.	-1
JS	CC2D2A	0.4751	0.09614	Subjects with CC2D2A-related JS were more likely to have ventriculomegaly (p<0.0001) and seizures (p=0.024) than subjects without CC2D2A mutations.	-1
epilepsy	SCN1A	0.4749	0.2903	Our objective was to examine whether the nature of a SCN1A mutation affects the epilepsy phenotype.	1
Dravet syndrome	SCN1A	0.4749	0.0754	This report of parental SCN1A nonsense mutation mosaicism in familial Dravet syndrome suggests that mosaicism might be more common than previously suspected and emphasizes the importance of taking mosaicism into account in genetic counselling of Dravet syndrome and SCN1A mutations.	-1
Batten disease	tripeptidyl peptidase 1	0.4748	0.3029	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
epilepsy	PEX 26	0.4748	0.09992	Genetic analysis demonstrated a new mutation in PEX 26 gene.The death occurred at the age of 8 months of refractor epilepsy and apneas.	-1
Rett syndrome	MECP2	0.4748	0.2347	However, early involvement of the aminergic neurons, suggested as the basic, pathognomonic lesion of Rett syndrome, has unfortunately not been investigated with the MECP2 mutation.	-1
myoclonus	NEU1	0.4748	0.3744	We suggest to screen the NEU1 mutations in patients presenting action myoclonus with abnormal VEPs, even without macular cherry-red spots.	-1
lissencephaly	LIS1	0.4745	0.305	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
myopathy	FHL1	0.4745	0.1322	FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718).	-1
CSS	SMARCA4	0.4745	0.1617	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
myokymia	KCNQ2	0.4745	0.3426	We propose that a difference in firing patterns between motoneurons and central neurons, combined with the drastically slowed voltage activation of the R207W mutant, explains why this particular KCNQ2 mutant causes myokymia in addition to BFNC.	-1
infantile-onset epilepsy	SCN1A	0.4745	0.1722	The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy.	1
epilepsy	NF1	0.4744	0.2098	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
epilepsies	SCN1A	0.4743	0.1832	Our finding extends the spectrum of SCN1A mutations related to GEFS+ and further confirms the contribution of the sodium channel genes to the etiology of idiopathic epilepsies.	1
epileptic encephalopathy	SCN1A	0.4743	0.3172	PURPOSE: Dravet syndrome is an autosomal dominant epileptic encephalopathy of childhood, which is caused mainly by SCN1A and PCHD19 mutations.	1
epileptic	SCN1A	0.4743	0.4029	Using multiplex ligation-dependent probe amplification (MLPA) assays with probes for the 5' noncoding exons, their upstream regions, and all coding exons of SCN1A, we investigated 130 epileptic patients who did not show any SCN1A mutations by sequence analysis of all coding exons and exon-intron boundaries.	1
abnormalities and progressive disease course	IT15	0.4742	0.1507	Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline, behavioural abnormalities and progressive disease course proves negative to the genetic testing for HD causative mutations, that is, IT15 gene trinucleotide-repeat expansion.	-1
SMEI	SCN2B	0.4742	0.1225	RESULTS: In both core SMEI and SMEB, various mutations of SCN1A including nonsense and missense mutations were identified, whereas no mutations of SCN2A, SCN1B, and SCN2B were found within the regions examined.	-1
DS	Nav1.1	0.4741	0.3315	A large number of SCN1A mutations identified from the DS patients lead to the loss of function or truncation of Nav1.1 that result in a haploinsufficiency effects, indicating that the exact expression level of SCN1A should be essential to maintain normal brain function.	-1
seizures	CDKL5	0.474	0.1716	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
seizure	NF1	0.4739	0.124	KEY FINDINGS: In individuals with NF1, 9.5% had a history of at least one unprovoked seizure, and 6.5% had documented epilepsy.	-1
DS	SCN1A	0.4739	0.1555	SCN1A mutations were found in 12 of the 71 patients (16.9%; ten with DS, and two with seizures in a Generalized Epilepsy with Febrile Seizures+(GEFS+) context).	-1
seizures	SCN1A	0.4739	0.1187	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
seizures	SCN1A-related	0.4739	0.09424	Each child of an individual with an SCN1A-related seizure disorder has a 50% chance of inheriting the pathogenic variant; however, the risk of developing seizures is less than 100% because of reduced penetrance.	-1
Atypical RS	Cyclin-Dependent Kinase-like 5	0.4738	0.139	Atypical RS with severe early-onset encephalopathy and therapy-resistant epilepsy can be due to mutations in the CDKL5 (Cyclin-Dependent Kinase-like 5) gene in Xp22.	-1
seizure	SCN2A	0.4738	0.1149	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
septicaemia	CRP	0.4738	0.08887	Higher sensitivity of 75% was observed when CRP was used to diagnose gram negative septicaemia compared to 50% that was observed in the diagnosis of gram positive septicaemia.	-1
JS	CC2D2A	0.4738	0.2767	METHODS: Subjects with JS from 209 families were evaluated to identify mutations in CC2D2A.	-1
PDD	MeCP2	0.4738	0.2341	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
mental retardation	STK9	0.4737	0.1384	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
metabolic disorder	inv	0.4737	0.2826	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
Dravet syndrome	SCN1A	0.4737	0.468	We describe a 15-year-old girl with SCN1A mutation (Dravet syndrome), refractory generalized tonic-clonic seizures, and prior posterior instrumentation and fusion for scoliosis, who presented with progressive lower extremity weakness.	-1
BFNC	KCNQ2	0.4736	0.1175	In 1998, mutations in the voltage gated potassium channel gene KCNQ2 were found to be the main cause underlying the autosomal dominant inherited syndrome of benign familial neonatal convulsions (BFNC).	-1
epilepsy	SCN1A	0.4735	0.3204	An initial definition of SCN1A gene-related epilepsy would perhaps be more suitable when a mutation of this gene is ascertained and the clinical picture is still ill defined.	1
deafness	CLC	0.4735	0.05967	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
epilepsy	CDKL5	0.4735	0.1361	METHODS: We reviewed the epilepsy histories and electroclinical analyses of three girls aged 9.5, 7.4, and 9.4 years, each with a mutation of the CDKL5 gene.	1
chromosome abnormality syndrome-2	inv	0.4735	0.1972	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
DS	SCN1A	0.4734	0.1806	This feature was observed in five of seven patients from groups A and B. SIGNIFICANCE: This study shows that seizure control improves and cSE become less frequent in DS as patients age, independent of their SCN1A mutation type.	-1
Charcot-Marie-Tooth disease	prion protein	0.4734	0.1379	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
Coffin-Siris syndrome	PHF6	0.4733	0.154	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
depressive disorders.We	AKR1C1	0.4733	0.1631	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
Dravet syndrome	SCN1A	0.4732	0.2693	CONCLUSIONS: Results from this relatively small series provide evidence that vaccinations do not significantly affect clinical and cognitive evolution of Dravet syndrome and generalized epilepsy with febrile seizure plus  patients even if they carry SCN1A mutations.	-1
idiopathic lymphopenia syndrome	CD4	0.4732	0.3131	[Cerebral intravascular lymphoma during T CD4+ idiopathic lymphopenia syndrome].	-1
neurodevelopmental disorders	MECP2	0.4732	0.1226	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
microcephaly	MEDS	0.4732	0.1511	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
febrile seizures	SCN1A	0.4732	0.2505	Generalized epilepsy with febrile seizures plus (GEFS+) spectrum: clinical manifestations and SCN1A mutations in Indonesian patients.	-1
immune dysfunction	MeCP2	0.4731	0.3326	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
JS	CC2D2A-related	0.4731	0.3662	No mutation-specific genotype-phenotype correlations could be identified, but the findings confirm the observation that mutations that cause CC2D2A-related JS are predicted to be less deleterious than mutations that cause CC2D2A-related Meckel syndrome.	-1
RTT	MECP2	0.4731	0.1456	RESULTS: We found that some RTT features can be correlated with MECP2 genotypes.	-1
focal epilepsies	MVP	0.473	0.0759	Over expression of MVP has also been reported in brain tissue samples from antiepileptic drug (AED)-resistant human focal epilepsies.	-1
seizures	SCN1A	0.473	0.1579	Several missense SCN1A mutations have been identified in probands affected by the syndrome of intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC), which bears similarity to SMEI.	-1
atherosclerosis	CYP2C9	0.473	0.2596	CONCLUSION: Our study indicates that young epileptic patients with the CYP2C9 polymorphism gene have a low risk of subclinical atherosclerosis.	-1
migraine	SCN1A	0.4728	0.2863	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
premature death	SCN1A	0.4727	0.07465	In this case, the combination of de novo single nucleotide polymorphisms (SNPs) and CNVs in the SCN1A and KCNA1 genes, respectively, is suspected to be the principal risk factor for both epilepsy and premature death.	-1
Rett syndrome	MeCP2_e1	0.4726	0.257	We report the identification of the first de novo mutation at a highly conserved residue within the polyalanine stretch in the N-terminal region of the brain-dominant protein isoform MeCP2_e1 in a girl with classical Rett syndrome.	-1
Miller-Dieker syndrome	LIS1	0.4726	0.2536	A 6-month-old infant with LIS1 17p13.3 deletion-positive Miller-Dieker syndrome (MDS) presented with increased seizures in the setting of a Pseudomonal and Enterococcal urinary tract infection and a buttock abscess associated with a lumbosacral dermal sinus tract.	-1
SQPS	SCN1A	0.4726	0.1596	SCN1A mutated patients (n = 58) seemed to exhibit worse psychomotor course than non-mutated ones (n = 9) (severe SQPS in 26% vs 0%), although their epilepsy tended to be less severe (tonic seizures in 12% vs 44% [p = 0.04], first status epilepticus before 6 m in 26% vs 67% [p = .02], mean number of SE 2.5 vs 4.5 [p = .09]).	-1
aromatic	3-phosphoglycerate dehydrogenase	0.4725	0.1112	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
genetic abnormalities	SCN2A	0.4725	0.09786	We screened for genetic abnormalities within exons and their flanking introns of the genes encoding major subunits of the Na+ channels (SCN1A, SCN2A, SCN1B, and SCN2B) by using a direct sequencing method.	-1
genetic abnormalities	SCN1B	0.4725	0.09786	We screened for genetic abnormalities within exons and their flanking introns of the genes encoding major subunits of the Na+ channels (SCN1A, SCN2A, SCN1B, and SCN2B) by using a direct sequencing method.	-1
seizure disorders	SCN1A-related	0.4724	0.4201	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	1
simple febrile seizures	SCN1A-related	0.4724	0.1502	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
developmental delay	KCNQ2	0.4723	0.1712	The phenotypic spectrum associated with KCNQ2 mutations is probably broader than initially thought, as patients with severe epilepsies and developmental delay, or with Rolando epilepsy have been described.	-1
complex IV deficiency in skeletal muscle	COX8A	0.4723	0.115	The loss of the wild-type COX8A protein severely impairs the stability of the entire cytochrome c oxidase enzyme complex and manifests in isolated complex IV deficiency in skeletal muscle and fibroblasts, similar to the frequent c.845_846delCT mutation in the assembly factor SURF1 gene.	-1
ASD	CDH13	0.4723	0.02472	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
ASD	CTNNA3	0.4723	0.02472	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
ASD	CNTNAP2	0.4723	0.02472	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
ASD	CDH9	0.4723	0.02472	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
juvenile epilepsy	KCNQ2	0.4722	0.283	KCNQ2 and KCNQ3 heteromultimers are thought to underlie the M-current; mutations in these genes may cause an inherited form of juvenile epilepsy.	1
myopathy	interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha	0.4721	0.1088	To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).	-1
posterior reversible encephalopathy syndrome	L-asparaginase	0.4721	0.295	The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment.	-1
Gitelman's syndrome	SLC12A3	0.472	0.1413	He was diagnosed with Gitelman's syndrome and cholesteryl ester transfer protein deficiency by identifying homozygous mutations of causative genes, SLC12A3 and CETP, respectively.	-1
seizure	SCN9A	0.4719	0.1117	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
seizure	SCN1A	0.4719	0.1117	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
Kleefstra syndrome	ZEB2	0.4719	0.09415	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
ADPEAF	LGI3	0.4716	0.1075	No mutations in LGI2, LGI3, or LGI4 were found in the other two ADPEAF families.	-1
Unverricht-Lundborg disease	laforin	0.4716	0.109	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
epilepsy	GBP	0.4715	0.1734	Although GBP has few side effects and acts as an anticonvulsant in subjects with resistant partial epilepsy, some reports suggest that it can lose its efficacy around the 18th or 19th month.	-1
LTE	KCNAB1	0.4715	0.2181	The allele and genotype frequencies of 14 KCNAB1 intronic SNPs were determined in 142 Italian LTE patients and 104 healthy controls and statistically evaluated.	-1
Pitt-Hopkins syndrome	TCF4	0.4715	0.1742	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
DS	SCN1A	0.4714	0.3099	Patients with DS who did not have a SCN1A sequencing mutation or copy number variation were studied.	-1
Wolfram syndrome	WFS1	0.4714	0.2088	To explain the complex phenotype of a patient with WHS and features reminiscent of Wolfram syndrome (WFS (MIM 222300)), we performed extensive clinical evaluation and classical and molecular cytogenetic (GTG banding, FISH and array-CGH) and WFS1 gene mutation analyses.	-1
thoracic kyphosis	alpha 1 antitrypsin	0.4714	0.07851	One of them also had a marfanoid habitus, thoracic kyphosis, and arachnodactyly, and was heterozygous for alpha 1 antitrypsin deficiency.	-1
seizures	MECP2	0.4714	0.2634	Eating seizures were also reported in rare patients with MECP2 duplication or mutation.	-1
RTT	MECP2	0.4713	0.1413	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	-1
Rett syndrome	FOXG1-gene-related	0.4713	0.1447	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
generalized epilepsy	GABRG2	0.4713	0.5946	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
NES	CLN8	0.4713	0.3541	Northern epilepsy syndrome (NES, CLN8)--MRI and electrophysiological studies.	-1
cerebellar atrophy	PEHO	0.4712	0.09073	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
acute necrotizing encephalopathy	SCN1A	0.4712	0.1815	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
autistic disorder	MeCP2	0.4712	0.1943	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
WRS	IER3IP1	0.4712	0.5354	We expand the phenotypic spectrum of MEDS caused by IER3IP1 gene mutations and propose that WRS and MEDS are overlapping clinical syndromes, displaying significant gene-dependent clinical variability.	-1
benign familial neonatal convulsions	EBN1	0.4711	0.2028	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
hypertrophic cardiomyopathy	COQ2	0.4711	0.2579	Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2).	-1
epileptic encephalopathies	CDKL5	0.4711	0.16	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	1
muscle stiffness	CLC	0.471	0.1237	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
SMEI	SCN1A	0.471	0.2994	Five adult patients with SMEI and SCN1A mutations are reported, in which motor and behavioural abnormalities were outstanding symptoms.	-1
Dravet syndrome	SCN1A	0.4709	0.34	CONCLUSIONS: We report an inherited SCN1A gene deletion not exclusively associated with Dravet syndrome.	-1
metabolic syndrome	matrix metalloproteinase-9	0.4709	0.3307	This narrative review considers the influence of AEDs on some predictors of vascular risk [i.e. weight, insulin resistance, metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, vitamins, coagulation factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix metalloproteinase-9].	-1
febrile seizure	SCN1A	0.4708	0.1694	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
Ehlers-Danlos syndrome	FKBP14	0.4708	0.25	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Williams syndrome	frizzled 9	0.4708	0.2171	We conclude that frizzled 9 is a critical determinant of hippocampal development and is very likely to be a contributing factor to the neurodevelopmental and behavioral phenotype of patients with Williams syndrome.	-1
fever	SCN1A	0.4708	0.1997	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
lack cerebellar hypoplasia	PEHO-like	0.4707	0.2337	A heterogeneous group of PEHO-like patients, who lack cerebellar hypoplasia but have varying supratentorial abnormalities, have been reported.	-1
benign familial neonatal seizures	KCNQ2	0.4707	0.3318	PURPOSE: KCNQ2 mutations have been found in patients with benign familial neonatal seizures, myokymia, or early onset epileptic encephalopathy (EOEE).	-1
global developmental arrest	STK9	0.4706	0.1906	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
tumor	granzyme B	0.4706	0.152	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
hypochondroplasia	FGFR3	0.4706	0.5536	Does the co-occurrence of FGFR3 gene mutation in hypochondroplasia, medial temporal lobe dysgenesis, and focal epilepsy suggest a syndrome?	-1
Dravet syndrome	SCN1B	0.4705	0.1175	Approximately 80% of patients with Dravet syndrome have been associated with heterozygous mutations in SCN1A gene encoding voltage-gated sodium channel (VGSC) a(I) subunit, whereas a homozygous mutation (p.Arg125Cys) of SCN1B gene encoding VGSC b(I) subunit was recently described in a patient with Dravet syndrome.	-1
myoclonic epilepsies	ASA	0.4705	0.1629	The still-unknown relationship between the pathologic level of ASA activity and myoclonic epilepsies suggests introduction of ASA assays in patients with PME.	-1
CP	NF1	0.4705	0.2954	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
seizures	neurofibromatosis type 1	0.4705	0.2242	On the other hand, response to these drugs was correlated with some clinical findings in symptomatic cases; all infants with neurocutaneous syndrome (tuberous sclerosis, neurofibromatosis type 1) had controlled infantile spasms, while none of patients with severe neonatal asphyxia or with prior other seizures responded.	-1
mitochondrial disease	SCN1A	0.4704	0.4958	PURPOSE: To review our cohort of patients with Dravet syndrome and determine if patients with SCN1A mutations can also express mitochondrial disease due to electron transport chain dysfunction.	-1
renal salt loss	CLC	0.4704	0.09023	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
cognitive impairment	SCN1A	0.4703	0.4568	Dravet syndrome and SCN1A gene mutation related-epilepsies: cognitive impairment and its determinants.	-1
focal epilepsy	FGFR3	0.4703	0.3224	CONCLUSIONS: The present case of hypochondroplasia and FGFR3 mutation in Asn540Lys associated with characteristic abnormalities involving bilaterally medial temporal lobe structures, probable hippocampal cortex focal dysplasia, and early onset of focal epilepsy underscores the possibility of a rare syndrome.	-1
Muscle-eye-brain disease	CMD1C	0.4702	0.4598	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
generalized epilepsy	SCN1A	0.4702	0.2928	We report 2 families harboring a novel SCN1A mutation, one of whom had Panayiotopoulos syndrome and the other a phenotype consistent with generalized epilepsy with febrile seizures plus.	-1
myoclonic epilepsy of infancy (SMEI) or Dravet syndrome	SCN1A	0.4702	0.2686	Subsequently, mutations of SCN1A were also found in patients with severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome, and in patients with borderline SMEI (SMEB), a milder form of Dravet syndrome.	-1
RTT	MECP2	0.4702	0.1856	A large degree of phenotypic variation has been observed in patients with RTT, both those with and without MECP2 mutations.	-1
epileptic	CYP1A2	0.47	0.1429	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2 and CYP2C19 in vivo in epileptic patients.	-1
epileptiform activity	TRPC3	0.47	0.06142	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
DS	SCN1A	0.47	0.3807	Our findings showed that 12.5% of DS patients who are mutation negative have MLPA-detected SCN1A CNVs with an overall frequency of about 2-3%.	-1
Rett syndrome	MeCP2_e1	0.47	0.3521	The first missense mutation causing Rett syndrome specifically affecting the MeCP2_e1 isoform.	-1
XLAG syndrome	TUBA3	0.4699	0.186	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
hypochondroplasia	FGFR3	0.4699	0.4469	CONCLUSIONS: The present case of hypochondroplasia and FGFR3 mutation in Asn540Lys associated with characteristic abnormalities involving bilaterally medial temporal lobe structures, probable hippocampal cortex focal dysplasia, and early onset of focal epilepsy underscores the possibility of a rare syndrome.	-1
LQTS	KCNQ1	0.4698	0.03557	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
Dravet syndrome	SCN1A	0.4697	0.4204	[Genetic and phenotypic characteristics of SCN1A mutations in Dravet syndrome].	-1
genetic epilepsies	SCN1A	0.4696	0.2618	METHODS: We screened a discovery cohort of 448 patients with a broad range of common genetic epilepsies and 734 controls for previously reported SCN1A mutations that were assumed to be disease causing.	-1
Rett syndrome	MECP2	0.4694	0.1253	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	-1
Dravet syndrome	protocadherin 19	0.4694	0.1659	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
neonatal hypotonia	MECP2	0.4692	0.1039	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
epileptic disorders	SCN1A	0.4691	0.3182	This finding emphasizes the significance of SCN1A mutations also in epileptic disorders with features of LGS, particularly in the myoclonic variant of the disorder.	1
seizure	interleukin-6, -8, and -10	0.4691	0.1559	An elevation of interleukin-6, -8, and -10, and tumor necrosis factor in the serum and that of interleukin-4, -6, and-8 in the cerebrospinal fluid were observed at the onset of a late seizure.	-1
progressive myoclonic epilepsy	laforin	0.469	0.2569	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
refractory epilepsy	SCN1A	0.469	0.4903	In this case series, the authors describe the clinical features, surgical pathology, and outcomes in 6 patients with SCN1A mutations and refractory epilepsy who underwent focal cortical resection prior to uncovering the genetic basis of their epilepsy.	1
splanchnic vein thrombosis	JAK2	0.469	0.2935	JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.	-1
mental retardation	cyclin-dependent kinase-like 5 and aristaless-related homeobox	0.469	0.5112	Two genes causally involved in refractory epilepsy with mental retardation, cyclin-dependent kinase-like 5 and aristaless-related homeobox, could account for at least some forms of early onset epileptic encephalopathy that still lack etiological explanation.	-1
Dravet syndrome	SCN1A	0.4689	0.4901	Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes.	-1
hydrocephalus	CSF	0.4688	0.1273	In univariate analysis, other factors associated with developing hydrocephalus were elevated maximum daily temperatures, elevated white blood cell counts, decreased CSF protein, and increased CSF red blood cell counts.	-1
encephalopathy	SCN1A	0.4688	0.2357	Acute encephalopathy with a truncation mutation in the SCN1A gene: a case report.	-1
EE	cyclin-dependent kinase-like 5	0.4688	0.2664	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	1
Rasmussen syndrome and of the hemiconvulsion-hemiplegia syndrome	SCN1A	0.4687	0.5729	Recent descriptions of Rasmussen syndrome and of the hemiconvulsion-hemiplegia syndrome in isolated patients with SCN1A mutations are of uncertain meaning but might indicate that co-occurring immunomediated or seizure-induced structural changes can, in turn, become a substrate for the severe epileptic encephalopathy.	-1
epilepsy	KCNH1	0.4687	0.2571	Here we report three de novo missense KCNH1 mutations in four patients with syndromic developmental delay and epilepsy.	1
Dravet syndrome	SCN1A	0.4687	0.216	It was reported recently that a proportion of patients previously diagnosed with alleged vaccine encephalopathy might possess SCN1A mutations and clinical histories that enabled a diagnosis of Dravet syndrome, but these results have not been replicated.	-1
SSPE	SCN1A	0.4687	0.1029	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	-1
seizure	SCN1a	0.4686	0.1922	Evidence has emerged of the consequences of SCN1a dysfunction in different neuronal networks across the brain pointing toward a channelopathy model causing the neurologic features of Dravet syndrome that is beyond purely seizure related damage.	-1
diabetes	INSR	0.4686	0.2316	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
dysmorphic and neurologic features	GABRD	0.4685	0.264	Other genes deleted in a subset of the patients likely play a contributory role in the phenotypes, including GABRD and seizures, PRKCZ and neurologic features, and SKI and dysmorphic and neurologic features.	-1
sCJD	PrP(Sc	0.4685	0.05969	Western blot analysis of the protease-resistant PrP (PrP(Sc) ) in the right temporal pole revealed the type 2 pattern, which is characterized by a single unglycosylated band, in contrast to the doublet described for the typical MV2 subtype of sCJD.	-1
hemiconvulsion-hemiplegia-epilepsy	SCN1A	0.4684	0.502	Low incidence of SCN1A genetic mutation in patients with hemiconvulsion-hemiplegia-epilepsy syndrome.	-1
genetic epilepsy syndrome	NaV1.1	0.4684	0.02623	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
syndromic MIDs	CMT2	0.4684	0.1604	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
SVT	JAK2(V617F	0.4684	0.1372	The presence of JAK2(V617F) mutation should be considered per se a prothrombotic state for cerebral, coronary and peripheral microvascular disturbances and for SVT but not for deep vein thrombosis.	-1
epilepsy	KCNH1	0.4684	0.1963	Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy.	1
neonatal hypoglycemia	INSR	0.4684	0.2508	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
seizures	CDKL5	0.4683	0.3854	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
neurodevelopmental disorders	NRXN1	0.4683	0.1902	NRXN1 deletions identified by array comparative genome hybridisation in a clinical case series - further understanding of the relevance of NRXN1 to neurodevelopmental disorders.	-1
Rett syndrome	TCF4	0.4683	0.08984	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
RSTS	CREBBP	0.4682	0.3679	Eight novel mutations extended the genetic spectrum of CREBBP mutations in RSTS patients.	-1
LQTS	SCN5A	0.4682	0.1151	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
Emery-Dreifuss muscular dystrophy	FHL1	0.4682	0.3829	Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy.	-1
DS	March 1	0.4682	0.1026	Between March 1, 1990 and May 31, 2007, 59 patients who met diagnostic criteria for DS were studied in our department.	-1
epilepsy	EPM2A	0.4682	0.3019	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	1
epilepsy	neurofibromatosis	0.4681	0.1167	[Relationship between child epilepsy and MRI findings in von Recklinghausen neurofibromatosis (NF 1)].	-1
hearing loss	ROGDI	0.4681	0.1549	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
CSS	SMARCA2	0.4681	0.05951	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
CSS	SMARCE1	0.4681	0.05951	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
CSS	ARID1A	0.4681	0.05951	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
epileptic encephalopathy	KCC2	0.4681	0.09277	Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.	1
myoclonic epilepsy	SCN1A	0.4681	0.1311	INTRODUCTION: Mutations in the voltage-gated sodium channel SCN1A gene are the main genetic cause of Dravet syndrome (previously called severe myoclonic epilepsy of infancy or SMEI).	-1
Rett syndrome	CDKL5	0.468	0.2597	Moreover, this report reinforces the observation that the CDKL5 phenotype overlaps with Rett syndrome and that CDKL5 gene analysis is recommended in females with a seizure disorder commencing in the first weeks of life.	-1
edema	PEHO	0.468	0.3532	Epilepsy and the electroencephalogram in progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (the PEHO syndrome).	-1
ICEGTC	SCN1A	0.468	0.2101	Mutations in SCN1A are found in both SMEI and ICEGTC at high rates of 70-81%.	1
epileptic	SCN1A	0.468	0.3144	We describe here the progressive neurocognitive decline in two children (one male), carrying de novo SCN1A truncating mutations and presenting with different epileptic phenotypes.	1
ASD	MBD5	0.468	0.2559	We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense variant, p.79Gly>Glu (c.236G>A) (p = 0.012).	-1
DS	SCN1A	0.468	0.179	In this study, we have identified five variants c.*1025T>C, c.*1031A>T, c.*1739C>T, c.*1794C>T and c.*1961C>T in the SCN1A 3' UTR in the patients with DS.	-1
GCPS	GLI3	0.4679	0.1693	This deleted region included GLI3 and GCK genes (where heterozygous mutations cause GCPS and MODY2, respectively), and many other contiguous genes.	-1
Neuronal ceroid lipofuscinosis	NCL	0.4679	0.5009	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
convulsions	IL-6	0.4679	0.2041	METHODS: Results of liver function tests, mainly the elevation of transaminase and IL-6 in rotavirus gastroenteritis with or without convulsions, were evaluated.	-1
Rasmussen encephalitis	SCN1A	0.4679	0.1765	An example is the finding of SCN1A gene mutations in association with a large spectrum of neurological diseases, from generalized epilepsy with febrile seizures plus (GEFS +) to severe myoclonic epilepsy of infancy and to vaccine-induced encephalopathy and Rasmussen encephalitis, Panayiotopoulos syndrome and familial hemiplegic migraine.	-1
epilepsy	CDKL5	0.4679	0.3114	OBJECTIVE: To determine the frequency of mutations in CDKL5 in both male and female patients with infantile spasms or early onset epilepsy of unknown cause, and to consider whether the breadth of the reported phenotype would be extended by studying a different patient group.	1
Dravet syndrome	SCN1A	0.4679	0.1326	Mutations in the voltage-gated sodium channel gene SCN1A are a major cause of severe myoclonic epilepsy of infancy (Dravet syndrome) and generalized epilepsy with febrile seizures plus.	-1
DS	SCN1A	0.4679	0.08253	When a baby exhibits two or more features of complex febrile seizures in the first year of life, a diagnosis of DS should be considered, and SCN1A gene mutation screening should be performed as early as possible.	-1
autism	MeCP2	0.4678	0.2634	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	DHCR7	0.4678	0.1197	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
volvulus	CSF	0.4678	0.3836	CONCLUSION: The observed trend towards an association of intraparenchymal cerebral pathological results on MRI and a positive skin PCR for O. volvulus despite negative PCR of CSF is intriguing and deserves further attention.	-1
West syndrome	SCN2A	0.4678	0.2245	RESULTS: We found 14 novel SCN2A missense mutations in 15 patients: 9 of 67 OS cases (13.4%), 1 of 150 West syndrome cases (0.67%), and 5 of 111 with unclassified EOEEs (4.5%).	-1
intellectual disability	MECP2	0.4677	0.06646	Furthermore, a complex duplication spanning of the MECP2 gene was identified in two brothers who presented with developmental delay and intellectual disability.	-1
Rett syndrome	Mecp2	0.4677	0.3205	Rett syndrome patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as mental retardation, autism, and epilepsy.	-1
neurotoxicity	DPD	0.4676	0.1778	It implies that DPD deficiency can cause neurotoxicity in 5-FU-treated patients and advocates for the prospective screening of DPD deficiency before starting any 5-FU-containing chemotherapy so as to prevent such side effects in the future.	-1
myoclonic epilepsy	SCN1A	0.4676	0.08049	PURPOSE: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients.	-1
amyloidosis	TTR	0.4676	0.3782	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
Dravet syndrome	SCN1a	0.4676	0.2651	Evidence has emerged of the consequences of SCN1a dysfunction in different neuronal networks across the brain pointing toward a channelopathy model causing the neurologic features of Dravet syndrome that is beyond purely seizure related damage.	-1
temporal lobe epilepsy	SCN1A	0.4676	0.1809	Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 * 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59].	-1
SJS/TEN	HLA-B	0.4675	0.09898	"The HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 alleles may be ""protectors"" against AED-induced SJS/TEN, especially CBZ-SJS/TEN."	-1
immunodeficiency	AP3D1	0.4675	0.2126	Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.	-1
sporadic Dravet syndrome	SCN1A	0.4675	0.2133	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
hypsarrhythmia	3-phosphoglycerate dehydrogenase	0.4674	0.09235	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
AS	OCA2	0.4674	0.1759	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	AUH	0.4673	0.1164	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
tented mouth	alkaline phosphatase	0.4673	0.07012	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
PWS	OCA2	0.4673	0.2131	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
Walker-Warburg syndrome	CMD1C	0.4672	0.4743	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
BFNS	KCNQ3	0.4671	0.09519	No mutations were found in the genes (KCNQ2, KCNQ3) associated with BFNS, and CGH was negative.	-1
seizure	SCN1A	0.4671	0.2769	METHODS: We retrospectively studied patients with Dravet syndrome who had mutations in SCN1A, whose first seizure was a convulsion, and for whom validated source data were available.	-1
spasms	CDKL5	0.4671	0.1841	Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms.	-1
Epilepsy in Rett syndrome	CDKL5	0.4671	0.2252	Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.	1
Wolfram syndrome	CMT2	0.4671	0.2419	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
AR-SJS/TEN	HLA-A	0.4671	0.07731	HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC and AR-SJS/TEN with SOC.	-1
SJS/TEN	HLA-B	0.467	0.1348	Furthermore, the carrier rates of HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 were lower in the SJS/TEN group compared with the AED-tolerant group.	-1
febrile seizures	SCN1A	0.467	0.172	We report 2 families harboring a novel SCN1A mutation, one of whom had Panayiotopoulos syndrome and the other a phenotype consistent with generalized epilepsy with febrile seizures plus.	-1
kyphoscoliosis	ACAD8	0.467	0.07135	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
AGS	CSF	0.467	0.2872	CSF investigations in three patients with classic AGS also showed increased pterins and partially lowered folate levels.	-1
Rett syndrome	methyl-CpG binding protein 2	0.467	0.2548	However, the lack of methyl-CpG binding protein 2 mutations in a small group of classic Rett syndrome cases, and the low frequency of these mutations in atypical Rett syndrome patients, suggest that other gene defects may play a role in this disorder.	-1
cardiac long QT syndrome type 2	EAG-related	0.4669	0.05683	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
Dravet syndrome	SCN1A	0.4669	0.218	SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis.	-1
rolandic epilepsy	GRIN2A	0.4669	0.1639	Here we demonstrate that about 20% of cases of LKS, CSWSS and electroclinically atypical rolandic epilepsy often associated with speech impairment can have a genetic origin sustained by de novo or inherited mutations in the GRIN2A gene (encoding the N-methyl-D-aspartate (NMDA) glutamate receptor a2 subunit, GluN2A).	-1
seizures	SCN1A	0.4669	0.1532	We studied 132 patients with epilepsy syndromes with seizures precipitated by fever, and performed phenotype-genotype correlations with SCN1A alterations.	-1
RS	MeCP2	0.4668	0.03298	Mutations in the gene MECP2, which encodes MeCP2, have been identified in 80% to 85% of girls and women with RS.	-1
obese	C-reactive protein	0.4668	0.2441	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
congenital myotonia	cystathionine beta-synthase	0.4668	0.1227	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
infantile spasms	biotinidase	0.4668	0.4769	Rarely, infantile spasms in association with biotinidase deficiency, phenylketonuria, and pyridoxine-dependent seizures are successfully treated with biotin, a low phenylalanine diet, and pyridoxine, respectively.	-1
seizure	SCN2A	0.4668	0.1251	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
epileptic seizures	SCN1A	0.4667	0.1054	Mutations in SCN1A can be identified in the majority of patients, and epileptic seizures in the setting of fever are a clinical hallmark.	1
tonic-clonic seizures	SCN1A-Related	0.4667	0.02927	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
seizure disorders	SCN1A-related	0.4667	0.3619	The phenotype of SCN1A-related seizure disorders can vary even within the same family.	1
LQTS	KCNE2	0.4667	0.2307	The appropriate MLPA kit contained probes for selected exons in LQTS genes KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2.	-1
Rett syndrome	MECP2	0.4665	0.1491	Mutations in methyl CpG binding protein 2 (MECP2) are identified in most patients with classic Rett syndrome.	-1
thrombotic	L-asparaginase	0.4665	0.1954	We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.	-1
SMEI	SCN2A	0.4665	0.2128	RESULTS: In both core SMEI and SMEB, various mutations of SCN1A including nonsense and missense mutations were identified, whereas no mutations of SCN2A, SCN1B, and SCN2B were found within the regions examined.	-1
encephalopathy	PEHO	0.4665	0.2596	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO)-like syndrome: what diagnostic characteristics are defining?	-1
Rett syndrome	FOXG1-gene-related	0.4664	0.2237	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
respiratory infections	MECP2	0.4664	0.3307	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
epileptic encephalopathy	CDKL5	0.4664	0.3682	AIM: Cyclin-dependent kinase-like 5 (CDKL5) gene abnormalities cause an early-onset epileptic encephalopathy.	1
DS	SCN1A	0.4664	0.3042	Deletions and duplications/amplifications of the a1-sodium channel subunit (SCN1A) gene occur in about 12% of patients with Dravet syndrome (DS) who are otherwise mutation-negative.	-1
Wilson syndrome	SLC9A6	0.4663	0.1111	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Creutzfeldt-Jakob disease	parvalbumin-immunoreactive	0.4663	0.1147	Distribution of parvalbumin-immunoreactive neurons in brain correlates with hippocampal and temporal cortical pathology in Creutzfeldt-Jakob disease.	-1
status epilepticus	SCN1A	0.4661	0.1815	We describe three children with genetically different sodium channel alpha 1 subunit (SCN1A) mutation associated epilepsy who experienced a sudden and sustained neurologic regression following status epilepticus in two and acute sepsis in one.	-1
epilepsies	ARX-related	0.4659	0.2993	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
LQTS	KCNH2	0.4659	0.06887	In 6 patients other mutations were found: in KCNQ1 (n=1), in KCNH2 (n=3) and in SCN5A (n=1) which were pathogenic for long-QT-syndromes (LQTS) and 2 mutations of unknown clinical significance in SCN5A.	-1
EE	CDKL5	0.4659	0.2222	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	1
(SADDAN) syndrome	fibroblast growth factor receptor 3	0.4658	0.229	[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene].	-1
non-neurodegenerative disorder	PrP	0.4658	0.2757	This group exhibited mean PrP values of 164 ng/ml while non-neurodegenerative disorder patients and healthy controls showed PrP levels of 208 ng/ml and 226 ng/ml, respectively.	-1
West syndrome	GRIN2B	0.4657	0.3494	INTERPRETATION: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe developmental delay as well as of ID with childhood onset focal epilepsy.	-1
familial hemiplegic migraine	SCN1A	0.4657	0.2242	Different SCN1A mutations are known to cause a variety of phenotypes, such as generalized epilepsy with febrile seizures plus (GEFS+), Dravet syndrome and familial hemiplegic migraine (FHM).	-1
RTT	CDKL5	0.4657	0.3582	Here we report on the clinical and CDKL5 molecular investigation in a very unusual RTT case, with severe, early-neurological involvement in which we have shown in a previous report, a novel P388S MECP2 mutation [Conforti et al. (2003); Am J Med Genet A 117A: 184-187].	-1
epileptic encephalopathy	SETD5	0.4657	0.07636	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
epileptic encephalopathy	SCN2A	0.4657	0.07636	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	1
cSE	SCN1A	0.4657	0.2242	This feature was observed in five of seven patients from groups A and B. SIGNIFICANCE: This study shows that seizure control improves and cSE become less frequent in DS as patients age, independent of their SCN1A mutation type.	-1
adrenal insufficiency	corticosteroid-binding-globulin	0.4657	0.1231	Therefore, patients investigated for Cushing's syndrome may show a falsely positive dexamethasone suppression test, and patients with adrenal insufficiency on steroid replacement may require increased doses of steroids; furthermore, increased corticosteroid-binding-globulin levels are also associated with chronic anticonvulsant administration.	-1
FS	GABRD	0.4656	0.132	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
channelopathy	KCNQ1	0.4656	0.1935	That long QT syndrome mutations in KCNQ1 cause epilepsy reveals the dual arrhythmogenic potential of an ion channelopathy coexpressed in heart and brain and motivates a search for genetic diagnostic strategies to improve risk prediction and prevention of early mortality in persons with seizure disorders of unknown origin.	-1
WS	NF1	0.4656	0.2339	WS and NF1: Onset of IS took place between 4 and 9 months of age.	-1
epileptiform activity	TRPC3	0.4656	0.2248	TRPC3 mediates hyperexcitability and epileptiform activity in immature cortex and experimental cortical dysplasia.	-1
KRS	ATP13A2	0.4656	0.3061	We report the clinical features of the original Chilean family with Kufor-Rakeb syndrome (KRS) that led to the discovery of the ATP13A2 gene at the PARK9 locus.	-1
epilepsy	inv	0.4655	0.05322	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
speech impairment	GRIN2A	0.4655	0.1979	Here we demonstrate that about 20% of cases of LKS, CSWSS and electroclinically atypical rolandic epilepsy often associated with speech impairment can have a genetic origin sustained by de novo or inherited mutations in the GRIN2A gene (encoding the N-methyl-D-aspartate (NMDA) glutamate receptor a2 subunit, GluN2A).	-1
tinnitus	KCNQ2/3	0.4655	0.03869	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Rett syndrome	MECP2	0.4655	0.1833	We aimed to improve the understanding of genotype-phenotype correlations in Rett syndrome (RS) by adopting a novel approach to categorising phenotypic dimensions - separating typicality of presentation, outcome severity and age of onset - and by classifying MECP2 mutations strictly by predicted functional attributes.	-1
isolated SMEI	SCN1A	0.4655	0.2972	Recently, we described de novo mutations of the neuronal sodium channel alpha-subunit gene SCN1A in seven isolated SMEI patients.	-1
infantile-onset epilepsy syndrome	SCN1A	0.4654	0.2094	BACKGROUND: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the a-subunit of the voltage-gated sodium channel Na(v)1.1.	1
Ohtahara syndrome	SCN2A	0.4654	0.1656	Paternal germline mosaicism of a SCN2A mutation results in Ohtahara syndrome in half siblings.	-1
Dravet syndrome	SCN1A	0.4652	0.5232	This critical review explores recent evidence relating to the pathogenicity of SCN1A mutations in Dravet syndrome and the effect these have on the wider disease phenotype and discusses whether knowledge of specific genotypes can influence clinical practice.	-1
hypersensitivity	HLA-A	0.4652	0.1144	We have identified HLA-A*31:01 as a potential risk marker for all phenotypes of carbamazepine-induced hypersensitivity with applicability in European and other populations.	-1
neurodegeneration	phospholipase A2	0.4652	0.2061	(1) Leukodystrophy and/or iron deposits in basal ganglia is a common feature of phospholipase A2 deficiency, fatty acid hydroxylase deficiency, and pantothenate kinase-associated neurodegeneration.	-1
epilepsy	CRK	0.4651	0.5243	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
cardiac arrhythmia	KCNQ4	0.4651	0.1082	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
amyloidosis	TTR	0.4651	0.07321	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
West syndrome	DCX	0.4651	0.0354	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
Dravet syndrome	SCN1A	0.4651	0.1282	Epilepsies linked to SCN1A mutations range from a relatively benign syndrome called generalized epilepsy with febrile seizures plus to severe childhood epilepsies such as severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
vascular dysfunction	A beta	0.465	0.399	These data add to evidence that inflammation against A beta can cause vascular dysfunction, a potential mechanism for the toxic response recently observed in clinical trials of A beta immunization.	-1
ANE	SCN1A	0.465	0.206	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
RS	MECP2	0.465	0.03695	Mutations in the gene MECP2, which encodes MeCP2, have been identified in 80% to 85% of girls and women with RS.	-1
Seizure	SCN1A-Related	0.465	0.313	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
infantile spasms	CDKL5	0.4649	0.4269	Furthermore, in contrast to Rett syndrome, patients with CDKL5 mutations, have seizures or infantile spasms starting in the first weeks of life.	-1
genetic susceptibility	SCN1A	0.4648	0.4749	Are SCN1A gene mutations responsible for genetic susceptibility to subacute sclerosing panencephalitis?	-1
autosomal dominant nocturnal frontal lobe epilepsy	laforin	0.4648	0.2054	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
AS	MECP2	0.4647	0.1037	We advise MECP2 examination in AS patients of unknown genetic etiology whose EEG examinations are/were pathognomonic for AS to exclude RS.	-1
Leukodystrophy	phospholipase A2	0.4647	0.06768	(1) Leukodystrophy and/or iron deposits in basal ganglia is a common feature of phospholipase A2 deficiency, fatty acid hydroxylase deficiency, and pantothenate kinase-associated neurodegeneration.	-1
hypsarrhythmia	STK9	0.4647	0.1727	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
RRFs	COX	0.4646	0.2432	In two patients with MERRF, neither SSV nor COX positive RRFs were seen and A8344G mutations were found from both muscle and blood samples.	-1
Dravet syndrome	SCN2A	0.4646	0.375	We screened for mutations of SCN1A, SCN2A and GABRG2 (the gene encoding gamma2 subunit of the GABA(A) receptor) in 59 patients with Dravet syndrome and found 29 SCN1A mutations and three missense SCN2A mutations.	-1
microcephaly	SCN2A	0.4646	0.08178	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
familial neonatal epilepsy	KCNQ2	0.4646	0.1896	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
psychomotor retardation	SCN1A	0.4645	0.1546	"Three criteria that were best evident in SCN1A mutation positive patients are as follows: ""Normal development before the onset of seizures, onset of seizure before age of one year, and psychomotor retardation after onset of seizures."	-1
seizures	NARP	0.4645	0.04972	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
seizures	SCN1A	0.4644	0.318	In addition to seizures, patients with SCN1A mutations often experience sleep abnormalities, suggesting that SCN1A may also play a role in the neuronal pathways involved in the regulation of sleep.	-1
Alzheimer's dementia	AD1	0.4644	0.4633	Particularly urgent for contemporary health services, more so in countries with a high mean age, are diseases such as e.g. Alzheimer's dementia, the AD1 locus of which is assumed to be on the 21st chromosome.	-1
infancy	GABRD	0.4643	0.03837	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
autistic disorder	methyl-CpG-binding protein 2	0.4643	0.214	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
RTT	MECP2-mutated	0.4643	0.3919	"CONCLUSIONS: Although RTT MECP2-mutated patients suffer from a serious and progressive encephalopathy, it is ""epileptogenic"" but not ""DREgenic"" as they have a decreased risk (16%) for DRE compared to the general epileptic population (DRE: 20-40%)."	-1
infantile spasms	PEHO	0.4643	0.2139	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
febrile seizures	GABRB2	0.4642	0.08663	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
febrile seizures	GABRA6	0.4642	0.08663	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
epileptic encephalopathy	TCF4	0.4642	0.1613	Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction.	1
Systemic Lupus Erythematosus	Anti-NMDA-NR2A/B	0.4642	0.2814	(3) Anti-NMDA-NR2A/B antibodies are present in a substantial number of patients with Systemic Lupus Erythematosus (SLE) with or without neuropsychiatric problems.	-1
ADPEAF	LGI4	0.4641	0.2111	No mutations in LGI2, LGI3, or LGI4 were found in the other two ADPEAF families.	-1
Dravet syndrome	SCN1A	0.4641	0.2208	Approximately 80% of patients with Dravet syndrome have been associated with heterozygous mutations in SCN1A gene encoding voltage-gated sodium channel (VGSC) a(I) subunit, whereas a homozygous mutation (p.Arg125Cys) of SCN1B gene encoding VGSC b(I) subunit was recently described in a patient with Dravet syndrome.	-1
Pitt   Hopkins syndrome	MECP2	0.4641	0.14	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
diabetes	HNF1 beta	0.464	0.1197	Deletions in chromosome 17q12 encompassing the HNF1 beta gene cause cystic renal disease and maturity onset diabetes of the young, and have been recently described as the first recurrent genomic deletion leading to diabetes.	-1
peripheral nerve hyperexcitability	KCNQ2	0.464	0.3132	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
Dravet syndrome	SCN1A	0.464	0.1738	A clinical and genetic (denovo mutation of a sodium channel, SCN1A) diagnosis of Dravet syndrome was made.	-1
Ohtahara syndrome	KCNQ2	0.464	0.3037	Whole exome sequencing identifies KCNQ2 mutations in Ohtahara syndrome.	-1
myoclonic jerks	NARP	0.464	0.04974	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
epilepsy	synapsin II	0.464	0.2663	Lack of association between synapsin II (SYN2) gene polymorphism and susceptibility epilepsy: a case-control study and meta-analysis.	-1
ID	PHF6	0.464	0.2131	METHODS AND RESULTS: We performed PHF6 mutational analysis and screening for intragenic deletions and duplications by quantitative real-time PCR and multiplex ligation dependent probe amplification (MLPA) in female patients with variable ID and a distinct appearance of sparse hair, remarkable facial features, hypoplastic nails, and teeth anomalies.	-1
RTT	CDKL5	0.464	0.1381	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
epilepsy	GBP	0.464	0.06871	In drug-resistant epilepsy the use of VGB, LTG, oxcarbazepine, FBM and GBP resulted in at least a 50% improvement in 20% to 60% of such patients treated and in 7% led to complete seizure control.	-1
febrile seizures	GABRB3	0.4639	0.08633	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
SMEI	SCN1A	0.4639	0.2211	The clinical spectrum of epilepsies harboring SCN1A mutations may be consisted of various phenotypes with GEFS+ on the mildest end and SMEI on the severest end of the spectrum.	-1
Caroli disease	ARPKD	0.4639	0.2591	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
mental deterioration	CSF and EEG	0.4638	0.1296	In a 64-year old woman with progressive visual impairment for 4 weeks, probable Creutzfeld-Jakob disease without myoclonus was diagnosed after rapidly progressive mental deterioration had also developed, and CSF and EEG showed characteristic findings.	-1
SMEI	SCN1A	0.4638	0.1837	CONCLUSIONS: We conclude that SMEI is caused either by complete loss of SCN1A function, or by dysfunctional sodium channels exhibiting mixed biophysical properties.	-1
non-neurodegenerative disorder	PrP	0.4637	0.1861	This group exhibited mean PrP values of 164 ng/ml while non-neurodegenerative disorder patients and healthy controls showed PrP levels of 208 ng/ml and 226 ng/ml, respectively.	-1
familial amyloid syndrome	TTR	0.4637	0.1199	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
mental retardation	STK9	0.4636	0.177	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
HD	IT15	0.4636	0.05668	The disorder was diagnosed as Huntington's disease (HD), but analysis of the IT15 gene for HD revealed normal alleles.	-1
growth arrest	MECP2	0.4636	0.1355	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
Rett syndrome	MECP2	0.4636	0.1378	Drug-resistant epilepsy and epileptic phenotype-EEG association in MECP2 mutated Rett syndrome.	-1
neurocutaneous syndrome	neurofibromatosis type 1	0.4635	0.3756	We included in the study 23 children diagnosed with different types of neurocutaneous syndrome (10 patients with tuberous sclerosis, 5 with Sturge-Weber syndrome and 8 with neurofibromatosis type 1 and epilepsy'.	-1
disintegrative disorder	MeCP2	0.4634	0.1564	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
DS	SCN1A	0.4632	0.4884	We investigated SCN1A mutations in 63 Chinese patients with DS and analyzed its inheritance.	-1
PME	laforin	0.4632	0.181	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
brain MRI abnormalities	CREBBP	0.4632	0.618	There were no remarkable significant differences in the clinical features between those with and without a CREBBP mutation, although brain MRI abnormalities were more frequently observed in those with a CREBBP mutation.	-1
Unverricht-Lundborg disease	CLN3	0.4632	0.1299	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
autistic	MECP2	0.4631	0.3876	Despite these connections, MECP2 mutations in nonspecific autistic and mentally retarded populations are rare.	-1
encephalopathy	SCN1A	0.4631	0.196	De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study.	-1
endocrine diseases	MEN 2A	0.4631	0.1908	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
neonatal diabetes	IER3IP1	0.463	0.1524	This is the first reported case of compound heterozygous mutations within IER3IP1 resulting in neonatal diabetes.	-1
unilateral perisylvian dysplasia	PTEN	0.463	0.126	We report the case of a girl with Cowden syndrome (CS) presenting with unilateral perisylvian dysplasia and with drug resistant focal seizures carrying a novel missense mutation 385G>A (G129R) in the PTEN gene.	-1
visual impairment	CSF and EEG	0.4629	0.09407	In a 64-year old woman with progressive visual impairment for 4 weeks, probable Creutzfeld-Jakob disease without myoclonus was diagnosed after rapidly progressive mental deterioration had also developed, and CSF and EEG showed characteristic findings.	-1
seizures	EA1	0.4629	0.09997	Animal models for EA1 include Kcna1-deficient mice, which recessively display severe seizures and die prematurely, and V408A-knock-in mice, which dominantly exhibit stress-induced loss of motor coordination.	-1
temporal lobe epilepsy	prion protein	0.4628	0.157	Cognitive performance of patients with mesial temporal lobe epilepsy is not associated with human prion protein gene variant allele at codons 129 and 171.	-1
intellectual disabilities	MBD5	0.4628	0.2366	Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.	-1
DS	Nav1.1	0.4628	0.1854	Mutations in the SCN1A gene-encoding voltage-gated sodium channel a-I subunit (Nav1.1) cause various spectrum of epilepsies including Dravet syndrome (DS), a severe and intractable form.	-1
microcephaly	SCN9A	0.4627	0.07947	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
microcephaly	SCN1A	0.4627	0.07947	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
hypothalamus	Scn1a	0.4627	0.1527	KEY FINDINGS: Immunohistochemistry revealed broad expression of Scn1a in the neocortex, hippocampus, hypothalamus, thalamic reticular nuclei, dorsal raphe nuclei, pedunculopontine, and laterodorsal tegmental nuclei.	-1
Dravet syndrome	GABRA1	0.4626	0.3423	CONCLUSIONS: We show that GABRA1 and STXBP1 make a significant contribution to Dravet syndrome after SCN1A abnormalities have been excluded.	-1
IBD	DHCR7	0.4626	0.2635	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
IBD	AUH	0.4626	0.2635	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neurodegeneration	TBC1D24/Skywalker	0.4624	0.122	In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins.	-1
epileptic encephalopathies	GRIN2A	0.4624	0.1867	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	1
RTT	MECP2	0.4624	0.4065	In addition, no significant relationship was found between the DRE and the RTT genotype category (chi-square=1.147, DF=4, p=0.8867), or a specific MECP2 genotype (chi-square=30.958, DF=39, p=0.8173).	-1
Kleefstra syndrome	TCF4	0.4623	0.1299	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
benign neonatal epilepsy	syntaxin-1A	0.4622	0.1895	Novel KCNQ2 and KCNQ3 mutations in a large cohort of families with benign neonatal epilepsy: first evidence for an altered channel regulation by syntaxin-1A.	-1
Batten disease	CLN3	0.4622	0.07056	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
focal epilepsy	PTEN	0.4622	0.29	An atypical patient with Cowden syndrome and PTEN gene mutation presenting with cortical malformation and focal epilepsy.	-1
ketotic hyperglycinemia	H-protein	0.4621	0.131	Non ketotic hyperglycinemia is a rare inborn error of glycine metabolism due to deficient activity of glycine cleavage system, a multienzymatic complex consisting of four protein subunits: the P-protein, the H-protein, the T-protein and the L-protein.	-1
epilepsy	SCN1A	0.4621	0.375	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
seizure disorders	SCN1A-related	0.462	0.4762	DIAGNOSIS/TESTING: The diagnosis of SCN1A-related seizure disorders relies on detection of a heterozygous pathogenic variant in SCN1A.	1
benign tumors	mTOR	0.4619	0.1184	The mammalian target of rapamycin (mTOR) signaling pathway is activated in several disorders associated with benign tumors and malformations of the cerebral cortex.	-1
epilepsy	SCN2A	0.4619	0.087	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	1
IS	CDKL5	0.4619	0.1513	Noteworthy, the CDKL5 mutation rate is high (28%) in women with early-onset seizures and IS.	-1
septicaemia	CRP	0.4618	0.2618	Neonates with septicaemia due to gram negative bacteria were significantly found to have higher rates of positive CRP than neonates with gram positive septicaemia and with negative culture (p   <   0.001, OR 8.2, 95 CI; 2.9-26).	-1
facial dysmorphisms	MECP2	0.4618	0.1517	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
diabetes mellitus	TRMT10A	0.4618	0.281	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
Seizure	SCN1A-involvement	0.4618	0.1743	Seizure onset was in the neonatal period in eight patients with SCN1A-involvement, in infancy in one patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
Borjeson-Forssman-Lehmann syndrome	PHF6	0.4617	0.1491	In adolescent or older patients, this phenotype overlaps but is not identical with Borjeson-Forssman-Lehmann syndrome in males, caused by X-linked recessive mutations in PHF6.	-1
epilepsy	MRI	0.4616	0.1819	The success of epilepsy surgery is in part dependent upon identification of a lesion on MRI.	-1
adrenal pheochromocytoma	NF1	0.4616	0.3367	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
absence seizures	SCN1A	0.4616	0.4227	However, the subjects harboring SCN1A mutations and CACNA1A variants had absence seizures more frequently than the patients with only SCN1A mutations (8/20 vs. 0/20, p=0.002).	-1
Dravet syndrome	SCN1A	0.4615	0.1519	Heterozygous de novo mutations in the SCN1A gene, which encodes the neuronal voltage-gated sodium channel a subunit type 1 (Nav1.1), are responsible for Dravet syndrome, with a broad spectrum of mutations and rearrangements having been reported.	-1
infancy	SCN1A	0.4615	0.08722	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
diabetic	SUR1	0.4615	0.3126	One-half of the SUR1 neonatal diabetic patients presented with de novo mutations.	-1
XLAG syndrome	LIS1	0.4614	0.2703	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
seizures	neurofibromatosis type 1	0.4614	0.3411	PURPOSE: To describe the clinical characteristics and outcomes of individuals with neurofibromatosis type 1 (NF1) and seizures in the largest cohort reported to date.	-1
epilepsy	neurofibromatosis type 1	0.4614	0.2591	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
Dravet syndrome	SCN1A	0.4613	0.1867	BACKGROUND: SCN1A is the most clinically relevant epilepsy gene, most mutations causing Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI).	-1
IBD	ROGDI	0.4613	0.09603	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
SMEI/DS	ARX	0.4613	0.1465	METHODS: Twenty-eight patients with early onset SMEI/DS before 6 months negative for SCN1A mutational screening were selected and screened for mutations in the ARX gene in males (n=14) or the CDKL5 gene in females (n=14).	-1
epilepsy	NaV1.1-L1649Q	0.4613	0.1587	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	1
Chiari type I malformation	MECP2	0.4613	0.2046	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
generalized epilepsy with	SCN1A	0.4613	0.4369	De-novo mutations and genetic variation in the SCN1A gene in Malaysian patients with generalized epilepsy with febrile seizures plus (GEFS+).	-1
death	PEX 26	0.4612	0.3179	Genetic analysis demonstrated a new mutation in PEX 26 gene.The death occurred at the age of 8 months of refractor epilepsy and apneas.	-1
febrile seizures	GABRG2	0.4612	0.08535	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
ASD	SETDB2	0.4612	0.3415	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
infantile spasms	CDKL5	0.4611	0.03762	OBJECTIVE: Epilepsy with mutation of the CDKL5 gene causes early seizures and is a variant of Rett syndrome (MIM (312750), which is reported typically as infantile spasms.	-1
DS	Scn1a	0.461	0.55	We hypothesized that children with DS with Scn1a mutations would have abnormal oscillatory activity.	-1
Dravet syndrome	SCN1A	0.4607	0.2325	Adults with a history of possible Dravet syndrome: an illustration of the importance of analysis of the SCN1A gene.	-1
epileptic	SCN1A	0.4607	0.2302	Using multiplex ligation-dependent probe amplification (MLPA) assays with probes for the 5' noncoding exons, their upstream regions, and all coding exons of SCN1A, we investigated 130 epileptic patients who did not show any SCN1A mutations by sequence analysis of all coding exons and exon-intron boundaries.	1
DS	SCN1B	0.4607	0.3636	In this report we aim to make the molecular analysis of the SCN1A and SCN1B genes in two Tunisian patients affected with DS.	-1
AEDs	CD4	0.4607	0.186	In a nested cohort of 55 AED-treated patients receiving cART and aviremic, chronic exposure to sodium and calcium channel blocking AEDs was associated with increased CD4+ T cell levels (p <0.05) with no change in CD8+ T cell levels over 12 months from the beginning of AED therapy.	-1
corpus callosum	DCX	0.4607	0.07504	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
autosomal recessive disorders	MEDS	0.4606	0.1908	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
malignant tumors	LAT	0.4606	0.0802	The amino acid transport system L (LAT) is a major nutrient transport system, and LAT1 is highly expressed in malignant tumors to support tumor cell growth.	-1
TBS-associated	KCNH1	0.4606	0.4063	Characterization of the mutant channels in both Xenopus laevis oocytes and human HEK293T cells showed a decreased threshold of activation and delayed deactivation, demonstrating that TBS-associated KCNH1 mutations lead to deleterious gain of function.	-1
RTT	MECP2	0.4606	0.3649	Since the discovery of mutations in the methyl-CpG binding protein-2 (MECP2) gene in Rett Syndrome (RTT) a large number of females have been diagnosed worldwide.	-1
spasticity and/or ataxia	MECP2	0.4605	0.1304	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
febrile seizure	SCN1A	0.4605	0.169	SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome.	-1
IBD	EDSKMH	0.4603	0.1047	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Wolf-Hirschhorn syndrome	CMT2	0.4603	0.2581	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
SMEI	GABRD	0.4603	0.06458	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
epilepsies	SCN1A	0.4603	0.4504	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	1
myoclonic epilepsy of infancy	SCN1A-related	0.4603	0.2412	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
SMEI	SCN1A	0.4603	0.2767	The identification of germline mosaicisms has important consequences in genetic counseling of SMEI when SCN1A mutations appear to occur de novo with standard screening methods.	-1
neuroblastoma	anti-CV2	0.4603	0.1528	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
epilepsy	CSTB	0.4602	0.292	The majority were found in established epilepsy genes (e.g., SCN1A, KCNQ2, CSTB), but in 11 families, this cohort contributed to the initial discovery (e.g., KCNT1, PCDH19, TBC1D24).	1
intellectual disability	CDKL5	0.4602	0.1174	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
infancy	SCN1A	0.4602	0.1397	Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies.	-1
polymicrogyria	NF1	0.4601	0.3534	Complex epileptic (Foix-Chavany-Marie like) syndrome in a child with neurofibromatosis type 1 (NF1) and bilateral (opercular and paracentral) polymicrogyria.	-1
methyl-CpG-binding domain	MECP2	0.4601	0.0746	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
MERRF syndrome	CARS2	0.4601	0.1996	CONCLUSION: CARS2 is a novel disease gene associated with a severe progressive myoclonic epilepsy most resembling MERRF syndrome.	-1
epilepsy	SCN1A	0.46	0.08455	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	1
movement disorders	IT15	0.46	0.07556	Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline, behavioural abnormalities and progressive disease course proves negative to the genetic testing for HD causative mutations, that is, IT15 gene trinucleotide-repeat expansion.	-1
idiopathic generalized epilepsy syndrome	KCNQ2	0.4599	0.128	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	-1
seizures	L-asparaginase	0.4599	0.3195	We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.	-1
Batten disease	CLN5	0.4599	0.1724	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
SSPE	SCN1A	0.4599	0.1737	In addition to Dravet syndrome, several other types of acute and subacute encephalopathic syndromes having clinical and electroencephalographic resemblance to SSPE are associated with SCN1A gene mutations.	-1
long QT syndrome	KCNQ4	0.4598	0.1194	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
Caroli syndrome	ARPKD	0.4598	0.252	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
essential thrombocythemia	JAK2	0.4598	0.3396	JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.	-1
TBS	KCNH1	0.4597	0.1861	Here we report damaging de novo mutations in KCNH1 (encoding a protein called ether    go-go, EAG1 or KV10.1), a voltage-gated potassium channel that is predominantly expressed in the central nervous system (CNS), in six individuals with TBS.	-1
seizures	SCN1A	0.4595	0.3022	Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities.	-1
epilepsy	SYN2	0.4593	0.258	Lack of association between synapsin II (SYN2) gene polymorphism and susceptibility epilepsy: a case-control study and meta-analysis.	-1
DS	SCN1A	0.4593	0.07705	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	-1
myoclonus epilepsy	EPM1	0.4592	0.2821	The gene for human U2 snRNP auxiliary factor small 35-kDa subunit (U2AF1) maps to the progressive myoclonus epilepsy (EPM1) critical region on chromosome 21q22.3.	-1
seizures	SCN2A	0.4592	0.1093	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
SJS/TEN	HLA-A	0.4592	0.1573	Three single nucleotide polymorphisms, rs1150738, rs3869066 and rs259945, were in absolute linkage disequilibrium with HLA-A*31:01 in 210 Japanese SJS/TEN patients.	-1
seizures	CDKL5	0.4591	0.2185	OBJECTIVE: Epilepsy with mutation of the CDKL5 gene causes early seizures and is a variant of Rett syndrome (MIM (312750), which is reported typically as infantile spasms.	-1
genetic disorder	Inv	0.4591	0.1708	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
family epilepsy syndrome	SCN1A	0.4591	0.3851	"One patient has a family history consistent with the family epilepsy syndrome diagnosis of GEFS+, whilst the second has a de novo SCN1A mutation in the setting of ""severe"" Febrile Seizures."	1
epileptic	CDKL5	0.459	0.3612	The purpose of this study was to analyze the epileptic histories and EEGs of patients with the CDKL5 mutation.	1
seizure	PRNP	0.459	0.1173	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	-1
epilepsy	KCNQ1	0.459	0.187	That long QT syndrome mutations in KCNQ1 cause epilepsy reveals the dual arrhythmogenic potential of an ion channelopathy coexpressed in heart and brain and motivates a search for genetic diagnostic strategies to improve risk prediction and prevention of early mortality in persons with seizure disorders of unknown origin.	-1
X-linked cyclin-dependent kinase-like 5	CDKL5	0.459	0.3109	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome (RTT)-like phenotype.	-1
X-linked cyclin-dependent kinase-like 5	CDKL5	0.459	0.3109	Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause infantile spasms as well as Rett syndrome-like phenotype.	-1
DS	SCN1A	0.4589	0.5322	This study examines whether microdeletions and duplications of the gene encoding a1 subunit of the sodium channel (SCN1A) are underlying causes in Dravet syndrome (DS) with SCN1A missense mutation.	-1
Susac's syndrome	tumour necrosis factor	0.4589	0.2007	We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.	-1
myopathy	ACAD8	0.4589	0.06912	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
GCPS	MODY2	0.4589	0.3852	This deleted region included GLI3 and GCK genes (where heterozygous mutations cause GCPS and MODY2, respectively), and many other contiguous genes.	-1
Wolf-Hirschhorn syndrome	WFS1	0.4589	0.7354	Unmasking of a hemizygous WFS1 gene mutation by a chromosome 4p deletion of 8.3 Mb in a patient with Wolf-Hirschhorn syndrome.	-1
RS	T-bet	0.4588	0.3485	No association between SNPs of T-bet and RS onset was found.	-1
epileptic	SCN1A	0.4588	0.09121	Here we present a meta-analysis on the SCN1A gene variants and provide comprehensive information on epilepsy-associated gene variants, their frequency, the predicted effect on the protein, the ethnicity of the affected along with the inheritance pattern and the associated epileptic phenotype.	1
sleep disturbances	MECP2	0.4587	0.2899	Seizures and sleep disturbances were more common than in those with MECP2 mutations whereas features of regression and spinal curvature were less common.	-1
RS	GluR3	0.4586	0.1987	In patients with RS, several kinds of autoantibodies against neuronal molecules, for example, GluR3, GluRepsilon2 (NMDA-R2B), etc., are reported.	-1
Dravet syndromes	SCN1A	0.4585	0.1684	Besides classical Sanger sequencing, mutation analysis of the SCN1A gene also requires a method that allows the detection of genomic rearrangements (MAQ, MLPA), since microdeletions or whole gene deletions also result in Dravet syndromes.	-1
encephalopathy	PEHO	0.4585	0.2976	Dutch patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.	-1
epileptic encephalopathy	ALG13	0.4585	0.06907	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
BFNS	KCNQ2	0.4585	0.1787	Linkage analysis in this family confirmed a previous report of genetic heterogeneity in BFIS - since linkage was excluded at the above-mentioned known BFIS loci - and suggested a possible linkage to the KCNQ2 gene, which is believed to be a voltage gated potassium channel gene responsible for benign familial neonatal seizures (BFNS).	-1
autoimmune polyglandular disease	HPE1	0.4585	0.321	In conclusion, the map location and the homology to a gene family involved in a large variety of biological processes including signal transduction and development make PWP2H an intriguing candidate for EPM1 as well as for APECED (autoimmune polyglandular disease) and HPE1 (holoprosencephaly-1) that also map in this region of chromosome 21.	-1
seizures	BDNF	0.4585	0.08379	CONCLUSIONS: Early onset of seizures is linked to the combined MECP2 and BDNF genotypes.	-1
TSC	LAT1	0.4584	0.1225	MATERIALS AND METHODS: LAT1 expression was investigated by LAT1 mRNA using reverse transcription-polymerase chain reaction and immunohistochemical staining with anti-human LAT1 antibody in nine patients with TSC and three control brains.	-1
autism	MECP2	0.4584	0.1134	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
neonatal epilepsy	KCNQ3	0.4583	0.3183	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	1
epilepsy	GABRA1	0.4583	0.1002	Further multivariate logistic regression and multifactor dimensionality reduction analyses of interactions between these genes showed that under adjustment of clinical factors, the epilepsy treatment outcomes were significantly associated with the genotype combinations of GABRA1 rs6883877, GABRA2 rs511310 and GABRA3 rs4828696 (p < 0.0001; adjusted r(2) = 0.149).	1
WWS	FCMD	0.4583	0.1411	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
CMDs	CMD1A	0.4583	0.2183	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
ragged-red fibers	COX	0.4582	0.2467	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
X-linked mental retardation	MECP2	0.4582	0.2412	Furthermore, the panorama of phenotypes with MECP2 mutations now extends far beyond RS to include normal girls and women, mild learning disability, autistic spectrum disorders, and X-linked mental retardation.	-1
epilepsy	LIS1	0.4582	0.5185	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
PTHS	TCF4	0.4581	0.1518	In addition, 27 patients with 18q deletion encompassing the TCF4 gene but without given PTHS diagnosis have been published, and thus, the number of reported patients with a TCF4 abnormality exceeds 100.	-1
hyperventilation	TCF4	0.4581	0.09595	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
epileptic syndrome	prion protein	0.4581	0.1105	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	1
ASDs	MECP2	0.4581	0.1362	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
JME	laforin	0.458	0.2544	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
epilepsy	SCN1A	0.4579	0.3706	SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome.	1
MAE	SCN1A	0.4579	0.2136	Analysis of SCN1A revealed a heterozygous de novo frameshift mutation (c.4205_4208delGAAA) in the patient with DS, and a recurrent missense mutation (c.3521C>G) in that suffering from MAE.	-1
cancers	PTEN	0.4579	0.2617	Phosphatase and tensin homolog (PTEN) gene mutations are associated with a spectrum of clinical disorders characterized by skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers.	-1
PME	malin	0.4578	0.2494	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
neurological disorders	prion protein	0.4578	0.1996	Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders.	-1
FHM-III	NaV1.1	0.4577	0.2397	Recently, we have identified a folding defective FHM-III NaV1.1 mutant that showed overall gain of function when rescued, consistent with a differential pathomechanism.	-1
congenital deafness	KCNQ2	0.4577	0.2407	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
hearing loss	HMGCS2	0.4576	0.06854	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
KSS	LBSL	0.4576	0.4828	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4576	0.2442	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
febrile seizures	SCN1A	0.4575	0.2897	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
epilepsy	EA1	0.4575	0.2773	EA1 is a dominant human neurological disorder characterized by variable phenotypes of brief episodes of ataxia, myokymia, neuromyotonia, and associated epilepsy.	-1
SMEI	SCN1A	0.4575	0.4227	Four novel SCN1A mutations in Turkish patients with severe myoclonic epilepsy of infancy (SMEI).	-1
deficiency syndrome	phosphatase	0.4574	0.1556	Serine deficiency syndrome is due to a deficiency of one of three enzymes in the endogenous serine biosynthesis pathway: phosphoglycerate dehydrogenase, phosphoserine transaminase, or, most rarely, phosphoserine phosphatase.	-1
seizures	SCN9A	0.4573	0.1063	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
seizures	SCN1A	0.4573	0.1063	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
AMRF	beta-GC	0.4573	0.1707	With the present study, we demonstrate that disruption of the coiled-coil structure or AMRF disease-causing mutations abolish beta-GC binding, indicating the importance of an intact coiled-coil structure for the interaction of LIMP-2 and beta-GC.	-1
polymicrogyria	NF1	0.4572	0.05889	We report on a 10-year-old (molecularly proven) NF1 girl manifesting a complex epileptic syndrome resembling the Foix-Chavany-Marie spectrum (also known as opercular syndrome) associated with bilateral (opercular and paracentral lobular) polymicrogyria (PMG).	-1
intellectual disability syndrome	KANSL1	0.4572	0.1235	GENETIC COUNSELING: The KANSL1-related intellectual disability syndrome, caused by a microdeletion or a mutation of KANSL1, is inherited in an autosomal dominant manner, but to date almost all cases result from a de novo deletion or KANSL1 mutation.	-1
West syndrome	DCX	0.4571	0.1151	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
neonatal diabetes	ABCC8	0.4571	0.5593	New ABCC8 mutations in relapsing neonatal diabetes and clinical features.	-1
low-energy fractures	MECP2	0.4571	0.4088	Further, spine and hip aBMD and vBMAD of patients were associated with clinical risk factors of low BMD, low-energy fractures, MECP2 mutation groups, and X chromosome inactivation (XCI).	-1
CHARGE syndrome	CHD2	0.4571	0.05529	The deletion encompasses only 2 genes: CHD2, which is part of a gene family already involved in CHARGE syndrome, and RGMA which exerts a negative control on axon growth.	-1
Muscle-eye-brain disease	CMD1D	0.4571	0.3163	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
Walker-Warburg syndrome	CMD1D	0.457	0.521	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
intellectual disability	interleukin-6	0.457	0.1465	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
Rett syndrome	MECP2-mutated	0.457	0.1978	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	-1
seizures	AGC1	0.457	0.1095	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
SMEI	SCN1B	0.4569	0.1411	RESULTS: In both core SMEI and SMEB, various mutations of SCN1A including nonsense and missense mutations were identified, whereas no mutations of SCN2A, SCN1B, and SCN2B were found within the regions examined.	-1
autistic	CDKL5	0.4569	0.1167	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	-1
multiple sclerosis	CD4	0.4568	0.1201	Cytokines also have a key role in the pathogenesis of multiple sclerosis and most data suggest that this effect is mediated by myelin-specific CD4 T lymphocytes secreting Th type 1 cytokines.	-1
Creutzfeldt-Jakob disease	prion protein	0.4568	0.4147	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
PHS	GLI3	0.4568	0.2074	Approximately 5% of HH cases are associated with Pallister-Hall syndrome (PHS), which is caused by haploinsufficiency of GLI3.	-1
epilepsy	GABRA2	0.4568	0.102	Further multivariate logistic regression and multifactor dimensionality reduction analyses of interactions between these genes showed that under adjustment of clinical factors, the epilepsy treatment outcomes were significantly associated with the genotype combinations of GABRA1 rs6883877, GABRA2 rs511310 and GABRA3 rs4828696 (p < 0.0001; adjusted r(2) = 0.149).	-1
MS	MECP2	0.4567	0.1604	We describe a rare and complete video-polygraphic study of a girl with Rett syndrome (MECP2 mutation) and MS misdiagnosed as movement disorders and disclosed after video-polygraphic recordings.	-1
neurodevelopmental disorders	GRIN2A	0.4565	0.2169	Rare pathogenic deletions that include GRIN2A have been implicated in neurodevelopmental disorders.	-1
West syndrome	CDKL5	0.4565	0.2611	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
disintegrative disorder	methyl-CpG-binding protein 2	0.4565	0.173	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
rolandic epilepsy	KCNQ2	0.4564	0.3044	METHODS: Sequence analysis of the KCNQ2, Q3, and Q5 coding regions was performed in a screening sample consisting of 58 nuclear families with rolandic epilepsy.	-1
tter-T  nz syndrome	FKBP14	0.4564	0.06915	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
SMEI	SCN1A	0.4564	0.2362	The frequencies of SCN1A mutations in suspected severe myoclonic epilepsy of infancy (SMEI), its borderline phenotype (SMEB) and intractable epilepsy were 56.2%, 41.9% and 28.9% respectively.	-1
cognitive disorders	Nav1.1	0.4564	0.1666	Here, we examined the possible effects on cognition of Nav1.1 down-regulation, a sodium channel principally involved in Dravet syndrome but also implicated in other cognitive disorders, including autism and Alzheimer's disease.	-1
diabetes	HNF1 beta	0.4563	0.1798	Deletions in chromosome 17q12 encompassing the HNF1 beta gene cause cystic renal disease and maturity onset diabetes of the young, and have been recently described as the first recurrent genomic deletion leading to diabetes.	-1
West syndrome	SETD5	0.4563	0.1947	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
West syndrome	SCN2A	0.4563	0.1947	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
Rett syndrome	MeCP2	0.4562	0.1837	Developmental studies suggest an important role for MeCP2 in the formation and/or maintenance of synapses, and clarify the molecular biological aspects of Rett syndrome.	-1
seizures	NF1	0.4562	0.4108	PURPOSE: To describe the clinical characteristics and outcomes of individuals with neurofibromatosis type 1 (NF1) and seizures in the largest cohort reported to date.	-1
dominantly inherited neonatal seizures	KCNQ2	0.4562	0.05864	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
seizures	CSF	0.4562	0.4427	Viral encephalitis causes an altered level of consciousness, which may be associated with fever, seizures, focal deficits, CSF pleocytosis, and abnormal neuroimaging.	-1
epilepsy	SCN1A	0.4561	0.3518	We report on two patients with SCN1A mutations and severe epilepsy within the spectrum of generalized epilepsy with febrile seizures plus syndrome (GEFS+), the phenotypes being consistent with DS and MAE, respectively.	1
MBD	MECP2	0.4561	0.0992	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
autism	MeCP2	0.456	0.2184	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
CMDs	CMD1C	0.456	0.2172	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
diabetes	HNF1A	0.4559	0.3159	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
severe combined immunodeficiency	IL2RG	0.4559	0.2641	We report a male infant who suffered from WS and X-linked T-B+NK- severe combined immunodeficiency (X-SCID) with a missense mutation of the IL2RG gene (c.202G>A, p.Glu68Lys).	-1
PTHS	TCF4	0.4559	0.1861	No significant difference in clinical severity has been reported to date between PTHS patients carrying 18q21 deletions including the TCF4 gene, and those harboring TCF4 point mutations, suggesting a lack of genotype/phenotype correlation.	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	ROGDI	0.4559	0.0988	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neonatal diabetes	ABCC8	0.4558	0.2134	In our present study, we identified six new heterozygous ABCC8 mutations, mainly in patients presenting the transient form of neonatal diabetes (six of eight), with a median duration of initial insulin therapy of 17 months (range 0.5-38.0).	-1
MCDs	SCN1A	0.4558	0.3848	SIGNIFICANCE: MCDs and SCN1A gene mutations can co-occur.	-1
seizure	Abeta	0.4558	0.3477	These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.	-1
PL	NF1	0.4557	0.06694	MATERIAL AND METHODS: We studied 15 patients with WS and DS with a follow-up of 1.5 to 9 years, 5 patients with WS and NF1 followed-up form 2 to 6 years and 10 patients with WS associated with CP and PL followed-up during 2.5 to 12 years.	-1
epileptic encephalopathy	EIEE2	0.4555	0.4291	One of them is a type 2 severe epileptic encephalopathy (EIEE2), caused by dominant mutation in CDKL5 gene (Xp22.3).	1
GEFS	SCN1A	0.4555	0.4614	(2) Our study failed to provide evidence supporting a causal relation between the SCN1A mutation and the etiologic gene in the GEFS+ family B, which indicates that GEFS+ has the phenotypic and genotypic heterogeneity.	-1
epilepsy	SCN1A	0.4554	0.1892	We studied 132 patients with epilepsy syndromes with seizures precipitated by fever, and performed phenotype-genotype correlations with SCN1A alterations.	1
neuroblastoma	anti-Ma2	0.4553	0.189	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
epilepsies	CDKL5	0.4553	0.2553	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	1
autosomal MBD family members	MBD5	0.4553	0.5073	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
dysplastic	TRPC3	0.4552	0.125	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
epileptic encephalopathy	SCN1A-mutations	0.4551	0.4678	OBJECTIVES: To determine the prevalence of Dravet syndrome, an epileptic encephalopathy caused by SCN1A-mutations, often with seizure onset after vaccination, among infants reported with seizures following vaccination.	1
spinal cord involvement	CMT2	0.4551	0.4352	Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome.	-1
epileptic	SCN1A	0.4551	0.1656	CONCLUSION: Epilepsies associated with SCN1A mutations range in severity from febrile seizures to severe epileptic encephalopathies including Dravet syndrome and severe infantile multifocal epilepsy.	1
Rasmussen syndrome	Granzyme B	0.4551	0.08136	A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF.	-1
genetic epilepsy	SCN2A	0.455	0.2111	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
Fragile X syndrome	neurofibromatosis-1	0.455	0.2235	Several paediatric neurological disorders such as neurofibromatosis-1, Fragile X syndrome, Rett syndrome, and other syndromic and non-specific forms of mental retardation involve lesions in these signalling pathways.	-1
Microcephaly	IER3IP1	0.455	0.1681	Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder.	-1
CHF	ARPKD	0.4549	0.1302	OBJECTIVES: The published natural history of congenital hepatic fibrosis (CHF) was examined to inform clinical decision making in autosomal recessive polycystic kidney disease (ARPKD).	-1
neonatal epilepsy	KCNQ1	0.4549	0.2464	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
BFNC syndrome	KCNQ3	0.4549	0.05389	BFNC syndrome exhibits genetic heterogeneity, as has been hypothesised to occur in Arabian foals, and is known to be caused by mutations in the voltage-gated potassium channel subunit KCNQ2 and KCNQ3 genes.	-1
seizure	TCF4	0.4548	0.4886	CONCLUSIONS: On the basis of an analysis of published cases, we propose a genotype-phenotype correlation of increased seizure activity with missense TCF4 mutations.	-1
epilepsies	ARX-related	0.4548	0.3663	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	1
Dravet syndrome	laforin	0.4547	0.1334	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
early infancy	PHF6	0.4547	0.1746	Recently, two patients with a clinical diagnosis of Coffin-Siris syndrome in early infancy had been found to harbour mutations in PHF6, and their phenotype in advanced ages is now described.	-1
myoclonic seizures	CDKL5	0.4545	0.07123	Generalized intractable seizures, as infantile spasms, and generalized tonic-clonic seizures and myoclonic seizures characterize the clinical picture of CDKL5 mutations.	-1
DS	SCN9A	0.4544	0.1129	DS cases without SCN1A mutation inherited have predicted SCN9A susceptibility variants, which may contribute to complex inheritance for these unexplained cases of DS.	-1
SMEI	SCN1A	0.4544	0.1514	We postulated that cases of so-called vaccine encephalopathy could have mutations in the neuronal sodium channel alpha1 subunit gene (SCN1A) because of a clinical resemblance to severe myoclonic epilepsy of infancy (SMEI) for which such mutations have been identified.	-1
Seizures	CDKL5	0.4543	0.2603	Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.	-1
edema	3-phosphoglycerate dehydrogenase	0.4543	0.1441	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
WT	SkM1	0.4542	0.1344	We have studied, in the HEK cells permanently transfected with the skeletal muscle sodium channel alpha-subunit (SkM1), the effects of a transient transfection of the wild type (WT) or C121W mutant beta 1-subunit.	-1
epilepsy	neurofibromatosis type 1	0.4542	0.1126	We believe this is the first report of composite adrenal pheochromocytoma and multiple GISTs occurring in an 82 year old woman with neurofibromatosis type 1 (NF1), manifested by clitoral and subcutaneous neurofibromas, epilepsy and Lisch nodules.	-1
epilepsy	MECP2	0.4541	0.2107	Interestingly, they did not exhibit other clinical features commonly observed in American-European patients with MECP2 duplication, including recurrent respiratory infections and epilepsy.	1
somatic growth failure	methyl CpG binding protein 2	0.4541	0.15	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
CJD	PrP	0.4541	0.1755	The finding of decreased PrP levels in the CSF of patients not only with CJD but also in other neurodegenerative disorders is intriguing.	-1
Rett syndrome	MECP2	0.4541	0.4778	METHOD: Information on 685 females with RTT recruited to the international Rett syndrome database (InterRett) with a pathogenic MECP2 mutation was obtained from family and clinician questionnaires.	-1
seizure	Abeta	0.454	0.1675	These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.	-1
neurological health	mGluR5	0.454	0.162	In addition, APP and its proteolytic fragments are emerging as biomarkers for neurological health, and pharmacological interventions that modulate their levels, such as secretase inhibitors, passive immunotherapy against Ab and mGluR5 antagonists, are reviewed.	-1
sclerosis	SCN1A	0.454	0.1065	Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A.	-1
Rett syndrome	MeCP2	0.454	0.1235	Rett syndrome, a neurodevelopmental disorder affecting mainly females, is caused by a mutation of the MeCP2 gene.	-1
RTT	CDKL5	0.454	0.3227	In conclusion, this report reinforces the observation that the CDKL5 phenotype overlaps with RTT and that CDKL5 analysis is recommended in patients with a seizure disorder commencing during the first months of life.	-1
Rett syndrome-like	MECP2	0.454	0.03827	Rett syndrome is a genetic neurodevelopmental disorder that affects mainly girls, but mutations in the causative MECP2 gene have also been identified in boys with classic Rett syndrome and Rett syndrome-like phenotypes.	-1
seizure	inv	0.4539	0.132	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
epilepsy	SCN1A	0.4538	0.3907	There has been a marked increase in genetic diagnoses of a number of key childhood-onset epilepsy syndromes, such as Dravet syndrome, which has been linked to mutations in the SCN1A gene.	1
CMD	FKRP	0.4537	0.1392	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CMD	FKTN	0.4537	0.1392	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizure	Cox	0.4536	0.239	Cox and Weibull regression were used to investigate and provide a model for predicting the effects of genetic and developmental factors on age at seizure onset.	-1
Christianson syndrome	MECP2	0.4535	0.1291	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Leigh-like syndrome	COX8A	0.4534	0.1058	Loss of the smallest subunit of cytochrome c oxidase, COX8A, causes Leigh-like syndrome and epilepsy.	-1
dysmorphic and neurologic features	PRKCZ	0.4534	0.2571	Other genes deleted in a subset of the patients likely play a contributory role in the phenotypes, including GABRD and seizures, PRKCZ and neurologic features, and SKI and dysmorphic and neurologic features.	-1
myoclonic epilepsy of infancy	cystatin B	0.4534	0.236	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
seizure	NF1	0.4533	0.08231	METHODS: A retrospective cross-sectional review of 536 individuals with NF1 was performed, and clinical data from 51 individuals with a history of at least one seizure were analyzed.	-1
RTT-like	CDKL5	0.4533	0.06555	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
dehydrated and the blood investigations	C reactive protein	0.4533	0.1188	The patient was moderately dehydrated and the blood investigations were remarkable for hyponatraemia (126 mEq/l), leukocytosis (19.4 * 10(3)/l (46% lymphocytes)), thrombocytosis (637 * 10(3)/l), hypoalbuminaemia (albumin 1.9 g/dl) and elevated C reactive protein (96 mg/l).	-1
seizure	cyclin-dependent kinase-like 5	0.4533	0.1729	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
diabetes	HNF4A	0.4533	0.3372	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
epilepsy	PrP(c	0.4532	0.2529	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	1
febrile seizures	SCN1A	0.4532	0.04742	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
epilepsies	SCN1A	0.4532	0.1111	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	1
dystroglycanopathies	ISPD	0.4531	0.3018	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Dravet syndrome	malin	0.453	0.1226	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
mental retardation	CLN8	0.453	0.483	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
Miller-Dieker Syndrome	LIS1	0.453	0.15	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
fatal familial insomnia	prion protein	0.4529	0.3082	Unexpected new genetic mechanisms have been discovered in human neurologic diseases, including (a) identical mutations of the prion protein gene in Creutzfeldt-Jakob disease and fatal familial insomnia with the phenotypic expression directed by an accompanying polymorphism; (b) stable duplications of chromosome 17 in Charcot-Marie-Tooth disease (type 1A) that involve many genes, only one of which appears to cause neuropathy; and (c) highly variable, dynamic mutations in myotonic dystrophy, fragile X syndrome, and Kennedy's syndrome that modulate variable expressivity in multiple tissues.	-1
Dravet syndrome	SCN1A	0.4529	0.1709	Heterozygous loss-of-function mutations in SCN1A result in Dravet syndrome, a severe infant-onset epileptic encephalopathy characterized by intractable seizures, developmental delays and increased mortality.	-1
idiopathic epilepsy syndromes	KCNQ3	0.4529	0.3018	KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes.	-1
microcephaly	TCF4	0.4529	0.0626	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
epilepsy disorders	Nav1.1	0.4529	0.1874	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	1
tubular injury	N-acetyl-b-D-glucosaminidase	0.4529	0.2852	The research is generally considered in two themes; the first comprises studies which indicate subclinical tubular injury measured by renal enzymes such as N-acetyl-b-D-glucosaminidase (NAG), and the second comprises clinical reports where Fanconi's syndrome has occurred.	-1
Dravet syndrome	SCN1A	0.4529	0.2916	Deletions and duplications/amplifications of the a1-sodium channel subunit (SCN1A) gene occur in about 12% of patients with Dravet syndrome (DS) who are otherwise mutation-negative.	-1
Rett syndrome	CDKL5	0.4529	0.08665	Mutations of the cyclin-dependent kinase-like 5 gene (CDKL5), reported almost exclusively in female subjects, have been recently found to be the cause of a phenotype overlapping Rett syndrome with early-onset epileptic encephalopathy.	-1
Williams-Beuren syndrome	NRXN1	0.4528	0.06204	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
myoclonic epilepsy	Arylsulfatase A	0.4528	0.4405	Arylsulfatase A pseudodeficiency and Lafora bodies in a patient with progressive myoclonic epilepsy.	-1
PS	SCN1A	0.4528	0.3833	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
epileptic encephalopathy	STXBP1	0.4528	0.1742	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
hydrocephalus	CSF	0.4527	0.1211	OBJECT: The authors sought to determine if clinical epilepsy variables, maximum daily temperature (Tmax), and blood and CSF findings were associated with the risk of developing hydrocephalus after first-time resection-disconnection hemispherectomy.	-1
epilepsy	TCF4	0.4527	0.158	It is mainly characterized by severe intellectual disability, overbreathing, a typical facial gestalt, tendency to epilepsy and is caused by TCF4 haploinsufficiency.	1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	AUH	0.4527	0.3047	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
CFC syndrome	BRAF	0.4527	0.318	We report the case of a 4-year-old girl who presented a CFC syndrome, confirmed by the presence of a pathogenic R257Q BRAF gene mutation, together with a muscular CoQ10 deficiency.	-1
LD	EPM2A	0.4526	0.2518	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
neuropsychiatric anomalies	GABRD	0.4526	0.2461	Genomic localisation, function, and expression would suggest that the GABRD gene represents a good candidate for the neurodevelopmental and neuropsychiatric anomalies seen in the 1p36 deletion syndrome.	-1
epilepsy	CBF	0.4525	0.1399	Longer duration of epilepsy was related to lower CBF (more negative CBF-AI, r = -0.58, P = .03) and low CBV (r = -0.55, P = .04) on the affected side.	-1
Dravet syndrome	SCN1A	0.4523	0.5869	In this study, the authors present 4 novel mutations and confirm 2 previously identified mutations in the SCN1A gene found in a cohort of Turkish patients with Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.4523	0.4091	A novel variant in the 3' UTR of human SCN1A gene from a patient with Dravet syndrome decreases mRNA stability mediated by GAPDH's binding.	-1
inflammation	CA4	0.4523	0.1667	A routine neuropathological examination showed no pronounced changes, such as neuronal loss, morphologically abnormal neurons, inflammation, vascular changes, Lafora bodies and tumor cells, except that mild gliosis was seen only in CA4 of the hippocampus.	-1
dementia	IL-6	0.4523	0.2727	By contrast, chronic progressive NB is characterized by intractable slowly progressive dementia and/or psychosis with persistent elevation of cerebrospinal fluid IL-6 activity, which is resistant to conventional steroid therapy.	-1
DRE	MECP2-mutated	0.4523	0.3769	RESULTS: Prevalence of DRE was 16% (i.e. 16 DRE out of 100 MECP2-mutated RTT epileptic patients).	1
Christianson syndrome	TCF4	0.4523	0.1163	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
subarachnoid haemorrhage	aura-like	0.4523	0.2134	BACKGROUND AND PURPOSE: Convexity subarachnoid haemorrhage (cSAH) has recently been recognised as a cause of recurrent aura-like symptoms, mimicking transient ischaemic attacks (TIAs).	-1
Rett syndrome	laforin	0.4522	0.2183	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
epilepsy	YWHAE	0.4522	0.5033	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
diabetes	IER3IP1	0.4522	0.3045	Identification of IER3IP1 mutations sheds light on the mechanisms of brain development and on the pathogenesis of infantile epilepsy and early-onset permanent diabetes.	-1
seizure	interleukin-6	0.4522	0.1044	The interleukin-6 level in the cerebrospinal fluid 2 hours after seizure onset was elevated to levels seen in patients with encephalitis.	-1
epilepsy	TBC1D24/Skywalker	0.4521	0.08512	In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins.	1
complex IV deficiency in skeletal muscle	SURF1	0.4521	0.1688	The loss of the wild-type COX8A protein severely impairs the stability of the entire cytochrome c oxidase enzyme complex and manifests in isolated complex IV deficiency in skeletal muscle and fibroblasts, similar to the frequent c.845_846delCT mutation in the assembly factor SURF1 gene.	-1
PME	malin	0.4521	0.1495	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
epileptic	CYP1A2	0.452	0.123	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients.	-1
Rubinstein-Taybi syndrome	FOXG1	0.452	0.4568	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Rett syndrome	CDKL5	0.452	0.1816	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
CMDs	CMD1C	0.452	0.3848	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
PHA	CD4	0.4519	0.1022	We measured white blood cell counts, lymphocyte counts, T/B cell counts, CD4(+) and CD8(+) T cell counts, CD 4/8 ratio, lymphocyte blastoid transformation by PHA or Con-A, and the levels of IgA, IgM, and IgG before, immediately after, and 1, 3, 6, and 12 months after ACTH therapy.	-1
muscular atrophy	SMA	0.4519	0.1721	"Even if the clinical picture is mainly dominated by the diffuse muscular atrophy, in some cases, patients may show associated, atypical clinical features (""SMA plus"")."	-1
immune dysfunction	MECP2	0.4518	0.1451	Increasing evidence on the relationship between MeCP2 and an immune dysfunction is reported, with, apparently, a link between MECP2 gene polymorphisms and autoimmune diseases, including primary Sj  gren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.	-1
infancy	SCN1A	0.4518	0.01516	Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic syndrome that is caused by mutations in the neuronal voltage-gated sodium channel alpha1 subunit gene SCN1A.	-1
epileptic encephalopathies	SCN2A	0.4518	0.5211	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	1
infantile spasms	GABRB3	0.4517	0.2692	Recently, mutations of GABRA1, GABRB2, and GABRB3 were associated with infantile spasms and Lennox-Gastaut syndrome.	-1
RS	MECP2	0.4517	0.07105	We advise MECP2 examination in AS patients of unknown genetic etiology whose EEG examinations are/were pathognomonic for AS to exclude RS.	-1
seizure disorder	SCN1A-related	0.4516	0.3	A proband with an SCN1A-related seizure disorder may have an inherited or de novo mutation.	1
epilepsy	CDKL5	0.4516	0.05884	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	1
PMG	NF1	0.4516	0.04857	We report on a 10-year-old (molecularly proven) NF1 girl manifesting a complex epileptic syndrome resembling the Foix-Chavany-Marie spectrum (also known as opercular syndrome) associated with bilateral (opercular and paracentral lobular) polymicrogyria (PMG).	-1
tumor	LAT1	0.4516	0.09902	The amino acid transport system L (LAT) is a major nutrient transport system, and LAT1 is highly expressed in malignant tumors to support tumor cell growth.	-1
Dravet syndrome	SCN1A	0.4516	0.6262	Early clinical features in Dravet syndrome patients with and without SCN1A mutations.	-1
epilepsy	SCN1A-gene	0.4515	0.08534	Dravet syndrome, often caused by mutations of SCN1A-gene, presents with prolonged clonic, generalized or unilateral seizures often occurring with fever during the first year of life, followed by usually severe epilepsy.	1
Lafora disease	CLN2	0.4515	0.2371	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
gastrointestinal problems	MECP2	0.4514	0.1119	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
L-CMD	SEPN1-related	0.4513	0.1	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Northern epilepsy syndrome	CLN8	0.4512	0.1305	Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs).	-1
refractory epilepsy	cyclin-dependent kinase-like 5 and aristaless-related homeobox	0.4512	0.5125	Two genes causally involved in refractory epilepsy with mental retardation, cyclin-dependent kinase-like 5 and aristaless-related homeobox, could account for at least some forms of early onset epileptic encephalopathy that still lack etiological explanation.	1
Rett syndrome	MECP2	0.4511	0.2575	Mutation of the X-linked methyl CpG binding protein 2 (MECP2) has been first identified as the cause of Rett syndrome.	-1
neonatal hypoglycemia	HNF4A	0.4511	0.2826	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
neonatal hypoglycemia	GCK	0.4511	0.2826	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
FS	SCN1A	0.4511	0.3338	We found that patients with FS and FS+ with SCN1A mutations had earlier median onset of febrile seizures compared to the population median.	-1
Triple-A syndrome--	AAAS	0.4511	0.2332	Triple-A syndrome--the first Chinese patient with novel mutations in the AAAS gene.	-1
lymphopenia	CD4	0.4511	0.3091	DISCUSSION: This case was particular as the patient had idiopathic CD4+ lymphopenia.	-1
tter-T  nz syndrome	HMGCS2	0.4511	0.06939	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neurological diseases	prion protein	0.4511	0.2678	We performed a study on levels of the total prion protein (PrP) in humans affected by different neurological diseases and assessed the influence of several factors such as age, gender, and disease severity on the cerebrospinal fluid PrP levels.	-1
inborn error of glycine metabolism	H-protein	0.4511	0.1922	Non ketotic hyperglycinemia is a rare inborn error of glycine metabolism due to deficient activity of glycine cleavage system, a multienzymatic complex consisting of four protein subunits: the P-protein, the H-protein, the T-protein and the L-protein.	-1
WRS	MEDS	0.451	0.2601	We expand the phenotypic spectrum of MEDS caused by IER3IP1 gene mutations and propose that WRS and MEDS are overlapping clinical syndromes, displaying significant gene-dependent clinical variability.	-1
epilepsy	KCNQ1	0.4509	0.2097	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
merosin deficiency	CMD1C	0.4508	0.2335	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
X-linked lissencephaly	DCX	0.4508	0.08552	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
rigid spine syndrome	SEPN1-related	0.4507	0.2568	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
PDD	methyl-CpG-binding protein 2	0.4506	0.2472	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
intellectual disability	PHF6	0.4506	0.1084	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
PMSE	LKB1	0.4506	0.03948	Thus, we suggest that the aberrant nuclear accumulation of LKB1 caused by STRADalpha deficiency contributes to hyperactivation of mTORC1 signaling and disruption of neuronal lamination during corticogenesis, and thereby the neurological features associated with PMSE.	-1
polyendocrinopathy	IPF1	0.4506	0.4482	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
SMC	OCA2	0.4505	0.0592	Chromosomal fluorescence in situ hybridization (FISH) showed the SMC to be originating from chromosome 15, dicentric and containing four copies of the Prader-Willi/Angelman Syndrome Critical Region (PWACR), including the OCA2 gene.	-1
) syndrome	ZEB2	0.4505	0.09626	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
cerebral heterotopia	neurofibromatosis type 1	0.4505	0.1179	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
epilepsy	Nav1.1	0.4504	0.01689	However, there are different potentially causative factors, including the specific effects on the Nav1.1 channels caused by the underlying genic or genomic defect; frequent and prolonged convulsive and non-convulsive seizures or status epilepticus; recurrent subtle ictal phenomena, such as that accompanying pronounced visual sensitivity; the use of antiepileptic drugs with cognitive side effects, especially in heavy multiple-drug therapy; and the restrictions that children with severe epilepsy inevitably undergo.	1
edema	PEHO	0.4504	0.2113	Dutch patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.	-1
encephalopathy	PEHO	0.4503	0.2546	Epilepsy and the electroencephalogram in progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (the PEHO syndrome).	-1
ISs	MAGI2	0.4503	0.1061	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
CMD	laminin alpha-2	0.4503	0.1166	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
intellectual disability syndrome	KANSL1	0.4503	0.2201	GENETIC COUNSELING: The KANSL1-related intellectual disability syndrome, caused by a microdeletion or a mutation of KANSL1, is inherited in an autosomal dominant manner, but to date almost all cases result from a de novo deletion or KANSL1 mutation.	-1
generalized epilepsy	SCN1A-related	0.4503	0.3137	In this review we describe the genetic advances in progressive myoclonus epilepsies, which are strictly monogenic disorders, genetic generalized epilepsies, mostly exhibiting complex genetic inheritance, and SCN1A-related phenotypes, namely genetic generalized epilepsy with febrile seizure plus and Dravet syndrome.	-1
ID	IL-6	0.4502	0.09712	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
WS	IL2RG	0.4502	0.1829	We report a male infant who suffered from WS and X-linked T-B+NK- severe combined immunodeficiency (X-SCID) with a missense mutation of the IL2RG gene (c.202G>A, p.Glu68Lys).	-1
epilepsy	KCNH1	0.4501	0.1582	Consistent with this result, we find that two mothers of children with TBS, who have epilepsy but are otherwise healthy, are low-level (10% and 27%) mosaic carriers of pathogenic KCNH1 mutations.	1
AS	ATP10C	0.45	0.165	We report here that a novel maternally expressed gene, ATP10C, maps within the most common interval of deletion and that ATP10C expression is virtually absent from AS patients with imprinting mutations, as well as from patients with maternal deletions of 15q11-q13.	-1
a	PEHO-like	0.45	0.2362	This is the second report of siblings with a PEHO-like syndrome, and supports the existence of a distinct, autosomal recessive condition in which neuroimaging abnormalities may be misinterpreted.	-1
WGS	KCNT1	0.4499	0.2008	In a third OS case, WGS revealed paternal isodisomy for chromosome 9, leading to identification of the causal homozygous missense variant in KCNT1, which produced a substantial increase in potassium channel current.	-1
infancy	SCN1A	0.4499	0.2119	Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB).	-1
Lafora disease	cystatin B	0.4499	0.08239	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
Seizure	SCN3A	0.4499	0.1542	Seizure onset was in the neonatal period in eight patients with SCN1A-involvement, in infancy in one patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
familial Dravet syndrome	SCN1A	0.4498	0.08408	This report of parental SCN1A nonsense mutation mosaicism in familial Dravet syndrome suggests that mosaicism might be more common than previously suspected and emphasizes the importance of taking mosaicism into account in genetic counselling of Dravet syndrome and SCN1A mutations.	-1
myoclonic epilepsy	SCN1A	0.4498	0.1242	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
PJS	STK11	0.4497	0.05821	BACKGROUND: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene.	-1
LHON	LBSL	0.4496	0.4775	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
genetic abnormalities	SCN1A	0.4496	0.07713	We screened for genetic abnormalities within exons and their flanking introns of the genes encoding major subunits of the Na+ channels (SCN1A, SCN2A, SCN1B, and SCN2B) by using a direct sequencing method.	-1
ASDs	MBD5	0.4496	0.2223	Individuals with deletions across the MBD5 gene also present with ASDs, impaired speech, intellectual difficulties, repetitive behaviors, and epilepsy.	-1
degree of deficits	SMA	0.4496	0.1075	The degree of deficits was consistent with the extent of the SMA resection in all patients.	-1
MRS	MEG	0.4495	0.3144	Several studies have been performed using neuroradiological or neurophysiological techniques, like SPECT, PET, MRS, fMRI, and MEG, in attempt to better characterize this neuronal migration disorder.	-1
DQ/IQ/SQPS	SCN1A	0.4495	0.2183	We studied the correlation between DQ/IQ/SQPS and age, epilepsy characteristics, and whether patients presented SCN1A mutation.	-1
OS	PIGQ	0.4495	0.292	This work reveals two novel genes for OS, KCNT1 and PIGQ.	-1
dysfibrinogenemia or	fibrinogen	0.4495	0.3455	[Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency].	-1
focal epilepsy	GRIN2B	0.4494	0.1933	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
Gitelman's syndrome	CETP	0.4494	0.1383	He was diagnosed with Gitelman's syndrome and cholesteryl ester transfer protein deficiency by identifying homozygous mutations of causative genes, SLC12A3 and CETP, respectively.	-1
plus	SCN1A	0.4494	0.2603	De-novo mutations and genetic variation in the SCN1A gene in Malaysian patients with generalized epilepsy with febrile seizures plus (GEFS+).	-1
PMSE	mTORC1	0.4493	0.06422	Thus, we suggest that the aberrant nuclear accumulation of LKB1 caused by STRADalpha deficiency contributes to hyperactivation of mTORC1 signaling and disruption of neuronal lamination during corticogenesis, and thereby the neurological features associated with PMSE.	-1
Unverricht-Lundborg disease	CLN2	0.4493	0.2981	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
cardiovascular risk factor	C-reactive protein	0.4492	0.1457	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
benign neonatal familial convulsions	KCNQ2	0.4491	0.04259	We here provide information regarding the in vivo distribution and biochemical characteristics of human brain KCNQ2 and KCNQ3, two channel subunits that form M-channels when expressed in vitro, and, when mutated, cause the dominantly inherited epileptic syndrome, benign neonatal familial convulsions.	-1
myoclonic epilepsy of infancy	Nav1.1	0.4491	0.2249	Familial severe myoclonic epilepsy of infancy: truncation of Nav1.1 and genetic heterogeneity.	-1
hypsarrhythmia	PEHO	0.4491	0.139	PEHO syndrome (progressive encephalopathy, peripheral edema, hypsarrhythmia, and optic atrophy) is a neurodegenerative disorder first characterized in Finnish patients.	-1
West syndrome	L-asparaginase	0.449	0.1017	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
Seizure	SCN1A	0.449	0.1133	Seizure onset was in the neonatal period in eight patients with SCN1A-involvement, in infancy in one patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
dominantly inherited syndrome	merlin	0.4489	0.0537	Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome caused by mutations of the tumour-suppressor NF2, which encodes the merlin protein.	-1
peripheral neuropathy	Neurofibromatosis 1	0.4489	0.2412	Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1.	-1
hearing loss	HSD17B10	0.4489	0.06599	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
(MEMSA) syndrome	NARP	0.4489	0.08389	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
hereditary diseases	prion protein	0.4489	0.2538	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
Rett syndrome	CDKL5	0.4489	0.1231	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	-1
tumor	anti-Ma2	0.4488	0.2038	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
severe developmental delay	GRIN2B	0.4488	0.1081	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
isolated lissencephaly	LIS1	0.4487	0.1844	The location and type of mutation predict malformation severity in isolated lissencephaly caused by abnormalities within the LIS1 gene.	-1
myoclonic epilepsies	ASA	0.4487	0.2723	The still-unknown relationship between the pathologic level of ASA activity and myoclonic epilepsies suggests introduction of ASA assays in patients with PME.	-1
SMEI	SCN1A	0.4487	0.1754	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
schematic syndrome	SCN1A	0.4487	0.06815	Intrafamilial variability in phenotype severity indicates that SCN1A loss of function causes a phenotypic spectrum in which seizures precipitated by fever are prominent and schematic syndrome subdivisions would be inappropriate.	-1
Epilepsy in Muenke syndrome	FGFR3-related	0.4486	0.2852	Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.	-1
convulsions	KCNQ3	0.4485	0.08779	Two highly homologous voltage-gated potassium channels, KCNQ2 and KCNQ3, were found to be mutated in benign familial neonatal convulsions.	-1
cholesteryl ester transfer protein deficiency	CETP	0.4485	0.1589	He was diagnosed with Gitelman's syndrome and cholesteryl ester transfer protein deficiency by identifying homozygous mutations of causative genes, SLC12A3 and CETP, respectively.	-1
epilepsy	KLHL17	0.4484	0.1346	Finally, we provide evidence that ISS in deletion 1p36 may be associated with deletion of KLHL17 and expand the epilepsy phenotype in that syndrome to include early infantile epileptic encephalopathy.	-1
epilepsy	LQT2	0.4484	0.2458	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
dysplastic	anti-TRPC3	0.4483	0.0643	Intracellular application of anti-TRPC3 antibody to block TRPC3 channels and bath application of the selective TRPC3 inhibitor Pyr3 greatly diminished depolarization in immature control and both immature and mature dysplastic cortex with strong TRPC3 expression.	-1
myoclonic epilepsy of infancy	malin	0.4483	0.2244	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
infantile multifocal epilepsy	SCN1A	0.4483	0.4777	Within the latter group, a distinctive subgroup designated as severe infantile multifocal epilepsy had SCN1A mutations in three of five cases.	1
generalized epilepsy with febrile seizures	SCN1A	0.4482	0.19	Recent studies provided evidence that mutations in SCN1A represent the most frequent cause of generalized epilepsy with febrile seizures plus an autosomal-dominant epilepsy syndrome.	-1
PMSE	STRADalpha	0.4482	0.04991	Thus, we suggest that the aberrant nuclear accumulation of LKB1 caused by STRADalpha deficiency contributes to hyperactivation of mTORC1 signaling and disruption of neuronal lamination during corticogenesis, and thereby the neurological features associated with PMSE.	-1
Smith-Lemli-Opitz syndrome	AUH	0.4482	0.0958	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Dravet syndrome	SCN1A	0.4482	0.3422	PURPOSE: To review our cohort of patients with Dravet syndrome and determine if patients with SCN1A mutations can also express mitochondrial disease due to electron transport chain dysfunction.	-1
Miller-Dieker Syndrome	YWHAE	0.4481	0.1751	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
ataxia	LBSL	0.4481	0.07469	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Dravet syndrome	SCN2A	0.448	0.1353	We screened for mutations of SCN1A, SCN2A and GABRG2 (the gene encoding gamma2 subunit of the GABA(A) receptor) in 59 patients with Dravet syndrome and found 29 SCN1A mutations and three missense SCN2A mutations.	-1
MERRF	NCL	0.448	0.2105	Electron microscopy was helpful in the diagnosis NCL and MERRF.	-1
infancy or atypical Dravet syndrome	SCN1A	0.4479	0.2293	Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?	-1
SMEI/SMEB	SCN1A	0.4479	0.3881	CONCLUSION: We obtained a frequency of 71%SCN1A abnormalities in SMEI/SMEB and of 11.5% in GEFS+ probands.	-1
developmental disability	KPNA7	0.4478	0.2356	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
epileptic	CYP3A4	0.4477	0.1305	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients.	-1
premature death	KCNA1	0.4477	0.08107	In this case, the combination of de novo single nucleotide polymorphisms (SNPs) and CNVs in the SCN1A and KCNA1 genes, respectively, is suspected to be the principal risk factor for both epilepsy and premature death.	-1
RTT	CDKL5	0.4477	0.1611	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
Dravet syndrome	SCN1A	0.4477	0.4383	A case of SUDEP in a patient with Dravet syndrome with SCN1A mutation.	-1
Rett syndrome	cyclin-dependent kinase-like 5	0.4476	0.09149	Mutations of the cyclin-dependent kinase-like 5 gene (CDKL5), reported almost exclusively in female subjects, have been recently found to be the cause of a phenotype overlapping Rett syndrome with early-onset epileptic encephalopathy.	-1
Dravet syndrome	SCN1A	0.4476	0.1091	The band 2q24 constitutes the smallest commonly deleted segment in these patients, and contains the voltage-gated sodium channel genes SCN1A and SCN2A, associated with Dravet syndrome and benign familial neonatal-infantile seizures, respectively.	-1
seizure disorder	SCN1A-related	0.4476	0.422	Each child of an individual with an SCN1A-related seizure disorder has a 50% chance of inheriting the pathogenic variant; however, the risk of developing seizures is less than 100% because of reduced penetrance.	1
febrile seizures	SCN2A	0.4476	0.1484	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	-1
Christianson syndrome	SLC9A6	0.4476	0.246	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Shprintzen-Goldberg syndrome	SKI	0.4475	0.1921	Recently, dominant mutations in SKI were identified to be correlated with Shprintzen-Goldberg syndrome.	-1
LMNA-related CMD	SEPN1-related	0.4475	0.1649	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
TSC	LAT1	0.4475	0.1672	CONCLUSION: LAT1 mRNA was detectable only in fresh-frozen tissues of TSC, and it was upregulated in the cortical tuber lesion.	-1
hypoplasia	alkaline phosphatase	0.4475	0.09844	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
KS	PROKR2	0.4474	0.1418	Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation.	-1
febrile seizures plus	SCN2A	0.4474	0.1546	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
SMEI/DS	CDKL5	0.4473	0.1344	METHODS: Twenty-eight patients with early onset SMEI/DS before 6 months negative for SCN1A mutational screening were selected and screened for mutations in the ARX gene in males (n=14) or the CDKL5 gene in females (n=14).	-1
AS	MECP2	0.4473	0.1829	We advise MECP2 examination in AS patients of unknown genetic etiology whose EEG examinations are/were pathognomonic for AS to exclude RS.	-1
RTT	MECP2	0.4472	0.2144	Mutations of MECP2 cause Rett syndrome (RTT), a neurodevelopmental disorder leading to loss of motor and cognitive functions, impaired social interactions, and seizure at young ages.	-1
severe mental retardation	PAFAH1B1	0.4472	0.03966	BACKGROUND: Genetic aberrations in PAFAH1B1 result in isolated lissencephaly sequence (ILS), a neuronal migration disorder associated with severe mental retardation and intractable epilepsy.	-1
Dravet syndrome	SCN1A	0.4472	0.1289	This study examines whether microdeletions and duplications of the gene encoding a1 subunit of the sodium channel (SCN1A) are underlying causes in Dravet syndrome (DS) with SCN1A missense mutation.	-1
Dravet syndrome	SCN2A	0.4471	0.1882	In Dravet syndrome, only one nonsense mutation of SCN2A was identified, while hundreds of mutations were found in the paralogue gene, SCN1A, which encodes the alpha1 subunit.	-1
MAS	inv	0.447	0.1129	METHODS: Among 14 patients with MAS observed in three centers, 5 had typical cryptogenic myoclonic absence epilepsy (MAE), 2 had MAS associated with other seizure types (1 with signs of a neuronal migration abnormality and 1 with signs of a metabolic disorder), and 7 had MAS, with or without other seizure types, complicating a chromosome abnormality syndrome-2 with trisomy 12p, 4 with Angelman syndrome, and 1 with inv dup (15).	-1
growth arrest	methyl CpG binding protein 2	0.447	0.1254	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
epilepsies	CDKL5/STK9	0.447	0.1764	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
ASD	SETDB1	0.447	0.4718	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
L-CMD	POMGNT1	0.4469	0.08312	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epilepsy	SCN1A	0.4469	0.231	BACKGROUND: SCN1A is the most clinically relevant epilepsy gene, most mutations causing Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI).	1
CAA	aura-like	0.4469	0.08716	Subarachnoid haemorrhage and recurrent aura-like episodes can occur in patients with cerebral amyloid angiopathy (CAA), which has been the presumed cause in the majority of reported cases.	-1
epilepsy	CDKL5	0.4469	0.2034	More recently, in the variants with early epilepsy, mutations have been found in another gene--CDKL5.	1
Rett syndrome	cyclin-dependent kinase-like 5	0.4468	0.07961	BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 (CDKL5) (NM_003159.2) gene have been associated with early-onset epileptic encephalopathies or Hanefeld variants of RTT(Rett syndrome).	-1
fatal familial insomnia	prion protein	0.4468	0.1635	These include fatal familial insomnia, with involvement of the prion protein gene on chromosome 20, Norrie disease, the Prader-Willi syndrome and the Moebius syndrome.	-1
epilepsy	SCN1A	0.4468	0.09224	OBJECTIVE: The SCN1A gene, coding for the voltage-gated Na+ channel alpha subunit NaV1.1, is the clinically most relevant epilepsy gene.	1
RS	FOXG1	0.4468	0.06645	When faced with a diagnosis of RS with no alterations in the MECP2 and CDKL5 genes, especially in the case of the congenital variant, the FOXG1 gene must be investigated.	-1
NES	CLN3	0.4467	0.06243	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
Encephalopathy	SCN1A	0.4467	0.2789	Encephalopathy and SCN1A mutations.	-1
focal deficits	CSF	0.4467	0.4276	Viral encephalitis causes an altered level of consciousness, which may be associated with fever, seizures, focal deficits, CSF pleocytosis, and abnormal neuroimaging.	-1
epilepsy	EPM2A	0.4467	0.2129	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	1
channelopathies	CMD1O	0.4466	0.2944	KATP channelopathies implicated in patients with mechanical and/or electrical heart disease include dilated cardiomyopathy (with ventricular arrhythmia; CMD1O) and adrenergic atrial fibrillation.	-1
NB	IL-6	0.4466	0.1874	By contrast, chronic progressive NB is characterized by intractable slowly progressive dementia and/or psychosis with persistent elevation of cerebrospinal fluid IL-6 activity, which is resistant to conventional steroid therapy.	-1
SSPE	SCN1A	0.4465	0.1334	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	-1
neonatal epilepsy	KCNQ4	0.4465	0.2562	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	1
myoclonic epilepsy	SPG7	0.4465	0.03944	"This produced an early-onset clinical syndrome that combines the severe phenotypes of SPG7 and SCA28, in additional to other ""mitochondrial"" features such as oculomotor apraxia, extrapyramidal dysfunction, and myoclonic epilepsy."	-1
metabolic syndrome	C-reactive protein	0.4464	0.1336	Rimonabant, a new and selective central and peripheral cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factor (metabolic syndrome) in obese patients by increasing HDL-cholesterol and adiponectin blood levels as well as decreasing LDL-cholesterol, leptin, and C-reactive protein (a proinflammatory marker) concentrations.	-1
SMEI	SCN1A	0.4462	0.2605	In the present study, we report new SCN1A mutations and the clinical features of SMEI cases.	-1
Rett syndrome	CDKL5	0.4462	0.08584	This combination of clinical features, suggestive of early onset variant of Rett syndrome led us to screen the CDKL5 gene.	-1
neuroblastoma	CRMP5	0.4462	0.1389	Although the patient's neuroblastoma had been successfully treated 8 years prior to presentation and an extensive workup did not show a tumor reoccurrence, testing for onconeuronal antibodies was positive for anti-Ma2 and anti-CV2/CRMP5 antibodies.	-1
seizure	mGluR(5	0.4461	0.1895	Herein, we assess (1) human APP(Swe) and Abeta levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR(5) blockade.	-1
CMD	CMD1C	0.4461	0.2713	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
intravascular lymphoma	CD4	0.446	0.2749	[Cerebral intravascular lymphoma during T CD4+ idiopathic lymphopenia syndrome].	-1
dysplastic	TRPC3	0.446	0.04705	Intracellular application of anti-TRPC3 antibody to block TRPC3 channels and bath application of the selective TRPC3 inhibitor Pyr3 greatly diminished depolarization in immature control and both immature and mature dysplastic cortex with strong TRPC3 expression.	-1
myoclonic epilepsy	GABRD	0.446	0.06743	"GABAA Receptor Subunit Mutations and Genetic Epilepsies
Mutations in inhibitory GABAA receptor subunit genes (GABRA1, GABRB3, GABRG2 and GABRD) have been associated with idiopathic epilepsy syndromes (IES) including childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), pure febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) (also known as severe myoclonic epilepsy in infancy, SMEI)."	-1
Rett disorder	MECP2	0.4459	0.2694	People with MECP2 mutation-positive Rett disorder who converse.	-1
Rasmussen encephalitis	CXCR3/CXCL10	0.4459	0.1947	A role for the CXCR3/CXCL10 axis in Rasmussen encephalitis.	-1
LTE	LGI1	0.4459	0.2262	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
acute encephalopathy	SCN1A	0.4459	0.2192	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
epileptic encephalopathy	CDKL5	0.4458	0.3514	SIGNIFICANCE: We observed that 5% of the male patients and 14% of the female patients with epileptic encephalopathy had CDKL5 alterations.	1
LD	laforin	0.4458	0.2566	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
BFNC	EBN2	0.4458	0.1733	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
isobutyryl-CoA dehydrogenase deficiency	FKBP14	0.4458	0.1639	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	KCNQ3	0.4458	0.1285	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	1
BFNC syndrome	KCNQ2	0.4458	0.05223	BFNC syndrome exhibits genetic heterogeneity, as has been hypothesised to occur in Arabian foals, and is known to be caused by mutations in the voltage-gated potassium channel subunit KCNQ2 and KCNQ3 genes.	-1
epilepsy	SCN1A	0.4457	0.144	Advances in the identification and management of severe epilepsy syndromes of early childhood: focus on SCN1A.	1
CMD	CMD1C	0.4457	0.2404	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
seizures	NF2	0.4457	0.06906	Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2.	-1
focal epilepsy	FGFR3	0.4456	0.2479	Does the co-occurrence of FGFR3 gene mutation in hypochondroplasia, medial temporal lobe dysgenesis, and focal epilepsy suggest a syndrome?	-1
LD	EPM2A	0.4456	0.1296	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
optic atrophy	SCN2A	0.4455	0.2963	Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.	-1
FIRES	POLG	0.4454	0.07979	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
idiopathic epilepsy	BFIC	0.4454	0.1284	G812T of KCNQ2 gene is a novel mutation found in BFIC and functional expression of KCNQ2 G812T is required for understanding the mechanism of BFIC and other idiopathic epilepsy.	-1
somatic growth failure	MECP2	0.4453	0.1752	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
ADNFLE	nAChR	0.4452	0.1036	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
seizures	LBSL	0.4452	0.04071	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
autosomal dominant nocturnal frontal lobe epilepsy	SCN1A	0.4452	0.1441	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
Epileptic encephalopathy	CDKL5	0.4452	0.1662	Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.	1
neurological disorders	AbPP	0.4451	0.1977	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
epileptic	mammalian target of rapamycin	0.4451	0.03368	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	1
epileptic encephalopathy	CDKL5/STK9	0.4451	0.3407	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	1
Myoclonic encephalopathy	CDKL5	0.445	0.3243	Myoclonic encephalopathy in the CDKL5 gene mutation.	-1
Dravet syndrome	SCN1A	0.4449	0.1448	In Dravet syndrome, only one nonsense mutation of SCN2A was identified, while hundreds of mutations were found in the paralogue gene, SCN1A, which encodes the alpha1 subunit.	-1
generalized epilepsy with	SCN1A	0.4449	0.1869	We recently described mutations of the neuronal sodium-channel alpha-subunit gene, SCN1A, on chromosome 2q24 in two families with generalized epilepsy with febrile seizures plus (GEFS+) type 2.	-1
SLE	Anti-NMDA-NR2A/B	0.4448	0.2828	(3) Anti-NMDA-NR2A/B antibodies are present in a substantial number of patients with Systemic Lupus Erythematosus (SLE) with or without neuropsychiatric problems.	-1
transmissible spongiform encephalopathies	prion protein	0.4448	0.1379	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
NGS	CDKL5	0.4447	0.2924	RESULTS: We identified alterations involving CDKL5 in four boys (5.4%) using NGS in one and MLPA in three.	-1
myoclonic jerks	LBSL	0.4447	0.04072	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
gait abnormalities	SCN1A	0.4447	0.3434	Future studies with larger cohorts will be required to formally assess an association of gait abnormalities with particular SCN1A mutations.	-1
mitochondrial diseases	COX	0.4445	0.05917	The histochemical methods including COX stain are useful for the confirmation and differentiation of mitochondrial diseases.	-1
epileptic	CYP2C9	0.4445	0.1904	CONCLUSION: Our study indicates that young epileptic patients with the CYP2C9 polymorphism gene have a low risk of subclinical atherosclerosis.	-1
Neuropshychiatric SLE	anti-NMDA-NR2A/B	0.4445	0.09075	The exact percentage of SLE patients having anti-NMDA-NR2A/B antibodies varies in different studies from 14 to 35%, and in one study such antibodies were found in 81% of patients with diffuse 'Neuropshychiatric SLE', and in 44% of patients with focal 'Neuropshychiatric SLE'.	-1
haploinsufficiency syndrome	KANSL1	0.4445	0.2136	CONCLUSIONS: In KANSL1 haploinsufficiency syndrome, chromosome deletions are greatly prevalent compared with KANSL1 mutations.	-1
postoperative fever	CSF	0.4445	0.2163	A dural patch covering the iatrogenic dural defect could not prevent or reduce postoperative CSF leakage, but prolonged the postoperative fever period.	-1
white matter abnormalities	laminin alpha-2-deficient	0.4444	0.2261	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
benign familial neonatal convulsions	KCNQ2	0.4444	0.2339	Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization.	-1
Dravet syndrome	SCN1A-mutations	0.4443	0.3962	We report a retrospective analysis of bromide therapy in 32 patients suffering from Dravet syndrome with SCN1A-mutations who received bromide.	-1
ROS	prohibitin	0.4443	0.1676	Recently, we showed that the excess ROS could damage voltage-dependent anion channel, prohibitin, Lon protease, and aconitase in the MERRF cells.	-1
myoclonic epilepsy	myoclonin/EFHC1	0.4443	0.2273	Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity.	-1
IS	SCN1A	0.4443	0.2669	This study extends the phenotypic heterogeneity of mutations in SCN1A to include IS.	-1
neurodegenerative or metabolic disease	SMA	0.4442	0.08799	CONCLUSION: The association of SMA with PME may constitute a separate and, probably, genetically independent syndrome with unique clinical and electroencephalographic findings or, at least, a variant of a neurodegenerative or metabolic disease, due to yet unknown causes.	-1
L-CMD	FKRP	0.4441	0.08344	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
L-CMD	POMT2	0.4441	0.08344	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
L-CMD	FKTN	0.4441	0.08344	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizure	CSF) 1	0.4441	0.1132	We studied six patients (two including CSF) 1 to 14 weeks (median 3 weeks) and six patients 1 to 6 years (median 3.5 years) after seizure onset.	-1
retinal anomalies	SMARCB1	0.4441	0.3212	Distinguishing features include retinal anomalies, Dandy-Walker malformation, scoliosis, rocker bottom feet, respiratory difficulties and absence of seizures, and 2-oxoglutaric aciduria in the patients with the SMARCB1 mutation.	-1
epileptic encephalopathy	GRIN1	0.4441	0.2557	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
generalized epilepsy with febrile seizures	SCN1A	0.4439	0.1798	More than 800 mutations in the voltage-gated sodium channel SCN1A have been reported in patients with generalized epilepsy with febrile seizures plus and Dravet syndrome.	-1
Febrile Seizures	SCN1A	0.4438	0.1267	Diseases caused by mutations in SCN1A are currently named Genetic Epilepsies with Febrile Seizures Plus, and this term stands for expanded spectrum of syndrome previously called as GEFS+ (Generalized Epilepsy with Febrile Seizures Plus).	-1
IS	mammalian target of rapamycin	0.4438	0.09446	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
dystroglycanopathies	laminin alpha-2-deficient	0.4436	0.1288	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
diabetes	MODY2	0.4436	0.1025	Fasting hyperglycemia in the diabetic range, impaired glucose tolerance, and lack of diabetes autoantibodies were compatible with MODY2.	-1
seizures	SMA	0.4435	0.3316	Propagation of tonic posturing in supplementary motor area (SMA) seizures.	-1
CSS	SMARCB1	0.4434	0.05384	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
seizure	interleukin-1-beta	0.4434	0.2295	Authors observed the data of clinical and laboratory investigations concerning the cytokines and TF-neurotropic effects and also the original results dedicated to investigation of tumor necrosis factor-alpha and interleukin-1-beta influence on experimental seizure syndrome.	-1
Rett (	ZEB2	0.4433	0.06593	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
hearing loss	DHCR7	0.4433	0.07407	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Wilson syndrome	MECP2	0.4432	0.1232	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
neonatal epilepsy	KCNQ2	0.4431	0.4384	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	1
neuronal migration disorder	PAFAH1B1	0.4431	0.07741	BACKGROUND: Genetic aberrations in PAFAH1B1 result in isolated lissencephaly sequence (ILS), a neuronal migration disorder associated with severe mental retardation and intractable epilepsy.	-1
genetic epilepsies	SCN1A	0.4431	0.2195	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4431	0.1135	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Rett syndrome	MECP2	0.4431	0.3634	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
optic atrophy (	PEHO	0.443	0.3455	Dutch patients with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.	-1
optic atrophy (	PEHO	0.443	0.3455	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
NES	CLN5	0.443	0.09342	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
Dandy-Walker malformation	SMARCB1	0.4429	0.2961	Distinguishing features include retinal anomalies, Dandy-Walker malformation, scoliosis, rocker bottom feet, respiratory difficulties and absence of seizures, and 2-oxoglutaric aciduria in the patients with the SMARCB1 mutation.	-1
MCDs	SCN1A	0.4428	0.3752	OBJECTIVE: To report on six patients with SCN1A mutations and malformations of cortical development (MCDs) and describe their clinical course, genetic findings, and electrographic, imaging, and neuropathologic features.	-1
Dravet syndrome	Na(v)1.1	0.4428	0.08372	De novo mutations of SCN1A, which encode the Na(v)1.1 neuronal voltage-gated sodium channel, are considered the major cause of Dravet syndrome.	-1
hearing loss	AUH	0.4428	0.07194	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Dravet syndrome	cystatin B	0.4428	0.08013	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
congenital adrenal hyperplasia	MEN 2A	0.4428	0.189	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
MELAS	COX	0.4427	0.2116	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
ASD	SHANK3	0.4427	0.03314	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
epileptic	NAG	0.4427	0.2498	This article goes on to analyse the current data and draws on recurring patterns to suggest that a specific subpopulation of severely disabled epileptic children may benefit hugely from the close monitoring of enzymes which are indicative of renal tubular injury, particularly NAG or in the very least periodical urinalysis.	-1
idiopathic epilepsy	KCNQ2	0.4426	0.08202	G812T of KCNQ2 gene is a novel mutation found in BFIC and functional expression of KCNQ2 G812T is required for understanding the mechanism of BFIC and other idiopathic epilepsy.	-1
epileptic syndrome	Prnp	0.4425	0.1053	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	1
tter-T  nz syndrome	HSD17B10	0.4424	0.06681	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
WS	CDKL5	0.4424	0.1211	Analysis of the CDKL5 gene, which is responsible for female patient with WS, did not show any disease-causing mutation.	-1
tumour	NF2	0.4424	0.06412	In this patient, we identified the novel c.428_430delCTTdel mutation in NF2, involving the amino-terminal FERM domain, which is fundamental for the correct tumour suppressor function of the protein.	-1
neurological diseases	PrP	0.4422	0.2923	We performed a study on levels of the total prion protein (PrP) in humans affected by different neurological diseases and assessed the influence of several factors such as age, gender, and disease severity on the cerebrospinal fluid PrP levels.	-1
SMEI	SCN1A	0.4421	0.1222	Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB).	-1
thrombosis	JAK2	0.442	0.1874	No clear explanation has been given for the occurrence of thrombosis in this unusual site in patients with ET, but the existence of a specific association between unexplained SVT and the JAK2 mutation has been reported.	-1
LMNA-related CMD	ISPD	0.442	0.1417	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
infancy	SCN1A	0.442	0.1582	His autopsy was unremarkable, but genetic testing revealed a frame shift mutation in SCN1A, consistent with severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
DS	SCN1A	0.442	0.0124	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
SJS/TEN	CYP2C9	0.442	0.164	The higher risk of phenytoin-related SJS/TEN was observed in the patients with CYP2C9*3 (odds ratio=4.30, 95% confidence interval=1.41-13.09, P<0.05).	-1
TSC	LAT1	0.4419	0.1533	MATERIALS AND METHODS: LAT1 expression was investigated by LAT1 mRNA using reverse transcription-polymerase chain reaction and immunohistochemical staining with anti-human LAT1 antibody in nine patients with TSC and three control brains.	-1
seizures	TEN 4	0.4418	0.2116	A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.	-1
Ehlers-Danlos syndrome	ROGDI	0.4418	0.1174	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
BFNC	KCNQ2	0.4418	0.1686	We propose that a difference in firing patterns between motoneurons and central neurons, combined with the drastically slowed voltage activation of the R207W mutant, explains why this particular KCNQ2 mutant causes myokymia in addition to BFNC.	-1
neonatal seizures	KCNQ3 p.Ala381Val	0.4417	0.2745	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
psychosis	IL-6	0.4417	0.1824	By contrast, chronic progressive NB is characterized by intractable slowly progressive dementia and/or psychosis with persistent elevation of cerebrospinal fluid IL-6 activity, which is resistant to conventional steroid therapy.	-1
microcephaly	MEDS	0.4417	0.09387	While liver and renal symptoms are more severe in WRS, neurodevelopmental characteristics are more pronounced in MEDS patients, in which microcephaly and uncontrolled epilepsy are uniformly present.	-1
benign familial neonatal-infantile seizures	SCN2A	0.4416	0.1519	Mutations of the gene encoding the alpha2 subunit of the neuronal sodium channel, SCN2A, have been found in benign familial neonatal-infantile seizures (BFNIS).	-1
myoclonic epilepsy	SCN1A	0.4416	0.133	Mutations in SCN1A (encoding the neuronal voltage-gated sodium channel alpha1 subunit, Na(V)1.1, or SCN1A) are associated with genetic epilepsy syndromes including generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy.	-1
XLAG syndrome	ARX	0.4415	0.3217	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
epilepsy	SCN3A	0.4415	0.3552	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	1
Aicardi syndrome	CDKL5	0.4415	0.2	The screening was negative for all men as well as for women with Aicardi syndrome, excluding the CDKL5 gene as a candidate for this neurodevelopmental disorder.	-1
Hemiconvulsion-hemiplegia syndrome	interleukin-6	0.4414	0.1685	Hemiconvulsion-hemiplegia syndrome and elevated interleukin-6: case report.	-1
epilepsy	NF1	0.4414	0.05767	Individuals with seizures and NF1 typically require more aggressive therapy than those without NF1 and should be considered for epilepsy surgery when appropriate.	-1
benign familial neonatal convulsions	KCNQ3	0.4413	0.2068	Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization.	-1
HIE	parvalbumin	0.4413	0.1296	Recently, we reported the reduced expression of tyrosine hydroxylase, methionine enkephalin and parvalbumin in the brainstem in autopsy cases of lissencephaly and sequels of HIE manifested as WS/LGS, regardless of the cerebral changes.	-1
encephalopathy	PEHO	0.4411	0.2319	The PEHO syndrome (progressive encephalopathy, hypsarrhythmia and optic atrophy) is a rare, autosomal recessive, encephalopathy of infancy.	-1
DS	Na(v) 1.1	0.4411	0.03006	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
mitochondrial disorders	LBSL	0.4411	0.05157	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
ISs	CDKL5	0.4411	0.03437	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
Dravet syndrome	SCN1A	0.4411	0.2742	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
dysfibrinogenemia or	fibrinogen	0.441	0.2707	Three patients with dysfibrinogenemia or fibrinogen deficiency showed normal or slightly prolonged PT values and normal APTT values.	-1
Dravet syndrome	SCN1A	0.441	0.1652	SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome.	-1
SSPE	SCN1A	0.441	0.5765	It can also be argued that because of striking clinical resemblance between Dravet and various epileptic and encephalopathic syndromes associated with SCN1A gene mutations and SSPE, SCN1A gene abnormalities may also be responsible for susceptibility to SSPE in measles infected children.	-1
Epilepsy	SCN1A	0.4409	0.1104	Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?	1
dyslexia	EPM2A	0.4409	0.2175	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
SMEI	SCN1A	0.4409	0.1207	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
isolated lissencephaly	LIS1	0.4409	0.1848	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
Rasmussen syndrome	TNFalpha	0.4409	0.1324	A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF.	-1
myoclonus	CSF and EEG	0.4409	0.1018	In a 64-year old woman with progressive visual impairment for 4 weeks, probable Creutzfeld-Jakob disease without myoclonus was diagnosed after rapidly progressive mental deterioration had also developed, and CSF and EEG showed characteristic findings.	-1
intellectual disability	KCNQ2	0.4408	0.05356	A family with dominantly inherited neonatal seizures and intellectual disability was atypical for neonatal and infantile seizure syndromes associated with potassium (KCNQ2 and KCNQ3) and sodium (SCN2A) channel mutations.	-1
hippocampal oscillations	Nav1.1	0.4408	0.09336	We show that reduction of Nav1.1 expression in the medial septum and diagonal band of Broca leads to a dysregulation of hippocampal oscillations in association with a spatial memory deficit.	-1
neurodevelopmental disorder	CDKL5	0.4407	0.1806	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
febrile seizures	SCN1A	0.4407	0.2245	CONCLUSION: Epilepsies associated with SCN1A mutations range in severity from febrile seizures to severe epileptic encephalopathies including Dravet syndrome and severe infantile multifocal epilepsy.	-1
PME	SCN1A	0.4407	0.127	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
intellectual disability	MBD5	0.4407	0.0573	Notably a deletion in a psychotic VCFS patient at 2q23.1 hit the gene MBD5 which when deleted gives rise to intellectual disability, epilepsy, and autistic features.	-1
seizure	SCN1A	0.4406	0.1939	The purpose of this study is to correlate different types of SCN1A mutations and (1) seizure control, (2) occurrence of convulsive status epilepticus (cSE), and (3) the presence of crouch gait in adult patients.	-1
spasms	MECP2	0.4406	0.07383	We report the case of a boy carrying a maternally-inherited MECP2 duplication and describe the video-EEG sequence of a cluster of eating-induced spasms, the only epileptic manifestation of the patient.	-1
Cowden syndrome	PTEN	0.4405	0.09279	We report the case of a girl with Cowden syndrome (CS) presenting with unilateral perisylvian dysplasia and with drug resistant focal seizures carrying a novel missense mutation 385G>A (G129R) in the PTEN gene.	-1
mentally retarded	MECP2	0.4405	0.3299	Despite these connections, MECP2 mutations in nonspecific autistic and mentally retarded populations are rare.	-1
cancer	DPD	0.4405	0.6142	5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.	-1
migraine	SCN1A	0.4405	0.2029	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
seizure	SCN1A-mutations	0.4404	0.1048	OBJECTIVES: To determine the prevalence of Dravet syndrome, an epileptic encephalopathy caused by SCN1A-mutations, often with seizure onset after vaccination, among infants reported with seizures following vaccination.	-1
Rett syndrome	methyl-CpG binding protein 2	0.4404	0.2585	However, the lack of methyl-CpG binding protein 2 mutations in a small group of classic Rett syndrome cases, and the low frequency of these mutations in atypical Rett syndrome patients, suggest that other gene defects may play a role in this disorder.	-1
PME	SMA	0.4404	0.1585	In particular, the association of SMA and progressive myoclonic epilepsy (PME) has been rarely described.	-1
CMDs	CMD1D	0.4404	0.4314	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
TSE	prion protein	0.4403	0.1032	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
alcoholism	NR2B	0.4403	0.3842	Previously we had reported a lack of association between the single nucleotide polymorphism (SNP) rs1806201 in the NR2B gene (GRIN2B) and alcoholism.	-1
SMEI	GABRG2	0.4403	0.2098	Recently, mutations in SCN1A and GABRG2 have been described in SMEI patients.	-1
PRES	spin	0.4402	0.3084	The aim of this retrospective study was to examine the contribution of epileptic ictal hyperperfusion in patients with PRES using combined magnetic resonance perfusion imaging with arterial spin labeling (ASL) and diffusion-weighted magnetic resonance imaging (MRI).	-1
Lissencephaly	DCX	0.4402	0.3252	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
enteropathy X-linked syndrome	IPF1	0.4401	0.4914	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
febrile seizures	SCN1A	0.4401	0.2744	We describe the five gene loci localized in children with febrile seizures (FEB 1 5), the three genes identified in patients with generalized epilepsy with febrile seizures plus (GEFS+ 1 3) and the de novo mutations of gene SCN1A that have been identified to date in children with SMEI.	-1
seizures	SCN1A-mutations	0.44	0.102	OBJECTIVES: To determine the prevalence of Dravet syndrome, an epileptic encephalopathy caused by SCN1A-mutations, often with seizure onset after vaccination, among infants reported with seizures following vaccination.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.44	0.178	Causative variants in SCN1A gene which codes the main, pore-forming subunit of the channel expressed in central nervous system are associated predominantly with Dravet syndrome (DS), as well as with generalized epilepsy with febrile seizures plus (GEFS+) making it one of the most significant epilepsy gene.	-1
scoliosis	neurofibromatosis type 1	0.4399	0.1491	Other malformations included: subcortical hamartoma associated with neurofibromatosis type 1, craniofacial dysmorphism secondary to Noonan syndrome, congenital occipital plagiocephaly, os odontoideum, craniofacial cleft, juvenile rheumathoid arthritis with platybasia, and osteogenesis imperfecta with bathrocephaly and scoliosis.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	HSD17B10	0.4399	0.2223	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neurological deficit	SMA	0.4398	0.3981	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
psychomotor retardation	KCNQ2	0.4398	0.1539	"In addition to benign familial neonatal epilepsy (BFNE), KCNQ2 mutations have been recently found in families with one or more family members with a severe outcome, including drug-resistant seizures with psychomotor retardation, electroencephalogram (EEG) suppression-burst pattern (Ohtahara syndrome), and distinct neuroradiological features, a condition that was named ""KCNQ2 encephalopathy."""	-1
Smith-Lemli-Opitz syndrome	HMGCS2	0.4398	0.2756	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	KCNQ1	0.4398	0.3134	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
epilepsy	SCN1A	0.4397	0.2454	SCN1A is the most relevant epilepsy gene.	1
rigid spine syndrome	POMGNT1	0.4396	0.1073	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
DS	SCN1A	0.4396	0.08198	BACKGROUND Mutations in SCN1A can cause genetic epilepsy with febrile seizures plus (GEFS+, inherited missense mutations) or Dravet syndrome (DS, de novo mutations of all types).	-1
autism	Nav1.1	0.4396	0.1882	Here, we examined the possible effects on cognition of Nav1.1 down-regulation, a sodium channel principally involved in Dravet syndrome but also implicated in other cognitive disorders, including autism and Alzheimer's disease.	-1
Rasmussen encephalitis	R1575C-SCN 1 A	0.4396	0.5482	We herein report the R1575C-SCN 1 A mutation identified in a patient with Rasmussen encephalitis.	-1
congenital hepatic fibrosis	ARPKD	0.4396	0.1288	OBJECTIVES: The published natural history of congenital hepatic fibrosis (CHF) was examined to inform clinical decision making in autosomal recessive polycystic kidney disease (ARPKD).	-1
seizures	MECP2	0.4395	0.2714	Patients with MECP2 duplications show severe ID, intractable seizures and recurrent infections.	-1
DS	SCN1A	0.4394	0.2874	A large number of SCN1A mutations identified from the DS patients lead to the loss of function or truncation of Nav1.1 that result in a haploinsufficiency effects, indicating that the exact expression level of SCN1A should be essential to maintain normal brain function.	-1
BMD	MECP2	0.4394	0.3663	Further, spine and hip aBMD and vBMAD of patients were associated with clinical risk factors of low BMD, low-energy fractures, MECP2 mutation groups, and X chromosome inactivation (XCI).	-1
scoliosis	SMARCB1	0.4394	0.3108	Distinguishing features include retinal anomalies, Dandy-Walker malformation, scoliosis, rocker bottom feet, respiratory difficulties and absence of seizures, and 2-oxoglutaric aciduria in the patients with the SMARCB1 mutation.	-1
acid decarboxylase deficiency	dihydropteridine reductase	0.4394	0.1191	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
moyamoya disease	neurofibromatosis 1	0.4394	0.235	An association between moyamoya disease and neurofibromatosis 1, a neurocutanoeus disorder, is well established in the literature.	-1
Rasmussen syndrome	CD4	0.4394	0.08508	A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF.	-1
epilepsy	YWHAE	0.4393	0.2682	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
mental retardation	MECP2	0.4393	0.1304	CONCLUSION: This study suggested clinical implications of the MECP2 duplication syndrome not only in the male but also in female patients with unexplained mental retardation.	-1
epilepsy	SCN1A	0.4392	0.1699	Mutations in the SCN1A gene have been identified in a variety of epilepsy phenotypes, from severe encephalopathies such as Dravet syndrome to milder familial forms such as generalized epilepsy with febrile seizures plus.	1
ISs	STXBP1	0.4392	0.02354	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
RTT	MECP2	0.4391	0.149	Over 120 different mutations in the methyl-CpG binding protein 2 gene (MECP2) have been reported in patients with RTT, but a genotype-phenotype correlation has not been established.	-1
myoclonic epilepsy of infancy	SCN1A	0.439	0.09395	The relationship between severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) and the related syndrome SMEI-borderland (SMEB) with mutations in the sodium channel alpha 1 subunit gene SCN1A is well established.	-1
diabetes mellitus	tRNA methyltransferase 10 homologue A	0.4389	0.2196	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
epilepsy disorders	KCC2	0.4389	0.1358	KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described.	1
hypoplasia	ALP	0.4388	0.1248	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
RTT	CDKL5	0.4387	0.2374	In conclusion, this report reinforces the observation that the CDKL5 phenotype overlaps with RTT and that CDKL5 analysis is recommended in patients with a seizure disorder commencing during the first months of life.	-1
temporal lobe epilepsy	MVP	0.4387	0.1737	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
autistic disorder	PTEN	0.4387	0.2705	Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy.	-1
Bloch-Sulzberger syndrome	Incontinentia pigmenti	0.4387	0.3071	Incontinentia pigmenti (Bloch-Sulzberger syndrome): report of a case and review of the Indian literature.	-1
Bloch-Sulzberger syndrome	Incontinentia pigmenti	0.4387	0.3071	Incontinentia pigmenti (Bloch-Sulzberger syndrome).	-1
epileptic encephalopathy	cyclin-dependent kinase-like 5	0.4386	0.2918	Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.	1
fever	SCN1A	0.4386	0.1885	Moreover, our data show that SCN1A gene does not contribute significantly to susceptibility to autonomic seizures during fever in patients with PS.	-1
ISs	KCNQ2	0.4386	0.02333	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
ET	JAK2	0.4385	0.2358	No clear explanation has been given for the occurrence of thrombosis in this unusual site in patients with ET, but the existence of a specific association between unexplained SVT and the JAK2 mutation has been reported.	-1
SMEI	SCN1A	0.4385	0.4824	CONCLUSIONS: The rate of SCN1A mutations in this cohort of SMEI patients suggests that other factors may be important in SMEI.	-1
DS	SCN1A	0.4385	0.09844	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
LGS	CHD2	0.4384	0.2219	We have previously identified one patient with a large deletion affecting the CHD2 gene in a group of 22 patients with LGS or LGS-like epilepsy.	-1
IBD	ACAD8	0.4384	0.122	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Miller-Dieker Syndrome	DCX	0.4384	0.1004	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
JME	SCN1A	0.4384	0.1817	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
JS	CC2D2A	0.4383	0.09832	CONCLUSIONS: CC2D2A testing should be prioritised in patients with JS and ventriculomegaly and/or seizures.	-1
synaptic disorders	NMT--	0.4383	0.08527	In conclusion, the term NMT--LE--VGKC should be changed to NMT--LE with LGII and CASPR2 antibodies and classified as auto immune synaptic disorders.	-1
ataxia	MECP2	0.4383	0.09051	Non-progressive neuropsychiatric symptoms in female relatives of a male child with learning disability, ataxia and progressive spasticity may constitute a clue to inherited, MECP2 pathogenesis.	-1
GEFS	SCN1A	0.4382	0.1696	(2) Our study failed to provide evidence supporting a causal relation between the SCN1A mutation and the etiologic gene in the GEFS+ family B, which indicates that GEFS+ has the phenotypic and genotypic heterogeneity.	-1
complex I deficiency	PUFA-enriched	0.4381	0.321	Here, we report a 7-year-old boy with Lennox-Gastaut syndrome combined with mitochondrial respiratory chain complex I deficiency, whose medically intractable seizures have been successfully controlled with a PUFA-enriched modified Atkins diet without any significant adverse events.	-1
Kleefstra syndrome	MECP2	0.4381	0.1046	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
neurodegenerative disorders	PrP	0.4381	0.2121	The finding of decreased PrP levels in the CSF of patients not only with CJD but also in other neurodegenerative disorders is intriguing.	-1
Ehlers-Danlos syndrome	ACADSB	0.438	0.1316	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
proteinuria	CLC	0.438	0.03685	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
neonatal sepsis	CRP	0.438	0.3807	CONCLUSION: In place where blood culture is limited neonates having clinical features of neonatal sepsis with positive qualitative CRP assay and increased WBC should urgently be initiated on appropriate sepsis management in order to reduce morbidity and mortality associated with neonatal sepsis.	-1
RS	MECP2	0.438	0.305	METHODS: A 6-year-old girl with RS and a proven MECP2 mutation was described.	-1
Rett syndrome	CDKL5	0.4379	0.1253	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
movement disorders	MECP2	0.4379	0.2244	We describe a rare and complete video-polygraphic study of a girl with Rett syndrome (MECP2 mutation) and MS misdiagnosed as movement disorders and disclosed after video-polygraphic recordings.	-1
BFNC	EBN1	0.4379	0.1481	Here we report on a second BFNC family in which linkage to the EBN1 locus on chromosome 20q was excluded, confirming the genetic heterogeneity of this disorder.	-1
West-syndrome	NARP	0.4379	0.05738	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
myoclonus epilepsy	PWP2H	0.4379	0.2006	A periodic tryptophan protein 2 gene homologue (PWP2H) in the candidate region of progressive myoclonus epilepsy on 21q22.3.	-1
NES	JNCL	0.4378	0.1277	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
SMEI	cystatin B	0.4377	0.185	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
Rasmussen syndrome	GluR3	0.4377	0.205	In Rasmussen syndrome, antibodies against GluA3 (GluR3) were found to be the primary pathological factor.	-1
convulsive status epilepticus	SCN1A	0.4377	0.139	The purpose of this study is to correlate different types of SCN1A mutations and (1) seizure control, (2) occurrence of convulsive status epilepticus (cSE), and (3) the presence of crouch gait in adult patients.	-1
microcephalic	NRXN1	0.4377	0.1358	It thus appears that the phenotype of the mildly affected mother can be explained by the NRXN1 deletion, whereas the more severe and complex microcephalic phenotype of the two affected brothers is due to the simultaneous deletion in NRXN1 and the homozygous missense mutation affecting RBBP8.	-1
Batten disease	CLN2	0.4376	0.22	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
channelopathies	KCNQ2	0.4376	0.2282	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
generalized epilepsy and	SCN1A	0.4374	0.1675	SCN1A is the most clinically relevant epilepsy gene and is associated with generalized epilepsy and febrile seizure plus (GEFS+) and Dravet syndrome.	-1
edema	PEHO	0.4374	0.2663	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
seizures	SCN1A-R1575C	0.4374	0.6388	The SCN1A-R1575C mutation was detected in a patient with a history of acute encephalitis with refractory, repetitive partial seizures (AERRPS) and also in the patient's apparently healthy father.	-1
Seizures	MECP2	0.4373	0.1155	Seizures and sleep disturbances were more common than in those with MECP2 mutations whereas features of regression and spinal curvature were less common.	-1
epileptic seizures	ACMSD	0.4373	0.2145	Due to the previous association of ACMSD deficiency with the development of epileptic seizures, we concluded that the identified nonsense mutation in the ACMSD gene, which encodes for a critical enzyme of the kynurenine pathway of the tryptophan metabolism, is the disease-segregating mutation most likely to be responsible for the phenotype described in our family.	-1
West syndrome	NF1	0.4372	0.2466	Fifteen patients with neurofibromatosis type one (NF1) and West syndrome (WS) were studied.	-1
Dravet syndrome	SCN1A	0.4372	0.1899	On the likelihood of SCN1A microdeletions or duplications in Dravet syndrome with missense mutation.	-1
aromatic	dihydropteridine reductase	0.4371	0.08987	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
infancy or Dravet syndrome	SCN1A	0.4371	0.07951	Mutations in the alpha-subunit of the first neuronal sodium channel gene SCN1A have been described in isolated patients with severe myoclonic epilepsy in infancy or Dravet syndrome and in families with generalized epilepsy with febrile seizures plus.	-1
Miller-Dieker Syndrome	VLDLR	0.437	0.1011	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
Miller-Dieker Syndrome	TUBA1A	0.437	0.1011	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
neurodevelopmental disorders	methyl-CpG binding protein 2	0.437	0.1916	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
Rett syndrome	Cyclin-dependent kinase-like 5	0.437	0.334	Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders.	-1
Dravet syndrome	SCN1A	0.437	0.2314	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	-1
X-linked cyclin-dependent kinase-like 5	CDKL5	0.437	0.3276	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	-1
cystic renal disease	HNF1 beta	0.4369	0.3195	Deletions in chromosome 17q12 encompassing the HNF1 beta gene cause cystic renal disease and maturity onset diabetes of the young, and have been recently described as the first recurrent genomic deletion leading to diabetes.	-1
DS	SCN1A	0.4369	0.1483	However, 25-30% of patients with DS are negative for the SCN1A mutation screening, suggesting that other molecular mechanisms may account for these disorders.	-1
rolandic epilepsy	STXBP1-related	0.4369	0.2727	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
atherosclerosis	insulin	0.4369	0.2604	PURPOSE: We investigated the influence of the CYP2C9 polymorphism on the lipid profile, insulin resistance, and subclinical atherosclerosis in young epileptic patients.	-1
SMEI	SCN1A	0.4369	0.1452	RESULTS: In both core SMEI and SMEB, various mutations of SCN1A including nonsense and missense mutations were identified, whereas no mutations of SCN2A, SCN1B, and SCN2B were found within the regions examined.	-1
tter-T  nz syndrome	DHCR7	0.4368	0.07498	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
retinitis pigmentosa	cystathionine beta-synthase	0.4368	0.09228	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
wild type	SkM1	0.4368	0.1742	We have studied, in the HEK cells permanently transfected with the skeletal muscle sodium channel alpha-subunit (SkM1), the effects of a transient transfection of the wild type (WT) or C121W mutant beta 1-subunit.	-1
intellectual disability	IL-6	0.4367	0.3007	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
dysmyelination	MRI	0.4367	0.08719	The MRI features of some lesions such as FCD may differ in infants compared to children and adults; the white matter adjacent to FCD may demonstrate lower T2 and higher T1 signal in some infants due to premature myelination, while in others, the white matter demonstrates higher T2 or lower T1 signal due to demyelination, dysmyelination or gliosis, similar to children and adults.	-1
West syndrome	ARX	0.4367	0.06181	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
WRS	MEDS	0.4366	0.3349	We expand the phenotypic spectrum of MEDS caused by IER3IP1 gene mutations and propose that WRS and MEDS are overlapping clinical syndromes, displaying significant gene-dependent clinical variability.	-1
Lafora disease	CLN3	0.4366	0.1217	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	ACAD8	0.4366	0.08354	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
FXS	Abeta	0.4364	0.1461	These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.	-1
epileptiform activity	TRPC3	0.4364	0.1679	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
epilepsy	GABRB2	0.4363	0.09349	MATERIALS AND METHODS: We investigated the association of single-nucleotide polymorphisms in GABA(A) receptor subunit subtype genes namely; rs2279020 (GABRA1), rs3219151 (GABRA6), rs2229944 (GABRB2), and rs211037 (GABRG2) with predisposition to epilepsy and AED resistance.	1
RTT	methyl-CpG binding protein 2	0.4363	0.1421	Over 120 different mutations in the methyl-CpG binding protein 2 gene (MECP2) have been reported in patients with RTT, but a genotype-phenotype correlation has not been established.	-1
fever	SCN1A	0.4363	0.1396	We studied 132 patients with epilepsy syndromes with seizures precipitated by fever, and performed phenotype-genotype correlations with SCN1A alterations.	-1
cerebral creatine deficiency	Mota	0.4363	0.3738	OBJECTIVES: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients, followed in Hospital Pedi  trico Carmona da Mota.	-1
tter-T  nz syndrome	AUH	0.4363	0.07282	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
febrile seizures	SCN1A	0.4362	0.1151	We recently described mutations of the neuronal sodium-channel alpha-subunit gene, SCN1A, on chromosome 2q24 in two families with generalized epilepsy with febrile seizures plus (GEFS+) type 2.	-1
DS	SCN1A	0.4361	0.2	RESULTS: Novel SCN1A CNVs were found in 12.5% of DS patients where sequence-based mutations had been excluded.	-1
seizures	SUR1	0.436	0.2106	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
scoliosis	SCN1A	0.436	0.2394	We describe a 15-year-old girl with SCN1A mutation (Dravet syndrome), refractory generalized tonic-clonic seizures, and prior posterior instrumentation and fusion for scoliosis, who presented with progressive lower extremity weakness.	-1
RTT	MECP2	0.4359	0.4334	Here we report on the clinical and CDKL5 molecular investigation in a very unusual RTT case, with severe, early-neurological involvement in which we have shown in a previous report, a novel P388S MECP2 mutation [Conforti et al. (2003); Am J Med Genet A 117A: 184-187].	-1
myoclonic epilepsy	SCN1A	0.4359	0.2591	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
Dravet syndrome	SCN1A	0.4359	0.5553	RESULTS: We generated iPSCs from a Dravet syndrome patient with a c.4933C>T substitution in SCN1A, which is predicted to result in truncation in the fourth homologous domain of the protein (p.R1645*).	-1
intellectual disability	IL-6	0.4358	0.06919	High seizure frequency and severe intellectual disability emerged as predictors for elevated serum levels of IL-6.	-1
West/Ohtahara syndromes	CDKL5/STK9	0.4358	0.1808	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
WS/LGS	parvalbumin	0.4357	0.1107	Recently, we reported the reduced expression of tyrosine hydroxylase, methionine enkephalin and parvalbumin in the brainstem in autopsy cases of lissencephaly and sequels of HIE manifested as WS/LGS, regardless of the cerebral changes.	-1
West-syndrome	LBSL	0.4357	0.04004	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
cognitive delay, structural brain and/or eye abnormalities	laminin alpha-2-deficient	0.4357	0.1054	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
seizures	PRKCZ	0.4356	0.4697	Other genes deleted in a subset of the patients likely play a contributory role in the phenotypes, including GABRD and seizures, PRKCZ and neurologic features, and SKI and dysmorphic and neurologic features.	-1
SMEI/SMEB	SCN1A	0.4355	0.2206	We performed a clinical and genetic study focusing on SCN1A, using dHPLC, gene sequencing, and MLPA to detect genomic deletions/duplications on SMEI/SMEB patients.	-1
epileptic encephalopathy	CDKL5	0.4355	0.2167	This is the first description of a male patient with a deletion of these genes, showing the involvement of CDKL5 in severe epileptic encephalopathy in males.	1
menstrual disorders	OR 1.64	0.4355	0.1777	There is significant difference of menstrual disorders between VPA treated women and non-VPA treated women (7 studies included, P<0.05, OR 1.64, 95% CI 1.19-2.25).	-1
mental retardation	STK9	0.4355	0.3307	We show that STK9 is subject to X-inactivation in normal female somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X. Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation) strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal locus for this disorder.	-1
HPMRS	alkaline phosphatase	0.4355	0.09681	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
Angelman syndrome	TCF4	0.4354	0.08437	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Epilepsy	PEHO	0.4354	0.1689	Epilepsy and the electroencephalogram in progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (the PEHO syndrome).	-1
Miller-Dieker Syndrome	ARX	0.4354	0.1004	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
ED	PDE-5	0.4354	0.133	Treatment options that may improve ED include exercise and oral PDE-5 inhibitors.	-1
neurological deficit	SMA	0.4353	0.05302	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
dementia	EPM2A	0.4353	0.08512	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
encephalopathy	Netrin G1	0.4353	0.165	This study tested a sample of 91 female patients with a clinically heterogeneous phenotype ranging from encephalopathy with epilepsy to atypical Rett syndrome without epilepsy for mutations in the Netrin G1 gene, to evaluate its involvement in this condition.	-1
hippocampal cortex focal dysplasia	FGFR3	0.4353	0.1817	CONCLUSIONS: The present case of hypochondroplasia and FGFR3 mutation in Asn540Lys associated with characteristic abnormalities involving bilaterally medial temporal lobe structures, probable hippocampal cortex focal dysplasia, and early onset of focal epilepsy underscores the possibility of a rare syndrome.	-1
hypsarrhythmia	PEHO	0.4353	0.1476	The PEHO syndrome (progressive encephalopathy, hypsarrhythmia and optic atrophy) is a rare, autosomal recessive, encephalopathy of infancy.	-1
febrile seizures	SCN1A	0.4353	0.04781	When a baby exhibits two or more features of complex febrile seizures in the first year of life, a diagnosis of DS should be considered, and SCN1A gene mutation screening should be performed as early as possible.	-1
speech impairment	TCF4	0.4353	0.0638	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
Rett syndrome	MECP2	0.4352	0.2212	Mutations in a gene on the X-chromosome encoding methyl-CpG-binding protein 2 (MECP2) cause Rett syndrome.	-1
Rett syndrome	cystatin B	0.4352	0.3408	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
West syndrome	CRK	0.4352	0.5333	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
SJS/TEN	HLA-DRB1	0.4352	0.1123	Furthermore, the carrier rates of HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 were lower in the SJS/TEN group compared with the AED-tolerant group.	-1
severe myoclonic epilepsy of infancy	SCN1A	0.4351	0.03409	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	-1
seizures	SCN1A	0.4351	0.01894	(2) SCN1A testing should be considered in people with possible DS where the typical initial presentation is of a developmentally normal infant presenting with recurrent, febrile or afebrile prolonged, hemiclonic seizures or generalized status epilepticus.	-1
Bethlem myopathy	CMD1D	0.435	0.2976	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
Miller-Dieker Syndrome	RELN	0.4349	0.109	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
malformations of cortical development	SCN1A	0.4349	0.4303	OBJECTIVE: To report on six patients with SCN1A mutations and malformations of cortical development (MCDs) and describe their clinical course, genetic findings, and electrographic, imaging, and neuropathologic features.	-1
malignant tumors	LAT1	0.4349	0.1435	The amino acid transport system L (LAT) is a major nutrient transport system, and LAT1 is highly expressed in malignant tumors to support tumor cell growth.	-1
neurotoxic	cytochrome P450 2C9	0.4349	0.06531	In particular, two polymorphisms of cytochrome P450 2C9 are known to slow down the metabolism of phenytoin to a degree that increases the risk of the neurotoxic adverse effects of this drug among carriers of these polymorphisms.	-1
congenital deafness	KCNQ1	0.4348	0.5138	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
focal epilepsy	NR2B	0.4347	0.0555	The patient with ID and focal epilepsy had a missense mutation in the extracellular glutamate-binding domain (p.Arg540His), whereas both West syndrome patients carried missense mutations within the NR2B ion channel-forming re-entrant loop (p.Asn615Ile, p.Val618Gly).	-1
epilepsy	SCN9A	0.4347	0.09231	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	1
hypotonia	PEHO	0.4347	0.1956	Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome) is an apparently autosomal recessive disorder manifested by infantile spasms, severe hypotonia, and early arrest of psychomotor development.	-1
Rett syndrome	CDKL5	0.4347	0.2403	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
ragged-red fibers	cytochrome oxidase	0.4346	0.2159	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
maturity	HNF1 beta	0.4346	0.1037	Deletions in chromosome 17q12 encompassing the HNF1 beta gene cause cystic renal disease and maturity onset diabetes of the young, and have been recently described as the first recurrent genomic deletion leading to diabetes.	-1
pituitary deficiency	NF-1	0.4346	0.5003	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
epilepsy	SCN1A	0.4345	0.08444	Although SCN1A is considered as the major contributor to the epilepsy phenotype, the role of other sodium channel genes that map within this cluster has not been delineated.	1
opercular syndrome	NF1	0.4344	0.1348	We report on a 10-year-old (molecularly proven) NF1 girl manifesting a complex epileptic syndrome resembling the Foix-Chavany-Marie spectrum (also known as opercular syndrome) associated with bilateral (opercular and paracentral lobular) polymicrogyria (PMG).	-1
CMD	POMT1	0.4344	0.2465	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Dravet syndrome	SCN1A	0.4343	0.1518	Parental mosaicism in another case of Dravet syndrome caused by a novel SCN1A deletion: a case report.	-1
Temple-Baraitser syndrome	KCNH1	0.4342	0.2207	Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy.	-1
infantile spasms	ARX	0.4342	0.07434	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
benign familial neonatal-infantile seizures	SCN2A	0.4342	0.07888	The band 2q24 constitutes the smallest commonly deleted segment in these patients, and contains the voltage-gated sodium channel genes SCN1A and SCN2A, associated with Dravet syndrome and benign familial neonatal-infantile seizures, respectively.	-1
encephalopathies	SCN1A	0.4342	0.09138	Mutations in the SCN1A gene have been identified in a variety of epilepsy phenotypes, from severe encephalopathies such as Dravet syndrome to milder familial forms such as generalized epilepsy with febrile seizures plus.	-1
lissencephaly-pachygyria	LIS1	0.4342	0.1082	Most cases of lissencephaly-pachygyria are caused by mutations of LIS1 and XLIS genes.	-1
CMDs	CMD1A	0.4341	0.1369	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
CMD	laminin alpha-2	0.434	0.06963	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epileptic	neurofibromatosis type 1	0.434	0.3113	Complex epileptic (Foix-Chavany-Marie like) syndrome in a child with neurofibromatosis type 1 (NF1) and bilateral (opercular and paracentral) polymicrogyria.	-1
ADNFLE	CHRNB3	0.434	0.06284	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
ADNFLE	CHRNA7	0.434	0.06284	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
ADNFLE	CHRNB2	0.434	0.06284	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
Dravet syndrome	GPHN	0.434	0.1382	We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome.	-1
acute encephalopathy	SCN1A	0.4339	0.1528	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
amyloid plaques	PrP	0.4339	0.1014	However, histopathological examination revealed unique features: severe extensive spongiform changes with perivacuolar deposits in the cerebrum and basal ganglia, plaque-like PrP deposits in the cerebrum, and only mild changes in the cerebellum with small amyloid plaques (   20    m in diameter), smaller than those in the MV2K subtype or variant CJD (40-50    m in diameter).	-1
seizures	alien	0.4339	0.1673	"We report an unusual presentation of seizures in a 65-year-old woman with a presumed low-grade glioma involving the mesial frontal lobe region, with the ""alien hand"" seen only during a seizure."	-1
partial epilepsy	substance P.	0.4337	0.0517	Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P. Pregabalin can be prescribed in Turkey at 150-600 mg to treat neuropathic pain, generalized anxiety disorder, and fibromyalgia, and as concomitant therapy in adult patients with partial epilepsy.	-1
neurodevelopmental disorders	MECP2	0.4337	0.106	In studies on related neurodevelopmental disorders, a relationship is suggested between the MECP2 gene and autism-related gene, with overlapping pathways, but this is not common to other neurodevelopmental disorders.	-1
PCOS	OR 1.37	0.4336	0.2895	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
SMEI	SCN1A	0.4335	0.2051	Here we report the functional characterization of eight SCN1A mutations (G177E, I227S, R393H, Y426N, H939Q, C959R, delF1289, and T1909I) previously identified in SMEI probands.	-1
neurological deterioration	CRMP5	0.4333	0.08918	After a three-year period of progressive neurological deterioration, a high titre of anti-CV2/CRMP5 antibodies was detected, on the basis of which the clinical syndrome was diagnosed as paraneoplastic.	-1
seizure	CDKL5	0.4332	0.1782	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
seizure	SCN3A	0.4331	0.1553	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
neurodevelopmental disorders	CDKL5	0.4331	0.2676	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
SJS/TEN	HLA-B	0.4331	0.2799	RESULTS: Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS.	-1
cognitive involvement	laminin alpha-2-deficient	0.4331	0.1354	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
infantile multifocal epilepsy	SCN1A	0.4331	0.0773	CONCLUSION: Epilepsies associated with SCN1A mutations range in severity from febrile seizures to severe epileptic encephalopathies including Dravet syndrome and severe infantile multifocal epilepsy.	1
Dravet syndrome	SCN1A	0.433	0.1182	Most Dravet syndrome patients possess heterozygous mutations of SCN1A gene encoding voltage-gated sodium channel aI subunit (Nav1.1).	-1
A	PEHO-like	0.433	0.2077	A PEHO-like syndrome has been described, in which the affected individuals have neither optic atrophy nor the typical neuroradiological findings.	-1
developmental disorder	IL-6	0.4329	0.1042	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
Miller-Dieker syndrome	Classical (type I) lissencephaly	0.4329	0.2204	Classical (type I) lissencephaly and Miller-Dieker syndrome.	-1
CHF	ARPKD	0.4329	0.511	METHODS: A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.	-1
epileptic	MECP2	0.4329	0.03789	Moreover, the definition of a more specific epileptic phenotype could be useful in order to suspect MECP2 duplication syndrome in older undiagnosed patients.	1
Dravet syndrome	SCN1A	0.4329	0.194	METHODS: Seventy-two patients diagnosed with Dravet syndrome or generalized epilepsy with febrile seizure plus, carrying SCN1A mutations or not, were included.	-1
L-CMD	POMT1	0.4328	0.1959	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
myoclonus	SCA-14	0.4328	0.1421	This case illustrates that both myoclonus and dystonia are part of the clinical spectrum in SCA-14 and that myoclonus can even be the presenting symptom.	-1
Rett syndrome	cyclin-dependent kinase-like 5	0.4328	0.132	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
isolated lissencephaly	LIS1	0.4328	0.1162	LIS1 is the deleted gene within this region and is thought to directly cause isolated lissencephaly sequence and contribute to Miller-Dieker syndrome.	-1
autism spectrum disorder	MBD5	0.4327	0.184	Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder.	-1
febrile seizures	GABRD	0.4327	0.08167	In fact, mutations or genetic variations of the genes encoding the a1, a6, b2, b3, y2, or    subunits (GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) have been associated with human epilepsy, both with and without febrile seizures.	-1
renal abnormalities	HNF1B	0.4326	0.1968	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
epileptic seizures	ACMSD	0.4325	0.1738	Due to the previous association of ACMSD deficiency with the development of epileptic seizures, we concluded that the identified nonsense mutation in the ACMSD gene, which encodes for a critical enzyme of the kynurenine pathway of the tryptophan metabolism, is the disease-segregating mutation most likely to be responsible for the phenotype described in our family.	-1
CDG-I	CDG-II	0.4325	0.251	Neonatal findings and clinical features in the first months of life were studied in 36 children with CDG-I and 22 with CDG-II.	-1
Alpers-Huttenlocher-syndrome	LBSL	0.4325	0.08205	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
CMDs	CMD1D	0.4325	0.223	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
Disclosed anomalies	neurofibromatosis type 1	0.4324	0.1011	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
developmental delay	MECP2	0.4324	0.0717	Furthermore, a complex duplication spanning of the MECP2 gene was identified in two brothers who presented with developmental delay and intellectual disability.	-1
seizure	Nav1.1	0.4323	0.3049	Febrile temperatures unmask biophysical defects in Nav1.1 epilepsy mutations supportive of seizure initiation.	-1
X-chromosome duplications	MECP2	0.4323	0.06237	Xq28, which includes MECP2 is the major locus for submicroscopic X-chromosome duplications, whereas duplications in Xq25 and Xq26 have been reported in only a few cases.	-1
Dravet syndrome	SCN1A	0.4322	0.2999	De novo SCN1A mutations in Dravet syndrome and related epileptic encephalopathies are largely of paternal origin.	-1
epileptic encephalopathy	biotinidase	0.4321	0.386	The authors present a rare case of this type of epileptic encephalopathy in which a treatable metabolic condition such as biotinidase deficiency was suspected and diagnosed, and early institution of appropriate therapy led to a good clinical outcome.	-1
benign familial neonatal convulsions	KCNQ2	0.432	0.1564	In 1998, mutations in the voltage gated potassium channel gene KCNQ2 were found to be the main cause underlying the autosomal dominant inherited syndrome of benign familial neonatal convulsions (BFNC).	-1
severe mental retardation	MECP2	0.432	0.2764	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
epilepsy-related	SCN1A	0.432	0.1014	Suggestive evidence for an association with GGEs was found in the region 2q24.3 (rs11890028, P(meta) = 4.0   10(-6)) nearby the SCN1A gene, which is currently the gene with the largest number of known epilepsy-related mutations.	1
generalized epilepsies	SCN1A	0.432	0.1606	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
autoimmune polyglandular disease	PWP2H	0.4319	0.1883	In conclusion, the map location and the homology to a gene family involved in a large variety of biological processes including signal transduction and development make PWP2H an intriguing candidate for EPM1 as well as for APECED (autoimmune polyglandular disease) and HPE1 (holoprosencephaly-1) that also map in this region of chromosome 21.	-1
cognitive impairment	Scn1a	0.4319	0.3077	Focal Scn1a knockdown induces cognitive impairment without seizures.	-1
Dravet syndrome	N-CLB	0.4318	0.1434	AIM: The aim of this study was to describe the pharmacokinetics of clobazam and its active metabolite N-desmethylclobazam (N-CLB) in children with Dravet syndrome receiving the stiripentol/valproic acid/clobazam combination therapy of reference and to determine the concentrations of clobazam and N-CLB obtained in this population for the usual 0.2 mg/kg twice-daily dose.	-1
spasms	neurofibromatosis type 1	0.4318	0.1668	On the other hand, response to these drugs was correlated with some clinical findings in symptomatic cases; all infants with neurocutaneous syndrome (tuberous sclerosis, neurofibromatosis type 1) had controlled infantile spasms, while none of patients with severe neonatal asphyxia or with prior other seizures responded.	-1
DOORS syndrome	TBC1D24	0.4318	0.2446	18 families had individuals with all five main features of DOORS syndrome, and TBC1D24 mutations were identified in half of these families.	-1
LGS	SCN1A	0.4318	0.1692	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
IBD	FKBP14	0.4317	0.1078	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
toxicity	LDP	0.4316	0.1196	DISCUSSION: Exposure to LDP can cause significant toxicity, particularly in infants and toddlers.	-1
epileptic syndrome	KCNQ2	0.4316	0.03572	We here provide information regarding the in vivo distribution and biochemical characteristics of human brain KCNQ2 and KCNQ3, two channel subunits that form M-channels when expressed in vitro, and, when mutated, cause the dominantly inherited epileptic syndrome, benign neonatal familial convulsions.	1
benign familial neonatal convulsions	KCNQ2/3	0.4316	0.08628	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
agranulocytosis	granulocyte colony-stimulating factor	0.4314	0.08813	High-dose steroid therapy for the former symptoms of AHS, and immunoglobulin, granulocyte colony-stimulating factor, and cefepime for the latter agranulocytosis were successfully performed.	-1
Rett syndrome	MECP2	0.4313	0.2248	METHODS: We used the British Isles Rett syndrome survey to identify 137 subjects with one of the nine most frequent MECP2 gene mutations and invited their parents or carers to participate in a postal questionnaire and telephone interview.	-1
Rett Syndrome	MECP2	0.4312	0.3504	Since the discovery of mutations in the methyl-CpG binding protein-2 (MECP2) gene in Rett Syndrome (RTT) a large number of females have been diagnosed worldwide.	-1
long QT syndrome	KCNQ3	0.4312	0.3709	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
TSE	PRNP	0.4312	0.138	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
CMD	POMGNT1	0.4312	0.1506	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
ADNFLE	CHRNA3	0.4312	0.06089	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
GEFS	SCN1A	0.4311	0.1043	(2) A samesense mutation (c. 1212A > G) of SCN1A gene was found in the proband and an unaffected individual of pedigree B of GEFS.	-1
Mucopolysaccharidosis I	alpha-L-iduronidase	0.4311	0.07037	Mucopolysaccharidosis I is a metabolic disease of autosomal recessive inheritance caused by deficient activity of alpha-L-iduronidase.	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	HMGCS2	0.4311	0.1887	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
febrile seizure	SCN1A-related	0.431	0.1721	In this review we describe the genetic advances in progressive myoclonus epilepsies, which are strictly monogenic disorders, genetic generalized epilepsies, mostly exhibiting complex genetic inheritance, and SCN1A-related phenotypes, namely genetic generalized epilepsy with febrile seizure plus and Dravet syndrome.	-1
DS	SCN1A	0.431	0.04354	PURPOSE: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients.	-1
West/Ohtahara syndromes	ARX-related	0.4309	0.2325	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
HH	GLI3	0.4309	0.1896	Additionally, resequencing and fine mapping with SNP genotyping were completed for the GLI3 gene with comparisons between peripheral blood and HH tissue pairs.	-1
seizure	prion protein	0.4308	0.06132	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	-1
ADNFLE	CHRNA5	0.4308	0.06268	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
ADNFLE	CHRNA4	0.4308	0.06268	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
ADNFLE	CHRNA6	0.4308	0.06268	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
HH syndrome	interleukin-6	0.4307	0.1303	We measured both plasma and cerebrospinal fluid cytokine levels in a girl with HH syndrome, and found elevated plasma concentrations of soluble interleukin-2 receptor and tumor necrosis factor-alpha, and a slightly increased plasma level of interleukin-6.	-1
epileptic encephalopathy	SCN1A	0.4307	0.1511	Dravet syndrome (DS) is a genetically determined epileptic encephalopathy mainly caused by de novo mutations in the SCN1A gene.	1
epilepsy	SCN1A	0.4306	0.05853	These results provide a deeper level of understanding of mutant SCN1A dysfunction in an inherited epilepsy syndrome, which will enable more precise computational studies of abnormal neuronal activity in epilepsy and may help guide new targeted therapeutic strategies.	1
generalized epilepsy	SCN1A	0.4306	0.4688	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
seizure disorder	SCN1A-related	0.4306	0.3875	The proportion of cases caused by de novo mutation varies by phenotype: the percentage of probands with an SCN1A-related seizure disorder and an affected parent decreases as the severity of the phenotype in the proband increases; thus, most SCN1A-related SMEI and ICE-GTC are the result of de novo mutation.	1
cardiac arrhythmia	SCN1A	0.4306	0.2724	CONCLUSIONS: Our patient supports the hypothesis that SCN1A mutation might have a role as a common substrate to both epilepsy and cardiac arrhythmia.	-1
epilepsy	MECP2	0.4305	0.3811	The aim of the study is to describe the electroclinical features of epilepsy in MECP2 duplication patients in order to refine the epilepsy phenotype and its evolution.	1
sporadic CJD	PrP	0.4305	0.5071	Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.	-1
Epileptic	Spin	0.4305	0.2465	Epileptic Ictal Hyperperfusion on Arterial Spin Labeling Perfusion and Diffusion-Weighted Magnetic Resonance Images in Posterior Reversible Encephalopathy Syndrome.	-1
MERRF syndrome	COII/tRNA	0.4305	0.1942	High prevalence of the COII/tRNA(Lys) intergenic 9-bp deletion in mitochondrial DNA of Taiwanese patients with MELAS or MERRF syndrome.	-1
myoclonic epilepsy	SCN1A	0.4305	0.019	Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic syndrome that is caused by mutations in the neuronal voltage-gated sodium channel alpha1 subunit gene SCN1A.	-1
mucosal involvement	HLA-B	0.4304	0.1323	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.	-1
seizures	laminin alpha-2-deficient	0.4304	0.12	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
autistic	SCN1A	0.4304	0.1395	BACKGROUND: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the a-subunit of the voltage-gated sodium channel Na(v)1.1.	-1
SFS	TIMP-1	0.4303	0.03424	Serum TIMP-1 levels in AEPFS patients were significantly lower than those in PFS, SFS, CSE and West syndrome patients and in controls.	-1
HD-like	IT15	0.4302	0.03612	Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline, behavioural abnormalities and progressive disease course proves negative to the genetic testing for HD causative mutations, that is, IT15 gene trinucleotide-repeat expansion.	-1
SVT	JAK2	0.4301	0.3596	No clear explanation has been given for the occurrence of thrombosis in this unusual site in patients with ET, but the existence of a specific association between unexplained SVT and the JAK2 mutation has been reported.	-1
epileptic	CLB	0.4301	0.2356	We insist on the role of some anti epileptic drugs in triggering the problem and withdrawal of these drugs as the most important aspect of the treatment of these complications replacing them by CLB in all cases.	-1
seizures	NF1	0.4301	0.2685	Individuals with seizures and NF1 typically require more aggressive therapy than those without NF1 and should be considered for epilepsy surgery when appropriate.	-1
epilepsy and neonatal diabetes	ABCC8	0.4301	0.3823	We identified a novel heterozygous mutation, F132L, in the ABCC8 gene of a patient with severe developmental delay, epilepsy and neonatal diabetes (DEND syndrome).	-1
DS	SCN1A	0.43	0.2758	Abnormalities of the sodium channel gene SCN1A are found in 75% of DS patients.	-1
peripheral edema	PEHO	0.43	0.1469	PEHO syndrome (progressive encephalopathy, peripheral edema, hypsarrhythmia, and optic atrophy) is a neurodegenerative disorder first characterized in Finnish patients.	-1
Rett syndrome	MECP2	0.43	0.2135	[Mutation spectrum and genotype-phenotype correlation of MECP2 in patients with Rett syndrome].	-1
Angelman syndrome	OCA2	0.4299	0.2854	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
Seizures	SCN1A-related	0.4298	0.2578	Seizures in children with SCN1A-related Dravet syndrome occurred more often with a body temperature below 38.5  C (57.9% vs. 32.6%, p=0.020) and reoccurred more often after following vaccinations (26.7% vs. 4.0%, p=0.003), than in children without a diagnosis of SCN1A-related Dravet Syndrome.	-1
disease progression	ATP13A2	0.4297	0.2126	There was no significant correlation between DNA methylation of the ATP13A2 promoter region and disease progression.	-1
SMEI	laforin	0.4297	0.1694	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
epilepsy	MECP2	0.4297	0.04763	Further, vBMAD(neck) was significantly associated to a diagnosis of epilepsy, antiepileptic treatment, and MECP2 mutation group, but none of the associations with vBMAD(neck) remained clinically significant in a multiple adjusted model including age and BMI.	1
seizures	TCF4	0.4296	0.1058	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
meningeal syndrome	CSF	0.4296	0.3595	Side-effects were mild, lasting up to 7 days: cephalea, meningeal syndrome with sterile CSF in three subjects, and CSF leak lasting up to 3 days in seven subjects.	-1
Lafora disease	CLN5	0.4295	0.1242	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
syndrome	SCN1A	0.4295	0.3335	Low incidence of SCN1A genetic mutation in patients with hemiconvulsion-hemiplegia-epilepsy syndrome.	1
idiopathic neonatal epilepsy	Kv7.4	0.4295	0.3325	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
Rett Syndrome	methyl-CpG binding protein-2	0.4295	0.3584	Since the discovery of mutations in the methyl-CpG binding protein-2 (MECP2) gene in Rett Syndrome (RTT) a large number of females have been diagnosed worldwide.	-1
seizures	MECP2	0.4295	0.1108	CONCLUSIONS: Early onset of seizures is linked to the combined MECP2 and BDNF genotypes.	-1
a	PEHO-like	0.4294	0.2573	We describe two sisters with a PEHO-like syndrome.	-1
neurological deterioration	anti-CV2	0.4294	0.0843	After a three-year period of progressive neurological deterioration, a high titre of anti-CV2/CRMP5 antibodies was detected, on the basis of which the clinical syndrome was diagnosed as paraneoplastic.	-1
Panayiotopoulos syndrome	SCN1A	0.4294	0.1941	Panayiotopoulos syndrome: probable genetic origin, but not in SCN1A.	-1
fetal valproate syndrome	ascl1b/Ascl1	0.4294	0.1657	Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome.	-1
infantile spasms	CDKL5	0.4293	0.09042	Generalized intractable seizures, as infantile spasms, and generalized tonic-clonic seizures and myoclonic seizures characterize the clinical picture of CDKL5 mutations.	-1
hypertrophic cardiomyopathy	CoQ2	0.4293	0.1255	CONCLUSIONS: In contrast to previously reported patients with CoQ2 the proband presented with early myoclonic epilepsy, hypertrophic cardiomyopathy and only in a later stage developed a nephrotic syndrome.	-1
aphasia	MEG	0.4293	0.1693	A high-dose corticosteroid was effective, with disappearance of ECDs, appearance of auditory evoked fields (AEF) in the bilateral Heschl gyri on MEG, and improvement of behavioral problems and amelioration of acquired aphasia.	-1
IGE	KCNQ2	0.4292	0.1614	In KCNQ2, a silent single nucleotide polymorphism (rs1801545) was found overrepresented in both epilepsy samples (IGE, p = 0.004).	-1
Prader-Willi/Angelman	OCA2	0.4292	0.1753	Hexasomy of the Prader-Willi/Angelman critical region, including the OCA2 gene, in a patient with pigmentary dysplasia: case report.	-1
severe mental retardation	STK9	0.4292	0.3203	Mutations in the CDKL5 gene (also known as STK9) have recently been shown to cause early onset epilepsy and severe mental retardation (ISSX or West syndrome).	-1
CMD	POMT2	0.4291	0.127	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
febrile seizures	SCN1B	0.429	0.2522	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
metabolic disease	alpha-L-iduronidase	0.429	0.1008	Mucopolysaccharidosis I is a metabolic disease of autosomal recessive inheritance caused by deficient activity of alpha-L-iduronidase.	-1
ISs	MAGI2	0.4289	0.4062	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
autosomal MBD family members	MBD6	0.4289	0.5129	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
convulsion	FCMD	0.4288	0.2155	The familial FCMD patients showed relatively more severe motor disability than that in the sporadic FCMD patients, while in mental and convulsion states no significant difference was found in both groups.	-1
Cognitive impairment	laminin alpha-2-deficient	0.4287	0.116	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
RS	MECP2	0.4287	0.2292	When faced with a diagnosis of RS with no alterations in the MECP2 and CDKL5 genes, especially in the case of the congenital variant, the FOXG1 gene must be investigated.	-1
hypoplasia	MECP2	0.4285	0.08421	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
Unverricht-Lundborg disease	EBN2	0.4283	0.05164	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
neurocognitive decline	SCN1A	0.4283	0.3307	Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes.	-1
DRE	MECP2	0.4282	0.1384	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
respiratory infections	methyl CpG-binding protein 2	0.4282	0.276	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
long QT syndrome	KCNQ2/3	0.428	0.3526	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
fever	CSF	0.428	0.1994	Viral encephalitis causes an altered level of consciousness, which may be associated with fever, seizures, focal deficits, CSF pleocytosis, and abnormal neuroimaging.	-1
epileptic aphasia	SLK	0.4279	0.5308	The dysphasia of development and epilepsy may be associated by chance, as a result of the same cause or the epilepsy be responsible for the TC, either because of seizures or continuously (acquired epileptic aphasia, SLK).	-1
generalized epilepsy with febrile	SCN1A	0.4279	0.1259	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	-1
AHS	caspase-9	0.4279	0.1368	Both AHS iPSCs-Hep are more sensitive to VPA-induced mitochondrial-dependent apoptosis than controls, showing more activated caspase-9 and cytochrome c release.	-1
epilepsies	SCN2A	0.4279	0.114	Mutations in SCN2A, the gene encoding a2 subunit of the neuronal sodium channel, are associated with a variety of epilepsies: benign familial neonatal-infantile seizures (BFNIS); genetic epilepsy with febrile seizures plus (GEFS+); Dravet syndrome (DS); and some intractable childhood epilepsies.	1
Lennox-Gastaut syndrome	PUFA-enriched	0.4278	0.2467	Here, we report a 7-year-old boy with Lennox-Gastaut syndrome combined with mitochondrial respiratory chain complex I deficiency, whose medically intractable seizures have been successfully controlled with a PUFA-enriched modified Atkins diet without any significant adverse events.	-1
RE	ATP13A4	0.4278	0.03391	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
epileptic encephalopathy	gephyrin	0.4277	0.2859	Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy.	-1
ketotic hyperglycinemia	P-protein	0.4276	0.113	Non ketotic hyperglycinemia is a rare inborn error of glycine metabolism due to deficient activity of glycine cleavage system, a multienzymatic complex consisting of four protein subunits: the P-protein, the H-protein, the T-protein and the L-protein.	-1
epilepsies	SCN1A	0.4276	0.2282	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	1
myoclonic epilepsies	SCN1A	0.4276	0.1086	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
ID	NR2B	0.4276	0.04268	The patient with ID and focal epilepsy had a missense mutation in the extracellular glutamate-binding domain (p.Arg540His), whereas both West syndrome patients carried missense mutations within the NR2B ion channel-forming re-entrant loop (p.Asn615Ile, p.Val618Gly).	-1
AMRF	LIMP-2	0.4275	0.2055	With the present study, we demonstrate that disruption of the coiled-coil structure or AMRF disease-causing mutations abolish beta-GC binding, indicating the importance of an intact coiled-coil structure for the interaction of LIMP-2 and beta-GC.	-1
limbic encephalitis	GluN2B	0.4274	0.2256	In patient with non-paraneoplastic, non-herpetic acute limbic encephalitis (NHALE), antibodies against GluN2B (GluR  2) and GluN1 (Glu  1) are detected in the sera and CSF.	-1
symptomatic epilepsy	neurofibromatosis type 1	0.4274	0.2676	The association of brain malformations and symptomatic epilepsy in the setting of neurofibromatosis type 1 (NF1) is rarely reported.	-1
Dravet syndrome	SCN1A	0.4274	0.3896	Brain magnetic resonance imaging (MRI) studies in patients with Dravet syndrome and SCN1A mutations have shown abnormal findings in a small minority of patients.	-1
Alzheimer's disease	Abeta	0.4273	0.1045	These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.	-1
epilepsy	LIS1	0.4273	0.1703	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
Bartter syndrome	cystathionine beta-synthase	0.4273	0.2121	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
epilepsy	LIS1	0.4273	0.4243	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
generalized epilepsy	SCN1B	0.4272	0.379	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
immune dysregulation	IPF1	0.4272	0.6729	Moreover, FOXP3 and IPF1 mutations were analyzed in a patient with immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome and with pancreatic agenesis, respectively.	-1
MERRF	prohibitin	0.4272	0.07463	Recently, we showed that the excess ROS could damage voltage-dependent anion channel, prohibitin, Lon protease, and aconitase in the MERRF cells.	-1
demyelination	MRI	0.4272	0.1282	The MRI features of some lesions such as FCD may differ in infants compared to children and adults; the white matter adjacent to FCD may demonstrate lower T2 and higher T1 signal in some infants due to premature myelination, while in others, the white matter demonstrates higher T2 or lower T1 signal due to demyelination, dysmyelination or gliosis, similar to children and adults.	-1
progressive myoclonic epilepsy	SCN1A	0.4271	0.1278	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
renal abnormalities	HNF1B	0.427	0.1155	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
autosomal recessive congenital hyperinsulinism	SUR1	0.427	0.1147	There was homozygous mutation in the ABCC8 gene encoding SUR1, which confirmed the diagnosis of autosomal recessive congenital hyperinsulinism.	-1
epilepsy	LIS1	0.427	0.2002	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
cancer	STK11	0.427	0.1769	BACKGROUND: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene.	-1
epilepsy	MEDS	0.4269	0.1567	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	1
Smith-Lemli-Opitz syndrome	FKBP14	0.4268	0.2257	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	GABRA1	0.4266	0.1289	MATERIALS AND METHODS: We investigated the association of single-nucleotide polymorphisms in GABA(A) receptor subunit subtype genes namely; rs2279020 (GABRA1), rs3219151 (GABRA6), rs2229944 (GABRB2), and rs211037 (GABRG2) with predisposition to epilepsy and AED resistance.	1
epileptic syndrome	KCNQ2	0.4266	0.1625	Recently, mutations of potassium channel genes (KCNQ2, KCNQ3) were identified as responsible for this autosomic dominant epileptic syndrome.	1
neonatal diabetes	SUR1	0.4265	0.3828	As SUR1 is expressed in neurones as well as in beta cells, this mutation can account for both neonatal diabetes and the neurological phenotype.	-1
infantile spasms	CDKL5	0.4265	0.06227	CONCLUSIONS: Mutations in CDKL5 gene are responsible for 7 with Hanefeld variants of RTT and 2 with early-onset epileptic encephalopathy in 71 girls as well as for 1 infantile spasms in 31 males.	-1
LTE	KCNAB1	0.4264	0.3918	We investigated association between polymorphic variants across the KCNAB1 gene and LTE.	-1
inflammation	A beta	0.4264	0.2132	These data add to evidence that inflammation against A beta can cause vascular dysfunction, a potential mechanism for the toxic response recently observed in clinical trials of A beta immunization.	-1
RTT	MECP2	0.4264	0.1258	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
KS	PROK2	0.4264	0.1142	Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation.	-1
Rett syndrome	SCN1A	0.4263	0.1492	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
SMEI	SCN1A-related	0.4263	0.3066	The proportion of cases caused by de novo mutation varies by phenotype: the percentage of probands with an SCN1A-related seizure disorder and an affected parent decreases as the severity of the phenotype in the proband increases; thus, most SCN1A-related SMEI and ICE-GTC are the result of de novo mutation.	-1
guanidinoacetate methyltransferase deficiency	SLC6A8	0.4263	0.2295	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
intellectual disability	TRMT10A	0.4262	0.2876	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
Rasmussen syndrome	GluA3	0.4262	0.2974	In Rasmussen syndrome, antibodies against GluA3 (GluR3) were found to be the primary pathological factor.	-1
malformations	mTOR	0.4261	0.06463	The mammalian target of rapamycin (mTOR) signaling pathway is activated in several disorders associated with benign tumors and malformations of the cerebral cortex.	-1
MELAS	cytochrome oxidase	0.4261	0.1773	In two patients with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were observed, and A3243G mutations were found from the muscle samples.	-1
febrile seizures	SCN1A	0.4261	0.05748	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
seizure-related	guanidinoacetate methyltransferase	0.4261	0.2506	AIM: Describe the seizure-related manifestations of guanidinoacetate methyltransferase (GAMT) deficiency in two new cases and compare these to the related literature.	-1
DS	Na(V)1.1	0.426	0.3285	We studied the effect of two DS truncated Na(V)1.1 mutants, R222* and R1234*, on coexpressed wild-type Na(+) channels.	-1
myotonia	SCN4A	0.426	0.09794	A patient with cold-aggravated myotonia did not harbour any of the common SCN4A mutations.	-1
encephalopathy	3-phosphoglycerate dehydrogenase	0.4259	0.07972	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
autosomal MBD family members	SETDB1	0.4259	0.322	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
Dravet syndrome	SCN1A	0.4258	0.08257	Dravet syndrome (DS) is a genetically determined epileptic encephalopathy mainly caused by de novo mutations in the SCN1A gene.	-1
neonatal diabetes	SUR1	0.4258	0.1554	The functional consequence of this ABCC8 mutation mirrors that of KCNJ11 mutations causing neonatal diabetes and provides new insights into the interaction of Kir6.2 and SUR1.	-1
autosomal MBD family members	MECP2	0.4256	0.1313	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
neurological disorders	neurofibromatosis-1	0.4256	0.3	Several paediatric neurological disorders such as neurofibromatosis-1, Fragile X syndrome, Rett syndrome, and other syndromic and non-specific forms of mental retardation involve lesions in these signalling pathways.	-1
hypoplasia of the corpus callosum	MECP2	0.4256	0.1505	In addition, large duplications, including MECP2 and GDI1, induce hypoplasia of the corpus callosum.	-1
Panayiotopoulos syndrome	SCN1A	0.4255	0.3989	We report 2 families harboring a novel SCN1A mutation, one of whom had Panayiotopoulos syndrome and the other a phenotype consistent with generalized epilepsy with febrile seizures plus.	-1
rigid spine syndrome	ISPD	0.4255	0.1564	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
neuropsychiatric illness	MECP2	0.4255	0.04851	BACKGROUND: Duplications of the X-linked MECP2 gene are associated with moderate to severe intellectual disability, epilepsy, and neuropsychiatric illness in males, while triplications are associated with a more severe phenotype.	-1
epileptic	CYP2C19	0.4254	0.1635	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2 and CYP2C19 in vivo in epileptic patients.	1
Wolcott-Rallison syndrome	MEDS	0.4254	0.04526	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
RE	GRIN2A	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	CDH13	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	CTNNA3	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	CNTNAP2	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	CDH9	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	MDGA2	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
RE	DIAPH3	0.4254	0.01119	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
epilepsies	SCN1A	0.4252	0.08209	Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies.	1
hearing loss	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4251	0.07698	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Rett (	MECP2	0.4251	0.313	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
NLS	Importin 13	0.4251	0.09184	The NLS regions are required for correct nuclear import facilitated by Importin 13 (IPO13).	-1
benign familial neonatal convulsions	EBN2	0.425	0.2335	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
myoclonic seizures	SCN1A	0.4249	0.09699	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
Dravet syndrome	Nav1.1	0.4249	0.1063	Most Dravet syndrome patients possess heterozygous mutations of SCN1A gene encoding voltage-gated sodium channel aI subunit (Nav1.1).	-1
dysfibrinogenemia	fibrinogen	0.4249	0.3085	Details are follows: 1) decreased synthesis: 26 patients, suspected of decreased synthesis (albumin: 3.1-3.4 g/dl): 4 patients, 2) increased consumption: 15 patients, suspected of increased consumption (FDP D-dimer: 5.0-9.9 g/dl): 1 case, 3) decreased synthesis combined with increased consumption: 24 patients, suspected of decreased synthesis and/or suspected of increased consumption: 14 patients, 4) side-effect of L-asparaginase administration: 24 patients, 5) heterozygous dysfibrinogenemia: 1 patient, 6) heterozygous fibrinogen deficiency: 1 patient, suspected of heterozygous fibrinogen deficiency: 1 patient, 7) unidentified: 2 patients with West syndrome treated with a combination of ACTH and valproic acid.	-1
encephalopathy	PEHO	0.4249	0.1525	The PEHO syndrome (progressive encephalopathy, hypsarrhythmia and optic atrophy) is a rare, autosomal recessive, encephalopathy of infancy.	-1
epilepsy	glutamate/AMPA receptor subtype 3	0.4249	0.2332	"Autoantibodies (Ab's) to the ""B"" peptide (amino acids 372-395) of glutamate/AMPA receptor subtype 3 (GluR3) are found in serum and cerebrospinal fluid of some patients with different types of epilepsy."	-1
Coffin-Siris syndrome	BAF	0.4248	0.2295	Numerous BAF complex genes are mutated in Coffin-Siris syndrome.	-1
guanidinoacetate methyltransferase deficiency	SLC6A8	0.4248	0.2207	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
dystroglycanopathies	POMT2	0.4248	0.2988	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizures	biotinidase	0.4248	0.2315	Rarely, infantile spasms in association with biotinidase deficiency, phenylketonuria, and pyridoxine-dependent seizures are successfully treated with biotin, a low phenylalanine diet, and pyridoxine, respectively.	-1
MDS	MECP2	0.4247	0.3636	To date, no data on oxidative stress have been reported for the MECP2 gain-of-function mutations in patients with MDS.	-1
MAE	SCN1A	0.4245	0.1505	One novel Dravet syndrome causing mutation and one recurrent MAE causing mutation in SCN1A gene.	-1
Borjeson-Forssman-Lehmann syndrome	PHF6	0.4245	0.08956	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
L-CMD	ISPD	0.4244	0.09366	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
ischemia	neurokinin B	0.4243	0.1448	The utero-placental ischemia causes the release of certain molecules such as neurokinin B, inflammatory cytokines, endothelins, and tissue plasminogen activator.	-1
autism spectrum disorders	MECP2	0.4243	0.1389	The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations.	-1
Dravet syndrome	SCN1A	0.4243	0.1013	CONCLUSION: Epilepsies associated with SCN1A mutations range in severity from febrile seizures to severe epileptic encephalopathies including Dravet syndrome and severe infantile multifocal epilepsy.	-1
CCA	ARPKD	0.4242	0.07238	Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years).	-1
autism	MeCP2	0.4242	0.2952	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
Dravet syndrome	SCN3A	0.4241	0.2465	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	-1
Sturge-Weber syndrome	GNAQ	0.424	0.07334	The underlying somatic mosaic mutation causing both Sturge-Weber syndrome and isolated port-wine birthmarks was recently discovered and is an activating mutation in GNAQ.	-1
West syndrome	ALG13	0.424	0.1929	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
seizures	SCN2A	0.424	0.1316	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	-1
convulsions	SCN1A	0.4239	0.218	The lack of association between febrile convulsions and polymorphisms in SCN1A.	-1
RS	CDKL5	0.4239	0.1456	When faced with a diagnosis of RS with no alterations in the MECP2 and CDKL5 genes, especially in the case of the congenital variant, the FOXG1 gene must be investigated.	-1
epilepsy	CA4	0.4239	0.1743	Furthermore, greater SG widths correlated with lower hilar and CA4 neuron densities, but not with age at first seizure or duration of epilepsy.	1
seizure	GAMT	0.4239	0.07335	Based on a literature search, we found that the clinical picture of GAMT deficiency has been described in a total of 58 cases, including our two patients, 45 of whom had at least some description of EEG and/or seizure manifestation.	-1
lactic acidosis	COX1	0.4238	0.1645	A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis.	-1
epilepsy	MECP2	0.4238	0.1805	We report a novel C-terminal MECP2 frameshift deletion (1135_1142delCCCGTG CC) in a 19-year-old woman with mental retardation and epilepsy.	1
seizures	PTEN	0.4238	0.1385	We report the case of a girl with Cowden syndrome (CS) presenting with unilateral perisylvian dysplasia and with drug resistant focal seizures carrying a novel missense mutation 385G>A (G129R) in the PTEN gene.	-1
Dravet syndrome	NaV1.1	0.4237	0.01012	Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare genetic epilepsy syndrome commonly associated with loss-of-function mutations in SCN1A, the gene encoding the a subunit of the voltage-gated sodium channel NaV1.1, resulting in haploinsufficiency.	-1
Dravet syndrome	SCN1A	0.4237	0.1046	BACKGROUND Mutations in SCN1A can cause genetic epilepsy with febrile seizures plus (GEFS+, inherited missense mutations) or Dravet syndrome (DS, de novo mutations of all types).	-1
febrile seizures	SCN1A	0.4236	0.1519	We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation.	-1
intellectual disability	KANSL1	0.4235	0.2418	The degree of intellectual disability (ID) appears to be milder than expected in a considerable number of subjects with either chromosome deletion or KANSL1 mutation.	-1
Walker-Warburg syndrome	FCMD	0.4235	0.1585	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
BFNIE	SCN2A	0.4235	0.0857	Mutations in SCN2A have been identified in patients with benign familial neonatal-infantile epilepsy (BFNIE), generalised epilepsy with febrile seizures plus (GEFS+), and a small number of reported cases of other infantile-onset severe intractable epilepsy.	-1
seizures	ANKH	0.4235	0.09586	Autosomal dominant early childhood seizures associated with chondrocalcinosis and a mutation in the ANKH Gene.	-1
nephrotic syndrome	CoQ2	0.4234	0.1891	CONCLUSIONS: In contrast to previously reported patients with CoQ2 the proband presented with early myoclonic epilepsy, hypertrophic cardiomyopathy and only in a later stage developed a nephrotic syndrome.	-1
BFNC	EPM1	0.4233	0.1899	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
autoimmune polyglandular disease	APECED	0.4233	0.3213	In conclusion, the map location and the homology to a gene family involved in a large variety of biological processes including signal transduction and development make PWP2H an intriguing candidate for EPM1 as well as for APECED (autoimmune polyglandular disease) and HPE1 (holoprosencephaly-1) that also map in this region of chromosome 21.	-1
ADPEAF	LGI3	0.4233	0.1772	ADPEAF is genetically heterogeneous, but mutations in LGI2, LGI3, or LGI4 did not account for families without LGI1 mutations.	-1
Rett syndrome	MECP2	0.4233	0.0628	Rett syndrome is a genetic neurodevelopmental disorder that affects mainly girls, but mutations in the causative MECP2 gene have also been identified in boys with classic Rett syndrome and Rett syndrome-like phenotypes.	-1
IBD	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4232	0.1435	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
febrile seizures	SCN1A	0.4232	0.1768	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
ILS	PAFAH1B1	0.4232	0.09251	BACKGROUND: Genetic aberrations in PAFAH1B1 result in isolated lissencephaly sequence (ILS), a neuronal migration disorder associated with severe mental retardation and intractable epilepsy.	-1
epilepsy	endostatin	0.423	0.1387	Despite the small sample size, we found low endostatin plasma levels in those patients with mutations leading to deficiency of all isoforms; in addition, it seems that absence of all collagen XVIII isoforms causes predisposition to epilepsy.	-1
Kufor-Rakeb syndrome	ATP13A2	0.423	0.2215	Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations.	-1
tter-T  nz syndrome	EDSKMH	0.4229	0.1366	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	MECP2	0.4229	0.2771	Eight boys with a MECP2 gene duplication and epilepsy were retrospectively studied.	1
autosomal dominant	FGFR1	0.4229	0.3672	It can be confirmed by identification of either an FGFR1 heterozygous pathogenic variant (in those with autosomal dominant inheritance) or FGFR1 biallelic pathogenic variants (in those with autosomal recessive inheritance).	-1
PME	laforin	0.4226	0.238	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
Langer-Giedion syndrome	EXT1	0.4225	0.2203	The deletion included the region for Langer-Giedion syndrome (TRPS1 and EXT1) in the girl only.	-1
epilepsy	LBSL	0.4224	0.04614	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Miller-Dieker Syndrome	LIS1	0.4223	0.1239	Six different genes could be responsible for this entity (LIS1, DCX, TUBA1A, VLDLR, ARX, RELN), although co-delection of YWHAE gene with LIS1 could result in Miller-Dieker Syndrome.	-1
myopathy	ROGDI	0.4223	0.09875	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	EXOC6B	0.4223	0.3215	Disruption of EXOC6B in a patient with developmental delay, epilepsy, and a de novo balanced t(2;8) translocation.	-1
epilepsy	GABRG2	0.4222	0.1305	MATERIALS AND METHODS: We investigated the association of single-nucleotide polymorphisms in GABA(A) receptor subunit subtype genes namely; rs2279020 (GABRA1), rs3219151 (GABRA6), rs2229944 (GABRB2), and rs211037 (GABRG2) with predisposition to epilepsy and AED resistance.	1
Generalized Epilepsy	SCN1A	0.4222	0.1465	Diseases caused by mutations in SCN1A are currently named Genetic Epilepsies with Febrile Seizures Plus, and this term stands for expanded spectrum of syndrome previously called as GEFS+ (Generalized Epilepsy with Febrile Seizures Plus).	-1
Dravet syndrome	SCN1A	0.4222	0.2991	Our genetic testing showed that 1 of 3 (33.3%) patients with clinical Dravet syndrome and 3 of 20 (15%) patients that diagnosed as GEFS+, had SCN1A mutation.	-1
ASD	MBD6	0.4222	0.4356	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
BFNC	KCNQ2	0.4221	0.2678	In a large pedigree with BFNC, a five-base pair insertion would delete more than 300 amino acids from the KCNQ2 carboxyl terminus.	-1
Rett	CDKL5	0.4221	0.5283	Our results also suggest the need of screening for CDKL5 mutations in patients with Rett phenotype tested negative for MECP2 mutations.	-1
intellectual disability	MECP2-containing	0.4221	0.1995	A case report of Chinese brothers with inherited MECP2-containing duplication: autism and intellectual disability, but not seizures or respiratory infections.	-1
West syndrome	LIS1	0.4221	0.3996	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
Seizures	SCN3A	0.4221	0.2004	Seizures recurred at the age of 3 years in the patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
optic atrophy	PEHO	0.422	0.427	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
seizures	SCN1A	0.422	0.08283	SCN1A mutations were found in 12 of the 71 patients (16.9%; ten with DS, and two with seizures in a Generalized Epilepsy with Febrile Seizures+(GEFS+) context).	-1
deficiency disorders	3-phosphoglycerate dehydrogenase	0.4219	0.1647	So far, three serine deficiency disorders have been reported; 3-phosphoglycerate dehydrogenase deficiency, 3-phosphoserine phosphatase deficiency and a still unexplained serine deficiency disorder.	-1
seizures	MBD5	0.4219	0.2132	Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.	-1
myoclonic epilepsy	SCN1A	0.4219	0.1948	His autopsy was unremarkable, but genetic testing revealed a frame shift mutation in SCN1A, consistent with severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
RTT	MECP2	0.4218	0.1121	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
endometrial cancer	AKR1C1	0.4218	0.05675	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
Dravet syndrome	STXBP1	0.4218	0.2007	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	-1
tented mouth	ALP	0.4218	0.06766	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
plus	SCN1A	0.4218	0.25	We describe the five gene loci localized in children with febrile seizures (FEB 1 5), the three genes identified in patients with generalized epilepsy with febrile seizures plus (GEFS+ 1 3) and the de novo mutations of gene SCN1A that have been identified to date in children with SMEI.	-1
seizures	SCN1A	0.4217	0.1568	DS has a genetic etiology: between 70% and 80% of patients carry sodium channel a1 subunit gene (SCN1A) abnormalities, and truncating mutations account for about 40% and have a significant correlation with an earlier age of seizures onset.	-1
West syndrome	GRIN2B	0.4216	0.2172	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
Kufor-Rakeb syndrome	ATP13A2	0.4216	0.2926	We report the clinical features of the original Chilean family with Kufor-Rakeb syndrome (KRS) that led to the discovery of the ATP13A2 gene at the PARK9 locus.	-1
HS	MRI	0.4216	0.272	These twelve patients were compared with twenty-one patients with MTLE with unilateral hippocampal sclerosis (HS) on MRI who underwent intracranial EEG before resection (control group).	-1
CCHS	dopamine-beta-hydroxylase	0.4215	0.06286	We studied three children who had CCHS associated with episodes of severe hypoglycaemia and hyperinsulinaemia; we discuss the possible relationship with impaired dopamine-beta-hydroxylase function.	-1
Dravet syndrome	SCN1A	0.4214	0.4768	CONCLUSIONS: These findings confirm that SCN1A gene mutations are strongly associated to a more severe phenotype in patients with Dravet syndrome.	-1
lissencephaly	ARX	0.4214	0.09058	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
seizures	SCN1A	0.4214	0.2692	We report the first case of musicogenic reflex seizures in a 7-year-old male with a mutation in the SCN1A gene causing Dravet syndrome.	-1
dystroglycanopathies	POMGNT1	0.4214	0.3837	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CPEO syndrome	Mn-SOD	0.4211	0.04735	On the other hand, we observed that the RNA, protein and activity levels of Mn-SOD are increased two- to three-fold in skin fibroblasts of the patients with CPEO syndrome but are dramatically decreased in patients with MELAS or MERRF syndrome.	-1
WS	NF1	0.4211	0.3084	WS with NF1 seems remarkably benign and resembles idiopathic WS more than symptomatic WS.	-1
IS	NF1	0.421	0.3204	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
hypsarrhythmia	PEHO	0.4209	0.1416	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO)-like syndrome: what diagnostic characteristics are defining?	-1
familial neonatal epilepsy	SCN2A	0.4209	0.1902	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
vascular malformations	ELAM-1	0.4208	0.1249	There is an aberrant expression of ELAM-1 and VCAM-1 in the meningeal vascular proliferation similar to what is observed with other vascular malformations and tumors.	-1
myoclonic epilepsies	SCN2A	0.4208	0.1007	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
tinnitus	KCNQ5	0.4208	0.3474	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
inherited syndrome	MECP2	0.4208	0.2286	A family study indicates that this inherited syndrome is most likely due to an unreported MECP2 variant, p.V122A, located in the methyl binding domain of the MECP2 protein.	-1
dyspraxia	SRPX2-related	0.4207	0.1525	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
optic nerve atrophy	PEHO	0.4207	0.3331	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO)-like syndrome: what diagnostic characteristics are defining?	-1
DS	Na(V)1.1	0.4207	0.1392	Therefore, Na(V)1.1 truncated mutants are not dominant negative, consistent with haploinsufficiency as the cause of DS.	-1
epileptiform activity	TRPC3	0.4206	0.05914	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	ACADSB	0.4205	0.1161	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	collagen XVIII	0.4205	0.1549	Despite the small sample size, we found low endostatin plasma levels in those patients with mutations leading to deficiency of all isoforms; in addition, it seems that absence of all collagen XVIII isoforms causes predisposition to epilepsy.	-1
Epilepsy	neurofibromatosis type 1	0.4205	0.2049	Epilepsy in individuals with neurofibromatosis type 1.	-1
gliosis	MRI	0.4204	0.09958	The MRI features of some lesions such as FCD may differ in infants compared to children and adults; the white matter adjacent to FCD may demonstrate lower T2 and higher T1 signal in some infants due to premature myelination, while in others, the white matter demonstrates higher T2 or lower T1 signal due to demyelination, dysmyelination or gliosis, similar to children and adults.	-1
generalized epilepsy	SCN1A	0.4204	0.2533	METHODS: Seventy-two patients diagnosed with Dravet syndrome or generalized epilepsy with febrile seizure plus, carrying SCN1A mutations or not, were included.	-1
LKS	GRIN2A	0.4204	0.2195	We conclude that immunotherapy should be considered as a therapeutic option in patients with LKS who are also found to harbour GRIN2A mutations.	-1
febrile seizures	SCN1A	0.4203	0.1241	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	-1
Muscle-eye-brain disease	CMD1A	0.4202	0.03452	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
deficiency syndrome	SMA	0.4202	0.2199	In this article, the authors report their experience with surgically induced supplementary motor area (SMA) deficiency syndrome in a prospective clinical trial of 28 patients who underwent surgery for tumorous (19 patients) or nontumorous (nine patients) lesions.	-1
idiopathic epilepsy syndromes	KCNQ2	0.4202	0.1745	CONCLUSION: Sequence variations of the KCNQ2 and KCNQ3 genes may contribute to the etiology of common idiopathic epilepsy syndromes.	-1
RTT-like	CDKL5	0.4202	0.1282	We have screened the CDKL5 gene in 94 patients with RTT or a RTT-like phenotype who had tested negative for MECP2 mutations (13 classical RTT female subjects, 25 atypical RTT female subjects, 40 RTT-like female and 16 RTT-like male subjects; 33 of the patients had early onset seizures).	-1
epilepsy	prion protein	0.4202	0.06887	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	1
Dravet syndrome	mTOR	0.4201	0.2591	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
inflammation	A beta	0.4199	0.4102	These data add to evidence that inflammation against A beta can cause vascular dysfunction, a potential mechanism for the toxic response recently observed in clinical trials of A beta immunization.	-1
seizure	GPR98/MASS1	0.4198	0.2507	Haploinsufficiency of GPR98/MASS1 is probably responsible for the seizure phenotype in our patients.	-1
isolated lissencephaly sequence	PAFAH1B1	0.4198	0.1505	BACKGROUND: Genetic aberrations in PAFAH1B1 result in isolated lissencephaly sequence (ILS), a neuronal migration disorder associated with severe mental retardation and intractable epilepsy.	-1
CoQ10 deficiency	COQ2	0.4198	0.2221	Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2).	-1
RSTS	CREBBP	0.4197	0.533	In addition, there are no reports on the analysis of CREBBP mutations in Korean RSTS patients.	-1
Korean Dravet syndrome	SCN1A	0.4197	0.3405	CONCLUSIONS: SCN1A mutational analysis of Korean Dravet syndrome patients resulted in the identification of 15 novel mutations, which could expand the spectrum of SCN1A mutations and confirms the current understanding of genotype-phenotype correlations.	-1
Phelan   McDermid syndrome	KANSL1	0.4197	0.08609	The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan   McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion).	-1
Christianson syndrome	FOXG1	0.4197	0.2633	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
TLE	A beta	0.4196	0.1431	A beta deposition in the form of senile plaques (SPs) has recently been described in patients with temporal lobe epilepsy (TLE).	-1
) syndrome	EHMT1	0.4195	0.08987	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
epilepsy syndrome	SCN1A	0.4195	0.1835	Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations.	1
encephalopathy	SCN1A	0.4194	0.1123	The biochemical and MRI characteristics of this case are different from any known type of encephalopathy, and may suggest a vulnerability of neurons expressing mutant SCN1A in the brain.	-1
seizures	somatostatin	0.4194	0.1612	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	HSD17B10	0.4193	0.1736	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
malformations	mammalian target of rapamycin	0.4193	0.08405	The mammalian target of rapamycin (mTOR) signaling pathway is activated in several disorders associated with benign tumors and malformations of the cerebral cortex.	-1
Dravet syndrome	SCN1A	0.4193	0.1845	CONCLUSIONS: These cases confirm parental mosaicism in the transmission of Dravet syndrome and add to the spectrum of known mutations of the SCN1A gene.	-1
myoclonic epilepsy of infancy	laforin	0.4193	0.2572	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
tonic-clonic seizures	SCN1A-related	0.4192	0.03778	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
benign familial neonatal seizures	KCNQ2	0.4191	0.1942	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
SMEI	SCN1A	0.4191	0.0916	The relationship between severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) and the related syndrome SMEI-borderland (SMEB) with mutations in the sodium channel alpha 1 subunit gene SCN1A is well established.	-1
synaptic disorders	CASPR2	0.419	0.1829	In conclusion, the term NMT--LE--VGKC should be changed to NMT--LE with LGII and CASPR2 antibodies and classified as auto immune synaptic disorders.	-1
CS	PTEN	0.4189	0.1173	We report the case of a girl with Cowden syndrome (CS) presenting with unilateral perisylvian dysplasia and with drug resistant focal seizures carrying a novel missense mutation 385G>A (G129R) in the PTEN gene.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	ROGDI	0.4188	0.09015	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Miller-Dieker syndrome	LIS1	0.4187	0.1479	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
NES	NCL	0.4187	0.1042	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
L-CMD	laminin alpha-2	0.4187	0.1066	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
plus	SCN1A	0.4187	0.04751	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	-1
Cerebral creatine deficiency	GAMT	0.4186	0.0147	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
ISs	GRIN2A	0.4186	0.02987	In the present study, we performed genetic screening of 73 patients with different types of ISs by array-CGH and molecular analysis of 5 genes: CDKL5, STXBP1, KCNQ2, and GRIN2A, whose mutations cause different types of epileptic encephalopathies, including ISs, as well as MAGI2, which was suggested to be related to a subset of ISs.	-1
T/T	T-bet	0.4186	0.11	Regarding SNPs in promoter regions (rs4794067 and rs17250932) of T-bet, however, IQ below 50 was found in 19% of wild type (T/T) and 0% of heterologous (T/C) genotype of rs4794067, and in 19% of wild type (T/T) and 0% of heterologous (T/C) genotype of rs17250932.	-1
hypofibrinogenemias	fibrinogen	0.4185	0.1704	[Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency].	-1
DS	SCN1A	0.4185	0.1481	We report on two patients with SCN1A mutations and severe epilepsy within the spectrum of generalized epilepsy with febrile seizures plus syndrome (GEFS+), the phenotypes being consistent with DS and MAE, respectively.	-1
SCAR	CYP2C9	0.4185	0.3283	This study investigated the associations between the genetic polymorphisms of HLA class I and CYP2C9 and phenytoin-related SCAR in a Thai population.	-1
FS	SCN1A	0.4184	0.1394	Several genes have been localized for FS by linkage analysis, and three GEFS+ genes (SCN1A, SCN1B, GABRG2) have been identified.	-1
seizures	SMARCB1	0.4184	0.3334	Distinguishing features include retinal anomalies, Dandy-Walker malformation, scoliosis, rocker bottom feet, respiratory difficulties and absence of seizures, and 2-oxoglutaric aciduria in the patients with the SMARCB1 mutation.	-1
seizure	SCN7A	0.4183	0.1056	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
ROS	Lon protease	0.4183	0.2009	Recently, we showed that the excess ROS could damage voltage-dependent anion channel, prohibitin, Lon protease, and aconitase in the MERRF cells.	-1
migraine	SCN1A	0.4183	0.04577	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
West syndrome	TBL1XR1	0.4183	0.301	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
Dravet syndrome	gephyrin	0.4183	0.1307	We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome.	-1
growth retardation	MEDS	0.4183	0.185	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
plus	SCN1A	0.4182	0.05238	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
Unverricht-Lundborg disease	laforin	0.4182	0.1326	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
sclerosis	SCN1A	0.4181	0.1427	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	-1
Dravet syndrome	SCN1A-related	0.418	0.1082	Seizures in children with SCN1A-related Dravet syndrome occurred more often with a body temperature below 38.5  C (57.9% vs. 32.6%, p=0.020) and reoccurred more often after following vaccinations (26.7% vs. 4.0%, p=0.003), than in children without a diagnosis of SCN1A-related Dravet Syndrome.	-1
XLAG syndrome	DCX	0.418	0.1875	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
CMD	POMT1	0.418	0.06731	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	ACADSB	0.4179	0.161	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
MDC1A	ISPD	0.4179	0.1982	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
convulsion	FCMD	0.4179	0.1384	The familial FCMD patients showed relatively more severe motor disability than that in the sporadic FCMD patients, while in mental and convulsion states no significant difference was found in both groups.	-1
genetic defect	PTEN-gene	0.4178	0.1863	The predisposing genetic defect has been assignated to chromosomal 10 (PTEN-gene mutation).	-1
CFD	dihydropteridine reductase	0.4177	0.07177	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
rotavirus gastroenteritis	IL-6	0.4176	0.2283	METHODS: Results of liver function tests, mainly the elevation of transaminase and IL-6 in rotavirus gastroenteritis with or without convulsions, were evaluated.	-1
AEDs	C-reactive protein	0.4176	0.2088	This narrative review considers the influence of AEDs on some predictors of vascular risk [i.e. weight, insulin resistance, metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, vitamins, coagulation factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix metalloproteinase-9].	-1
X-linked	PHF6	0.4175	0.08659	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
developmental delay	CDKL5	0.4175	0.08407	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	-1
epileptic encephalopathy	CDKL5	0.4174	0.1639	One of them is a type 2 severe epileptic encephalopathy (EIEE2), caused by dominant mutation in CDKL5 gene (Xp22.3).	1
sepsis	SCN1A	0.4174	0.09226	We describe three children with genetically different sodium channel alpha 1 subunit (SCN1A) mutation associated epilepsy who experienced a sudden and sustained neurologic regression following status epilepticus in two and acute sepsis in one.	-1
febrile seizures	SCN1A	0.4173	0.2481	[Phenotype and SCN1A gene mutation screening in 39 families with generalized epilepsy with febrile seizures plus].	-1
abnormalities, motor incoordination	TCF4	0.4173	0.05919	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
ventricular arrhythmia	CMD1O	0.4171	0.2857	KATP channelopathies implicated in patients with mechanical and/or electrical heart disease include dilated cardiomyopathy (with ventricular arrhythmia; CMD1O) and adrenergic atrial fibrillation.	-1
myoclonic epilepsy	LBSL	0.4171	0.06591	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
mental retardation	SCN1A	0.4171	0.1897	OBJECTIVES: The aim of this study was to determine the genetic defect in a 4-generational family with an epileptic disorder characterized by febrile and afebrile polymorphic seizures and mild to severe mental retardation by means of analyzing the neuronal voltage-gated sodium channel alpha-subunit gene SCN1A for mutations.	-1
epileptic encephalopathy	SCN1A	0.417	0.1353	PURPOSE: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients.	1
chondrocalcinosis	ANKH	0.417	0.2401	Autosomal dominant early childhood seizures associated with chondrocalcinosis and a mutation in the ANKH Gene.	-1
KSS	NARP	0.4169	0.2711	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
PMSE	LKB1	0.4169	0.1144	We found that neurons in human PMSE cortex exhibited abnormal nuclear localization of LKB1.	-1
Dravet syndrome	SCN1A	0.4168	0.3469	There has been a marked increase in genetic diagnoses of a number of key childhood-onset epilepsy syndromes, such as Dravet syndrome, which has been linked to mutations in the SCN1A gene.	-1
myopathy	LBSL	0.4168	0.06675	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
epilepsy	CHD2	0.4168	0.2391	We have previously identified one patient with a large deletion affecting the CHD2 gene in a group of 22 patients with LGS or LGS-like epilepsy.	1
Seizure	SCN2A	0.4168	0.1592	Seizure onset was in the neonatal period in eight patients with SCN1A-involvement, in infancy in one patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
inborn error of glycine metabolism	P-protein	0.4168	0.1674	Non ketotic hyperglycinemia is a rare inborn error of glycine metabolism due to deficient activity of glycine cleavage system, a multienzymatic complex consisting of four protein subunits: the P-protein, the H-protein, the T-protein and the L-protein.	-1
epilepsy	CRK	0.4167	0.2991	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
neuropsychiatric	Anti-NMDA-NR2A/B	0.4164	0.1939	(3) Anti-NMDA-NR2A/B antibodies are present in a substantial number of patients with Systemic Lupus Erythematosus (SLE) with or without neuropsychiatric problems.	-1
fever	SCN1A	0.4164	0.3621	Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities.	-1
neuropathic pain	substance P.	0.4163	0.05015	Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P. Pregabalin can be prescribed in Turkey at 150-600 mg to treat neuropathic pain, generalized anxiety disorder, and fibromyalgia, and as concomitant therapy in adult patients with partial epilepsy.	-1
Cerebral creatine deficiency	SLC6A8	0.4163	0.02136	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
Cerebral creatine deficiency	SLC6A8	0.4163	0.02136	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
allelic disorders	SCN4A	0.4163	0.03019	Over the past decade mutations in genes encoding three ion channels, CACN1AS, SCN4A and KCNJ2, have been identified and account for at least 70% of the identified cases of PP and several allelic disorders.	-1
tumors	ELAM-1	0.4163	0.1139	There is an aberrant expression of ELAM-1 and VCAM-1 in the meningeal vascular proliferation similar to what is observed with other vascular malformations and tumors.	-1
Walker-Warburg syndrome	CMD1A	0.4163	0.0333	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
isolated lissencephaly	YWHAE	0.4162	0.3648	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
X-linked defect	SLC6A8	0.4162	0.2182	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
DS	SCN1A	0.4162	0.1277	(3) In contrast to DS, the clinical utility of SCN1A testing for GEFS+ remains questionable.	-1
PTHS	TCF4	0.4161	0.08172	In addition, 27 patients with 18q deletion encompassing the TCF4 gene but without given PTHS diagnosis have been published, and thus, the number of reported patients with a TCF4 abnormality exceeds 100.	-1
DS	March 1	0.4161	0.08619	METHODS: Between March 1, 1990, and August 31, 2004, 52 patients who met diagnostic criteria for DS were enrolled in a study at our department.	-1
genetic syndromes	MECP2	0.416	0.116	Three had CNVs and clinical features consistent with known genetic syndromes: 22q13.3 deletion, 2q23.1 deletion, and MECP2 duplication.	-1
Batten disease	CLN5	0.416	0.08972	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
respiratory infections	MECP2	0.416	0.1218	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
epilepsy	KCNQ3	0.416	0.461	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	1
LGS	CHD2	0.4158	0.2494	In our original material of 22 patients with LGS features, we have now found two (9%) with mutations in the CHD2 gene.	-1
tumor	LAT	0.4158	0.07029	The amino acid transport system L (LAT) is a major nutrient transport system, and LAT1 is highly expressed in malignant tumors to support tumor cell growth.	-1
Rett syndrome-like features	CDKL5	0.4158	0.1505	Recent studies have shown that aberrations of CDKL5 in female patients cause early-onset intractable seizures, severe developmental delay or regression, and Rett syndrome-like features.	-1
renal tubular injury	NAG	0.4158	0.5896	This article goes on to analyse the current data and draws on recurring patterns to suggest that a specific subpopulation of severely disabled epileptic children may benefit hugely from the close monitoring of enzymes which are indicative of renal tubular injury, particularly NAG or in the very least periodical urinalysis.	-1
language impairment	ATP13A4	0.4156	0.03295	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
retinoblastoma	KPNA2	0.4156	0.1335	Glu344 is conserved in all seven KPNA proteins, and we found that the Glu354Gln mutation in KPNA2 is sufficient to reduce binding to the retinoblastoma nuclear localization signal to approximately one-half that of wild-type protein.	-1
DRE	MECP2	0.4156	0.102	The presence of DRE is not related to abnormal EEG findings or a particular MECP2 mutant genotype.	1
epileptic syndrome	SCN1A	0.4155	0.04391	Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic syndrome that is caused by mutations in the neuronal voltage-gated sodium channel alpha1 subunit gene SCN1A.	1
Ehlers-Danlos syndrome	ACAD8	0.4155	0.09878	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
sensory	LBSL	0.4155	0.05628	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Seizures	SCN1A-related	0.4155	0.1667	Seizures in children with SCN1A-related Dravet syndrome occurred more often with a body temperature below 38.5  C (57.9% vs. 32.6%, p=0.020) and reoccurred more often after following vaccinations (26.7% vs. 4.0%, p=0.003), than in children without a diagnosis of SCN1A-related Dravet Syndrome.	-1
infancy	SCN1A	0.4154	0.3968	Review of the literature indicates that recurrent mutations account for 25% of SCN1A mutations in severe myoclonic epilepsy of infancy, including six sites of deamination at CpG dinucleotides.	-1
Ohtahara syndrome	biotinidase	0.4154	0.2012	Ohtahara syndrome with biotinidase deficiency.	-1
epilepsy	Nav1.2	0.4152	0.06069	The basis of epilepsy is an increase in neuronal excitability that, in some cases, may be caused by functional defects in neuronal voltage gated sodium channels, Nav1.1 and Nav1.2.	1
febrile seizures	NaV1.1	0.4152	0.09817	Familial febrile seizures is caused by mild loss-of-function mutations in NaV1.1 channels; mutations in these channels are implicated in febrile seizures associated with vaccination; and impaired alternative splicing of the mRNA encoding these channels may also predispose some children to febrile seizures.	-1
unusual behavioral syndrome	alien	0.4151	0.1395	This case provides supportive evidence for damage to the midbody of the corpus callosum as the anatomic basis of nondominant alien hand syndrome and conforms to a model of interhemispheric motor disconnection as the essential component of this unusual behavioral syndrome.	-1
SMEI-associated	SCN1A	0.4151	0.07224	Most SMEI-associated mutations are predicted to truncate the SCN1A protein, likely causing a loss of sodium channel function.	-1
brain tumor	TEN 4	0.4151	0.1386	A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.	-1
epileptic syndrome	PrPc	0.415	0.1513	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	1
CFD	3-phosphoglycerate dehydrogenase	0.4149	0.06809	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
febrile seizures plus	SCN1A	0.4149	0.1195	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.4149	0.2439	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.4149	0.3604	In a retrospective evaluation of 70 patients with Dravet syndrome and SCN1A mutations, seizures following vaccinations were reported in 27%.	-1
AHS	cytochrome c	0.4148	0.07545	Both AHS iPSCs-Hep are more sensitive to VPA-induced mitochondrial-dependent apoptosis than controls, showing more activated caspase-9 and cytochrome c release.	-1
microcephalic	RBBP8	0.4147	0.1105	It thus appears that the phenotype of the mildly affected mother can be explained by the NRXN1 deletion, whereas the more severe and complex microcephalic phenotype of the two affected brothers is due to the simultaneous deletion in NRXN1 and the homozygous missense mutation affecting RBBP8.	-1
dysplastic	TRPC3	0.4147	0.1279	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
febrile seizure	SCN1A	0.4146	0.265	We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation.	-1
cardiac defects	KLF13	0.4146	0.1464	Three patients with deletions had cardiac defects and deletion of the KLF13 gene, located in the critical region, may contribute to these abnormalities.	-1
neurodevelopmental disorder	NRXN1	0.4144	0.315	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
facial dysmorphology	alkaline phosphatase	0.4144	0.07858	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
AEDs	matrix metalloproteinase-9	0.4144	0.1721	This narrative review considers the influence of AEDs on some predictors of vascular risk [i.e. weight, insulin resistance, metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, vitamins, coagulation factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix metalloproteinase-9].	-1
seizure	SCN2A	0.4143	0.08738	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
epilepsy	SCN1A	0.4143	0.1492	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	1
drug-resistant epilepsy	MECP2	0.4142	0.08683	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
autosomal MBD family members	SETDB2	0.4141	0.256	We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene.	-1
neurocognitive impairment	MECP2	0.4139	0.1332	RESULTS: We observed a partial MECP2 duplication in an adult male with epilepsy and mild neurocognitive impairment who was able to function independently; this phenotype has not previously been reported among males harboring gains in MECP2 copy number.	-1
Ullrich CMD	CMD1C	0.4139	0.2065	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
arched eyebrows	PHF6	0.4139	0.0443	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
Dravet syndrome	SCN1A	0.4136	0.1495	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
septicaemia	CRP	0.4136	0.1227	Neonates with septicaemia due to gram negative bacteria were significantly found to have higher rates of positive CRP than neonates with gram positive septicaemia and with negative culture (p   <   0.001, OR 8.2, 95 CI; 2.9-26).	-1
SMEI	SCN1A	0.4135	0.05589	One third of the children with SMEI show de novo mutations of the SCN1A gene, and additional familial genes probably contribute to the phenotype.	-1
benign familial neonatal convulsions	EPM1	0.4135	0.1277	Linkage is established for three generalized syndromes: the EBN1 and EBN2 genes for benign familial neonatal convulsions (BFNC) map to chromosomes 20q and 8q (refs 2-5), the EPM1 gene for Unverricht-Lundborg disease maps to 21q (ref.	-1
hydrocephalus	neurofibromatosis type 1	0.4135	0.08269	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
infantile epileptic encephalopathy	SCN1A	0.4135	0.1643	OBJECTIVE: De novo mutations of the gene sodium channel 1a (SCN1A) are the major cause of Dravet syndrome, an infantile epileptic encephalopathy.	1
Rett syndrome	MECP2	0.4134	0.2353	Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.	-1
permanent neonatal diabetes	ABCC8	0.4134	0.06839	Activating mutations have been identified in the genes encoding these subunits, ABCC8 and KCNJ11, and account for approximately 40% of permanent neonatal diabetes cases.	-1
epileptiform activity	TRPC3	0.4133	0.06806	In conclusion, TRPC3 primarily mediates low Ca- and low Mg-induced depolarization and epileptiform activity, and the enhanced expression of TRPC3 could make dysplastic and immature cortex more hyperexcitable and more susceptible to epileptiform activity.	-1
AEDs	Nav1.7	0.4133	0.15	In contrast, novel AEDs, such as lacosamide, stabilize the slow-inactivated state in neuronal Nav1.1 and Nav1.7 isoforms.	-1
epilepsy	LBSL	0.4133	0.2066	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
developmental delay	CDKL5	0.4133	0.131	RESULTS: We have identified mosaic exonic deletions of CDKL5 in one male and two females with developmental delay and medically intractable seizures.	-1
lumbosacral dermal sinus tract	LIS1	0.4132	0.03069	A 6-month-old infant with LIS1 17p13.3 deletion-positive Miller-Dieker syndrome (MDS) presented with increased seizures in the setting of a Pseudomonal and Enterococcal urinary tract infection and a buttock abscess associated with a lumbosacral dermal sinus tract.	-1
congenital deafness	KCNQ4	0.4131	0.2244	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
Dravet syndrome	SCN1A	0.413	0.2341	PURPOSE: Our aim was to develop a screening test to predict Dravet syndrome before the first birthday based on the clinical characteristics of infants and the SCN1A mutation analysis.	-1
OS	SCN2A	0.413	0.09906	In two OS cases, we found de novo non-synonymous mutations in the genes KCNQ2 and SCN2A.	-1
temporal lobe epilepsy	A beta	0.413	0.1799	A beta deposition in the form of senile plaques (SPs) has recently been described in patients with temporal lobe epilepsy (TLE).	-1
congenital muscular dystrophy	FCMD	0.4129	0.132	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
autosomal dominant seizure disorders	SCN2A	0.4129	0.1626	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
SMEI	SCN1A	0.4129	0.1963	Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI patients.	-1
Rett syndrome	MECP2	0.4129	0.1395	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
Prade-Willi/Angelman syndrome	inv	0.4128	0.1498	Patients with a larger inv dup(15) marker chromosome including the PW/ASCR may have a higher risk of abnormalities, but not the typical Prade-Willi/Angelman syndrome phenotype.	-1
CMD	RSMD1	0.4127	0.3375	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Stevens-Johnson syndrome	HLA-B	0.4127	0.1299	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement.	-1
developmental disorder	interleukin-6	0.4127	0.1387	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
channelopathy	SCN1A	0.4126	0.03536	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
Neuropshychiatric SLE	anti-NMDA-NR2A/B	0.4126	0.06392	The exact percentage of SLE patients having anti-NMDA-NR2A/B antibodies varies in different studies from 14 to 35%, and in one study such antibodies were found in 81% of patients with diffuse 'Neuropshychiatric SLE', and in 44% of patients with focal 'Neuropshychiatric SLE'.	-1
Sneddon's syndrome	antithrombin III	0.4126	0.1461	Sneddon's syndrome and antithrombin III.	-1
focal epilepsy	NR2B	0.4125	0.1612	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
SMEI	SCN1A	0.4125	0.09634	CONCLUSION: The clinical features of SMEI were seizure onset within one year of age, first event is often a febrile seizure; multiple seizure types and mental delay occurred after the second year of life; seizures have a characteristic of temperature sensitivity; EEG was normal in the first year of life, followed by generalized, focal or multifocal discharges; early diagnosis by testing SCN1A mutation guides selection of antiepileptic drugs.	-1
seizure	SCN9A	0.4125	0.08492	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
seizure	SCN1A	0.4125	0.08492	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
dysfibrinogenemia or	fibrinogen	0.4125	0.3548	These data and our previous reports suggest that heterozygous patients with dysfibrinogenemia or fibrinogen deficiency do not demonstrate markedly prolonged PT and APTT values, differing from patients with afibrinogenemia.	-1
rigid spine syndrome	FKRP	0.4125	0.09791	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
rigid spine syndrome	POMT2	0.4125	0.09791	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
rigid spine syndrome	FKTN	0.4125	0.09791	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Rett syndrome	3-phosphoglycerate dehydrogenase	0.4124	0.09263	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
truncal obesity	PHF6	0.4124	0.2156	We present three males with PHF6 mutations whose features included deep-set eyes, large ears, coarse face, tapering fingers, and truncal obesity.	-1
CMD	CMD1A	0.4124	0.3708	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
acute encephalopathy	SCN1A	0.4121	0.4041	To determine whether SCN1A mutations are a predisposing factor of acute encephalopathy, we sought to identify SCN1A mutations in a large case series of acute encephalopathy including various syndromes.	-1
LHON	NARP	0.412	0.4467	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Dravet syndrome	STXBP1	0.412	0.226	CONCLUSIONS: We show that GABRA1 and STXBP1 make a significant contribution to Dravet syndrome after SCN1A abnormalities have been excluded.	-1
Rett syndrome	CDKL5	0.412	0.2444	Cyclin-dependent kinase-like 5 (CDKL5) mutation screening in Rett syndrome and related disorders.	-1
epilepsy	GABRA6	0.412	0.08487	MATERIALS AND METHODS: We investigated the association of single-nucleotide polymorphisms in GABA(A) receptor subunit subtype genes namely; rs2279020 (GABRA1), rs3219151 (GABRA6), rs2229944 (GABRB2), and rs211037 (GABRG2) with predisposition to epilepsy and AED resistance.	-1
epilepsy	NaV1.1	0.412	0.1153	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	1
L-CMD	RSMD1	0.4119	0.1253	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Pitt-Hopkins syndrome	SLC9A6	0.4119	0.06566	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
tumors	VCAM-1	0.4118	0.05231	There is an aberrant expression of ELAM-1 and VCAM-1 in the meningeal vascular proliferation similar to what is observed with other vascular malformations and tumors.	-1
rigid spine syndrome	RSMD1	0.4118	0.4244	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Batten disease	laforin	0.4118	0.1689	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
myoclonic epilepsies	SCN1B	0.4118	0.05467	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
sensorineural hearing loss	ATPase-related	0.4117	0.3019	Here, we present unique congenital disorders of glycosylation type 2-associated anomalies, including both ATPase-related and unrelated cutis laxa and sensorineural hearing loss, a recently recognized symptom of congenital disorders of glycosylation.	-1
learning disability	MECP2	0.4117	0.09967	Non-progressive neuropsychiatric symptoms in female relatives of a male child with learning disability, ataxia and progressive spasticity may constitute a clue to inherited, MECP2 pathogenesis.	-1
deafness	KCNQ2	0.4117	0.2084	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
) syndrome	SLC9A6	0.4114	0.08638	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Rett syndrome	CDKL5	0.4114	0.1031	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
epileptic	mTOR	0.4113	0.04229	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
KRS	PARK9	0.4113	0.3013	We report the clinical features of the original Chilean family with Kufor-Rakeb syndrome (KRS) that led to the discovery of the ATP13A2 gene at the PARK9 locus.	-1
lissencephalies	TUBA3	0.4112	0.1938	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
persistent hyperinsulinemic hypoglycemia of infancy	multiple endocrine neoplasia 2A	0.4112	0.1489	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
catamenial epilepsy	AKR1C1	0.4112	0.1152	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
rare skeletal dysplasia	fibroblast growth factor receptor 3	0.4112	0.09703	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
Gitelman's syndrome	kallikrein	0.411	0.2642	Renin-angiotensin-aldosterone and kallikrein investigations in a patient with resistant hypomagnesaemia due to Gitelman's syndrome.	-1
hydrocephalus	CSF	0.411	0.1021	These findings suggest that there are variable mechanisms for developing hydrocephalus after cerebral hemispherectomy depending on the procedure, and in resection-disconnection operations the mechanism may involve changes in CSF bulk flow that varies by histopathology.	-1
early death	PEHO	0.411	0.1781	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
mental deficiency	CHD2	0.411	0.4373	Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency.	-1
intellectual disability	PHF6	0.411	0.2331	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
PME	SMA	0.4109	0.2326	CONCLUSION: The association of SMA with PME may constitute a separate and, probably, genetically independent syndrome with unique clinical and electroencephalographic findings or, at least, a variant of a neurodegenerative or metabolic disease, due to yet unknown causes.	-1
language impairment	GRIN2A	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	CDH13	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	CTNNA3	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	CNTNAP2	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	CDH9	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	MDGA2	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
language impairment	DIAPH3	0.4108	0.0127	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
hypotonia	Inv	0.4108	0.1627	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
myoclonus	laforin	0.4107	0.3155	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
Christianson syndrome	CREBBP	0.4106	0.2419	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
AEDs	OR 1.37	0.4106	0.3454	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
ISS	KLHL17	0.4106	0.1183	Finally, we provide evidence that ISS in deletion 1p36 may be associated with deletion of KLHL17 and expand the epilepsy phenotype in that syndrome to include early infantile epileptic encephalopathy.	-1
KS	COL18A1	0.4105	0.1031	We report here the results of the screening of both the entire coding region and the exon-intron boundaries of the COL18A1 gene (which includes 43 exons), in eight unrelated patients with KS.	-1
CMD	ISPD	0.4105	0.07086	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Pitt-Hopkins syndrome	TCF4	0.4104	0.06371	Quantitative real-time polymerase chain reaction is another method to identify TCF4 and to confirm Pitt-Hopkins syndrome diagnosis.	-1
LMNA-related CMD	POMGNT1	0.4103	0.1044	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
ataxia	LBSL	0.4102	0.05619	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
plus	SCN1A	0.4101	0.08262	We recently described mutations of the neuronal sodium-channel alpha-subunit gene, SCN1A, on chromosome 2q24 in two families with generalized epilepsy with febrile seizures plus (GEFS+) type 2.	-1
DS	SCN1A	0.41	0.2236	All identified variants were found in DS patients with 85.7% sensitivity, thus supporting the role of profound SCN1A gene variants in etiology of DS phenotype.	-1
Dravet syndrome	SCN1A	0.4099	0.1669	Dravet syndrome and SCN1A gene mutation related-epilepsies: cognitive impairment and its determinants.	-1
West syndrome	YWHAE	0.4099	0.4065	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
supplementary motor area	SMA	0.4098	0.2808	In this article, the authors report their experience with surgically induced supplementary motor area (SMA) deficiency syndrome in a prospective clinical trial of 28 patients who underwent surgery for tumorous (19 patients) or nontumorous (nine patients) lesions.	-1
neonatal seizures	KCNQ3 p.Pro574Ser	0.4098	0.2119	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
ataxia	MECP2	0.4097	0.3195	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
SMEI	SCN1A	0.4097	0.01742	Severe Myoclonic Epilepsy in Infancy (SMEI) is an intractable epileptic syndrome with onset in the first year of life and is commonly caused by de novo mutations in the SCN1A gene, encoding the alpha1-subunit of the neuronal voltage-gated sodium channel.	-1
seizures	SCN2A	0.4097	0.5209	Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.	-1
transient ischaemic attacks	aura-like	0.4096	0.162	BACKGROUND AND PURPOSE: Convexity subarachnoid haemorrhage (cSAH) has recently been recognised as a cause of recurrent aura-like symptoms, mimicking transient ischaemic attacks (TIAs).	-1
mouse-model concept	KCNQ2	0.4096	0.02432	The similarity between the horse and the human, especially for the KCNQ2 gene, where the majority of mutations causing BFNC have been found, supports the hypothesis of similar heritable and genetic patterns of the disease in both species and suggests that contrary to the classic mouse-model concept, humans may be a more suitable model for the study of JIE in Arabian foals.	-1
status epilepticus	TK2-mutation	0.4095	0.1264	Clinical application of whole exome sequencing reveals a novel compound heterozygous TK2-mutation in two brothers with rapidly progressive combined muscle-brain atrophy, axonal neuropathy, and status epilepticus.	-1
Leigh-syndrome	LBSL	0.4094	0.0609	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
MELAS-syndrome	LBSL	0.4094	0.0609	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Ohtahara syndrome	SCN2A	0.4094	0.3259	Whole genome sequencing identifies SCN2A mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings.	-1
leukemia	L-asparaginase	0.4094	0.09359	A 46-year-old male with refractory biphenotypic acute leukemia was treated with doxorubicin (days 1-3, 15-17), vincristine (days 1, 8, 15, 22), prednisolone (days 1-28), and L-asparaginase (L-ASP: days 15-28) as reinduction therapy.	-1
CJD	CA1-4	0.4092	0.09951	In CJD, pathology was severe in pre-parasubiculum and temporal cortex, and little or absent in CA1-4; PV+ neurons were severely reduced or absent in all cases, whereas Cal+ neurons were largely preserved.	-1
Smith-Lemli-Opitz syndrome	DHCR7	0.4092	0.1906	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
ADNFLE	CHRNB4	0.4092	0.06194	Here, we investigated whether nine brain-expressed genes (CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB2, CHRNB3, CHRNB4), encoding distinct nAChR subunits, and CRH are associated with the disease in three distinct ADNFLE families from Southern Italy.	-1
Dravet syndrome	SCN1A	0.4092	0.1255	Subsequently, mutations of SCN1A were also found in patients with severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome, and in patients with borderline SMEI (SMEB), a milder form of Dravet syndrome.	-1
seizures	TTR	0.4092	0.1116	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
ocular anomalies	FCMD	0.409	0.155	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
secondary hypothyroidism	NF-1	0.409	0.53	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
epileptic	spin	0.4089	0.2786	The aim of this retrospective study was to examine the contribution of epileptic ictal hyperperfusion in patients with PRES using combined magnetic resonance perfusion imaging with arterial spin labeling (ASL) and diffusion-weighted magnetic resonance imaging (MRI).	-1
hyponatremia	PIP-syndrome	0.4089	0.4346	We describe four patients with left temporal lobe epilepsy who developed psychosis, intermittent polydipsia and hyponatremia (PIP-syndrome) while being treated with carbamazepine.	-1
kyphoscoliosis	ROGDI	0.4088	0.08931	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Kearns-Sayre syndrome	3-phosphoglycerate dehydrogenase	0.4087	0.08423	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
juvenile epilepsy	KCNQ3	0.4086	0.2691	KCNQ2 and KCNQ3 heteromultimers are thought to underlie the M-current; mutations in these genes may cause an inherited form of juvenile epilepsy.	1
glycine amidinotransferase deficiency	SLC6A8	0.4086	0.2112	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
glycine amidinotransferase deficiency	SLC6A8	0.4086	0.2112	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
CHF	ARPKD	0.4085	0.1082	CONCLUSIONS: Clinical decision making in ARPKD should reflect an understanding of the potential issues emanating from CHF.	-1
seizures	PUFA-enriched	0.4085	0.1453	Here, we report a 7-year-old boy with Lennox-Gastaut syndrome combined with mitochondrial respiratory chain complex I deficiency, whose medically intractable seizures have been successfully controlled with a PUFA-enriched modified Atkins diet without any significant adverse events.	-1
hearing loss	MeCP2	0.4085	0.1508	Neither the type of hearing loss nor the presence of preserved speech seemed to be correlated with the type of mutation in methyl-CpG-binding protein 2 (MeCP2) gene that is associated with RS.	-1
sclerosis	MVP	0.4083	0.131	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
febrile seizures	SCN1A	0.4081	0.3049	SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.	-1
neurocognitive impairment	MECP2	0.4081	0.08995	RESULTS: We observed a partial MECP2 duplication in an adult male with epilepsy and mild neurocognitive impairment who was able to function independently; this phenotype has not previously been reported among males harboring gains in MECP2 copy number.	-1
benign familial neonatal seizures	KCNQ2	0.4081	0.5657	Novel KCNQ2 mutation in a large Emirati family with benign familial neonatal seizures.	-1
RCDs	CSF	0.408	0.1556	Diagnosis of cognitive impairment from RCDs is based on neuropsychological testing, imaging studies, including MRI, PET, SPECT, or MR-spectroscopy, CSF investigations, or electroencephalography.	-1
seizures	solute carrier family 25, member 12	0.408	0.328	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
Dravet syndrome	neuronal voltage-gated sodium channel a subunit type 1 (Nav1.1	0.4078	0.1579	Heterozygous de novo mutations in the SCN1A gene, which encodes the neuronal voltage-gated sodium channel a subunit type 1 (Nav1.1), are responsible for Dravet syndrome, with a broad spectrum of mutations and rearrangements having been reported.	-1
febrile seizures	SCN1B	0.4077	0.05895	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
LMNA-related CMD	FKRP	0.4076	0.1047	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
LMNA-related CMD	POMT2	0.4076	0.1047	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
LMNA-related CMD	FKTN	0.4076	0.1047	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epilepsy	NF2	0.4076	0.1641	Even though cerebral cortical lesions are frequently associated with seizures, epilepsy is rarely described in NF2.	1
human embryonic kidney	hNa(V)1.6	0.4075	0.2513	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
Sturge-Weber syndrome	neurofibromatosis type 1	0.4074	0.2303	We included in the study 23 children diagnosed with different types of neurocutaneous syndrome (10 patients with tuberous sclerosis, 5 with Sturge-Weber syndrome and 8 with neurofibromatosis type 1 and epilepsy'.	-1
epilepsy	KCNH2	0.4074	0.1494	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
epileptic syndrome	KCNQ3	0.4074	0.1378	Recently, mutations of potassium channel genes (KCNQ2, KCNQ3) were identified as responsible for this autosomic dominant epileptic syndrome.	1
Rett (	TCF4	0.4074	0.06666	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
febrile seizures plus	SCN1A	0.4072	0.1979	Mutations in the gene encoding the a1 subunit of the voltage gated sodium channel (SCN1A) are associated with several epilepsy syndromes, ranging from relatively mild phenotypes found in families with genetic epilepsy with febrile seizures plus (GEFS+) to the severe infant-onset epilepsy Dravet syndrome.	-1
chromosomal abnormalities	GLI3	0.4072	0.4151	Together, these data provide evidence that the development of chromosomal abnormalities within GLI3 is associated with the pathogenesis of HH lesions in sporadic, nonsyndromic patients with HH and intractable epilepsy.	-1
MEBD	FCMD	0.4071	0.09626	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
microcephaly	tRNA methyltransferase 10 homologue A	0.4071	0.2693	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
LGS-like	CHD2	0.4071	0.1248	We have previously identified one patient with a large deletion affecting the CHD2 gene in a group of 22 patients with LGS or LGS-like epilepsy.	-1
idiopathic epilepsy	NF-1	0.407	0.368	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Kearns-Sayre syndrome	dihydropteridine reductase	0.4068	0.08265	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
mental retardation	neurofibromatosis-1	0.4068	0.1385	Several paediatric neurological disorders such as neurofibromatosis-1, Fragile X syndrome, Rett syndrome, and other syndromic and non-specific forms of mental retardation involve lesions in these signalling pathways.	-1
seizures	SCN1A	0.4068	0.1904	We report the first case of reflex seizures triggered by diaper change in a girl at 9 months old and 2 years old with a mutation in the SCN1A gene causing DS.	-1
PDD-NOS	MeCP2	0.4068	0.1321	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
epilepsy	KCNQ2/3	0.4067	0.4337	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	1
seizures	KCNQ2	0.4066	0.07552	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	-1
seizure	GBP	0.4066	0.1262	In drug-resistant epilepsy the use of VGB, LTG, oxcarbazepine, FBM and GBP resulted in at least a 50% improvement in 20% to 60% of such patients treated and in 7% led to complete seizure control.	-1
epileptic encephalopathy	TBL1XR1	0.4065	0.08011	RESULTS: We identified mutations in CDKL5, SCN2A, SETD5, ALG13, and TBL1XR1 in seven patients with West syndrome, and in SCN1A and GRIN1 in the two patients with unclassified epileptic encephalopathy.	-1
neuronal excitability	KCC2	0.4064	0.05347	Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.	-1
Hypochondroplasia	fibroblast growth factor receptor 3	0.4063	0.06621	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
infantile hypotonia	MECP2	0.4063	0.233	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
febrile seizure	SCN1A	0.4062	0.1717	We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation.	-1
Dravet syndrome	N-CLB	0.4062	0.3924	AIM: The aim of this study was to describe the pharmacokinetics of clobazam and its active metabolite N-desmethylclobazam (N-CLB) in children with Dravet syndrome receiving the stiripentol/valproic acid/clobazam combination therapy of reference and to determine the concentrations of clobazam and N-CLB obtained in this population for the usual 0.2 mg/kg twice-daily dose.	-1
RTT	MECP2	0.4062	0.1905	Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene have been found in up to 95% of classical RTT cases and a lesser proportion of atypical cases.	-1
genetic epilepsy	SCN1A-related	0.4061	0.1931	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
seizures	KCNQ2	0.4061	0.1258	A novel and rare mutation was identified in KCNQ2 and was likely responsible for the benign seizures segregating in the family though additional evidence would be required to be definitive.	-1
atrial fibrillation	CMD1O	0.4061	0.1154	KATP channelopathies implicated in patients with mechanical and/or electrical heart disease include dilated cardiomyopathy (with ventricular arrhythmia; CMD1O) and adrenergic atrial fibrillation.	-1
OS	KCNT1	0.406	0.2177	In a third OS case, WGS revealed paternal isodisomy for chromosome 9, leading to identification of the causal homozygous missense variant in KCNT1, which produced a substantial increase in potassium channel current.	-1
RTT	methyl CpG binding protein 2	0.406	0.1051	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
Langer-Giedion syndrome	TRPS1	0.406	0.2711	The deletion included the region for Langer-Giedion syndrome (TRPS1 and EXT1) in the girl only.	-1
mucocutaneous pigmentation	STK11	0.4059	0.1251	BACKGROUND: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene.	-1
Dravet syndrome	PCDH19	0.4057	0.07163	SCN1A-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for PCDH19 and TSPYL4 mutations.	-1
CMD	ISPD	0.4057	0.2138	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
sudden unexpected death in epilepsy	SCN1A	0.4057	0.3924	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	-1
tter-T  nz syndrome	ACAD8	0.4056	0.107	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
SMEI-borderland	SCN1A	0.4056	0.2328	The relationship between severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) and the related syndrome SMEI-borderland (SMEB) with mutations in the sodium channel alpha 1 subunit gene SCN1A is well established.	-1
epileptic syndrome	SCN1A	0.4056	0.04245	Severe Myoclonic Epilepsy in Infancy (SMEI) is an intractable epileptic syndrome with onset in the first year of life and is commonly caused by de novo mutations in the SCN1A gene, encoding the alpha1-subunit of the neuronal voltage-gated sodium channel.	1
merosin deficiency	CMD1A	0.4054	0.3714	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
Lennox-Gastaut syndrome	SCN1A	0.4053	0.1245	In a previous study, an SCN1A mutation was also identified in a patient with Lennox-Gastaut syndrome (LGS), and the aim of our study was to investigate the importance of mutations in the SCN1A gene in Norwegian patients with clinical features of LGS.	-1
psychiatric disorders	SCN1A	0.4053	0.2511	We investigated the roles of mutations in voltage-gated sodium channel alpha 1 subunit gene (SCN1A) in epilepsies and psychiatric disorders.	-1
MS	FGFR3	0.4052	0.05341	Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene.	-1
seizures	SCN1A	0.4051	0.4967	Vaccination and occurrence of seizures in SCN1A mutation-positive patients: a multicenter Italian study.	-1
AHS	LBSL	0.4051	0.06285	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
homocystinuria	cystathionine beta-synthase	0.405	0.3931	However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase).	-1
osteopetrosis	CLC	0.4049	0.03809	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
microcephaly	MECP2	0.4048	0.3205	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
West syndrome	LIS1	0.4048	0.4961	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
dysplasia	neurofibromatosis type 1	0.4048	0.3169	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
lissencephalies	LIS1	0.4047	0.1774	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
RTT-like	CDKL5	0.4047	0.2262	In conclusion, our report show that search for mutations in CDKL5 is indicated in girls with early onset of a severe intractable seizure disorder or infantile spasms with severe hypotonia, and in girls with RTT-like phenotype and early onset seizures, though, in our cohort, mutations in CDKL5 account for about 10% of the girls affected by these disorders.	-1
Rett syndrome	MECP2	0.4047	0.5495	[Clinical symptoms of the Rett syndrome patients with MECP2 gene abnormalities].	-1
Alpers-Huttenlocher-syndrome	NARP	0.4046	0.07998	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
complex epileptic syndrome	NF1	0.4046	0.1581	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
seizure	NF1	0.4045	0.4241	These observations suggest that all individuals with NF1 and a new seizure should undergo MRI despite previous normal neuroimaging.	-1
epilepsy	CRK	0.4045	0.1932	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
Rett (	SLC9A6	0.4044	0.05896	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Dravet's syndrome	SCN1A	0.4043	0.08859	Nearly 700 mutations of the SCN1A gene have been identified in patients with Dravet's syndrome (severe myoclonic epilepsy of infancy), making this the most commonly mutated gene in human epilepsy.	-1
isolated lissencephaly	CRK	0.4043	0.3672	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
CMD	CMD1A	0.4042	0.06528	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
Congenital bilateral perisylvian syndrome	CBPS	0.4042	0.2653	Congenital bilateral perisylvian syndrome(CBPS) is a recently described disease identify characterized by pseudobulbar palsy, epilepsy, mental retardation, and migration disorders in the bilateral perisylvian area.	-1
tter-T  nz syndrome	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4042	0.06576	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
sporadic Dravet syndrome	SCN1A	0.4042	0.2652	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
kyphoscoliosis	EDSKMH	0.4042	0.07851	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
microcephaly	TRMT10A	0.4041	0.2666	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
isobutyryl-CoA dehydrogenase deficiency	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.4041	0.1524	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
LTE	KCNAB1	0.404	0.1809	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
CNVs abnormalities	SCN1A	0.404	0.07489	The remaining CNVs abnormalities were four partial and nine whole SCN1A deletions involving contiguous genes.	-1
cerebral amyloid angiopathy	aura-like	0.4039	0.1374	Subarachnoid haemorrhage and recurrent aura-like episodes can occur in patients with cerebral amyloid angiopathy (CAA), which has been the presumed cause in the majority of reported cases.	-1
RTT	MECP2-mutated	0.4039	0.1747	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	-1
encephalitis	GluR3	0.4038	0.09021	While one mechanism underlying the pathogenesis of Rasmussen's encephalitis has been hypothesized to be mediated by production of excitotoxic GluR3 autoantibodies to the a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor, other neuropathological etiologies have also been indicated.	-1
epilepsy disorders	SCN1A	0.4038	0.07747	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	1
MDC1A	POMT1	0.4038	0.2284	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Sanjat-Sakati syndrome	multiple endocrine neoplasia 2A	0.4038	0.2107	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
MERRF	NCL	0.4037	0.06434	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
Rett syndrome	MECP2	0.4037	0.0792	Rett syndrome is a genetic neurodevelopmental disorder that affects mainly girls, but mutations in the causative MECP2 gene have also been identified in boys with classic Rett syndrome and Rett syndrome-like phenotypes.	-1
Pitt   Hopkins syndrome	TCF4	0.4036	0.2648	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
channelopathy	Na(v) 1.1	0.4036	0.008794	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
encephalopathy	PEHO	0.4036	0.247	PEHO syndrome (progressive encephalopathy, peripheral edema, hypsarrhythmia, and optic atrophy) is a neurodegenerative disorder first characterized in Finnish patients.	-1
FCDs	mammalian target of rapamycin	0.4035	0.1301	Disruption of the mammalian target of rapamycin (mTOR) signaling comprises a common pathway underlying the structural and electrical disturbances of some FCDs.	-1
hypovolemia	ClC-Kb/barttin	0.4035	0.08823	Loss-of-function of ClC-Kb/barttin channels impairs NaCl resorption in the limb of Henle and causes hyponatriaemia, hypovolemia and hypotension in patients suffering from Bartter syndrome.	-1
epilepsy	MEDS	0.4034	0.1114	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	1
depressive disorders.We	AKR1C1	0.4034	0.1044	Inhibitors of AKR1C1 are thus potential agents for treatment of endometrial cancer and endometriosis, as well as other diseases like premenstrual syndrome, catamenial epilepsy and depressive disorders.We have synthesized a series of pyrimidine, phthalimido and athranilic acid derivatives, and have here examined their inhibitory properties towards AKR1C1.	-1
leukocytosis	C reactive protein	0.4034	0.177	The patient was moderately dehydrated and the blood investigations were remarkable for hyponatraemia (126 mEq/l), leukocytosis (19.4 * 10(3)/l (46% lymphocytes)), thrombocytosis (637 * 10(3)/l), hypoalbuminaemia (albumin 1.9 g/dl) and elevated C reactive protein (96 mg/l).	-1
Rett syndrome	MECP2	0.4034	0.1368	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
Northern epilepsy syndrome	CLN8	0.4034	0.2246	Northern epilepsy syndrome (NES, CLN8)--MRI and electrophysiological studies.	-1
temporal lobe epilepsy	MVP	0.4033	0.1979	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
Dravet syndrome	SCN1A	0.4033	0.1409	Mutations in the SCN1A gene have been identified in a variety of epilepsy phenotypes, from severe encephalopathies such as Dravet syndrome to milder familial forms such as generalized epilepsy with febrile seizures plus.	-1
epilepsy	Jun	0.4032	0.1524	OBJECTIVE: To assess the prognosis of epilepsy, the possibility of achieving remission of seizures, in patients who were identified in a population-based study carried out in Jun  n, a city of about 70,000 inhabitants in Buenos Aires Province, Argentina.	1
severe developmental delay	NR2B	0.4032	0.1045	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
HPMRS	ALP	0.4031	0.08142	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
hypsarrhythmia	NF1	0.4031	0.1718	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
Dravet syndrome	Nav1.1	0.4031	0.09306	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
Dravet syndrome	SCN9A	0.403	0.1084	Two cases with partial deletion of SCN1A and SCN9A and whole SCN1A deletion had an epilepsy phenotype of Dravet syndrome.	-1
anxiety disorder	substance P.	0.403	0.04043	Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P. Pregabalin can be prescribed in Turkey at 150-600 mg to treat neuropathic pain, generalized anxiety disorder, and fibromyalgia, and as concomitant therapy in adult patients with partial epilepsy.	-1
benign familial neonatal-infantile seizures	SCN2A	0.4029	0.2234	Here, we describe a clinically intermediate variant, benign familial neonatal-infantile seizures, with mutations in the sodium-channel subunit gene SCN2A.	-1
atypical Rett syndrome	MECP2	0.4029	0.2377	CASE REPORT: We describe a female patient with Arnold Chiari type I malformation, atypical Rett syndrome characterized by postnatal onset microcephaly, stereotypic hand movements, ataxia, severe developmental delay, intractable tonic-clonic seizures, and a MECP2 mutation with a unique set of clinical findings.	-1
autosomal dominant nocturnal frontal lobe epilepsy	malin	0.4029	0.1549	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
FIRES	PCDH19	0.4028	0.0955	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
MERRF	Lon protease	0.4028	0.08382	Recently, we showed that the excess ROS could damage voltage-dependent anion channel, prohibitin, Lon protease, and aconitase in the MERRF cells.	-1
seizures	Kcna1-deficient	0.4028	0.0772	Animal models for EA1 include Kcna1-deficient mice, which recessively display severe seizures and die prematurely, and V408A-knock-in mice, which dominantly exhibit stress-induced loss of motor coordination.	-1
chemotaxis	CXCR3	0.4027	0.1699	Finally, the chemotaxis induced by the stimulated astrocytes was completely abrogated in the presence of a small molecule antagonist of CXCR3.	-1
Lafora disease	laforin	0.4027	0.2149	In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA).	-1
SMEI syndrome	GABRG2	0.4026	0.1555	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
myoclonic epilepsy	SCN1A	0.4026	0.09245	Nearly 700 mutations of the SCN1A gene have been identified in patients with Dravet's syndrome (severe myoclonic epilepsy of infancy), making this the most commonly mutated gene in human epilepsy.	-1
difficulties of maintaining set	PEN	0.4026	0.1324	Five indicators were calculated, including categories achieved (CA), perseverative errors in Milner (PEM) and Nelson (PEN), total errors (TE) and difficulties of maintaining set (DMS).	-1
seizures	IL-6	0.4024	0.0954	Elevated IL-6 response in patients with tonic-clonic seizures associated with inflammation of central nervous system might be due to the seizures themselves or related to the underling etiology (infection or trauma).	-1
long QT syndrome	KCNQ1	0.4023	0.4921	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
transmissible spongiform encephalopathies	PRNP	0.4023	0.1879	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
LKS	MEG	0.4022	0.07444	We report a 7-year-old boy with Landau-Kleffner syndrome (LKS), with emphasis on the effect of therapy and serial MEG.	-1
hypsarrhythmia	PEHO	0.4021	0.2032	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
seizure	IL-6	0.4021	0.05861	High seizure frequency and severe intellectual disability emerged as predictors for elevated serum levels of IL-6.	-1
seizures	SLK	0.402	0.2217	The dysphasia of development and epilepsy may be associated by chance, as a result of the same cause or the epilepsy be responsible for the TC, either because of seizures or continuously (acquired epileptic aphasia, SLK).	-1
glycosylation type 2-associated anomalies	ATPase-related	0.402	0.3026	Here, we present unique congenital disorders of glycosylation type 2-associated anomalies, including both ATPase-related and unrelated cutis laxa and sensorineural hearing loss, a recently recognized symptom of congenital disorders of glycosylation.	-1
seizures	SCN7A	0.4019	0.07104	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
Dravet syndrome	SCN1A	0.4019	0.1325	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	-1
generalized epilepsy with	SCN1A	0.4019	0.4592	[Phenotype and SCN1A gene mutation screening in 39 families with generalized epilepsy with febrile seizures plus].	-1
Rubinstein-Taybi syndrome	CASK	0.4019	0.2031	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
infancy	SCN1A	0.4019	0.4179	This study reports the identification of six de novo SCN1A mutations in patients with severe myoclonic epilepsy of infancy, including a tetranucleotide deletion in exon 26.	-1
optic atrophy	PEHO	0.4018	0.4356	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
epilepsy	CBPS	0.4018	0.1173	We have identified four CBPS patients based on neuroimaging and dysarthria patterns among the candidates for epilepsy surgery.	1
impairment of neuronal	gephyrin	0.4018	0.06325	Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy.	-1
seizures	SCN1A	0.4017	0.1524	SCN1A mutated patients (n = 58) seemed to exhibit worse psychomotor course than non-mutated ones (n = 9) (severe SQPS in 26% vs 0%), although their epilepsy tended to be less severe (tonic seizures in 12% vs 44% [p = 0.04], first status epilepticus before 6 m in 26% vs 67% [p = .02], mean number of SE 2.5 vs 4.5 [p = .09]).	-1
guanidinoacetate methyltransferase deficiency	GAMT	0.4015	0.389	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
generalized epilepsy with	SCN1A	0.4015	0.137	PURPOSE: SCN1A is the most clinically relevant epilepsy gene, most mutations lead to severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
lissencephaly	parvalbumin	0.4014	0.211	Recently, we reported the reduced expression of tyrosine hydroxylase, methionine enkephalin and parvalbumin in the brainstem in autopsy cases of lissencephaly and sequels of HIE manifested as WS/LGS, regardless of the cerebral changes.	-1
rigid spine syndrome	POMT1	0.4014	0.2251	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epilepsy of infancy with migrating focal seizures	SLC12A5	0.4013	0.4342	Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS).	-1
epileptic	CYP2C19	0.4013	0.1634	Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients.	1
Smith-Lemli-Opitz syndrome	ROGDI	0.4013	0.07417	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
sudden death	KCNH2	0.4013	0.2745	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
epilepsy	FEB4	0.4013	0.3709	Genome-wide linkage of febrile seizures and epilepsy to the FEB4 locus at 5q14.3-q23.1 and no MASS1 mutation.	-1
depressed	MECP2	0.4012	0.06264	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
limbic encephalitis	anti-Ma2	0.4012	0.09041	The diagnosis of limbic encephalitis was based on rapidly progressive symptoms, inflammatory cerebrospinal fluid, increased signal intensity in the temporal lobes on magnetic resonance imaging and the presence of anti-neuronal anti-Ma2 antibodies.	-1
epileptic encephalopathy	CDKL5	0.4011	0.04453	CONCLUSIONS: Mutations in CDKL5 gene are responsible for 7 with Hanefeld variants of RTT and 2 with early-onset epileptic encephalopathy in 71 girls as well as for 1 infantile spasms in 31 males.	1
isobutyryl-CoA dehydrogenase deficiency	HMGCS2	0.4009	0.1547	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
partial epilepsy	SCN1A	0.4009	0.31	Thus, we screened SCN1A mutations in 13 families with partial epilepsy with antecedent febrile seizures (PEFS+) using denaturing high-performance liquid chromatography and sequencing.	1
mental retardation	CDKL5/STK9	0.4009	0.2286	Recently, we showed that truncation of the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene caused mental retardation and severe neurological symptoms in two female patients.	-1
Pitt-Hopkins syndrome	FOXG1	0.4008	0.05122	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
seizures	MECP2	0.4008	0.3987	Deep brain stimulation for the management of seizures in MECP2 duplication syndrome.	-1
RE	SHANK3	0.4007	0.01102	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
seizure	SCN1A	0.4006	0.1138	CONCLUSION: The clinical features of SMEI were seizure onset within one year of age, first event is often a febrile seizure; multiple seizure types and mental delay occurred after the second year of life; seizures have a characteristic of temperature sensitivity; EEG was normal in the first year of life, followed by generalized, focal or multifocal discharges; early diagnosis by testing SCN1A mutation guides selection of antiepileptic drugs.	-1
benign familial neonatal-infantile epilepsy	SCN2A	0.4002	0.1461	Mutations in SCN2A have been identified in patients with benign familial neonatal-infantile epilepsy (BFNIE), generalised epilepsy with febrile seizures plus (GEFS+), and a small number of reported cases of other infantile-onset severe intractable epilepsy.	-1
Unverricht-Lundborg disease	SCN1A	0.4001	0.0746	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
PDD-NOS	methyl-CpG-binding protein 2	0.4001	0.1466	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
generalized epilepsy with febrile seizures	SCN1A	0.4	0.09333	Mutations in the SCN1A gene have been identified in a variety of epilepsy phenotypes, from severe encephalopathies such as Dravet syndrome to milder familial forms such as generalized epilepsy with febrile seizures plus.	-1
epilepsy	PrP(c)	0.3999	0.06377	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	1
ventriculomegaly (p<0.0001) and seizures	CC2D2A	0.3998	0.2132	Subjects with CC2D2A-related JS were more likely to have ventriculomegaly (p<0.0001) and seizures (p=0.024) than subjects without CC2D2A mutations.	-1
encephalopathies	CDKL5	0.3998	0.2023	The progressive parting of CDKL5- and FOXG1-gene-related encephalopathies from the core Rett syndrome is reflected by the effort to produce clearer diagnostic criteria for typical and atypical Rett syndrome.	-1
Rett syndrome	methyl-CpG binding protein 2	0.3997	0.1055	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
infantile epileptic encephalopathy	CDKL5	0.3997	0.1646	Turkish cases of early infantile epileptic encephalopathy: two novel mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene.	1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	FKBP14	0.3997	0.1181	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
infancy	SCN1A	0.3996	0.1729	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
ILS	PAFAH1B1	0.3995	0.07068	CONCLUSIONS: This study expanded the spectrum of PAFAH1B1 variants and identified a unique genomic architecture including microhomology sequences in PAFAH1B1 underlying an intragenic tandem duplication leading to ILS.	-1
Lennox-Gastaut syndrome	KPNA7	0.3995	0.1519	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
migration disorders	CBPS	0.3995	0.1125	Congenital bilateral perisylvian syndrome(CBPS) is a recently described disease identify characterized by pseudobulbar palsy, epilepsy, mental retardation, and migration disorders in the bilateral perisylvian area.	-1
metabolic syndrome	C-reactive protein	0.3995	0.2771	This narrative review considers the influence of AEDs on some predictors of vascular risk [i.e. weight, insulin resistance, metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, vitamins, coagulation factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix metalloproteinase-9].	-1
epilepsy Dravet syndrome	SCN1A	0.3991	0.1364	Mutations in the gene encoding the a1 subunit of the voltage gated sodium channel (SCN1A) are associated with several epilepsy syndromes, ranging from relatively mild phenotypes found in families with genetic epilepsy with febrile seizures plus (GEFS+) to the severe infant-onset epilepsy Dravet syndrome.	1
dystroglycanopathies	FKRP	0.3991	0.3471	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
dystroglycanopathies	FKTN	0.3991	0.3471	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Dravet syndrome	SCN1B	0.3991	0.3661	Approximately 80% of patients with Dravet syndrome have been associated with heterozygous mutations in SCN1A gene encoding voltage-gated sodium channel (VGSC) a(I) subunit, whereas a homozygous mutation (p.Arg125Cys) of SCN1B gene encoding VGSC b(I) subunit was recently described in a patient with Dravet syndrome.	-1
atypical RTT	CDKL5	0.399	0.1674	The proportion of CDKL5 patients meeting the recent Neul criteria for atypical RTT was determined.	-1
Miller-Dieker syndrome	ARX	0.399	0.09553	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
ocular anomalies	TCF4	0.3988	0.06113	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
hypophosphatemia	C-reactive protein	0.3986	0.09028	Significant elevations in C-reactive protein levels and reductions in sodium levels were observed during hypophosphatemia episodes.	-1
pituitary deficiency	neurofibromatosis type 1	0.3985	0.3678	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Gitelman Syndrome	SLC12A3	0.3985	0.06764	Gitelman Syndrome in a School Boy Who Presented with Generalized Convulsion and Had a R642H/R642W Mutation in the SLC12A3 Gene.	-1
hereditary diseases	PRNP	0.3985	0.2648	Mutations in the human prion protein gene (PRNP) are responsible for hereditary diseases called transmissible spongiform encephalopathies (TSE) and a polymorphic site at codon 129 determines sensitivity to infectious forms of these maladies.	-1
lissencephaly-pachygyria	XLIS	0.3984	0.06231	Most cases of lissencephaly-pachygyria are caused by mutations of LIS1 and XLIS genes.	-1
tter-T  nz syndrome	ACADSB	0.3984	0.1077	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
DRE	MECP2	0.3982	0.1027	The relationship between DRE and RTT genotype category (i.e. gene deletion, gene duplication, early truncating mutation, late truncating mutation, and missense mutation) or a specific MECP2 genotype was tested using the chi-square test.	1
Dravet syndrome	SCN1A	0.3981	0.3038	Analysis of SCN1A mutation and parental origin in patients with Dravet syndrome.	-1
glioblastoma	TEN 4	0.3981	0.09863	A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.	-1
epilepsy	SCN1A	0.3979	0.1103	In this case series, the authors describe the clinical features, surgical pathology, and outcomes in 6 patients with SCN1A mutations and refractory epilepsy who underwent focal cortical resection prior to uncovering the genetic basis of their epilepsy.	1
CMD	CMD1D	0.3979	0.2094	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
hearing loss	KCNQ5	0.3978	0.3928	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
deafness	KCNQ4	0.3978	0.4438	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
HH syndrome	SCN1A	0.3978	0.2219	SCN1A mutations may need to be further explored in patients with HH syndrome without features of SMEI.	-1
LQTS	hERG	0.3978	0.18	Mutations in the human ether  -    -go  -go  -related gene (hERG) are responsible for long  -QT syndrome (LQTS) type 2 (LQT2).	-1
OS	KCNQ2	0.3977	0.1392	In two OS cases, we found de novo non-synonymous mutations in the genes KCNQ2 and SCN2A.	-1
WS	NF1	0.3976	0.351	MATERIAL AND METHODS: We studied 15 patients with WS and DS with a follow-up of 1.5 to 9 years, 5 patients with WS and NF1 followed-up form 2 to 6 years and 10 patients with WS associated with CP and PL followed-up during 2.5 to 12 years.	-1
infantile convulsions and choreoathetosis	BFIC	0.3976	0.2885	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
genetic disorder	FVIII	0.3976	0.1347	Hemophilia A is a genetic disorder leading to factor VIII (FVIII) deficiency, an important factor in the coagulation system.	-1
hippocampal sclerosis	prion protein	0.3975	0.0923	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
benign familial neonatal seizures type 1	Kv7.2	0.3973	0.2384	Mutations in voltage-gated potassium channel Kv7.2 are responsible for benign familial neonatal seizures type 1, a rare monogenic autosomal dominant inherited epilepsy syndrome.	-1
Cowden syndrome	PTEN	0.3973	0.3214	Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy.	-1
encephalopathy	MECP2-mutated	0.3972	0.2211	"CONCLUSIONS: Although RTT MECP2-mutated patients suffer from a serious and progressive encephalopathy, it is ""epileptogenic"" but not ""DREgenic"" as they have a decreased risk (16%) for DRE compared to the general epileptic population (DRE: 20-40%)."	-1
Dravet syndrome	SCN1A	0.3972	0.05838	In addition, genetic analysis for Dravet syndrome showed the presence of heterozygous disease-causing mutation SCN1A NM_001165963.1:c.4494delC; NP_001159435.1:p.	-1
epilepsy	thrombin	0.3972	0.1328	Other highlights included studies on neural repair, new guidelines for the treatment of epilepsy and important studies comparing the thrombin inhibitor ximelagatran to warfarin for the prevention of stroke.	-1
Nance-Horan syndrome	cyclin-dependent kinase-like 5	0.3971	0.1623	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
DRE	MECP2-mutated	0.3971	0.2017	RESULTS: Prevalence of DRE was 16% (i.e. 16 DRE out of 100 MECP2-mutated RTT epileptic patients).	1
Miller-Dieker syndrome	LIS1	0.3969	0.1277	LIS1 is the deleted gene within this region and is thought to directly cause isolated lissencephaly sequence and contribute to Miller-Dieker syndrome.	-1
Rett	CDKL5	0.3969	0.1369	A total of 62 (69%) patients remained without molecular genetics diagnosis that necessitates further search for mutations in other genes like CDKL5 and FOXG1 that are known to cause Rett phenotype.	-1
RTT	methyl CpG binding protein 2	0.3969	0.1217	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
neurodevelopmental disorder	MeCP2	0.3969	0.03682	Rett syndrome, a neurodevelopmental disorder affecting mainly females, is caused by a mutation of the MeCP2 gene.	-1
rolandic epilepsy	KCNQ3 p.Ala381Val	0.3969	0.2417	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
abdominal pain	C-reactive protein	0.3969	0.154	Eight weeks after the start of infliximab, her abdominal pain disappeared and C-reactive protein decreased, followed by the successful change to adalimumab infusion therapy.	-1
FS	SCN1A	0.3969	0.1947	We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation.	-1
ID	PHF6	0.3968	0.05886	CONCLUSIONS: Our findings indicate that de novo defects in PHF6 in females result in a recognisable phenotype which might have been under-recognised so far and which comprises variable ID, a characteristic facial gestalt, hypoplastic nails, brachydactyly, clinodactyly mainly of fingers IV and V, dental anomalies, and linear skin hyperpigmentation.	-1
stroke	thrombin	0.3968	0.1502	Other highlights included studies on neural repair, new guidelines for the treatment of epilepsy and important studies comparing the thrombin inhibitor ximelagatran to warfarin for the prevention of stroke.	-1
FS	SCN1B	0.3967	0.1132	Several genes have been localized for FS by linkage analysis, and three GEFS+ genes (SCN1A, SCN1B, GABRG2) have been identified.	-1
epilepsy	SCN1A	0.3967	0.07052	Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene.	1
temporal lobe epilepsy	PIP-syndrome	0.3966	0.1466	We describe four patients with left temporal lobe epilepsy who developed psychosis, intermittent polydipsia and hyponatremia (PIP-syndrome) while being treated with carbamazepine.	-1
hearing loss	ACADSB	0.3966	0.07171	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
LMNA-related CMD	POMT1	0.3966	0.2384	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
tumor	interleukin-6	0.3965	0.106	We measured both plasma and cerebrospinal fluid cytokine levels in a girl with HH syndrome, and found elevated plasma concentrations of soluble interleukin-2 receptor and tumor necrosis factor-alpha, and a slightly increased plasma level of interleukin-6.	-1
Dravet syndrome	Na(V)1.1	0.3965	0.03991	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	-1
Lissencephaly	LIS1	0.3964	0.1841	Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms.	-1
epileptic disorder	SCN1A	0.3964	0.09054	OBJECTIVES: The aim of this study was to determine the genetic defect in a 4-generational family with an epileptic disorder characterized by febrile and afebrile polymorphic seizures and mild to severe mental retardation by means of analyzing the neuronal voltage-gated sodium channel alpha-subunit gene SCN1A for mutations.	1
JME	malin	0.3963	0.1947	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
Dravet syndrome	GABRG2	0.3962	0.1702	We screened for mutations of SCN1A, SCN2A and GABRG2 (the gene encoding gamma2 subunit of the GABA(A) receptor) in 59 patients with Dravet syndrome and found 29 SCN1A mutations and three missense SCN2A mutations.	-1
Drug-resistant epilepsy	MECP2	0.3962	0.05896	Drug-resistant epilepsy and epileptic phenotype-EEG association in MECP2 mutated Rett syndrome.	1
DS	SCN1A	0.3962	0.08748	DS has a genetic etiology: between 70% and 80% of patients carry sodium channel a1 subunit gene (SCN1A) abnormalities, and truncating mutations account for about 40% and have a significant correlation with an earlier age of seizures onset.	-1
cutis laxa	ATPase-related	0.3961	0.2844	Here, we present unique congenital disorders of glycosylation type 2-associated anomalies, including both ATPase-related and unrelated cutis laxa and sensorineural hearing loss, a recently recognized symptom of congenital disorders of glycosylation.	-1
epileptic encephalopathy	SCN1A	0.396	0.0846	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	1
developmental delay and	fibroblast growth factor receptor 3	0.3959	0.1914	[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene].	-1
TIAs	aura-like	0.3958	0.1381	BACKGROUND AND PURPOSE: Convexity subarachnoid haemorrhage (cSAH) has recently been recognised as a cause of recurrent aura-like symptoms, mimicking transient ischaemic attacks (TIAs).	-1
isobutyryl-CoA dehydrogenase deficiency	ACAD8	0.3958	0.1909	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Rett (	EHMT1	0.3956	0.05251	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
FCDs	mTOR	0.3956	0.1429	Disruption of the mammalian target of rapamycin (mTOR) signaling comprises a common pathway underlying the structural and electrical disturbances of some FCDs.	-1
seizures	SCN2A	0.3955	0.09956	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	-1
Muenke syndrome	FGFR3	0.3955	0.162	The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.	-1
Cowden syndrome	PTEN	0.3954	0.2743	An atypical patient with Cowden syndrome and PTEN gene mutation presenting with cortical malformation and focal epilepsy.	-1
RTT	CDKL5	0.3954	0.1102	CONCLUSIONS: Mutations in CDKL5 gene are responsible for 7 with Hanefeld variants of RTT and 2 with early-onset epileptic encephalopathy in 71 girls as well as for 1 infantile spasms in 31 males.	-1
seizures	SLC25A12	0.3953	0.1427	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
seizures	TCF4	0.3953	0.061	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
constipation	TCF4	0.3953	0.061	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
Dravet syndrome	SCN1A	0.3952	0.0776	Dravet syndrome is most frequently caused by various mutations of the SCN1A gene encoding the type 1 subunit of the neuronal voltage-gated sodium channel.	-1
optic nerve atrophy	PEHO	0.3952	0.4133	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are associated with subcutaneous edema, visual deficit, early arrest of psychomotor development, seizures, and cerebellar atrophy.	-1
Lhermitte-Duclos Syndrome	Neurofibromatosis 1	0.3952	0.288	Continuous Spike and Wave in Slow-Wave Sleep in a Patient With Rett Syndrome and in a Patient With Lhermitte-Duclos Syndrome and Neurofibromatosis 1.	-1
AEDs	CD8	0.3951	0.09874	In a nested cohort of 55 AED-treated patients receiving cART and aviremic, chronic exposure to sodium and calcium channel blocking AEDs was associated with increased CD4+ T cell levels (p <0.05) with no change in CD8+ T cell levels over 12 months from the beginning of AED therapy.	-1
Dravet syndrome	SCN2A	0.3951	0.234	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	-1
seizure	SCN1A	0.3951	0.1729	In the present work, the impact of vaccination on seizure onset and clinical outcome of SCN1A mutation-positive patients is addressed.	-1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	EDSKMH	0.3949	0.07964	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
infancy	SCN1A	0.3949	0.2281	BACKGROUND: SCN1A is the most clinically relevant epilepsy gene, most mutations causing Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI).	-1
callosal injury	MRI	0.3949	0.2991	This is, to the best of our knowledge, the most extensive callosal injury documented by MRI to date.	-1
oedema	PEHO	0.3949	0.2231	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
seizures	SCN1A	0.3947	0.1891	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
Convulsion	SLC12A3	0.3947	0.07488	Gitelman Syndrome in a School Boy Who Presented with Generalized Convulsion and Had a R642H/R642W Mutation in the SLC12A3 Gene.	-1
cerebral amyloid angiopathy	A beta	0.3946	0.1343	To explore the clinical effects of inflammation associated with vascular deposits of the amyloid beta peptide (A beta), we analyzed 42 consecutive patients with pathologically diagnosed cerebral amyloid angiopathy (CAA) for evidence of an inflammatory response.	-1
DS	SCN1A	0.3946	0.009972	Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic syndrome that is caused by mutations in the neuronal voltage-gated sodium channel alpha1 subunit gene SCN1A.	-1
impaired glucose tolerance	MODY2	0.3946	0.04437	Fasting hyperglycemia in the diabetic range, impaired glucose tolerance, and lack of diabetes autoantibodies were compatible with MODY2.	-1
RTT	methyl-CpG binding protein 2	0.3945	0.04299	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
CSS	ARID1B	0.3945	0.09023	We identified heterozygous mutations in either of six genes (SMARCA4, SMARCB1, SMARCA2, SMARCE1, ARID1A, and ARID1B) in 20 out of 23 CSS patients.	-1
severe mental retardation	methyl CpG-binding protein 2	0.3945	0.2276	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
SMEI/DS-like epilepsies	SCN1A	0.3944	0.1116	Furthermore, our study supports that array CGH is a competent technique for screening SCN1A mutation-negative patients diagnosed with SMEI/DS-like epilepsies and dysmorphic features, generating rapid and high-resolution data of genomic imbalances present in the patients.	1
DS	Nav1.1	0.3944	0.05191	We previously characterized two Nav1.1 mutants-R859H (GEFS+) and R865G (DS)-at room temperature and reported a mixture of biophysical gating defects that could not easily predict the phenotype presentation as either GEFS+ or DS.	-1
psychoneurological disorders	NF-1	0.3944	0.3391	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
allelic disorders	KCNJ2	0.3943	0.03219	Over the past decade mutations in genes encoding three ion channels, CACN1AS, SCN4A and KCNJ2, have been identified and account for at least 70% of the identified cases of PP and several allelic disorders.	-1
Rett syndrome	MECP2	0.3943	0.2369	We analysed 185 females from three cohorts: 42 with Rett syndrome who were negative for MECP2 and CDKL5 mutations, 57 with autism spectrum disorders, and 86 with epilepsy with or without intellectual disability.	-1
SCA28	SPG7	0.3943	0.2769	"This produced an early-onset clinical syndrome that combines the severe phenotypes of SPG7 and SCA28, in additional to other ""mitochondrial"" features such as oculomotor apraxia, extrapyramidal dysfunction, and myoclonic epilepsy."	-1
sporadic Dravet syndrome	SCN1B	0.3942	0.1813	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
language dysfunction	GRIN2A	0.3942	0.2537	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.	-1
cerebellar vermis hypoplasia	KPNA7	0.3941	0.2372	Here, we describe autosomal recessive mutations in KPNA7 found by whole exome sequencing in a sibling pair with severe developmental disability, infantile spasms, subsequent intractable epilepsy consistent with Lennox-Gastaut syndrome, partial agenesis of the corpus callosum, and cerebellar vermis hypoplasia.	-1
myoclonic epilepsy	SCN1A	0.3941	0.07091	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
PHA	CD8	0.3941	0.1122	We measured white blood cell counts, lymphocyte counts, T/B cell counts, CD4(+) and CD8(+) T cell counts, CD 4/8 ratio, lymphocyte blastoid transformation by PHA or Con-A, and the levels of IgA, IgM, and IgG before, immediately after, and 1, 3, 6, and 12 months after ACTH therapy.	-1
generalized epilepsy with febrile seizures plus additional symptoms	SCN1A	0.394	0.1629	Missense mutations in the voltage-gated sodium channel a1 subunit gene (SCN1A) were firstly identified in patients with generalized epilepsy with febrile seizures plus additional symptoms (GEFS + ).	-1
genetic epilepsy	SCN2A	0.3939	0.2023	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
DS	SCN1A	0.3939	0.1259	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
long QT syndrome	KCNQ1	0.3938	0.1248	Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome.	-1
myoclonic epilepsy	SCN1A	0.3938	0.3822	Review of the literature indicates that recurrent mutations account for 25% of SCN1A mutations in severe myoclonic epilepsy of infancy, including six sites of deamination at CpG dinucleotides.	-1
HEK	hNa(V)1.6	0.3938	0.2782	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
refractory epilepsy	interleukin-6	0.3936	0.1406	The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy.	-1
Dravet syndrome	SCN1A	0.3936	0.36	Mosaicism of a missense SCN1A mutation and Dravet syndrome in a Roma/Gypsy family.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	ACAD8	0.3936	0.0695	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
WRS	MEDS	0.3935	0.03825	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
BFLS	PHF6	0.3935	0.1517	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
respiratory infections	MECP2	0.3935	0.2591	Interestingly, they did not exhibit other clinical features commonly observed in American-European patients with MECP2 duplication, including recurrent respiratory infections and epilepsy.	-1
ataxia	NARP	0.3933	0.05627	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
) syndrome	TCF4	0.3933	0.1075	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
febrile seizures	MASS1	0.3932	0.135	Genome-wide linkage of febrile seizures and epilepsy to the FEB4 locus at 5q14.3-q23.1 and no MASS1 mutation.	-1
cSE	SCN1A	0.3931	0.1159	The purpose of this study is to correlate different types of SCN1A mutations and (1) seizure control, (2) occurrence of convulsive status epilepticus (cSE), and (3) the presence of crouch gait in adult patients.	-1
temporal lobe epilepsy	SCN1A	0.3931	0.2429	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	-1
DS	c.4205_4208delGAAA	0.393	0.1775	Analysis of SCN1A revealed a heterozygous de novo frameshift mutation (c.4205_4208delGAAA) in the patient with DS, and a recurrent missense mutation (c.3521C>G) in that suffering from MAE.	-1
intractable childhood epilepsy with generalized tonic-clonic seizures	SCN1A	0.393	0.09846	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
dystonia	SCA-14	0.393	0.1288	This case illustrates that both myoclonus and dystonia are part of the clinical spectrum in SCA-14 and that myoclonus can even be the presenting symptom.	-1
neonatal diabetes syndrome	IER3IP1	0.3929	0.1771	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
autosomal recessive disorders	SLC6A8	0.3929	0.1817	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
autosomal recessive disorders	SLC6A8	0.3929	0.1817	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
vascular malformations	VCAM-1	0.3929	0.07988	There is an aberrant expression of ELAM-1 and VCAM-1 in the meningeal vascular proliferation similar to what is observed with other vascular malformations and tumors.	-1
Unverricht-Lundborg disease	cystatin B	0.3928	0.3033	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
hyperventilation	TCF4	0.3928	0.09232	Our review of previously reported cases with TCF4 mutations and deletions showed that all patients with Pitt-Hopkins syndrome reported to date have severe psychomotor retardation, the onsets of seizures and hyperventilation episodes are limited to the first decade in most reported patients with Pitt-Hopkins syndrome, hyperventilation episodes are more common than seizures and are seen in the oldest patients, and individuals with missense TCF4 mutations are more likely to develop seizures.	-1
BFNS	KCNQ2	0.3928	0.1736	This review is focused on recent findings on the neuronal K(V)7 channelopathies, in particular on benign familial neonatal seizures (BFNS) and peripheral nerve hyperexcitability (PNH, neuromyotonia, myokymia) caused by KCNQ2 mutations.	-1
Kufor-Rakeb syndrome	PARK9	0.3927	0.3188	We report the clinical features of the original Chilean family with Kufor-Rakeb syndrome (KRS) that led to the discovery of the ATP13A2 gene at the PARK9 locus.	-1
fCJD	PrPc	0.3927	0.04606	Patients with fCJD have mutations in the gene encoding PrPc (PRNP) (Vercueil 2006, Collins et al. 2004).	-1
agyria-pachygyria	LIS1	0.3926	0.06345	The most frequent forms of lissencephaly (agyria-pachygyria) are caused by mutations of LIS1.	-1
ragged red fibers	NCL	0.3924	0.05097	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
autism-associated	MECP2	0.3924	0.1849	Based on the published literature, MECP2 is the most autism-associated gene among the identified CNVs.	-1
Dravet syndrome	SCN1A	0.3923	0.3649	An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in seizures when treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine.	-1
tumor	CA4	0.3923	0.1514	A routine neuropathological examination showed no pronounced changes, such as neuronal loss, morphologically abnormal neurons, inflammation, vascular changes, Lafora bodies and tumor cells, except that mild gliosis was seen only in CA4 of the hippocampus.	-1
epilepsy	GluR3	0.3923	0.103	Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome.	-1
Peutz-Jeghers syndrome	STK11	0.3922	0.08393	BACKGROUND: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene.	-1
mental retardation	MECP2	0.3921	0.2502	We report a novel C-terminal MECP2 frameshift deletion (1135_1142delCCCGTG CC) in a 19-year-old woman with mental retardation and epilepsy.	-1
LGS	March 1	0.392	0.0758	METHODS: Between March 1, 1990 and April 1, 2013, 61 patients who met diagnostic criteria of LGS were seen at our department.	-1
Dravet syndrome	SCN1A	0.3919	0.3726	This report of parental SCN1A nonsense mutation mosaicism in familial Dravet syndrome suggests that mosaicism might be more common than previously suspected and emphasizes the importance of taking mosaicism into account in genetic counselling of Dravet syndrome and SCN1A mutations.	-1
intellectual disability	laminin alpha-2-deficient	0.3918	0.08444	Cognitive impairment ranging from intellectual disability to mild cognitive delay, structural brain and/or eye abnormalities, and seizures are found almost exclusively in the dystroglycanopathies while white matter abnormalities without major cognitive involvement tend to be seen in the laminin alpha-2-deficient subtype.	-1
CMD	POMT1	0.3917	0.2457	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
EA	HNF1B	0.3917	0.2308	Because EA has already been identified in patients with 17q12 duplication or HNF1B point mutation, we screened HNF1B (QMPSF and direct sequencing) in nine additional patients with EA and renal abnormalities but failed to identify any pathogenic variant.	-1
epilepsy	MBD5	0.3916	0.1213	Individuals with deletions across the MBD5 gene also present with ASDs, impaired speech, intellectual difficulties, repetitive behaviors, and epilepsy.	-1
developmental delay	ABCC8	0.3916	0.3576	We identified a novel heterozygous mutation, F132L, in the ABCC8 gene of a patient with severe developmental delay, epilepsy and neonatal diabetes (DEND syndrome).	-1
spasms	MECP2	0.3915	0.1497	Late onset epileptic spasms is frequent in MECP2 gene duplication: electroclinical features and long-term follow-up of 8 epilepsy patients.	-1
WFS	WFS1	0.3914	0.4171	We detected an 8.3 Mb terminal deletion and an adjacent 2.6 Mb inverted duplication in the short arm of chromosome 4, which encompasses a gene associated with WFS (WFS1).	-1
merosin deficiency	CMD1D	0.3913	0.1785	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
epilepsy	YWHAE	0.3912	0.1441	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
Landau-Kleffner syndrome	GRIN2A	0.3912	0.3755	Response to immunotherapy in a patient with Landau-Kleffner syndrome and GRIN2A mutation.	-1
HHE syndrome	SCN1A	0.3912	0.1318	We previously identified a 2 bp-deletion mutation in SCN1A in a Dravet patient, and we found out the patient also had HHE syndrome upon clinical re-evaluation.	1
West syndrome	GAMT	0.3912	0.4329	CONCLUSIONS: To our knowledge, this is the second report of the occurrence of West syndrome in GAMT deficiency.	-1
Christianson syndrome	EP300	0.3911	0.2915	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Smith-Lemli-Opitz syndrome	3-hydroxy-3-methylglutaryl-CoA synthase 2	0.3911	0.2833	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
BFNC	KCNQ2	0.391	0.04233	In one of those three children, a de novo missense mutation was detected in the voltage gated potassium channel gene KCNQ2, indicating a genetic relationship between drug refractory neonatal seizures of unknown etiology with tonic clonic or myoclonic sequences and the well-known syndrome of benign familial neonatal convulsions (BFNC).	-1
ventriculomegaly and/or seizures	CC2D2A	0.391	0.06552	CONCLUSIONS: CC2D2A testing should be prioritised in patients with JS and ventriculomegaly and/or seizures.	-1
cerebral palsy	NF1	0.3909	0.3201	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
limbic encephalitis	interleukin (IL)-6	0.3909	0.1339	We report two cases of non-herpetic acute limbic encephalitis (NHALE) which showed elevation of interleukin (IL)-6 in the cerebrospinal fluid (CSF).	-1
Rett syndrome	malin	0.3908	0.1652	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
SMEI	SCN1A	0.3907	0.2058	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
Dravet syndrome	sodium channel, voltage-gated, type I, alpha subunit	0.3906	0.3284	The child was subsequently found to have a de novo mutation of the sodium channel, voltage-gated, type I, alpha subunit (SCN1A) gene consistent with Dravet syndrome.	-1
inflammation	A beta	0.3905	0.2461	To explore the clinical effects of inflammation associated with vascular deposits of the amyloid beta peptide (A beta), we analyzed 42 consecutive patients with pathologically diagnosed cerebral amyloid angiopathy (CAA) for evidence of an inflammatory response.	-1
Lafora disease	MECP2	0.3905	0.03776	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
dystroglycanopathies	RSMD1	0.3905	0.1531	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
FS	SCN1A	0.3904	0.1646	We postulated that earlier onset of febrile seizures in the febrile seizure (FS) and febrile seizure plus (FS+) phenotypes may occur in the presence of a SCN1A mutation.	-1
epileptic	NF1	0.3904	0.3492	Complex epileptic (Foix-Chavany-Marie like) syndrome in a child with neurofibromatosis type 1 (NF1) and bilateral (opercular and paracentral) polymicrogyria.	-1
Rett syndrome	MECP2-related	0.3904	0.1405	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
CMD	FCMD	0.3902	0.1136	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
isobutyryl-CoA dehydrogenase deficiency	HSD17B10	0.3902	0.1356	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	SCN1A-Related	0.3902	0.03558	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	1
familial hemiplegic migraine	SCN1A	0.3901	0.07156	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
WWS	FCMD	0.3901	0.06499	"Based on these observations, we consider the clinical spectrum of FCMD to be much broader than previously described and to overlap with that of ""mild"" WWS and MEBD."	-1
GS	SLC12A3	0.3901	0.07662	A presumptive diagnosis of Gitelman syndrome (GS) was then made and the patient's peripheral blood mononuclear cells were subjected to sequence analysis of the SLC12A3 gene, which encodes a thiazide-sensitive sodium-chloride cotransporter.	-1
Ullrich CMD	CMD1A	0.39	0.1533	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
West syndrome	NR2B	0.39	0.2186	RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy.	-1
epilepsy	CDKL5	0.39	0.1052	METHODS: We performed mutation screening of CDKL5 in 60 female patients who had been identified as negative for the methyl CpG-binding protein 2 gene (MECP2) mutations, but who had current or past epilepsy, regardless of the age of onset, type, and severity.	1
seizures	Jun	0.3899	0.1772	OBJECTIVE: To assess the prognosis of epilepsy, the possibility of achieving remission of seizures, in patients who were identified in a population-based study carried out in Jun  n, a city of about 70,000 inhabitants in Buenos Aires Province, Argentina.	-1
rolandic epilepsy	KCNQ3 p.Pro574Ser	0.3898	0.2077	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
Dravet syndrome	SCN1A	0.3898	0.05298	More than 800 mutations in the voltage-gated sodium channel SCN1A have been reported in patients with generalized epilepsy with febrile seizures plus and Dravet syndrome.	-1
Aicardi-Gouti  res syndrome	3-phosphoglycerate dehydrogenase	0.3898	0.2149	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
Rett syndrome	MECP2	0.3897	0.3099	Here we explore the spectrum of mutations affecting the MECP2 gene in a group of 25 classic Rett syndrome girls and in three patients with the preserved speech variant.	-1
Rett syndrome	dihydropteridine reductase	0.3897	0.1188	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
FS	GABRG2	0.3896	0.09504	Several genes have been localized for FS by linkage analysis, and three GEFS+ genes (SCN1A, SCN1B, GABRG2) have been identified.	-1
tumor	MMP-9	0.3896	0.3322	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
seizures	hNav1.3	0.3895	0.0126	Subsequent structure-activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models.	-1
autoimmune polyglandular disease	holoprosencephaly-1	0.3895	0.2629	In conclusion, the map location and the homology to a gene family involved in a large variety of biological processes including signal transduction and development make PWP2H an intriguing candidate for EPM1 as well as for APECED (autoimmune polyglandular disease) and HPE1 (holoprosencephaly-1) that also map in this region of chromosome 21.	-1
Aicardi-Gouti  res syndrome	dihydropteridine reductase	0.3895	0.1155	Secondary forms of CFD have been recognized during chronic use of antifolate and anticonvulsant drugs and in various known conditions such as Rett syndrome, Aicardi-Gouti  res syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.	-1
Prader-Willi/Angelman Syndrome	OCA2	0.3895	0.1322	Chromosomal fluorescence in situ hybridization (FISH) showed the SMC to be originating from chromosome 15, dicentric and containing four copies of the Prader-Willi/Angelman Syndrome Critical Region (PWACR), including the OCA2 gene.	-1
limbic encephalitis	GluN1	0.3895	0.1309	In patient with non-paraneoplastic, non-herpetic acute limbic encephalitis (NHALE), antibodies against GluN2B (GluR  2) and GluN1 (Glu  1) are detected in the sera and CSF.	-1
severe myoclonic epilepsy of infancy	SCN1A	0.3894	0.2089	Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy.	-1
cardiac long QT syndrome	LQT1	0.3893	0.1784	Here, we find that epilepsy occurs in mouse lines bearing dominant human LQT1 mutations for the most common form of cardiac long QT syndrome, which causes syncopy and sudden death.	-1
SMEI	SCN1A	0.3891	0.1088	Several mutations of the sodium channel alpha 1 subunit (SCN1A ) gene were reported in patients with SMEI.	-1
infancy	SCN1A	0.389	0.07833	Recently, mutations of the neuronal voltage-gated sodium channel alphasubunit type 1 gene (SCN1A) have been found in SMEI [Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., De Jonghe, P., 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.	-1
neurodegenerative disorder	PEHO	0.3889	0.2235	PEHO syndrome (progressive encephalopathy, peripheral edema, hypsarrhythmia, and optic atrophy) is a neurodegenerative disorder first characterized in Finnish patients.	-1
status epilepticus	Nav1.1	0.3889	0.03371	However, there are different potentially causative factors, including the specific effects on the Nav1.1 channels caused by the underlying genic or genomic defect; frequent and prolonged convulsive and non-convulsive seizures or status epilepticus; recurrent subtle ictal phenomena, such as that accompanying pronounced visual sensitivity; the use of antiepileptic drugs with cognitive side effects, especially in heavy multiple-drug therapy; and the restrictions that children with severe epilepsy inevitably undergo.	-1
epilepsy	NF1	0.3888	0.09009	KEY FINDINGS: In individuals with NF1, 9.5% had a history of at least one unprovoked seizure, and 6.5% had documented epilepsy.	-1
developmental delay	MECP2	0.3888	0.2765	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
epileptic encephalopathy	STXBP1	0.3887	0.2322	Somatic mosaicism, including germline, has been described in several epileptic encephalopathies such as Dravet syndrome, KCNQ2 neonatal epileptic encephalopathy, SCN8A epileptic encephalopathy and STXBP1 related Ohtahara syndrome.	1
Dravet syndrome	SCN1A	0.3886	0.5192	This study examines whether microdeletions and duplications of the gene encoding a1 subunit of the sodium channel (SCN1A) are underlying causes in Dravet syndrome (DS) with SCN1A missense mutation.	-1
ICEGTC	SCN1A	0.3886	0.06082	The SCN1A gene was screened for mutations in three unrelated Japanese families with generalized epilepsy with febrile seizure plus (GEFS+), febrile seizure with myoclonic seizures, or intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC).	-1
status epilepticus	SCN1A	0.3885	0.01793	(2) SCN1A testing should be considered in people with possible DS where the typical initial presentation is of a developmentally normal infant presenting with recurrent, febrile or afebrile prolonged, hemiclonic seizures or generalized status epilepticus.	-1
Rubinstein-Taybi syndrome	CDKL5	0.3885	0.1765	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
neurofibroma	NF1	0.3885	0.0593	The neurofibroma is the hallmark lesion of NF1 that develops from peripheral nerves.	-1
PHS	TCF4	0.3884	0.1891	"These findings demonstrate that TCF4 anomalies are responsible for PHS and provide the first evidence of a human disorder related to class I basic helix-loop-helix transcription-factor defects (also known as ""E proteins"")."	-1
Febrile infection-related epilepsy syndrome	PCDH19	0.3884	0.1839	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
Huntington's disease	IT15	0.3884	0.06761	The disorder was diagnosed as Huntington's disease (HD), but analysis of the IT15 gene for HD revealed normal alleles.	-1
CMD	ISPD	0.3882	0.153	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
cardiovasculary disease and type 2 diabetes mellitus	CB1	0.3882	0.1408	It is therefore possible to speculate about a future clinical use of CB1 antagonists, as a means of improving gonadotrophin pulsatility and fertilization capacity as well as the prevention of cardiovasculary disease and type 2 diabetes mellitus.	-1
seizures	KCNQ2	0.3881	0.08083	CONCLUSION: Previously reported mutations of KCNQ2 were mainly identified in BFNC family in which at least one individual had an onset of seizures during the first week of life, a hallmark of the BFNC disorder.	-1
autosomal recessive disorders	GAMT	0.3881	0.1306	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
genetic generalized epilepsies	SCN1A-related	0.3881	0.1901	In this review we describe the genetic advances in progressive myoclonus epilepsies, which are strictly monogenic disorders, genetic generalized epilepsies, mostly exhibiting complex genetic inheritance, and SCN1A-related phenotypes, namely genetic generalized epilepsy with febrile seizure plus and Dravet syndrome.	-1
benign familial neonatal-infantile epilepsy	KCNQ2	0.3881	0.08066	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
febrile seizures plus syndrome	SCN1A-related	0.3881	0.07958	Underlying causes were identified in 15 children (65%) and included SCN1A-related Dravet syndrome (formerly severe myoclonic epilepsy of infancy) or genetic epilepsy with febrile seizures plus syndrome (n = 8 and n = 1, respectively), a protocadherin 19 mutation, a 1qter microdeletion, neuronal migration disorders (n = 2), and other monogenic familial epilepsy (n = 2).	-1
non-convulsive seizures	Nav1.1	0.3881	0.04027	However, there are different potentially causative factors, including the specific effects on the Nav1.1 channels caused by the underlying genic or genomic defect; frequent and prolonged convulsive and non-convulsive seizures or status epilepticus; recurrent subtle ictal phenomena, such as that accompanying pronounced visual sensitivity; the use of antiepileptic drugs with cognitive side effects, especially in heavy multiple-drug therapy; and the restrictions that children with severe epilepsy inevitably undergo.	-1
supplementary motor area	SMA	0.388	0.3622	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
febrile seizures	FEB4	0.388	0.2948	This candidate region overlapped with a previously reported locus for febrile seizures (FEB4) in the Japanese population, in which MASS1 was proposed as disease gene.	-1
Alzheimer's disease	AbPP	0.388	0.1402	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
17-beta-hydroxysteroid dehydrogenase X deficiency	EDSKMH	0.3879	0.08989	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
seizure	SCN1A	0.3879	0.1067	CONCLUSION: The clinical features of SMEI were seizure onset within one year of age, first event is often a febrile seizure; multiple seizure types and mental delay occurred after the second year of life; seizures have a characteristic of temperature sensitivity; EEG was normal in the first year of life, followed by generalized, focal or multifocal discharges; early diagnosis by testing SCN1A mutation guides selection of antiepileptic drugs.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.3879	0.09106	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
benign familial neonatal convulsions	KCNQ2	0.3878	0.1132	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	-1
neonatal diabetes syndrome	MEDS	0.3877	0.3474	Wolcott-Rallison syndrome (WRS) and the recently delineated microcephaly with simplified gyration, epilepsy, and permanent neonatal diabetes syndrome (MEDS) are clinically overlapping autosomal recessive disorders characterized by early onset diabetes, skeletal defects, and growth retardation.	-1
neuronal migration disorder	MEG	0.3876	0.1119	Several studies have been performed using neuroradiological or neurophysiological techniques, like SPECT, PET, MRS, fMRI, and MEG, in attempt to better characterize this neuronal migration disorder.	-1
rigid spine syndrome	laminin alpha-2	0.3876	0.1246	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epilepsy	laforin	0.3876	0.2057	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	1
developmental delay	EXOC6B	0.3875	0.4481	Disruption of EXOC6B in a patient with developmental delay, epilepsy, and a de novo balanced t(2;8) translocation.	-1
Wilson syndrome	ZEB2	0.3875	0.2244	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
hippocampal sclerosis	Prnp	0.3874	0.06265	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
pigmentary dysplasia	OCA2	0.3874	0.3878	Hexasomy of the Prader-Willi/Angelman critical region, including the OCA2 gene, in a patient with pigmentary dysplasia: case report.	-1
AED-responsive epilepsy syndrome	MVP	0.3874	0.04507	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
neurocutaneous syndrome	neurofibromatosis type 1	0.3872	0.436	On the other hand, response to these drugs was correlated with some clinical findings in symptomatic cases; all infants with neurocutaneous syndrome (tuberous sclerosis, neurofibromatosis type 1) had controlled infantile spasms, while none of patients with severe neonatal asphyxia or with prior other seizures responded.	-1
Dravet syndrome	MECP2	0.3872	0.03676	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
RTT	MECP2	0.3872	0.02982	Rett syndrome (RTT) is a severe neurodevelopmental disorder caused, in most classic cases, by mutations in the X-linked methyl-CpG-binding protein 2 gene (MECP2).	-1
SJS/TEN	HLA-A	0.3872	0.06426	Furthermore, the carrier rates of HLA-A*33:03, HLA-B*58:01, and HLA-DRB1*03:01 were lower in the SJS/TEN group compared with the AED-tolerant group.	-1
seizures	SCN1A	0.3871	0.1208	CONCLUSION: The clinical features of SMEI were seizure onset within one year of age, first event is often a febrile seizure; multiple seizure types and mental delay occurred after the second year of life; seizures have a characteristic of temperature sensitivity; EEG was normal in the first year of life, followed by generalized, focal or multifocal discharges; early diagnosis by testing SCN1A mutation guides selection of antiepileptic drugs.	-1
ICCA	BFIC	0.3869	0.1614	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
mental retardation	SRPX2-related	0.3869	0.1003	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
FMCD	mammalian target of rapamycin	0.3869	0.09597	Over the past decade, several FMCD subtypes have been linked to hyperactivation of the mammalian target of rapamycin (mTOR) signaling cascade.	-1
OS	KCNT1	0.3868	0.289	This work reveals two novel genes for OS, KCNT1 and PIGQ.	-1
seizures	ABCC8	0.3868	0.3284	We report a girl with congenital hyperinsulinism due to novel homozygous mutation (c.2041-25 G>A; aberrant splicing mutation) in the ABCC8 gene encoding SUR1 and during somatostatin analog (octreotide) discontinuation developed by nonhypoglycemic seizures.	-1
FS	SCN1A-Related	0.3868	0.07456	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
Christianson syndrome	CDKL5	0.3867	0.223	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
cardiac long QT syndrome type 2	LQT2	0.3867	0.4461	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
mitochondrial disorders	NARP	0.3866	0.03861	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Dravet syndrome	c.1458_1465delCTCTAAGT	0.3866	0.2028	Our data present a case of Dravet syndrome caused by a novel heterozygous SCN1A deletion (c.1458_1465delCTCTAAGT) in two affected siblings.	-1
epilepsy	CBF-AI	0.3866	0.09311	Longer duration of epilepsy was related to lower CBF (more negative CBF-AI, r = -0.58, P = .03) and low CBV (r = -0.55, P = .04) on the affected side.	-1
mental retardation	CBPS	0.3866	0.06622	Congenital bilateral perisylvian syndrome(CBPS) is a recently described disease identify characterized by pseudobulbar palsy, epilepsy, mental retardation, and migration disorders in the bilateral perisylvian area.	-1
Rett syndrome	CDKL5	0.3865	0.1522	Moreover, this report reinforces the observation that the CDKL5 phenotype overlaps with Rett syndrome and that CDKL5 gene analysis is recommended in females with a seizure disorder commencing in the first weeks of life.	-1
Cerebral creatine deficiency	AGAT	0.3864	0.02492	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
language impairment	SHANK3	0.3864	0.01251	A large number of these corresponded to genomic regions or genes (ATP13A4, CDH9, CDH13, CNTNAP2, CTNNA3, DIAPH3, GRIN2A, MDGA2, SHANK3) that have been either associated with ASD for most of them, or involved in speech or language impairment, or in RE.	-1
growth retardation	CRK	0.3864	0.1825	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
deafness	KCNQ1	0.3861	0.217	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
mental retardation	CDKL5	0.386	0.1881	Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.	-1
neonatal diabetes syndrome	MEDS	0.386	0.3873	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
DS	SCN1B	0.386	0.1145	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
neurodegeneration	CLC	0.386	0.04082	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
Dravet syndrome	SCN1A	0.3857	0.3989	METHODS: We retrospectively studied patients with Dravet syndrome who had mutations in SCN1A, whose first seizure was a convulsion, and for whom validated source data were available.	-1
cognitive impairment	CSF	0.3856	0.1498	Diagnosis of cognitive impairment from RCDs is based on neuropsychological testing, imaging studies, including MRI, PET, SPECT, or MR-spectroscopy, CSF investigations, or electroencephalography.	-1
MAE	SCN1A	0.3856	0.107	Although initially thought to be within the same spectrum as severe myoclonic epilepsy of infancy, the exclusion of SCN1A mutations in non-generalized epilepsy with febrile seizures plus (GEFS+) MAE cases has confirmed the genetic distinction of MAE.	-1
Panayiotopoulos syndrome	SCN1A	0.3856	0.2041	We present two cases of Panayiotopoulos syndrome in two monozygotic twins, who underwent a molecular analysis of SCN1A, but no alteration was found.	-1
Hemophilia A	FVIII	0.3856	0.1256	Hemophilia A is a genetic disorder leading to factor VIII (FVIII) deficiency, an important factor in the coagulation system.	-1
idiopathic generalized epilepsy syndrome	KCNQ3	0.3856	0.07557	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	-1
sporadic Dravet syndrome	SCN2A	0.3855	0.1902	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
arachnoid cyst	neurofibromatosis type 1	0.3855	0.3444	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
neurologic deterioration	EPM2A	0.3855	0.06558	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
infancy	SCN1A	0.3854	0.09881	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
SMEI/DS	CDKL5	0.3854	0.1587	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
seizure-related	GAMT	0.3853	0.1278	AIM: Describe the seizure-related manifestations of guanidinoacetate methyltransferase (GAMT) deficiency in two new cases and compare these to the related literature.	-1
isolated CHF	ARPKD	0.3853	0.4338	Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years).	-1
seizures	SCN3A	0.3852	0.04225	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
alcoholism	GRIN2B	0.3851	0.3288	Previously we had reported a lack of association between the single nucleotide polymorphism (SNP) rs1806201 in the NR2B gene (GRIN2B) and alcoholism.	-1
DS	SCN2A	0.385	0.08722	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
rolandic epilepsy	KCNQ2 p.Ile592Met	0.3849	0.1939	Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).	-1
FHM	SCN1A	0.3848	0.135	Mutations causing FHM type 3 have been identified in SCN1A, the gene encoding the Nav1.1 Na(+) channel, which is also a major target of epileptogenic mutations and is particularly important for the excitability of GABAergic neurons.	-1
benign familial neonatal convulsions	KCNQ1	0.3848	0.127	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Unverricht-Lundberg disease	NCL	0.3845	0.05559	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
myoclonus	ACMSD	0.3845	0.1522	The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
tinnitus	KCNQ1	0.3843	0.0507	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
seizure	SCN1A	0.3843	0.1008	CONCLUSION: The clinical features of SMEI were seizure onset within one year of age, first event is often a febrile seizure; multiple seizure types and mental delay occurred after the second year of life; seizures have a characteristic of temperature sensitivity; EEG was normal in the first year of life, followed by generalized, focal or multifocal discharges; early diagnosis by testing SCN1A mutation guides selection of antiepileptic drugs.	-1
AS	ATP10C	0.3842	0.05041	We report here that a novel maternally expressed gene, ATP10C, maps within the most common interval of deletion and that ATP10C expression is virtually absent from AS patients with imprinting mutations, as well as from patients with maternal deletions of 15q11-q13.	-1
epilepsy	KCNQ4	0.3842	0.3384	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	1
generalized epilepsies	SCN1B	0.3841	0.04672	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
Subarachnoid haemorrhage	aura-like	0.3841	0.1489	Subarachnoid haemorrhage and recurrent aura-like episodes can occur in patients with cerebral amyloid angiopathy (CAA), which has been the presumed cause in the majority of reported cases.	-1
loss of motor coordination	EA1	0.384	0.04857	Animal models for EA1 include Kcna1-deficient mice, which recessively display severe seizures and die prematurely, and V408A-knock-in mice, which dominantly exhibit stress-induced loss of motor coordination.	-1
seizures	SCN1A	0.384	0.1366	OBJECTIVES: The aim of this study was to determine the genetic defect in a 4-generational family with an epileptic disorder characterized by febrile and afebrile polymorphic seizures and mild to severe mental retardation by means of analyzing the neuronal voltage-gated sodium channel alpha-subunit gene SCN1A for mutations.	-1
epilepsy	MECP2	0.3839	0.09379	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	1
myoclonic seizures	EPM2A	0.3836	0.09924	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
seizures	hNav1.2	0.3836	0.01226	Subsequent structure-activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models.	-1
supplementary motor area (	SMA	0.3834	0.3257	BACKGROUND: In adults, resection of the medial frontal lobe has been shown to result in supplementary motor area (SMA) syndrome, a disorder characterized by transient motor impairment.	-1
cognitive deficits	SCN1A	0.3834	0.1572	BACKGROUND: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the a-subunit of the voltage-gated sodium channel Na(v)1.1.	-1
muscle-eye-brain disease	FCMD	0.3834	0.1376	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
epilepsy	SCN1A	0.3833	0.2198	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	1
hypofibrinogenemia	fibrinogen	0.3832	0.294	We analyzed the clinical factors resulting in hypofibrinogenemia, which is defined as less than 100mg/dl of plasma fibrinogen values determined by a procedure based on the Thrombin-time method.	-1
neonatal diabetes	Kir6.2	0.3831	0.09694	The functional consequence of this ABCC8 mutation mirrors that of KCNJ11 mutations causing neonatal diabetes and provides new insights into the interaction of Kir6.2 and SUR1.	-1
Congenital microcephaly and neonatal seizures	CDG-II	0.3831	0.152	Congenital microcephaly and neonatal seizures were common in CDG-II.	-1
CMDs	CMD1A	0.383	0.1468	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
epilepsy	MASS1	0.383	0.208	Genome-wide linkage of febrile seizures and epilepsy to the FEB4 locus at 5q14.3-q23.1 and no MASS1 mutation.	-1
developmental disorder	MECP2	0.383	0.09458	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
idiopathic neonatal epilepsy	Kv7.2	0.3829	0.1632	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
LMNA-related CMD	laminin alpha-2	0.3828	0.133	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizures	AP3D1	0.3827	0.1486	Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome.	-1
facial dysmorphology	ALP	0.3826	0.06588	Our patients lacked the characteristic features of HPMRS, such as facial dysmorphology (showing only a tented mouth) and hypoplasia of distal phalanges, and had only a mild elevation of serum alkaline phosphatase (ALP).	-1
panhypopituitarism	NF-1	0.3826	0.3184	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Dravet syndrome	SCN1A	0.3824	0.07792	His autopsy was unremarkable, but genetic testing revealed a frame shift mutation in SCN1A, consistent with severe myoclonic epilepsy of infancy (Dravet syndrome).	-1
familial hemiplegic migraine	NaV1.1	0.3824	0.09852	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
Severe Myoclonic Epilepsy in Infancy	SCN1A	0.3824	0.02203	Severe Myoclonic Epilepsy in Infancy (SMEI) is an intractable epileptic syndrome with onset in the first year of life and is commonly caused by de novo mutations in the SCN1A gene, encoding the alpha1-subunit of the neuronal voltage-gated sodium channel.	-1
CAA	A beta	0.3824	0.1161	To explore the clinical effects of inflammation associated with vascular deposits of the amyloid beta peptide (A beta), we analyzed 42 consecutive patients with pathologically diagnosed cerebral amyloid angiopathy (CAA) for evidence of an inflammatory response.	-1
epilepsy	cystatin B	0.3822	0.1423	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	1
neonatal hypoglycemia	HNF1A	0.3822	0.1082	In one patient with mild, transient neonatal hypoglycemia and nonautoimmune diabetes at age 11 years, no additional mutations were found in HNF1A, HNF4A, GCK, INS, and INSR.	-1
PHHI	MEN 2A	0.3822	0.1743	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
Smith-Lemli-Opitz syndrome	ACAD8	0.3821	0.05224	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
muscular hypotonia	SCN2A	0.382	0.2729	Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.	-1
Greig syndrome	MODY2	0.3819	0.2592	In order to delineate the genetic aberrations relevant both to MODY2 and Greig syndrome in this patient, we performed cytogenetic analysis, real-time PCR of the GCK gene, and comparative genomic hybridization (CGH) array.	-1
Panayiotopoulos syndrome	SCN1A	0.3819	0.3598	PURPOSE: To examine fever as a precipitating factor for focal seizures in patients with Panayiotopoulos syndrome (PS) and evaluate the role of SCN1A in PS patients with seizures triggered by fever.	-1
generalized epilepsy with febrile seizures plus syndrome	SCN1A	0.3819	0.2831	We report on two patients with SCN1A mutations and severe epilepsy within the spectrum of generalized epilepsy with febrile seizures plus syndrome (GEFS+), the phenotypes being consistent with DS and MAE, respectively.	-1
generalized epilepsy with febrile seizures	SCN1A	0.3817	0.2674	Mutations in the voltage-gated sodium channel gene SCN1A are a major cause of severe myoclonic epilepsy of infancy (Dravet syndrome) and generalized epilepsy with febrile seizures plus.	-1
hypoplasia of the corpus callosum	GDI1	0.3816	0.2052	In addition, large duplications, including MECP2 and GDI1, induce hypoplasia of the corpus callosum.	-1
growth retardation	LIS1	0.3816	0.2277	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
Unverricht-Lundborg disease	malin	0.3815	0.1075	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
Phelan   McDermid syndrome	MBD5	0.3815	0.1067	The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan   McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion).	-1
Rett syndrome	MECP2	0.3815	0.3613	Five patients with Rett syndrome, who did not show methyl CpG-binding protein 2 gene (MECP2) mutations, were also examined for CDKL5 mutations.	-1
Ehlers-Danlos syndrome	EDSKMH	0.3815	0.1135	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
lateral temporal epilepsy	LGI1	0.3815	0.1123	The KCNAB1 gene is a candidate susceptibility factor for lateral temporal epilepsy (LTE) because of its functional interaction with LGI1, the gene responsible for the autosomal dominant form of LTE.	-1
aggression	NF-1	0.3814	0.3093	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
infantile spasms	CDKL5	0.3814	0.3024	The CDKL5 gene has been implicated in infantile spasms and more recently in a Rett syndrome-like phenotype.	-1
Caroli syndrome	ARPKD	0.3813	0.1974	Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years).	-1
Blaschkoid linear skin hyperpigmentation	PHF6	0.381	0.04496	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
lissencephaly	LIS1	0.381	0.09784	The most frequent forms of lissencephaly (agyria-pachygyria) are caused by mutations of LIS1.	-1
infancy	SCN1B	0.381	0.03294	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
epilepsy	SCN2A	0.381	0.1169	A literature review revealed 33 different SCN2A mutations in 14 families with benign forms of epilepsy and in 21 cases with severe phenotypes.	1
WT	skeletal muscle sodium channel alpha-subunit	0.3808	0.1131	We have studied, in the HEK cells permanently transfected with the skeletal muscle sodium channel alpha-subunit (SkM1), the effects of a transient transfection of the wild type (WT) or C121W mutant beta 1-subunit.	-1
contiguous gene-deletion disorder	PAFAH1B1	0.3806	0.07406	Reverse transcription-PCR on RNA extracted from peripheral blood leukocytes revealed that the expression level of PAFAH1B1 decreased to that in a patient with Miller-Dieker syndrome, a contiguous gene-deletion disorder characterized by classical lissencephaly and a facial dysmorphism.	-1
microcephaly	SCN7A	0.3805	0.07701	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
severe myoclonic epilepsy of infancy	SCN1A	0.3805	0.1254	BACKGROUND: Mutations in SCN1A, the gene encoding the alpha1 subunit of the sodium channel, have been found in severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
Fukuyama CMD	FCMD	0.3805	0.3581	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
Viral infections	GluR3	0.3804	0.1374	Viral infections and antibodies to the GluR3 receptor have been implicated in the physiopathology of this illness and T-cell mediation may play a role in the cerebral inflammatory process.	-1
sleep abnormalities	SCN1A	0.3804	0.1741	To fill this gap, we tested the hypothesis that SCN1A contributes to the regulation of sleep architecture, and by extension, that SCN1A dysfunction contributes to the sleep abnormalities observed in patients with SCN1A mutations.	-1
epilepsy	Nav 1.1	0.3804	0.07796	METHODS: We studied a mouse model of Dravet syndrome, a severe childhood epilepsy caused by mutations in the human SCN1A gene encoding the voltage-gated sodium channel subunit Nav 1.1.	-1
myoclonic epilepsy	NARP	0.3804	0.05867	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
JME	MVP	0.3804	0.06306	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
acute encephalopathy	SCN1A	0.3803	0.09292	METHODS: We analyzed the SCN1A gene in 87 patients with acute encephalopathy, consisting of 20 with acute necrotizing encephalopathy (ANE), 61 with acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), and six with nonspecific (unclassified) acute encephalopathy.	-1
Maturity-onset diabetes of the young type 2	MODY2	0.3802	0.2152	Maturity-onset diabetes of the young type 2 (MODY2) is a form of monogenic diabetes, characterized by mild fasting hyperglycemia.	-1
obsession-compulsion syndromes	NF-1	0.3802	0.3382	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Wilson syndrome	EHMT1	0.3802	0.08073	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
resistant hypomagnesaemia	kallikrein	0.3801	0.444	Renin-angiotensin-aldosterone and kallikrein investigations in a patient with resistant hypomagnesaemia due to Gitelman's syndrome.	-1
epilepsy	KCNQ5	0.3801	0.2806	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
myopathy	NARP	0.3801	0.05942	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
lordosis	fibroblast growth factor receptor 3	0.3799	0.1341	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
MDC1A	FKRP	0.3799	0.2422	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
MDC1A	POMT2	0.3799	0.2422	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
MDC1A	FKTN	0.3799	0.2422	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
RTT	methyl CpG binding protein 2	0.3798	0.1346	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
Cytotoxic T	Granzyme B	0.3798	0.102	Cytotoxic T cells (CTLs) excreting Granzyme B were reported in resected brain tissue, and we confirmed the elevated levels of Granzyme B, not in sera, but in CSF.	-1
Pallister-Hall syndrome	GLI3	0.3797	0.1599	Approximately 5% of HH cases are associated with Pallister-Hall syndrome (PHS), which is caused by haploinsufficiency of GLI3.	-1
intellectual disability	MECP2	0.3797	0.1593	Consistently, the boys displayed clinical features in common with other patients carrying MECP2 duplications, including intellectual disability, autism, lack of speech, slight hypotonia and unsteadiness of movement.	-1
RTT	MECP2	0.3796	0.1519	In this article we present the clinical and developmental data of 120 RTT females with mutations in the MECP2 gene and individually describe typical and atypical cases.	-1
neurologic impairment	CDKL5	0.3795	0.1762	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	-1
congenital adrenal hyperplasia	multiple endocrine neoplasia 2A	0.3794	0.1419	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
epilepsy	CB1	0.3794	0.05317	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety, and stroke.	1
epilepsy	SCN1A	0.3794	0.1337	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	1
short-chain acyl-CoA dehydrogenase (SCAD) deficiency	DHCR7	0.3794	0.1905	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
myokymia/BFNC	KCNQ2	0.379	0.05806	All affected members of the myokymia/BFNC family carried a mutation (R207W) that neutralized a charged amino acid in the S4 voltage-sensor segment of KCNQ2.	-1
CAH	MEN 2A	0.3789	0.1356	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
convulsive	Nav1.1	0.3789	0.03154	However, there are different potentially causative factors, including the specific effects on the Nav1.1 channels caused by the underlying genic or genomic defect; frequent and prolonged convulsive and non-convulsive seizures or status epilepticus; recurrent subtle ictal phenomena, such as that accompanying pronounced visual sensitivity; the use of antiepileptic drugs with cognitive side effects, especially in heavy multiple-drug therapy; and the restrictions that children with severe epilepsy inevitably undergo.	-1
benign neonatal familial convulsions	KCNQ3	0.3788	0.02269	We here provide information regarding the in vivo distribution and biochemical characteristics of human brain KCNQ2 and KCNQ3, two channel subunits that form M-channels when expressed in vitro, and, when mutated, cause the dominantly inherited epileptic syndrome, benign neonatal familial convulsions.	-1
ID	MBD5	0.3788	0.08113	MBD5, the only gene deleted in all patients, is considered to be responsible for ID and epilepsy.	-1
Smith-Lemli-Opitz syndrome	ACADSB	0.3788	0.0739	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
IS	mTOR	0.3787	0.118	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
epilepsies	mammalian target of rapamycin	0.3786	0.08396	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	1
RTT	CDKL5	0.3786	0.1069	This study uses a large international data collection to describe the clinical profile of the CDKL5 disorder and compare with Rett syndrome (RTT).	-1
hypotonia	MECP2	0.3786	0.1074	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
Pitt   Hopkins syndrome	SLC9A6	0.3785	0.07986	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
autism	PTEN	0.3783	0.3016	Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy.	-1
Dravet syndrome	SCN1A	0.3783	0.09006	The treatment regimen of 12 children with Dravet syndrome and proven mutations in the alpha subunit of the sodium channel SCN1A is reported here.	-1
meningeal syndrome	CSF	0.3782	0.1023	Side-effects were mild, lasting up to 7 days: cephalea, meningeal syndrome with sterile CSF in three subjects, and CSF leak lasting up to 3 days in seven subjects.	-1
infantile spasms	CDKL5	0.3782	0.07308	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
seizure disorder	SCN1A-related	0.378	0.1104	The proportion of cases caused by de novo mutation varies by phenotype: the percentage of probands with an SCN1A-related seizure disorder and an affected parent decreases as the severity of the phenotype in the proband increases; thus, most SCN1A-related SMEI and ICE-GTC are the result of de novo mutation.	1
acanthosis nigricans	fibroblast growth factor receptor 3	0.3779	0.1383	[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene].	-1
DS	Na(V)1.1	0.3778	0.02523	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	-1
IBD	ACADSB	0.3778	0.1904	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
AHS	NARP	0.3778	0.06123	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
MDC1A	POMGNT1	0.3778	0.2444	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
genetic disease	CLC	0.3777	0.09178	Every human CLC channel gene has been linked to a genetic disease, and studying these mutations has provided much information about the physiological roles and the molecular basis of CLC channel function.	-1
seizure	MECP2	0.3775	0.1067	Early epileptic variant had severe seizure types in the first year of life, followed by a typical RTT picture; all were MECP2 negative.	-1
epilepsy	Na(v) 1.1	0.3775	0.04691	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	1
GCPS	GCK	0.3774	0.1658	This deleted region included GLI3 and GCK genes (where heterozygous mutations cause GCPS and MODY2, respectively), and many other contiguous genes.	-1
gyral pattern	MEDS	0.3773	0.09882	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
ataxia	Inv	0.3773	0.1205	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
MTLE	MRI	0.3773	0.3001	These twelve patients were compared with twenty-one patients with MTLE with unilateral hippocampal sclerosis (HS) on MRI who underwent intracranial EEG before resection (control group).	-1
Coffin-Siris syndrome	PHF6	0.3772	0.1258	Recently, two patients with a clinical diagnosis of Coffin-Siris syndrome in early infancy had been found to harbour mutations in PHF6, and their phenotype in advanced ages is now described.	-1
amyloidosis	TTR	0.3772	0.07815	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
DS	SCN1A	0.3771	0.2352	OBJECTIVE: We aimed to determine the type, frequency, and size of microchromosomal copy number variations (CNVs) affecting the neuronal sodium channel a 1 subunit gene (SCN1A) in Dravet syndrome (DS), other epileptic encephalopathies, and generalized epilepsy with febrile seizures plus (GEFS+).	-1
CMD	FKRP	0.3771	0.2791	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
neurodevelopmental entity	MECP2	0.3771	0.142	BACKGROUND: Rett disorder (RD) is a progressive neurodevelopmental entity caused by mutations in the MECP2 gene.	-1
Fukuyama type congenital muscular dystrophy	FCMD	0.3771	0.2993	West syndrome in 4, Fukuyama type congenital muscular dystrophy (FCMD) in 6.	-1
benign familial infantile convulsions	BFIC	0.3771	0.3404	[A novel mutation in KCNQ2 gene causes benign familial infantile convulsions (BFIC) in a Chinese family].	-1
epilepsy	SCN1A	0.377	0.09549	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	1
Dravet syndrome	Nav 1.1	0.3767	0.1022	METHODS: We studied a mouse model of Dravet syndrome, a severe childhood epilepsy caused by mutations in the human SCN1A gene encoding the voltage-gated sodium channel subunit Nav 1.1.	-1
autosomal recessive polycystic kidney disease	ARPKD	0.3766	0.3689	OBJECTIVES: The published natural history of congenital hepatic fibrosis (CHF) was examined to inform clinical decision making in autosomal recessive polycystic kidney disease (ARPKD).	-1
Alagille syndrome	JAG1	0.3766	0.3017	The majority of the reported 20p deletions are located on the 20p12 region, covering the JAG1 gene responsible for the Alagille syndrome.	-1
septo-optic dysplasia	neurofibromatosis type 1	0.3765	0.3225	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
craniopharyngioma	NF-1	0.3763	0.4338	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
low-grade glioma	alien	0.3761	0.1205	"We report an unusual presentation of seizures in a 65-year-old woman with a presumed low-grade glioma involving the mesial frontal lobe region, with the ""alien hand"" seen only during a seizure."	-1
myoclonic epilepsy	SCN1A	0.376	0.4838	This study reports the identification of six de novo SCN1A mutations in patients with severe myoclonic epilepsy of infancy, including a tetranucleotide deletion in exon 26.	-1
WS	IL-6	0.3758	0.03065	Both control groups had highly increased IL-6 levels in CSF (Group IIA: 193.05 +/- 185.52 pg/ml and Group IIB: 112.74 +/- 167.44 pg/ml) than those of the patients with WS.	-1
febrile seizures	SCN1A	0.3758	0.2691	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	-1
SMC	OCA2	0.3758	0.1921	This report supports the previous observations assuming that severity of phenotype in patients with SMC(15) depends on the dosage of the PWACR and that skin pigmentation is correlated to OCA2 gene copy number.	-1
Christianson syndrome	CASK	0.3757	0.2731	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Pitt   Hopkins syndrome	ZEB2	0.3756	0.1115	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Smith-Lemli-Opitz syndrome	EDSKMH	0.3756	0.07862	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
Tourette syndrome	neurofibromatosis type 1	0.3753	0.1287	PARTICIPANTS: Patients with neurofibromatosis type 1, epilepsy, or Tourette syndrome diagnosed using traditional clinical criteria; controls without disease; and controls with neurologic disease.	-1
Christianson syndrome	SLC9A6	0.3753	0.2086	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
long QT syndrome	KCNQ4	0.3752	0.2336	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
AD	Abeta	0.3752	0.07016	These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.	-1
tuber lesion	LAT1	0.3751	0.04945	CONCLUSION: LAT1 mRNA was detectable only in fresh-frozen tissues of TSC, and it was upregulated in the cortical tuber lesion.	-1
Pitt   Hopkins syndrome	EHMT1	0.3751	0.1127	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
infancy	SCN1A	0.375	0.05934	INTRODUCTION: Mutations in the voltage-gated sodium channel SCN1A gene are the main genetic cause of Dravet syndrome (previously called severe myoclonic epilepsy of infancy or SMEI).	-1
generalised epilepsy	SCN2A	0.375	0.06023	Mutations in SCN2A have been identified in patients with benign familial neonatal-infantile epilepsy (BFNIE), generalised epilepsy with febrile seizures plus (GEFS+), and a small number of reported cases of other infantile-onset severe intractable epilepsy.	1
Chromosomal abnormalities	GLI3	0.375	0.2266	Chromosomal abnormalities including the GLI3 locus were seen in 8 of 55 (15%) of the resected HH tissue samples.	-1
CMD	POMGNT1	0.375	0.2815	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
malformation	LIS1	0.375	0.1768	The location and type of mutation predict malformation severity in isolated lissencephaly caused by abnormalities within the LIS1 gene.	-1
Kleefstra syndrome	EHMT1	0.3749	0.2062	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
epilepsy	LIS1	0.3748	0.171	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
CMD	CMD1D	0.3747	0.2786	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
isolated lissencephaly	LIS1	0.3746	0.3333	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
epilepsy	NARP	0.3745	0.1682	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	1
neurodevelopmental disorder	WDR62	0.3743	0.1601	CONCLUSIONS: WES and subsequent filtering of the rare variants in a single affected family member led to the rapid and cost-effective identification of a novel homozygous frameshift mutation in WDR62, thereby explaining the severe neurodevelopmental disorder in this family and facilitating genetic counseling.	-1
Angelman syndrome	MECP2-related	0.3743	0.2139	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
subtle ictal phenomena	Nav1.1	0.3742	0.02376	However, there are different potentially causative factors, including the specific effects on the Nav1.1 channels caused by the underlying genic or genomic defect; frequent and prolonged convulsive and non-convulsive seizures or status epilepticus; recurrent subtle ictal phenomena, such as that accompanying pronounced visual sensitivity; the use of antiepileptic drugs with cognitive side effects, especially in heavy multiple-drug therapy; and the restrictions that children with severe epilepsy inevitably undergo.	-1
Dravet syndrome	SCN1A	0.3742	0.07668	PURPOSE: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients.	-1
hypopigmentation	OCA2	0.3742	0.1918	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
hippocampal sclerosis	MRI	0.3742	0.262	These twelve patients were compared with twenty-one patients with MTLE with unilateral hippocampal sclerosis (HS) on MRI who underwent intracranial EEG before resection (control group).	-1
DS	SCN1A	0.3742	0.145	On the other hand, 11 known single nucleotide polymorphisms were identified in the SCN1A gene and composed a putative disease-associated haplotype in patients with DS phenotype.	-1
Bartter syndrome	ClC-Kb/barttin	0.3742	0.05732	Loss-of-function of ClC-Kb/barttin channels impairs NaCl resorption in the limb of Henle and causes hyponatriaemia, hypovolemia and hypotension in patients suffering from Bartter syndrome.	-1
Hypochondroplasia	FGFR3	0.3742	0.06192	Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene.	-1
isobutyryl-CoA dehydrogenase deficiency	DHCR7	0.3739	0.1764	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
isobutyryl-CoA dehydrogenase deficiency	AUH	0.3739	0.1764	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
status epilepticus	SCN1A	0.3738	0.08162	SCN1A mutated patients (n = 58) seemed to exhibit worse psychomotor course than non-mutated ones (n = 9) (severe SQPS in 26% vs 0%), although their epilepsy tended to be less severe (tonic seizures in 12% vs 44% [p = 0.04], first status epilepticus before 6 m in 26% vs 67% [p = .02], mean number of SE 2.5 vs 4.5 [p = .09]).	-1
CMDs	CMD1C	0.3738	0.09331	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
SMEI	SCN1A	0.3737	0.02494	Mutations in SCN1A, the gene encoding the brain voltage-gated sodium channel alpha(1) subunit (Na(V)1.1), are associated with genetic forms of epilepsy, including generalized epilepsy with febrile seizures plus (GEFS+ type 2), severe myoclonic epilepsy of infancy (SMEI) and related conditions.	-1
benign familial neonatal convulsions	KCNQ2	0.3737	0.04258	In one of those three children, a de novo missense mutation was detected in the voltage gated potassium channel gene KCNQ2, indicating a genetic relationship between drug refractory neonatal seizures of unknown etiology with tonic clonic or myoclonic sequences and the well-known syndrome of benign familial neonatal convulsions (BFNC).	-1
Borjeson-Forssman-Lehmann syndrome	PHF6	0.3736	0.2052	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
CSE	TIMP-1	0.3736	0.03265	Serum TIMP-1 levels in AEPFS patients were significantly lower than those in PFS, SFS, CSE and West syndrome patients and in controls.	-1
epilepsy	SCN1A	0.3734	0.09368	The frequencies of SCN1A mutations in suspected severe myoclonic epilepsy of infancy (SMEI), its borderline phenotype (SMEB) and intractable epilepsy were 56.2%, 41.9% and 28.9% respectively.	1
Unverricht-Lundborg disease	MECP2	0.3734	0.0804	Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.	-1
MELAS	Mn-SOD	0.3733	0.04909	On the other hand, we observed that the RNA, protein and activity levels of Mn-SOD are increased two- to three-fold in skin fibroblasts of the patients with CPEO syndrome but are dramatically decreased in patients with MELAS or MERRF syndrome.	-1
seizures	SCN1A-related	0.373	0.2218	To determine differences in characteristics of reported seizures after vaccination in children with and without SCN1A-related Dravet syndrome.	-1
Leigh-syndrome	NARP	0.373	0.05418	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
MELAS-syndrome	NARP	0.373	0.05418	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Rett syndrome	CDKL5	0.3728	0.07556	It is now clearly emerging that epilepsy has distinctive characteristics in typical Rett syndrome and in the different syndromes caused by CDKL5 and FOXG1 gene alterations.	-1
biphenotypic	L-asparaginase	0.3728	0.1076	A 46-year-old male with refractory biphenotypic acute leukemia was treated with doxorubicin (days 1-3, 15-17), vincristine (days 1, 8, 15, 22), prednisolone (days 1-28), and L-asparaginase (L-ASP: days 15-28) as reinduction therapy.	-1
neurodevelopmental disorder	CDKL5	0.3728	0.3574	The screening was negative for all men as well as for women with Aicardi syndrome, excluding the CDKL5 gene as a candidate for this neurodevelopmental disorder.	-1
seizures	NF1	0.3728	0.112	SIGNIFICANCE: Compared to the general population, seizures are more common in individuals with NF1, where they are often focal and related to an intracranial neoplasm.	-1
GGEs	SCN1A	0.3728	0.1161	Suggestive evidence for an association with GGEs was found in the region 2q24.3 (rs11890028, P(meta) = 4.0   10(-6)) nearby the SCN1A gene, which is currently the gene with the largest number of known epilepsy-related mutations.	-1
edema	PEHO	0.3728	0.1888	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
DS	SCN1A	0.3727	0.1591	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
MDS	methyl-CpG binding protein 2	0.3727	0.03362	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
isobutyryl-CoA dehydrogenase deficiency	ROGDI	0.3727	0.05982	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	laforin	0.3726	0.1518	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	1
IP	NEMO	0.3726	0.1209	We describe a long follow-up case of a 12-year-old male with IP and a normal karyotype but a genomic deletion of the NEMO gene in the Xq28 position in the form of somatic mosaicism.	-1
neonatal septicaemia	C-reactive protein	0.3725	0.1281	In the present study the utility of serial qualitative C-reactive protein (CRP) assay and white blood cells count (WBC) in the diagnosis of neonatal septicaemia was investigated using blood culture as gold standard.	-1
neonatal septicaemia	CRP	0.3725	0.1281	In the present study the utility of serial qualitative C-reactive protein (CRP) assay and white blood cells count (WBC) in the diagnosis of neonatal septicaemia was investigated using blood culture as gold standard.	-1
febrile seizures	SCN1A	0.3725	0.04216	BACKGROUND: Mutations in SCN1A, the gene encoding the alpha1 subunit of the sodium channel, have been found in severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
carbohydrate-deficient glycoprotein syndromes	biotinidase	0.3724	0.1638	These include the carbohydrate-deficient glycoprotein syndromes or biotinidase deficiency.	-1
RTT	mecp2	0.3724	0.1091	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
benign familial neonatal seizures type 1	KCNQ2	0.3724	0.3559	To our knowledge, this report is the first of a KCNQ2 mutation in an Emirati family with benign familial neonatal seizures type 1.	-1
refractory epilepsy	GRIN2A	0.3724	0.1357	Whole-exome sequencing with a trio analysis (affected child compared to unaffected parents) was performed and identified a novel de novo missense mutation in GRIN2A, c.2449A>G, p.Met817Val, as the likely cause of the refractory epilepsy and global developmental delay.	1
lissencephalies	ARX	0.3721	0.1207	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
growth failure	MECP2	0.3721	0.1063	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
epileptic	MECP2	0.3721	0.09213	Early epileptic variant had severe seizure types in the first year of life, followed by a typical RTT picture; all were MECP2 negative.	1
hypotonia	SLC25A12	0.372	0.07763	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
Muenke syndrome	FGFR3	0.372	0.0771	Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene.	-1
familial amyloid syndrome	TTR	0.3719	0.06967	It appears that the rare TTR Val 107 variant causes a peculiar familial amyloid syndrome characterized by both widespread systemic TTR amyloidosis and central nervous system deposition sufficient to cause seizures, pointing out the extent of TTR amyloidosis phenotypic heterogeneity.	-1
AD	AbPP	0.3719	0.08701	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
ADPEAF	LGI4	0.3719	0.1405	ADPEAF is genetically heterogeneous, but mutations in LGI2, LGI3, or LGI4 did not account for families without LGI1 mutations.	-1
DS	SCN1A	0.3718	0.2446	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	-1
Dravet syndrome	SCN1A-related	0.3718	0.06846	In this review we describe the genetic advances in progressive myoclonus epilepsies, which are strictly monogenic disorders, genetic generalized epilepsies, mostly exhibiting complex genetic inheritance, and SCN1A-related phenotypes, namely genetic generalized epilepsy with febrile seizure plus and Dravet syndrome.	-1
idiopathic epilepsy	neurofibromatosis type 1	0.3717	0.2528	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
seizures	SCN2A	0.3715	0.02206	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
X-linked mental retardation	CDKL5	0.3714	0.1029	These findings confirm CDKL5 as another locus associated with epilepsy and X-linked mental retardation.	-1
microcephaly	MEDS	0.3714	0.09743	A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).	-1
Rett syndrome-like features	CDKL5	0.3712	0.07778	UNASSIGNED: In the last years, the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with epileptic encephalopathies characterized by the early onset of intractable epilepsy, severe developmental delay, autistic features, and often the development of Rett syndrome-like features.	-1
RTT	methyl CpG-binding protein 2	0.3712	0.06729	RTT is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene.	-1
Rett syndrome	methyl CpG-binding protein 2	0.3712	0.06729	Rett syndrome is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene.	-1
long QT syndrome	KCNQ5	0.3711	0.1885	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
X-linked recessive intellectual disability (ID) disorder	PHF6	0.3711	0.08608	BACKGROUND: Borjeson-Forssman-Lehmann syndrome (BFLS) is an X-linked recessive intellectual disability (ID) disorder caused by mutations in the PHF6 gene and characterised by variable cognitive impairment, a distinct facial gestalt, obesity, and hypogonadism.	-1
Alzheimer's disease	Nav1.1	0.3709	0.181	Here, we examined the possible effects on cognition of Nav1.1 down-regulation, a sodium channel principally involved in Dravet syndrome but also implicated in other cognitive disorders, including autism and Alzheimer's disease.	-1
Dravet syndrome	SCN1A	0.3708	0.03827	One novel Dravet syndrome causing mutation and one recurrent MAE causing mutation in SCN1A gene.	-1
genetic neurodevelopmental disorder	MECP2	0.3705	0.08712	Rett syndrome is a genetic neurodevelopmental disorder that affects mainly girls, but mutations in the causative MECP2 gene have also been identified in boys with classic Rett syndrome and Rett syndrome-like phenotypes.	-1
ULD	NCL	0.3705	0.0386	Case records of confirmed patients of Neuronal ceroid lipofuscinosis (NCL = 40), Lafora body disease (LBD = 38), Myoclonic epilepsy with ragged red fibers (MERRF = 10), and probable Unverricht-Lundberg disease (ULD = 9) were reviewed.	-1
neurodevelopmental disorder	methyl-CpG-binding protein 2	0.3705	0.1411	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
NLS	IPO13	0.3705	0.09651	The NLS regions are required for correct nuclear import facilitated by Importin 13 (IPO13).	-1
febrile seizures	SCN1A	0.3705	0.08997	SCN1A mutations account for a large proportion of Dravet syndrome patients, and are reported in other cases of epilepsy, such as some families with genetic epilepsy with febrile seizures plus (GEFS+).	-1
Rubinstein-Taybi syndrome	MECP2-related	0.3703	0.1057	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
FHM-III	NaV1.1	0.3702	0.05614	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
seizures	SCN3A	0.3702	0.1249	A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.	-1
wild type	skeletal muscle sodium channel alpha-subunit	0.3699	0.1956	We have studied, in the HEK cells permanently transfected with the skeletal muscle sodium channel alpha-subunit (SkM1), the effects of a transient transfection of the wild type (WT) or C121W mutant beta 1-subunit.	-1
CMD	FKRP	0.3699	0.06308	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CMD	POMT2	0.3699	0.06308	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CMD	FKTN	0.3699	0.06308	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
hearing loss	ACAD8	0.3698	0.06156	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neurodevelopmental disorder	mecp2	0.3697	0.1207	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
seizures	SCN9A	0.3697	0.0214	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
seizures	SCN1A	0.3697	0.0214	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
Pitt-Hopkins syndrome	CDKL5	0.3696	0.0459	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Pitt-Hopkins syndrome	CREBBP	0.3696	0.0459	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Rett	FOXG1	0.3696	0.152	A total of 62 (69%) patients remained without molecular genetics diagnosis that necessitates further search for mutations in other genes like CDKL5 and FOXG1 that are known to cause Rett phenotype.	-1
infantile hypotonia	methyl CpG-binding protein 2	0.3696	0.1899	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
sudden death	LQT1	0.3696	0.02512	Here, we find that epilepsy occurs in mouse lines bearing dominant human LQT1 mutations for the most common form of cardiac long QT syndrome, which causes syncopy and sudden death.	-1
generalized epilepsies	SCN2A	0.3694	0.07863	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
obesity	MBD5	0.3694	0.1863	A cryptic microdeletion including MBD5 occurring within the breakpoint of a reciprocal translocation between chromosomes 2 and 5 in a patient with developmental delay and obesity.	-1
learning disorder	EPM2A	0.3692	0.2239	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
epileptic	MECP2	0.3692	0.07164	We report the case of a boy carrying a maternally-inherited MECP2 duplication and describe the video-EEG sequence of a cluster of eating-induced spasms, the only epileptic manifestation of the patient.	1
dilated cardiomyopathy	CMD1O	0.3691	0.1147	KATP channelopathies implicated in patients with mechanical and/or electrical heart disease include dilated cardiomyopathy (with ventricular arrhythmia; CMD1O) and adrenergic atrial fibrillation.	-1
epilepsy	MECP2	0.3691	0.09614	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	1
Rett syndrome	CDKL5	0.369	0.07501	This study uses a large international data collection to describe the clinical profile of the CDKL5 disorder and compare with Rett syndrome (RTT).	-1
benign familial neonatal convulsions	KCNQ3	0.369	0.3294	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
RTT	MECP2	0.3689	0.1218	Since the discovery that RTT is caused by mutations in MECP2, large retrospective genotype-phenotype correlation studies have been performed.	-1
Lennox-Gastaut group	HLA-A, B	0.3689	0.1699	No significant differences existed in the frequencies of HLA-A, B, and C antigens between the Lennox-Gastaut group and the controls.	-1
epilepsy	NARP	0.3688	0.03449	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	1
epilepsy	interleukin-6	0.3685	0.2528	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
neurodevelopmental disorders	CDKL5	0.3684	0.06428	CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5   months of age.	-1
benign familial neonatal convulsions	KCNQ2/3	0.3684	0.1888	KCNQ2-5 channels are predominantly expressed in neurons and are important determinants of cellular excitability, as indicated by the occurrence of human genetic mutations in KCNQ channels that underlie inheritable disorders including, in the case of KCNQ2/3, the syndrome of benign familial neonatal convulsions.	-1
epilepsy	SCN2A	0.3682	0.06546	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	1
rolandic epilepsy	CDKL5/STK9	0.3682	0.1523	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
diabetes	SUR1	0.3681	0.1628	In some familial cases, diabetes is not always present in the adult carriers of SUR1 mutations, supporting variability in their clinical expressivity that remains to be fully explained.	-1
Williams-Beuren syndrome	NRXN1	0.3679	0.08308	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
CMD	POMGNT1	0.3679	0.0638	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
DS	Nav1.1	0.3676	0.04705	In Dravet syndrome (DS), a mutation in SCN1A, coding for the voltage-gated sodium channel Nav1.1, is associated with severe cognitive impairment and seizures.	-1
seizures	hNav1.6	0.3676	0.01485	Subsequent structure-activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models.	-1
ICEGTC	SCN1A	0.3675	0.094	Several missense SCN1A mutations have been identified in probands affected by the syndrome of intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC), which bears similarity to SMEI.	-1
Dravet syndrome	Na(v) 1.1	0.3674	0.02232	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
epilepsy disorders	SCN1A	0.3674	0.1784	PURPOSE: Mutations in the voltage-gated sodium channel (VGSC) gene SCN1A are responsible for a number of epilepsy disorders, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	1
Ullrich CMD	CMD1D	0.3673	0.1789	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
hypsarrhythmia	PEHO	0.3671	0.2597	UNASSIGNED: Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.	-1
seizure disorders	SCN1A	0.3671	0.1487	DIAGNOSIS/TESTING: The diagnosis of SCN1A-related seizure disorders relies on detection of a heterozygous pathogenic variant in SCN1A.	1
isobutyryl-CoA dehydrogenase deficiency	EDSKMH	0.367	0.06151	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
neurocutaneous syndrome	NF1	0.367	0.1655	Neurofibromatosis 1 (NF1) is the most common neurocutaneous syndrome.	-1
hyperglycemia	MODY2	0.3669	0.03465	Fasting hyperglycemia in the diabetic range, impaired glucose tolerance, and lack of diabetes autoantibodies were compatible with MODY2.	-1
SMEI	SCN1A	0.3668	0.07848	BACKGROUND: Mutations in SCN1A, the gene encoding the alpha1 subunit of the sodium channel, have been found in severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
Landau-Kleffner syndrome	MEG	0.3668	0.06899	We report a 7-year-old boy with Landau-Kleffner syndrome (LKS), with emphasis on the effect of therapy and serial MEG.	-1
Christianson syndrome	MECP2-related	0.3666	0.1116	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
SMEI	SCN1A	0.3665	0.09489	Subsequently, mutations of SCN1A were also found in patients with severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome, and in patients with borderline SMEI (SMEB), a milder form of Dravet syndrome.	-1
infancy	SCN2A	0.3663	0.05599	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
limbic encephalitis	GluR  2	0.3662	0.167	In patient with non-paraneoplastic, non-herpetic acute limbic encephalitis (NHALE), antibodies against GluN2B (GluR  2) and GluN1 (Glu  1) are detected in the sera and CSF.	-1
epilepsy	SLK	0.3662	0.03354	The dysphasia of development and epilepsy may be associated by chance, as a result of the same cause or the epilepsy be responsible for the TC, either because of seizures or continuously (acquired epileptic aphasia, SLK).	-1
Myokymia and neonatal epilepsy	KCNQ2	0.366	0.09475	Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel.	-1
trauma	methyl-CpG-binding protein 2	0.366	0.2788	Therefore, we investigated risk factors associated with low-energy trauma and the association to methyl-CpG-binding protein 2 (MECP2) mutations.	-1
Prader-Willi syndrome	OCA2	0.366	0.2166	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
tumor	TIMP-1	0.3659	0.1733	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
Dravet syndrome	SCN1A-Related	0.3658	0.02902	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
SMEI	SCN1A	0.3658	0.1327	BACKGROUND: SCN1A is the most clinically relevant epilepsy gene, most mutations causing Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI).	-1
Williams-Beuren syndrome	NRXN1	0.3658	0.4272	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
genetic defects	mammalian target of rapamycin	0.3658	0.0496	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
Fragile X syndrome	AbPP	0.3656	0.09298	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
Dravet syndrome	SCN2A	0.3653	0.04701	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
Dravet syndrome	SCN1A	0.3653	0.125	OBJECTIVE: We aimed to determine the type, frequency, and size of microchromosomal copy number variations (CNVs) affecting the neuronal sodium channel a 1 subunit gene (SCN1A) in Dravet syndrome (DS), other epileptic encephalopathies, and generalized epilepsy with febrile seizures plus (GEFS+).	-1
epilepsy	PTEN	0.3653	0.3363	Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy.	-1
Christianson syndrome	EHMT1	0.3652	0.1037	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
FXS	AbPP	0.3652	0.05351	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
FIRES	SCN1A	0.3652	0.039	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
epilepsy	ACMSD	0.3651	0.1305	The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
FS	SCN1A-related	0.365	0.1045	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
SJS/TEN	HLA-A, -B and -DRB1	0.3649	0.106	PURPOSE: The aim of this study was to investigate the pathogenesis of AED-induced SJS/TEN across a broader spectrum of HLA alleles, including the HLA-A, -B and -DRB1 alleles, to further explore the association between each HLA allele and SJS/TEN induced by aromatic AEDs.	-1
Dravet syndrome	SCN1A	0.3649	0.07444	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	-1
edema	PEHO	0.3649	0.1574	Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO)-like syndrome: what diagnostic characteristics are defining?	-1
hearing loss	KCNQ1	0.3649	0.09417	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
RTT	MECP2	0.3648	0.1024	However, a large scale study of adult RTT patients is required to determine more precisely the influence of MECP2 mutation types on the natural history and clinical phenotypes of RTT.	-1
typical behavior	TCF4	0.3646	0.05227	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
intellectual disability	KCNQ2	0.3646	0.03065	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	-1
Lennox-Gastaut group	DR4	0.3644	0.07575	In the Lennox-Gastaut group we found a significant increase in the frequency of DR5 antigen (55%, chi 2 = 5.6), and an indication of a decrease in the frequency of DR4 antigen (0%, chi 2 = 3.0) as compared with controls (20% and 28%, respectively).	-1
LMNA-related CMD	RSMD1	0.3644	0.1574	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
craniopharyngioma	neurofibromatosis type 1	0.3644	0.3197	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
SMEI	SCN1A-related	0.3643	0.08582	The proportion of cases caused by de novo mutation varies by phenotype: the percentage of probands with an SCN1A-related seizure disorder and an affected parent decreases as the severity of the phenotype in the proband increases; thus, most SCN1A-related SMEI and ICE-GTC are the result of de novo mutation.	-1
cranial neuropathies	VIII	0.3642	0.2738	The other patient with cranial neuropathies of VII, VIII and XII nerves associated with intellectual impairment was diagnosed with CADASIL only with the help of control MRI examination.	-1
growth retardation	YWHAE	0.3642	0.1725	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
non-epilepsy	MVP	0.3639	0.04446	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
seizures	SMA	0.3639	0.3087	We analyzed ictal motor symptoms in 10 patients diagnosed to have supplementary motor area (SMA) seizures based on ictal encephalographic (EEG) findings and ictal clinical semiology.	-1
endocrine abnormalities	PHF6	0.3637	0.04151	Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.	-1
sclerosis	MVP	0.3633	0.1079	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
epilepsy	tRNA methyltransferase 10 homologue A	0.3633	0.2391	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
epilepsy	KCNQ2	0.3632	0.1201	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
neurocutaneous syndrome	Neurofibromatosis 1	0.3632	0.1906	Neurofibromatosis 1 (NF1) is the most common neurocutaneous syndrome.	-1
brachydactyly	PHF6	0.363	0.03495	CONCLUSIONS: Our findings indicate that de novo defects in PHF6 in females result in a recognisable phenotype which might have been under-recognised so far and which comprises variable ID, a characteristic facial gestalt, hypoplastic nails, brachydactyly, clinodactyly mainly of fingers IV and V, dental anomalies, and linear skin hyperpigmentation.	-1
benign familial neonatal convulsions	KCNQ2	0.363	0.08317	Mutations of the nicotinic acetylcholine receptor subunits are found in familial nocturnal frontal lobe epilepsy, while defects in the voltage gated potassium channels (KCNQ2 and KCNQ3) have been identified in benign familial neonatal convulsions.	-1
autistic	DLX5	0.363	0.3152	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
glycine amidinotransferase deficiency	GAMT	0.3629	0.1507	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
genetic epilepsy	SCN1A	0.3628	0.1584	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
Bethlem myopathy	CMD1A	0.3627	0.04859	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
inherited prion disease	PrP	0.3625	0.2956	Here we describe the phenotype of inherited prion disease (PrP 144 bp insertion).	-1
epilepsy	CLC	0.3625	0.03919	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
secondary hypothyroidism	neurofibromatosis type 1	0.3625	0.3585	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
spasticity	MECP2	0.3624	0.3531	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
infantile spasms	IL-6	0.3623	0.2215	However, no elevated IL-6 response was found in patients with infantile spasms.	-1
MNGIE	TP	0.3622	0.04187	Here, we report the first Thai patient with MNGIE confirmed genetically by the identification of a homozygous novel ECGF1 gene mutation, c.100insC, which causes a frameshift and premature truncation of TP protein.	-1
sensory	NARP	0.3621	0.04219	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
autistic type behaviour	MECP2	0.3621	0.08092	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
optic atrophy	3-phosphoglycerate dehydrogenase	0.362	0.09565	The group of these findings is mimicking to clinical manifestations of 3-phosphoglycerate dehydrogenase deficiency, and has some overlap with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) like syndrome, however it is not compatible with these two conditions.	-1
lissencephalies	DCX	0.3619	0.2054	Four forms can be distinguished on the basis of their genetic aetiology: anomalies in the LIS1 gene (isolated lissencephaly and Miller-Dieker syndrome), anomalies in the TUBA3 and DCX genes, and lissencephalies caused by mutations in the ARX gene (XLAG syndrome, X-linked lissencephaly with agenesis of the corpus callosum).	-1
epileptic syndrome	KCNQ3	0.3619	0.02805	We here provide information regarding the in vivo distribution and biochemical characteristics of human brain KCNQ2 and KCNQ3, two channel subunits that form M-channels when expressed in vitro, and, when mutated, cause the dominantly inherited epileptic syndrome, benign neonatal familial convulsions.	1
congenital deafness	Kv7.4	0.3618	0.2753	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
epilepsy	MECP2	0.3618	0.05244	RESULTS: We observed a partial MECP2 duplication in an adult male with epilepsy and mild neurocognitive impairment who was able to function independently; this phenotype has not previously been reported among males harboring gains in MECP2 copy number.	1
permanent neonatal diabetes	KCNJ11	0.3618	0.05189	Activating mutations have been identified in the genes encoding these subunits, ABCC8 and KCNJ11, and account for approximately 40% of permanent neonatal diabetes cases.	-1
PCO	OR 1.37	0.3617	0.09712	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
epileptic amnesia	ALF	0.3616	0.08211	Transient epileptic amnesia is often associated with the rapid decline in recall of new information over hours to days (accelerated long-term forgetting - 'ALF').	-1
aphasia	SMA	0.3615	0.1201	Immediately after surgery, 25 (89%) of the 28 patients displayed additional neurological deficits (aphasia and/or hemiparesis) that depended on the extent of the SMA resection.	-1
epilepsy	SCN2A	0.3613	0.04937	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
migraine	SCN1A	0.3613	0.08	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
tinnitus	KCNQ3	0.3613	0.1094	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
hypotension	ClC-Kb/barttin	0.3612	0.08552	Loss-of-function of ClC-Kb/barttin channels impairs NaCl resorption in the limb of Henle and causes hyponatriaemia, hypovolemia and hypotension in patients suffering from Bartter syndrome.	-1
endocrine disorders	NF-1	0.3612	0.3965	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Pitt-Hopkins syndrome	CASK	0.361	0.1044	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
seizure	KCNQ1	0.361	0.04679	That long QT syndrome mutations in KCNQ1 cause epilepsy reveals the dual arrhythmogenic potential of an ion channelopathy coexpressed in heart and brain and motivates a search for genetic diagnostic strategies to improve risk prediction and prevention of early mortality in persons with seizure disorders of unknown origin.	-1
long  -QT syndrome	hERG	0.361	0.2183	Mutations in the human ether  -    -go  -go  -related gene (hERG) are responsible for long  -QT syndrome (LQTS) type 2 (LQT2).	-1
Rubinstein-Taybi syndrome	EP300	0.361	0.2154	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
infancy	SCN1A	0.3609	0.05874	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
febrile seizures	SCN2A	0.3609	0.0808	De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood.	-1
hemiparesis	SMA	0.3608	0.1065	Immediately after surgery, 25 (89%) of the 28 patients displayed additional neurological deficits (aphasia and/or hemiparesis) that depended on the extent of the SMA resection.	-1
Dravet syndrome	SCN9A	0.3608	0.02854	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
ICCA	benign familial infantile convulsions	0.3606	0.1962	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
NES	NCL	0.3605	0.06634	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
epilepsy	TRMT10A	0.3604	0.2366	BACKGROUND: A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been described.	-1
epilepsy	SCN1B	0.3602	0.0498	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
epilepsy	SCN1A	0.3602	0.1025	METHODS: We studied a mouse model of Dravet syndrome, a severe childhood epilepsy caused by mutations in the human SCN1A gene encoding the voltage-gated sodium channel subunit Nav 1.1.	1
benign familial neonatal convulsions	KCNQ4	0.3602	0.2993	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Seizures	SCN1A	0.3602	0.07936	Seizures recurred at the age of 3 years in the patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
idiopathic epilepsy syndromes	KCNQ3	0.3601	0.205	CONCLUSION: Sequence variations of the KCNQ2 and KCNQ3 genes may contribute to the etiology of common idiopathic epilepsy syndromes.	-1
AED-responsive epilepsy syndrome	MVP	0.36	0.05817	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
type II lissencephaly	FCMD	0.3599	0.1156	The association of congenital muscular dystrophy (CMD) with type II lissencephaly and ocular anomalies is found in Fukuyama CMD (FCMD), the Walker-Warburg syndrome (WWS), and muscle-eye-brain disease (MEBD).	-1
epilepsy	ACMSD	0.3598	0.06536	KEY MESSAGE: ACMSD is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
epilepsy	SCN2B	0.3597	0.09576	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
Rett syndrome	MECP2	0.3597	0.4674	We describe a rare and complete video-polygraphic study of a girl with Rett syndrome (MECP2 mutation) and MS misdiagnosed as movement disorders and disclosed after video-polygraphic recordings.	-1
infantile spasms	mTOR	0.3597	0.06321	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
epilepsies	RTLE-LAT	0.3596	0.01844	METHODS: One hundred fifty-two TLE patients with right mesial (n=37, RTLE-AHS), right lateral (n=31, RTLE-LAT), left mesial (n=42, LTLE-AHS), and left lateral (n=42, LTLE-LAT) lesions and epilepsies underwent comprehensive presurgical evaluation and neuropsychological assessment of mood and memory.	-1
psychoneurological disorders	neurofibromatosis type 1	0.3596	0.2297	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
glycine amidinotransferase deficiency	AGAT	0.3596	0.3872	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
hamartoma	GLI3	0.3596	0.2753	Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.	-1
persistent hyperinsulinemic hypoglycemia of infancy	MEN 2A	0.3594	0.1049	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
Dravet syndrome	SCN2A	0.3594	0.05433	The band 2q24 constitutes the smallest commonly deleted segment in these patients, and contains the voltage-gated sodium channel genes SCN1A and SCN2A, associated with Dravet syndrome and benign familial neonatal-infantile seizures, respectively.	-1
sudden death	KCNH2	0.3593	0.09753	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
Dysmorphic features	JAG1	0.3593	0.1014	Dysmorphic features in subtelomeric 20p13 deletion excluding JAG1: a recognizable microdeletion phenotype?	-1
neurologic impairment	cyclin-dependent kinase-like 5	0.3591	0.1965	OBJECTIVE: Mutations involving the cyclin-dependent kinase-like 5 (CDKL5) gene cause an early onset epileptic encephalopathy (EE) with severe neurologic impairment and a skewed 12:1 female-to-male ratio.	-1
sleep abnormalities	SCN1A	0.3586	0.07049	To fill this gap, we tested the hypothesis that SCN1A contributes to the regulation of sleep architecture, and by extension, that SCN1A dysfunction contributes to the sleep abnormalities observed in patients with SCN1A mutations.	-1
NES	CLN5	0.3586	0.0538	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
migraine	SCN1A	0.3584	0.1166	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	-1
Rett syndrome	CDKL5	0.3583	0.1505	Mutations in the X-linked gene cyclin-dependent kinase-like 5 (CDKL5) have been detected in patients presenting with seizures in the first few months of life and Rett syndrome features.	-1
long QT syndrome	KCNQ1	0.3582	0.4647	Neuronal KCNQ (Kv7) channels (KCNQ2-5 or Kv7.2-7.5, disclosed to date) were discovered by virtue of their homology with a known cardiac channel involved in long QT syndrome (KvLQT or KCNQ1, Kv7.1) and first disclosed in 1998.	-1
hyperthermia-induced	SCN1A	0.358	0.1157	We undertook the mutational analysis of the neuronal sodium channel alpha 1 subunit (SCN1A) gene which is the most representative gene for hyperthermia-induced seizure susceptibility.	-1
epilepsy	MEDS	0.3579	0.04262	While liver and renal symptoms are more severe in WRS, neurodevelopmental characteristics are more pronounced in MEDS patients, in which microcephaly and uncontrolled epilepsy are uniformly present.	1
epilepsy	SCN1A	0.3578	0.08387	These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.	1
supplementary motor area	SMA	0.3578	0.06658	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
seizure	SCN7A	0.3576	0.08896	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
epilepsy	methyl CpG binding protein 2	0.3575	0.1174	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	1
generalized epilepsy with febrile seizures plus	SCN1A-Related	0.3575	0.0555	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
guanidinoacetate methyltransferase deficiency	AGAT	0.3575	0.2334	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
Nance-Horan syndrome	CDKL5	0.3574	0.07027	Among these deleted genes are the gene for Nance-Horan syndrome and the cyclin-dependent kinase-like 5 gene (CDKL5), responsible for the early seizure variant of Rett syndrome.	-1
sudden death	KCNQ1	0.3574	0.1794	RESULTS: Altered exon copy number was detected in 3 (11.5%) patients: (1) an ex13-14del of the KCNQ1 gene in an 11-year-old boy with exercise-induced collapse (QTc 580 ms); (2) an ex6-14del of the KCNH2 gene in a 22-year-old woman misdiagnosed with epilepsy since age 9 years (QTc 560 ms) and a sibling with sudden death at age 13 years; and (3) an ex9-14dup of the KCNH2 gene in a 12 year-old boy (QTc 550 ms) following sudden nocturnal death of his 32-year-old mother.	-1
loss of consciousness	SMA	0.3573	0.1319	Inclusion criteria were (1) EEG seizure pattern in the vertex for the scalp recording or in the area over and/or adjacent to SMA for epicortical recording and (2) ictal motor semiology characterized, as previously reported, by sudden and a brief tonic posturing of extremities and trunk mainly occurring during sleep without loss of consciousness.	-1
Seizures	SCN2A	0.3573	0.1291	Seizures recurred at the age of 3 years in the patient with SCN2A and SCN3A, but no SCN1A involvement.	-1
CMD	RSMD1	0.3573	0.1009	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
seizures	hNav1.1	0.3573	0.02429	Subsequent structure-activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models.	-1
RTT-like	CDKL5	0.3572	0.07537	CONCLUSION: We report the first case of an exonic deletion of CDKL5 in a male and emphasize the importance of underappreciated mosaic exonic copy number variation in patients with early-onset seizures and RTT-like features of both genders.	-1
epileptic encephalopathies	SCN1A	0.3572	0.158	OBJECTIVE: We aimed to determine the type, frequency, and size of microchromosomal copy number variations (CNVs) affecting the neuronal sodium channel a 1 subunit gene (SCN1A) in Dravet syndrome (DS), other epileptic encephalopathies, and generalized epilepsy with febrile seizures plus (GEFS+).	1
epilepsy	SCN1A	0.3572	0.127	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	1
epileptic	N-CLB	0.3572	0.1768	CONCLUSION: This is the first simultaneous pharmacokinetic model for clobazam and N-CLB in epileptic children.	-1
ataxia	NARP	0.3571	0.04212	RESULTS: Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.	-1
Rubinstein-Taybi syndrome	CREBBP	0.3569	0.1473	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
idiopathic neonatal epilepsy	KCNQ3	0.3568	0.2044	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
optic atrophy	PEHO	0.3568	0.1005	The PEHO syndrome (progressive encephalopathy, hypsarrhythmia and optic atrophy) is a rare, autosomal recessive, encephalopathy of infancy.	-1
MDC1A	RSMD1	0.3567	0.1014	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
WS	IL-6	0.3567	0.06612	There was no statistically significant difference between the mean values of CSF IL-6 levels in patients with WS (2.95 +/- 2.31 pg/ml) and those of subgroups of WS (Group IA: 2.26 +/- 2.01 pg/ml and Group IB: 4.33 +/- 2.52 pg/ml).	-1
benign familial neonatal convulsions	KCNQ3	0.3566	0.09153	In 1998, the discovery of two novel genes KCNQ2 and KCNQ3, mutated in a rare inherited form of epilepsy known as benign familial neonatal convulsions, for the first time enabled insight into the molecular etiology of a human idiopathic generalized epilepsy syndrome.	-1
Fanconi's syndrome	NAG	0.3566	0.01794	The research is generally considered in two themes; the first comprises studies which indicate subclinical tubular injury measured by renal enzymes such as N-acetyl-b-D-glucosaminidase (NAG), and the second comprises clinical reports where Fanconi's syndrome has occurred.	-1
PHHI	multiple endocrine neoplasia 2A	0.3566	0.1158	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
epilepsy	SCN1A	0.3565	0.1119	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
epileptic	MECP2	0.3564	0.2709	This report expands our knowledge of the epileptic phenotype of MECP2 duplication syndrome and may contribute to a better definition and comprehension of the electroclinical spectrum of patients affected by this disease.	1
febrile seizures plus	SCN2A	0.3564	0.02725	Mutations in SCN2A have been identified in patients with benign familial neonatal-infantile epilepsy (BFNIE), generalised epilepsy with febrile seizures plus (GEFS+), and a small number of reported cases of other infantile-onset severe intractable epilepsy.	-1
benign familial neonatal convulsions	KCNQ5	0.3562	0.2456	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Enterococcal urinary tract infection	LIS1	0.3561	0.08357	A 6-month-old infant with LIS1 17p13.3 deletion-positive Miller-Dieker syndrome (MDS) presented with increased seizures in the setting of a Pseudomonal and Enterococcal urinary tract infection and a buttock abscess associated with a lumbosacral dermal sinus tract.	-1
epilepsy	SCN1B	0.356	0.08779	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	1
neurological diseases	PrP	0.356	0.09722	We performed a study on levels of the total prion protein (PrP) in humans affected by different neurological diseases and assessed the influence of several factors such as age, gender, and disease severity on the cerebrospinal fluid PrP levels.	-1
infantile spasms	CDKL5	0.3557	0.1302	OBJECTIVE: To determine the frequency of mutations in CDKL5 in both male and female patients with infantile spasms or early onset epilepsy of unknown cause, and to consider whether the breadth of the reported phenotype would be extended by studying a different patient group.	-1
mental impairment	SCN1A-mutations	0.3556	0.2605	Our observations are consistent with the hypothesis that SCN1A-mutations can be responsible not only for epilepsy, but also for early and progressive severe mental impairment.	-1
Smith-Lemli-Opitz syndrome	HSD17B10	0.3554	0.1545	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
arachnoid cyst	NF-1	0.3554	0.3924	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
glioma	NF-1	0.3553	0.4218	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
epilepsy	SCN7A	0.3553	0.1045	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
developmental delay	methyl CpG-binding protein 2	0.355	0.2011	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
epilepsy	Nav1.1	0.3545	0.0593	The basis of epilepsy is an increase in neuronal excitability that, in some cases, may be caused by functional defects in neuronal voltage gated sodium channels, Nav1.1 and Nav1.2.	1
MERRF syndrome	Mn-SOD	0.3543	0.04734	On the other hand, we observed that the RNA, protein and activity levels of Mn-SOD are increased two- to three-fold in skin fibroblasts of the patients with CPEO syndrome but are dramatically decreased in patients with MELAS or MERRF syndrome.	-1
benign familial neonatal convulsions	KCNQ2	0.3541	0.4767	The first Korean case of KCNQ2 mutation in a family with benign familial neonatal convulsions.	-1
plus	SCN1A	0.3541	0.0565	BACKGROUND: Mutations in SCN1A, the gene encoding the alpha1 subunit of the sodium channel, have been found in severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
epileptic spasms	MECP2	0.3541	0.2385	Eating-induced epileptic spasms in a boy with MECP2 duplication syndrome: insights into pathogenesis of genetic epilepsies.	1
behavioral problems	MEG	0.3539	0.09877	A high-dose corticosteroid was effective, with disappearance of ECDs, appearance of auditory evoked fields (AEF) in the bilateral Heschl gyri on MEG, and improvement of behavioral problems and amelioration of acquired aphasia.	-1
RTT	methyl-CpG-binding protein 2	0.3539	0.1155	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
BFNC disorder	KCNQ2	0.3538	0.06961	CONCLUSION: Previously reported mutations of KCNQ2 were mainly identified in BFNC family in which at least one individual had an onset of seizures during the first week of life, a hallmark of the BFNC disorder.	-1
infantile epilepsy	GABRA1	0.3538	0.3901	In this study, we searched for GABRA1 mutations in patients with infantile epilepsy to investigate the phenotypic spectrum of GABRA1 mutations.	1
tonic-clonic seizures	CDKL5	0.3538	0.05422	Generalized intractable seizures, as infantile spasms, and generalized tonic-clonic seizures and myoclonic seizures characterize the clinical picture of CDKL5 mutations.	-1
CMD	POMT2	0.3537	0.2507	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CMD	FKTN	0.3537	0.2507	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
SUDEP	SCN1A	0.3536	0.1668	SCN1A mutations are found in up to 80  % of patients with Dravet syndrome (DS), and the sudden unexpected death in epilepsy (SUDEP) rate is higher in DS than in most forms of severe epilepsy.	-1
epilepsy	SMA	0.3536	0.03006	OBJECTIVE: To characterize the development of SMA syndrome and to analyze seizure outcomes after surgery in the medial frontal lobe for medically intractable epilepsy.	-1
plus	SCN1A	0.3535	0.181	[Phenotype and SCN1A gene mutation screening in 39 families with generalized epilepsy with febrile seizures plus].	-1
seizures	AGC1	0.3534	0.1153	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
thrombocytosis	C reactive protein	0.3534	0.1509	The patient was moderately dehydrated and the blood investigations were remarkable for hyponatraemia (126 mEq/l), leukocytosis (19.4 * 10(3)/l (46% lymphocytes)), thrombocytosis (637 * 10(3)/l), hypoalbuminaemia (albumin 1.9 g/dl) and elevated C reactive protein (96 mg/l).	-1
Cytotoxic T	Granzyme B	0.3534	0.03832	Cytotoxic T cells (CTLs) excreting Granzyme B were reported in resected brain tissue, and we confirmed the elevated levels of Granzyme B, not in sera, but in CSF.	-1
DS	SCN1A	0.3532	0.1766	CONCLUSION: This study extended the spectrum of SCN1A mutations in Taiwanese DS patients and confirms the high sensitivity of SCN1A for the DS phenotype.	-1
JME	MVP	0.3532	0.08094	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
RD	MECP2	0.3531	0.05587	BACKGROUND: Rett disorder (RD) is a progressive neurodevelopmental entity caused by mutations in the MECP2 gene.	-1
Dravet syndrome	SCN3A	0.3531	0.05061	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
growth-retarded	MECP2	0.353	0.2331	Low bone mass is reported in growth-retarded patients harboring mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene causing Rett syndrome (RTT).	-1
infantile convulsions and choreoathetosis	benign familial infantile convulsions	0.353	0.2779	New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.	-1
dysphasia	SLK	0.353	0.01637	The dysphasia of development and epilepsy may be associated by chance, as a result of the same cause or the epilepsy be responsible for the TC, either because of seizures or continuously (acquired epileptic aphasia, SLK).	-1
Dravet syndrome	SCN1A	0.3527	0.01401	Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic syndrome that is caused by mutations in the neuronal voltage-gated sodium channel alpha1 subunit gene SCN1A.	-1
PS	SCN1A	0.3527	0.0693	Moreover, our data show that SCN1A gene does not contribute significantly to susceptibility to autonomic seizures during fever in patients with PS.	-1
myoclonic epilepsy	SCN1A	0.3526	0.164	BACKGROUND: SCN1A is the most clinically relevant epilepsy gene, most mutations causing Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI).	-1
developmental delay	MBD5	0.3523	0.2038	A cryptic microdeletion including MBD5 occurring within the breakpoint of a reciprocal translocation between chromosomes 2 and 5 in a patient with developmental delay and obesity.	-1
severe achondroplasia	fibroblast growth factor receptor 3	0.3521	0.08619	[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene].	-1
lissencephaly	LIS1	0.3518	0.04497	The isolated lissencephaly sequence may be caused by point mutations of the LIS1 gene or by FISH-detectable microdeletions of the 17p13.3 region, which carries the LIS1 gene.	-1
respiratory difficulties	SMARCB1	0.3518	0.1977	Distinguishing features include retinal anomalies, Dandy-Walker malformation, scoliosis, rocker bottom feet, respiratory difficulties and absence of seizures, and 2-oxoglutaric aciduria in the patients with the SMARCB1 mutation.	-1
febrile seizures	SCN1A	0.3516	0.1961	PURPOSE: Mutations in the voltage-gated sodium channel (VGSC) gene SCN1A are responsible for a number of epilepsy disorders, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
epilepsy	SCN1A	0.3516	0.1303	One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1.	1
schizophrenia	EAG-like	0.3515	0.01657	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
Sneddon's syndrome	antithrombin III	0.3513	0.05394	In this article, two cases who had increased amounts of antithrombin III and were diagnosed with Sneddon's syndrome are presented.	-1
BPP	NF1	0.3512	0.092	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
Dravet syndrome	SCN1A	0.3512	0.09697	Most patients with Dravet syndrome have de novo mutations in the neuronal voltage-gated sodium channel type 1 (SCN1A) gene.	-1
tumor	s-TNFR 1	0.351	0.2462	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
Long QT Syndrome	KCNQ1	0.3506	0.3205	The same conserved amino acid was also found to be mutated in the KCNQ1 gene in a family with Long QT Syndrome.	-1
infantile spasms	mammalian target of rapamycin	0.3505	0.05537	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
hemorrhagic colitis	FVIII	0.3503	0.0813	Increased amounts of recombinant FVIII (rFVIII) had to be administered during the acute phase of the disease to reach acceptable blood levels of FVIII, in order to control the hemorrhagic colitis and to prevent severe neurological complications.	-1
dysmorphic features	SCN1A	0.3503	0.118	Furthermore, our study supports that array CGH is a competent technique for screening SCN1A mutation-negative patients diagnosed with SMEI/DS-like epilepsies and dysmorphic features, generating rapid and high-resolution data of genomic imbalances present in the patients.	-1
DMS	PEN	0.3502	0.08242	Five indicators were calculated, including categories achieved (CA), perseverative errors in Milner (PEM) and Nelson (PEN), total errors (TE) and difficulties of maintaining set (DMS).	-1
dyspraxia	ARX-related	0.3501	0.08055	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
Fanconi's syndrome	N-acetyl-b-D-glucosaminidase	0.35	0.02684	The research is generally considered in two themes; the first comprises studies which indicate subclinical tubular injury measured by renal enzymes such as N-acetyl-b-D-glucosaminidase (NAG), and the second comprises clinical reports where Fanconi's syndrome has occurred.	-1
epileptic	X-R, CT and MRI	0.3498	0.2398	In a 33 years-old epileptic woman with a traumatic impact to the vertex, clinical and radiological studies (skull X-R, CT and MRI) disclosed an extensive callosal section under the topography of the falx, associated to fronto-basal contusions.	-1
CMD	RSMD1	0.3498	0.03365	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
Dravet syndrome	SCN1A	0.3497	0.2963	The child was subsequently found to have a de novo mutation of the sodium channel, voltage-gated, type I, alpha subunit (SCN1A) gene consistent with Dravet syndrome.	-1
Febrile infection-related epilepsy syndrome	SCN1A	0.3495	0.05414	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
genetic epilepsy	SCN1A	0.3495	0.5387	Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus.	-1
Rett syndrome	CDKL5	0.3492	0.2362	Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.	-1
tumor	tissue inhibitor of metalloproteinase-1	0.3492	0.2091	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
WS	NF1	0.3491	0.2955	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
lissencephaly	PAFAH1B1	0.3489	0.03641	Reverse transcription-PCR on RNA extracted from peripheral blood leukocytes revealed that the expression level of PAFAH1B1 decreased to that in a patient with Miller-Dieker syndrome, a contiguous gene-deletion disorder characterized by classical lissencephaly and a facial dysmorphism.	-1
Death	MECP2	0.3488	0.04706	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
chromosomal abnormalities	GLI3	0.3486	0.08213	Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.	-1
X-linked defect	SLC6A8	0.3486	0.2571	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
psychosis	PIP-syndrome	0.3485	0.1474	We describe four patients with left temporal lobe epilepsy who developed psychosis, intermittent polydipsia and hyponatremia (PIP-syndrome) while being treated with carbamazepine.	-1
X-linked defect	GAMT	0.3485	0.122	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
mental retardation	MECP2	0.3485	0.05154	PURPOSE: Duplications encompassing the MECP2 gene on the Xq28 region have been described in male patients with moderate to severe mental retardation, absent speech, neonatal hypotonia, progressive spasticity and/or ataxia, recurrent severe respiratory infections, gastrointestinal problems, mild facial dysmorphisms (midface hypoplasia, depressed nasal bridge, large ears) and epilepsy.	-1
seizures	CDKL5	0.3484	0.05068	CONCLUSION: We report the first case of an exonic deletion of CDKL5 in a male and emphasize the importance of underappreciated mosaic exonic copy number variation in patients with early-onset seizures and RTT-like features of both genders.	-1
seizure	SCN1A	0.3484	0.08608	We undertook the mutational analysis of the neuronal sodium channel alpha 1 subunit (SCN1A) gene which is the most representative gene for hyperthermia-induced seizure susceptibility.	-1
PDD	MeCP2	0.3483	0.1259	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
panhypopituitarism	neurofibromatosis type 1	0.3482	0.2135	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
seizure	SMA	0.3481	0.06038	OBJECTIVE: To characterize the development of SMA syndrome and to analyze seizure outcomes after surgery in the medial frontal lobe for medically intractable epilepsy.	-1
apneas	PEX 26	0.3478	0.04323	Genetic analysis demonstrated a new mutation in PEX 26 gene.The death occurred at the age of 8 months of refractor epilepsy and apneas.	-1
neurodevelopmental disorder	NRXN1	0.3476	0.2997	Five patients who had deletions in NRXN1 had a second CNV implicated in neurodevelopmental disorder: a CNTNAP2 and CSMD3 deletion in patients with exonic NRXN1 deletions, and a Williams-Beuren syndrome deletion and two 22q11.2 duplications in patients with intronic NRXN1 deletions.	-1
SMEI syndrome	SCN1A	0.3475	0.1512	The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations.	-1
inherited long QT syndrome	LQT1	0.3475	0.2911	Mutations in this channel can cause one form of inherited long QT syndrome (LQT1), as well as being associated with a form of deafness.	-1
West syndrome	TIMP-1	0.3475	0.02611	Serum TIMP-1 levels in AEPFS patients were significantly lower than those in PFS, SFS, CSE and West syndrome patients and in controls.	-1
hippocampal sclerosis	PrPc	0.3473	0.05316	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
hypotonia	AGC1	0.3473	0.07306	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
aggression	neurofibromatosis type 1	0.347	0.2065	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
mental retardation	NF1	0.347	0.04605	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
CMD	SEPN1-related	0.3469	0.03403	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
CMD	CMD1A	0.3468	0.1191	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
BFNC	KCNQ2	0.3468	0.08777	CONCLUSION: Previously reported mutations of KCNQ2 were mainly identified in BFNC family in which at least one individual had an onset of seizures during the first week of life, a hallmark of the BFNC disorder.	-1
septo-optic dysplasia	NF-1	0.3467	0.3692	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
MAE	SCN1A	0.3465	0.1303	Although initially thought to be within the same spectrum as severe myoclonic epilepsy of infancy, the exclusion of SCN1A mutations in non-generalized epilepsy with febrile seizures plus (GEFS+) MAE cases has confirmed the genetic distinction of MAE.	-1
Dravet syndrome	SCN2A	0.3465	0.02545	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
atrophy	CBF-AI	0.3462	0.03351	Brain atrophy was more severe in the low-perfusion group (P = .01) and was related to both CBF-AI and CBV-AI (r = -0.69, P = .007; r = -0.64, P = .014, respectively).	-1
DS	SCN1A	0.3461	0.04978	Mutations of the SCN1A subunit of the sodium channel is a cause of genetic epilepsy with febrile seizures plus (GEFS(+) ) in multiplex families and accounts for 70-80% of Dravet syndrome (DS).	-1
obsession-compulsion syndromes	neurofibromatosis type 1	0.3459	0.229	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
autosomal recessive disorders	AGAT	0.3458	0.2111	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
Neurofibromatosis	NF1	0.3458	0.3782	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
seizures	CT/MRI	0.3458	0.05941	Common factors in 4 children who were continuously seizure free include (1) normal or almost normal findings of brain CT/MRI, (2) normal development prior to the onset of epileptic seizures, and (3) a short time interval between the onset of seizures and the acute viral infection.	-1
SMEI	SCN1A	0.3457	0.04649	INTRODUCTION: Mutations in the voltage-gated sodium channel SCN1A gene are the main genetic cause of Dravet syndrome (previously called severe myoclonic epilepsy of infancy or SMEI).	-1
Parkinson's disease	AbPP	0.3454	0.09401	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
epilepsy	SCN1A-related	0.3454	0.04583	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	1
Dravet syndrome	SCN1B	0.3454	0.02568	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
dystroglycanopathies	SEPN1-related	0.3451	0.1239	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
RTT	MECP2	0.3449	0.05515	OBJECTIVE: X chromosome inactivation and the MECP2 genotype do not provide the full explanations for the clinical differences between patients with Rett syndrome (RTT), suggesting the involvement of other factors.	-1
myoclonus	ACMSD	0.3449	0.1593	KEY MESSAGE: ACMSD is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
seizures	hNav1.1	0.3446	0.01218	Subsequent structure-activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models.	-1
lissencephaly	LIS1	0.3446	0.03102	The isolated lissencephaly sequence may be caused by point mutations of the LIS1 gene or by FISH-detectable microdeletions of the 17p13.3 region, which carries the LIS1 gene.	-1
spasticity	MECP2	0.3445	0.1135	Duplication of MECP2 causes a recently described X-linked mental retardation syndrome, of which the typical features are infantile hypotonia, poor speech development, recurrent infections, epilepsy, and progressive spasticity.	-1
dental anomalies	PHF6	0.3442	0.04161	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
autistic	MeCP2	0.3441	0.1467	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
seizures	Scn1a	0.344	0.03928	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
DRE	MECP2-mutated	0.3438	0.06789	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
encephalitis	interleukin-6	0.3436	0.06652	The interleukin-6 level in the cerebrospinal fluid 2 hours after seizure onset was elevated to levels seen in patients with encephalitis.	-1
neurodevelopmental disorder	methyl CpG binding protein 2	0.3436	0.1079	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
benign familial neonatal convulsions	KCNQ2	0.3434	0.3055	By linkage analysis and mutation analysis of KCNQ2 gene, we found a novel frameshift mutation of KCNQ2 gene, 1931delG, in a large Chinese family with benign familial neonatal convulsions.	-1
PMG	NF1	0.3432	0.1523	Anecdotal cases of unilateral PMG in the setting of NF1 have been described in association with other-than-opercular epileptic syndromes.	-1
epilepsy	SCN1A	0.3431	0.02499	Causative variants in SCN1A gene which codes the main, pore-forming subunit of the channel expressed in central nervous system are associated predominantly with Dravet syndrome (DS), as well as with generalized epilepsy with febrile seizures plus (GEFS+) making it one of the most significant epilepsy gene.	1
autistic	MeCP2	0.343	0.2696	Decreased dendritic arborization is common to RS and autism, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to autism, like DLX5 and genes on 15q11-13 region.	-1
cancer	EAG-like	0.3426	0.01645	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
Christianson syndrome	ZEB2	0.3426	0.08988	The single-gene disorders include Pitt   Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat   Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.	-1
Rett syndrome	methyl CpG binding protein 2	0.3426	0.1759	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
seizures	SCN1A-related	0.3424	0.0902	Of all reported seizures following vaccinations in the first year of life, 2.5% (95%CI:1.3 to 3.6%) were due to SCN1A-related Dravet syndrome, as were 5.9% of reported seizures (95%CI:3.1 to 8.7%) after 2(nd) or 3(rd) DTP-IPV-Hib vaccination.	-1
neurodevelopmental disorders	NRXN1	0.3423	0.1922	CONCLUSIONS: Exonic deletions in the NRXN1 gene, predominantly affecting the alpha isoform, were found in patients with a range of neurodevelopmental disorders referred for diagnostic cytogenetic analysis.	-1
epilepsies	LTLE-LAT	0.3423	0.1681	METHODS: One hundred fifty-two TLE patients with right mesial (n=37, RTLE-AHS), right lateral (n=31, RTLE-LAT), left mesial (n=42, LTLE-AHS), and left lateral (n=42, LTLE-LAT) lesions and epilepsies underwent comprehensive presurgical evaluation and neuropsychological assessment of mood and memory.	-1
acute encephalopathy	SCN1A	0.3421	0.2151	Recently, there have been sporadic case reports of epilepsy/febrile seizure and acute encephalopathy with a neuronal sodium channel alpha 1 subunit (SCN1A) mutation.	-1
brain malformations	neurofibromatosis type 1	0.3421	0.02396	The association of brain malformations and symptomatic epilepsy in the setting of neurofibromatosis type 1 (NF1) is rarely reported.	-1
PDD	methyl-CpG-binding protein 2	0.342	0.1399	Except for Rett syndrome--attributable in most affected individuals to mutations of the methyl-CpG-binding protein 2 (MeCP2) gene--the other PDD subtypes (autistic disorder, Asperger disorder, disintegrative disorder, and PDD Not Otherwise Specified [PDD-NOS]) are not linked to any particular genetic or nongenetic cause.	-1
DRE	MECP2-mutated	0.3419	0.02127	"CONCLUSIONS: Although RTT MECP2-mutated patients suffer from a serious and progressive encephalopathy, it is ""epileptogenic"" but not ""DREgenic"" as they have a decreased risk (16%) for DRE compared to the general epileptic population (DRE: 20-40%)."	1
glioma	neurofibromatosis type 1	0.3419	0.1385	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Dravet syndrome	SCN1A	0.3417	0.05961	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
juvenile myoclonic epilepsy	MVP	0.3415	0.0727	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
myoclonic-astatic epilepsy	March 1	0.3415	0.06981	Between March 1, 1990 and August 31, 2004, 30 patients who met diagnostic criteria of myoclonic-astatic epilepsy were seen at our department.	-1
encephalomyopathy	Thymidine Phosphorylase	0.3415	0.01684	Mitochondrial neuro-gastro-intestinal encephalomyopathy is an autosomal recessive disorder of juvenile onset, caused by mutations in the gene encoding Thymidine Phosphorylase.	-1
epileptic encephalopathy	Na(V)1.1	0.3414	0.02647	PURPOSE: Dravet syndrome (DS), a devastating epileptic encephalopathy, is mostly caused by mutations of the SCN1A gene, coding for the voltage-gated Na(+) channel Na(V)1.1 a subunit.	1
Pitt-Hopkins syndrome	MECP2-related	0.3414	0.1105	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
FHM-III	SCN1A	0.3412	0.05193	UNASSIGNED: Mutations of the voltage gated Na(+) channel NaV1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).	-1
facial dysmorphism	PAFAH1B1	0.3412	0.01845	Reverse transcription-PCR on RNA extracted from peripheral blood leukocytes revealed that the expression level of PAFAH1B1 decreased to that in a patient with Miller-Dieker syndrome, a contiguous gene-deletion disorder characterized by classical lissencephaly and a facial dysmorphism.	-1
hypothalamic obesity	NF-1	0.3411	0.2669	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
juvenile myoclonic epilepsy	GABRA1	0.3411	0.09935	We report that an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy.	-1
neurological complications	FVIII	0.3409	0.04862	Increased amounts of recombinant FVIII (rFVIII) had to be administered during the acute phase of the disease to reach acceptable blood levels of FVIII, in order to control the hemorrhagic colitis and to prevent severe neurological complications.	-1
inflammation	IL-6	0.3409	0.0758	Elevated IL-6 response in patients with tonic-clonic seizures associated with inflammation of central nervous system might be due to the seizures themselves or related to the underling etiology (infection or trauma).	-1
Cholangiocarcinoma	ARPKD	0.3408	0.09568	Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years).	-1
Dravet syndrome	SCN1A	0.3407	0.3738	The role of neuronal voltage-gated sodium channel, a-1 subunit (SCN1A) gene mutations in Dravet syndrome is well-established.	-1
epileptic encephalopathy	gephyrin	0.3405	0.2164	We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome.	-1
SMEI	SCN1A	0.3405	0.1508	In 30 to 70% of SMEI patients, truncating and missense mutations in the neuronal voltage-gated sodium-channel alpha-subunit gene (SCN1A) have been identified.	-1
optic atrophy	PEHO	0.3403	0.2416	Epilepsy and the electroencephalogram in progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (the PEHO syndrome).	-1
West syndrome	FCMD	0.3403	0.1655	West syndrome in 4, Fukuyama type congenital muscular dystrophy (FCMD) in 6.	-1
Gitelman syndrome	SLC12A3	0.3402	0.05696	A presumptive diagnosis of Gitelman syndrome (GS) was then made and the patient's peripheral blood mononuclear cells were subjected to sequence analysis of the SLC12A3 gene, which encodes a thiazide-sensitive sodium-chloride cotransporter.	-1
hemorrhagic colitis	FVIII	0.3401	0.09	Increased amounts of recombinant FVIII (rFVIII) had to be administered during the acute phase of the disease to reach acceptable blood levels of FVIII, in order to control the hemorrhagic colitis and to prevent severe neurological complications.	-1
epilepsy syndrome	MVP	0.3398	0.05232	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
Dravet syndrome	SCN2A	0.3398	0.02654	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
NES	CLN3	0.3398	0.08689	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
loss of motor coordination	Kcna1-deficient	0.3397	0.02729	Animal models for EA1 include Kcna1-deficient mice, which recessively display severe seizures and die prematurely, and V408A-knock-in mice, which dominantly exhibit stress-induced loss of motor coordination.	-1
neurotoxicity	DPD	0.3396	0.08079	It implies that DPD deficiency can cause neurotoxicity in 5-FU-treated patients and advocates for the prospective screening of DPD deficiency before starting any 5-FU-containing chemotherapy so as to prevent such side effects in the future.	-1
seizure	Scn1a	0.3396	0.06981	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
JS	CC2D2A	0.3395	0.3215	The clinical consequences of CC2D2A mutations in patients with JS have been incompletely reported.	-1
Alzheimer's and Parkinson's diseases	CB1	0.3392	0.09333	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety, and stroke.	-1
neurofibromatosis	NF1	0.3391	0.2768	Fifteen patients with neurofibromatosis type one (NF1) and West syndrome (WS) were studied.	-1
HCH	FGFR3	0.3389	0.03543	Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene.	-1
epilepsy	Kir6.1	0.3387	0.1105	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
clinodactyly	PHF6	0.3386	0.02844	CONCLUSIONS: Our findings indicate that de novo defects in PHF6 in females result in a recognisable phenotype which might have been under-recognised so far and which comprises variable ID, a characteristic facial gestalt, hypoplastic nails, brachydactyly, clinodactyly mainly of fingers IV and V, dental anomalies, and linear skin hyperpigmentation.	-1
Rett syndrome	MECP2	0.3385	0.0765	Diagnosis of Rett syndrome was confirmed by molecular detection of the Ser134Cys mutation in the MECP2 gene, which has previously been described only in classic Rett syndrome.	-1
spongiform changes	PrP	0.3384	0.1054	However, histopathological examination revealed unique features: severe extensive spongiform changes with perivacuolar deposits in the cerebrum and basal ganglia, plaque-like PrP deposits in the cerebrum, and only mild changes in the cerebellum with small amyloid plaques (   20    m in diameter), smaller than those in the MV2K subtype or variant CJD (40-50    m in diameter).	-1
Dravet syndrome	SCN1A	0.3381	0.02574	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
intellectual disability	GRIN2A	0.3378	0.1015	Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.	-1
holoprosencephaly	neurofibromatosis type 1	0.3377	0.1511	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
epileptic	MECP2-mutated	0.3375	0.03023	"CONCLUSIONS: Although RTT MECP2-mutated patients suffer from a serious and progressive encephalopathy, it is ""epileptogenic"" but not ""DREgenic"" as they have a decreased risk (16%) for DRE compared to the general epileptic population (DRE: 20-40%)."	1
non-epilepsy	MVP	0.3373	0.05739	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
Dravet syndrome	SCN1A	0.3373	0.1799	CONCLUSIONS: Frequency of mutations in SCN1A in Dravet syndrome and GEFS+ in Polish populations are similar to other countries.	-1
febrile seizures	SCN1A-related	0.3372	0.06799	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	-1
anorexia	NF-1	0.3372	0.2484	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
epilepsy	SCN9A	0.3371	0.04908	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
febrile seizures	SCN1A	0.337	0.3394	Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus.	-1
Dravet's syndrome	SCN1A	0.3366	0.3559	Some of the rare genetic epilepsies enable treatment stratification through testing for the causal mutation, for example SCN1A mutations in patients with Dravet's syndrome.	-1
deafness	KCNQ3	0.3366	0.1064	Voltage-gated K+channels of the K(V)7 (KCNQ) family have been identified in the last 10-15 years by discovering the causative genes for three autosomal dominant diseases: cardiac arrhythmia (long QT syndrome) with or without congenital deafness (KCNQ1), a neonatal epilepsy (KCNQ2 and KCNQ3) and progressive deafness alone (KCNQ4).	-1
DRE	MECP2	0.3365	0.1308	In addition, no significant relationship was found between the DRE and the RTT genotype category (chi-square=1.147, DF=4, p=0.8867), or a specific MECP2 genotype (chi-square=30.958, DF=39, p=0.8173).	1
generalized epilepsy with febrile seizures plus	SCN1A	0.3364	0.04447	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
neurologic disease	neurofibromatosis type 1	0.3362	0.04366	PARTICIPANTS: Patients with neurofibromatosis type 1, epilepsy, or Tourette syndrome diagnosed using traditional clinical criteria; controls without disease; and controls with neurologic disease.	-1
dyspraxia	CDKL5/STK9	0.3361	0.05285	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
drug-resistant epilepsy	MECP2-mutated	0.3361	0.06962	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
isobutyryl-CoA dehydrogenase deficiency	ACADSB	0.3354	0.09843	The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlsch  tter-T  nz syndrome).	-1
epilepsy	CDKL5	0.3354	0.04978	It is now clearly emerging that epilepsy has distinctive characteristics in typical Rett syndrome and in the different syndromes caused by CDKL5 and FOXG1 gene alterations.	1
MEBD	FCMD	0.3352	0.0408	"Based on these observations, we consider the clinical spectrum of FCMD to be much broader than previously described and to overlap with that of ""mild"" WWS and MEBD."	-1
RTT	MECP2	0.3351	0.04097	Because most cases of RTT are caused by mutations in the MECP2 gene it is reasonable to assume that convulsions are based on common pathogenetic mechanisms and thus should have a similar response to antiepileptic drugs.	-1
seizures	SCN1A	0.3349	0.02838	Lossin and colleagues from Al George's lab report in this issue of Neuron that three missense mutations of SCN1A found in a dominant epilepsy syndrome disrupt inactivation, thereby producing small persistent inward Na(+) currents that may result in hyperexcitability and seizures.	-1
infantile spasms	NF1	0.3348	0.1764	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
inborn errors of creatine metabolism	SLC6A8	0.3348	0.1192	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
inborn errors of creatine metabolism	SLC6A8	0.3348	0.1192	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
benign neonatal convulsions	KCNQ2	0.3345	0.1958	RESULTS: An in-frame deletion of codon 116 in KCNQ2 (p.Lys116del) and a missense mutation in KCNQ3 (p.Glu299Lys) were detected in two index cases exhibiting rolandic epilepsy and benign neonatal convulsions.	-1
X-linked defect	AGAT	0.3344	0.1092	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
IBS	thymidine kinase 2	0.3343	0.1803	Whole exome sequencing coupled with 'identity-by-state' (IBS) analysis revealed a compound heterozygous missense mutation (p.M117V, p.A139V) in the thymidine kinase 2 (TK2) gene that segregated with the phenotype.	-1
schizophrenia	ERG	0.3342	0.02098	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
seizure	CT/MRI	0.3342	0.1528	Common factors in 4 children who were continuously seizure free include (1) normal or almost normal findings of brain CT/MRI, (2) normal development prior to the onset of epileptic seizures, and (3) a short time interval between the onset of seizures and the acute viral infection.	-1
CMD	CMD1C	0.3341	0.01589	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
seizures	NF1	0.334	0.06218	Individuals with seizures and NF1 typically require more aggressive therapy than those without NF1 and should be considered for epilepsy surgery when appropriate.	-1
infancy	SCN1A	0.3339	0.03054	Nearly 700 mutations of the SCN1A gene have been identified in patients with Dravet's syndrome (severe myoclonic epilepsy of infancy), making this the most commonly mutated gene in human epilepsy.	-1
tinnitus	KCNQ4	0.3336	0.3275	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
fCJD	PRNP	0.3336	0.06023	Patients with fCJD have mutations in the gene encoding PrPc (PRNP) (Vercueil 2006, Collins et al. 2004).	-1
seizure	PrP(c)	0.3334	0.07437	Ablation of the cellular prion protein (PrP(c)) gene (PRNP) enhances neuronal excitability of the hippocampus in vitro and sensitivity to seizure in vivo, indicating that PrP(c) might be related to epilepsy.	-1
hearing loss	KCNQ4	0.3334	0.1762	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
Pitt-Hopkins syndrome	TCF4	0.3332	0.2134	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
Dravet syndrome	SCN1A	0.3331	0.0462	Mutations of the SCN1A subunit of the sodium channel is a cause of genetic epilepsy with febrile seizures plus (GEFS(+) ) in multiplex families and accounts for 70-80% of Dravet syndrome (DS).	-1
corpus callosum	neurofibromatosis type 1	0.333	0.1394	RESULTS: Disclosed anomalies included: congenital hydrocephalus (n = 11), cervicomedullary kinking (n = 5), focal cerebral heterotopia with epilepsy (n = 4), partial agenesis of the corpus callosum (n = 4), hypoplastic brain stem (n = 2), holoprosencephaly (n = 1), and subcortical dysplasia in the context of neurofibromatosis type 1 (n = 1).	-1
lower extremity weakness	SCN1A	0.3329	0.1785	We describe a 15-year-old girl with SCN1A mutation (Dravet syndrome), refractory generalized tonic-clonic seizures, and prior posterior instrumentation and fusion for scoliosis, who presented with progressive lower extremity weakness.	-1
neuronal degeneration	PrP	0.3328	0.2321	The disorder is due to neuronal degeneration resulting from the accumulation of a pathological isoform (PrP) of the prion protein (PrPc).	-1
kidney stones	CLC	0.3328	0.0163	Human mutations in CLC channels are known to cause diseases as diverse as myotonia (muscle stiffness), Bartter syndrome (renal salt loss) with or without deafness, Dent's disease (proteinuria and kidney stones), osteopetrosis and neurodegeneration, and possibly epilepsy.	-1
Dravet syndrome	SCN1A	0.3327	0.1611	METHODS: We studied a mouse model of Dravet syndrome, a severe childhood epilepsy caused by mutations in the human SCN1A gene encoding the voltage-gated sodium channel subunit Nav 1.1.	-1
epilepsy	NF 1	0.3327	0.09176	[Relationship between child epilepsy and MRI findings in von Recklinghausen neurofibromatosis (NF 1)].	-1
schizophrenia	NRXN1	0.3326	0.1164	Chromosomal deletions of 1q21.1, 3q29, 15q13.3, 22q11.2, and NRXN1 and duplications of 15q11-q13 (maternal), 16p11, and 16p13.3 have the strongest association with schizophrenia.	-1
FHM	Nav1.1	0.3321	0.06418	Mutations causing FHM type 3 have been identified in SCN1A, the gene encoding the Nav1.1 Na(+) channel, which is also a major target of epileptogenic mutations and is particularly important for the excitability of GABAergic neurons.	-1
epileptic encephalopathy	GPHN	0.332	0.245	We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome.	-1
mental retardation	Inv	0.332	0.1393	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
symptomatic epilepsy	NF1	0.3318	0.1685	The association of brain malformations and symptomatic epilepsy in the setting of neurofibromatosis type 1 (NF1) is rarely reported.	-1
Encephalopathy	CDKL5	0.3312	0.1061	Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.	-1
benign neonatal convulsions	KCNQ3	0.331	0.05835	RESULTS: An in-frame deletion of codon 116 in KCNQ2 (p.Lys116del) and a missense mutation in KCNQ3 (p.Glu299Lys) were detected in two index cases exhibiting rolandic epilepsy and benign neonatal convulsions.	-1
febrile seizures	SCN1A	0.3309	0.1791	Thus, we screened SCN1A mutations in 13 families with partial epilepsy with antecedent febrile seizures (PEFS+) using denaturing high-performance liquid chromatography and sequencing.	-1
febrile seizures	SCN1A	0.3308	0.1109	OBJECTIVE: To summarize the phenotypes and identify SCN1A mutations in families with generalized epilepsy with febrile seizures plus (GEFS(+)), and analyze the genotype- phenotype correlations in GEFS(+) families.	-1
genetic epilepsy	SCN1A	0.3307	0.205	Mutations in the gene encoding the a1 subunit of the voltage gated sodium channel (SCN1A) are associated with several epilepsy syndromes, ranging from relatively mild phenotypes found in families with genetic epilepsy with febrile seizures plus (GEFS+) to the severe infant-onset epilepsy Dravet syndrome.	-1
RS	CD4	0.3306	0.08211	DISCUSSION: The present findings suggest that complex pathophysiologic mechanisms involving CD4(+) T cells and CD8(+) T cells change evolutionally during the progression of RS.	-1
epilepsy	KCNQ3	0.3305	0.08569	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
epilepsies	mTOR	0.3305	0.07758	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
SMEI/DS	ARX-related	0.3305	0.2014	Given the overlapping and heterogeneous clinical features of CDKL5- and ARX-related epilepsies and SMEI/DS, we postulated that CDKL5 mutations in females and ARX mutations gene in males may be associated with early onset seizures forms of SMEI/DS.	-1
inborn errors of creatine metabolism	GAMT	0.3303	0.08395	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
epilepsy	Inv	0.3303	0.1286	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
ILS	LIS1	0.3302	0.03297	Approximately 65% of patients with isolated lissencephaly sequence (ILS) show intragenic mutations or deletions of the LIS1 gene.	-1
long QT syndrome	Kv7.1	0.3298	0.2265	Neuronal KCNQ (Kv7) channels (KCNQ2-5 or Kv7.2-7.5, disclosed to date) were discovered by virtue of their homology with a known cardiac channel involved in long QT syndrome (KvLQT or KCNQ1, Kv7.1) and first disclosed in 1998.	-1
schizophrenia	EAG	0.3298	0.04421	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
spasticity	methyl CpG-binding protein 2	0.3296	0.2645	Male patients with large duplications of the methyl CpG-binding protein 2 (MECP2) gene have been identified with a characteristic phenotype consisting of infantile hypotonia replaced by spasticity, developmental delay, severe mental retardation and recurrent respiratory infections.	-1
CMDs	CMD1D	0.3292	0.07929	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
cancer	ERG	0.3289	0.01713	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
neurologic deterioration	EPM2A	0.3288	0.1535	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
ovulatory dysfunction	OR 1.37	0.3288	0.1102	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
MAE	SCN1A	0.3288	0.04029	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
genetic epilepsy	SCN1A	0.3286	0.1106	SCN1A mutations account for a large proportion of Dravet syndrome patients, and are reported in other cases of epilepsy, such as some families with genetic epilepsy with febrile seizures plus (GEFS+).	-1
Dravet syndrome	SCN1A	0.3285	0.05759	This study provides the first case of microdeletion limited to the SCN1A 5' promoter region with the coding sequence preserved, and indicates the critical involvement of this upstream region in the molecular pathology of Dravet syndrome.	-1
febrile seizures	FEB4	0.3281	0.08436	Genome-wide linkage of febrile seizures and epilepsy to the FEB4 locus at 5q14.3-q23.1 and no MASS1 mutation.	-1
focal epilepsies	SRPX2	0.3279	0.1772	Recent reports on the involvement of the SRPX2 and ELP4 genes with possible roles in cell motility, migration, and adhesion have provided first insights into the complex molecular bases of childhood focal epilepsies.	-1
MAE	c.4205_4208delGAAA	0.3278	0.1089	Analysis of SCN1A revealed a heterozygous de novo frameshift mutation (c.4205_4208delGAAA) in the patient with DS, and a recurrent missense mutation (c.3521C>G) in that suffering from MAE.	-1
Lennox-Gastaut group	DR5	0.3278	0.09085	In the Lennox-Gastaut group we found a significant increase in the frequency of DR5 antigen (55%, chi 2 = 5.6), and an indication of a decrease in the frequency of DR4 antigen (0%, chi 2 = 3.0) as compared with controls (20% and 28%, respectively).	-1
opercular syndrome	NF1	0.3277	0.04221	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
facial dysmorphisms	Inv	0.3277	0.1095	Inverted duplicated chromosome 15 (Inv dup [15]) syndrome is a genetic disorder characterized by psychologic or intellectual language delay; neurologic signs, such as hypotonia, ataxia, and epilepsy; mental retardation ranging from mild to severe; and facial dysmorphisms.	-1
endocrine disorders	neurofibromatosis type 1	0.3277	0.2763	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
developmental delay	Kir6.1	0.3277	0.07803	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
oligomenorrhea	OR 1.37	0.3275	0.1238	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
PD	AbPP	0.3275	0.06126	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
benign familial neonatal-infantile epilepsy	SCN2A	0.3271	0.04095	Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy.	-1
syndactyly of the toes	PHF6	0.327	0.03682	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
febrile seizures	MASS1	0.327	0.1403	This candidate region overlapped with a previously reported locus for febrile seizures (FEB4) in the Japanese population, in which MASS1 was proposed as disease gene.	-1
epilepsy	SCN1A	0.3269	0.06119	Furthermore, whether the migraine of the mother could be influenced by her SCN1A mutation mosaicism is not known, but increased awareness of migraine in future studies of SCN1A related epilepsies could clarify this intriguing link between migraine and epilepsy.	1
Rett's Syndrome	methyl CpG binding protein 2	0.3268	0.07675	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
MAE	SCN1A	0.3265	0.09989	We report on two patients with SCN1A mutations and severe epilepsy within the spectrum of generalized epilepsy with febrile seizures plus syndrome (GEFS+), the phenotypes being consistent with DS and MAE, respectively.	-1
hypotonia	solute carrier family 25, member 12	0.3261	0.126	We describe AGC1 deficiency, a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein.	-1
rare skeletal dysplasia	FGFR3	0.3261	0.08896	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
epilepsy	IL-6	0.3259	0.07635	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
genetic defects	mTOR	0.3259	0.04411	We will review selected animal models of early-life epileptic encephalopathies that have addressed the dyscognitive features of frequent interictal spikes, the pathogenesis and treatments of infantile spasms (IS) or Dravet syndrome, disorders with mammalian target of rapamycin (mTOR) dysregulation, and selected early-life epilepsies with genetic defects.	-1
AEDs	Nav1.1	0.3258	0.1076	In contrast, novel AEDs, such as lacosamide, stabilize the slow-inactivated state in neuronal Nav1.1 and Nav1.7 isoforms.	-1
epilepsy	LIS1	0.3258	0.1176	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
bilateral perisylvian PMG	NF1	0.3256	0.06921	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
SMEI	SCN1A	0.3254	0.03713	SMEI is a channelopathy and the genetic studies have shown a mutation in the SCN1A gene in 70 to 80% of the patients, including the borderline forms.	-1
dental anomalies, and linear skin hyperpigmentation	PHF6	0.3251	0.02482	CONCLUSIONS: Our findings indicate that de novo defects in PHF6 in females result in a recognisable phenotype which might have been under-recognised so far and which comprises variable ID, a characteristic facial gestalt, hypoplastic nails, brachydactyly, clinodactyly mainly of fingers IV and V, dental anomalies, and linear skin hyperpigmentation.	-1
human embryonic kidney	hNa(V)1.2	0.325	0.0826	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
cancer	EAG	0.3245	0.03627	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
DRE	MECP2-mutated	0.3245	0.02718	"CONCLUSIONS: Although RTT MECP2-mutated patients suffer from a serious and progressive encephalopathy, it is ""epileptogenic"" but not ""DREgenic"" as they have a decreased risk (16%) for DRE compared to the general epileptic population (DRE: 20-40%)."	1
familial generalized epilepsy	GABRA1	0.3241	0.1015	OBJECTIVE: GABRA1 mutations have been identified in patients with familial juvenile myoclonic epilepsy, sporadic childhood absence epilepsy, and idiopathic familial generalized epilepsy.	-1
intellectual disability	SCN2A	0.324	0.02766	Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur.	-1
Dravet syndrome	Nav1.1	0.3238	0.1432	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	-1
genetic epilepsy	SCN1A	0.3232	0.2338	PURPOSE: Mutations in the voltage-gated sodium channel (VGSC) gene SCN1A are responsible for a number of epilepsy disorders, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
fibromyalgia	substance P.	0.3229	0.03019	Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P. Pregabalin can be prescribed in Turkey at 150-600 mg to treat neuropathic pain, generalized anxiety disorder, and fibromyalgia, and as concomitant therapy in adult patients with partial epilepsy.	-1
cataract	CDKL5	0.3229	0.1494	Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.	-1
albinism type 2	OCA2	0.3228	0.2955	Association of the pink-eye-dilution gene (P) with hypopigmentation is seen in patients who have oculocutaneous albinism type 2 (OCA2) and Prader-Willi syndrome (PWS) or Angelman syndrome (AS).	-1
amenorrhea	OR 1.37	0.3228	0.1167	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
Dravet syndrome	SCN9A	0.3227	0.0253	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
HH	GLI3	0.3226	0.06166	Approximately 5% of HH cases are associated with Pallister-Hall syndrome (PHS), which is caused by haploinsufficiency of GLI3.	-1
Dravet syndrome	SCN1A-related	0.3224	0.03745	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
polymenorrhea	OR 1.37	0.3222	0.1154	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
progressive myoclonic epilepsy	cystatin B	0.3219	0.1479	PRO: In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely (1) SCN1A, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); (2) laforin (dual specificity protein phosphatase) and malin (ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy (PME); and (3) cystatin B in Unverricht-Lundborg type of PME.	-1
Hypochondroplasia	FGFR3	0.3217	0.06053	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
MDC1A	SEPN1-related	0.3216	0.08857	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
schizophrenia	EAG-related	0.3215	0.01899	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
generalized epilepsy with	SCN1A	0.3211	0.1905	OBJECTIVE: To summarize the phenotypes and identify SCN1A mutations in families with generalized epilepsy with febrile seizures plus (GEFS(+)), and analyze the genotype- phenotype correlations in GEFS(+) families.	-1
DRE	MECP2-mutated	0.321	0.05885	OBJECTIVE: To determine in MECP2-mutated Rett syndrome (RTT [MIM 312750]): (1) the prevalence of drug-resistant epilepsy (DRE); (2) whether the presence of DRE is related to the abnormal EEG patterns or to the particular MECP2 mutant genotype.	1
Rett syndrome	MECP2	0.3208	0.03949	OBJECTIVE: X chromosome inactivation and the MECP2 genotype do not provide the full explanations for the clinical differences between patients with Rett syndrome (RTT), suggesting the involvement of other factors.	-1
Rett disorder	MECP2	0.3206	0.08433	BACKGROUND: Rett disorder (RD) is a progressive neurodevelopmental entity caused by mutations in the MECP2 gene.	-1
tumor	matrix metalloproteinase-9	0.3203	0.1989	Immunological biomarkers including cytokines, chemokines, granzyme B, soluble tumor necrosis factor receptor 1 (s-TNFR 1), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in 22 patients.	-1
FHM	NaV1.1	0.3201	0.09119	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	-1
lordosis	FGFR3	0.3196	0.1401	BACKGROUND: Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionately short stature, lumbar lordosis, and limited extension of the elbow caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene that plays a role in controlling nervous system development.	-1
sudden unexplained death	KCNQ1	0.3195	0.1057	Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death.	-1
Febrile infection-related epilepsy syndrome	POLG	0.3194	0.07866	Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations.	1
tubular injury	NAG	0.3192	0.2675	The research is generally considered in two themes; the first comprises studies which indicate subclinical tubular injury measured by renal enzymes such as N-acetyl-b-D-glucosaminidase (NAG), and the second comprises clinical reports where Fanconi's syndrome has occurred.	-1
pseudobulbar palsy	NF1	0.3189	0.07762	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
neurological complications	FVIII	0.3185	0.04282	Increased amounts of recombinant FVIII (rFVIII) had to be administered during the acute phase of the disease to reach acceptable blood levels of FVIII, in order to control the hemorrhagic colitis and to prevent severe neurological complications.	-1
childhood absence epilepsy	GABRA1	0.3183	0.1107	OBJECTIVE: GABRA1 mutations have been identified in patients with familial juvenile myoclonic epilepsy, sporadic childhood absence epilepsy, and idiopathic familial generalized epilepsy.	-1
RTT	MECP2	0.318	0.03488	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
myoclonic astatic epilepsy	SCN1A	0.3179	0.02807	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
juvenile myoclonic epilepsy	MVP	0.3179	0.08053	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
seizures	SCN7A	0.3174	0.02249	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
channelopathy	SCN1A	0.3174	0.05311	SMEI is a channelopathy and the genetic studies have shown a mutation in the SCN1A gene in 70 to 80% of the patients, including the borderline forms.	-1
neurological deficits	SMA	0.3173	0.1062	Immediately after surgery, 25 (89%) of the 28 patients displayed additional neurological deficits (aphasia and/or hemiparesis) that depended on the extent of the SMA resection.	-1
human embryonic kidney	hNa(V)1.1	0.3171	0.06293	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
compulsive ideas and movements	NF-1	0.3169	0.2175	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
encephalomyopathy	CSF	0.3168	0.0801	In the present patient with mitochondrial complex I encephalomyopathy a low 5-methyltetrahydrofolate level was found in the CSF.	-1
neuronal degeneration	prion protein	0.3168	0.1893	The disorder is due to neuronal degeneration resulting from the accumulation of a pathological isoform (PrP) of the prion protein (PrPc).	-1
Pitt-Hopkins syndrome	EP300	0.3165	0.04508	Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).	-1
neonatal diabetes syndrome	SUR1	0.3165	0.09573	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
Dravet syndrome	SCN7A	0.3165	0.04014	Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.	-1
West syndrome	interleukin-6	0.3155	0.1782	Cerebrospinal fluid interleukin-6 levels in patients with West syndrome.	-1
intellectual disability	interleukin-6	0.3154	0.1849	The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy.	-1
Miller-Dieker syndrome	PAFAH1B1	0.3153	0.1129	Reverse transcription-PCR on RNA extracted from peripheral blood leukocytes revealed that the expression level of PAFAH1B1 decreased to that in a patient with Miller-Dieker syndrome, a contiguous gene-deletion disorder characterized by classical lissencephaly and a facial dysmorphism.	-1
ILS	PAFAH1B1	0.3152	0.06652	Approximately 60 % of patients with ILS show a 17p13.3 deletion or an intragenic variation of PAFAH1B1 that can be identified by fluorescence in situ hybridization (FISH) analysis or gene sequencing.	-1
febrile seizures plus	Nav1.1	0.3152	0.09268	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	-1
disorders of behavior	NF-1	0.3149	0.2328	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
SJS/TEN	HLA-A, -B and -DRB1	0.3146	0.219	PURPOSE: The aim of this study was to investigate the pathogenesis of AED-induced SJS/TEN across a broader spectrum of HLA alleles, including the HLA-A, -B and -DRB1 alleles, to further explore the association between each HLA allele and SJS/TEN induced by aromatic AEDs.	-1
generalized epilepsy with febrile seizures plus	SCN1A-related	0.3145	0.07106	"SCN1A-Related Seizure Disorders
DISEASE CHARACTERISTICS: SCN1A-related seizure disorders encompass a spectrum that ranges from simple febrile seizures (FS) and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end."	-1
polydipsia	PIP-syndrome	0.3143	0.1959	We describe four patients with left temporal lobe epilepsy who developed psychosis, intermittent polydipsia and hyponatremia (PIP-syndrome) while being treated with carbamazepine.	-1
CMD	SEPN1-related	0.3137	0.08067	The main CMD subtypes, grouped by involved protein function and gene in which causative mutations occur, are laminin alpha-2 (merosin) deficiency (MDC1A), collagen VI-deficient CMD, the dystroglycanopathies (caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related CMD (previously known as rigid spine syndrome, RSMD1) and LMNA-related CMD (L-CMD).	-1
epilepsy	FOXG1	0.3136	0.04587	It is now clearly emerging that epilepsy has distinctive characteristics in typical Rett syndrome and in the different syndromes caused by CDKL5 and FOXG1 gene alterations.	-1
Down Syndrome	NF1	0.3134	0.2798	However new evidences arose in the last few years showing that particular association of WS with Down Syndrome (DS), type 1 Neurofibromatosis (NF1) and cerebral palsy (CP) with periventricular leukomalacia (PL) tend to behave as cryptogenic or idiopathic cases showing control of infantile spasms (IS) and disappearance of hypsarrhythmia after treatment.	-1
intellectual disability	SCN2A	0.3134	0.317	Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.	-1
cancer	EAG-related	0.3131	0.01885	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
Dravet syndrome	SCN1A	0.3131	0.1539	OBJECTIVE: To study SCN1A gene mutations and their inheritance in patients with Dravet syndrome(DS), and to analyze the phenotypes of their family members and genotype-phenotype correlations.	-1
supplementary motor area	SMA	0.3125	0.03957	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
FCs	SCN1A	0.3122	0.1098	By performing an association study, we used single nucleotide polymorphisms to investigate the distribution of genotypes of SCN1A in patients with FCs.	-1
autosomal recessive disorder	Thymidine Phosphorylase	0.3119	0.02077	Mitochondrial neuro-gastro-intestinal encephalomyopathy is an autosomal recessive disorder of juvenile onset, caused by mutations in the gene encoding Thymidine Phosphorylase.	-1
Dravet syndrome	KCNQ2	0.3119	0.05548	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
neurological impairment	SMA	0.3118	0.1764	RESULTS: After resection in the region of the SMA, 23 patients (59%) developed postoperative neurological impairment; 17 (74%) were identified as SMA syndrome.	-1
febrile seizures	SCN1A	0.3117	0.06225	Mutations in the alpha-subunit of the first neuronal sodium channel gene SCN1A have been described in isolated patients with severe myoclonic epilepsy in infancy or Dravet syndrome and in families with generalized epilepsy with febrile seizures plus.	-1
WS	IL-6	0.3116	0.06717	There was no statistically significant difference between the mean values of CSF IL-6 levels in patients with WS (2.95 +/- 2.31 pg/ml) and those of subgroups of WS (Group IA: 2.26 +/- 2.01 pg/ml and Group IB: 4.33 +/- 2.52 pg/ml).	-1
generalized epilepsy with febrile seizures plus	SCN2A	0.3113	0.05415	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
Dravet syndrome	SCN1A	0.3111	0.102	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
neonatal diabetes syndrome	Kir6.1	0.311	0.1047	We compared Kir6.x/SUR1 channels carrying the V59G substitution, a cause of the developmental delay, epilepsy, and neonatal diabetes syndrome, with a V59A substitution and the equivalent I60G mutation in the related Kir6.1 subunit from vascular smooth muscle.	-1
EIMFS	SLC12A5	0.3108	0.1586	Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS).	-1
rolandic epilepsy	ARX-related	0.3105	0.1796	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
autism	AbPP	0.3105	0.0884	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
Susac's syndrome	TNF	0.3105	0.1862	We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.	-1
Rett syndrome	MECP2	0.3104	0.04997	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	-1
Rett syndrome	methyl-CpG-binding protein 2	0.3103	0.09788	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
epilepsy	interleukin-6	0.3101	0.08902	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
brain malformations	NF1	0.3099	0.07937	The association of brain malformations and symptomatic epilepsy in the setting of neurofibromatosis type 1 (NF1) is rarely reported.	-1
neurodegenerative disorders	PrP	0.3099	0.08804	We found a significant reduction of CSF PrP levels in patients suffering from all neurodegenerative disorders analyzed.	-1
neurologic deterioration	EPM2A	0.3098	0.161	Here we related mutations in EPM2A with phenotypes of 22 patients (14 families) and identified two subsyndromes: (i) classical LD with adolescent-onset stimulus-sensitive grand mal, absence and myoclonic seizures followed by dementia and neurologic deterioration, and associated mainly with mutations in exon 4 (P = 0.0007); (ii) atypical LD with childhood-onset dyslexia and learning disorder followed by epilepsy and neurologic deterioration, and associated mainly with mutations in exon 1 (P = 0.0015).	-1
trauma	MECP2	0.3096	0.2331	Therefore, we investigated risk factors associated with low-energy trauma and the association to methyl-CpG-binding protein 2 (MECP2) mutations.	-1
epilepsy	SLK	0.3093	0.07028	The dysphasia of development and epilepsy may be associated by chance, as a result of the same cause or the epilepsy be responsible for the TC, either because of seizures or continuously (acquired epileptic aphasia, SLK).	-1
MERRF	COX	0.3092	0.1356	Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX) and the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency.	-1
MNGIE	endothelial cell growth factor 1	0.309	0.06969	MNGIE is caused by mutations in the nuclear gene, endothelial cell growth factor 1 (ECGF1), encoding thymidine phosphorylase (TP).	-1
benign familial neonatal convulsions	KCNQ2	0.3087	0.1446	By linkage analysis and mutation analysis of KCNQ2 gene, we found a novel frameshift mutation of KCNQ2 gene, 1931delG, in a large Chinese family with benign familial neonatal convulsions.	-1
myoclonus	SCA-14	0.3087	0.08193	This case illustrates that both myoclonus and dystonia are part of the clinical spectrum in SCA-14 and that myoclonus can even be the presenting symptom.	-1
hypothalamic obesity	neurofibromatosis type 1	0.3086	0.1746	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
Sanjat-Sakati syndrome	MEN 2A	0.3083	0.07076	OBJECTIVE: To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A).	-1
human embryonic kidney	hNa(V)1.3	0.3083	0.09576	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
viral infection	CT/MRI	0.3082	0.0503	Common factors in 4 children who were continuously seizure free include (1) normal or almost normal findings of brain CT/MRI, (2) normal development prior to the onset of epileptic seizures, and (3) a short time interval between the onset of seizures and the acute viral infection.	-1
temporal lobe epilepsy	Prnp	0.3077	0.04924	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
epilepsy	IL-6	0.3074	0.1932	We aimed to study the influences of active epilepsy and intellectual disability (ID) on the serum interleukin-6 (IL-6) by determining levels in 74 patients with developmental disorder with epilepsy and 63 healthy controls.	-1
CMD	CMD1D	0.3072	0.02578	We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency.	-1
neurological deficit	SMA	0.3068	0.00694	AIM: Surgical resection of lesions involving the dominant supplementary motor area (SMA) may result in immediate postoperative motor and speech deficits which in most cases are reversible.We report 12 patients with frontal lesions involving the SMA and aim to analyse the clinical data and the correlation of neurological deficit with the extent of SMA resection.	-1
Rett's Syndrome	mecp2	0.3066	0.0923	Rett's Syndrome (RTT) is a neurodevelopmental disorder resulting from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional repressor.	-1
Dravet syndrome	KCNQ3	0.3061	0.03164	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
NES	JNCL	0.306	0.07196	The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES.	-1
familial nocturnal frontal lobe epilepsy	KCNQ3	0.3058	0.02031	Mutations of the nicotinic acetylcholine receptor subunits are found in familial nocturnal frontal lobe epilepsy, while defects in the voltage gated potassium channels (KCNQ2 and KCNQ3) have been identified in benign familial neonatal convulsions.	-1
generalized epilepsy with	SCN1A	0.3058	0.09768	BACKGROUND: Mutations in SCN1A, the gene encoding the alpha1 subunit of the sodium channel, have been found in severe myoclonic epilepsy of infancy (SMEI) and generalized epilepsy with febrile seizures plus (GEFS+).	-1
Congenital muscular dystrophy	LAMA2	0.3056	0.05984	Congenital muscular dystrophy type 1A is caused by mutations in the LAMA2 gene, which encodes the a2-chain of laminin.	-1
optic atrophy	PEHO	0.3056	0.1054	PEHO syndrome (progressive encephalopathy, peripheral edema, hypsarrhythmia, and optic atrophy) is a neurodegenerative disorder first characterized in Finnish patients.	-1
LKS	GRIN2A	0.3054	0.1399	Recently, some cases of LKS have been shown to be secondary to glutamate receptor (GRIN2A) mutations.	-1
SMEI	SCN1A	0.3051	0.01731	Several missense SCN1A mutations have been identified in probands affected by the syndrome of intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC), which bears similarity to SMEI.	-1
HEK	hNa(V)1.2	0.305	0.09819	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
anorexia	neurofibromatosis type 1	0.3048	0.1611	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
hearing loss	KCNQ3	0.3035	0.09778	BACKGROUND: KCNQx genes encode slowly activating-inactivating K+ channels, are linked to physiological signal transduction pathways, and mutations in them underlie diseases such as long QT syndrome (KCNQ1), epilepsy in adults (KCNQ2/3), benign familial neonatal convulsions in children (KCNQ3), and hearing loss or tinnitus in humans (KCNQ4, but not KCNQ5).	-1
DS	SCN1A	0.3033	0.05314	DS is caused by a mutation in the neuronal voltage-gated sodium-channel alpha-subunit gene (SCN1A).	-1
Rett syndrome	MECP2	0.3031	0.1418	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
epilepsy	hERG	0.3031	0.1861	In the present study, a heterozygous missense mutation (A561V) linked to LQT2, syncope and epilepsy was identified in the S5/pore region of the hERG protein.	-1
epilepsy syndrome	MVP	0.3023	0.05165	To investigate the relationship between single nucleotide polymorphisms (SNPs) involving the MVP gene and AED-resistance, we compared the distribution of three SNPs in the MVP gene, rs4788187, rs3815824 and rs3815823, among 220 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), 201 patients with juvenile myoclonic epilepsy (JME) (prototype of AED-responsive epilepsy syndrome) and 213 ethnically matched non-epilepsy controls.	-1
growth retardation	LIS1	0.3022	0.08503	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
plus	SCN1A	0.3019	0.07202	OBJECTIVE: To summarize the phenotypes and identify SCN1A mutations in families with generalized epilepsy with febrile seizures plus (GEFS(+)), and analyze the genotype- phenotype correlations in GEFS(+) families.	-1
inborn errors of creatine metabolism	AGAT	0.3014	0.1607	Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036).	-1
seizure	Abeta	0.3013	0.06757	Herein, we assess (1) human APP(Swe) and Abeta levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR(5) blockade.	-1
epilepsy	LIS1	0.3013	0.1067	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
neuronal degeneration	PrPc	0.3011	0.1888	The disorder is due to neuronal degeneration resulting from the accumulation of a pathological isoform (PrP) of the prion protein (PrPc).	-1
idiopathic neonatal epilepsy	Kv7.3	0.3004	0.1007	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
Rett syndrome	MECP2	0.3003	0.06319	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
mentally retarded	inv	0.2998	0.1321	We studied the prevalence of inv dup(15) in a nationwide screening programme for mentally retarded children in Taiwan and tried to correlate the genotype and phenotype in those patients.	-1
psychomotor impairment	CDKL5	0.2995	0.1299	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have recently been reported in patients with severe neurodevelopmental disorder characterized by early-onset seizures, infantile spasms, severe psychomotor impairment and very recently, in patients with Rett syndrome (RTT)-like phenotype.	-1
primary microcephaly	IER3IP1	0.2993	0.05865	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	-1
mental retardation	ARX-related	0.2991	0.07029	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
Dravet syndrome	SCN1A	0.299	0.1038	BACKGROUND: Mutations in the voltage-gated sodium channel SCN1A gene are responsible for the majority of Dravet syndrome cases.	-1
Doose syndrome	SCN1A	0.2987	0.0193	Mutations in SCN1A gene, encoding the voltage-gated sodium channel a1-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome).	-1
intractable epilepsy	SCN2A	0.2987	0.02633	Mutations in SCN2A have been identified in patients with benign familial neonatal-infantile epilepsy (BFNIE), generalised epilepsy with febrile seizures plus (GEFS+), and a small number of reported cases of other infantile-onset severe intractable epilepsy.	1
temporal lobe epilepsy	prion protein	0.2983	0.04846	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
Dravet syndrome	SCN1A	0.2981	0.1393	OBJECTIVE: De novo mutations of the gene sodium channel 1a (SCN1A) are the major cause of Dravet syndrome, an infantile epileptic encephalopathy.	-1
Rett syndrome	methyl-CpG-binding protein 2	0.2981	0.04596	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	-1
NICHHD	OR 1.37	0.2978	0.1411	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
MERRF	COX	0.2977	0.08453	Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX) and the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency.	-1
HEK	hNa(V)1.1	0.2974	0.07512	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
epilepsy	MECP2	0.2966	0.02659	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	1
familial nocturnal frontal lobe epilepsy	KCNQ2	0.2964	0.03585	Mutations of the nicotinic acetylcholine receptor subunits are found in familial nocturnal frontal lobe epilepsy, while defects in the voltage gated potassium channels (KCNQ2 and KCNQ3) have been identified in benign familial neonatal convulsions.	-1
AS	PLM	0.2949	0.0667	Sleep stages were scored according to standard criteria slightly modified in order to take into account the specific EEG patterns of AS, also the apnea/hypopnea index (AHI) was quantified; PLMs were identified and the PLM index (PLMI) was computed.	-1
neurological disorders	APP	0.2949	0.05004	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
Dravet syndrome	SCN1A	0.2948	0.03832	Over 800 mutations have been identified in the voltage-gated sodium channel genes SCN1A and SCN2A in human epilepsies, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
primary microcephaly	immediate early response-3 interacting protein-1	0.2943	0.05671	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	-1
antiphospholipid syndrome	GluR3	0.2938	0.06454	Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome.	-1
epilepsy	GluR3	0.2938	0.07271	Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome.	-1
Rett syndrome	FOXG1	0.2935	0.05365	It is now clearly emerging that epilepsy has distinctive characteristics in typical Rett syndrome and in the different syndromes caused by CDKL5 and FOXG1 gene alterations.	-1
WS	IL-6	0.2935	0.09665	We measured IL-6 levels in cerebrospinal fluid (CSF) obtained from the newly diagnosed patients with WS.	-1
seizures	MECP2	0.2934	0.06377	Death was attributed to the complications of Rett syndrome, an uncommon developmental disorder characterized by autistic type behaviour, hypotonia, stereotyped movements, seizures and growth failure, caused by mutations in the MECP2 gene on the X chromosome.	-1
seizure	APP	0.2929	0.03919	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
CAR	RANTES	0.2926	0.01059	The proportion of patients with serumregulated on activation normal T cell expressed and secreted (RANTES) levels higher than the upper limit of normal range was significantly higher in CAR group than in non-CAR group.	-1
RTT	MECP2	0.2921	0.1173	RTT is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene.	-1
Rett syndrome	MECP2	0.2921	0.1173	Rett syndrome is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene.	-1
Muenke syndrome	FGFR3	0.2917	0.08797	Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.	-1
epilepsy	AbPP	0.2913	0.07746	Altered levels of amyloid b-protein precursor (AbPP) and/or amyloid beta (Ab) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy.	-1
epilepsy	SCN1A	0.2912	0.05243	Nearly 700 mutations of the SCN1A gene have been identified in patients with Dravet's syndrome (severe myoclonic epilepsy of infancy), making this the most commonly mutated gene in human epilepsy.	1
hyperandrogenism	OR 1.37	0.2909	0.1162	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
subtle brain abnormalities	TCF4	0.2909	0.05367	By evaluating clinical features of patients with a proven TCF4 mutation with those of patients without, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combination of the following characteristics: ID with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing abnormalities, motor incoordination, ocular anomalies, constipation, seizures, typical behavior, and subtle brain abnormalities.	-1
MDS	MECP2	0.2904	0.03466	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
DS	SCN2B	0.2902	0.1347	In this study, we determined the prevalence of SCN1A mutations (SCN1A, SCN2A, SCN1B and SCN2B) in 448 patients with suspected DS and intractable childhood epilepsy.	-1
tonic-clonic seizures	IL-6	0.29	0.1751	Elevated IL-6 response in patients with tonic-clonic seizures associated with inflammation of central nervous system might be due to the seizures themselves or related to the underling etiology (infection or trauma).	-1
cancer	LQT2	0.2899	0.1177	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
National Institutes of Child Health and Human Development	OR 1.37	0.2898	0.1191	However, in the criteria of PCO with ovulatory dysfunction (polymenorrhea, amenorrhea, or oligomenorrhea), clinical and/or biochemical evidence of hyperandrogenism according to National Institutes of Child Health and Human Development (NICHHD) and The National Institutes of Health (NIH) Consensus Conference, VPA did not increase the PCOS incidence compared with other AEDs (4 studies included, P>0.05, OR 1.37, 95% CI 0.59-3.19).	-1
non-CAR	RANTES	0.2898	0.008902	The proportion of patients with serumregulated on activation normal T cell expressed and secreted (RANTES) levels higher than the upper limit of normal range was significantly higher in CAR group than in non-CAR group.	-1
IBS	TK2	0.2898	0.1295	Whole exome sequencing coupled with 'identity-by-state' (IBS) analysis revealed a compound heterozygous missense mutation (p.M117V, p.A139V) in the thymidine kinase 2 (TK2) gene that segregated with the phenotype.	-1
febrile seizures plus	SCN1A	0.2885	0.03716	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	-1
RTT	MECP2	0.288	0.1371	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
malformations	PHF6	0.2871	0.03463	Two very recent papers revealed de novo PHF6 defects in seven female patients with intellectual disability and a phenotype resembling Coffin-Siris syndrome (sparse hair, bitemporal narrowing, arched eyebrows, synophrys, high nasal root, bulbous nasal tip, marked clinodactyly with the hypoplastic terminal phalanges of the fifth fingers and cutaneous syndactyly of the toes, Blaschkoid linear skin hyperpigmentation, dental anomalies and occasional major malformations).	-1
Benign familial neonatal seizures	SCN2A	0.287	0.04509	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
infection	IL-6	0.2866	0.04283	Elevated IL-6 response in patients with tonic-clonic seizures associated with inflammation of central nervous system might be due to the seizures themselves or related to the underling etiology (infection or trauma).	-1
mental retardation	CDKL5/STK9	0.2863	0.04594	Although a complex inheritance has long been suspected in epilepsy, recent data indicate that many sporadic rare epileptic disorders, such as Dravet syndrome, CDKL5/STK9 Rett-like epileptic encephalopathy, ARX-related epilepsies, SRPX2-related rolandic epilepsy associated with oral and speech dyspraxia and mental retardation, and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.	-1
Dravet syndrome	SCN1A	0.2863	0.02866	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
Benign familial neonatal seizures	SCN1B	0.286	0.04548	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
FHM	NaV1.1-L1649Q	0.2858	0.06813	In particular, it has been shown that the NaV1.1-L1649Q mutant is nonfunctional when expressed in a human cell line because of impaired plasma membrane expression, similarly to NaV1.1 mutants that cause severe epilepsy, but we have observed gain-of-function effects for other NaV1.1 FHM mutants.	-1
compulsive ideas and movements	neurofibromatosis type 1	0.2857	0.139	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
mental retardation	MECP2	0.2855	0.02083	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	-1
epilepsy	methyl-CpG-binding protein 2	0.2846	0.02441	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	1
Rett syndrome	MECP2	0.2844	0.02635	Rett syndrome (RTT) is a severe neurodevelopmental disorder caused, in most classic cases, by mutations in the X-linked methyl-CpG-binding protein 2 gene (MECP2).	-1
benign familial neonatal convulsions	KCNQ3	0.2841	0.05709	Mutations of the nicotinic acetylcholine receptor subunits are found in familial nocturnal frontal lobe epilepsy, while defects in the voltage gated potassium channels (KCNQ2 and KCNQ3) have been identified in benign familial neonatal convulsions.	-1
neuron loss	CA4	0.284	0.07717	Maximal neuron loss (mean loss 38%) occurred in the CA4 region in six patients with PTLE (end folium sclerosis).	-1
epilepsy	APP	0.284	0.03729	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
disorders of behavior	neurofibromatosis type 1	0.2838	0.1499	RESULTS: Various forms of symptomatic and idiopathic epilepsy and other psychoneurological disorders (disorders of behavior and emotions, obsession-compulsion syndromes, stereotypias, aggression, compulsive ideas and movements, anorexia or hypothalamic obesity) coincident with one or more endocrine disorders such as precocious or delayed puberty, multihormonal pituitary deficiency, panhypopituitarism and secondary hypothyroidism were detected in 42 patients with suprasellar arachnoid cyst (7 patients), septo-optic dysplasia (8 patients), craniopharyngioma (15 patients), glioma of the optic chiasm in neurofibromatosis type 1 (NF-1) (12 patients).	-1
FMCD	mTOR	0.2829	0.07658	Over the past decade, several FMCD subtypes have been linked to hyperactivation of the mammalian target of rapamycin (mTOR) signaling cascade.	-1
BFNS	SCN2A	0.2829	0.0322	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
Benign familial neonatal seizures	SCN1A	0.2827	0.1028	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
BFNS	SCN1B	0.2819	0.03249	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
Muenke syndrome	fibroblast growth factor receptor 3	0.2818	0.04312	Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.	-1
neurodevelopmental disorder	MECP2	0.281	0.04542	Rett syndrome (RTT) is a severe neurodevelopmental disorder caused, in most classic cases, by mutations in the X-linked methyl-CpG-binding protein 2 gene (MECP2).	-1
infantile epileptic encephalopathy	immediate early response-3 interacting protein-1	0.2809	0.09043	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	1
long QT syndrome	KCNH2	0.2807	0.1216	Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome.	-1
isolated lissencephaly	LIS1	0.2807	0.3242	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
RRF	COX	0.2803	0.1217	Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX) and the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency.	-1
permanent neonatal diabetes	IER3IP1	0.2796	0.04153	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	-1
BFNS	SCN1A	0.2787	0.07471	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
epilepsy	MBD5	0.2784	0.03367	MBD5, the only gene deleted in all patients, is considered to be responsible for ID and epilepsy.	-1
schizophrenia	LQT2	0.2773	0.1278	The KCNH voltage-dependent potassium channels (ether-  -go-go, EAG; EAG-related gene, ERG; EAG-like channels, ELK) are important regulators of cellular excitability and have key roles in diseases such as cardiac long QT syndrome type 2 (LQT2), epilepsy, schizophrenia and cancer.	-1
MNGIE	thymidine phosphorylase	0.2772	0.03756	MNGIE is caused by mutations in the nuclear gene, endothelial cell growth factor 1 (ECGF1), encoding thymidine phosphorylase (TP).	-1
apnea/hypopnea	PLM	0.2767	0.0433	Sleep stages were scored according to standard criteria slightly modified in order to take into account the specific EEG patterns of AS, also the apnea/hypopnea index (AHI) was quantified; PLMs were identified and the PLM index (PLMI) was computed.	-1
infantile epileptic encephalopathy	IER3IP1	0.276	0.08075	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	1
intellectual disability	TBC1D24	0.276	0.2384	BACKGROUND: Recessive TBC1D24 gene mutations have been described in two families: an Italian family afflicted with familial infantile myoclonic epilepsy, and an Arab family with focal epilepsy and intellectual disability syndrome.	-1
encephalopathy	SCN1A	0.276	0.08133	We postulated that cases of so-called vaccine encephalopathy could have mutations in the neuronal sodium channel alpha1 subunit gene (SCN1A) because of a clinical resemblance to severe myoclonic epilepsy of infancy (SMEI) for which such mutations have been identified.	-1
epilepsy/febrile seizure	SCN1A	0.275	0.05548	Recently, there have been sporadic case reports of epilepsy/febrile seizure and acute encephalopathy with a neuronal sodium channel alpha 1 subunit (SCN1A) mutation.	-1
focal epilepsies	ELP4	0.2749	0.06144	Recent reports on the involvement of the SRPX2 and ELP4 genes with possible roles in cell motility, migration, and adhesion have provided first insights into the complex molecular bases of childhood focal epilepsies.	-1
permanent neonatal diabetes	immediate early response-3 interacting protein-1	0.2748	0.04013	A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.	-1
generalized epilepsy with febrile seizures plus	SCN1A	0.2746	0.09373	OBJECTIVE: We aimed to determine the type, frequency, and size of microchromosomal copy number variations (CNVs) affecting the neuronal sodium channel a 1 subunit gene (SCN1A) in Dravet syndrome (DS), other epileptic encephalopathies, and generalized epilepsy with febrile seizures plus (GEFS+).	-1
congenital deafness	KCNQ2	0.2743	0.08138	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
mental retardation	methyl-CpG-binding protein 2	0.2738	0.01911	BACKGROUND: Duplications involving the methyl-CpG-binding protein 2 gene (MECP2) locus at Xq28 have been frequently identified in male patients who exhibit a phenotype unique from that of Rett syndrome, which is mainly characterized by severe mental retardation, recurrent infections, and epilepsy.	-1
epilepsy	Nav1.1	0.2734	0.0493	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	1
severe myoclonic epilepsy in infancy	SCN1A	0.2728	0.07948	We report on the use of the voltage-gated calcium channel blocker (Vg-CCB), verapamil, as an add-on anticonvulsant medication in two girls, 4 and 14 years of age, who were affected by severe myoclonic epilepsy in infancy (SMEI) or Dravet syndrome, a channelopathy caused by abnormalities in the voltage-gated sodium channel neuronal type alpha1 subunit (SCN1A) gene at 2q24.	-1
FS	SCN1A-related	0.2723	0.06501	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	-1
neurodevelopmental disorders	MECP2	0.2717	0.1377	UNASSIGNED: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) are neurodevelopmental disorders caused by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression.	-1
Dravet syndrome	SCN2A	0.27	0.0468	Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile seizures plus (GEFS+).	-1
global developmental delay	GRIN2A	0.2694	0.0394	Whole-exome sequencing with a trio analysis (affected child compared to unaffected parents) was performed and identified a novel de novo missense mutation in GRIN2A, c.2449A>G, p.Met817Val, as the likely cause of the refractory epilepsy and global developmental delay.	-1
epilepsy	SCN2A	0.269	0.0132	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
HEK	hNa(V)1.3	0.2689	0.1033	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
Benign familial neonatal seizures	KCNQ2	0.2686	0.1004	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
epilepsy	SCN1B	0.268	0.01332	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
Sneddon's syndrome	GluR3	0.2675	0.03666	Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome.	-1
Kearns-Sayre syndrome syndrome	CSF	0.2675	0.04862	Failure of ATP production in Kearns-Sayre syndrome syndrome provides one explanation for the finding of low spinal fluid (CSF) 5-methyltetrahydrofolate (5MTHF) levels in this condition.	-1
brain abnormalities	SCN2A	0.2674	0.2494	Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.	-1
isolated lissencephaly sequence	LIS1	0.2666	0.04537	Approximately 65% of patients with isolated lissencephaly sequence (ILS) show intragenic mutations or deletions of the LIS1 gene.	-1
MNGIE	TP	0.2663	0.02787	MNGIE is caused by mutations in the nuclear gene, endothelial cell growth factor 1 (ECGF1), encoding thymidine phosphorylase (TP).	-1
epilepsy	SCN1A	0.2663	0.03775	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	1
Down's syndrome	APP	0.266	0.03034	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
Benign familial neonatal seizures	SCN9A	0.2657	0.04482	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
deafness	TBC1D24/Skywalker	0.2655	0.02501	In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins.	-1
infancy	SCN1A	0.2652	0.01436	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
epilepsy	SCN1A	0.2649	0.03143	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
RTT	MECP2	0.264	0.103	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
trauma	IL-6	0.2638	0.03656	Elevated IL-6 response in patients with tonic-clonic seizures associated with inflammation of central nervous system might be due to the seizures themselves or related to the underling etiology (infection or trauma).	-1
Benign familial neonatal seizures	KCNQ3	0.2634	0.05844	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
sleep abnormalities	Scn1a	0.263	0.01575	In addition, the expression of Scn1a in specific cell types/brain regions that are known to play critical roles in seizure generation and sleep now provides a mechanistic basis for the clinical features (seizures and sleep abnormalities) associated with human SCN1A mutations.	-1
autism	APP	0.2625	0.02745	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
paroxysmal extreme pain disorder	SCN2A	0.2619	0.01011	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
BFNS	SCN9A	0.2618	0.03201	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
epilepsy	NF1	0.2615	0.03719	The typical clinical opercular syndrome consisting in mild mental retardation, epilepsy and pseudobulbar palsy is usually associated to bilateral perisylvian PMG (BPP) CONCLUSION: To the best of our knowledge, the complex epileptic syndrome hereby reported has not been previously recorded in the setting of NF1.	-1
paroxysmal extreme pain disorder	SCN1B	0.261	0.0102	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
neurologic deterioration	laforin	0.2605	0.09794	Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause an autosomal recessive fatal disorder called Lafora's disease (LD) classically described as an adolescent-onset stimulus-sensitive myoclonus, epilepsy and neurologic deterioration.	-1
generalized epilepsy	SCN1A	0.2585	0.05417	Mutations in the alpha-subunit of the first neuronal sodium channel gene SCN1A have been described in isolated patients with severe myoclonic epilepsy in infancy or Dravet syndrome and in families with generalized epilepsy with febrile seizures plus.	-1
ID	MECP2	0.2581	0.07441	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
human embryonic kidney	hNa(V)1.1	0.258	0.05636	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
syncope	hERG	0.2579	0.067	In the present study, a heterozygous missense mutation (A561V) linked to LQT2, syncope and epilepsy was identified in the S5/pore region of the hERG protein.	-1
paroxysmal extreme pain disorder	SCN1A	0.2579	0.02419	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
West syndrome	LIS1	0.2563	0.0946	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
fragile X syndrome	APP	0.256	0.02798	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
osteodystrophy	TBC1D24/Skywalker	0.2551	0.01805	In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins.	-1
Dravet syndrome	SCN1A	0.2534	0.08564	PURPOSE: Mutations in the voltage-gated sodium channel (VGSC) gene SCN1A are responsible for a number of epilepsy disorders, including genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.	-1
BFNS	KCNQ2	0.2522	0.06962	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
PEPD	SCN2A	0.2516	0.009375	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
ID	methyl CpG binding protein 2	0.2509	0.08485	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
PEPD	SCN1B	0.2507	0.00946	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
epilepsy	KCNQ3	0.2505	0.02581	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
growth retardation	LIS1	0.2503	0.07926	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	-1
myoclonic epilepsy	SCN1A	0.2499	0.01261	These results illustrate that the clinical spectrum of SCN1A mutations ranges from febrile seizures, febrile seizures plus, over a milder type to the classical form of severe myoclonic epilepsy in infancy, and confirm the clinical experience that severe myoclonic epilepsy in infancy is the most severe form on this spectrum.	-1
temporal lobe epilepsy	PrPc	0.2495	0.03349	Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171.	-1
Dravet syndrome	SCN1A	0.249	0.04569	Mutations in the SCN1A gene, which encodes the central nervous system (CNS) voltage-gated sodium channel (VGSC) Nav1.1, are responsible for several human epilepsy disorders including Dravet syndrome and genetic (generalized) epilepsy with febrile seizures plus (GEFS+).	-1
epilepsy	SCN9A	0.2485	0.01312	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
anxiety	CB1	0.2479	0.01701	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety, and stroke.	-1
channelopathy	SCN1A	0.2479	0.1271	We report on the use of the voltage-gated calcium channel blocker (Vg-CCB), verapamil, as an add-on anticonvulsant medication in two girls, 4 and 14 years of age, who were affected by severe myoclonic epilepsy in infancy (SMEI) or Dravet syndrome, a channelopathy caused by abnormalities in the voltage-gated sodium channel neuronal type alpha1 subunit (SCN1A) gene at 2q24.	-1
BFNS	KCNQ3	0.2471	0.03996	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
MNGIE	ECGF1	0.2465	0.06298	MNGIE is caused by mutations in the nuclear gene, endothelial cell growth factor 1 (ECGF1), encoding thymidine phosphorylase (TP).	-1
human embryonic kidney	Na(V)1.1	0.2446	0.06753	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
PEPD	SCN1A	0.2444	0.01519	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
paroxysmal extreme pain disorder	KCNQ3	0.2444	0.01748	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
Rett syndrome	MECP2	0.2431	0.08024	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
paroxysmal extreme pain disorder	SCN9A	0.2418	0.01005	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
HEK	hNa(V)1.1	0.2407	0.06736	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
Alzheimer's disease	APP	0.2396	0.04439	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
epilepsy	KCNQ2	0.2393	0.0292	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	1
dominantly inherited neonatal seizures	SCN1A	0.2373	0.07316	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
paroxysmal extreme pain disorder	KCNQ2	0.2333	0.0198	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
PEPD	SCN9A	0.2321	0.009319	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
PEPD	KCNQ3	0.2314	0.01095	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
RRF	COX	0.2296	0.1005	Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX) and the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency.	-1
HEK	Na(V)1.1	0.2279	0.08054	METHODS: We engineered R222* or R1234* in the human cDNA of Na(V)1.1 (hNa(V)1.1) and studied their effect on coexpressed wild-type hNa(V)1.1, hNa(V)1.2 or hNa(V)1.3 cotransfecting tsA-201 cells, and on hNa(V)1.6 transfecting an human embryonic kidney (HEK) cell line stably expressing this channel.	-1
epilepsy	LIS1	0.2254	0.07116	Using microarray-based comparative genomic hybridization, 3 patients with epilepsy were revealed to have genomic copy number aberrations at 17p13.3: a partial LIS1 deletion in a patient with isolated lissencephaly and epilepsy, a triplication of LIS1 in a patient with symptomatic West syndrome, and a terminal deletion of 17p including YWHAE and CRK but not LIS1 in a patient with intractable epilepsy associated with distinctive facial features and growth retardation.	1
focal epilepsy	TBC1D24	0.2241	0.2666	BACKGROUND: Recessive TBC1D24 gene mutations have been described in two families: an Italian family afflicted with familial infantile myoclonic epilepsy, and an Arab family with focal epilepsy and intellectual disability syndrome.	-1
DEND syndrome	ABCC8	0.2238	0.1308	We identified a novel heterozygous mutation, F132L, in the ABCC8 gene of a patient with severe developmental delay, epilepsy and neonatal diabetes (DEND syndrome).	-1
FS	SCN1A-related	0.2223	0.02252	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	-1
PEPD	KCNQ2	0.2208	0.01241	These channelopathies include genes encoding voltage-gated channels specific for sodium (SCN1A, SCN2A, SCN1B, SCN9A) and potassium (KCNQ2, KCNQ3) which account for a variety of epilepsy phenotypes ranging from mild, such as Benign familial neonatal seizures (BFNS) to severe, such as Dravet syndrome (severe myoclonic epilepsy of infancy, SMEI) and the rare and unusual syndrome paroxysmal extreme pain disorder (PEPD).	-1
neurodevelopmental disorder	MECP2	0.2201	0.09962	PURPOSE: Rett syndrome (RTT), an X-linked, dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, presents with acquired microcephaly, autistic regression, hand usage loss, and stereotypies.	-1
epilepsy	SCN1A-related	0.2165	0.01805	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	1
FS	SCN1A-related	0.2142	0.02016	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	-1
dominantly inherited neonatal seizures	SCN2A	0.2073	0.05288	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
congenital deafness	Kv7.2	0.2052	0.03569	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
congenital deafness	KCNQ3	0.2036	0.0424	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
congenital deafness	Kv7.3	0.2006	0.06964	The involvement of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) in a benign idiopathic neonatal epilepsy, KCNQ4 (Kv7.4) in a form of congenital deafness, and the discovery that neuronal KCNQ heteromultimers were among the molecular substrates of M-channels, resulted in a high level of interest for potential drug development strategies.	-1
dominantly inherited neonatal seizures	SCN3A	0.2002	0.02226	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
intellectual disability	MECP2	0.1981	0.05672	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
mental retardation	TBC1D24/Skywalker	0.1963	0.01746	In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins.	-1
stroke	CB1	0.194	0.02068	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety, and stroke.	-1
brain injury	APP	0.1887	0.01997	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
Dravet syndrome	SCN1A-related	0.182	0.01719	OBJECTIVE: Most mutations in SCN1A-related epilepsies are novel and when an infant presents with febrile seizures (FS) it is uncertain if they will have simple FS, FS+, or develop a severe epilepsy such as Dravet syndrome.	-1
intellectual disability	methyl CpG binding protein 2	0.1808	0.07174	BACKGROUND: Most cases of Rett syndrome (RTT) are caused by mutations in methyl CpG binding protein 2 (MECP2), and individuals with RTT have somatic growth failure, growth arrest of brain, epilepsy, and intellectual disability (ID).	-1
intellectual disability	SCN1A	0.1727	0.01788	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
parkinsonism	ACMSD	0.1603	0.02999	KEY MESSAGE: ACMSD is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
parkinsonism	ACMSD	0.1602	0.05257	The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.	-1
Parkinson's disease	APP	0.1597	0.01865	Accumulating evidence suggests that dysregulated levels of amyloid b-protein precursor (APP) and its catabolites contribute to the impaired synaptic plasticity and seizure incidence observed in several neurological disorders, including Alzheimer's disease, fragile X syndrome, Down's syndrome, autism, epilepsy and Parkinson's disease as well as in brain injury.	-1
intellectual disability	SCN3A	0.1468	0.01272	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
intellectual disability	SCN2A	0.1376	0.01636	Recently, microduplication of chromosome 2q24.3 (containing eight genes including SCN2A, SCN3A, and the 3' end of SCN1A) was reported in a family with dominantly inherited neonatal seizures and intellectual disability.	-1
